<SEC-DOCUMENT>0001493152-22-008417.txt : 20220331
<SEC-HEADER>0001493152-22-008417.hdr.sgml : 20220331
<ACCEPTANCE-DATETIME>20220331160135
ACCESSION NUMBER:		0001493152-22-008417
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220331
DATE AS OF CHANGE:		20220331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GlucoTrack, Inc.
		CENTRAL INDEX KEY:			0001506983
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				980668934
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41141
		FILM NUMBER:		22792267

	BUSINESS ADDRESS:	
		STREET 1:		301 RT 17 NORTH
		STREET 2:		SUITE 800
		CITY:			RUTHERFORD
		STATE:			NJ
		ZIP:			07070
		BUSINESS PHONE:		972 (8) 675-7878

	MAIL ADDRESS:	
		STREET 1:		301 RT 17 NORTH
		STREET 2:		SUITE 800
		CITY:			RUTHERFORD
		STATE:			NJ
		ZIP:			07070

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Integrity Applications, Inc.
		DATE OF NAME CHANGE:	20101203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:IGAP="http://integrity-app.com/20211231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_IGAP_integrity%2Dapp.com_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20210101_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001506983 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06F_Israel_0_iso4217%2D%2DILS -->
<!-- Field: Set; Name: xdx; ID: xdx_068_Segments_5_Segment -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityCentralIndexKey">0001506983</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0056" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl0059" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0203" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0204" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0205" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0209" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0223" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0224" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="IGAP:WarrantsIssuedAsConsiderationForPlacementServices" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="IGAP:WarrantsIssuedAsConsiderationForPlacementServices" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="IGAP:WarrantsIssuedAsConsiderationForPlacementServices" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0235" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InventoryAdjustments" contextRef="AsOf2020-12-31" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl0640" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0675" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0677" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0724" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0745" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="IGAP:BadDebtExpense" contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="xdx2ixbrl0786" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl0820" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2020-12-31" id="xdx2ixbrl0821" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="igap-20211231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_BoardOfMembersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:BoardOfMembersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_BoardOfMembersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:BoardOfMembersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-112021-08-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-11</xbrli:startDate>
        <xbrli:endDate>2021-08-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-132020-02-14_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-13</xbrli:startDate>
        <xbrli:endDate>2020-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-14_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ComputersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">IGAP:ComputersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">IGAP:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">IGAP:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_VehiclesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_OfficeSpaceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">IGAP:OfficeSpaceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_VehiclesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">IGAP:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">IGAP:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2003-01-012004-12-31_custom_ShareHoldersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:ShareHoldersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2003-01-01</xbrli:startDate>
        <xbrli:endDate>2004-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">IGAP:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2004-03-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">IGAP:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2004-03-03</xbrli:startDate>
        <xbrli:endDate>2004-03-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">IGAP:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2004-03-03</xbrli:startDate>
        <xbrli:endDate>2004-03-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2005-03-04_custom_IsraeliInnovationAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IGAP:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2005-03-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_IsraeliInnovationAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IGAP:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-292017-08-01_custom_AdvisoryAgreementMember_custom_AndrewGarrettIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IGAP:AdvisoryAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IGAP:AndrewGarrettIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-29</xbrli:startDate>
        <xbrli:endDate>2017-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-132020-02-14_custom_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_custom_AccreditedInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IGAP:SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:AccreditedInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-13</xbrli:startDate>
        <xbrli:endDate>2020-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-14_custom_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_custom_AccreditedInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IGAP:SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:AccreditedInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-132022-02-14_custom_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_custom_AccreditedInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IGAP:SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:AccreditedInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-13</xbrli:startDate>
        <xbrli:endDate>2022-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PlacementAgentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IGAP:PlacementAgentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">IGAP:TwoThousandandSeventeenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">IGAP:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">IGAP:TwoThousandandSeventeenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">IGAP:WarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">IGAP:TwoThousandandSeventeenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">IGAP:WarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">IGAP:TwoThousandandSeventeenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">IGAP:WarrantFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwoThousandandTwentyOfferingMember_custom_PlacementAgentMember_custom_WarrantFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">IGAP:TwoThousandandTwentyOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:PlacementAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">IGAP:WarrantFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2007-08-31_custom_IntegrityIsraelsPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">IGAP:IntegrityIsraelsPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2007-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2007-08-012007-08-31_custom_IntegrityIsraelsPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">IGAP:IntegrityIsraelsPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2007-08-01</xbrli:startDate>
        <xbrli:endDate>2007-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-282020-06-30_custom_ErezBenZviMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:ErezBenZviMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-28</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-282020-11-30_custom_ShalomShushanMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:ShalomShushanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-28</xbrli:startDate>
        <xbrli:endDate>2020-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-20_custom_MrPaulVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:MrPaulVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-182021-11-20_custom_MrPaulVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:MrPaulVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-18</xbrli:startDate>
        <xbrli:endDate>2021-11-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-20_custom_MrPaulVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:MrPaulVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-03_custom_MrJamesPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:MrJamesPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-20_custom_MrJamesPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:MrJamesPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-182021-12-20_custom_MrJamesPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:MrJamesPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-18</xbrli:startDate>
        <xbrli:endDate>2021-12-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_MeasurementInputFairValueMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">IGAP:MeasurementInputFairValueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IGAP:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IGAP:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IGAP:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IGAP:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IGAP:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IGAP:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_IsraelTaxAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_AndrewGarrettIncMember_custom_AndrewSycoffMember_custom_PlacementAgentFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IGAP:AndrewGarrettIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:AndrewSycoffMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IGAP:PlacementAgentFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_AndrewGarrettIncMember_custom_AndrewSycoffMember_custom_PlacementAgentFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506983</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IGAP:AndrewGarrettIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:AndrewSycoffMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IGAP:PlacementAgentFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Israel">
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segments">
      <xbrli:measure>IGAP:Segment</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="xdx2ixbrl0235" toRefs="Footnote000308"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0285" toRefs="Footnote000308"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_908_edei--DocumentType_c20210101__20211231_zQIuhajKorTf"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--DocumentAnnualReport_c20210101__20211231_zvTqcfvOPCy8"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended <span style="text-decoration: underline"><span id="xdx_90A_edei--DocumentPeriodEndDate_c20210101__20211231_zCHVKasgpDl5"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_90D_edei--CurrentFiscalYearEndDate_c20210101__20211231_zd9qyWmKZYn9"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_902_edei--DocumentFiscalYearFocus_c20210101__20211231_zJeDwDLTfNea"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric></span></ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_901_edei--DocumentTransitionReport_c20210101__20211231_zEenrbcc7pa4"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from _________________________ to _________________________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number <span style="text-decoration: underline"><span id="xdx_90B_edei--EntityFileNumber_c20210101__20211231_zQhfjZiNK4x9"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityFileNumber">000-54785</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90E_edei--EntityRegistrantName_c20210101__20211231_zn1wVcc3Ix5h"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityRegistrantName">GLUCOTRACK,
INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>(FORMERLY:
INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20210101__20211231_zMEsqvQfZQp4"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20210101__20211231_z0IUsK4vYBH8"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityTaxIdentificationNumber">98-0668934</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityAddressAddressLine1_c20210101__20211231_zIxHsALW2E1a"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine1">8 Ariel Sharon Street</ix:nonNumeric></span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityAddressAddressLine2_c20210101__20211231_z8SV0M7kPuEl"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine2">P.O. Box 6037607</ix:nonNumeric></span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityAddressCityOrTown_c20210101__20211231_zatT6LjF1sxg"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressCityOrTown">Or Yehuda</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressCountry_c20210101__20211231_zaqic2tFLSgk"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Israel</ix:nonNumeric></span></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">L3
    <span id="xdx_907_edei--EntityAddressPostalZipCode_c20210101__20211231_zDQrnNutYbAl"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressPostalZipCode">7760049</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code <span style="text-decoration: underline"><span id="xdx_90D_edei--CityAreaCode_c20210101__20211231_zNqzcJuVFIEk"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:CityAreaCode">972</ix:nonNumeric></span> (8) <span id="xdx_90F_edei--LocalPhoneNumber_c20210101__20211231_z3fDlGDTAvP7"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:LocalPhoneNumber">675-7878</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act: <span style="text-decoration: underline">None</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act: <span style="text-decoration: underline"><span id="xdx_909_edei--Security12bTitle_c20210101__20211231_znMIOJm66Nlg"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
<span style="background-color: white">&#9744; </span> <span id="xdx_90D_edei--EntityWellKnownSeasonedIssuer_c20210101__20211231_zAqokhTkcfik"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> <span style="background-color: white">&#9746;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
<span style="background-color: white">&#9744;</span> <span id="xdx_90F_edei--EntityVoluntaryFilers_c20210101__20211231_zqQqlOlpZlij"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> <span style="background-color: white">&#9746;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntityCurrentReportingStatus_c20210101__20211231_zQfpe8ATRLPg"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>
<span style="background-color: white">&#9746;</span> No <span style="background-color: white">&#9744;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityInteractiveDataCurrent_c20210101__20211231_zzIpUYdFZ7Fc"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>
<span style="background-color: white">&#9746; </span> No <span style="background-color: white">&#9744;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this
Form 10-K or any amendment to this Form 10-K &#9746;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221;
in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--EntityFilerCategory_c20210101__20211231_zoZYyd0NcDei"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    Reporting Company <span id="xdx_90C_edei--EntitySmallBusiness_c20210101__20211231_zrEwJFyhTAuh"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Emerging growth Company <span id="xdx_909_edei--EntityEmergingGrowthCompany_c20210101__20211231_zUJncqforbdj"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; <span id="xdx_901_edei--EntityShellCompany_c20210101__20211231_zCJgi0MRplX4"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--Security12bTitle_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zP8EWxs2lMW8"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" name="dei:Security12bTitle">Common
    Stock</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0ojB0FdFKng"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" name="dei:TradingSymbol">GCTK</ix:nonNumeric></span></span></p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--SecurityExchangeName_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7PooN2NWmr3"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the voting stock held by non-affiliates is approximately $<span id="xdx_907_edei--EntityPublicFloat_iI_c20210630_zP5BsNMcVAm1"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,694,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">based on the closing price of $5.33
per share of the registrant&#8217;s common stock, as reported on the OTCQB on June 30, 2021, the last business day of the registrant&#8217;s
most recently completed second fiscal quarter of 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 30, 2022, <span id="xdx_90D_edei--EntityCommonStockSharesOutstanding_iI_c20220330_zUOHRYTVC4s3"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-03-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,455,109</ix:nonFraction></span> shares of the registrant&#8217;s common stock, par value $0.001 per share, were outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOCUMENTS
INCORPORATED BY REFERENCE:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--DocumentsIncorporatedByReferenceTextBlock_c20210101__20211231_zyT4pDqPl713" title="Documents Incorporated by Reference"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock">None,
except as noted for Part III information in the Company&#8217;s Schedule 14A to be filed on or before April 30, 2022.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ha_001">GENERAL</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 0.5in; text-align: center">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ha_002">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ha_003">PART I</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ha_004">Item 1. Business.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ha_005">Item 1A. Risk Factors.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">22</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ha_006">Item 1B. Unresolved Staff Comments.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">37</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ha_007">Item 2. Properties.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">37</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ha_008">Item 3. Legal Proceedings.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">37</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ha_009">Item 4. Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">37</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_001">Part II</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_002">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_003">Item 6. Selected Financial Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_004">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_005">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">41</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_006">Item 8. Financial Statements and Supplementary Data.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">41</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_007">Item 9. Change in and Disagreements With Accountants on Accounting and Financial Disclosure.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">41</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_008">Item 9A. Controls and Procedures.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">42</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_009">Item 9B. Other Information.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">42</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_010">PART III</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">42</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_011">Item 10. Directors, Executive Officers and Corporate Governance.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">42</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_012">Item 11. Executive Compensation.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">43</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_013">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">43</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_014">Item 13. Certain Relationships and Related Transactions, and Director Independence.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">43</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_015">Item 14. Principal Accounting Fees and Services.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">43</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_016">PART IV</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">43</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_017">Item 15. Exhibits, Financial Statement Schedules.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">43</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_018">SIGNATURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center">46</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ha_001"></span>GENERAL</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires, the terms &#8220;we&#8221;, &#8220;our&#8221;, &#8220;ours&#8221; &#8220;us&#8221;, &#8220;GlucoTrack&#8221;
and &#8220;Integrity&#8221;, refer to A.D. Integrity Applications, Ltd., an Israeli corporation (&#8220;Integrity Israel&#8221;), for
all periods prior to July 15, 2010 and to Integrity Israel and GlucoTrack, Inc. (Formerly: Integrity Applications, Inc.),
a Delaware corporation, on a combined basis, for all periods from and including July 15, 2010 to March 31, 2022, and thereafter
to Integrity Israel and GlucoTrack, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ha_002"></span>CAUTIONARY
NOTE REGARDING FORWARD LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K includes forward-looking statements. These forward-looking statements include statements about our expectations,
beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies or
prospects. All statements other than statements of historical fact included in this Annual Report on Form 10-K, including statements
regarding our future activities, events or developments, including such things as future revenues, product development, clinical trials,
regulatory approval, market acceptance, responses from competitors, capital expenditures (including the amount and nature thereof), business
strategy and measures to implement strategy, competitive strengths, goals, expansion and growth of our business and operations, plans,
references to future success, projected performance and trends, and other such matters, are forward-looking statements. <span style="background-color: white">Risks
that could affect our business include the duration and scope of the COVID-19 pandemic and the impact on the demand for our products;
actions by governments, businesses and individuals taken in response to the pandemic; the length of time of the COVID-19 pandemic and
the possibility of its reoccurrence; the timing required to develop effective treatments and a vaccine in the event of future outbreaks;
the eventual impact of the pandemic and actions taken in response to the pandemic on global and regional economies; and the pace of recovery
when the COVID-19 pandemic subsides.</span> The words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221;
&#8220;estimate,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should&#8221;
and other similar words and phrases or the negative of such terms, are intended to identify forward-looking statements. The forward-looking
statements made in this Annual Report on Form 10-K are based on certain historical trends, current conditions and expected future developments,
as well as other factors we believe are appropriate in the circumstances. These statements relate only to events as of the date on which
the statements are made and we undertake no obligation to update publicly any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law. All of the forward-looking statements made in this Annual Report
on Form 10-K are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by us will
be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or
operations. Whether actual results will conform to our expectations and predictions is subject to a number of risks and uncertainties
that may cause actual results to differ materially. Risks and uncertainties, the occurrence of which could adversely affect our business,
include the risks identified in this Annual Report on Form 10-K under the caption &#8220;Risk Factors,&#8221; beginning on page 30. We
undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise
after the date of this report unless required by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ha_003"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ha_004"></span>Item
1. Business.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
in Delaware in May 2010, we are a medical device company focused on the design, development and commercialization of non-invasive glucose
monitoring devices for use by people with diabetes and pre-diabetics. On July 15, 2010, we completed a reverse triangular merger with
Integrity Israel and Integrity Acquisition Corp. Ltd., an Israeli corporation and a wholly owned subsidiary of ours, pursuant to which
Integrity Acquisition Corp. Ltd. merged with and into Integrity Israel and all of the stockholders and option holders of Integrity Israel
became entitled to receive shares and options in us in exchange for their shares and options in Integrity Israel (the &#8220;Reorganization&#8221;).
Following the Reorganization, the former equity holders of Integrity Israel were entitled to the same proportional ownership in us as
they had in Integrity Israel prior to the Reorganization. As a result of the Reorganization, Integrity Israel became a wholly owned subsidiary
of ours. We operate primarily through Integrity Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrity
Israel was founded in 2001 with a mission to develop, produce and market non-invasive glucose monitors for home use by diabetics. We
have developed a non-invasive glucose monitor, the GlucoTrack&#174; glucose monitoring device, which is designed to help people with
diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, cost and difficulty of conventional
(invasive) spot finger stick devices. The first generation GlucoTrack (&#8220;GlucoTrack 1.0&#8221;) utilizes a combination of
ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that
is clipped onto one&#8217;s earlobe and connected to a small, handheld control and display unit, all without drawing blood or
interstitial fluid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently developing our own companion applications and a cloud-based solution, as well as conducting ongoing discussions with potential
partners, to offer an effective platform to provide real time, data driven personalized tools to effectively help a user manage their
diabetes. In addition to being a critical and effective management tool for the end user, we believe that third parties such as insurers,
pharmaceutical companies and advertisers would be willing to pay for the de-identified data that we will obtain through our platform,
and that this is an opportunity for us to develop an additional revenue source.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a home-based short calibration process of approximately thirty minutes consisting of three typical blood glucose reference measurements,
GlucoTrack 1.0 can be used to non-invasively measure glucose levels for six months before a user is required to repeat the calibration
process. The entire calibration process can be performed by the user themselves without the need for a trained calibrator. We believe
the simple-to-perform calibration, as well as the infrequency of the required re-calibration are significant advantages over our competition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GlucoTrack
1.0  received the initial Conformit&#233; Europ&#233;ene (CE) Mark (indicating the conformity of the Company&#8217;s product with
health, safety, and environmental protection standards for products sold within the European Economic Area) approval for the GlucoTrack
1.0 from DEKRA Certification B.V., our European notified body (the &#8220;Notified Body&#8221;), which is an entity that has been accredited
by a member state of the European Union (&#8220;EU&#8221;) to assess whether a product to be placed on the market meets certain preordained
standards. The intended use for GlucoTrack 1.0 received by the Notified Body is for both those subjects with Type 2 diabetes as well
as those suffering from pre-diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receipt
of the CE Mark allows us to market and sell GlucoTrack 1.0 glucose monitoring device in EU member countries that have adopted the European
Medical Device Directive (the &#8220;MDD&#8221;) without being subject to additional national regulations with regard to demonstration
of performance and safety. However, although the MDD is applicable throughout the EU, in practice it does not ensure uniform regulation
throughout the EU. Accordingly, member countries may apply and enforce the MDD&#8217;s terms differently, and certain EU member countries
may request or require performance and/or safety data in addition to the MDD&#8217;s requirements from time to time, on a case-by-case
basis. The CE Mark also permits the sale in countries that have an MDD Mutual Recognition Agreement with the EU. This would include some
countries in South East Asia as well as in Latin America, opening new potential markets for Integrity on a global basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safety
and quality are non-negotiables in the medical devices industry. Regulatory requirements are increasingly stringent throughout every
step of a product&#8217;s life cycle, including service and delivery. More and more, organizations in the industry are expected to demonstrate
their quality management processes and ensure best practice in everything they do. ISO 13485 is an internationally agreed standard that
sets out the requirements for a quality management system specific to the medical devices industry. On March 1, 2019, we received an
extension of our ISO 13485:2016 certificate and Annex II certification from the EU. The ISO 13485:2016 certification signifies that we
have met the standards required for company-wide implementation of device quality management system(s). The scope of the certification
is design, development, manufacture and service of non-invasive glucose monitoring systems for home use. Annex II also addresses quality
control systems. The certification allows us to self-certify certain modifications and changes and simplifies some of the reporting to
and review by the relevant Notified Body. This can shorten the CE-mark review process of future GlucoTrack enhancements or revisions,
including software updates and other improvements of the device that do not affect the intended use and/or safety performance. The ISO
13485:2016 and Annex II certifications enable us to potentially reduce the time to market for product sales on new, enhanced or modified
GlucoTrack devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials conducted in Germany by Pfutzner Science &amp; Health Institute, GmbH, headed by Prof. Dr. Andreas Pfutzner, on subjects with
Type 2 diabetes and pre-diabetes, as well as at Soroka University Medical Center, Beer-Sheva, Israel, demonstrated favorable results.
Results from the trials show 99.3% of the study data points were within the clinically accepted A and B zones of the Clarke Error Grid
(which is a tool used to quantify the clinical accuracy of blood glucose estimates generated by meters as compared to a reference value),
and 17.0% Mean Absolute Relative Difference. In addition, the German trial concluded that the data confirms the performance of the GlucoTrack
among its intended users, including pre-diabetic patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Company has demonstrated (1) GlucoTrack 1.0 demonstrates consistent glucose measurement repeatability between different
GlucoTrack devices and on each earlobe of the same subject; (2) the repeatability of different GlucoTrack 1.0 devices is similar at all
tested glucose ranges and post-prandial time periods; and (3) the GlucoTrack 1.0 mean precision absolute relative difference (PARD) of
8.2% is equivalent or better than the independently reported PARD values of commercially available continuous glucose monitoring systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company conducted an additional study that evaluated GlucoTrack accuracy in 172 adults with type 2 diabetes who were prescribed one or
more medications for major medical conditions associated with diabetes and presented key findings of this study at the European Association
for the Study of Diabetes Congress (EASD) in Lisbon, Portugal. The experiment stratified participants into five medication groups, focusing
on anti-cholesterolemia, anti-hypertension, anti-thrombotic, and anti-diabetic (prolonged duration and short and mixed duration) medications.
The study demonstrated that the use of these common concomitant medications in diabetes had no effect on the performance of GlucoTrack
1.0.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had begun the implementation of a proof-of-concept pilot program for GlucoTrack 1.0 in the Netherlands, a country chosen based
on the relatively smaller size of the marketplace to allow us to rapidly assess our performance and make adjustments as necessary. We
have been working closely with our exclusive distributor in the Netherlands, Medireva B.V., and have accomplished product and disease
area training across the organization and segmentation of the local target audiences including key opinion leaders, treating physicians,
and diabetes nurses. The most important aspect of our pilot program in the Netherlands are the discussions held with many health insurance
companies. Approval of full or partial reimbursement by the health insurance companies will be a key factor in enabling us to achieve
significant sales volume. The Company has made progress with several of these companies on initial programs with GlucoTrack 1.0 as an
important step towards reimbursement approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Talent
development, recruiting and organizational health have been a critical focus of the Company. A number of high-quality individuals have
joined the Company, each of whom bring extensive experience in their respective fields. We have bolstered our Senior Management with
the recruitment of Erez Ben-Zvi, a highly experienced MedTech development professional who joined us last year as Vice President of Product,
and later on took on the additional role of General Manager. Paul, V. Goode PhD, who has a decorated career developing innovative medical
technologies, including at DexCom and MiniMed and was a member of the Board of Directors of the Company, was appointed as President and
Chief Operating Officer. In addition, James P. Thrower PhD, a seasoned executive formerly of Sterling Medical Devices, Mindray DS
USA and DexCom, Inc. joined as Vice President of Engineering. Luis J. Malav&#233;, formerly of Insulet Corp, Medtronic and MiniMed
has joined as an independent board member. Several highly talented and accomplished executives joined the Company as senior advisors
to the Board. These include Yair Briman, the former CEO of Philips Healthcare Informatics, Daniel McCaffrey MBA MA, a world-renowned
behavioral scientist and digital health expert formerly at Samsung Health and Dexcom, Inc., Dr. Alexander Raykhman PhD,
a measurement and artificial intelligence expert and Dr. David C. Klonoff, world renowned endocrinologist and diabetes technology thought
leader. We intend to continue to invest in our talent and to expand and strengthen all areas within the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently,
the Company performed a top-down analysis of the GlucoTrack 1.0 model to identify areas of potential enhancement, as it relates to the
platform, integrations, sensor technologies, accuracy as well as manufacturing costs. The result of this comprehensive review is an accelerated
development plan for GlucoTrack 2.0. GlucoTrack 2.0 will be a completely wireless and rechargeable earclip to be paired with a smartphone,
with more capabilities and features, increased accuracy, significantly greater margins for the Company and lower cost to the end-user
as compared to GlucoTrack 1.0.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously reported, the Company  made significant progress towards receiving insurance reimbursement in the Netherlands. With the
new accelerated development plan for GlucoTrack 2.0, and all of the expected advantages over GlucoTrack 1.0, it became clear to the Company
that introducing GlucoTrack 2.0 rather than the GlucoTrack 1.0 would serve the diabetes market and the Company more effectively. We are
currently working with our European partners on the roadmap for distribution of GlucoTrack 2.0 when completed and ready to market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the European markets, the Company is now focused on the U.S. market as well, including building out its U.S. go-to-market
strategy and planning the required FDA clinical trials and field testing to support its entrance into the market. The Company is currently
in the process of identifying clinical sites in the U.S., interviewing Contract Research Organizations (CRO&#8217;s), and forming its
Scientific and Medical Advisory Boards. We intend to build out a team to support the U.S. activities while continuing our technology
development in our R&amp;D facility located in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2021, Luis J. Malav&#233; has been appointed to the Company&#8217;s Board of Directors. Mr. Malav&#233; brings more than
30 years of leadership experience in the MedTech industry, primarily in diabetes management, spanning all company stages, from private
startups to large-cap publicly listed companies. He has extensive expertise in product development, operations, marketing, strategic
partnerships, and US FDA regulatory strategy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
October 2017, Mr. Malav&#233; has served as President of EOFLOW CO. Ltd., a company listed on the Korea Stock Exchange that has developed
a wearable disposable insulin pump. From October 2014 to June 2016, he was COO of Mikroscan Technologies. Prior to that, Mr. Malav&#233;
was the President and CEO of Palyon Medical, maker of an implantable drug-delivery system that spun out from German medical-technology
giant Fresenius SE. Prior to Palyon, he spent nearly a decade at insulin pump maker Insulet Corp., including as its Senior Vice President
of Research, Development and Engineering, and as Chief Operating Officer. He also held various senior positions at Medtronic and MiniMed,
overseeing product development of various diabetes management devices. Mr. Malav&#233; earned his Bachelor&#8217;s degree in Mathematics
and Computer Science from the University of Minnesota, a Master&#8217;s degree in Software Engineering from the University of St. Thomas,
and an MBA from the University of Maryland.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 19, 2021, Paul V. Goode was appointed as President and Chief Operating Officer of the Company, effective November 1, 2021 (&#8220;Effective
Date&#8221;). He has served as a member of Integrity&#8217;s Board of Directors since December 17, 2020. Concurrent with his new appointment,
Mr. Goode will be stepping down from the Board. In this role, Goode will lead the company&#8217;s operations, overseeing strategy, design,
manufacturing, business and product development and begin to build the U.S. infrastructure in preparation for the U.S. clinical trials
of GlucoTrack. He will devote such time as necessary to perform his duties but shall be able to pursue other professional opportunities
at the same time. His base salary shall be $175,000 per year, and he shall be entitled to a cash bonus of up to 20% of his annual base
salary as determined by the Company&#8217;s Compensation Committee and shall be granted options to purchase up to One and half Percent
(1.5%) of the fully diluted common stock, par value $0.001 per share, of the Company (&#8220;Common Stock&#8221;) as of the Effective
Date, with a per share exercise price equal to the greater of (A) $5.20 per share or (B) the closing price of a share of Common Stock
on the Effective Date, as reported by Bloomberg L.P., which shall vest in equal monthly installments over a three year period following
the Effective Date. The bonus and equity incentives shall be subject to clawback rights if there is a misstatement of financials which
changes any metrics upon which a bonus or incentives are based and the clawback will be pro rata based upon the changes in the financials
with respect to the effect on any underlying metrics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with our</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> application to list our shares of common stock
on Nasdaq Capital Market (&#8220;NASDAQ&#8221;), on August 13, 2021, we effected a reverse split of our common stock in a ratio of
1 for 13 (the &#8220;Reverse Share Split&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2021, our shelf registration statement on Form S-3 (file no. 333-259664) was declared effective by the SEC. The shelf registration
statement permits us to register up to $100,000,000 of certain equity and debt securities of the Company via prospectus supplement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 8, 2021, we announced that our shares of common stock were approved for listing on the NASDAQ. Trading on NASDAQ commenced
on December 10, 2021 under its existing trading symbol, IGAP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 14, 2022, we changed our name to GlucoTrack, Inc. with Nasdaq and our trading symbol to GCTK.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">On
March 22, 2022, Shalom Shushan, Chief Technology Officer, provided notice of his resignation from the Company, effective May 22, 2022,
for personal reasons. In connection with the Company&#8217;s previously announced plans to migrate certain aspects of product development
to the United States, James P. Thrower PhD, Vice President of Engineering, will be assuming Mr. Shushan&#8217;s responsibilities.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
may be at risk as a result of the current COVID-19 pandemic. Risks that could affect our business include the duration and scope of the
COVID-19 pandemic and the impact on the demand for our products; actions by governments, businesses and individuals taken in response
to the pandemic; the length of time of the COVID-19 pandemic and the possibility of its reoccurrence; the timing required to develop
effective treatments and a vaccine in the event of future outbreaks; the eventual impact of the pandemic and actions taken in response
to the pandemic on global and regional economies; and the pace of recovery when the COVID-19 pandemic subsides.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
its inception date, the Company did not conduct any material operations other than those carried out by Integrity Israel. The development
and commercialization of the Product is expected to require substantial expenditures. The Group has not yet generated significant revenues
from operations, and therefore they are dependent upon external sources for financing their operations. As of December 31, 2021, the
Group has incurred accumulated deficit of $97,466 thousand. During the year ended December 31, 2021 the Company incurred losses from
ongoing operation and has negative cash flow from operating activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2020, the Company closed on a $15&#160;million private placement of its common stock, for which it received net cash in
excess of $13,009&#160;thousand. In addition, on September 27, 2021, the Company&#8217;s shelf registration statement on Form S-3
was declared effective by the Securities and Exchange Commission (SEC) which permits the Company to register up to $100,000 thousand
of certain equity and debt securities of the Company via prospectus supplement. To date, funds have not been raised through this
shelf registration statement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
believes the cash balance amounted to $6,062 thousand as of December 31, 2021, is sufficient to meet its capital needs of the Group for
at least 12 months from the issuance date of these consolidated financial statements. Thus, it is expected that the Company will be able
to operate as a going concern for at least 12 months from the date hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Opportunity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Diabetes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diabetes
is a chronic, life-threatening disease for which there is no known cure. Diabetes is caused by the body&#8217;s inability to produce
or effectively utilize the hormone insulin. This inability prevents the body from adequately regulating blood glucose levels. Glucose,
the primary source of energy for cells, must be maintained at certain concentrations in the blood in order to permit optimal cell function
and health. Normally, the pancreas provides control of blood glucose levels by secreting the hormone insulin to decrease blood glucose
levels when concentrations are too high. In people with diabetes, blood glucose levels fluctuate between very high levels, a condition
known as hyperglycemia, and very low levels, a condition known as hypoglycemia. Hyperglycemia can lead to serious long-term complications,
such as blindness, kidney disease, nervous system disease, amputations, stroke and cardiovascular disease. Hypoglycemia can lead to confusion,
loss of consciousness or death.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diabetes
is typically classified into two major groups: Type 1 and Type 2. Type 1 diabetes is characterized by the body&#8217;s inability to produce
insulin, resulting from destruction of the insulin producing cells of the pancreas. Individuals with Type 1 diabetes must rely on frequent
insulin injections in order to regulate and maintain blood glucose levels. Type 1 diabetes is frequently diagnosed during childhood or
adolescence, although disease onset can occur at any age. Type 2 diabetes, the more common form of diabetes, is characterized by the
body&#8217;s inability to either properly utilize insulin or produce enough insulin. Type 2 diabetes is associated with older age, obesity,
family history of diabetes, history of gestational diabetes, impaired glucose metabolism, physical inactivity and race or ethnicity.
Depending on the severity of Type 2 diabetes, individuals may require diet and nutrition management, exercise, oral medications or insulin
injections to regulate blood glucose levels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Diabetes Atlas (Ninth Edition) published by the International Diabetes Federation in 2019, approximately 463 million adults worldwide,
between the ages of 20 and 79, or over 9% of the world&#8217;s adult population, were estimated to suffer from diabetes in 2019 (not
including those persons who suffer from impaired glucose tolerance or gestational diabetes, diabetic conditions first arising during
pregnancy). The International Diabetes Federation estimates that this number will grow to approximately 700 million adults worldwide
by 2045.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.65pt; text-align: justify; text-indent: 36.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Glucose
Monitoring</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Blood
glucose levels can be affected by many factors, including the carbohydrate and fat content of meals, exercise, stress, illness or impending
illness, hormonal releases, variability in insulin absorption and changes in the effects of insulin in the body. Given the many factors
that affect blood glucose levels, maintaining glucose within a normal range can be difficult. Diabetics generally manage their blood
glucose levels by administering insulin or ingesting carbohydrates throughout the day to maintain blood glucose within normal ranges.
Normal ranges in diabetics vary from person to person. In order to maintain blood glucose levels within normal ranges, diabetics must
first measure their blood glucose levels so that they can make the proper therapeutic adjustments. As adjustments are made, additional
blood glucose measurements may be necessary to gauge the individual&#8217;s response to the adjustments. More frequent testing of blood
glucose levels provides patients with information that can be used to better understand and manage their diabetes. Testing of blood glucose
levels is usually done before meals, after meals and before going to sleep. Diabetics who take insulin usually need to test more often
than those who do not take insulin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
data supports the recommendation that frequent monitoring of blood glucose levels is an important component of effective diabetes management.
The Diabetes Control and Complications Trial<sup>1</sup>, consisting of patients with Type 2 diabetes, and the 1993 UK Prospective Diabetes
Study<sup>2</sup>, consisting of patients with Type 2 diabetes, demonstrated that patients who intensely managed blood glucose levels
delayed the onset and slowed the progression of diabetes-related complications. In the Diabetes Control and Complications Trial, a major
component of intensive management was monitoring blood glucose levels at least four times per day using conventional spot finger stick
blood glucose meters. The Diabetes Control and Complications Trial demonstrated that intensive management reduced the risk of complications
by 76% for eye disease, 60% for nerve disease and 50% for kidney disease. Furthermore, a recent meta-analysis of over 25 prospective
studies concluded that chronic hyperglycemia in type 2 diabetes is associated with increased risks of all-cause mortality and cardiovascular
outcomes independently from other conventional risk factors.<sup>3</sup> However, despite the evidence that intensive glucose management
reduces the long-term complications associated with diabetes, Karter et al. reported in the 2000 issue of Diabetes Care that 67% of people
with type 2 diabetes fail to routinely monitor their glucose levels.<sup>4</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.65pt; text-align: justify; text-indent: 33.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spot
finger stick devices are the most prevalent devices for blood glucose monitoring. These devices require users to insert a strip into
a glucose meter, take a blood sample with a finger stick and place a drop of blood on a test strip that yields a single point in time
blood glucose measurement. Despite continued developments in the field of blood glucose monitors, the routine measurement of glucose
levels remains invasive, painful, inconvenient, difficult and costly. This has resulted in a sub-optimal and irregular measurement regimen
for many diabetics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1
</sup>Group, U. P. D. S. (UKPDS); others Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment
and risk of complications in patients with type 2 diabetes (UKPDS 33). <i>The Lancet</i> <b>1998</b>, <i>352</i>, 837&#8211;853.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>2
</sup>Diabetes Control and Complications Research Group; others The effect of intensive treatment of diabetes on the development and
progression of long-term complications in insulin-dependent diabetes mellitus. <i>N Engl J Med</i> <b>1993</b>, <i>329</i>, 977&#8211;986.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>3
</sup>hang, Y.; Hu, G.; Yuan, Z.; Chen, L. Glycosylated Hemoglobin in Relationship to Cardiovascular Outcomes and Death in Patients with
Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>PLOS ONE</i> <b>2012</b>, <i>7</i>, e42551, doi:10.1371/journal.pone.0042551.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>4
</sup>Karter, A. J.; Ferrara, A.; Darbinian, J. A.; Ackerson, L. M.; Selby, J. V. Self-monitoring of blood glucose: language and financial
barriers in a managed care population with diabetes. <i>Diabetes Care</i> <b>2000</b>, <i>23</i>, 477&#8211;483.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has approved continuous glucose monitoring system (&#8220;CGMS&#8221;) devices for blood glucose monitoring, when prescribed by a
doctor. CGMS devices use sensors inserted under the skin to check glucose levels in interstitial fluid. The sensor stays in place for
up to fourteen days and then must be replaced. A transmitter sends information about glucose levels via radio waves from the sensor to
a pager-like wireless monitor. According to the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes
of Health, CGMS device users must check blood samples with a conventional glucose meter to calibrate the CGMS devices, and because currently
approved CGMS devices are not as accurate as standard blood glucose meters, users should confirm glucose levels with a conventional glucose
meter when making treatment decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The FDA has previously approved a single non-invasive product for glucose trend analysis, the
GlucoWatch&#174;, so long as the device was used with conventional finger stick glucose monitoring devices. However, the device is no
longer available commercially. We are not aware of any other devices that have been approved for use in either the United Stated or the
EU for spot or continuous non-invasive blood glucose measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that a significant market opportunity exists for a reliable, inexpensive, non-invasive blood glucose measurement device and that
such a device could greatly increase compliance with blood glucose measurement recommendations and help many diabetics better manage
their disease, providing significant benefits to both patients and payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Product</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
first generation non-invasive blood glucose monitor, the GlucoTrack 1.0, utilizes a patented combination of ultrasound, electromagnetic
and thermal technologies to obtain blood glucose measurements in less than one minute via a small sensor that is clipped onto one&#8217;s
earlobe and connected to a handheld control and display unit. GlucoTrack 2.0, currently under development, utilizes substantially identical
underlying sensor technology, and is expected to be a completely wireless sensor to be clipped on the earlobe. GlucoTrack eliminates
the handheld unit and will transmit results directly to a user&#8217;s smartphone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that GlucoTrack addresses the unmet need for more frequent monitoring of blood glucose among people with diabetes by overcoming
two of the most significant challenges facing the market:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pain,
    as GlucoTrack is a truly non-invasive device; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost,
    as we anticipate that the total cost of purchasing a device and purchasing replacement ear clips every six months (anticipated to
    be the only recurring cost) over the useful life of the device will be significantly lower than the cost of purchasing single use
    glucose sticks over that same period.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the overall costs associated with owning and using a GlucoTrack&#174; device are expected to be substantially lower than
the cost of purchasing and using single use invasive devices over an extended period of time. We intend to seek reimbursement approval
for GlucoTrack&#174; from third-party payors, including government payors (such as the Medicare and Medicaid programs in the United States,
in the event GlucoTrack&#174; is approved for commercial sale in the United States), managed care organizations and other third-party
payors. There can be no assurance that such third party-payors will provide reimbursement coverage for GlucoTrack&#174; or, if so, whether
such reimbursement coverage will be adequate. See &#8220;Risk Factors - If GlucoTrack&#174; or our future product candidates, if any,
fail to achieve market acceptance or reimbursement coverage from managed care organizations or third-party payors, we may not be able
to generate significant revenue or achieve or sustain profitability&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Instead
of directly measuring the glucose level of a user&#8217;s blood, as conventional spot finger stick devices do, GlucoTrack&#174; uses a
small, non-invasive sensor that is clipped onto a user&#8217;s earlobe to obtain certain body measurements using three technologies.
Within one minute, GlucoTrack&#174; will produce a blood glucose measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the GlucoTrack&#174; non-invasive measurement does not directly measure glucose levels in the blood, but rather measures a series of physiological
characteristics that correlate with glucose levels, each patient must be calibrated by using a reference to a measurement obtained from
an invasive device. Calibration consists of comparing an individual patient&#8217;s physiological measurements obtained using GlucoTrack&#174;
to measurements obtained from an invasive device under different circumstances over a defined 30-minute period (three measurements that
require approximately 10 minutes each).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three different technologies used by GlucoTrack&#174;, ultrasound, electromagnetic and thermal, simultaneously measure three independent
criteria. These three measurements (criteria) are combined together by a unique (online) algorithm to produce an acceptable measurement
of a user&#8217;s blood glucose level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
technologies operate as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Ultrasound</i>:
    GlucoTrack&#174; uses ultrasound technology to measure the change of speed of sound through the earlobe, which is impacted by the
    glucose concentration in the capillary blood vessels.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Electromagnetic</i>:
    GlucoTrack&#8217;s electromagnetic technology uses a measurement of conductivity to measure the change in tissue impedance, which
    is a function of glucose concentration. GlucoTrack&#8217;s electromagnetic technology analyzes criteria similar to those analyzed
    by conventional invasive devices, such as spot finger stick devices, but does so in a non-invasive manner.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Thermal</i>:
    GlucoTrack&#8217;s thermal technology uses a measurement of heat capacity characteristics of the tissue, which are influenced by
    glucose concentration.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-invasive
devices generally require frequent recalibration. The main reasons for calibration are that tissue parameters generally fluctuate in
the area of the measurement and are sensitive to the location of the sensor and the impact of potential disturbances. Disturbances are
less frequent in the earlobes, where GlucoTrack&#174; takes its measurements. Utilizing three channels simultaneously reduces the noise
contribution in the measurement. In addition, the personal ear-clip contains sensors to help users attach the device to the proper part
of the ear lobe. The Notified Body for our CE Mark approval has determined that the initial calibration of the GlucoTrack 1.0 device
is valid for a period of six months which we believe is a significant competitive advantage, while to our knowledge, competing products
require recalibration significantly much more frequently. Therefore, we expect GlucoTrack&#174; will require only an initial calibration
upon use of a new personal ear-clip (to be replaced every six months) and will not require further recalibration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.65pt; text-align: justify; text-indent: 33.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GlucoTrack&#174;
does not use any optical method (either Infra-Red (IR) or Near Infra-Red (NIR) technology), which we understand are being used by other
developers of non-invasive blood glucose measurement devices. We believe that optical technologies are less reliable than the GlucoTrack&#8217;s
combination of ultrasound, electromagnetic and thermal technologies due to inherent physiological limitations with optical technology.
More specifically, optical technology is based on dispersion of a beam that is analyzed by spectrometric methods. As such devices are
non-invasive, the beam passes through other components in the fingertip, such as skin, bone, muscle and fat tissue, which interfere with
the measurements. Generally, most of these interferences have been overcome, but not the epidermis, primarily due to roughness, pigmentation
and perspiration, which act like lenses in optical wavelengths.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlike
conventional spot finger stick devices, which require single-use glucose test strips, GlucoTrack&#174; requires no short- term disposables.
We believe that the GlucoTrack&#8217;s personal ear-clip will need to be replaced only once every six months, although regulatory authorities
may require that replacement occur more frequently. Since there is no additional cost or pain involved with each blood glucose measurement
using GlucoTrack&#174;, we believe that users of our device would be encouraged to take multiple blood glucose measurements per day, significantly
increasing compliance with blood glucose measurement recommendations and helping diabetics better manage their disease. More frequent
testing of blood glucose levels may provide a patient with information that can be used to determine optimal timing and dosage for corrective
treatments such as insulin, and can also direct a patient to seek a clinical analysis or detailed testing and diagnosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have commercial manufacturing facilities and do not intend to build commercial manufacturing facilities of our own in the foreseeable
future. Our suppliers and their manufacturing facilities must comply with applicable regulations in the jurisdictions in which GlucoTrack&#174;
is to be marketed (including ISO 13485 in the EU), current quality system regulations, which include current good manufacturing practices,
and to the extent laboratory analysis is involved, current good laboratory practices. There can be no assurance that we will be able
to enter into agreements with qualified manufacturers on terms acceptable to us, or at all, or that, once contracted, such manufacturers
will perform as expected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the manufacturing of GlucoTrack&#174; may be impacted by the Recast Directive on the Restriction of Hazardous Substances in Electrical
and Electronic Equipment, 2011/65/EU (&#8220;RoHS 2&#8221;). RoHS 2 is a new EU directive that came into force on July 22, 2014. Like
the MDD, RoHS 2, a recast of Directive 2002/95/EC that will cover electrical and electronic medical devices, is relevant in order to
obtain CE Marking for certain products. RoHS 2 compliance requires medical device manufacturers to: draw up required technical documentation;
conduct an internal control procedure in accordance with Module A of Annex II to Decision No. 768/2008/EC; prepare a Declaration of Conformity;
and affix CE Marking to a finished product. Although these requirements are similar to those of the MDD, RoHS 2 does not require a Notified
Body assessment of compliance. However, if they are not compliant with RoHS 2, medical device manufacturers face the risk of being barred
from selling medical devices in the EU after July 22, 2014.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
&amp; Marketing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a limited number of dedicated sales and marketing personnel, as we intend to collaborate with third parties with established sales
and marketing operations in the medical device industry (such as the distributors described below) to market and sell GlucoTrack&#174;
to point of sale end users and/or local distributors. However, there can be no assurance that we will be able to enter into additional
distribution agreements on terms acceptable to us or at all or that, once contracted, our distributors will perform as expected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently in the process of developing our wireless 2.0 model and upon readiness, we intend to conduct clinical trials in the U.S.
for eventual domestic commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
&amp; Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
focus significant time and resources on research and development in connection with our efforts to continue to develop, improve and commercialize
GlucoTrack&#174;, as well as in connection with our development of other GlucoTrack&#174; models. Our continuing research and development
activities are primarily focused on software and algorithm improvements intended to improve the accuracy of the device, clinical trials
to test the performance of the GlucoTrack&#174; device when used by children and teenagers between the ages of six and 18, preparation
for future FDA trials, testing new characteristics of the device, development of a new device in the GlucoTrack&#174; family and seeking
to streamline and continue to simplify the calibration process. See &#8220;Item 7 &#8211; Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operation &#8211; Results of Operation&#8221; below for a discussion of the research and development
expenses for the fiscal years ended 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.65pt; text-align: justify; text-indent: 33.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategic priorities include the research and development of product enhancements that will improve the ease and usability of GlucoTrack
for patients with a future generation of products. We are focusing our research and development activities around 2 main strategic areas:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.65pt; text-align: justify; text-indent: 33.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GlucoTrack&#174;
    2.0</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 57.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
objective of this project is to transform the existing device into a simple, easy to use wireless ear-clip which would measure glucose
and communicate the results seamlessly to any other platform through a wireless connection or a Bluetooth connection to a smart device
such as a smartphone, tablet or computer, eliminating the current handheld display. The result would be a user-friendly, inconspicuous
measuring device for the management of diabetes and pre-diabetes. We expect this new device to have much greater patient desire to purchase
and user acceptance. We also expect this new device will have a significantly lower cost to manufacture than our current device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 57.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Digital
    Health Applications</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 57.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently developing smart device applications (&#8220;Apps&#8221;) to facilitate the interaction of users with Glucotrack&#174; and
the glucose data collected. The Apps will be compatible with both IOS and Android operating systems. We intend to develop Apps that support
the management of Type 2 diabetes and pre-diabetic patients by providing immediate feedback and insights that can be derived from glucose
measurements. Enhanced capabilities within the Apps may include goal setting, alarms and reminders, and diabetes management tips and
tools. It will also be designed to provide analyses of trends over multiple time periods. The goal is to provide relevant information
to guide patients in their journey to change behaviors and improve the management of their condition. The Apps are expected to have a
user-directed capability to connect with third party healthcare providers (physicians, dieticians, and nurse practitioners) in order
to receive professional guidance based on the accumulated information leading to improved management of the condition and better disease
outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulatory
Considerations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
is heavily regulated by federal, state and local governments in the United States, and by similar authorities in other countries. Any
product that we develop must receive all relevant regulatory approvals or clearances, as the case may be, before it may be marketed in
a particular country. The laws and regulations affecting healthcare change regularly, thereby increasing the uncertainty and risk associated
with any healthcare- related venture. The United States government has in the past considered, is currently considering and may in the
future consider healthcare policies and proposals intended to curb rising healthcare costs, including those that could significantly
and adversely affect reimbursement for healthcare products such as GlucoTrack&#174; devices. These policies have included, and may in
the future include: basing reimbursement policies and rates on clinical outcomes, the comparative effectiveness and costs of different
treatment technologies and modalities; imposing price controls and taxes on medical device providers; and other measures. Future significant
changes in the healthcare systems in any jurisdiction in which GlucoTrack&#174; or our future products, if any, may be cleared for sale
could also have a negative impact on the demand for the GlucoTrack&#174; or our future products, if any. These include changes that may
reduce reimbursement or payment rates for such products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the federal government regulates healthcare through various agencies, including but not limited to the following:
(i) the FDA, which administers the Food, Drug, and Cosmetic Act, as well as other relevant laws; (ii) the Centers for Medicare &amp;
Medicaid Services (&#8220;CMS&#8221;), which administers the Medicare and Medicaid programs; (iii) the Office of Inspector General, which
enforces various laws aimed at curtailing fraudulent or abusive practices including, by way of example, the Anti-Kickback Law, the Anti-Physician
Referral Law, commonly referred to as the Stark Law, the Anti-Inducement Law, the Civil Money Penalty Law, and the laws that authorize
the Office of Inspector General to exclude health care providers and others from participating in federal healthcare programs; and (iv)
the Office of Civil Rights which administers the privacy and security aspects of the Health Insurance Portability and Accountability
Act of 1996 (&#8220;HIPAA&#8221;). All of the aforementioned are agencies within the Department of Health and Human Services. Healthcare
is also provided or regulated, as the case may be, by the Department of Defense through its TriCare program, the Department of Veterans
Affairs under, among other laws, the Veterans Health Care Act of 1992, the Public Health Service within the Department of Health and
Human Services under the Public Health Service Act, the Department of Justice through the Federal False Claims Act and various criminal
statutes, and state governments under the Medicaid program and their internal laws regulating all healthcare activities. If and when
we receive FDA approval to market GlucoTrack&#174; in the United States, we will be subject to regulation by some or all of the foregoing
agencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable regulatory schemes in the EU are significantly more diverse than those in the United States and do not lend themselves to
similar summary. Although the CE Mark system and the MDD require a minimum level of harmonization in the EU, each EU member country may
impose additional regulatory requirements. Because there are numerous EU member countries with distinct legal systems, the scope of potential
regulatory requirements in each of the EU countries (additional to the harmonized EU requirements) is difficult to summarize or predict.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulation
of the Design, Manufacture and Distribution of Medical Devices</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product that we develop must receive all relevant regulatory clearances or approvals, as the case may be, before it may be marketed in
a particular country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of medical devices outside the United States are subject to foreign regulatory requirements that vary widely from country to country.
These laws and regulations range from simple product registration requirements in some countries to complex clearance and production
controls in others. As a result, the processes and time periods required to obtain foreign marketing approval may be longer or shorter
than those necessary to obtain FDA approval (as described below). These differences may affect the efficiency and timeliness of international
market introduction of GlucoTrack&#174;. For countries in the EU, medical devices must display a CE Mark before they may be imported or
sold and must comply with the requirements of the MDD or the Active Implantable Medical Device Directive. On June 4, 2013, we received
our CE Mark approval for the first generation GlucoTrack&#174; non-invasive glucose monitoring device from the Notified Body. Receipt
of the CE Mark allows us to market and sell the GlucoTrack&#174; 1.0 model glucose monitoring device in EU member countries that have
adopted the MDD without being subject to additional national regulations with regard to demonstration of performance and safety. However,
although the MDD is applicable throughout the EU, in practice it does not ensure uniform regulation throughout the EU. Rather, the MDD
requires only a minimum level of harmonization in the EU. Accordingly, member countries may apply and enforce the MDD&#8217;s terms differently,
and certain EU member countries may request or require performance and/or safety data in addition to the MDD&#8217;s requirements from
time to time, on a case-by-case basis. The CE Mark also permits the sale in countries that have an MDD Mutual Recognition Agreement with
the EU. On August 31, 2015, we received approval from the Notified Body for improvements to the GlucoTrack&#174; 1.0 model which simplify
and shorten (from approximately 2.5 hours to approximately half an hour) the initial calibration process for the device. These improvements
are intended to reduce the backlog created as purchasers of the device await calibration. In addition, we received approval from the
Notified Body on the updated intended use for the device, which expands the intended user population to include not only Type 2 diabetics,
but persons suffering from pre-diabetes conditions as well, which we believe represents a material expansion of the potential market
for the device. In December 2015, we received approval from the Notified Body for further improvements to the GlucoTrack&#174; model 1.0
that increase the accuracy and efficacy of the device. On February 19, 2016, we received an extension of our ISO 13485:2003 certificate
and Annex II certification from the EU. The ISO 13485:2003 certification signifies that we have met the standards required for company-wide
implementation of device quality management system(s). The scope of the certification is design, development, manufacture and service
of non-invasive glucose monitoring systems for home use. Annex II also addresses quality control systems. The certification allows us
to self-certify certain modifications and changes and simplifies some of the reporting to and review by the relevant Notified Body. This
can shorten CE-mark review process of future GlucoTrack&#174; enhancements or revisions. Without an Annex II certification, each new device
enhancement or modified version would be subject to the full EU CE-mark review process. The ISO 13485:2003 and Annex II certifications
enable us to potentially improve the time to market for product sales on new, enhanced or modified GlucoTrack&#174; devices. On January
21, 2020, the Company announced that it has received CE Mark approval for a major enhancement to GlucoTrack, allowing for a user to perform
the calibration process by themselves, without the need for a certified calibrator. The initial CE Mark approval received for GlucoTrack
required a calibration process that took three hours to complete, required eight invasive finger stick reference measurements, needed
to be repeated every thirty days and required a certified calibrator to perform the calibration. After a series of successful enhancements
and approvals, the calibration process now takes just thirty minutes, requires just three invasive reference measurements, and needs
to be repeated only once every six months. With self-calibration, a user can now perform this simplified process in the privacy and convenience
of their own home. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, under Section 201(h) of the Food, Drug, and Cosmetic Act, a medical device is an article which, among other things,
is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment or prevention of disease in
man or other animals. We believe that GlucoTrack&#174; devices will be classified as medical devices and subject to regulation by numerous
agencies and legislative bodies, including the FDA and its foreign counterparts. Devices are subject to varying levels of regulatory
control, the most comprehensive of which requires that a clinical evaluation be conducted before a device receives approval for commercial
distribution. The FDA classifies medical devices into one of three classes. Class I devices are relatively simple and can be manufactured
and distributed with general controls. Class II devices are somewhat more complex and require greater scrutiny. Class III devices are
new and frequently help sustain life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, a company generally can obtain permission to distribute a new device in two ways &#8211; through a so-called &#8220;510(k)&#8221;
premarket notification application or through a Section 515 premarket approval (&#8220;PMA&#8221;) application. The 510(k) submission
applies to any device that is substantially equivalent to a device first marketed prior to May 28, 1976 or to another device marketed
after that date, but which was substantially equivalent to a pre-May 28, 1976 device. These devices are either Class I or Class II devices.
Under the 510(k) submission process, the FDA will issue an order finding substantial equivalence to a predicate device (pre-May 28, 1976
or post-May 28, 1976 device that was substantially equivalent to a pre- May 28, 1976 device) and permitting commercial distribution of
that device for its intended use. A 510(k) submission must provide information supporting its claim of substantial equivalence to the
predicate device. The FDA permits certain low risk medical devices to be marketed without requiring the manufacturer to submit a premarket
notification. In other instances, the FDA may require that a premarket notification not only be submitted, but also be accompanied by
clinical data. If clinical data from human experiments are required to support the 510(k) submissions, these data must be gathered in
compliance with investigational device exemption regulations for investigations performed in the United States. The FDA review process
for premarket notifications submitted pursuant to section 510(k) should take about 90 days, but it can take substantially longer if the
FDA has concerns, and there is no guarantee that the FDA will clear the device for marketing, in which case the device cannot be lawfully
distributed in the United States. If the FDA finds that the device subject to the premarket notification is substantially equivalent
to a proper predicate device, then the FDA may &#8220;clear&#8221; that device for marketing. These devices are not &#8220;approved&#8221;
by the FDA. There is no guarantee, however, that the FDA will deem the device subject to the 510(k) process, as opposed to the more time-consuming,
resource intensive and problematic PMA application process described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
more comprehensive PMA process applies to a new device that either is not substantially equivalent to a pre-May 28, 1976 product or is
to be used in supporting or sustaining life or preventing impairment. These devices are normally Class III devices and can only be marketed
following approval of a PMA application. For example, most implantable devices are subject to the PMA approval process. Two steps of
FDA approval generally are required before a company can market a product in the U.S. that is subject to Section 515 PMA approval, as
compared to a Section 510(k) clearance. First, a company must comply with investigational device exemption regulations in connection
with any human clinical investigation of the device; however, those regulations permit a company to undertake a clinical study of a &#8220;non-significant
risk&#8221; device without formal FDA approval. Prior express FDA approval is required if the device is a significant risk device. If
there is any doubt as to whether a device is a &#8220;non-significant risk&#8221; device, companies normally seek prior approval from
the FDA. Normally, clinical studies of new diagnostic products are conducted in tandem with a cleared or approved device and treatment
decisions are based on the results from the existing diagnostic device. In such a setting, the FDA may consider the clinical trial as
one not posing a significant risk. However, FDA action is always uncertain and dependent on the contours of the design of the clinical
trial and the device and there is no assurance that the FDA would consider any proposed clinical trial as one posing a non-significant
risk. Moreover, before undertaking any clinical trial, the company sponsoring the trial and the investigator conducting the trial are
required by federal law to seek and obtain the approval of institutional review boards (&#8220;IRB&#8221;). An IRB weighs the risks and
benefits of a proposed trial to ensure that the human subjects are not exposed to unnecessary risk and reviews the informed consent form
to ensure that it meets federal requirements and accurately describes the risks and benefits, if any, of the clinical trial. IRB review
occurs annually, and annual re-approval is required. University medical centers as well as other entities maintain and operate IRB. Second,
the FDA must review a company&#8217;s PMA, which contains, among other things, clinical information acquired under the investigational
device exemption. The FDA will approve the PMA if it finds there is reasonable assurance that the device is safe and effective for its
intended use. The premarket approval process takes substantially longer than the 510(k) process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
GlucoTrack&#174; 1.0 has not  been approved for commercial sale in the United States. The GlucoTrack&#174; 2.0 is still under development
and has not yet been approved for commercial sale in or outside the United States. In discussions with the FDA regarding the regulatory
pathway, the FDA is not yet entirely sure whether a de novo pathway is acceptable and recommended that the Company should plan to support
this approach through risk analysis and an explanation of why the new measurement paradigm it is proposing does not introduce greater
risks. FDA noted that no decision has been made that a PMA will be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 10, 2015, we submitted pre-submission documents to the FDA in connection with our proposed future application for FDA approval
of our U.S. clinical trial protocol. The pre-submission documentation was submitted to the FDA in order to obtain the FDA&#8217;s guidance
regarding the U.S. regulatory pathway for the GlucoTrack&#174; 1.0, the proper approach to refining the trial protocol, and preparing
the pre-marketing application. On October 19, 2015, we met with the FDA to discuss the pre-submission documents, including the approach
to and details of the clinical trial protocol for the GlucoTrack&#174; 1.0. On May 10, 2016, we submitted a pre-submission supplement
(including clinical trial protocol) to the FDA which modifies the pre-submission documentation to reflect the feedback received from
the FDA at the meeting. On July 18, 2016, we completed a teleconference with the FDA to further discuss our pre-submission supplement.
At the end of this discussion, we received verbal confirmation from the FDA that clinical trials of the GlucoTrack&#174; 1.0 constitute
non-significant risk device studies, which allows the trials to proceed without an Investigational Device Exemption (IDE) application.
Such trials are assessed by the FDA and not considered to present a potential for serious risk to the health, safety or the welfare of
subjects. The initiation of clinical trials in the USA requires adequate financing to fund the clinical program through completion. With
the closing of our recent financing, we have restarted out internal planning for commencing such clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
when a clinical study has been approved or cleared by the FDA or a notified body or deemed approved, the study is subject to factors
beyond a manufacturer&#8217;s control, including, but not limited to the fact that the IRB at a given clinical site might not approve
the study, might decline to renew approval which is required annually, or might suspend or terminate the study before the study has been
completed. Also, the interim results of a study may not be satisfactory, in which case the sponsor may terminate or suspend the study
on its own initiative or the FDA or a notified body may terminate or suspend the study. There is no assurance that a clinical study at
any given site will progress as anticipated; there may be an insufficient number of patients who qualify for the study or who agree to
participate in the study, or the investigator at the site may have priorities other than the study. Also, there can be no assurance that
the clinical study will provide sufficient evidence to assure the FDA or a notified body that the product is safe and effective, a prerequisite
for FDA approval of a PMA, or substantially equivalent in terms of safety and effectiveness to a predicate device, a prerequisite for
clearance under 510(k). Even if the FDA or a notified body approves or clears a device, it may limit its intended uses in such a way
that manufacturing and distributing the device may not be commercially feasible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
clearance or approval to market is given, the FDA and foreign regulatory agencies, upon the occurrence of certain events, are authorized
under various circumstances to withdraw the clearance or approval or require changes to a device, its manufacturing process or its labeling
or additional proof that regulatory requirements have been met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
manufacturer of a device approved through the PMA process is not permitted to make changes to the device which affects its safety or
effectiveness without first submitting a supplement application to its PMA and obtaining FDA approval for that supplement. In some instances,
the FDA may require clinical trials to support a supplement application. A manufacturer of a device cleared through a 510(k) submission
must submit another premarket notification if it intends to make a change or modification in the device that could significantly affect
the safety or effectiveness of the device, such as a significant change or modification in design, material, chemical composition, energy
source or manufacturing process. Any change in the intended uses of a PMA device or a 510(k) device requires an approval supplement or
cleared premarket notification. Exported devices are subject to the regulatory requirements of each country to which the device is exported,
as well as certain FDA export requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Patient Protection and Affordable Care Act was signed into law on March 23, 2010, and on March 30, 2010, a reconciliation bill that modifies
certain provisions of the same was signed into law. These two laws are jointly referred to as the &#8220;Affordable Care Act&#8221; or
&#8220;ACA.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal aim of the ACA was to expand health insurance coverage to approximately 32 million Americans who were uninsured. The law&#8217;s
most far-reaching changes did not take effect until 2014, including a requirement that most Americans carry health insurance. The consequences
of these significant coverage expansions on the sales of our products is still unknown and speculative at this point, although the ACA
and certain state initiatives may compel private insurers to reduce coverage or reimbursement for various items and services, including
medical devices of the type that we contemplate distributing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
legislation contains many provisions designed to generate the revenues necessary to fund the coverage expansions. The most relevant of
these provisions are those that impose fees or taxes on certain health-related industries, including medical device manufacturers. Beginning
in 2013, each medical device manufacturer is required to pay an excise tax (or sales tax) in an amount equal to 2.3% of the price for
which such manufacturer sells its medical devices. The tax applies to all medical devices, including our products and product candidates.
The ACA also provides for increased enforcement of the fraud and abuse regulations previously mentioned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are ongoing discussions in the EU regarding amending the relevant regulatory framework. It is difficult to predict what effect any amendments
to the existing EU legislation may have. Furthermore, each individual EU member country has the authority to amend its regulations and
requirements additional to the minimum harmonization required by the MDD. Because the EU member countries have diverse legal systems,
it is difficult to predict what, if any, amendments may be implemented in each of the EU member countries and whether they may adversely
affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that sales volumes and prices of GlucoTrack&#174; and any other products we commercialize will depend in large part on the
availability of reimbursement from third-party payors. Third-party payors include governmental programs such as Medicare and Medicaid,
private insurance plans and workers&#8217; compensation plans. These third-party payors may deny reimbursement for a product or therapy
if they determine that the product was not medically appropriate or necessary. Also, third-party payors are increasingly challenging
the prices charged for medical products and services. Some third-party payors must also approve coverage for new or innovative devices
before they will reimburse health care providers who use the products. Even though a new product may have been cleared for commercial
distribution, it may find limited demand for the device until reimbursement approval has been obtained from governmental and private
third-party payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inasmuch
as a percentage of the projected patient population that could potentially benefit from GlucoTrack&#174; is elderly, Medicare would likely
be a potential source of reimbursement in the United States. Medicare is a federal program that provides certain hospital and medical
insurance benefits to persons age 65 and over, certain disabled persons, persons with end-stage renal disease and those suffering from
Lou Gehrig&#8217;s disease. In contrast, Medicaid is a medical assistance program jointly funded by United States federal and state governments
and administered by each state pursuant to which benefits are available to certain indigent patients. The Medicare and Medicaid statutory
framework is subject to administrative rulings, interpretations and discretion that affect the amount and timing of reimbursement made
under Medicare and Medicaid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medicare
reimburses for medical devices in a variety of ways depending on where and how the device is used. However, Medicare only provides reimbursement
if CMS determines that the device should be covered and that the use of the device is consistent with the coverage criteria. A coverage
determination can be made at the local level by the Medicare administrative contractor (formerly called carriers and fiscal intermediaries)
or a private contractor that processes and pays claims on behalf of CMS for the geographic area where the services were rendered, or
at the national level by CMS. There are new statutory provisions intended to facilitate coverage determinations for new technologies
under the Medicare Prescription Drug Improvement and Modernization Act of 2003 &#167;731 and &#167;942, but it is unclear how these new
provisions will be implemented. Coverage presupposes that the device has been cleared or approved by the FDA and, further, that the coverage
will be no broader than the approved intended uses of the device (i.e., the device&#8217;s label) as cleared or approved by the FDA,
but coverage can be narrower. In that regard, a narrow Medicare coverage determination may undermine the commercial viability of a device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
a coverage determination, whether local or national, is a time-consuming, expensive and highly uncertain proposition, especially for
a new technology, and inconsistent local determinations are possible. On average, according to an industry report, Medicare coverage
determinations for medical devices lag 15 months to five years or more behind FDA approval for respective devices. Moreover, Medicaid
programs and private insurers are frequently influenced by Medicare coverage determinations. A key component in the reimbursement decision
by most private insurers will be whether GlucoTrack&#174; is reimbursed by virtue of a national coverage determination by CMS. We may
negotiate contracted rates for GlucoTrack&#174; with private insurance providers for the purchase of GlucoTrack&#174; by their members
pending a coverage determination by CMS. Our inability to obtain a favorable coverage determination for GlucoTrack&#174; may adversely
affect our ability to market GlucoTrack&#174; and thus, the commercial viability of the product. In international markets, reimbursement
and healthcare payment systems vary significantly by country and many countries have instituted price ceilings on specific product lines.
Distributors expressly support the reimbursement process and, depending on the distribution agreement and geographic area, may assume
responsibility for the process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the overall escalating cost of medical products and services has led to, and will continue to lead to, increased pressures
on the healthcare industry to reduce the costs of products and services. Furthermore, deficit reduction and austerity measures in the
United States and abroad may put further pressure on governments to limit coverage of, and reimbursement for, our products. There can
be no assurance that third-party reimbursement and coverage will be available or adequate, or that future legislation, regulation, or
reimbursement policies of third-party payors will not adversely affect the demand for our products or our ability to sell these products
on a profitable basis. The unavailability or inadequacy of third-party payor coverage or reimbursement could have a material adverse
effect on our business, operating results and financial condition. Until reimbursement or insurance coverage is established, patients
will have to bear the financial cost of GlucoTrack&#174;. Third-party coverage may be particularly difficult to obtain while GlucoTrack&#174;
is not approved by the FDA as a replacement for existing single-point finger stick devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the United States, availability of reimbursement from third parties varies widely from country to country. Within the EU, member countries&#8217;
medical reimbursement and healthcare coverage regulations and systems differ significantly. It is, therefore, difficult to analyze and
predict the prospect of consistent availability of adequate reimbursement in the various EU member countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-Fraud
and Abuse Rule</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are extensive United States federal and state laws and regulations prohibiting fraud and abuse in the healthcare industry that can result
in significant criminal and civil penalties that can materially affect us, if and when we receive FDA approval to market GlucoTrack&#174;
in the United States. These federal laws include, by way of example, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    anti-kickback statute (Section 1128B(b) of the Social Security Act), which prohibits certain business practices and relationships
    that might affect the provision and cost of healthcare services reimbursable under Medicare, Medicaid and other federal healthcare
    programs, including the payment or receipt of remuneration for the referral of patients whose care will be paid by Medicare or other
    governmental programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    physician self-referral prohibition (Ethics in Patient Referral Act of 1989, as amended, commonly referred to as the Stark Law, Section
    1877 of the Social Security Act), which prohibits referrals by physicians of Medicare or Medicaid patients to providers of a broad
    range of designated healthcare services in which the physicians (or their immediate family members) have ownership interests or with
    which they have certain other financial arrangements;</span></td></tr>

</table>

<p style="margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    anti-inducement provisions of the Civil Monetary Penalties Law (Section 1128A(a)(5) of the Social Security Act), which prohibit providers
    from offering anything to a Medicare or Medicaid beneficiary to induce that beneficiary to use items or services covered by either
    program;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    False Claims Act (31 U.S.C. &#167; 3729 et seq.), which prohibits any person from knowingly presenting or causing to be presented
    false or fraudulent claims for payment to the federal government (including the Medicare and Medicaid programs); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Civil Monetary Penalties Law (Section 1128A of the Social Security Act), which authorizes the United States Department of Health
    and Human Services to impose civil penalties administratively for fraudulent or abusive acts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanctions
for violating these federal laws include criminal and civil penalties that range from punitive sanctions, damage assessments, monetary
penalties, imprisonment and/or denial of Medicare and Medicaid payments or exclusion from the Medicare and Medicaid programs, or both.
These laws also impose an affirmative duty on those receiving Medicare or Medicaid funding to ensure that they do not employ or contract
with persons excluded from the Medicare and other government programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states have adopted or are considering legislative proposals similar to the federal fraud and abuse laws, some of which extend beyond
the Medicare and Medicaid programs, to prohibit the payment or receipt of remuneration for the referral of patients and physician self-referrals
regardless of whether the service was reimbursed by Medicare or Medicaid. Many states have also adopted or are considering legislative
proposals to increase patient protections, such as limiting the use and disclosure of patient specific health information. These state
laws also impose criminal and civil penalties similar to the federal laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
the EU and EU member countries may have similar fraud and abuse laws which would regulate our business in those jurisdictions. However,
given the diversity of legal systems within the EU, it is difficult to predict with specificity what anti-fraud legislation and regulations
may be implemented and the penalties that they impose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of their business, medical device manufacturers and suppliers have been and are subject regularly to inquiries, investigations
and audits by federal and state agencies that oversee these laws and regulations. Recent federal and state legislation has greatly increased
funding for investigations and enforcement actions, which have increased dramatically over the past several years. This trend is expected
to continue. Private enforcement of healthcare fraud also has increased due in large part to amendments to the civil False Claims Act
in 1986 that were designed to encourage private persons to sue on behalf of the government. These whistleblower suits by private persons,
known as qui tam relators, may be filed by almost anyone, including present and former patients or nurses and other employees, as well
as competitors. HIPAA, in addition to its privacy provisions, created a series of new healthcare-related crimes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
federal and state budget pressures continue, federal and state administrative agencies may also continue to escalate investigation and
enforcement efforts to root out waste and to control fraud and abuse in governmental healthcare programs. A violation of any of these
federal and state fraud and abuse laws and regulations could have a material adverse effect on a supplier&#8217;s liquidity and financial
condition. An investigation into the use of a device by physicians may dissuade physicians from recommending that their patients use
the device. This could have a material adverse effect on our ability to commercialize GlucoTrack&#174;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Privacy Provisions of HIPAA</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, HIPAA, among other things, protects the privacy and security of individually identifiable health information by limiting
its use and disclosure. HIPAA directly regulates &#8220;covered entities,&#8221; such as healthcare providers, insurers and clearinghouses,
and regulates &#8220;business associates,&#8221; with respect to the privacy of patients&#8217; medical information. All entities that
receive and process protected health information are required to adopt certain procedures to safeguard the security of that information.
It is uncertain whether we would be deemed to be a covered entity under HIPAA and, owing to changes in the law, it is uncertain, based
on our current business model, whether we would be a business associate. Nevertheless, we will likely be contractually required to physically
safeguard the integrity and security of any patient information that we receive, store, create or transmit in the United States. If we
fail to adhere to our contractual commitments, then our physician, hospital or insurance customers may be subject to civil monetary penalties,
which could adversely affect our ability to market our devices. Changes in the law wrought by the provisions of Health Information Technology
for Economic and Clinical Health (HITECH) Act, enacted as part of the American Recovery and Reinvestment Act of 2009, increase the duties
of business associates and covered entities with respect to protected health information that thereby subject them to direct government
regulation, increasing its compliance costs and exposure to civil monetary penalties and other government sanctions. While HITECH does
not alter the definition of a business associate, it makes it more likely that covered entities with whom we are likely to do business
in the United States, if and when we receive FDA approval to market GlucoTrack&#174; in the United States, will require us to enter into
business associate agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a proactive intellectual property strategy, which includes patent filings in multiple jurisdictions, including the United States
and other commercially significant markets. We currently hold 59 issued patents in various regions including patents issued by the United
States, Australian, Brazilian, Canadian, Chinese, European, Hong Kong, Indian, Israeli, Japanese, Korean, Mexican, Philippine, Russian,
South African, and Taiwanese patent offices that cover various parts of our technology, which include <i>A Method Of Monitoring Glucose
Levels, Device For Non-Invasively Measuring Glucose, Individual Measuring Channels For Non-Invasively Measuring Glucose, Ear Clip For
Medical Monitoring Device.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
understand the importance of obtaining patent and trade secret protection for new technologies, products and processes. Our success will
depend in large part on our ability to file for and obtain patent protection of our principal products and procedures, to defend existing
or future patents, to maintain trade secrets and to operate without infringing upon the proprietary rights of others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have obtained trademark registrations for GlucoTrack&#174; in 24 countries, including the US, Europe, China and Israel, and also own an
allowed trademark applications for GlucoTrack&#174; in Canada. Trademark registrations were issued in ten countries for &#8220;JUST CLIP
IT,&#8221; including France and China, and additional applications are pending in three countries, including the United States. In addition,
trademark registrations were issued in seven countries for &#8220;YOUR TRACK TO HEALTH,&#8221; including France and China, and additional
applications are pending in three countries, including the United States. Trademark registrations have been issued in Israel to register
&#8220;Integrity,&#8221; the Company&#8217;s logo and the GlucoTrack logo. Registration have issued in Hong Kong and Taiwan and are pending
in China and Singapore to register GlucoTrack in Chinese characters. Our application in South Korea to register GlucoTrack in Korean
characters has been allowed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our patents and products do not and will not infringe patents or violate proprietary rights of others, although it is possible
that our existing patent rights may not be valid or that infringement of existing or future patents or proprietary rights may occur.
Litigation may be necessary to defend or enforce our patent rights or to determine the scope and validity of the proprietary rights of
others. Defense and enforcement of patent claims can be expensive and time consuming, even in those instances in which the outcome is
favorable, and could result in the diversion of substantial resources and management time and attention from our other activities. An
adverse outcome could subject us to significant liability to third parties, require us to obtain licenses from third parties, require
us to alter our products or processes, or require that we cease altogether any related research and development activities or product
sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
protection is highly uncertain and involves complex legal and factual questions and issues. The patent application and issuance process
can be expected to take several years and entails considerable expense. There can be no assurance that patents will be issued as a result
of any applications or that any patents resulting from such applications or our existing patents will be sufficiently broad to afford
protection against competitors with similar or competing technology. Patents that we obtain may be challenged, invalidated or circumvented,
or the rights granted under such patents may not provide us with any competitive advantages.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for blood glucose monitoring devices is intensely competitive, subject to rapid change and significantly affected by new product
introductions. Four companies, Roche; LifeScan, Inc., a division of Johnson &amp; Johnson; Abbott Laboratories; and Ascensia, a spin
off from the Bayer Corporation, currently account for substantially all of the worldwide sales of self-monitored glucose testing systems.
These competitors&#8217; products use a meter and disposable test strips to test blood obtained by pricking the finger or, in some cases,
the palm or forearm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
the last few years, Continuous Glucose Monitoring (CGM) devices have been introduced into the market and will compete with GlucoTrack&#174;
and our future devices. Currently, to our knowledge, three different brands have obtained FDA clearance to market and are selling CGM
devices in the U.S. and EU markets. These brands are sold by Medtronic plc. Abbott Laboratories and Dexcom, Inc. CGM devices are invasive
devices, in which a needle is inserted under the skin (either in the abdomen or the upper arm) and measures interstitial fluid. Although
we cannot predict what standards will be employed by applicable regulatory authorities as we seek FDA clearance, the results achieved
by GlucoTrack&#174; 1.0 in our safety and performance clinical trial conducted were similar to the results obtained from the CGM devices
that have been introduced to the market, as of the time of their introduction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other companies are developing non-invasive glucose testing devices and technologies that could compete with our devices. There
are also a number of academic and other institutions involved in various phases of technology development regarding blood glucose monitoring
devices. We believe that the majority of non-invasive glucose monitors in development require frequent calibrations (from a few hours
to a few days, compared to the GlucoTrack&#174; 1.0, which has a demonstrated efficacy period of six months from the initial calibration).
Other companies developing continuous measurement devices, based on minimally invasive methods, such as implants or subdermal needles
include Medtronic, Inc., Abbot Laboratories and Dexcom, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our competitors are either publicly traded or are divisions of publicly-traded companies, and they enjoy several competitive advantages,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significantly
    greater name recognition;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">established
    relations with healthcare professionals, customers and third-party payors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">established
    distribution networks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    lines of products, and the ability to offer rebates or bundle products to offer higher discounts or incentives to gain a competitive
    advantage;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
    experience in conducting research and development, manufacturing, clinical trials, obtaining regulatory approval for products and
    marketing approved products; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
    financial and human resources for product development, sales and marketing, and patent litigation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our other non-publicly traded competitors also enjoy these competitive advantages. As a result, we cannot assure that we will be able
to compete effectively against these companies or their products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, a summary of potential competitors with non-invasive products in development is set forth below in Figure A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Technology</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Calibration</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Required</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Measurement</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Technology
    Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mediwise</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glucowise</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiowave
    spectroscopy</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spot</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Measures
    blood glucose in capillaries using high- frequency radio waves. Includes a wearable sensor and displays the data on smartphone.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrates
    a range of measurements including exercise, diet, body mass index, medication and illness and includes cloud-based data management
    system to store historical Glucowise data.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cnoga</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TensorTip</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CGM
    Combo<br />
    Glucometer</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optical
    lookup<br />
    table</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spot</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four
    LED signals are beamed through the finger; color image sensor executes a special algorithm</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diamontech</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DMT
    Pocket/<br />
    DMT Band</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mid-infrared
    absorption spectroscopy</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spot</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uses
    mid-infrared pulses from an infrared laser to excite glucose molecules in the interstitial layer of skin. Absorption of these pulses
    depends on the concentration of glucose and results in a heat wave migrating to the skin surface, where it is picked up by photo-thermal
    detection.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ESER</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GlucoGenius</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Metabolic
    heat confirmation (MHC)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spot</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Combination
    of 9 independent measurements that are performed simultaneously and based on method of metabolic heat conformation (MHC) by radiation,
    convection and evaporation with electromagnetic technologies. The device integrates 3 types of sensors: temperature, humidity and
    infrared.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
<tr>
    <td style="width: 9%"><span style="font-size: 10pt">GlucoActive</span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">Gluco Station</span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">Optical</span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="text-align: center; width: 9%"><span style="font-size: 10pt">Yes</span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="text-align: center; width: 11%"><span style="font-size: 10pt">Spot</span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="text-align: justify; vertical-align: top; width: 41%"><span style="font-size: 10pt">Using spectrophotometry to measure the scattering of
    light by glucose molecules to determine glucose concentration.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GlucoTrack&#174;
does not directly measure the glucose level concentration in the blood. Rather, it measures several physiological phenomena that are
correlated with the glucose level. In order to correlate between the measured signal and the glucose level, a translation is needed.
This translation is accomplished through the individual calibration of the device by reference to a measurement obtained from an invasive
device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-invasive
devices under different stages of development generally require frequent recalibration. For example, GlucoWatch, a single non-invasive
product for glucose trend analysis that was previously approved for sale by the FDA, but which is no longer available commercially, required
recalibrations approximately every 13 hours. The main reasons for calibration are that tissue parameters generally fluctuate in the area
of the measurement and are sensitive to the location of the sensor and the impact of potential disturbances. Disturbances are less frequent
in the earlobes, where GlucoTrack&#174; takes its measurements. Utilizing three channels simultaneously reduces the noise contribution
in the measurement. In addition, the personal ear clip contains sensors to help users attach the device to the proper part of the ear
lobe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GlucoTrack&#174;
1.0 has received CE Mark approval, which allows us to market and sell GlucoTrack&#174; 1.0 glucose monitoring device in EU member countries
that have adopted the MDD without being subject to additional national regulations with regard to demonstration of performance and safety.
While the MDD is applicable throughout the EU, it requires only a minimum level of harmonization among member countries. Accordingly,
member countries may apply and enforce the MDD&#8217;s terms differently, and certain EU member countries may request or require performance
and/or safety data additional to the MDD&#8217;s requirements from time to time, on a case-by-case basis. Moreover, the MDD notwithstanding,
because the regulatory regimes of the EU member countries are significantly diverse, it is difficult to predict future regulatory developments
and risks. GlucoTrack&#174; 1.0 has not yet been cleared or approved for commercial sale in any other jurisdiction, including the United
States. See &#8220;<i>Government Regulation - Regulation of the Design, Manufacture and Distribution of Medical Devices</i>&#8221; below
for a discussion of the approval process for commercial sale in the United States. There can be no assurance that approval for commercial
sale in any additional jurisdiction will be obtained on a timely basis or at all. GlucoTrack 2.0 is currently under development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal offices are located at 8 Ariel Sharon Street, P.O. Box 6037607, Or Yehuda, Israel, 7760049 and our telephone number is 972-8-675-7878.
Our website address is http://www.integrity-app.com; the reference to such website address does not constitute incorporation by reference
of the information contained on the website and such information should not be considered part of this report. There is no relationship
between us and Integrity Applications, Incorporated, the engineering and software services company based in Chantilly, Virginia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
and Committees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have five members on our Board, four of whom are independent. The Board has an Audit Committee and a Compensation Committee and Nominating
and Corporate Governance Committee, the Audit consisting solely of independent directors. We are continuing to consider expansion of
the Board and the establishment of additional appropriate Board committees to support the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we had 5 full-time employees. None of our employees are represented by a collective bargaining agreement.
In addition, as of December 31, 2021, we had 5 consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ha_005"></span>Item
1A. Risk Factors.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in our common stock involves a high degree of risk. Before making an investment decision, you should carefully consider the
following risk factors. If any of these risks actually occur, our business, financial condition and results of operations could be materially
harmed. In addition, risks and uncertainties not presently known to us or that we currently deem immaterial may also materially harm
our business, financial condition and results of operations. If this were to happen, the value of our common stock could decline significantly,
and you could lose all or part of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a history of operating losses, and there is no assurance that we will generate material revenues or become profitable in the near
future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a medical device company with a limited operating history. We are not profitable and have incurred losses since our inception. To
date we have not generated material revenue from the sale of products, and we do not anticipate that we will report operating income
in the near future. Our initial product, GlucoTrack&#174; 1.0, has not been approved for marketing in the United States and may not be
sold or marketed without FDA clearance or approval in the United States. Our next generation product, GlucoTrack&#174; 2.0 is currently
under development. We continue to incur research and development and
selling, marketing and general and administrative expenses related to our operations, development and commercialization of our first
product. Our operating losses for the years ended December 31, 2021 and 2020 were approximately $4.0 million and $3.1 million,
respectively, and we had an accumulated deficit of approximately $97.5 million as of December 31, 2021. We expect to continue
to incur losses for the foreseeable future, and these losses will likely increase as we develop and prepare to commercialize GlucoTrack&#174;
2.0. If we are not successful in developing, manufacturing and distributing GlucoTrack&#174; 2.0, or if GlucoTrack&#174; 2.0 does not achieve
market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability
in subsequent periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have never declared or paid any cash dividends on our Common Stock and do not anticipate paying any dividends on our Common Stock in
the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our Common Stock and do not anticipate paying any dividends on our Common Stock in
the foreseeable future. Any cash that might be available for payment of dividends will be used to expand our business. Payments of any
cash dividends in the future will depend on our financial condition, results of operation and capital requirements, as well as other
factors deemed relevant to our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Economic
crises and market instability may materially and adversely affect the demand for our products, as well as our ability to obtain credit
or secure funds through sales of our stock, which may materially and adversely affect our business, financial condition and ability to
fund our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Economic
crises may reduce the demand for new and innovative medical devices, resulting in delayed market acceptance of our products, if and when
they are approved. Such a delay could have a material adverse impact on our business, expected cash flows, results of operations and
financial condition. Additionally, we have funded our operations to date primarily through private sales of securities, including common
stock and other securities convertible into or exercisable for shares of our common stock. Economic turmoil and instability in the world&#8217;s
equity and credit markets and in the unstable world may materially adversely affect our ability to sell additional securities and/or
borrow cash. There can be no assurance that we will be able to raise additional working capital on acceptable terms or at all, and any
failure to do so may materially adversely affect our ability to continue operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>GlucoTrack&#174;
may not be approved for sale in the United States or other (non-CE Mark) jurisdictions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will likely be required to undertake significant clinical trials to demonstrate to the FDA that GlucoTrack&#174; is either safe and effective
for its intended use or is substantially equivalent in terms of safety and effectiveness to an existing, lawfully marketed non-Section
515 premarket approval (PMA) device (refer to &#8220;<i>Management Discussion and Analysis - Government Regulatory</i>&#8221;). We may
also be required to undertake clinical trials by non-U.S. regulatory agencies in non-CE Mark jurisdictions. Clinical trials are expensive
and uncertain processes that may take years to complete. Failure can occur at any point in the process and early positive results do
not ensure that the entire clinical trial will be successful. Product candidates in clinical trials may fail to show desired efficacy
and safety traits despite early promising results. A number of companies in the medical device industry have suffered significant setbacks
in advanced clinical trials, even after their product candidates demonstrated promising results at earlier points.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Positive
results from the limited pre-clinical trials and safety and performance clinical trial that we have conducted should not be relied upon
as evidence that later-stage or large-scale clinical trials will succeed. These trials involved limited patient populations and there
is no assurance that the experimental protocol or protocols, as the case may be, used in these informal trials will be methodologically
similar to ones submitted to the FDA or any other regulatory body for its approval. Because of the sample size, possible variation in
methodology, differences in exclusion/inclusion criteria, or differences in endpoints, the results of these pre-clinical trials may not
be indicative of future results. We will likely be required to demonstrate through well-controlled clinical trials that GlucoTrack&#174;
or future product candidates, if any, are safe and effective for their intended uses. In the event that the FDA deems GlucoTrack&#174;
to be a Class II device, which we do not believe is likely at this point, then we would be required to demonstrate that it is substantially
equivalent in terms of safety and effectiveness to a device lawfully marketed either through a premarket notification or prior to May
28, 1976.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
although we have received our CE Mark approval for GlucoTrack&#174; 1.0, EU member countries may request or require additional performance
and/or safety data from time to time, on a case-by-case basis. GlucoTrack&#174; 2.0 is currently under development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
GlucoTrack&#174; or our future product candidates, if any, may not be cleared or approved, as the case may be, even if the clinical data
are satisfactory and support, in our view, its or their clearance or approval. The FDA or other non-U.S. regulatory authorities may disagree
with our trial design or interpretation of the clinical data. In addition, any of these regulatory authorities may change requirements
for the clearance or approval of a product candidate even after reviewing and providing comment on a protocol for a pivotal clinical
trial that has the potential to result in FDA approval. In addition, any of these regulatory authorities may also clear or approve a
product candidate for fewer or more limited uses than we request or may grant clearance or approval contingent on the performance of
costly post-marketing clinical trials. In addition, the FDA or other non-regulatory authorities may not approve the labeling claims necessary
or desirable for the successful commercialization of GlucoTrack&#174; or our future product candidates, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are highly dependent on the success of our next generation product candidate, GlucoTrack&#174; 2.0, and cannot give any assurance that
it will receive regulatory approval or clearance or be successfully commercialized.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on the success of our next generation product candidate, GlucoTrack&#174; model 2.0. We cannot give any assurance
that the FDA will permit us to clinically test the device, nor can we give any assurance that the clinical trials will be successful
or that GlucoTrack&#174; 2.0 will receive regulatory clearance or approval or be successfully commercialized, for a number of reasons,
including, without limitation, the potential introduction by our competitors of more clinically-effective or cost-effective alternatives,
failure in our sales and marketing efforts, or the failure to obtain positive coverage determinations or reimbursement. Any failure to
obtain approval to conduct clinical trials, favorable clinical data, clearance or approval of or to successfully commercialize GlucoTrack&#174;
2.0 would have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our competitors develop and market products that are more effective, safer or less expensive than GlucoTrack&#174; or our future product
candidates, if any, our commercial opportunities will be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
life sciences industry is highly competitive and we face significant competition from many medical device companies that are researching
and marketing products designed to address the needs of persons suffering from diabetes. We are currently developing medical devices
that will compete with other medical devices that currently exist or are being developed. Some of our competitors have significantly
greater financial, manufacturing, marketing and product development resources than we do. Large medical device companies, in particular,
have extensive experience in clinical testing and in obtaining regulatory clearances or approvals for medical devices. These companies
also have significantly greater research and marketing capabilities than us. Some of the medical device companies that we expect to compete
with include Roche; LifeScan, Inc., a division of Johnson &amp; Johnson; the MediSense and TheraSense divisions of Abbott Laboratories;
Ascensia, a spin off from Bayer Corporation; Dexcom, Inc. and Medtronic, Inc. In addition, many other universities and private and public
research institutions are or may become active in research involving blood glucose measurement devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our ability to successfully compete will depend on, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to have partners manufacture and sell commercial quantities of any approved products to the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of product candidates by physicians and other health care providers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to recruit and enroll patients for our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    efficacy, safety, performance and reliability of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    speed at which we develop product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain prompt and favorable IRB review and approval at each of our clinical sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to commercialize and market any of our product candidates that may receive regulatory clearance or approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to design and successfully execute appropriate clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and scope of regulatory clearances or approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate
    coverage and adequate levels of reimbursement under private and governmental health insurance plans, including Medicare; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to protect intellectual property rights related to our products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our competitors market products that are more effective, safer, easier to use or less expensive than GlucoTrack&#174; or our future product
candidates, if any, or that reach the market sooner than GlucoTrack&#174; or our future product candidates, if any, we may not achieve
commercial success. In addition, the medical device industry is characterized by rapid technological change. It may be difficult for
us to stay abreast of the rapid changes in each technology. If we fail to stay at the forefront of technological change, we may be unable
to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates
obsolete or less competitive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product development activities could be delayed or stopped.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not know whether our future clinical trials will begin on time, or at all, and whether ongoing and/or future clinical trials will
be completed on schedule, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commencement of future clinical trials could be substantially delayed or prevented by several factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure to obtain sufficient funding to pay for all necessary clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
    number of, and competition for, suitable patients that meet the protocol&#8217;s inclusion criteria and do not meet any of the exclusion
    criteria;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
    number of, and competition for, suitable sites to conduct the clinical trials, and delay or failure to obtain FDA approval, if necessary,
    to commence a clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure to obtain sufficient supplies of the product candidate for clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to provide the medical device required in clinical trials at cost, which may require significant expenditures that we are unable
    or unwilling to make;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or
    investigators; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure to obtain IRB approval or renewal of such approval to conduct a clinical trial at a prospective or accruing site, respectively.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
completion of clinical trials in connection with our application for FDA approval could also be substantially delayed or prevented by
several factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower
    than expected rates of patient recruitment and enrollment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of patients to complete the clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    safety issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of efficacy evidenced during clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    of clinical trials by one or more clinical trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    or unwillingness of patients or medical investigators to follow clinical trial protocols; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to monitor patients adequately during or after treatment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB for any given site, or us.
Any failure or significant delay in completing clinical trials for GlucoTrack&#174; or future product candidates, if any, could materially
harm our financial results and the commercial prospects for our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
regulatory approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization
of GlucoTrack&#174; or our future product candidates, if any.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research, testing, manufacturing, labeling, approval, selling, marketing and distribution of medical devices are subject to extensive
regulation by the FDA and other non-U.S. regulatory authorities, which regulations differ from country to country. We are not permitted
to market our product candidates in the United States until we receive a clearance letter under the 510(k)-premarket notification process
or approval of a Section 515 premarket approval, from the FDA, depending on the nature of the device. We have not submitted an application
or premarket notification for or received marketing clearance or approval for any of our product candidates. Obtaining approval of any
premarket approval can be a lengthy, expensive and uncertain process. While the FDA normally reviews, and clears a premarket notification
in three months, there is no guarantee that our products will qualify for this more expeditious regulatory process, which is reserved
for Class I and II devices, nor is there any assurance that, even if a device is reviewed under the 510(k)-premarket notification process,
the FDA will review it expeditiously or determine that the device is substantially equivalent to a lawfully marketed non-premarket approval
device. If the FDA fails to make this finding, then we cannot market the device. In lieu of acting on a premarket notification, the FDA
may seek additional information or additional data which would further delay our ability to market the product. In addition, failure
to comply with FDA, non-U.S. regulatory authorities or other applicable U.S. and non-U.S. regulatory requirements may, either before
or after product clearance or approval, if any, subject us to administrative or judicially imposed sanctions, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the products, manufacturers or manufacturing process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    inspectional observations (Form 483), warning letters or non-warning letters incorporating inspectional observations, i.e., so-called
    &#8220;untitled letter&#8221;;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil
    and criminal penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of regulatory clearances or approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizures, detentions or import bans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary
    or mandatory product recalls and publicity requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">total
    or partial suspension of production;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of restrictions on operations, including costly new manufacturing requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to clear or approve pending applications or premarket notifications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
approval of a PMA or PMA supplement or clearance pursuant to a 510(k)-premarket notification is not guaranteed, and the approval or clearance
process, as the case may be, is expensive and may, especially in the case of the PMA, take several years. The FDA also has substantial
discretion in the medical device clearance or approval processes. Despite the time and expense exerted, failure can occur at any stage
and we could encounter problems that cause us to abandon clinical trials or to repeat or perform additional pre-clinical studies and
clinical trials. The number of pre-clinical studies and clinical trials that will be required for FDA clearance or approval varies depending
on the medical device candidate, the disease or condition that the medical device candidate is designed to address, and the regulations
applicable to any particular medical device candidate. The FDA can delay, limit or deny clearance or approval of a medical device candidate
for many reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    medical device candidate may not be deemed safe or effective, in the case of a PMA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    medical device candidate may not be deemed to be substantially equivalent to a lawfully marketed non-premarket approval device in
    the case of a 510(k)-premarket notification;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    officials may not find the data from the clinical trials sufficient;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA might not approve our third-party manufacturer&#8217;s processes or facilities; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may change its clearance or approval policies or adopt new regulations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
while we have received CE Mark approval for GlucoTrack&#174; 1.0, the MDD requires only minimum harmonization. In practice, uniform regulation
throughout the EU is not ensured. Rather, member countries may apply and enforce the MDD&#8217;s terms differently, and certain EU member
countries may request or require performance and/or safety data additional to the MDD&#8217;s requirements from time to time, on a case-by-case
basis. Therefore, we cannot predict whether we will be able to successfully commercialize GlucoTrack&#174; or our future product candidates,
if any, in the EU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to recruit and enroll patients for clinical trials may cause the development of our product candidates to be delayed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may encounter delays if we are unable to recruit and enroll and retain enough patients to complete clinical trials. Patient enrollment
depends on many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical
sites and the eligibility criteria for the trial. Delays in patient enrollment are not unusual. Any such delays in planned patient enrollment
may result in increased costs, which could harm our ability to develop products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
terms of clearances or approvals and ongoing regulation of our products may limit how we manufacture and market our product candidates,
which could materially impair our ability to generate anticipated revenues.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
regulatory clearance or approval has been granted, the cleared or approved product and its manufacturer are subject to continual review.
Any cleared or approved product may only be promoted for its indicated uses. In addition, if the FDA or other non-U.S. regulatory authorities
clear or approve GlucoTrack&#174; or our future product candidates, if any, the labeling, packaging, adverse event reporting, storage,
advertising and promotion for the product will be subject to extensive regulatory requirements. We, and the manufacturers of our products,
if other than us, also will be required to comply with the FDA&#8217;s Quality System Regulation, which includes requirements relating
to quality control and quality assurance, as well as the corresponding maintenance of records and documentation. Moreover, device manufacturers
are required to report adverse events by filing Medical Device Reports with the FDA, which are publicly available. Further, regulatory
agencies must approve our manufacturing facilities before they can be used to manufacture products, and these facilities are subject
to ongoing regulatory inspection. If we fail to comply with the regulatory requirements of the FDA and other non-U.S. regulatory authorities,
or if previously unknown problems with our products, manufacturers or manufacturing processes are discovered, we could be subject to
administrative or judicially imposed sanctions, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the products, manufacturers or manufacturing process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    inspectional observations (Form 483), warning letters, or non-warning letters incorporating inspectional observations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil
    or criminal penalties or fines;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizures, detentions or import bans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary
    or mandatory product recalls and publicity requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of regulatory clearances or approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">total
    or partial suspension of production;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of restrictions on operations, including costly new manufacturing requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to clear or approve pending applications or premarket notifications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA and other non-U.S. regulatory authorities, including the EU and each of the EU member countries individually, may change
their policies and additional regulations may be enacted that could prevent or delay regulatory clearance or approval of our product
candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative
action, either in the United States or abroad. If we are not able to maintain regulatory compliance, we will likely not be permitted
to market future product candidates and may not achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we receive regulatory clearance or approval to market GlucoTrack&#174; or our future product candidates, if any, the market may not
be receptive to our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if GlucoTrack&#174; or our future product candidates, if any, obtain regulatory clearance or approval, resulting products may not gain
market acceptance among physicians, patients, health care payors or the medical community. We believe that the degree of market acceptance
will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing
    of market introduction of competitive products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safety
    and efficacy of our product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevalence
    and severity of any side effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    advantages or disadvantages over alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strength
    of marketing and distribution support;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price
    of our product candidates, both in absolute terms and relative to alternative treatments; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of coverage and reimbursement from government and other third-party payors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the GlucoTrack&#174; or our future product candidates, if any, fail to achieve market acceptance, we may not be able to generate significant
revenue or achieve or sustain profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
coverage and reimbursement status of newly cleared or approved medical devices is uncertain, and failure to obtain adequate coverage
and adequate reimbursement could limit our ability to market GlucoTrack&#174; or future product candidates, if any, and may inhibit our
ability to generate revenue from GlucoTrack&#174; or our future product candidates, if any, that may be cleared or approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to the third-party coverage and reimbursement of newly cleared or approved medical devices. The commercial
success of GlucoTrack&#174; or our future product candidates, if any, in both domestic and international markets will depend in part on
the availability of coverage and adequate reimbursement from third-party payors, including government payors, such as the Medicare and
Medicaid programs, managed care organizations and other third-party payors. Government and other third-party payors are increasingly
attempting to contain health care costs by limiting both coverage and the level of reimbursement for new products and, as a result, they
may not cover or provide adequate payment for GlucoTrack&#174; or our future product candidates, if any. These payors may conclude that
our products are not as safe or effective as existing devices or that the overall cost of using one of our devices exceeds the overall
cost of the competing device, and third-party payors may not approve GlucoTrack&#174; or our future product candidates, if any, for coverage
and adequate reimbursement. Furthermore, deficit reduction and austerity measures in the United States and abroad may put further pressure
on governments to limit coverage of, and reimbursement for, our products. The failure to obtain coverage and adequate reimbursement for
GlucoTrack&#174; or our future product candidates, if any, or health care cost containment initiatives that limit or restrict reimbursement
for such products may reduce any future product revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not obtain insurance coverage to adequately cover all significant risk exposures.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be exposed to liabilities that are unique to the products we provide. We currently maintain premises insurance and there can be
no assurance that we will acquire or maintain insurance for certain risks, that the amount of our insurance coverage will be adequate
to cover all claims or liabilities, or that we will not be forced to bear substantial costs resulting from risks and uncertainties of
business. It is also not possible to obtain insurance to protect against all operational risks and liabilities. The failure to obtain
adequate insurance coverage on terms favorable to us, or at all, could have a material adverse effect on our business, financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
product liability lawsuits are brought against us, we may incur substantial liabilities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face a potential risk of product liability as a result of any of the products that we offer for sale. For example, we may be sued if
any product we sell allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or
sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of
dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer
protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities. Even
successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability
claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for products that we may offer for sale;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    to defend the related litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    diversion of management&#8217;s time and our resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to trial participants or patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls, withdrawals or labeling, marketing or promotional restrictions; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decline in our stock price. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability
claims could prevent or inhibit the commercialization of products we develop. We currently maintain product liability insurance up to
$5,000 thousand per claim and in the aggregate. Although we have product liability coverage, we may have to pay amounts awarded by a
court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have,
or be able to obtain, sufficient capital to pay such amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to attract and retain key management and scientific personnel, we may be unable to successfully develop or commercialize GlucoTrack&#174;
or our future product candidates, if any.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to expand and effectively manage our managerial, operational, financial, development and other resources in order to successfully
pursue our research, development and commercialization efforts for GlucoTrack&#174; or our future product candidates, if any. Our success
depends on our continued ability to attract, retain and motivate highly qualified management and pre-clinical and clinical personnel.
The loss of the services of any of our senior management could delay or prevent the development or commercialization of GlucoTrack&#174;
or our future product candidates, if any. At present, we do not have key man insurance policies with respect to any of our employees.
We will need to hire additional personnel as we continue to expand our research and development activities and build a sales and marketing
function.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to attract or retain qualified management and scientific personnel in the future due to the intense competition for qualified
personnel among medical device and other businesses. If we are not able to attract and retain the necessary personnel to accomplish our
business objectives, we may experience constraints that will significantly impede the achievement of our research and development objectives,
our ability to raise additional capital and our ability to implement our business strategy. In particular, if we lose any members of
our senior management team, we may not be able to find suitable replacements in a timely fashion or at all and our business may be harmed
as a result.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
we continue to evolve from a company primarily involved in development to a company also involved in commercialization, we may encounter
difficulties in managing our growth and expanding our operations successfully.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that, as our operations expand, we will need to expand our manufacturing, marketing and sales capabilities by contracting
with third parties. Maintaining these relationships and managing our future growth will impose significant added responsibilities on
members of our management. We must be able to manage our development efforts effectively; manage our clinical trials effectively; hire,
train and integrate additional management, development, administrative and sales and marketing personnel; improve managerial, development,
operational and finance systems; and expand our facilities, all of which may impose a strain on our administrative and operational infrastructure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on third parties to manufacture and supply our product.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate manufacturing facilities for clinical or commercial production of GlucoTrack&#174;, other than a prototype lab.
We have no experience in medical device manufacturing and lack the resources and the capability to manufacture the GlucoTrack&#174; on
a commercial scale. To date we have manufactured GlucoTrack&#174; with a third-party manufacturer in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our manufacturing partners are unable to produce our products in the amounts, timing or pricing that we require, we may not be able to
establish a contract and obtain a sufficient alternative supply from another supplier on a timely basis and in the quantities or pricing
we require. We expect to depend on third-party contract manufacturers for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GlucoTrack&#174;
does, and our future product candidates, if any, likely will require precise, high quality manufacturing. Any of our contract manufacturers
will be subject to ongoing periodic unannounced inspections by the FDA and other non-U.S. regulatory authorities to ensure strict compliance
with quality system regulations, including current good manufacturing practices and other applicable government regulations and corresponding
standards. If our contract manufacturers fail to achieve and maintain high manufacturing standards in compliance with quality system
regulations, we may experience manufacturing errors resulting in patient injury or death, product recalls or withdrawals, delays or interruptions
of production or failures in product testing or delivery, delay or prevention of filing or approval of marketing applications for our
products, cost overruns or other problems that could seriously harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
performance failure on the part of our contract manufacturers could delay clinical development or regulatory clearance or approval of
our product candidates or commercialization of our future product candidates, depriving us of potential product revenue and resulting
in additional losses. In addition, our dependence on a third-party for manufacturing may adversely affect our future profit margins.
Our ability to replace an existing manufacturer may be difficult because the number of potential manufacturers is limited and the FDA
must approve any replacement manufacturer before it can begin manufacturing our product candidates. Such approval would require additional
non-clinical testing and compliance inspections. It may be difficult or impossible for us to identify and engage a replacement manufacturer
on acceptable terms in a timely manner, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are dependent on third-party distributors to market and sell our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited internal marketing, sales or distribution capabilities and currently we do not intend to develop extensive internal marketing,
sales or distribution capabilities in the future. Rather, we intend to utilize third-party distributors to market our products, and have
entered into exclusive distribution agreements with respect to certain territories. There is no assurance that third party distributors
will achieve acceptable levels of sales or that, if any of our existing arrangements expire or terminate, we will be able to replace
any distributors on terms advantageous to us, or at all. Further, there is no assurance that we will be able to expand our distribution
network by adding additional distributors. If third party distributors cease to promote our products, or if we are unable to make acceptable
arrangements with distributors or sales personnel in other markets, our business prospects, operating results or financial condition
could be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Independent
clinical investigators and contract research organizations that we engage to conduct our clinical trials may not be diligent, careful
or timely.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will depend on independent clinical investigators to conduct our clinical trials. Contract research organizations may also assist us
in the collection and analysis of data. These investigators and contract research organizations will not be our employees and we will
not be able to control, other than by contract, the amount of resources, including time that they devote to products that we develop.
If independent investigators fail to devote sufficient resources to the clinical trials, or if their performance is substandard, it will
delay the approval or clearance and commercialization of any products that we develop. Further, the FDA requires that we comply with
standards, commonly referred to as good clinical practice, for conducting, recording and reporting clinical trials to assure that data
and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. If
our independent clinical investigators and contract research organizations fail to comply with good clinical practice, the results of
our clinical trials could be called into question and the clinical development of our product candidates could be delayed. Failure of
clinical investigators or contract research organizations to meet their obligations to us or comply with federal regulations could adversely
affect the clinical development of our product candidates and harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to obtain and enforce patent protection for our products, our business could be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends, among other things, on our ability to protect proprietary methods and technologies that we develop under the patent
and other intellectual property laws of the United States and other countries, so that we can prevent others from unlawfully using our
inventions and proprietary information. However, we may not hold proprietary rights to some patents required for us to commercialize
proposed products. For this and other reasons, we may be unable to secure desired patent rights, thereby losing desired exclusivity.
Although we do not believe that we need any licenses for GlucoTrack&#174;, we may need to obtain licenses in the future for other products
or in certain circumstances, such as if one of our patents were declared invalid in the future. If such licenses are not available to
us on acceptable terms, we will not be able to market the affected products or conduct the desired activities, unless we successfully
challenge the validity, enforceability or infringement of the third-party patent or otherwise circumvent the third-party patent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy depends on our ability to rapidly identify and seek patent protection for our discoveries. The process of obtaining patent protection
is expensive and time-consuming. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and
use information that we regard as proprietary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of a patent does not guarantee that it is valid or enforceable. Any patents we have obtained, or which we may obtain in the
future, may be challenged, invalidated, unenforceable or circumvented. Moreover, the United States Patent and Trademark Office (the &#8220;USPTO&#8221;)
may commence interference proceedings involving our patents or patent applications. Any challenge to, finding of unenforceability or
invalidation or circumvention of our patents or patent applications would be costly, would require significant time and attention of
our management and could have a material adverse effect on our business. In addition, court decisions may introduce uncertainty in the
enforceability or scope of patents owned by medical device companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
pending patent applications may not result in issued patents. The patent position of medical device companies, including us, is generally
uncertain and involves complex legal and factual considerations. The standards that the USPTO and its foreign counterparts use to grant
patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy regarding the subject
matter and scope of claims granted or allowable in medical device patents. Accordingly, we do not know the degree of future protection
for our proprietary rights or the breadth of claims that will be allowed in any patents issued to us or to others. The legal systems
of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not protect our rights
to the same extent as the laws of the United States. Therefore, the enforceability or scope of our patents in the United States or in
foreign countries cannot be predicted with certainty, and, as a result, any patents that we own may not provide sufficient protection
against competitors. We may not be able to obtain or maintain patent protection for our pending patent applications or those we may file
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that any patents that will issue, that may issue or that may be licensed to us will be enforceable or valid or will
not expire prior to the commercialization of our product candidates, thus allowing others to more effectively compete with us. Therefore,
any patents that we own may not adequately protect our product candidates or our future products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could
be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, know-how and confidential
and proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we will seek to enter into
confidentiality and non- disclosure agreements with our employees, consultants and collaborators upon the commencement of their relationships
with us. These agreements generally require that all confidential information developed by the individual or made known to the individual
by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements
with employees also generally provide and will generally provide that any inventions conceived by the individual in the course of rendering
services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with
whom we have these agreements may not comply with their terms. In the event of unauthorized use or disclosure of our trade secrets or
proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for trade secrets or
other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third
parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adequate
remedies may not exist in the event of unauthorized use or disclosure of our confidential information. The disclosure of trade secrets
would impair our competitive position and may materially harm our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Some
jurisdictions may require us to grant licenses to third parties. Such compulsory licenses could be extended to include some of our product
candidates, which may limit potential revenue opportunities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant
licenses to third parties. In addition, most countries limit the enforceability of patents against government agencies or government
contractors. In these countries, the patent owner may be limited to monetary relief and may be unable to enjoin infringement, which could
materially diminish the value of the patent. Compulsory licensing of life-saving products is also becoming increasingly popular in developing
countries, either through direct legislation or international initiatives. Such compulsory licenses could be extended to include some
of our product candidates, which may limit our potential revenue opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third
parties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
entities may have or obtain patents or proprietary rights that could limit our ability to manufacture, use, sell, offer for sale or import
products or impair our competitive position. In addition, to the extent that a third party develops new technology that covers our products,
we may be required to obtain licenses to that technology, which licenses may not be available on commercially reasonable terms, if at
all. If licenses are not available on acceptable terms, we will not be able to market the affected products or conduct the desired activities
unless we successfully challenge the validity, enforceability or infringement of the third-party patent or circumvent the third-party
patent, which would be costly and would require significant time and attention of our management. Third parties may have or obtain valid
and enforceable patents or proprietary rights that could block us from developing products using our technology. Our failure to obtain
a license to any technology that we require may materially harm our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and
expenses, substantial liability for damages or be required to stop our product development and commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may sue us for infringing their patent rights. Likewise, we may need to resort to litigation to enforce a patent issued or licensed
to us or to determine the scope and validity of proprietary rights of others. In addition, a third party may claim that we have improperly
obtained or used our confidential or proprietary information. The cost to us of any litigation or other proceeding relating to intellectual
property rights, even if resolved in our favor, could be substantial, and the litigation would divert management&#8217;s efforts. Some
of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially
greater resources. Uncertainties resulting from the initiation and continuation of any litigation could limit our ability to continue
our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any parties successfully claim that our creation or use of proprietary technologies infringes upon their intellectual property rights,
we might be forced to pay damages, potentially including treble damages, if we are found to have willfully infringed on such parties&#8217;
patent rights. In addition to any damages we might have to pay, a court could require us to stop the infringing activity or obtain a
license. Any license required under any patent may not be made available on commercially acceptable terms, if at all. In addition, such
licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same technology. If we fail to obtain
a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and products,
which could limit our ability to generate revenues or achieve profitability and possibly prevent us from generating revenue sufficient
to sustain operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to obtain additional regulatory approvals outside the United States will prevent or limit us from marketing our product candidates abroad.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to market our product candidates in non-U.S. markets. In order to market product candidates in the EU and many other non-U.S.
jurisdictions, we must obtain separate regulatory approvals. In December 2012, we submitted our technical file to the Notified Body in
connection with our application to obtain CE Mark approval for GlucoTrack&#174; 1.0. On June 4, 2013, we received CE Mark approval for
the GlucoTrack&#174; 1.0 from the Notified Body. Receipt of the CE Mark allows us to market and sell the GlucoTrack&#174; 1.0 in EU member
countries that have adopted the MDD without being subject to additional national regulations with regard to demonstration of performance
and safety. The CE Mark also permits the sale in countries that have an MDD Mutual Recognition Agreement with the EU. However, member
countries may apply and enforce the MDD&#8217;s terms differently, and certain EU member countries may request or require that we provide
performance and/or safety data additional to the MDD&#8217;s requirements from time to time, on a case-by-case basis, in order to be
cleared to market and sale GlucoTrack&#174; in such countries. Receipt of FDA approval does not ensure approval by regulatory authorities
in countries, and approval by one or more non-U.S. regulatory authorities (including receipt of the CE Mark) does not ensure approval
by regulatory authorities in other countries or by the FDA. The non-U.S. regulatory approval process may include all of the risks associated
with obtaining FDA approval or clearance. We may not obtain additional non-U.S. regulatory approvals on a timely basis, if at all. We
may not be able to file for additional non-U.S. regulatory approvals and may not receive necessary approvals to commercialize our product
candidates in any market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-U.S.
governments often impose strict price controls, which may adversely affect our future profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to seek approval to market GlucoTrack&#174; and our future product candidates, if any, in both the U.S. and in non-U.S. jurisdictions.
If we obtain approval in one or more non-U.S. jurisdictions, we will be subject to rules and regulations in those jurisdictions relating
to our products. In some countries, particularly countries of the EU, each of which has developed its own rules and regulations, pricing
may be subject to governmental control under certain circumstances. In these countries, pricing negotiations with governmental authorities
can take considerable time after the receipt of marketing approval for a medical device candidate. Each of the EU member states has its
own unique legal system and thus it is difficult to predict the particular requirements to which we may be subject. To obtain reimbursement
or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product
to other available products. If reimbursement of our product candidates is unavailable or limited in scope or amount, or if pricing is
set at unsatisfactory levels, we may be unable to achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business may become subject to economic, political, regulatory and other risks associated with international operations, which could
harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to risks associated with conducting business internationally. Accordingly, our future results could be harmed by
a variety of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in compliance with non-U.S. laws and regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in non-U.S. regulations and customs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in non-U.S. currency exchange rates and currency controls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in a specific country&#8217;s or region&#8217;s political or economic environment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trade
    protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    consequences from changes in tax laws; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    associated with staffing and managing foreign operations, including differing labor relations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to enforce covenants not-to-compete under current Israeli law, which might result in added competition for our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have non-competition agreements or provisions with all of our employees and executive officers, all of which are governed by Israeli
law. These agreements or provisions prohibit our employees from competing with us or working for our competitors, generally during, and
for up to nine months after termination of, their employment with us. However, Israeli courts are reluctant to enforce non-compete undertakings
of former employees and tend, if at all, to enforce those provisions for only relatively brief periods of time or in restricted geographical
areas. In addition, Israeli courts typically require the presence of additional circumstances, such as a demonstration of an employer&#8217;s
legitimate interest which was damaged; breach of fiduciary duties, loyalty and acting not in good faith; a payment of a special consideration
for employee&#8217;s non-compete obligation; material concern for disclosing employer&#8217;s trade secrets; or a demonstration that
an employee has unique value to the employer specific to that employer&#8217;s business, before enforcing a non-competition undertaking
against such employee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
funding that we received through the Israeli Innovation Authority (IIA) for research and development activities restricts our
ability to manufacture products or to transfer technology outside of Israel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 4, 2004, the OCS agreed to provide us with a grant of 420 thousand New Israeli Shekels (&#8220;NIS&#8221;), or approximately $93
thousand at an exchange rate of 4.502 NIS/dollar (the exchange rate in effect on such date), for our plan to develop a non-invasive blood
glucose monitor (the &#8220;development plan&#8221;). This grant constituted 60% of our research and development budget for the development
plan at that time. Due to our acceptance of this grant, we are subject to the provisions of the Israeli Law for the Encouragement of
Industrial Research and Development, 1984 (the &#8220;R&amp;D Law&#8221;). Among other things, the R&amp;D Law restricts our ability
to sell or transfer rights in technology or know-how developed with OCS funding or transfer any Means of Control (as defined in the R&amp;D
Law) of us to non-Israeli entities. The Industrial Research and Development Committee at the OCS (the &#8220;research committee&#8221;)
may, under special circumstances, approve the transfer outside of Israel of rights in technology or know-how developed with OCS funding
subject to certain conditions, including the condition that certain payments be made to the OCS. Additionally, we may not manufacture
products developed with OCS funding outside of Israel without the approval of the research committee. The restrictions regarding the
sale or transfer of technology or manufacturing rights out of Israel could have a material adverse effect on our ability to enter into
strategic alliances or enter into merger or acquisition transactions in the future that provide for the sale or transfer of our technology
or manufacturing rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to certain employee severance obligations, which may result in an increase in our expenditures.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Israeli law, employers are required to make severance payments to dismissed employees and employees leaving employment in certain other
circumstances, on the basis of the latest monthly salary for each year of service. This obligation results in an increase in our expenses,
including accrued expenses. Integrity Israel currently makes monthly deposits to insurance policies and severance pay funds in order
to provide for this liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s and its Israeli subsidiary&#8217;s agreements with all of their Israeli employees are in accordance with Section 14 of
the Israeli Severance Pay Law -1963 (&#8220;Section 14&#8221;). Payments in accordance with Section 14 release the Company from any other
future severance payments in respect of those employees. Deposits under Section 14 are not recorded as an asset in the Company&#8217;s
balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be at risk for delay in product development and other economic repercussions as a result of the COVID-19 pandemic.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
may be at risk as a result of the current COVID-19 pandemic. Risks that could affect our business include the duration and scope of the
COVID-19 pandemic and the impact on the demand for our products; actions by governments, businesses and individuals taken in response
to the pandemic; the length of time of the COVID-19 pandemic and the possibility of its reoccurrence; the timing required to develop
effective treatments and a vaccine in the event of future outbreaks; the eventual impact of the pandemic and actions taken in response
to the pandemic on global and regional economies; and the pace of recovery when the COVID-19 pandemic subsides.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We had identified a material weakness in
our internal control over financial reporting, and we may not be able to successfully implement remedial measures.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">We
identified material weaknesses related to our internal control over financial reporting as of December 31, 2021 and concluded that internal
control over financial reporting as at December 31, 2021 were not effective. The ineffectiveness of the Company&#8217;s internal control
over financial reporting was due to identification of material weaknesses related to lack of sufficient internal accounting personnel,
se<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">gregation of duties, and lack of sufficient internal controls
(including IT general controls) that encompass the Company as a whole with respect to entity and transactions level controls in order
to ensure complete documentation of complex and non-routine transactions and adequate financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to complete our remediation plan within the next 12 months. However, we have not tested the effectiveness of our internal control
over financial reporting and cannot assure you that we will be able to successfully remediate this material weakness and, even if we
do, we cannot assure you that we will not suffer from other material weaknesses in the future. Except for additional personnel costs,
the cost of systems and the costs of our third-party service providers, we do not expect to incur any material costs related to our remediation
plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
there can be no assurance that we will not suffer from other material weaknesses or significant deficiencies in the future. If we fail
to remediate these material weaknesses or fail to otherwise maintain effective internal controls over financial reporting in the future,
such failure could result in a material misstatement of our annual or quarterly financial statements that would not be prevented or detected
on a timely basis and which could cause investors and other users to lose confidence in our financial statements, limit our ability to
raise capital and have a negative effect on the trading price of our common stock. Additionally, failure to remediate the material weakness
or otherwise maintain effective internal controls over financial reporting may also negatively impact our operating results and financial
condition, impair our ability to timely file our periodic and other reports with the SEC, subject us to additional litigation and regulatory
actions and cause us to incur substantial additional costs in future periods relating to the implementation of remedial measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our common stock may fluctuate significantly.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of the common stock may fluctuate significantly in response to numerous factors, some of which are beyond our control, such
as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    announcement of new products or product enhancements by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    concerning intellectual property rights and regulatory approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
    in our and our competitors&#8217; results of operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in earnings estimates or recommendations by securities analysts, if the common stock is covered by analysts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    in the medical device industry; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of product liability or intellectual property lawsuits;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    issuances of common stock or other securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    addition or departure of key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of acquisitions, investments or strategic alliances; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market conditions and other factors, including factors unrelated to our operating performance.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
in recent years, the stock market in general, and the market for medical device companies in particular, have experienced extreme price
and volume fluctuations. Continued or renewed market fluctuations could result in extreme volatility in the price of our common stock,
which could cause a decline in the value of the common stock. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
our common stock is a &#8220;penny stock,&#8221; it may be more difficult for investors to sell shares of the common stock, and the market
price of the common stock may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock may be a penny stock if, among other things, the stock price is below $5.00 per share. Broker-dealers who sell penny
stocks must provide purchasers of these stocks with a standardized risk- disclosure document prepared by the SEC. This document provides
information about penny stocks and the nature and level of risks involved in investing in the penny-stock market. A broker must also
give a purchaser, orally or in writing, bid and offer quotations and information regarding broker and salesperson compensation, make
a written determination that the penny stock is a suitable investment for the purchaser and obtain the purchaser&#8217;s written agreement
to the purchase. Broker-dealers must also provide customers that hold penny stock in their accounts with such broker-dealer a monthly
statement containing price and market information relating to the penny stock. If a penny stock is sold to an investor in violation of
the penny stock rules, the investor may be able to cancel its purchase and get its money back.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
applicable, the penny stock rules may make it difficult for investors to sell their shares of common stock. Because of the rules and
restrictions applicable to a penny stock, there is less trading in penny stocks and the market price of the common stock may be adversely
affected. Also, many brokers choose not to participate in penny stock transactions. Accordingly, investors may not always be able to
resell their shares of common stock publicly at times and prices that they feel are appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compliance
with changing regulations concerning corporate governance and public disclosure may result in additional expenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley
Act of 2002, new regulations promulgated by the SEC and rules promulgated by the national securities exchanges. These new or changed
laws, regulations and standards are subject to varying interpretations in many cases due to their lack of specificity, and, as a result,
their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result
in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance
practices. As a result, our efforts to comply with evolving laws, regulations and standards are likely to continue to result in increased
general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance
activities. Our directors, Chief Executive Officer and Chief Financial Officer could face an increased risk of personal liability in
connection with the performance of their duties. As a result, we may have difficulty attracting and retaining qualified directors and
executive officers, which could harm our business. If our efforts to comply with new or changed laws, regulations and standards differ
from the activities intended by regulatory or governing bodies, we could be subject to liability under applicable laws or our reputation
may be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
a certain portion of our expenses is incurred in currencies other than the NIS, our results of operations may be harmed by currency fluctuations
and inflation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency of Integrity Israel is the NIS, and we pay a substantial portion of our expenses in NIS. However, we expect a portion
of our future revenues to be denominated in U.S. dollars or in Euros. As a result, we will be exposed to the currency fluctuation risks
relating to the recording of our revenues in NIS. For example, if the NIS strengthens against either the U.S. dollar or the Euro, our
reported expenses in NIS may be higher than anticipated. The Israeli rate of inflation has not offset or compounded the effects caused
by fluctuations between the NIS and the U.S. dollar or the Euro. To date, we have not engaged in hedging transactions. Although the Israeli
rate of inflation has not had a material adverse effect on our financial condition to date, we may, in the future, decide to enter into
currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of the currencies mentioned
above in relation to the NIS. These measures, however, may not adequately protect us from material adverse effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
adoption of the &#8220;Conflict Minerals&#8221; regulations may adversely affect the manufacturing of our current and future products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
requirements regarding the use of &#8220;conflict minerals&#8221; could affect the sourcing and availability of the raw materials used
by our third-party manufacturers. We may be subject to costs associated with the new regulations, including for the diligence pertaining
to the presence of any conflict minerals used in our products and the cost of remediation and other changes to products, processes, or
sources of supply as a consequence of such verification activities. The impact of the regulations may result in a limited pool of suppliers
who provide conflict free minerals, and we cannot assure that we will be able to obtain products in sufficient quantities or at competitive
prices. We may face reputational challenges with our customers and other stakeholders if we are unable to sufficiently verify the origins
for the metals used in the products we sell. As a result, we may not be able to obtain the materials necessary to manufacture our products,
which could force us to cease production or search for alternative supply sources, possibly at a higher cost. Such disruptions may have
a material adverse effect on our business, financial condition, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ha_006"></span>Item
1B. Unresolved Staff Comments.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ha_007"></span>Item
2. Properties.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
Integrity Israel have several non-cancellable operating lease agreements for few vehicles. the Company&#8217;s leases have original
lease periods expiring between 2023 and 2024. Payments due under such lease contracts include primarily fixed payments. The Company does
not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably assured at lease commencement.
The company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since March 2021 Integrity Israel rents several workspaces at designated office building in the city Or &#8211; Yehoda. such rent replace
the principal offices of the Company in the city Ashdod. According to the new agreements the Company rents those flexible shared workspaces
for periods shorter than one year (mostly 6 month), and renews the agreement in accordance with its needs.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ha_008"></span>Item
3. Legal Proceedings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not presently a party to any material litigation. We may, however, become involved in litigation from time to time relating to claims
arising in the ordinary course of our business. These claims, even if not meritorious, could result in the expenditure of significant
financial and managerial resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ha_009"></span>Item
4. Mine Safety Disclosures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_001"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_002"></span>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
March 30, 2022, there were approximately 358 holders of record of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our Common Stock and do not anticipate paying any dividends on our Common Stock in
the foreseeable future. Any cash that might be available for payment of dividends will be used to expand our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_003"></span>Item
6. Selected Financial Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved].</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_004"></span>Item
7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prospective
investors should read the following discussion and analysis of our financial condition and results of operations together with our financial
statements and the related notes </i>and <i>other financial information included elsewhere in this report. Some of the information contained
in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for
our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should review the &#8220;Risk
Factors&#8221; section of this report for a discussion of important factors that could cause actual results to differ materially from
the results described in or implied by the forward-looking statements contained in the following discussion and analysis</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for
use by people with diabetes. Integrity Israel was founded in 2001 with a mission to develop, produce and market non-invasive glucose
monitors for home use by diabetics. We have developed a non-invasive blood glucose monitor, GlucoTrack&#174;, which is designed to help
people with diabetes obtain blood glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive)
spot finger stick devices. Our first generation product, GlucoTrack&#174; 1.0 utilizes a patented combination of ultrasound, electromagnetic
and thermal technologies to obtain blood glucose measurements in less than one minute via a small sensor that is clipped onto one&#8217;s
earlobe and connected to a small, handheld control and display unit, all without drawing blood. Our next generation product, GlucoTrack&#174;
2.0 which is currently under development, utilizes substantially identical underlying sensor technology, and is expected to be a completely
wireless sensor to be clipped on the earlobe. GlucoTrack eliminates the handheld unit and will transmit results directly to a user&#8217;s
smartphone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
may be at risk as a result of the current COVID-19 pandemic. Risks that could affect our business include the duration and scope of the
COVID-19 pandemic and the impact on the demand for our products; actions by governments, businesses and individuals taken in response
to the pandemic; the length of time of the COVID-19 pandemic and the possibility of its reoccurrence; the timing required to develop
effective treatments and a vaccine in the event of future outbreaks; the eventual impact of the pandemic and actions taken in response
to the pandemic on global and regional economies; and the pace of recovery when the COVID-19 pandemic subsides.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations discuss our financial statements, which have
been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).
In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events,
and apply judgments that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosures. We base our
assumptions, estimates and judgments on historical experience, current trends and other factors that management believes to be relevant
at the time our consolidated financial statements are prepared. On a regular basis, management reviews the accounting policies, assumptions,
estimates and judgments to ensure that our financial statements are presented fairly and in accordance with U.S. GAAP. However, because
future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates,
and such differences could be material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
significant accounting policies are discussed in Note 2, Summary of Significant Accounting Policies, of the Notes to Consolidated Financial
Statements included elsewhere in this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Critical accounting estimates.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our discussion and analysis of our financial condition
and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with USGAAP. The
preparation of our consolidated financial statements and related disclosures requires us to make estimates, assumptions and judgments
that affect the reported amounts of assets, liabilities, net sales, costs and expenses and related disclosures. management believes that
there are no critical accounting estimates in these financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In June
2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments&#8221; (&#8220;ASU 2016-13&#8221;), which changes the impairment model for most financial assets and certain other instruments.
For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities will be required to use a new
forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. The
guidance also requires increased disclosures. For the Company, the amendments in the update were originally effective for fiscal years
beginning after December 15, 2019, including interim periods within those fiscal years. In November 2019, the FASB issued ASU No. 2019-10,
which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined by the SEC) and other non-SEC reporting entities
to fiscal years beginning after December 15, 2022, including interim periods within those fiscal periods. Early adoption is permitted.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As the company is eligible to considered as smaller
reporting company ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those
fiscal years. The adoption of this standard is not expected to result in a material impact to the Company&#8217;s financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion of our operating results explains material changes in our results of operations for the years ended December 31,
2021 and December 31, 2020. The discussion should be read in conjunction with the financial statements and related notes included elsewhere
in this report.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>Year Ended December 31, 2021 Compared to Year Ended December 31,
2020</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and development expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses were $1,810 thousand for the year ended December 31, 2021, as compared to $1,532 thousand for
the prior-year period. The increase is attributable to expenses due to slow inventory write-off.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of salaries and other personnel-related expenses, including stock-based compensation expenses,
materials, travel expenses, clinical trials and other expenses. We expect research and development expenses to increase in 2022 and beyond,
primarily due to hiring additional personnel and developing our product line, as well the development of GlucoTrack&#174; 2.0; however,
we may adjust or allocate the level of our research and development expenses based on available financial resources and based on our
commercial needs, including the FDA registration process, specific requirements from customers, development of new GlucoTrack&#174; models
and others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Selling
and marketing expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Selling and marketing expenses were $139 thousand
for the year ended December 31, 2021, as compared to $415 thousand for the prior-year period. The decrease is primarily attributable
to the Company&#8217;s decision to reduce its business development expenses until the completion of the development of the GlucoTrack&#174;
2.0.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Selling and marketing expenses
consist primarily of professional services, salaries, travel expenses and other related expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
and administrative expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were $2,091 thousand for the year ended December 31, 2021, as compared to $1,185 thousand for
the prior-year period. The increase is primarily attributable to hiring of new and augmented personnel to move forward
our business agenda.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of professional services, salaries, travel expenses and other related expenses for executive,
finance and administrative personnel, including stock-based compensation expenses. Other general and administrative costs and expenses
include facility-related costs not otherwise included in research and development costs and expenses, and professional fees for legal
and accounting services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Financing
Income, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
Income, net was $26 thousand for the year ended December 31, 2021, as compared to financing Income, net, of $98
thousand for the prior-year period. The decrease in the financing income is attributed to the decrease in interest income resulting
from the reduction in the company&#8217;s cash balance over the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Loss</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss was $4,067 thousand for the year ended December 31, 2021, as compared to a net loss of $2,696 thousand for the prior-year
period. The increase in net loss is attributable primarily to the increase in our general and administrative expenses and development expenses as described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, and December 31, 2020, cash on hand was $6,062 thousand and $9,823 thousand, respectively. During 2020,
we received $13,009 thousand from the issuance and sale of our common stocks, We do not anticipate that our income from operations will
be sufficient to sustain our operations in the next 12 months. Based on our current cash burn rate, strategy and operating plan, we believe
that our cash and cash equivalents will enable us to operate for a period of significantly more than one year from the date of this report
to cover our current operating needs and initial clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years 2003-2004, Integrity Israel received loans from stockholders (four separate lenders) in a total amount of approximately $400
thousand. However, following the repayment of the entire balance to lender in 2015, the remaining balance as of December 31, 2021 is
approximately $210 thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to pay royalties to the Office of the Chief Scientist at a rate ranging between 3-5% of the proceeds from the sale of the
Company&#8217;s products arising from the development plan up to an amount equal to $93 thousand, plus interest at LIBOR from the date
of grant. As of December 31, 2021, the contingent liability with respect to royalty payment on future sales equals to approximately $43
thousand, excluding interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 33.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Year
Ended December 31, 2021 Compared to Year Ended December 31, 2020</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Used in Operating Activities for the Years Ended December 31, 2021 and December 31, 2020</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $3,769 thousand and $3,501 thousand for the years ended December 31, 2021 and 2020, respectively.
Net cash used in operating activities primarily reflects the net loss for those periods of $4,067 thousand and $2,696 thousand,
respectively offset by the net changes in operating assets and liabilities that during the year ended December 31, 2021 increased
our net cash used in operating activities for the year ended December 31, 2021 by $981 thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Used in Investing Activities for the Years Ended December 31, 2021 and December 31, 2020</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $1 thousand and $53 thousand for the years ended December 31, 2021 and 2020, respectively,
mainly consisting of equipment purchases (such as computers, research and development and office equipment).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Provided by Financing Activities for the Years Ended December 31, 2021 and December 31, 2020</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $0 thousand and $13,009 thousand for the years ended December 31, 2021 and 2020,
respectively. Cash provided by financing activities for the years ended December 31, 2020 reflected net capital raised in February
2020 throughout issuance of 37.5 million common stocks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_005"></span>Item
7A. Quantitative and Qualitative Disclosures About Market Risk.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
required for smaller reporting companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_006"></span>Item
8. Financial Statements and Supplementary Data.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements required by this Item 8 are filed herewith commencing on page F-1 hereto and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_007"></span>Item
9. Change in and Disagreements with Accountants on Accounting and Financial Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_008"></span>Item
9A. Controls and Procedures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Evaluation
of Disclosure Controls and Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our Principal Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our
disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31,
2021, or the Evaluation Date. Based on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure
controls and procedures are ineffective in recording, processing, summarizing and reporting, on a timely basis, information required
to be included in periodic filings under the Exchange Act and that such information is not accumulated and communicated to management,
including our principal executive and financial officers, in a manner sufficient to allow timely decisions regarding required disclosure,
due to the material weaknesses in internal control over financial reporting described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Management&#8217;s
Report on Internal Control Over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined
in Rule 13a-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive
Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting
based principally on the framework and criteria established in Internal Control - Integrated Framework (2013) issued by the Committee
of Sponsoring Organizations of the Treadway Commission as of the end of the period covered by this report. Based on that evaluation,
we have identified material weaknesses related to our internal control over financial reporting as of December 31, 2021 and concluded
that internal control over financial reporting as at December 31, 2021 were not effective. As defined in Regulation 12b-2 under the Securities
Exchange Act, a &#8220;material weakness&#8221; is a deficiency, or combination of deficiencies, in internal control over financial reporting,
such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented,
or detected on a timely basis. Specifically, as of December 31, 2021, the ineffectiveness of the Company&#8217;s internal control over
financial reporting was due to identification of material weaknesses related to lack of sufficient internal accounting personnel, segregation
of duties, and lack of sufficient internal controls (including IT general controls) that encompass the Company as a whole with respect
to entity and transactions level controls in order to ensure complete documentation of complex and non-routine transactions and adequate
financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has identified corrective actions to remediate such material weaknesses, which includes hiring additional employees. Management intends
to implement procedures to remediate such material weaknesses during the fiscal year 2022; however, the implementation of these initiatives
may not fully address any material weaknesses that we may have in our internal control over financial reporting.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, there</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> were no
changes in our internal control over financial reporting  that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting. As the Company has historically had personnel both in the
U.S. and Israel, there has been no change in working status due to working remotely as a result of COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Attestation
Report of the Registered Public Accounting Firm</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.6pt">This Annual Report does not
include an attestation report of the Company&#8217;s registered public accounting firm regarding internal control over financial reporting.
Management&#8217;s report was not subject to attestation by the Company&#8217;s registered public accounting firm pursuant to rules of
the SEC that permit the Company to provide only management&#8217;s report in this Annual Report.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_009"></span>Item
9B. Other Information.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9 C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspection</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_010"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_011"></span>Item
10. Directors, Executive Officers, and Corporate Governance.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the information about our Code of Ethics below, the information required by this Item 10 is incorporated by reference from our definitive
proxy statement for our 2021 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;). The definitive Proxy Statement will
be filed with the Securities and Exchange Commission within 120 days after the close of the fiscal year covered by this Annual Report
on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a Code of Business Conduct and Ethics (Code) that applies to all employees, including our principal executive officer, principal
financial officer, principal accounting officer, controller and persons performing similar functions, and including our independent directors,
who are not employees of the Company, with regard to their Integrity-related activities. The Code incorporates guidelines designed to
deter wrongdoing and to promote honest and ethical conduct and compliance with applicable laws, rules and regulations. The Code also
incorporates our expectations of our employees that enable us to provide accurate and timely disclosure in our filings with the SEC and
other public communications. In addition, the Code incorporates guidelines pertaining to topics such as complying with applicable laws,
rules, and regulations; insider trading; reporting Code violations; and maintaining accountability for adherence to the Code. The full
text of our Code is published on our web site at http://www.integrity-app.com/investor-relations/corporate-governance/ and is incorporated
by reference herein. We intend to disclose future amendments to certain provisions of our Code, or waivers of such provisions granted
to our principal executive officer, principal financial officer, principal accounting officer or controller and persons performing similar
functions on our web site. Except as expressly stated herein, the information contained on our website does not constitute a part of
this Annual Report on Form 10-K and is not incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_012"></span>Item
11. Executive Compensation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required for this Item is incorporated by reference from our Proxy Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_013"></span>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required for this Item is incorporated by reference from our Proxy Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_014"></span>Item
13. Certain Relationships and Related Transactions, and Director Independence.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required for this Item is incorporated by reference from our Proxy Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_015"></span>Item
14. Principal Accountant Fees and Services.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required for this Item is incorporated by reference from our Proxy Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_016"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_017"></span>Item
15. Exhibits, Financial Statement Schedules.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Document
    List</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(1)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
    Statements:</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company filed herewith are set forth in Part II, Item 8 of this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(2)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
    Statement Schedules:</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -46.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(3)</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exhibits:</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 72px"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex2-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger Agreement and Plan of Reorganization, dated as of May 25, 2010, by and among Integrity Applications, Inc., Integrity Acquisition Ltd. and A.D. Integrity Applications Ltd. (1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation of Integrity Applications, Inc. (1)</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex3-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation of Integrity Applications, Inc. (1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex3-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws of Integrity Applications, Inc. (1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891313000746/exhibit_3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of Preferences and Rights of Series A 5% Convertible Preferred Stock (2)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891314002852/exhibit_3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of Preferences and Rights of Series B 5.5% Convertible Preferred Stock (3)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891316005077/exhibit_3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of Preferences and Rights of Series C 5.5% Convertible Preferred Stock (8)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">3.7</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex3-7.htm">Amendments to The Company's Certificate of Incorporation**</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Certificate Evidencing Shares of Common Stock (1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant (1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891313000746/exhibit_4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series A Securities Purchase Agreement (2)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891313000746/exhibit_4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series A Common Stock Purchase Warrant (2)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891313000746/exhibit_4-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series A Registration Rights Agreement (2)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891314002852/exhibit_4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series B Securities Purchase Agreement (3)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891314002852/exhibit_4-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series B-1 Common Stock Purchase Warrant (3)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891314002852/exhibit_4-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series B-2 Common Stock Purchase Warrant (3)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891314002852/exhibit_4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series B Registration Rights Agreement (3)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891316005077/exhibit_4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series C Securities Purchase Agreement (8)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891316005077/exhibit_4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series C-1 Common Stock Purchase Warrant (8)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891316005077/exhibit_4-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series C-2 Common Stock Purchase Warrant (8)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891316005077/exhibit_4-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series C Registration Rights Agreement (8)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891318000782/exhibit_4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series D Securities Purchase Agreement (12)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891318000782/exhibit_4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series D-1 Common Stock Purchase Warrant (12)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891318000782/exhibit_4-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series D-2 Common Stock Purchase Warrant (12)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891318000782/exhibit_4-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series D-3 Common Stock Purchase Warrant (12)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891318000782/exhibit_4-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series D Registration Rights Agreement (12)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrity Applications, Inc. 2010 Incentive Compensation Plan (1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891316004823/exhibit_10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Integrity Applications, Inc. 2010 Incentive Compensation Plan (13)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891317001119/exhibit_10-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 2 to Integrity Applications, Inc. 2010 Incentive Compensation Plan (11)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex10-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Director and Officer Indemnification Agreement (1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex10-7.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personal Employment Agreement, dated as of October 19, 2010, between A.D. Integrity Applications Ltd. and Avner Gal (1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891317001119/exhibit_10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter Agreement, effective as of April 7, 2017, among Integrity Applications, Inc., A.D. Integrity Applications Ltd., and Avner Gal (11)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891317001119/exhibit_10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Personal Employment Agreement, effective as of April 7, 2017, between A.D. Integrity Applications Ltd. and David Malka (11)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex10-10.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irrevocable Undertaking of Indemnification, dated as of July 26, 2010, by and among Integrity Applications, Inc., Avner Gal, Zvi Cohen, Ilana Freger, David Malka and Alexander Raykhman (1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex10-11.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Agreement, dated February 18, 2003, between A.D. Integrity Applications Ltd., Avner Gal, Zvi Cohen, David Freger and David Malka and Yigal Dimri (1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex10-14.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Stock Option Agreement (1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411048873/v232648_ex10-15.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Stock Option Agreement (ESOP) (1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411062924/v240011_ex10-16.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter of Approval, addressed to Integrity Applications Ltd. from the Ministry of Industry, Trade and Employment of the State of Israel (6)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411056920/v236650_ex10-17.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter of Undertaking, addressed to the Ministry of Industry, Trade and Employment of the State of Israel &#8211; Office of the Chief Scientist from Integrity Applications Ltd. (4)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000114420411056920/v236650_ex10-18.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Agreement, dated March 16, 2004, by and among A.D. Integrity Applications Ltd., Yitzhak Fisher, Asher Kugler and Nir Tarlovsky. (4)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891314001124/exhibit_10-15.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personal Employment Agreement, dated as of October 22, 2013, between A.D. Integrity Applications Ltd. and Eran Hertz. (7)</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891317001006/exhibit_10-14.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personal Employment Agreement, dated as of February 1, 2017, between A.D. Integrity Applications Ltd. and Sami Sassoun (9)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891317001006/exhibit_10-15.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Consulting Agreement, dated as of February 6, 2017, between Integrity Applications, Inc. and Strand Strategy (9)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891317001006/exhibit_10-16.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personal Employment Agreement, dated as of March 20, 2017, between Integrity Applications, Inc. and John Graham (9)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891317001119/exhibit_10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to Employment Agreement, effective as of April 7, 2017, between Integrity Applications, Inc. and John Graham (11)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891317002404/exhibit_10-6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, effective as of June 26, 2017, between Integrity Applications, Inc. and David Podwalski (5)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891317001006/exhibit_14-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Ethics (9)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1506983/000117891317003057/exhibit_21-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries of Integrity Applications, Inc. (10)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">23.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex23-1.htm">Consent of Marcum LLP</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification of Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a) or 15(d)-14(a), as Adopted Pursuant to Section 302 of the Sarbanes Oxley Act of 2002 **</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification of Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a) or 15(d)-14(a), as Adopted Pursuant to Section 302 of the Sarbanes Oxley Act of 2002 **</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002 **</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002 **</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inline <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Instance Document **</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inline<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    XBRL Schema Document **</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inline <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Calculation Linkbase Document **</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inline <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Calculation Linkbase **</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inline <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Label Linkbase Document **</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inline <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRE
    XBRL Presentation Linkbase Document **</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">104</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed as an exhibit to the Company&#8217;s Registration Statement on Form S-1, as filed with the SEC on August 22, 2011.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed as an exhibit to the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on March 18, 2013.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed as an exhibit to the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on September 5, 2014.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed as an exhibit to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1, as filed with the SEC on October
    7, 2011.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended June 30, 2017, as filed with the SEC
    on August 18, 2017.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed as an exhibit to Amendment No. 3 to the Company&#8217;s Registration Statement on Form S-1, as filed with the SEC on November
    10, 2011.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as filed with
    the SEC on March 27, 2014.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed as an exhibit to the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on April 15, 2016.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, as filed with
    the SEC on March 31, 2017. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Previously
    filed as an exhibit to the Company&#8217;s Registration Statement on Form S-1, as filed with the SEC on November 7, 2017.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed as an exhibit to the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on April 15, 2017</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed as an exhibit to the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on March 7, 2018.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed as an exhibit to the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on March 23, 2016. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
    Plan or Arrangement or Management Contract.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_018"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized as of March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>GLUCOTRACK, INC.</b></p>

<p style="margin: 0"><b>(FORMERLY<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
INTEGRITY APPLICATIONS, INC.)</span></b></p>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Paul Goode</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Goode</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer (Principal Executive Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jolie Kahn</i></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jolie
    Kahn</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial Officer)</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jolie Kahn </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jolie
    Kahn</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive and Financial Officer and Principal Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Robert Fischell</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Robert Fischell</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Allen Danzig</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allen
    Danzig</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Shimon Rapps</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shimon
    Rapps</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Andrew Sycoff</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Sycoff</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Paul V.Goode</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COO
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    V.Goode</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Luis Malave</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Luis
    Malave</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>as
of December 31, 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 62px; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#sur_019">Report
    of Independent Registered Public Accounting Firm &#8211; ID No. <span id="xdx_903_edei--AuditorFirmId_c20210101__20211231_zajtRvVP3BYd"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:AuditorFirmId">1375</ix:nonNumeric></span></a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
    Financial Statements</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_020">Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_021">Statements of Operations and Comprehensive Loss</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_022">Statements of Changes in Stockholders&#8217; Equity (Deficit)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_023">Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_024">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7
    &#8211; F-23</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td rowspan="9" style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fahn
    Kanne &amp; Co.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head
    Office</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32
    Hamasger Street</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel-Aviv
    6721118, ISRAEL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PO
    Box 36172, 6136101</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">T
    +972 3 7106666</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F
    +972 3 7106660</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.gtfk.co.il</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_019"></span>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors and the Stockholders of</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the financial statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of GlucoTrack Inc. (Formerly: Integrity Applications, Inc.) (the &#8220;Company&#8221;)
as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217;
equity (deficit) and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively
referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each
of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States
of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Emphasis of a matter</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">As discussed in Note 1B to the financial statements,
the Company has suffered recurring losses from operations and negative cash flow from operating activities. Management&#8217;s evaluation
of the events and conditions and management&#8217;s plans to mitigate these matters are also described in Note 1B.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
accounting matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be
communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and
(2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>/s/
<span id="xdx_90E_edei--AuditorName_c20210101__20211231_zFX6AAnJ1Jqd"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:AuditorName">FAHN KANNE &amp; CO. GRANT THORNTON ISRAEL</ix:nonNumeric></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified
Public Accountants (Isr.)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2010.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--AuditorLocation_c20210101__20211231_zoJeBM2o2Ri1"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:AuditorLocation">Tel-Aviv,
Israel</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_020"></span>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_111_pn3n3_z5GPUpPsqaxi" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none">&#160;</td>
    <td colspan="2" id="xdx_49C_20211231_zCNfIZXsXvkc" style="display: none">&#160;</td><td style="display: none">&#160;</td><td style="display: none">&#160;</td>
    <td colspan="2" id="xdx_49B_20201231_zLOzOkMMUDlb" style="display: none">&#160;</td><td style="display: none">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In thousand of US dollars</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(except
                                            stock data)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrentAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_maACzD1t_zshyoNFV1Ocl" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,062</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,823</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccountsReceivableNetCurrent_i01I_pn3n3_maACzD1t_zF8JpQ5kYVgf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0056">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InventoryNet_i01I_pn3n3_maACzD1t_zcoSQb7xlU01" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Inventory (Note 3)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0059">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">284</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAssetsCurrent_i01I_pn3n3_maACzD1t_zJjZHMEeUcB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrent_i01TI_pn3n3_mtACzD1t_maAz3Ql_zTwQfCXRrW8g" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,105</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,229</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3n3_maAz3Ql_zlhbPgSVlHrf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease right-of-use assets, net (Note 4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">166</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_maAz3Ql_zreM3fKXaD6h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net (Note 5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">149</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_maAz3Ql_ze7278laG9td" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">62</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Assets_iTI_pn3n3_mtAz3Ql_zUwChxV50hFl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,265</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,606</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableCurrent_i02I_pn3n3_maLCzyzb_z9oQbHRDN4j9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">869</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pn3n3_maLCzyzb_zxi5BMNATyP" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Operating lease liabilities, current (Note 4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherLiabilitiesCurrent_i02I_pn3n3_maLCzyzb_z8xYAwXRJgzc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other current liabilities (Note 6)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">229</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">392</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrent_i02TI_pn3n3_mtLCzyzb_maLzk4d_zfiy5sAQaUnc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">883</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,345</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesNoncurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DueToOfficersOrStockholdersNoncurrent_i02I_pn3n3_maLNzZaS_z9Nn8KoRKoSf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Loans from stockholders (Note 7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DueToOfficersOrStockholdersNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DueToOfficersOrStockholdersNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">197</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_pn3n3_maLNzZaS_zTaImT1hS5a8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Operating lease liabilities, non-current (Note 4)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesNoncurrent_i02TI_pn3n3_mtLNzZaS_maLzk4d_zXLFEAk3Y9Ee" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">279</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Liabilities_i01TI_pn3n3_mtLzk4d_maLASEzegH_zdRDWQr0Kj4l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,624</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzegH_zqlkp1netOf8" style="vertical-align: bottom; background-color: White">
    <td>Commitments and contingent liabilities (Note 8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Common Stock of $ <span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211231_zC9kJ5YlMY41" title="Common stock, par value"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20201231_zVHgTRrZFdg3" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value (&#8220;Common Stock&#8221;):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CommonStockValue_i02I_pn3n3_maSEzi4m_zNX0xNVormEh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20211231_z06wFqsbefZ8" title="Common stock, shares authorized"><span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20201231_zyMh9ghdXOlg" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_pid_c20211231_zKt2WZoVNH63" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231_zS0siDHl4XH1" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,452,285</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20201231_z0q1MaNsHjK3" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20201231_zTQiL7SwKbs8" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,444,697</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2021 and 2020, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommonStockValue_i02I_pn3n3_maSEzi4m_zusQYV0uQq6l" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; padding-left: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Value</span></td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></span></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></span></td><td style="display: none; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_pn3n3_maSEzi4m_zqiDvGRzwoQ4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102,612</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102,351</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_pn3n3_maSEzi4m_zs0GTXw22OMe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accumulated other comprehensive income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_maSEzi4m_z1lyG89wbPLa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">97,466</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">93,399</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquity_i02TI_pn3n3_mtSEzi4m_maLASEzegH_zpwcRTYdHyGa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,155</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,982</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_mtLASEzegH_zusqVcA8QPKg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,265</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,606</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
accompanying notes are an integral part of these  consolidated financial statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_021"></span>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_113_pn3n3_zaj1GlIS4Bod" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_z9vmluwzMhLd" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2021</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20200101__20201231_z3XimS1M8gjc" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2020</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars (<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
    stock and per stock amounts)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_maOEzVM0_zv5wCQW5gipi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development expenses (Note 10)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,810</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,532</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--SellingAndMarketingExpense_maOEzVM0_zgisdnhsJC42" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marketing expenses (Note 11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">415</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_maOEzVM0_zcyOTm94dH98" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">General and administrative expenses (Note 12)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,091</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,185</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpenses_iT_pn3n3_mtOEzVM0_msOILz7GN_zzAVmWyB3XCl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,040</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,132</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_iNT_pn3n3_di_mtOILz7GN_maNILzCQn_zMmMGFnBa2Rd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,040</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,132</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherNonoperatingIncomeExpense_iN_pn3n3_di_maNILzCQn_zvpxONp2jx9d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other expense (Income)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">53</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">338</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--FinancingIncomeExpenseNet_iN_pn3n3_di_maNILzCQn_zluSWXBm6J35" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Financing income, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">(<ix:nonFraction name="IGAP:FinancingIncomeExpenseNet" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="IGAP:FinancingIncomeExpenseNet" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">98</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_iNT_pn3n3_di_mtNILzCQn_maCINOTz2q5_z0aUlvqxL1D6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,067</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,696</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other comprehensive loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_i01N_pn3n3_di_maCINOTz2q5_z0H3CJ967jnk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ComprehensiveIncomeNetOfTax_i01NT_pn3n3_di_mtCINOTz2q5_zF2bcc3QQKOh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Comprehensive loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,088</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,805</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EarningsPerShareDiluted_pid_zINl3kMVsyvc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Loss per share (Basic and Diluted)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.19</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_zf6BIE0pmZs7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Weighted average number of common stock outstanding used in computing basic
    and diluted net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">15,450,824</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">15,079,182</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
accompanying notes are an integral part of the consolidated financial statements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_022"></span>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STATEMENTS
OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_114_pn3n3_zqvKp4QbVEl7" summary="xdx: Statement - Statements of Changes In Stockholders&apos; Equity(Deficit)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; font-weight: bold; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Number<br /> of shares</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zh3897Efzszi" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Amount</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z9gaZ7tqo2rk" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">paid in <br /> capital</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zI0x4owsahyl" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">comprehensive<br /> loss</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zHGPEJIFp395" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Accumulated<br /> deficit</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_zq42Yuk5fMk2" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">(deficit)<br /> surplus</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars (except
    stock data)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total<br /> Stockholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">paid in <br /> capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">comprehensive income (loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br /> deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin: 0">Equity</p>(deficit)<br /> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_432_c20200101__20201231_eus-gaap--StockholdersEquity_iS_zx71uagzjUi1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance as of January 1, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8x5KLRcuDea" title="Beginning balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,450,649</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">89,155</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">124</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">90,703</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,412</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zHcy0ZMga2X3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0203">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0204">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0205">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,696</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,696</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zDQkdlnFqIfc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0209">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0210">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">109</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0212">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">109</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zZEqAPk8Meb8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0215">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0217">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0218">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zPCq8keG5I8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Common Stock, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsAAd3L3KOWb" title="Issuance of Common Stock, net, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,884,615</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0223">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0224">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,253</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--WarrantsIssuedAsConsiderationForPlacementServices_z4cTMakKGgS2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants issued as consideration for placement services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0229">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="IGAP:WarrantsIssuedAsConsiderationForPlacementServices" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">756</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0231">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0232">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="IGAP:WarrantsIssuedAsConsiderationForPlacementServices" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">756</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zQnD79S5W8C3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Issuance of restricted shares as compensation to directors</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkBti6aCVzY7" title="Issuance of restricted shares as compensation to directors, shares" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">109,433</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0235">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<sup id="xdx_F2F_zb0UGMudA3tl">*</sup>)
                                            -</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">168</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0237">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">168</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20200101__20201231_eus-gaap--StockholdersEquity_iE_zFRVoDBU8nv" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance as of December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziTNVBxMYUJ5" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,444,697</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102,351</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">93,399</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,982</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zwt0rxKPxoJ1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance as of January 1, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5yENDKJULb1" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,444,697</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102,351</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">93,399</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,982</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zmjarcAGyrHh" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Beginning balance, value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfNcDwp6Fa97" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,444,697</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102,351</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">93,399</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,982</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--NetIncomeLoss_zFOHGhy557Q7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0268">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0269">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,067</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,067</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zylPgLjRGwZ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0273">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0276">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zByceRz7xQJg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0279">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">223</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0281">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">223</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_z1UUw8SWtpkc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Issuance of restricted shares as compensation to directors</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTqddbcpgu26" title="Issuance of restricted shares as compensation to directors, shares" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,588</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0285">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<sup id="xdx_F20_z8Tw8zJzSNad">*</sup>)
                                            -</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zh2fqidtSWph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance as of December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDx8pVKZ1zFe" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,452,285</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102,612</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">97,466</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,155</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20210101__20211231_eus-gaap--StockholdersEquity_iE_znYwFEWJGZn8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Ending balance, value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhjkZhNHnlSj" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,452,285</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102,612</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">97,466</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,155</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td id="xdx_F0E_z1iYG3YBXw9g" style="width: 3%">(*)</td>
  <td id="xdx_F1F_z9tF4nbENQ18" style="width: 97%"><ix:footnote id="Footnote000308" xml:lang="en-US">Less than 1 thousand</ix:footnote></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
accompanying notes are an integral part of the consolidated financial statements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_023"></span>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_112_pn3n3_zJkxCC0a3EVe" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20211231_zh7bNTCcTFQ7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20200101__20201231_zGWZZBFTkCO8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_pn3n3_maNCPBUzQAL_zABaT3MmRUCl" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Loss for the year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,067</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,696</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Adjustments to reconcile loss for the year to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Depreciation_i02_pn3n3_maNCPBUzQAL_zo8vMjlQd46l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">47</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i02N_pn3n3_di_msNCPBUzQAL_zNc769HbXcSj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Capital loss from sale of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_i02_pn3n3_maNCPBUzQAL_zPcTFruEiLv" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">223</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors_i02_pn3n3_maNCPBUzQAL_zK0QH7lZsaM5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Issuance of restricted shares as compensation to directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="IGAP:IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="IGAP:IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">168</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--LinkageDifferenceOnPrincipalOfLoansFromStockholders_i02_pn3n3_maNCPBUzQAL_zVtmFzGiQcE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Linkage difference on principal of loans from stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="IGAP:LinkageDifferenceOnPrincipalOfLoansFromStockholders" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="IGAP:LinkageDifferenceOnPrincipalOfLoansFromStockholders" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 10pt">Changes in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_pn3n3_di_msNCPBUzQAL_zA8EtxRLGm5b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Decrease in accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInInventories_i03N_pn3n3_di_msNCPBUzQAL_zgdeEsCj2dbf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Decrease (increase) in inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">293</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInOtherCurrentAssets_i03N_pn3n3_di_msNCPBUzQAL_zzo0LyDtQAR1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Decrease (increase) in other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInAccountsPayableTrade_i03_pn3n3_maNCPBUzQAL_zYZKUInxMPk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Decrease in accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">257</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">714</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i03_pn3n3_maNCPBUzQAL_znRND1Fy2DE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Decrease in other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">172</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">236</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pn3n3_mtNCPBUzQAL_maCCERCzYxF_z0sNh1zil0m7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,769</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,501</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from investment activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_i01_pn3n3_maNCPBUzQ4F_zIjyOh8b8hLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sale of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pn3n3_di_msNCPBUzQ4F_zBe3tZ3I9an9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Purchase of property and equipment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">53</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pn3n3_mtNCPBUzQ4F_maCCERCzYxF_zOIm6InjRUg2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Net cash used in investment activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">53</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_pn3n3_maNCPBUzOae_zz0L506mgJX5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Proceeds from issuance of common stock, net of cash
    issuance costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,009</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pn3n3_mtNCPBUzOae_maCCERCzYxF_zHkEl2kgVgt8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,009</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_maCCERCzYxF_zJuKDncECv16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Effect of exchange rate changes on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">46</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pn3n3_mtCCERCzYxF_zeFM739TAes9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in cash, cash equivalents, and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,772</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,409</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_pn3n3_zkqsO4AwIQSb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash, cash equivalents, and restricted cash at beginning of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,885</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">476</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pn3n3_z4zAses0Ad7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Cash, cash equivalents, and restricted cash at end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,113</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,885</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supplementary
information on financing activities not involving cash flows:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ending December 31, 2021 and 2020, the Company settled a portion of the outstanding board fees in the amount of $<span id="xdx_905_ecustom--NumberOfCommonStockIssuedForSettlementOfFees_pn3n3_c20210101__20211231__srt--TitleOfIndividualAxis__custom--BoardOfMembersMember_zaCYFAvH4q9j" title="Number of common stock issued for settlement of fees" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ2FzaCBGbG93cyAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="IGAP:NumberOfCommonStockIssuedForSettlementOfFees" contextRef="From2021-01-012021-12-31_custom_BoardOfMembersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></span> and $<span id="xdx_907_ecustom--NumberOfCommonStockIssuedForSettlementOfFees_pn3n3_c20200101__20201231__srt--TitleOfIndividualAxis__custom--BoardOfMembersMember_ztALIjBqFaK1" title="Number of common stock issued for settlement of fees" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ2FzaCBGbG93cyAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="IGAP:NumberOfCommonStockIssuedForSettlementOfFees" contextRef="From2020-01-012020-12-31_custom_BoardOfMembersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">168</ix:nonFraction></span>
thousand through the issuance of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ending December 2020, $<span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ2FzaCBGbG93cyAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200101__20201231_zaGqmHi47FOc" title="Fair value of warrants issued"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">756</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand representing the fair value of warrants
issued as consideration for placement agent services. This amount was accounted for as warrants with down-round protection. Upon
issuance, the fair value was recognized as an increase in additional paid in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
accompanying notes are an integral part of the consolidated financial statements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_024"></span>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zeoMebonz0R8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zQgOjzDROmtf">GENERAL</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GlucoTrack
    Inc (Formerly: Integrity Applications, Inc.) (the &#8220;Company&#8221;) was incorporated on May 18, 2010 under the laws of
    the State of Delaware. On July 15, 2010, GlucoTrack Acquisition Corp. Ltd. (hereinafter: &#8220;Integrity Acquisition&#8221;), a
    wholly owned Israeli subsidiary of the Company, which was established on May 23, 2010, completed a merger with A.D. Integrity Applications
    Ltd. (hereinafter: &#8220;Integrity Israel&#8221;), an Israeli corporation that was previously held by the stockholders of the Company.
    Pursuant to the merger, all equity holders of Integrity Israel received the same proportional ownership in the Company as they had
    in Integrity Israel prior to the merger. Following the merger, Integrity Israel remained a wholly-owned subsidiary of the Company.
    As the merger transaction constituted a structural reorganization, the merger has been accounted for at historical cost in a manner
    similar to a pooling of interests. Integrity Israel was incorporated in 2001 and commenced its operations in 2002 (The Company
    and Integrity Israel are referred as the &#8220;Group&#8221;) Integrity Israel, a medical device company, focuses on the design,
    development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Since its incorporation,
    the Company did not conduct any material operations other than those carried out by Integrity Israel. The development and commercialization
    of Integrity Israel&#8217;s product is expected to require substantial expenditures. Integrity Israel and the Company (collectively,
    the &#8220;Group&#8221;) have not yet generated significant revenues from operations, and therefore they are dependent upon external
    sources for financing their operations. As of December 31, 2021, the Group has incurred accumulated deficit of $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20211231_z44uHmdWrmD5"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">97,466</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand, and negative operating cash flows.
    As of December 31, 2021, the Company had $<span id="xdx_905_eus-gaap--Cash_iI_c20211231_zROskKYjTqS3"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,062</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in cash, which is sufficient to meet its capital
    needs for fiscal 2022 and for at least 12 months from the date of issuance of these financial statements, thus it is expected that
    the company will be able to operate as a going concern for at least 12 months from the date hereof. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin-top: 0; margin-bottom: 0">On December 8, 2021, we announced that our shares of common stock were approved for listing on the Nasdaq Capital Market (&#8220;NASDAQ&#8221;). Trading on NASDAQ commenced on December 10, 2021 under its existing trading symbol, IGAP.</p>
                                                                              <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0">On March 14, 2022, we announced that it has completed its corporate name and ticker symbol change on
the Nasdaq Capital Market (from IGAP to GCTK), to be effective at the commencement of trading on March 14, 2022.</p>

</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In connection with its application to list its shares on Nasdaq Capital Market (&#8220;NASDAQ&#8221;), as detailed above, on August 13, 2021, the Company
    effected a reverse split of its Common Stock in a ratio of <span id="xdx_90C_eus-gaap--StockholdersEquityReverseStockSplit_c20210811__20210813_z4gwqNKXxOCb" title="Stockholders&apos; Equity, Reverse Stock Split"><ix:nonNumeric contextRef="From2021-08-112021-08-13" name="us-gaap:StockholdersEquityReverseStockSplit">1 for 13</ix:nonNumeric></span> (the &#8220;Reverse Share Split&#8221;). For accounting purposes,
    all Shares, options and warrants to purchase Common Stock and loss per share amounts have been adjusted to give retroactive effect
    to this Reverse Share Split for all periods presented in these consolidated financial statements. Any fractional shares resulting
    from the Reverse Share Split were rounded up to the nearest whole share.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">B.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Liquidity and capital resources</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since
its inception date, the Company did not conduct any material operations other than those carried out by Integrity Israel. The development
and commercialization of the Product is expected to require substantial expenditures. The Group has not yet generated significant revenues
from operations, and therefore they are dependent upon external sources for financing their operations. As of December 31, 2021, the
Group has incurred accumulated deficit of $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20211231_zf5PUvewJyO3"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">97,466</ix:nonFraction></span> thousand. During the year ended December 31, 2021 the Company incurred losses from
ongoing operation and has negative cash flow from operating activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 14, 2020, the Company closed on a
$<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20200213__20200214__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zKhk6IOqC86a" title="Private placement of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2020-02-132020-02-14_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">15</ix:nonFraction></span>&#160;million private placement of its common stock, for which it received net cash in excess of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20200213__20200214__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zw68En5p8nbg"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-02-132020-02-14_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,009</ix:nonFraction></span>&#160;thousand. In addition,
on September 27, 2021, the Company&#8217;s shelf registration statement on Form S-3 was declared effective by the Securities and Exchange
Commission (SEC) which permits the Company to register up to $<span id="xdx_904_eus-gaap--DebtSecurities_iI_pn3n3_c20200214__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z54tJQVgsUkb"><ix:nonFraction name="us-gaap:DebtSecurities" contextRef="AsOf2020-02-14_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100,000</ix:nonFraction></span> thousand of certain equity and debt securities of the Company via
prospectus supplement. To date, funds have not been raised through this shelf registration statement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0">The management believes the cash balance amounted to $<span id="xdx_900_eus-gaap--Cash_iI_pn3n3_c20211231_zF0g2rsB2lU1" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,062</ix:nonFraction></span> thousand as of December 31, 2021, is sufficient to
meet its capital needs of the Group for at least 12 months from the issuance date of these consolidated financial statements. Thus, it
is expected that the Company will be able to operate as a going concern for at least 12 months from the date hereof.</p>

</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect
    of the spread of the Coronavirus on the Company</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    December 2019, the Covid-19 epidemic erupted in China (hereinafter - the &#8220;Corona Virus&#8221;, the &#8220;Event&#8221; or the
    &#8220;Crisis&#8221;) and at the beginning of 2020, it spread to additional countries across the globe. In January 2020, the World
    Health Organization declared the outbreak of Corona as a global health emergency and in March 2020, it declared the Corona virus
    to be a global pandemic. The spreading of the Corona Virus is an extraordinary macroeconomic event in many countries worldwide. As
    a result of the event, many countries, including Israel, have taken significant steps in an attempt to stem the spreading of the
    virus. These steps include, inter alia, restriction of civilian movement and employment, closure of businesses and malls, restrictions
    of gatherings and events, restriction of the transportation of people and goods, closure of international border crossings, reduction
    in the number of employees permitted to come to their workplaces, etc. The event and the steps being taken by the various countries,
    as mentioned above, have had a significant impact on many global and local economies as well as on global capital markets, characterized
    by sharp decreases and extreme volatility in the prices of many securities. In addition, there is an ever-increasing risk of a market
    recession.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    a result of the COVID-19 pandemic, as near-term measures, the Company has transitioned some of its employees to remote
    working arrangements. which has had no material impact on the Company&#8217;s operations. Due to the uncertainty of
    COVID-19, the Company will continue to assess the situation, including abiding by any government-imposed restrictions, market
    by market.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_807_eus-gaap--SignificantAccountingPoliciesTextBlock_z1BKyx44ItVb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_zVso9ItbFJ2e">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States
    of America (US GAAP).</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_841_eus-gaap--UseOfEstimates_ziKlARtDDxOa" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;<span id="xdx_862_zEWBiyXPFVmg">Use of estimates in the preparation of financial statements</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                                         preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States
                                                         (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and
                                                         liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the
                                                         reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As
                                                         applicable to the consolidated financial statements, the most significant estimates and assumptions relate to the going concern
                                                         assumptions.</span></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
  <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
  <td><span id="xdx_863_ztnpQCdFXv9d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Functional currency</b></span></td></tr>
</table>




<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    functional currency of the Company is the US dollar, which is the currency of the primary economic environment in which it operates.
    In accordance with ASC 830, &#8220;Foreign Currency Matters&#8221; (ASC 830), balances denominated in or linked to foreign currency
    are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions
    included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses
    arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses.
    The functional currency of Integrity Israel is the New Israeli Shekel (&#8220;NIS&#8221;) and its financial statements are included
    in consolidation, based on translation into US dollars. Accordingly, assets and liabilities were translated from NIS to US dollars
    using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or
    losses resulting from translation adjustments are reflected in stockholders&#8217; equity, under &#8220;accumulated other
    comprehensive income (loss)&#8221;.</span></td></tr>
  </table>
<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_z1sWopOdwVWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-transform: uppercase"><span id="xdx_8BA_z28uggO1Vjtd" style="display: none">SCHEDULE
OF OFFICIAL EXCHANGE RATE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; float: left; border-collapse: collapse; width: 87%; margin-left: 1in">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Official exchange rate of NIS 1 to US dollar</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90C_ecustom--AverageForeignCurrencyExchangeRateTranslation_pid_uPure_c20210101__20211231_znrsJigW8zN9" title="Official exchange rate of NIS 1 to US dollar"><ix:nonFraction name="IGAP:AverageForeignCurrencyExchangeRateTranslation" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.321</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_ecustom--AverageForeignCurrencyExchangeRateTranslation_pid_uPure_c20200101__20201231_zfN93fVY2Di6" title="Official exchange rate of NIS 1 to US dollar"><ix:nonFraction name="IGAP:AverageForeignCurrencyExchangeRateTranslation" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.311</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Increase (decrease) of the official exchange rate of NIS 1 to US dollar during
    the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage_pid_dp_uPure_c20210101__20211231_zYT7ZqLx3uid" title="Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2021"><ix:nonFraction name="IGAP:IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.22</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo_pid_dp_uPure_c20210101__20211231_zRqPDmfBAOg5" title="Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2020"><ix:nonFraction name="IGAP:IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.2</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric><p id="xdx_8A7_zyM3csyKUrU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_z2phvkjRX7Fg" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_862_zRzDn3jIhzna" style="font-family: Times New Roman, Times, Serif">Principles
    of consolidation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions
    have been eliminated in consolidation.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zFIoQm3Vw01f" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
&#160;&#160;&#160;<span id="xdx_86E_z8UwjAFbWYIc">Cash and cash equivalents</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less
    at the date of purchase, to be cash equivalents.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zr59NmoMCee3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
&#160;&#160;&#160;&#160;<span id="xdx_864_zOgYx08MLb5l">Inventories</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
    are stated at the lower of cost or net realizable value.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    is determined as follows:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    respect to raw materials, the Group calculates cost using the average cost method.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    respect to work in process and finished products, the Group calculates the cost on the basis of the average direct manufacturing
    costs, including materials, labor, subcontracting costs and other direct manufacturing costs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management evaluated
                                                         periodically whether inventory is required to be written-down due to slow-moving or obsolete items and recognize
                                                         inventory impairment, as applicable
..</span></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zBem59oZXABa" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
&#160;&#160;&#160;&#160;<span id="xdx_86D_zOiwGzfYuAWl">Property and equipment, net</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 96px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over
    the estimated useful lives of the assets. When an asset is retired or otherwise disposed of, the related carrying value and accumulated
    depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected
    in the statements of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rates
    of depreciation:</span></td></tr>
  </table>
<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="IGAP:ScheduleOfPropertyRatesOfDepreciationTableTextBlock"><p id="xdx_897_ecustom--ScheduleOfPropertyRatesOfDepreciationTableTextBlock_zDE5uvUBGOJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-transform: uppercase"><span id="xdx_8B7_z9HqlgAfPPq2" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION</span></span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; width: 70%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_zNsi2Hf6ZZ9" title="Property plant and equipment depreciation rate"><ix:nonFraction name="IGAP:PropertyPlantAndEquipmentDepreciationRate" contextRef="From2021-01-012021-12-31_custom_ComputersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">33</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zyefZsav84we" title="Property plant and equipment depreciation rate"><ix:nonFraction name="IGAP:PropertyPlantAndEquipmentDepreciationRate" contextRef="From2021-01-012021-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span>-<span id="xdx_90F_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zWQ5zTaFrD62" title="Property plant and equipment depreciation rate"><ix:nonFraction name="IGAP:PropertyPlantAndEquipmentDepreciationRate" contextRef="From2021-01-012021-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zaCfxQEeQjR7" title="Estimated useful life" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_LeaseholdImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives">Shorter
    of lease term <br />
    and 10 years</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_zrshgJhPm0e3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ze82Gzge5Av3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.
&#160;&#160;&#160;<span id="xdx_862_zIFCa5yk36p">Impairment of long-lived assets</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group&#8217;s long-lived assets are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment&#8221;,
    whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability
    of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows
    expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by
    the amount by which the carrying amount of the asset exceeds its fair value. To date the Group did not incur any material impairment
    losses related to long lived assets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zhsaGHsnbdFg" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.
&#160;&#160;&#160;<span id="xdx_86F_zCStbuEbnwma">Restricted cash</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
                                            cash is invested in certificates of deposit, which are used to secure Integrity Israel&#8217;s
                                            obligations in respect of its headquarters lease and credit card (See also Note 8B).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    presentation of statement of cash flows purposes, restrict cash balances are included with cash and cash equivalents, when reconciling
    the reported period total amounts.</span></p></td></tr>
  </table>
<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zx2RjUoNBbvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none; text-transform: uppercase">SCHEDULE
OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; border-collapse: collapse; width: 85%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20211231_z0KKbVEHNyc3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20201231_zvJCzkll1hz1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzao3_z16YpaGo1Qh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,062</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,823</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RestrictedCash_iI_pn3n3_maCCERCzao3_zPyLjxmhuVOb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">62</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzao3_zsG11z4lis63" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,113</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,885</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zILf7TSGrnh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z3ySOspGUR39" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.
&#160;&#160;&#160;&#160;&#160;<span id="xdx_86B_zYL7iQmDU1K1">Income tax</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221;. Accordingly, deferred income taxes are determined
    utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting
    and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax
    rates expected to be in effect when these differences reverse. Valuation allowances in respect of deferred tax assets are provided
    for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial
    statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise&#8217;s financial statements.
    According to ASC Topic 740-10, tax positions must meet a more- likely-than-not recognition threshold. The Group&#8217;s accounting
    policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Group did not recognize
    such items in its fiscal 2021 and 2020 financial statements and did not recognize any liability with respect to unrecognized tax
    position in its balance sheet.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy"><p id="xdx_84F_eus-gaap--PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_zXrcacv4Rm95" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.
&#160;&#160;&#160;&#160;<span id="xdx_86B_zxZD9iX9mnw5">Liability for employee rights upon retirement</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrity
    Israel&#8217;s liability for employee rights upon retirement with respect to its Israeli employees is calculated pursuant to the
    Israeli Severance Pay Law, based on the most recent salary of each employee multiplied by the number of years of employment of each
    such employee as of the balance sheet date. Employees are entitled to one month&#8217;s salary for each year of employment, or ratable
    portion thereof for periods less than one year. Integrity Israel makes monthly deposits to insurance policies and severance pay funds.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    deposited funds may be withdrawn upon the fulfillment of Integrity Israel&#8217;s severance obligations pursuant to Israeli severance
    pay laws or labor agreements with its employees. The value of the deposited funds is based on the cash surrender value of these policies,
    and includes immaterial profits or losses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
    in 2011, Integrity Israel&#8217;s agreements with its Israeli employees are in accordance with Section 14 of the Severance Pay Law.
    Payments in accordance with Section 14 release the employer from any future severance payments in respect of those employees. Related
    obligations and liabilities under Section 14 are not recorded as an asset or as a liability in the Company&#8217;s balance sheet.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    year ended December 31, 2021, and 2020, severance expenses amounted to $<span id="xdx_90F_eus-gaap--SeveranceCosts1_pn3n3_c20210101__20211231_zY7fX3k5BpIb" title="Severance expenses"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43</ix:nonFraction></span>
    and $<span id="xdx_902_eus-gaap--SeveranceCosts1_pn3n3_c20200101__20201231_zEO4WrqohWq1" title="Severance expenses"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction> </span> thousand,
    respectively.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zirsgiEM0ulf" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>K.
&#160;&#160;&#160;<span id="xdx_868_zpXQro7zIyQ3">Research and development expenses</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development expenses are charged to operations as incurred.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="IGAP:RoyaltyBearingGrantsPolicyTextBlock"><p id="xdx_845_ecustom--RoyaltyBearingGrantsPolicyTextBlock_z8sKHmrDPlp6" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>L.
&#160;&#160;&#160;<span id="xdx_862_zwtYQaEmhRE1">Royalty-bearing grant</span>s</b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalty-bearing
grants from the Israeli Innovation Authority (IIA) to fund approved research and development projects are recognized at the time
Integrity Israel is entitled to such grants, on the basis of the costs incurred and reduce research and development costs. To date,
the cumulative research and development grants received by Integrity Israel from amounted to $<span id="xdx_900_ecustom--CumulativeResearchAndDevelopment_pn3n3_c20210101__20211231_zFrVLd4EqThb" title="Cumulative research and development"><ix:nonFraction name="IGAP:CumulativeResearchAndDevelopment" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93</ix:nonFraction></span> thousand.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:StandardProductWarrantyPolicy"><p id="xdx_84A_eus-gaap--StandardProductWarrantyPolicy_zvlibdTueNw9" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>M.
&#160;&#160;<span id="xdx_865_zaFGQFrnS42l">Warranty</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group provides a 24-month warranty for its products at no cost. The group estimates the costs that may be incurred during
    the warranty period and records a liability for the amounts of such costs at the time revenues are recognized. For the year ended
    December 31, 2021 and 2020 warranty expenses were clearly insignificant.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_z4dUfCu8MIal" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;<span id="xdx_861_zHwZZ6eGcibe">Basic and diluted loss per share</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is computed by dividing the loss for the period applicable
for Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon
    the exercise of options or warrants issued or granted using the &#8220;treasury stock method&#8221;, if the effect of each of such
    financial instruments is dilutive.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In computing diluted loss per share, the average stock price for the
    period is used in determining the number of common stock assumed to be purchased from the exercise of stock options or stock warrants.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares that will be issued upon exercise of all stock
    options and stock warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods
    for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these
    instruments was anti-dilutive</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An amount of <span id="xdx_90F_ecustom--NumberOfStockOptionsExcluded_c20210101__20211231_zOt36ZugXE08" title="Number of stock options excluded"><ix:nonFraction name="IGAP:NumberOfStockOptionsExcluded" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">6,404,238</ix:nonFraction></span> and <span id="xdx_904_ecustom--NumberOfStockWarrantsExcluded_c20210101__20211231_z3TLRD8mnoWk" title="Number of stock warrants excluded"><ix:nonFraction name="IGAP:NumberOfStockWarrantsExcluded" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">6,446,920</ix:nonFraction></span> outstanding stock
    options and stock warrants have been excluded from the calculation of the diluted net loss per share for the years ended December
    31, 2021 and 2020, respectively, because the effect of the common shares issuable as a result of the exercise of such instruments
    was determined to be anti-dilutive.</td></tr>
</table>

<p style="margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zhK42UAblaGb" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>O.
&#160;&#160;&#160;<span id="xdx_863_zgLyhfyW8zsa">Stock-based compensation</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values
    in accordance with ASC 718, &#8220;Compensation-Stock Compensation&#8221;. Share-based payments including grants of stock options
    are recognized in the statement of operations as an operating expense based on the fair value of the award at the date of grant.
    The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Group has expensed compensation
    costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit
    service period when a performance condition affects the vesting, and it is considered probable that the performance condition will
    be achieved.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
    January 1, 2019, following the adoption of ASU 2018-07, which aligns the measurement and classification guidance for share-based
    payments to nonemployees with the guidance for share-based payments to employees (with certain exceptions), share-based payments
    to non-employees are accounted in accordance with ASC 718.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zeCThVgBkQi2" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>P.
&#160;&#160;&#160;<span id="xdx_86A_z0MkNh8cKSO3">Fair value of financial instruments</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
    Topic 825-10, &#8220;Financial Instruments&#8221; defines financial instruments and requires disclosure of the fair value of financial
    instruments held by the Group. The Group considers the carrying amount of cash and cash equivalents, restricted cash, accounts receivable,
    other current assets, accounts payable and other current liabilities balances, to approximate their fair values due to the short-term
    maturities of such financial instruments. ASC Topic 825-10, establishes the following fair value hierarchy, which prioritizes the
    inputs used in the valuation methodologies in measuring fair value:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair
    value hierarchy gives the highest priority to Level 1 inputs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 - Unobservable inputs are used when little or no market data is available. Level 3 inputs are considered as the lowest priority
    under the fair value hierarchy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group did not estimate the fair value of the  loans from stockholders since their repayment schedule has not yet been determined.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zjGnLFw00Rp1" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;<span id="xdx_86C_zCHn20XqlR39">Concentrations of credit risk</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash and cash equivalents, and
    restricted cash. Cash and cash equivalents and restricted cash are deposited with major banks in Israel and the United States of
    America. Management believes that such financial institutions are financially sound, accordingly, minimal credit risk exists with
    respect to these financial instruments. The Group does not have any significant off-balance-sheet concentration of credit risk, such
    as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock"><p id="xdx_847_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zay9jLDrdGd6" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>R.
&#160;&#160;&#160;<span id="xdx_867_zuq6SO3iGgmh">Contingencies</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability
    has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional
    information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_840_eus-gaap--DerivativesPolicyTextBlock_zShPDLLDHhh5" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>S.
&#160;&#160;&#160;&#160;<span id="xdx_86C_zpnCZhkuvNI4">Warrants with Down-Round Protection</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
    the application of Accounting Standard Update (ASU) No. 2017-11, &#8220;Earnings Per Share&#8221; (ASU 2017-11), the Company disregard
    the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or
    equity classification. Based on its evaluation, management has determined that such warrants with Down-Round Protection are eligible
    for equity classification.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    accordance with the provisions of ASU 2017-11, upon the occurrence of an event that triggers a down round protection (i.e., when
    the exercise price of the warrants is adjusted downward because of the down round feature), the effect is accounted for as a deemed
    dividend and as a reduction of income available to common shareholders for purposes of basic earnings per share (EPS) calculation.</span></p></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="IGAP:ModificationOfEquityclassifiedContractsPolicyTextBlock"><p id="xdx_846_ecustom--ModificationOfEquityclassifiedContractsPolicyTextBlock_zXJeETtbbN6i" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>T.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;<span id="xdx_86A_ziJkWwfyEW19">Modification of equity-classified contracts</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification
    or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification
    of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value
    of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase
    of accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified
    share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment
    to earnings available to common shareholders for purposes of calculating earnings per share.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_z7eoZqo6Uc0d" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;<span id="xdx_86B_zp8JaOuYjnM2">Allowance for doubtful accounts</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The allowance for doubtful accounts is determined with
    respect to amounts the Company has determined to be doubtful of collection, in order to reflect the expected credit losses on accounts
    receivable balances. Judgment is required in the estimation of the allowance for doubtful accounts and the Company evaluates the
    collectability of its accounts receivable based on a combination of factors (including, among other things, the length of time that
    the balance is past due and the customer&#8217;s current ability to pay. If it&#8217;s becomes aware of a customer&#8217;s inability to meet
    its financial obligations, an allowance is recorded to reduce the net receivable to the amount reasonably believed to be collectible
    from such customer</td></tr>
</table>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock"><p id="xdx_845_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zYlRL3q7WdYf" style="margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>V.</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span id="xdx_865_zMkUXWRi3xs9">Operating Lease</span></b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company entered into several non-cancelable lease agreements for vehicles for use in its operations, which are classified as operating
    leases.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
    January 1, 2019, the Company applies ASC Update 2016-02, Leases (Topic 842).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company determines if an arrangement is a lease at inception. Under the new guidance, arrangements meeting the definition of a lease
    are classified as operating or financing leases. A classification of a lease is determined based on the following criteria:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 96px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lease transfers ownership of the underlying asset to the lessee by the end of the lease term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lease term is for the major part of the remaining economic life of the underlying asset (Generally, 75% or more of the remaining
    economic life of the underlying assets).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    present value of the sum of the lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all
    of the fair value of the underlying asset (Generally, 90% or more of the fair value of the underlying asset).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease
    term.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these five criteria is met, the lease is classified as a finance lease. Otherwise, the lease is classified as an operating lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
are recorded on the consolidated balance sheet as both a right of use asset and a lease liability, calculated by discounting fixed lease
payments over the lease term at the rate implicit in the lease or the Company&#8217;s incremental borrowing rate. Lease liabilities are
increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating
leases, interest on the lease liability and the amortization of the right of use asset results in straight-line rent expense over the
lease term. Variable lease expenses, if any, are recorded when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also elected the short-term lease recognition exemption for all leases that qualify (leases with a term shorter than <span id="xdx_907_eus-gaap--LessorOperatingLeaseTermOfContract_iI_dtM_c20190102_zT2oUyH9Lhek" title="Lessor, Operating Lease, Term of Contract"><ix:nonNumeric contextRef="AsOf2019-01-02" format="ixt-sec:durmonth" name="us-gaap:LessorOperatingLeaseTermOfContract">12</ix:nonNumeric></span> months).
For those leases, right-of-use assets or lease liabilities are not recognized and rent expense is recognized on a straight-line basis
over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had no material capital leases throughout the reporting periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
note 4 for further discussion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zMFGQ4NQ6qF8" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>W.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>&#160;&#160;&#160;<span id="xdx_86A_zHQvnAq3pgAf">Reclassification</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    comparative figures have been reclassified to conform to the current year presentation. Such reclassifications did not have any significant
    impact on the Company&#8217;s equity, net income or cash flows.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zegEC1G2JUS5" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><b><span id="xdx_868_zXTHdpqWn82">X. &#160;&#160;Recent Accounting Pronouncements</span></b></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments&#8221; (&#8220;ASU 2016-13&#8221;), which changes the impairment model for most financial assets and certain other instruments.
For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities will be required to use a new
forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. The
guidance also requires increased disclosures. For the Company, the amendments in the update were originally effective for fiscal years
beginning after December 15, 2019, including interim periods within those fiscal years. In November 2019, the FASB issued ASU No. 2019-10,
which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined by the SEC) and other non-SEC reporting entities
to fiscal years beginning after December 15, 2022, including interim periods within those fiscal periods. Early adoption is permitted.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the company
is eligible to considered as smaller reporting company ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including
interim periods within those fiscal years. The adoption of this standard is not expected to result in a material impact to the Company&#8217;s
financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><b>&#160;</b></p>


<ix:exclude><!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_801_eus-gaap--InventoryDisclosureTextBlock_z1YXDWujlYnd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3</b> &#8211; <span id="xdx_826_ztCMg31uZDb6"><b>INVENTORIES</b></span></span></p>


<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zc8V0fXVWzC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zrnsXl8O4ds2" style="display: none; text-transform: uppercase">SCHEDULE
OF INVENTORIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_ztdjoh3Df3Rb">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20201231_zOgIXePL4TF6">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Inventory</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryRawMaterials_iI_pn3n3_maIGzn5N_zQ5GzIkfahI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">94</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">95</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maIGzn5N_zWDi36o1kNZ6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">194</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">155</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maIGzn5N_zaLMdy8upMJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InventoryGross_iTI_pn3n3_mtIGzn5N_maINzWYt_zLNeCkoh9e4e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right"></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">321</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">284</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InventoryAdjustments_iNTI_pn3n3_di_msINzWYt_z9gv4rshjGo9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">inventory write-down</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InventoryAdjustments" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">321</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InventoryNet_iTI_pn3n3_mtINzWYt_znPOi37l1bi2" style="vertical-align: bottom; background-color: White">
    <td></td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0517">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">284</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zDJGTmscObKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)
Management evaluated periodically whether inventory is required to be written-down due to slow-moving or obsolete items
and recognize inventory impairment, as applicable. As a result of the development of the second generation of the glucose monitoring
device the Group has recorded in the fourth quarter of 2021 inventory written-down in the amount of approximately $ <span id="xdx_90F_eus-gaap--InventoryAdjustments_iI_pn3n3_c20211231_z8x8VFUNiLkg"><ix:nonFraction name="us-gaap:InventoryAdjustments" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">321</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_804_eus-gaap--LesseeOperatingLeasesTextBlock_zPf1ye7BZtEg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_826_zLOdFgHGoyWf">LEASES</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into several non-cancellable operating lease agreements for few vehicles. the Company&#8217;s leases have
original lease periods expiring between 2023 and 2024. Payments due under such lease contracts include primarily fixed payments. the
Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably assured at lease
commencement. the company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_89D_eus-gaap--LeaseCostTableTextBlock_zLbcPSlBJLOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease costs, lease term and discount rate are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zRsGUCR3CFsh" style="display: none; text-transform: uppercase">SCHEDULE
OF LEASE COSTS, LEASE TERM AND DISCOUNT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In
                                            thousand of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US
                                            dollars</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Operating lease cost:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: justify">Vehicles</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseCost_pn3n3_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_z0mDVy94eAJ1"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-01-012021-12-31_us-gaap_VehiclesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">72</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Office space <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Over 12 month</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_909_ecustom--LongTermLeaseCost_pn3n3_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceMember_zXYtEbGj2g98" title="Office space: Over 12 month"><ix:nonFraction name="IGAP:LongTermLeaseCost" contextRef="From2021-01-012021-12-31_custom_OfficeSpaceMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">53</ix:nonFraction></span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify"><p style="margin: 0">Short term leases</p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0"><span id="xdx_902_eus-gaap--ShortTermLeaseCost_pn3n3_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceMember_zXgDvxIa4iT6" title="Office space: Short term leases"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2021-01-012021-12-31_custom_OfficeSpaceMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46</ix:nonFraction></span></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseCost_pn3n3_c20210101__20211231_zwYNiMxQj5jb" title="Total Operating lease cost"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">171</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Remaining Lease Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Vehicles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zZ0I6Rm1ey75" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2021-12-31_us-gaap_VehiclesMember" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.01</ix:nonNumeric>
                                            </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Weighted Average Discount Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Vehicles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zz2FmmxhiL9h"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-12-31_us-gaap_VehiclesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_z1eJGaAsTBy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211; LEASES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zxu4SEPCq9V3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a schedule, by years, of maturities of operating lease liabilities as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zBYWPBLIkEM3" style="display: none; text-transform: uppercase">SCHEDULE
OF OPERATING LEASE MATURITY PAYMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20211231_zpyzv9EMEht8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In
                                            thousand of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US
                                            dollars</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzYou_zoSxFXo8Kvea" style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: justify">2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzYou_zR5T5VV0j14b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzYou_zF2vTrQGuc3h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total operating lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_zL5ELAg733eh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Less: imputed interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zwWf4InZ9Uj3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_z2JIF9lQ6ihe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zndzD9QDn7xg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_822_zshg62bIbfd2">PROPERTY AND EQUIPMENT, NET</span></b></span></p>


<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6wHxThoOcPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zKONlzkJRMz4" style="display: none; text-transform: uppercase">SCHEDULE
OF PROPERTY AND EQUIPMENT, NET</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Property and Equipment</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Computers</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpwgU3E7tlPf" title="Property and equipment, gross" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">306</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zIzfuCWk5Py3" title="Property and equipment, gross" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">380</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zdMJOGy5YJNe" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_FurnitureAndOfficeEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">183</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zgxvPnsd5GAa" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_custom_FurnitureAndOfficeEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">312</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z4NhPEhmhcr9" title="Property and equipment, gross" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zzfKXgKvNa79" title="Property and equipment, gross" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231_zvwAoM2vko4c" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">489</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231_zPjFhlZi4Fua" title="Property and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">774</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20211231_zymk2K4tPJL8" title="Less - accumulated depreciation" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">420</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20201231_zMxf3fkw4KQa" title="Less - accumulated depreciation" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20211231_zvFTbtn2CRqk" title="Property and equipment, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231_zaf1kzpQIA17" title="Property and equipment, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">149</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zAOdjaMv6ZVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the years ended December 31, 2021 and 2020, depreciation expenses amounted to $<span id="xdx_90C_eus-gaap--Depreciation_pn3n3_c20210101__20211231_zbWBJHvtFlJe"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90C_eus-gaap--Depreciation_pn3n3_c20200101__20201231_zb8KGAHxe07i"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">47</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand respectively, and new equipment
    purchases amounted to $<span id="xdx_90D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_pn3n3_c20210101__20211231_z4270O9O71Ec"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_905_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_pn3n3_c20200101__20201231_zHMDRRy98yXg"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">53</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand, respectively.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:OtherLiabilitiesDisclosureTextBlock"><p id="xdx_80A_eus-gaap--OtherLiabilitiesDisclosureTextBlock_zHruYjp0sjY7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8211; <span id="xdx_825_zXCBHpmM3bwb">OTHER CURRENT LIABILITIES</span></b></span></p>


<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock"><p id="xdx_899_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zpVYTO3IUP6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zpdOqWdmDMi3" style="display: none; text-transform: uppercase">SCHEDULE
OF OTHER CURRENT LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zjPxOE5dmKeb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20201231_zNlP70h9iU7c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Other Current Liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maOLCzeFZ_zqb8htmtCzZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Employees and related institutions</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">98</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">244</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maOLCzeFZ_zUhlcLPgVGVl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued expenses and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">131</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">148</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCzeFZ_zcKkXLdVZWQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">229</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">392</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zUORVe4P7Ivh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:LongTermDebtTextBlock"><p id="xdx_808_eus-gaap--LongTermDebtTextBlock_zVNGOwuv5Moj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7</b> &#8211; <span id="xdx_823_z9hbW0tranJe"><b>LOANS FROM STOCKHOLDERS</b></span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the years 2003-2004, Integrity Israel received loans from stockholders (four separate lenders) in a total amount of approximately
    $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfLongTermDebt_pn3n3_c20030101__20041231__srt--TitleOfIndividualAxis__custom--ShareHoldersMember_zAdJwHh04dR4"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="From2003-01-012004-12-31_custom_ShareHoldersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">400</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand. However, following the repayment
    of the entire balance to certain lender in 2015, the remaining balance as of December 31,2021 is approximately $<span id="xdx_907_eus-gaap--DueToOfficersOrStockholdersNoncurrent_iI_pn3n3_c20211231_ze8tjFHbhHyj"><ix:nonFraction name="us-gaap:DueToOfficersOrStockholdersNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">210</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand. The loans are indexed to the Israeli
    consumer price index from their origination date and bear no insert.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group will be required to pay the loans, in quarterly installments, commencing on the first quarter following the first fiscal year
    in which the Group reports net profit in its annual report. At such time, the Group will be required to make quarterly payments equal
    to <span id="xdx_90D_ecustom--QuarterlyPaymentsEqualsToSalesPercentage_pid_dp_uPure_c20210101__20211231_zfSLo7WVcgsh"><ix:nonFraction name="IGAP:QuarterlyPaymentsEqualsToSalesPercentage" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
    of its total sales for each quarter until the loans have been repaid in full. Notwithstanding the repayment mechanism, the Group
    will not be required to repay the loans during any period in which such payment would cause a deficit in the Group&#8217;s working
    capital.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2021, the Group does not expect to make any additional material repayments during the following 12-month period,
    if any, and accordingly the entire remaining balance of the loans from stockholders have been presented as long-term liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zMVzl2xtMgra" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8211; <span id="xdx_824_zjrrsy7TI636">COMMITMENTS AND CONTINGENT LIABILITIES</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 86%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    March 4, 2004, the Israel innovation authority (IIA) provided Integrity Israel with a grant of approximately $<span id="xdx_909_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember_z9lChnwDXDZh"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand (NIS <span id="xdx_905_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_uIsrael_c20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember_zGv5YAbyijrg"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Israel">420</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand), for its plan to develop a non-invasive
    blood glucose monitor (the &#8220;Development Plan&#8221;). Integrity Israel is required to pay royalties to the IIA at a
    rate ranging between <span id="xdx_90A_ecustom--RoyaltyPercentage_pid_dp_c20040303__20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MinimumMember_zYl6u9tAhxtk"><ix:nonFraction name="IGAP:RoyaltyPercentage" contextRef="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span id="xdx_90B_ecustom--RoyaltyPercentage_pid_dp_c20040303__20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MaximumMember_z5sP4qqOTPx7"><ix:nonFraction name="IGAP:RoyaltyPercentage" contextRef="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction>%</span></span>
    of the proceeds from the sale of the Group&#8217;s products arising from the Development Plan up to an amount equal to $<span id="xdx_90C_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20050304__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_z80bmMo4o7k3"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2005-03-04_custom_IsraeliInnovationAuthorityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93</ix:nonFraction>
    </span><span style="font-family: Times New Roman, Times, Serif">thousand, plus interest at LIBOR from the date of grant. As
    of December 31, 2021, the remaining contingent liability with respect to royalty payment on future sales equals approximately $<span id="xdx_902_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20211231__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_zQtMsBfaAJE2"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2021-12-31_custom_IsraeliInnovationAuthorityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif">thousand, excluding interest. Such contingent obligation has
    no expiration date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2021, the Group accrued royalties to the IIA in insignificant amounts.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 1, 2017 the Company entered into an Advisory Agreement with Andrew Garrett, Inc. (AGI), pursuant to which <span id="xdx_90C_ecustom--AdvisoryServicesPeriod_c20170729__20170801__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__dei--LegalEntityAxis__custom--AndrewGarrettIncMember_zTImE9yTfk39"><ix:nonNumeric contextRef="From2017-07-292017-08-01_custom_AdvisoryAgreementMember_custom_AndrewGarrettIncMember" name="IGAP:AdvisoryServicesPeriod">the
    Company engaged AGI as placement agent on a non-exclusive basis to provide certain advisory services to the Company for a period
    of 9 months which was subsequently extended twice and was in effect until October 31, 2019</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2020 the Company paid the placement Agent approximately $<span id="xdx_909_eus-gaap--PaymentsOfStockIssuanceCosts_pn6n6_c20200101__20201231_zxr4yrYXdH16"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million for placement services (see above)
    in cash. In addition, during the year ended December 31, 2020, $<span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200101__20201231_z7Wdp3F1o84b"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">756</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand representing the fair value of warrants
    issued as consideration for placement agent services to AGI. This amount was accounted for as warrants with down-round protection.
    Upon issuance, the fair value was recognized as an increase in additional paid in capital.</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 11%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 87%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Since March 2021 Integrity Israel is renting several workspaces
    at office building in the city Or &#8211; Yehoda. This workspace rent replaces the principal offices the Company in the city Ashdod.
    According to the new agreement the Company renting those flexible shared workspaces for period shorter than one year.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zVV6odsJGr38" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_82D_zIbT1ADCmog6">COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    of the rights attached to the Common Stock</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    share of Common Stock entitles the holder to one vote, either in person or by proxy, on each matter submitted to the approval of
    the Company&#8217;s stockholders. The holders of Common Stock are not permitted to vote their shares cumulatively. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><b>2.</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Description of February 14, 2020 Issuance of common
    stock</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0">On February 14, 2020, the Company
                                            entered into a Securities Purchase Agreement and Registration Rights Agreement with an accredited
                                            investor, pursuant to which the accredited investor purchased <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200213__20200214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zFVcyh1RViMg" title="Number of common shares issued"><span style="background-color: white"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-02-132020-02-14_custom_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_custom_AccreditedInvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,884,615</ix:nonFraction></span></span> shares of the Company&#8217;s
                                            common stock, par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20200214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zdbBiuwm9lu9" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-02-14_custom_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_custom_AccreditedInvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share, for an aggregate gross purchase price of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn6n6_c20200213__20220214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zRzNHAy0wsZ1" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-02-132022-02-14_custom_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_custom_AccreditedInvestorMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">15</ix:nonFraction></span> million,
                                            less cash expenses of approximately $<span id="xdx_90C_ecustom--CashExpensesOnIssuanceOfStock_pn6n6_c20200213__20220214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zQhwLsbbka76" title="Cash expenses on issuance of stock"><ix:nonFraction name="IGAP:CashExpensesOnIssuanceOfStock" contextRef="From2020-02-132022-02-14_custom_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_custom_AccreditedInvestorMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Placement Agent Compensation</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
    to a placement agent agreement (the &#8220;Placement Agent Agreement&#8221;) with the placement agent for the Offering (the &#8220;Placement
    Agent&#8221;), at the closing of the above mentioned sale of the common stock the Company paid the Placement Agent, as a commission,
    a cash amount equal to <span id="xdx_907_ecustom--CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits_iI_pid_dp_c20211231__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zH5GSxzu4NCe" title="Commission as a percentage of cash amount equal to aggregate sale price of units"><ix:nonFraction name="IGAP:CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits" contextRef="AsOf2021-12-31_custom_PlacementAgentAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction>%</span> of the aggregate sales price of the Units, plus 3% of the aggregate sales price as a management fee plus
    a non-accountable expense allowance equal to <span id="xdx_904_ecustom--NonaccountableExpenseAllowancePercenatge_iI_pid_dp_c20211231__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zSnFiIi9s2ui" title="Non-accountable expense allowance percenatge"><ix:nonFraction name="IGAP:NonaccountableExpenseAllowancePercenatge" contextRef="AsOf2021-12-31_custom_PlacementAgentAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction>%</span> of the aggregate sales price of the Units. In addition, pursuant to the placement
    agent agreement, the company is required to issue to the Placement Agent warrants to purchase up to such number of shares of Common
    Stock equal to <span id="xdx_90F_ecustom--AggregateSalesPriceOfUnitsPercentage_iI_pid_dp_c20211231__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zDdkHJBkAekf" title="Commission as a percentage of aggregate sales price"><ix:nonFraction name="IGAP:AggregateSalesPriceOfUnitsPercentage" contextRef="AsOf2021-12-31_custom_PlacementAgentAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction>%</span> of the aggregate Shares sold in the Offering plus warrants equal to 10% of the total number of the Warrants issued
    to the Purchasers in the Offering (collectively, the &#8220;Placement Agent Warrants&#8221;). The terms of the Placement Agent Warrants
    will be substantially similar to the Warrants except that the Placement Agent Warrants will also be exercisable on a cashless basis
    and will include full ratchet anti-dilution protection.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
    compensation</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grants
    to non-employees</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    connection with the 2017 Offering, the Company has issued to the Placement Agent (a) <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zhNsRFRtbNI9"><ix:nonNumeric contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantOneMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
    warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zZdniGU28zh3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,062,717</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock at an exercise price
    of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zSu3HABMcfa8"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.354</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, (b) <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zZqOOwFF1Vml"><ix:nonNumeric contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantTwoMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
    warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zbF2M5eKdh82"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">108,305</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock at an exercise price
    of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zqHO0BvfgJxb"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23.40</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.(c) <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_zIfeaWgKJXDa"><ix:nonNumeric contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantThreeMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
    warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_z6EsU55v2hH2"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,331</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock at an exercise price
    of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_zV866NZbTnti"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">46.80</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, and (d) <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFourMember_zWMygPyCKyl9"><ix:nonNumeric contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantFourMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
    warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFourMember_zos7YD9MmrXe"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,331</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock at an exercise price
    of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFourMember_zrg6EoIcxzr3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">70.20</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The terms of the Placement Agent
    warrants are substantially similar to the terms of the Series D warrants except that the Placement Agent warrants may also be exercisable
    on a cashless basis at all times.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            connection with February 2020 Offering, the Company has issued to the Placement Agent <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandTwentyOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFiveMember_zfJ1R2VokEtc"><ix:nonNumeric contextRef="AsOf2021-12-31_custom_TwoThousandandTwentyOfferingMember_custom_PlacementAgentMember_custom_WarrantFiveMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
                                            warrants to purchase up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandTwentyOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFiveMember_zst9e293yR82"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-12-31_custom_TwoThousandandTwentyOfferingMember_custom_PlacementAgentMember_custom_WarrantFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">288,462</ix:nonFraction>
                                            </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            of Common Stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandTwentyOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFiveMember_zl6F5A7rLUX6"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_custom_TwoThousandandTwentyOfferingMember_custom_PlacementAgentMember_custom_WarrantFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.2</ix:nonFraction>
                                            </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
                                            share.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ending December 31, 2020, $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200101__20201231_z4pmWHm9FTT9"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">756</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand, respectively, representing the
    fair value of warrants issued as consideration for placement agent services to AGI. This amount was accounted for as Warrants with
    down-round protection. Upon issuance, the fair value was recognized as an increase in additional paid in capital</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2020, the key inputs used in the fair value calculations of the warrant that were affected by the down-round protection
    were as follows:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zjCncJ4E5oH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><span id="xdx_8BA_zqKLcqcL0dIl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; border-collapse: collapse; width: 58%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Fair value calculations &#8211; Warrant</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31-Dec-20</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zG6kiQss7US5"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Expected volatility (%)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zOPAtKKPxUh3"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">56.32</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z39F9w5I5Xtk"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">2.5</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zBonNKFffTbc"><ix:nonNumeric contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price (US dollars)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmXooMm7mJU3"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.2</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Share price (US dollars)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIn838AN9blh"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2020-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.2</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value (US dollars)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairValueMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfTuNhbuoQB3"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2020-12-31_custom_MeasurementInputFairValueMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">2.6</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zbdKy8bGZnw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grants
    to employees</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    August 2007, Integrity Israel&#8217;s Board of Directors (&#8220;Integrity Israel&#8217;s Board&#8221;) approved a stock option plan
    (&#8220;Integrity Israel&#8217;s plan&#8221;) for the grant, without consideration of options exercisable into ordinary shares of
    NIS <span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20070831__us-gaap--PlanNameAxis__custom--IntegrityIsraelsPlanMember_zhMHHDwg8sV7" style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2007-08-31_custom_IntegrityIsraelsPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">par value of Integrity Israel to employees,
    officers and directors of Integrity Israel. The exercise price and vesting period for each grantee of options was determined by Integrity
    Israel&#8217;s Board and specified in such grantee&#8217;s option agreement. <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20070801__20070831__us-gaap--PlanNameAxis__custom--IntegrityIsraelsPlanMember_zhQcFV1IPP95"><ix:nonNumeric contextRef="From2007-08-012007-08-31_custom_IntegrityIsraelsPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">The
    options vested over a period of 1-12 quarters based on each grantee&#8217;s option agreements. Any option not exercised within 10
    years after the date of grant thereof will expire</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
    compensation (cont.)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grants
    to employees (cont.)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    July 2010, following the merger with Integrity Israel, the Company adopted the 2010 Share Incentive Plan (the &#8220;2010 Share Incentive
    Plan&#8221;), pursuant to which the Company&#8217;s Board of Directors is authorized to grant options exercisable into Common Stock
    of the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    purpose of the 2010 Share Incentive Plan is to offer an incentive to employees, directors, officers, consultants, advisors, suppliers
    and any other person or entity whose services are considered valuable to the Company, as well as to replace the Integrity Israel
    Plan and to replace all options granted in the past by Integrity Israel.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
                                            June, 2020, Erez Ben-Zvi has joined the Company as its Vice President of Product.</span></p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 8, 2021, the Company announced that it has promoted Erez Ben-Zvi to General Manager in addition to his current role as Vice
    President of Product, effective immediately</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company granted Mr. Ben-Zvi annual award of NIS <span id="xdx_90C_eus-gaap--OfficersCompensation_pn3n3_uIsrael_c20200628__20200630__srt--TitleOfIndividualAxis__custom--ErezBenZviMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXzeXtxRz076"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2020-06-282020-06-30_custom_ErezBenZviMember_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Israel">210</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand worth (approximately $ <span id="xdx_901_eus-gaap--OfficersCompensation_pn3n3_c20200628__20200630__srt--TitleOfIndividualAxis__custom--ErezBenZviMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdIJm3QzZJB1"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2020-06-282020-06-30_custom_ErezBenZviMember_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand) of restricted stock units (the
    &#8220;RSU&#8221;) effective as of the employee Start Date and on each one-year anniversary following the employee Start Date subject
    to the approval of the board of directors (the &#8220;additional RSU&#8221;). The RSU and each of the Additional RSU (if approved
    by the board of directors), as applicable, shall be based on the stock price at actual the date of grant (and not lower than US$
    5.20 per share). <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20200628__20200630__srt--TitleOfIndividualAxis__custom--ErezBenZviMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsQwno8EbTc2"><ix:nonNumeric contextRef="From2020-06-282020-06-30_custom_ErezBenZviMember_us-gaap_RestrictedStockUnitsRSUMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">1/12
    of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall
    vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the employee continues to be employed
    by the Company at the applicable date of vesting</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
    The vesting schedule shall be also applied to each of the Additional RSUs granted, mutatis mutandis, such that the vesting period
    of each of the respective Additional RSU shall commence from its actual date of grant</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
                                            November, 2020, Mr. Shalom Shushan has joined the Company as its Chief Technology Officer,
                                            Mr. Shushan will lead all technology and research and development activities for Integrity
                                            and will serve on the Company&#8217;s executive leadership team.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company granted Mr. Shushan annual award of NIS <span id="xdx_907_eus-gaap--OfficersCompensation_pn3n3_uIsrael_c20201128__20201130__srt--TitleOfIndividualAxis__custom--ShalomShushanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJ88080QpFha"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2020-11-282020-11-30_custom_ShalomShushanMember_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Israel">90</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand worth (approximately <span id="xdx_90D_eus-gaap--OfficersCompensation_pn3n3_c20201128__20201130__srt--TitleOfIndividualAxis__custom--ShalomShushanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkFRWxhLCpg6">$<ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2020-11-282020-11-30_custom_ShalomShushanMember_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand) of restricted stock units (the
    &#8220;RSU&#8221;) effective as of the employee Start Date. Furthermore, on each one-year anniversary following the employee Start
    Date subject to the approval of the board of directors, Company shall grant the Employee with NIS 60 thousand worth of restricted
    stock units (the &#8220;Additional RSU&#8217;&#8217;). Both the RSU and each of the Additional RSU (if approved by the board of directors),
    as applicable, shall be based on the stock price at actual the date of grant (and not lower than US$ 5.20 per share). <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20201128__20201130__srt--TitleOfIndividualAxis__custom--ShalomShushanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLwY45ycWlJ7"><ix:nonNumeric contextRef="From2020-11-282020-11-30_custom_ShalomShushanMember_us-gaap_RestrictedStockUnitsRSUMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">1/12
    of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall
    vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the Employee continues to be employed
    by the Company at the applicable date of vesting</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
    The vesting schedule shall be also applied to each of the Additional RSUs granted to the Employee, mutatis mutandis, such that the
    vesting period of each of the respective Additional RSU shall commence from its actual date of grant</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            October 19, 2021, Paul V. Goode was appointed as President and Chief Operating Officer of
                                            the company, Inc, effective November 1, 2021. He has served as a member of Integrity&#8217;s
                                            Board of Directors since December 17, 2020. Concurrent with his appointment, Mr. Goode has
                                            stepped down from the Board.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0">Effective November 20201, the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
granted Mr. Paul V. Goode options to purchase up to <span id="xdx_909_ecustom--PercentageOfDulitedCommonStock_iI_pid_c20211120__srt--TitleOfIndividualAxis__custom--MrPaulVMember_z6tzXnTsnSbd"><ix:nonFraction name="IGAP:PercentageOfDulitedCommonStock" contextRef="AsOf2021-11-20_custom_MrPaulVMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.5</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the fully diluted common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211120__srt--TitleOfIndividualAxis__custom--MrPaulVMember_zszgl8i0E16k"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-11-20_custom_MrPaulVMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (approximately <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20211118__20211120__srt--TitleOfIndividualAxis__custom--MrPaulVMember_zzc6LDjFnmIb" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-11-182021-11-20_custom_MrPaulVMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">330</ix:nonFraction></span> thousand options),
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the Company (&#8220;Common Stock&#8221;) as of
the Effective Date, with a per share exercise price equal to the greater of (A) $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20211020__srt--TitleOfIndividualAxis__custom--MrPaulVMember_zlzQwBYYVhib"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-10-20_custom_MrPaulVMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.20</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share or (B) the closing price of a share
of Common Stock on the Effective Date, as reported by Bloomberg L.P., which shall vest in equal monthly installments over a three year
period following the Effective Date.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            December 3, 2021, James p. thrower was appointed as Vice President Engineering of the company.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    December 20201, the</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Company granted Mr. James
    p. Thrower options to purchase up to <span id="xdx_905_ecustom--PercentageOfDulitedCommonStock_iI_pid_c20211203__srt--TitleOfIndividualAxis__custom--MrJamesPMember_zHHHXGwbHqQ3"><ix:nonFraction name="IGAP:PercentageOfDulitedCommonStock" contextRef="AsOf2021-12-03_custom_MrJamesPMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.15</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
    of the fully diluted common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211220__srt--TitleOfIndividualAxis__custom--MrJamesPMember_zLiTUYHQD1Sc"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-20_custom_MrJamesPMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (approximately <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20211218__20211220__srt--TitleOfIndividualAxis__custom--MrJamesPMember_zPDtlpEup8O"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-12-182021-12-20_custom_MrJamesPMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">250</ix:nonFraction></span> thousand
    options), of the Company (&#8220;Common Stock&#8221;) as of the Effective Date, with a per share exercise price equal to the
    greater of (A) $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20211220__srt--TitleOfIndividualAxis__custom--MrJamesPMember_zAz2IRkZrMGf"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-12-20_custom_MrJamesPMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.20</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share or (B) the closing price of a share
    of Common Stock on the Effective Date, as reported by Bloomberg L.P., which shall vest in equal monthly installments over a three
    year period following the Effective Date.</span></p></td></tr>
  </table>
<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgTR23sZjut8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8BB_z804badvxNda" style="display: none">SCHEDULE
OF STOCK GRANTS ACTIVITY</span></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 82%; margin-left: 1.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Grants to Employees</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price (US$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; padding-bottom: 1.5pt">Balance outstanding as of December 31,2019</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zbzfYCNDNbm2" title="Number outstanding beginning balance" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">156,007</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zXIfIndJGbNh" title="Weighted average exercise price outstanding, beginning balance" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">63.44</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Balance exercisable of December 31,2019</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20200101__20201231_zIfi1YoFzeGl" title="Number exercisable, beginning balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">132,630</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zp2yw1rOxRFd" title="Weighted average exercise price exercisable, beginning balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60.19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Granted during 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zMQngjh5lMgl" title="Number shares, grants" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0675">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_z4Bprvx2fi78" title="Weighted average exercise price, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0677">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Forfeited during 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231_zHIzTlEkEyL6" title="Number, forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">25,770</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zggqNa5rzt7e" title="Weighted average exercise price, forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">58.63</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance outstanding as of December 31,2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zZuvFDQJdUW1" title="Number outstanding beginning balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">130,237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zfmzeJgTmwZb" title="Weighted average exercise price outstanding, beginning balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">64.35</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Balance exercisable of December 31,2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20210101__20211231_zt8AGEdZH1cd" title="Number exercisable, beginning balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">128,296</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_pid_c20210101__20211231_z5ua8Ql99sFk" title="Weighted average exercise price exercisable, beginning balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">64.48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Granted during 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zxj2ZiyXilCb" title="Number, grants" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">577,064</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_z4mH7EONhW25" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Forfeited during 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231_z7LgUYtZDtpc" title="Number, forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">98,177</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zxZtW5O8XOOc" title="Weighted average exercise price, forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">64.64</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance outstanding as of December 31,2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_zCa0YdSQQXWd" title="Number outstanding ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">609,124</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zRbdkWAs6nY" title="Weighted average exercise price outstanding, ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.10</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Balance exercisable of December 31,2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20211231_zAgh22zbiUQ4" title="Number exercisable, ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">39,223</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zKH4QqiQmyba" title="Weighted average exercise price exercisable, ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">46.41</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric><p id="xdx_8A0_zrjGCV9FZQ99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zVgfwIHJyx75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize information about options outstanding at December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8B3_zKrNsKm2uhik" style="display: none">SCHEDULE
OF STOCK GRANTS, BY EXERCISE PRICE RANGE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; border-collapse: collapse; width: 64%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>price
                                            (US$)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding at December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable at December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average remaining contractual
    life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zub7MEbx4Vlf"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-01-012021-12-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.2</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zuhEAQqCPheg"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">579,004</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBDndmflcIT4"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,103</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zL7uz27QZdKd"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_ExercisePriceOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">2.75</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zo4CMb3x2C77"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-01-012021-12-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">58.5</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUTjAZuuGJ53"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,274</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z2KivElePXFd"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,274</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zd21c6BBm3vi"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_ExercisePriceTwoMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">5.18</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWTtEQU3iu0c"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-01-012021-12-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">100.75</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zBzFgPivlowj"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,846</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zL0f2niBp6jj"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2021-12-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,846</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z6I7Y9tz8loh"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_ExercisePriceThreeMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">5.26</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231_zt0bXd0J8t3l"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">609,124</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231_zlRFEYgLjLya"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,223</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zbBkszpbZLaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
                                            INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>NOTE 9</b>
&#8211; <b>COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
    compensation (cont.)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grants
    to employees (cont.)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fair value of options granted to employees during the years ended on December 31, 2021 was estimated at the dates of grant using
    the Black-Scholes option model. The following are the data and assumptions used:</span></td></tr>
  </table>
<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLL1OEK6u81g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8BC_zfKXlYxCnMd2" style="display: none">SCHEDULE
OF ASSUMPTIONS USED TO VALUE OPTIONS</span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; width: 82%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
    value calculations - Warrant</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31, 2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zue5XlZzHbBk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0724">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility (%) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zbd5VVjAuA9c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">49.21</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    free interest rate (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_z9pq2FJk3Lv" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term of options (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zTrn6VHbCiQ" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    price (US dollars)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20211231_zHWICVB3oYJh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.2</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    price (US dollars) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20211231__srt--RangeAxis__srt--MinimumMember_znuEcG7VTrSl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.1</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20211231__srt--RangeAxis__srt--MaximumMember_zZF4yc5rk9Kf"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.65</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value (US dollars)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zTwn5sG0ukhh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.6</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zy60RI1frbdl"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.48</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table></ix:nonNumeric><p id="xdx_8A8_zufHsVROlNUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"><p id="xdx_80A_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zcccsdkPSwne" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_827_zxVETZ3pFKNk">RESEARCH AND DEVELOPMENT EXPENSES</span></b></span></p>


<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="IGAP:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock"><p id="xdx_89B_ecustom--ScheduleOfResearchAndDevelopmentExpensesTableTextBlock_zj1niLzcqLz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8BD_zgjnOeehpJ7k" style="display: none">SCHEDULE
OF RESEARCH AND DEVELOPMENT EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20211231_zJkwsET1pU5j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20200101__20201231_z31ccH8YmWL7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><p style="margin: 0">Research and Development</p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LaborAndRelatedExpense_maRADEzgxz_zy7obYeNTb64" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Salaries and related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">916</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">754</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProfessionalFees_maRADEzgxz_zuFNn5S2zVm1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">337</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">462</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InventoryWriteDown_maRADEzgxz_zSeGenFyUPyf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expenses due to slow inventory write-off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">321</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DepreciationAndAmortization_maRADEzgxz_zrxmDqMWj5g4" style="vertical-align: bottom; background-color: White">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfPropertyRepairsAndMaintenance_maRADEzgxz_znL8tU2Lk2wa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vehicle maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">47</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherGeneralExpense_maRADEzgxz_zmbi7AQ6gqqj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">162</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEzgxz_zHdJWSUSuhRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total research and development
    expenses, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,810</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,532</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric><p id="xdx_8A8_zyau6CMNXzMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="IGAP:SellingAndMarketingExpensesTextBlock"><p id="xdx_804_ecustom--SellingAndMarketingExpensesTextBlock_zbLmABdAAtph" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8211; <span id="xdx_823_zGaun3mk2yg5">MARKETING EXPENSES</span></b></span></p>


<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="IGAP:ScheduleOfSellingAndMarketingExpensesTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfSellingAndMarketingExpensesTableTextBlock_zH5ac9akaOp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8BC_zkjCBInLSFw8" style="display: none">SCHEDULE
OF SELLING AND MARKETING EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Selling and Marketing</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231_zohCQLqIHKr1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December
    31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20200101__20201231_zfvdPLlHFJv6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December
    31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--SalariesAndRelatedExpenses_maSGAAEz1YR_zTvk3hgUK9t9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Salaries and related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="IGAP:SalariesAndRelatedExpenses" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="IGAP:SalariesAndRelatedExpenses" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">156</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ResearchAndDevelopmentProfessionalFees_maSGAAEz1YR_zMazA1bRJbn3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="IGAP:ResearchAndDevelopmentProfessionalFees" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">115</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="IGAP:ResearchAndDevelopmentProfessionalFees" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">241</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--SellingAndMarketingOtherExpenses_maSGAAEz1YR_zs0inEMN6Yfb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="IGAP:SellingAndMarketingOtherExpenses" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="IGAP:SellingAndMarketingOtherExpenses" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--SellingGeneralAndAdministrativeExpense_iT_pn3n3_mtSGAAEz1YR_zxrFStdDZe83" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total selling and marketing
    expenses</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">415</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zlTbfS1xV4a1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="IGAP:GeneralAndAdministrativeExpensesTextBlock"><p id="xdx_805_ecustom--GeneralAndAdministrativeExpensesTextBlock_zBaFdEAgPQo9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 &#8211; <span id="xdx_824_zsTxyLV4rMia">GENERAL AND ADMINISTRATIVE EXPENSES</span></b></span></p>


<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="IGAP:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"><p id="xdx_893_ecustom--ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_ze3X159d1ns8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8B2_z9VxWPN7iCsk" style="display: none">SCHEDULE
OF GENERAL AND ADMINISTRATIVE EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZe2zEorLkb7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsUypMV9dnYh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">General and Administrative</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LaborAndRelatedExpense_pn3n3_maGAAEzQ9k_ze209rYWDyd7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Salaries and related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">608</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">368</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProfessionalFees_pn3n3_maGAAEzQ9k_zxYv3yAsdMni" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">694</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--BadDebtExpense_pn3n3_maGAAEzQ9k_zTh3ST4sVCE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bad debt expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="IGAP:BadDebtExpense" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0786">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CostOfPropertyRepairsAndMaintenance_pn3n3_maGAAEzQ9k_zox4jP414Iuj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vehicle maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DepreciationAndAmortization_pn3n3_maGAAEzQ9k_z1i1Fii3c0o" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InvestmentIncomeInvestmentExpense_pn3n3_maGAAEzQ9k_z5XvhHsnifhb" style="vertical-align: bottom; background-color: White">
    <td>Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInvestmentExpense" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInvestmentExpense" contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">73</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_maGAAEzQ9k_zdFEX10ajw0j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_iT_pn3n3_mtGAAEzQ9k_zDWzqMVW1rZ9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total general and
    administrative expenses</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,091</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,185</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_z5Wn1FFQtVed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_802_eus-gaap--IncomeTaxDisclosureTextBlock_zD1206RLb38h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 &#8211; <span id="xdx_823_zQfhPQppk788">INCOME TAX</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Measurement
    of results for tax purposes under the Israeli Income Tax (Inflationary Adjustments) Law, 1985 (the &#8220;Inflationary Adjustment
    Law&#8221;)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
    January 1, 2008, the results of operations of Integrity Israel for tax purposes have been measured on a nominal basis.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax
    assessments</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    federal, state and local income tax purposes the Company remains open for examination by the tax authorities for the tax years from
    2017 through 2020 under the general statute of limitations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding,
    pursuant and subject to the provisions of article 145 of the Income Tax Ordinance, Integrity Israel&#8217;s tax returns that were
    filed with the tax authority up to and including 2016 are considered final.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carryforward
    tax losses</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the Company had cumulative net operating losses (NOL) for US federal purposes of approximately $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231_z5AesVbqpV58"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.5</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. Integrity Israel has losses carry
forward balances for Israeli income tax purposes of approximately $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zj4KdvCzNdG4"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31_us-gaap_IsraelTaxAuthorityMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">41.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to offset against future taxable
income for an indefinite period of time.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2021 and 2020, the main reconciling item between the statutory tax rate of the Company and the effective
tax rate at the rate of <span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20210101__20211231_zFL23d7MV5Wi"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20210101__20211231_zvV9c6rX2yDf"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></ix:nonFraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
for 2021 and 2020, respectively, is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating
losses carried forward and other permanent and temporary differences due to the uncertainty of the realization of such deferred taxes
and withholding taxes that were deducted by the Company&#8217;s customers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13</b> &#8211; <b>INCOME TAX (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    taxes result principally from temporary differences in the recognition of certain revenue and expense items for financial and income
    tax reporting purposes. Significant components of the Group&#8217;s future tax assets are as follows:</span></td></tr>
  </table>
<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxta6JHExGt7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zBxd64DGl1Y7" style="display: none; text-transform: uppercase">SCHEDULE
OF DEFERRED TAXES</span></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zMyzFB15wbV6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20201231_z0NYxt4dnPcl" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Composition of deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_maDTANztgP_zBh0msQw1KXg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Provision for employee-related obligation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></p></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 16%"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANztgP_zIRN9dDuIgt4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-capital loss carry forwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,654</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,889</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxAssetValuationAllowance_iI_pn3n3_msDTANztgP_z1DF1u6Qv6R3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0">(<ix:nonFraction name="IGAP:DeferredTaxAssetValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,660</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="IGAP:DeferredTaxAssetValuationAllowance" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,912</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3_z8qN6Od92Ql3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total deferred
    tax assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0820">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-hidden: xdx2ixbrl0821">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">-</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

</ix:nonNumeric><p id="xdx_8AB_zpghoy2Je6L2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80F_eus-gaap--SegmentReportingDisclosureTextBlock_z4GWlBfIRW67" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14</b> &#8211; <span id="xdx_82F_zxMqzbny23mc"><b>SEGMENT INFORMATION</b></span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates in <span id="xdx_904_eus-gaap--NumberOfOperatingSegments_dc_uSegments_c20210101__20211231_zDoyREnm7Iye"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2021-01-01to2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segments">one</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating segment with no income in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
long-lived assets are owned by Integrity Israel and are located in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zL4MFU8V2Ryh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 &#8211; <span id="xdx_820_z6LIDgdQs7id">RELATED PARTIES</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Garrett, Inc., which is controlled by one of our directors, Andrew Sycoff, received during the year ended December 31, 2020, cash
    approximately $<span id="xdx_90A_eus-gaap--RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_pn5n6_c20200101__20201231__dei--LegalEntityAxis__custom--AndrewGarrettIncMember__srt--TitleOfIndividualAxis__custom--AndrewSycoffMember__us-gaap--AwardTypeAxis__custom--PlacementAgentFeesMember_z5f5yxVYmoyd"><ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="From2020-01-012020-12-31_custom_AndrewGarrettIncMember_custom_AndrewSycoffMember_custom_PlacementAgentFeesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in placement agent fees and <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20201231__dei--LegalEntityAxis__custom--AndrewGarrettIncMember__srt--TitleOfIndividualAxis__custom--AndrewSycoffMember__us-gaap--AwardTypeAxis__custom--PlacementAgentFeesMember_zKZvKPMI9W34"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-12-31_custom_AndrewGarrettIncMember_custom_AndrewSycoffMember_custom_PlacementAgentFeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750,000</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants for Placement Agent fees in 2020
    from us.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2020, $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200101__20201231_zjpRS4cnfMld"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">756</ix:nonFraction>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand, representing the fair value of
    warrants issued as consideration for placement agent services to AGI. This amount was accounted for as Warrants with down-round protection.
    Upon issuance, the fair value was recognized as an increase in additional paid in capital</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zJ6r4XDoepWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    16</b> &#8211;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_zynLQNENpgC8">SUBSEQUENT
    EVENTS</span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated all subsequent events through the date when these
financial statements were issued to determine if these must be reported. The Company determined that there were no reportable subsequent
events to disclose in these financial statements.</span></p>
</ix:nonNumeric><p id="xdx_81E_zaZR8pjU4uv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.7
<SEQUENCE>2
<FILENAME>ex3-7.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 3.7</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex3-7_001.jpg" ALT="" STYLE="height: 866px; width: 670px"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex3-7_002.jpg" ALT="" STYLE="height: 866px; width: 670px"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex3-7_003.jpg" ALT="" STYLE="height: 868px; width: 670px"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex3-7_004.jpg" ALT="" STYLE="height: 868px; width: 670px"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
23.1</U></B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-1_001.jpg" ALT="" STYLE="height: 90pt; width: 246pt"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; width: 70%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fahn</FONT> Kanne &amp;
  Co.</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; width: 70%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head Office</FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; width: 70%">&nbsp;
  <TD STYLE="text-align: left; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32 Hamasger
  Street</FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; width: 70%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel-Aviv</FONT>
  6721118, ISRAEL</FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; width: 70%">&nbsp;
  <TD STYLE="text-align: left; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PO Box 36172,
  6136101</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 70%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T +972 3 7106666</FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; width: 70%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F
  +972 3 7106660</FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; width: 70%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 30%"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">www.gtfk.co.il</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT<BR>
REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have issued our report dated March 31, 2022 with respect to the consolidated financial statements included in the Annual Report of GlucoTrack
Inc. (formerly: Integrity Applications Inc.) on Form 10-K for the year ended December 31, 2021. We consent to the incorporation by reference
of the said report in the Registration Statement of GlucoTrack Inc. (formerly: Integrity Applications Inc.) on Form S-3 (File No. 333-259664).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>/S/
FAHN KANNE &amp; CO. GRANT THORNTON ISRAEL</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel-Aviv,
Israel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
31.1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Paul Goode, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2021 of GlucoTrack, Inc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Paul Goode</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Goode</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Executive Officer </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 37; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
31.2</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Jolie Kahn, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2021 of GlucoTrack, Inc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Jolie Kahn</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jolie
    Kahn</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Financial Officer </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
32.1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report on Form 10-K of GlucoTrack Inc. (formerly: Integrity Applications, Inc.) (the &ldquo;Company&rdquo;)
for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;),
I, Paul Goode, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Paul Goode</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Goode</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 39; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
32.2</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report on Form 10-K of GlucoTrack, Inc. (the &ldquo;Company&rdquo;) for the period ended December 31, 2021
as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Jolie Kahn, Principal Financial
Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that, to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Jolie Kahn</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jolie
    Kahn</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex3-7_001.jpg
<TEXT>
begin 644 ex3-7_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" <6!7P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **JWVH6FF6KW=_=06EK'C?//($1<D 98G R2!^-4-'\6>'_$#[-)UFQO)
M=I<Q0S*TBJ#@DKG<!D@9([CUH V:*S[W7-+TRSCO-0U*RM+64A8Y[B=$1R1D
M ,2 20">.PK._P"$[\(?]#7H?_@PA_\ BJ .AHKGO^$[\(?]#7H?_@PA_P#B
MJW;>>&ZMHKBWECF@E0/')&P974C(((X((YS0!)14-W=06-E/>7,JQ6\$;2RR
M-T15&23] *6WN(;N".XMY8YH)4#QRQL&5U(R""."".] $M%9VLZ[I?AZQ%[J
M]]!9VQ<())FP"QZ >IX)P.P/I7/_ /"U/ _?Q+8_]]'_  H [&BN.'Q3\$8_
MY&6Q_P"^C_A6QIWBG1]8T]K_ $R\^W6JRF%GMHGDPX .,*">A'/TH V:*X\?
M%/P0?^9DLC]&/^%'_"T_ ^,_\)-8?]]'_"@#L**0'(S2T %%86M>,-!\/7<%
MGJ>I1Q7EQCR;9$:6:3+;1MC0%CD\# YY]#56]\?^'M,CAEU&XO+"&8[4EO-.
MN($W8;Y2SQ@ _*3@D'O0!T]%5[&_M-3LTO+"[@N[:3.R:"0.C8)!PPX.""/P
MK$UGQUX>\.RM'K%^UB<,5,]O*HDV]=AVX?''W<]1ZC(!T=%<HGQ%\/2:;_:2
M/J;6'E&7[2-'NS%L R6W^5C  //3BK?ACQOX>\8FZ_L'4/M?V7;YW[F2/;NS
MM^^HS]T],T =!13)9!%&SD,0H)(52QX] .3^%<=<?%7P?:ZLVDS:I*NHB40_
M9A87#.7. % $?4D@8]Z .THKEM3^(?AK1+R*UU6^GL))<^6UU93Q(^ "<.R!
M3C(SSW ZUT<%S'=017$$L<L$J!XY$8,KJ1D$$<$$8YH FHKD=;^)?A3PW?+9
M:QJ4MI<,GF!)+.?E<D9&$.1D'\JE_P"%@Z#_ &=_: .J&R\KSOM/]C7GE^7C
M._=Y6-N.<]* .IHK"\->,-"\7V\\^A7PNXH'"2-Y3IM)&<?.HK/U[XE>%/#&
MH_8-:U-[.Y*;PCVDQRN2-P(0@C*GIZ4 =;163X<UP>(M'@U1+"[LX+A1)"MW
MY8>2,@%7 1FP#GN0>.G2M:@ HI"2/I6!I'C+1=<UW5=%L;Q7O],DV3Q'@D<9
M9?[P#$H?1AR,%20#H**0G )KS+7/C=HWAO4FT_6- \0V=TH!V200_,#D94B7
M##(/(..#Z4 >G45B77B&6#0[?5;?1-3OHY8!.T%J(FEC7;NP5,@W'MA"Q)Z5
MRGA;XS:!XOUZ'1]-L-36YE!8&X$$:X')_P"6N6..<*"< G& < 'HU%8OB37I
M?#VDMJBZ;/?VL&Z2[^SR(KPPK&S&0!R V"JC:#GYLC.,&WHUW>WVD6MUJ%BM
MC=S1AY+42^9Y6>0I;:N3C&>.#D<]: +]%8'C/Q5;>#/"UWK=S"\XAPL<*$ R
M.QPJY/09/)YP >#TK2TG5;'7-+M]3TVYCN;.X7?%*AX8?S!!R"#R""#R* +M
M%9VM7.JVFGO-I&GV]_<KD_9YKHP;@ 3\K;&&[.!@X'/)%>9>%OC/J7BWQ(="
MLO"MO!>*KLWVG4V55V=1E82<_A0!Z]17ENK_ !;U#PGX@L[#Q;X4;3+&YD=5
MOX+\7*E5."ZJ$!(R5)!PP!SC/!]$LM4MM6TR._TNX@N[>5"T4B2?(QY[C..1
M@\9!SQ0!>HKQ+7OC[?>&]>O=&U'P>JW5I(4?;J1*MQD,,PYP001D#@BNKD\8
M?$&.-G/PQ8A020NN0,>/0!<GZ#F@#T*BN3\ >,IO&NCWM[<:2^ESVEZ]G);2
M2%V5D52<Y52#EL8(XQ764 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?.
M_COQ/;6/[0ED_B5&ET+3%1(XGB\Q%$D.?-V'KAV!) )_=C&2H%>K>+/"F@?$
M[PPJ&Z@F7YFLM1M663RGS@E2#AER,,N<''8@$9'Q&^&&F?$%I[RVN7M=<M(_
MLZ2'/E.<!U608SC#'YEY&_G=@"O"M7\+^.?A-<1:DMR]G%)*L:W5E<9CD<98
M*R_Q#Y2<,N".W44 ?1.O^"H/%7AWP]I&K1R_9K2>&:ZCC< MLA==I/H6(!V\
MX/!'4>4_M!^&M-T:VT"XTG1;2Q@9YTGDM+58E+$1E%8J!S@.0#Z-CO7MW@[Q
M%'XK\)Z;KD:;/M4673'"R E7 ]@RM^E>2?M+6Y>R\.7/F1 1R7$?EEP';<(S
MD+U*C;R>Q*^HH T_AMX"\,^*/@WIR:EI%J;BZ2=6O8X46X4B>0*PDQG(P.N1
M@8((XKU3P_IIT;PWI>ELX=K*TBMRXZ,40+G]*Y'X)_\ )(M#_P"WC_T?)7?9
M% 'F7QN\5'0?!+Z9;JTE[JX>%5&X%85&97X'("D+C(^_GD BH/@)XG_MOP,V
MESRL]WI$GDG<68^2V3&<GCC#J .@0=.*R[/4=(U?Q?XIUW4='UW5K2^4Z78O
M9V,UQ"+55\N4Q2)QAWW?=Z8.#\QKRWP7K5[\-/B7&EREY#82RFWN$NX#;M);
ML<+*R."5QP_7L1G!- 'T7\1/!/\ PGNE:;I3W7V:UBU!+FY=1ES&L<BE4XQN
M)8#)X R><8/*_&O3;+1_@_\ 8=.M8K6UAN81'%"NU5^8D_J2<]R2:]97O_C7
MF'Q]Y^&$^.?]*A_F: *_P*L+.\^$WV>ZM8)H+BZF\Z.6,,LG('S C!X Z^@K
MJ?A]X+3P+INHZ9!<-/:37S7-N[G,@0QQKA^ ,AD;IVQWX'/? +CX80?]?<W\
MQ7J% 'R[\(D1_CE<ET5BANV7(^Z<D9'IP2/QKVCQ-HUA\1=%\1:3)9VK7>GS
M-:6=VY!*3>3%*&# $H-[!6 SD(<]<#PWX9Z7#JOQIN8+B2YCC5[I\VUP\#'D
MC&]"& Y[$=/3(KWGX=^'I_#,/B&PFFN[A3J[S17-VQ=YU:&$[BQ W'.02.ZD
M=J .R'3FL#QGXD7PCX1U'7'A>;[+&-D8[NS!$SS]W<PR>N,\&MBSO;?4(&FM
M9/,C662$G:1AXW:-QSZ,K#WQQQ7*?%31[W6_AIK5AIT+3W3QI(D2C)?9(KD
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MO"/B&W@FCUBWFM;KSOM#L'1)@64HS;0N,GY0#D#W!]IH *^8/&7_ "=!;?\
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MAMY'S"O2_A;HUYH'PUT73[]/+N5B:5T((*>8[2!6! (8!P".Q!%>!>*]!O\
MX1?$NQUFSM]NF_:FGL52XR7B!'F1$G+#Y7VY(/!ZGFOI+PKXHTSQAH,6L:7*
MS02$JR28$D3CJK@$X/0_0@]#0!\N_&S'_"W==]?]'_\ 2>.O<3\3M)U_XB>&
M/#^@7;W,<CR75S<1,5C*_9I2L1'!8Y(8@_=*@?>SM\-^-G/Q>UW_ +=__1$=
M?3^K^&X-0\3Z!KD4,*W>G3REYF)#-$\$B%0!P3O,9YZ '!YP0"[INC6>DSZC
M)9IY?V^Z-W-& H42%$0D  ==@8YR268YYXTZQ=,\16.KZYJFF6+>:=,\M)YE
MR4$K;\Q ]V4*-V#QNQP016U0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!Y=?W'CO1OB?J=_I?AZ2^\,2F+[3&DT2O*XB0&6,,P;>  N.C;<=<%=/XA-?
M^(O"\GA[1-&>]FU-A#)+>120PVJ9SYK%@"2" 0!DYYYQM;O<4;02/:@#)\->
M'[3PKX<L=&L=Q@M(]@9B278G+,<GNQ)QT&<#C%>>_&[0O%'BS3M.T?0=&-W:
MQS?:;B<RQIA\%$5=S@]&<M\N/NX/45ZP1D8HVT <-\)=.UK0O MMHNNZ4UA<
MV<DBH?/CE$RL[/N&PG!!8C!],YYP+GQ!G\3KX;FL_"FDO>:A>*T7GBY2$6JD
M8+@EU)?D[<=",D\ -UI4&C;QU_&@#F? =M=Z?X*TS3K_ $F33;FR@2WDB>2-
MPY51EP48C!.>N#G/&.3YA\9? 7B'Q=XEM;C0?#+2>1#Y<]\;N%/M'0J C.#A
M,D;B 3DCHJD^ZX]Z,4 <;\.9O%47AR'3O%VFW,-_:@H+R6XAF%PF?ER48G<!
M@'(YQG<22!C?%W3/$'BGPY+H.B^';NY<SQR?:FN+>.(J 2=N9-Q.2!@J._/3
M/I9&: ,"@#ROX.Z7XJ\*Z.^@:_X?G@A-PTT%VES Z("O*LJONZKP0&R7YP!F
MO2-2OI[*V62WTR[U!V8+Y5JT2L!@G<?,=!CC'7/(XZXN;?>@+B@#YU\$?#WQ
M_HOQ&C\0RZ%!;Q!IW>.XU)%1@ZL-I:/>>"P/W<?+VZUZ?XJ?XC7/A^XAT33-
M%MKM@1OCU%Y9-N""$#PHH;D8+' P>.F.[(R*3:* ,'P1X<_X1+P7I>AF3S)+
M:+]ZX;(,C$N^TX'R[F;&1G&,UT%%% 'D6J_#&]\*^,$\9^!K>WED5P)M$;$*
M.C K)Y;Y 3@@A3P""02,)6AJ=U\2?%.G3Z1!X;M/#*SKMEO[G4DN?W><,B(B
MG#D'J>  >0<$>FGFDVXH Y'P#\/M-\ Z5+;6,TMQ<7+*]S<R@ N57&% Z*#N
M(!)(W'DUS?Q/\%>,O'UO:Z?:MHUEI]M.\O[R[D=ISC;&Q A^0@%N Q'S=\ U
MZD!@8I: .1\ Z1X@\/>'['1-7M]+,-G"46YM+N1V<[N 8VB4#Y3R=QY'3GCK
MJ** (K@S"WD:V2.2<(3&DCE%9L< L 2!GO@X]#TKPW6OA!XUUOXAGQ2=6T>S
MD:ZBG1HV>1K<)MVX4Q@.5"C&<!L9.,X'N]% '"^(O!GB;Q3:QV%]XOAM-.8[
M;J'3-.:%[B,XRI=IGP,9' Q\W(;I70^'O"NB^%+%[/0[".S@=M[A69V8^[,2
M3^)XK9HH \O\??"G5/'^H037WB>"WMK7>+:WATS[@8@DLQERS$!03P/ER%&3
MG9T[PMXOTKPS;:):^+=/5;:!8(;IM%)F15X7_EOL) P.5Z#G)YKMZ* .0\'^
M$=6\/ZEJVH:SXDEUN[U 0KODM_*\H1ESM4!B "9"<  #GCFN1\9_!C4?''B!
MM6U'Q7#&PC$,446F86.,$D+GS<DY)))[D]!@#UVB@#S2S^'_ (XT_2H=,M?B
M4T5I!"((U&BQ%E0#  8MNX'?.:M^%/ASJ'AV^UG5;OQ,^JZU?VX@@OKFV.ZW
M'S'H9#N7=L.W('R ?3T"B@#@?!W@'6_#'B/4M7O/%2ZL=4*M>K-8;'<J&";6
M$A" ;L8VD8& !QCH?%GAY_%&@2Z.;J.WM[EU6Y9K<2LT0.6";CA'X&'(;;U
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MKC_XW4]C\7O VI:A;6%IKOF75S*D,4?V28;G8X49* #)(ZUXS^SC_P E"O\
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M/+=&U:ZEC>$IY !0%6)X+9?^'</E//3/60P0VMM';VT,<,$2!(XHU"JB@8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ IK?A3J0C- 'R!\&'2/XM:&7=44M, 6/&3!(
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M 0 7QR/X<U]&Z5JD.KVGVF"&\A&[#1WEK);N#@'[KJ"1SU&1P<'B@#0KY?\
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M07(!&<D;LC4\6:?XN\?^%KG0O[$AT.&5XC-->WJ2%D5@V$6(/GE0>67MUR<
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M6./'WH])A=OR*K_.NI\*>$[?POISQFZGO]1N-K7VHW3%YKIP,#<22=H'"KG
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"\DDC;510,DDGH .<UPZ_&GX?NKE?$"_(,D&TG!/(' V<GGH* .^HH'(S10
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/-';HS9$,>XG@ +DY8D@_,PQ7<TT<4[(]: (+NXCM+::YESY<2%VP,\ 9/\
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M^W=R/ESR.M<CXBG\=6'A:_F\8V7@_5-"BMS]LMXYYX)9AC"[78;5?=@C SG
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M$$)@@CG-2?VU:_\ /*^_\ )__B* -"BL_P#MJU_YY7W_ ( 3_P#Q%']M6O\
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M6[90K;C@*1G<-NTY(')(QQD][10!Y]_PEOQ#_P"B8?\ E>M__B:/^$M^(?\
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M\'(/'![V@#D7\,^*F=F7Q[>1@DD*NFVV%]AE#3?^$7\5_P#10;[_ ,%EI_\
M$5UQ?';MFC?TXY]* .1_X1?Q7_T4&^_\%EI_\12?\(SXKSC_ (6!??\ @LM/
M_B*Z_=QG!K'O-*U&?Q1IVJ6^M3P65O%+%<:;Y:M'<;APV>"K @'// P-N6W
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MI5P6P6*J5;:">1C@C.<9 .QK+U'Q%I6E;ENKQ/.4J/L\(,LQ)(  B0%S]X=
M>N>E3ZMJD.C:/?:I<H[06=O)<2+& 6*HI8@9(&>#WKA?@Q:Q3>"6\1R*#J.N
M7EQ>7DFT#+^:ZA1@9VC!(!)P6;UH ["#Q/HMQ);P_P!H107-R2L-K=YMYW([
M>5)M?WZ="#T-:P.1FN4\5>)/#.DWVFZ=KTTL=W+.D]B$LI92TBM@!&5&&[G:
M0/FP^. PS>F\0N=:U'3+*WMY)-/MHKBXDN;@PHOF;\#(1N@CR3T^8>] &]17
M :+\4K37?"6NZM:V&+_1(GDN[)K@,AVJQ^29 5=3L8!@.2.F""5U?XBW>A^&
MK+Q+?>'FBTBX$1=&NQ]KCW]/W6S81T/,@.#R <B@#O32;>.OXUS.N>.=+T/Q
M#;Z)<75C!=2VK7;/?77V>-4#A%&XJ068[L <X0Y[9K^&_'*^)KWQ!8V5O92W
M&E&/RY;>^\ZVN?,0LF) F1RI#?*<'IF@#KMM+D#K7'>&O%^N>)$TF]3PG+:Z
M1?1EGNI[Q0\.$R&\K;ED9CM5L@D#<5 (SE7'Q"U6U\)0>-I=-L_^$>=(S):K
M,YNE#2A X;:$/!'[L@<Y^?L0#I?$7C*P\-:KHFGWEM>22:Q<BU@D@C4HCEE
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M' Y%:]16]NEM;Q0(TC)&H13)(78@#&2Q)+'U)))[U+0 4444 %%%% !1110
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M)*C;I'8H 2%. N[MDC)P =%XFO;B35M&\/VE]<6,NI&>26YMPF]88H^0I<,
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MD5ZU<^$4N;76;-]9U46>J^8);?=$RQ"1<.(R8R5!ZXSUR>I.:6H?#30;W3]
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M\]CY48"J&E3#IQP2KMD]3N/J:Z^V\$:+#IFL:9-%)>66L7#W5Y%<$$/*^-S
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M-TP*HV"9B^XD!&)=N>-K=L8'4KX4T=/%+^)5MY5U=X_*:87,N&3 &TINV$<
MXQC(SUYK-G^&?@RZ\02:Y<^'[6:_F<O(9-S1NQ&"3&3L)/7)7KSUYH L_#ZX
MAN?AYX;>":.51ID$99&# ,J*K#([A@01V(-9OQ'LK74&\)VM[;QW%M)KT(>*
M10RL/)FX(/!'M72Z%HFG>'=(@TO2K<V]E!N\N+>S[<L6/+$GJQ/6EUG1-/UZ
MT2UU&W\V..5)XV#M&\4BG*NCJ0R,/52#U'0F@#@?B/#!+XY\ O93RKKJZF-L
M4!P7M.LQ8@9P N,9&0S\'G#O&E_:^ O'>E>+Y5\K3M24Z;JK)'G! W0R@+@E
MAM8$G)V* !G%=OIOA[3=*N6N;>.XDN&0Q^?=W,MS(%R"5#2LS!20"0"!D UQ
M&G^(;KXBZ_?^'-0\,SV6C6-P);B6Z&\70CD_=Q%"H"[F4.>6&$*_Q9H [3PQ
M!)'HT=S<V*65Y?.UW<P+R4=SG:S8&YE7:N<?PCL!4^O:1:Z_HEWI5Y'')!=1
M-&P==P!QPV/4'!!&"" <BM*FMTH \F^&VJOXPM--TSQ!'+>:IX:DE^V_:QDQ
MW(?; _HY">:,D[@R$D$X:ND\17*0?%7P1&P8M/!J,:>QV1MS^"G]*ZJTTJQL
MK^_OK>V1+N_='N9@/FE*($7)] HX'3DG&225DTG39M3BU.73[1]0A0I%=-"I
ME1>>%?&0/F;@'N?6@#CM'^Q#XS^)!)Y?]H?V;:>1G[WE9;S,>V?*S^%&L:MI
MVC?%JQN-3U"UL8&T*=!)=3+$I;SXB "Q S@$X]C76_V#H_\ :_\ :_\ 9-C_
M &G_ ,_OV=/.^[M^_C=]WCKTXJ#6/#&A:]/;3ZMI-G>RVS$Q-/"KXR""#GJ/
MF)P<C.#C(! !YWINI:?H7QO\4WFK:A9V-K?V%I+:37-PD:3)L5<H6(!&58?A
M5<RQ^(/!OQ-L='87UU)?R3QQ0?.9(WBBVLN/O!O+;&,YQQG(KU+4="TC6O+_
M +6TFQOO*SY?VJW279G&<;@<9P/R%3VVF6%G=7-U:V5M!<71#7$L42J\Q&<%
MR!EL9/7UH \W@\2?#OQ?X=T^34KB&\FG9"-*GO99Y5N"N-BHQRQR2H; !SUY
MKT[/%9\/AK0K?5#JD&B:;%J!=G-VEJBREFSN.\#.3DY.><FM3% 'E'PZG?1_
MB-XVT#4[6*TO+V^?4[-F0B2YA9WR0XX95!4@=06?T;'2^&K99/B!XPU2W57M
M9S:6YF5@0\\2.)%^JAD![9R.H('3:CI.FZQ;K;ZII]I?0*X=8[J%95# $ @,
M",X)Y]S4GV"S_L[^S_LD'V'RO(^S>6/+\O&W9MQC;CC'3% 'G?P:GT^73O%7
M]F-#]C_X2*Z>W2$!5$)";-JCHN!QQV]J[#QG;RW7@7Q#!;Q/+/+IERD<<:EF
M=C$P  ')))Z5<TS0='T7S?[*TFQL/.QYGV6W2+?C.,[0,XR?S-:% 'B%OK6F
M77[-UU:V]] ]Q9Z:JW$:N-T3,Y55;T)(.!UZ>HK4UC4["/\ 9\T.5KVW$9@T
MR-6\P<NDD1=1ZLH1\@<C:WH:]7AMX;="D$,<2%V<JBA069BS'CN6))/<DFI*
M /'/B'I=DOCO0/'VJ1VFH^$XK9+6Y58_M& _F[)BN"K1 R1G()/3 )Q71>';
MSP9?:WITWA#PW8W(;S&FU2TT]8$LU"="Y0$R-N5?+'(5B3@#GT'%&!Z4 075
MI;WUE-:7,:RV\\;1RHW1U88(/U!KRGX=ZG<?#NPN?"GC*5+"WM;HC3+Z?Y(;
MB-V)(5P-HP?G^9L@28. M>NT8H \Z\0ZIH_B7Q!X5&B30:K=6.JI-/-8KYXM
MH3'(&WR("$!8)P2,[1P<5SWB Z%X7^*6L:GXRT**ZT36H[?[-J4]D+B.VECC
M*F,C:Q&[;GCG@<$98>S8HQ0!YMK6H:(WPU\5:IINF0Z?IL^E>1!>&V-NUWF$
MI'A"@/EC>B(3U^; "@%H?'44^L_ @1:9:W-[+=V=FT$=M"\CN-T;?= R/E!/
M(KT^C% 'E'BO4+[PS\5=,\72Z;<2>')M)%C?7<<#.;<&1WW%0=RX/EDDCH6
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MG=9)-Y4,%4(1P$R,MR3CC&3W.** "BBB@ HHHH **** "BBB@ HHHH ****
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ML/#VBW6K:E+Y5G;)O=\9[@ #U)) 'N: -&BDW#&>:-P_#UH 6B@G I-P [T
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M!UYXH OT50TW6]*UF-Y-+U*SODC8*[6LZRA3Z':3BK] !1110 4444 %%%%
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M/^(]3^(GA[6K9-+33-'>48DN)/.E69 LAVB/:" #M&XY.,D9P,R;PCXS\/\
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M&W.V$PH(&7/7/:@#IJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDR :"0* %HI"
MP'4TN: "BDR*,CUH 6BDW#UHR/6@!<44F12YS0 44F1G&>:,B@!:,4F:,B@!
M:*3(H) ZT +129%&10 M%)D4;AZT +129%&10 M&*,T9H **.M)F@!:*,TF1
M0 M%("#1D9QF@!:*3(HW#UH 6BDW"C>H[B@!:*3(HR/6@!:*3(]:,B@!:*3<
MH[T9% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>ZC')&,X]R\ >(Y_%O@G3M<NHHXI[I7\Q(@0@99&0X!)X^7/4]: .2^,VO\
MB#P;I%GKNBZU+$)+Q+9[-[>%XB"CMD$IO!^3!^;OQBMSPO8Z_J_@FPOKOQ?J
M'VW4+:"Z66.TM5$.Z/)0*8B",MDYY^48(YSRO[1W_)/-/_["L?\ Z*EK>\#:
M#J\G@+P_))XOU6/S+"%DCM[>T"1H4!5!NA9OE7 R6).">,XH Y/X-^*/%?CV
MXUE]7\27"Q64<:I'!:VRY:02 ,3Y9Y7:"!TSC.1D&O)XC\9M\;7\#)XMN19$
MG;<-8VS2 ?9_. /[L \\9JK^S+_S-/\ VZ?^UJHZS:7U]^U+<6VFZDVFWCJ!
M%=K"LIC/V$'[C<'(&/QH ]?T*S\0VNO++<>)7US2'MITD)M[>/RKA)$4#,8!
M)_UH(Z H<\XK@O%WB+Q5HGQ;T3PS!XMFBT[4O)=GFM("\8>5D**PA/)VX4D8
M!(R< FNU\&/_ ,(EX(T^R\17Q6\.HSV@EN-V^ZFDNI C#/S-OR&SZ'<>,FO.
MOB;%>3_M >$DL'>.Z^SVS(Z1&7;B>4DLH924 !+<CY0U &]X^\2>+/AE=V&K
MKJ;:]HEPYMYK:]AAB>)\!AAXE4DL%?'RD+CD$D5TGQ5U/5-"\"WNNZ/JDUE<
MV>S")'$Z2[Y43YMZ,> 3C:1UYS7DOB*ZF/QRL[+XCW"W6FV[K]D*((+15;#*
MQ1PP*$C:^6_A.6(3!]2^-7_)(M;Q_P!._3_KO'0!E>";WQ!XC\$:/JNH>-M0
MMM0U:>6&W2*QM3'E#(=N/))^Y"YR6 [?7M-(L==F\(FRU'6I1JXDFC_M**VC
M1F"S-L;RRI0 H%XQT)P<_-7F?PG\+7<OASP1KT.I7T]M!=WCS64LJ^1 K)-'
MO08#?>5!C+<NQ &6KUVSUBWO=7U'3H4G,FG^6)Y6B*Q[W4ML5C]Y@NUCCH)%
M]2  >6_"ZZ\1?$'PQ=:OJGBW5K>ZBN9;-%LX[>./:4B;)7RCELGALY S@C)S
M+\%O&>M>.=-UZS\07?VAK<Q;9XE$$FV57! ,>W&-F0PP<L>>!7/?!'PG;Z_\
M/=9:;4M5MWGNY+:-;>^EBCB/E)\XC1@&;YN=V00H&.N9O@'KEQ::WK'@U_L5
MS;VHDGCN[3;M<K($8A@ 9%;>"K'D  ="  "OX:NM=\*_'6+P[X@\0ZM<V+^8
M+-KN^D,<JNA,1(8A6/5. 1O&!R,UZ1XGL7U_QOI&DVEYJEJ8(_MNI2VM]<0)
M]G!98XMJ?(6D<MSD,%B;!Z5S7[0>B6-SX*@U=XC]NM+A8XI5/.Q^&4CN. 1Z
M$<=3GI_A1:(/ 5AJ<CR3W^I(+B\N9G+R3/C:"Q/HJ@?ADY))(!VXZ5Y!KGCC
M4_%WQ''@3PQ?3Z?:1>:FI:G%;;I4**P=5)/R+G:N_@[R,'&-WKX&!BOG_P ,
ME_!W[26KVNJA4763/]GF+%4(FD$J$%@,Y*^7Q_'P,XH ]1E\"RV^G1+I7BG7
M[;4H<[+VYOI+L.2"/WD,A,;#G/"K@@$$5RWC@:OI_P #H=1N[C5=/U[3K2WB
M>1+]U?S#)%&[,8WVR;@"06)/S=CFO5SR,5YY\8YX;KX-ZQ<6TJ30RI;/'+&P
M974SQD$$<$$<Y[T 8/@JRCU_X=>'I]5USQ,FJ:O<36XO;75YPRLC3/DJSE -
MD!7[IZCZCM-(\+7-QX#/A_7KZ_GF$TP6]-R?M&%N&>"42 G# "-AZ8 (ZBN"
M^$W@NVN?#?@OQ1;/*EW:37AN%>=RCQOYT?RH<@,"(_N[01NSDXKU32]?AU?4
M]6M;6(M#ILRVSW(=622;:&=% )/R!E!R!R2.QH \A^$?A^U\=^#[W5O$%SJ%
MSK$=^8+?4S>R?:;=5B!7RW+97!E=L="2,@X%6OA)XCUI?B#XG\(ZCJ=UJ=K9
MM,\%Q=R%Y%,4HBP&.3A@0<9P"O'4YYGX;^%+[Q'\'=:.CZEJ5GJJ7\GD"VO7
MCCGQ#&?*=-P3YLD;C@YQDX!!Z']GW5[."VU7PQ/IXL]9MY&GE+1N))D!"$/G
MH48A=O'WNF=Q(!4\?_"S0?#7PTUK6VB>YUOS8YOM+2MMC,DR!E51A2N&;E@3
MR3GH!'X,^%&@>+/@[:WZ6HBU^YCG,5X9Y HD29PFY<E=N% /RDXR1SS7?_&O
MGX1ZX,?\^_\ Z/CI?@H ?A%H?_;Q_P"CY* /-/VD=+L;34]#U*"UCCO+U)TN
M95&#*(_+V;O4@,1GKC [#'IOC/P5X:M/A;K-C;Z)9Q065C-<P!(\,DJ1963=
M]XM\BY8G+ 8.037GW[3 R?"XY_Y>^G_;&O7O'1/_  KWQ+_V"KK_ -%-0!XG
M\,-/T!OA+JM]JOAVSU>]DU,V5M$Z1K-*\B0HD:RMR@W/G<#\HR1TKT"X^$&C
MIX,US0;.W@8W%Q+<Z;)<_.UH[)'\H?&Y5W1@'&25X.[OQ7P@\+Q>(OAI/+"M
MM%JMCKRW=E<S1EE22)86 8*P)4Y8$9_BSU KW_UH \._9_O_ .S;GQ%X2OH(
MX-3M;@SL -S,5/ER*6&5PK!<<\[SCO7<>"/#5HNM:OXU$$45QK9WP11JH$=O
MD[6W*2"TH"2L?4X[$GS#XXV5M;?$K0+V'? ]Y$B7,EO*D#. ^W=YA^56VMC<
MQP !G@5]$1Q)%$B1HJ(JA551@ #H * ,G2?$^FZUJ^KZ79O(;K294BN59" "
MR[@0>XX8>N5/&,$[-9UC<Z3-?WL5C/927D;*+Q(&4R(3G;Y@'(/!QGT-:- !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S7C
M>QUW5_#=YI.AQ:<6OK>2WFFO9W01*XVG:J(VXE2W4C!P<-R*\^\'?#WXA^%M
M#N/#]MK6A6-C=SM/)>P)+/<Q,54?(K!4(.P#GD9)!R!7LV110!QO@3X=Z1X$
MTU8[2..?460I<:@T>))03G !)VKT^4''R@G)YK)\0_#B\C\6)XO\%W]OI6L=
M+FVFC/V:]RP+>9MY&1N)X.2%(VM\U>D44 >9:OX'\2^.]4M(_&5UI4&@V=PT
MZ6&EO*SSGHJR.X7H.-R@$AFQMR".D\:>$V\5^#I?#EM>1Z?!,8U9S;F7:B,&
M"J-ZX.57DYXSQR".IHH \Z\*^ O$GA#PW+HFE^*K'R6=W2:72"TD+, /E_?[
M3@\C<IYZY'%6K7P1K8\.^(=/U'Q6VI7NLQF$WD]G@0(5*LJQB0 <,V " "<X
M/(/=T4 >=P>%_B#::1_8L/C*P:U*HBW[Z;BZA0*054!]A^Z@RWS?O'.057/8
M>'-"LO#.@6>C:<KK:VJ;$WG+,2268GU)))P ,GH*U** .!^(_P /]1^($-O9
M-K\5CIL$@F$"V'F.TF"H9G,@X +8  ^\<YXQ=TGPUXHTCPG%H<'B>Q9[>);>
MVO'TDEXXPK 97SMK,/DP2,?)\P;.:[&C- 'F7PZ^%M]\/=4N9[?Q&EW972!;
MFV;3]A<KG8ROYA*D%CV(()XS@BH/A%JLGC\^,;GQDXU!I-[&UTU(RJ[-@5=S
MNH 7Y<L&X'.3S7J=Q=6]I%YMS/%#'G&^1PHS]34N<]* .!L? >M7&MV%_P"*
M?%TNN6^GRBXM[,6$=L@G (61MI.=NXD#CG'/&"NM_"W3]?\ %%OXBO=;UC^T
M+1E:U,9@580KET51Y7(4L<;LD]R:[VB@#D_%?@#1_&NCVUAK;7,TMJ,17J,J
M3*>-S<+L^;:,C;CT XQ4NOAO;7O@^/PK/X@UI]*0!-A-OO9%V%$+>5G"E 1C
M!Y()(P!V]% '$:)\._\ A'=(.E:5XL\0V]CN9A&7MWV%OO;6:$E>>>".23U-
M7=+\%IH^CW]A9Z[K"RWUV]W->O)$\Y=E52 3'@#"CH,CL17544 >>Z)\*;7P
MYI\]AH_BCQ)9VT[%I$BG@'S';R#Y60<*HR.<?C6]X3\$Z%X*LY(-%M3$TP3S
MYGD+O,5& 6)XZDG  &3P!7244 <QXS\&6GCC3(M-U&_O[>T1_,>.T:-?,8="
MQ9&/'. ,=><\8T/#.@6_A?P_:Z-:3W,]O:AA')=.&D(+%L$@ <9P..@%:^:*
M "L#Q+X.T#Q?%;Q:[IZW:V[%HCO=&0D8/S*0<' XSV%;]&10!RUCX+@M[.:T
MU#6=;UBWE3RS'J%Z2-N"I!V!=X8'G?NZ#WJ_JWA?1M<T=='O[/=IJHJ+:Q2O
M"@52I480C@;1@=L5/JOB#2-&PNHZC;6SD!@DD@#;2P7=CKM!(RW11DD@ FK&
MGZA9:I:K=V%Y;W=LY(66WE$B$@X(# D'% &3IG@K1-&TS^S=.2^MK,;ML4>I
M7(";NNW]YE><GC'))ZT[3/!^BZ)I5SIFF6]Q;6US,T\OEWDPD:1@ 6\S?O!P
MHZ'MZUN2R)%&TDCJB("S,QP% ZDGTJGH^LV&O:7%J6F7*W%I*7"2J" VUBK8
MR <94\]^W% &9X>\%:#X45DT2VGM(F?>T0O)GC+8P249R,XQSCL/057F^'GA
M:7Q$-?&E>1JN\R?:;:XE@)8YR3L8 DY.3CG)SFNJR/6C- &/KWAO2_%%@;#6
M(9I[,D,84N9(E?!R-P1ANP0" <X(S1H'AO2_"UC]@T>&:"T!W"%[F255R23M
M#L=H))) QD\UL49H YSQ)X)\/>+IK:77=/:\:U!$(,\B*N2">%8 YP.H[5JW
M6D6=YIC:?<K++:L&5T>=SO4@@JQW98$$C!)%7LBC- &-H/AG1_#<)@T>S%G"
MW+11R/L+8 +%2<;L <]>*V,"ES1F@#G=5\"^&==O/M>JZ3%>W&-HDN'9R%R3
MM&3P,DG XYKH(T$<:HI8A0 "S%CQZD\GZFG9%&: *%EHNFZ=?WM]9V<<-S?,
MK7,BCF4KG!/TR?SJ_1FC- !11FF,>N#0 ^BL+PKXFM?%NC+JMG;7=M$97B\N
M[C"."IP<@$CJ".O:MW(H **,BC(]: "BC(]:YSP;XK3QAI$NH)IMYI_EW+P>
M5=+M8@8*MCT*L/H<CG&2 ='1110 45C>)->/AVPCN_[)U74]\HB\G3+;SY%R
M"=Q7(^7C&?4CUKE;#XK0ZG=-;6G@WQ?)()_L\G_$O55BDX^5V,F$QD$[B, Y
M- 'H=%&:,CUH **H:OJUMHU@+RZ)$/G0PDC'RF258U)R0  7!)],]>E7EX7D
MT +11D4U9(W9U5U9D.U@#G:< X/IP0?QH =139)(XHVDD=41 69F.  .I)J%
M+^SDM6NDNX&MUZRB0%!^/2@"Q15:YU&RLF5;J\MX&89 EE521^)IUS>VEDJM
M=74,"L<*99 H)_&@">BH+J\MK.(275S# A;:&E<*"?3)^E8O@HZW_P (W$OB
M#4[#4M05W#75B08W7.1T51D XX Z#ZT =#17->+_ !;#X4.C>;"DO]I:E%8G
M=,(_*5\YEY!R%P...O45M6^J:==2"*VO[6:3&=D<RL<?0&@"W158ZC9+=?96
MO+<7!./*,J[\XSTSGI1<ZC8V;*MU>6\!89 EE5<C\30!9HI%974,K!E(R"#D
M&EH **XKQMKWBOPY;3ZCIFG:5>6$;1(L<D\BSN\CK& %"[?O,/XJTO!GB5_$
M^C/<7-L+34;2YELK^U5]XAFC."H;&#P5/&1SC)Q0!T=%9">*O#LHN#'K^EN+
M89GVWD9\H?[7/R_C4^G:]H^L;O[+U:QOMN=WV6X27&,==I/J/S% &A16(OC'
MPN]N]PGB31VAC(#R"^B*J3TR=V!5O3M=T?60W]EZM8WVW.?LUPDN.G7:3ZC\
MZ -"BN ^(:^)=(T36/$&F>*;BUBMH1)%9"S@= 0 #\S(6.3D\GO7>K[=* '4
M5S_BC6-(M]/O-*N_$UCHM]=6KK#+-=)%)%N#*LB@L#P<D$8Y'6CP1;?9/"%C
M!_PD/_"0[?,_XF?F;_/S(QZ[FSM^[U/W?PH Z"BLO6]?TGP[9M=ZOJ-O9PX8
M@S2 %\#)"CJQQV )/I5#3_'7AK4[^SL;35HI+V\+K%:E667Y5+'=&0&3A207
M R,8SD9 .CHK&UGQ5H>@GR]1U."&?:)%ME)>=U)QE8ER[#(/(!Z'T-3:)K^E
MZ_:-<:9=K,BG:Z%61XSZ,C ,OJ,@9&"."* -.BN*USXCZ/H/C"#1KVX>-#;R
MM,193NWFCRC&J%5(8%&D)QG&T9(Z';T/Q/I7B/S_ .S)IY/(V^9YMK+#C=G&
M/,49^Z>F<=^M &U17#_$/6_#D>BWWA_7M1N;%;RVRTT5G-*$0L1G<J%1RIX)
MKL[:9;BWCG0.$D0.HD1D8 C/*L 5/L0".] $M%8>K>+=#T:]CLKN]+7;D8MK
M>%[B49Z92-68 ]B1S3M(\4:/KEQ+;65YFZAR7MIXW@G4 @%O+D"MMR0-V,9X
MZB@#:HKCQ\2O"[H3#>W$T^0JVD=E/]H<G.-L10,02,;L;<X!()Q5SPSXSTSQ
M29X;:.\L[ZW&Z>ROK=H9H@6902#P>5/0G&1G!XH Z2BN3U[Q[IFAZA)IL-GJ
M>KZE$$>:STFT-Q)"C9PS] O0<$Y^93C!S4_AKQGIWBJZOK:SMK^":Q2)KB.\
MMS"R-(&^0@\[EV$'MGH30!TM%':B@ HHIK D\<4 .HKRGX@Z5J6DZGI-]:>+
M/$,1UK6X+":%;I!%#%*KJ?*4)\I"]#R<X8Y8 CM-+TK_ (0_P_>G[?KFM^7Y
MES_I<WVFY;"#]W'P,YV\+ZGWH Z*BO/E^*4=TI@TSPGXFN=2#F)[.2Q,7D2$
M Q^<Y.V-6W [LG R2!QG=\(>*T\5Z=/*^FWFF7MM(L-U97B;9(G**^0.NT[N
M"0I.,X% '245P5UX]U6]U"ZMO"?A*\UR.QF:"YNI+E+2$R#@K&S_ .LP0P;
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M6GO&DF29F9I#=2[N"O3.><D_GQS7@&P.B?&'Q58VFA7FF:;+:P210E0(D 7
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M-N^9[JV:=2N#D;5D0YSCG/8\<US&E^&/%VEW^J78\5Z=<-J-P+ATFT9ML;!
MF$VSJ<;40<D_<'<DD R_BAX+LM:@M-:@N+BPUV*YM+2WOX)&#1I)<"/[H(&!
MYK-Q@Y YQQ65XJ^'FA>$]*@\2Z.;Z#7;.]MG-^UV[RW#/*D<GF[B0=XD); &
M2<="0>Q\8^&-?\2&VBTSQ.FD6D+I*T8TY9VDE219$8LS# 5D4@ >N<@X%?Q7
MX.UWQ+H&G:6GBO[)Y*)]ME_LY)/MDB%&5\;AY>'0M@''S8Z"@#.^,VE:/>>
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MKNC:7<07LDNK221PR00F1$9 "=^.0"#U (&"3@ F@">'PUH5MJAU2#1=.BU
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MBC:,YQ2T4 )M!ZC-5=26_.GS#3);:*](_=/=1M)&#G^)593TXX/'7G&#;HH
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MLD#(& 2*ZRN=U;Q7%8:\-#M;&ZO]3^POJ#0P[5"PJ=N26(R6;*J%SSUVCYJ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3\\F A;';A%Z8Z9ZDUU%YXWGTW7=/@O] NX-'U*:*UM-1:5 S3R?=1X#AT&
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MM%6T":?&'7SEN"0S[F55"AS\S$8W^YH IZEXVUS6=9U>VT&Y?3[?1[H0(_\
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MOH*RS1H%(VB5I-Q'+<\9R<]376:/H"6+_;KY;&ZUN1#'<:G#9+!),N> <$G
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M@GY<DM@')]?VTN#ZT >-^ BMMXNL[+PG%?77AO\ ?F]AU2VD#Z+. Q,,;L
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MIU% #=@.,\X]:@OK/[=I]S:?:)[?SXFB\^W?9)'N!&Y6[,,Y!]:LT4 >?_\
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M !BF[?<TZB@!-ON:4#%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"%(! SSV)RMRRTGQ=J]G<#Q%J%II\ABEA@CT9I%VLR;!.SD@L1ERJ8P,@G+
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M/.>W K>'?"GC/2;$Z)=^*+.32+<11VUQ!8[+LQ*H!CSNV1XVX#8D8@DY4XP
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M4%YO24C"NV["C9L'8J.BYP.WT+PU?6&HMJ6L:Y/K%ZL3002R0I"L,3,&8!$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7!5)7F7:Y8_,1Y0Y 7J>.U="#GH*P+,X^(.L_P#8*L.O_76[H Z(=**!THH
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MH!?E/REOO+NR"#T'3@@&;I]E';>/+G2()X[!+#1;./3XX7CDE-OOE5\F1"P
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M<1Z;(N.P\J1>??*FMOP]X/L/#TANEFOM0U)X1 ^H:C<M/.T88L$W'A5R>B@
MX&<D9HNO!/AV^\3P>)+K2TFU:#;Y<\CN0I4?*=F=N1U!QD'!Z@&@#S:<Z?X@
M^'_C?4='N(K;P[*UY<$/LEEO+OAS*V_<(E)"JD>U7QA\J2*VO&/[SPY\.73Y
ME_M[3&RO(QM;G]16];_"WP79WEY=6^@6\4MY%+#+M>3 20$.$7=B/()'R $
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MMR5S+C'VJ0[2"5?E0AZK#P/WF![/!;Q6MM%;6\*0P1($CCC4*J*!@  =  ,
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M?&W<WS?+F/@Y.W+^,^A:CKWPYNXM-EE\RUD2ZD@C_P"7B-,[D/(X&=^.<E
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MGWQQ_P"#C_["@#T"BO/_ /A5G_4^>./_  ;_ /V%,'PJ42-(/''C;>RA2_\
M:W) R0/N>Y_,T >AT5Y1=? 7PW?.9+_6/$%U(0P62>[1F7+ER03'U+,Q.<Y+
ML<9-367P$\$6L:)-!?7I68R,\]T07!7;L.P*-H)W< -D=2/EH ]1HKS_ /X4
ME\//^A>_\G;C_P".4G_"DOAY_P!"]_Y.W'_QR@#T&BO/O^%)?#S_ *%[_P G
M;C_XY1_PI/X>?]"]_P"3MQ_\<H ]!J.>XAM8&FGE2*)<9=V"@=NIK@O^%)_#
MO_H7_P#R=G_^.4?\*3^'G_0O?^3MQ_\ '* .]\U1*(RZARI8+GD@8R0/Q'Y^
M]4AKVD=]5L?_  (3_&N0_P"%)?#S_H7O_)VX_P#CE'_"DOAY_P!"]_Y.W'_Q
MR@#L/[>T?_H+6/\ X$)_C1_;VC_]!:Q_\"$_QKEK+X0> ]/O$NH/#D#/'G G
MEDF3D$<H[%3P>X..O6M@>!/"&.?"FA_^"Z+_ .)H T?[>T?_ *"UC_X$)_C1
M_;VC_P#06L?_  (3_&L__A!/"'_0J:'_ ."^+_XFC_A!/"'_ $*FA_\ @OB_
M^)H T/[>T?\ Z"UC_P"!"?XU9@NH+N/S+:>.:/.-\;AAGZBL;_A!/"'_ $*F
MA_\ @OB_^)K4L-,L=)MA:Z;8VUG;@EO)MHEC0$]3@8% %RBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF>1P/WN] D2'=RVWS"PQGI@\,*[#M0 45G-K^D)*D3ZI8K(\@B1#<)EG)P%
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M('P4Z?Q 9Z]Z -LG%)D5S,7Q \,W,D<=KJ37,LELMVD=K;2S.T9V_P **3N
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M3H=4FU.+3[2._F39+=)"HE=>.&<#)'RKQGL/059N+A+:WEGD#E(U+L(T9V(
MSPJ@EC[ $GM7(:9\4/#NK#3OLOVUFOKG[* +5F$+Y<+YK+E4+&/(4G=AE8@+
MD@ [0<#%%<OJWCJPTE+JY:ROKG3;*40WE_;+&\5N^X!@07#MMW#=L5L<CJK
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M< <9(R[+QA=:;XV_X1+Q+]F%S=1B?3;VUA:*&X7'S1LK.^QP0V/F((QT) 8
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M^([G(&6.6/)SR3ZUIZKX5TK2K'PAX@LHI8M8DU6P$E[Y[F219=D;HQ)^X5&
MOW5&0  2" >HWNH6>FV;WE_=0VMK'C?-/((T7) &6. ,D@?C4D%S!=6\5Q;S
M1S0RH'CDC8,KJ1D$$=01S7F6I:9+XD^+NI0-?:61IVEQ)!8ZE8_:T99B3+(J
M>8F&&U5+<Y#@'M6]X%\%R^#9=81M5@N8K^Y^UK:V]I]GBMF;.X*N]L*1M ';
M9CF@#M**0=*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD@DNK&VG<#:&EB5B!Z9(JRJJJA54!0,  <"@#R;QUJ\O@?XKZ)XKO(P=$O;
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MH?B+1O&EO<);JZV,\0NEX0GSEQ&JX<XD8@[4P1C&/<8M_E)YBJKX&Y5.0#W
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M<'G'&-P-M-#O[OQK;:_?S0+!9V3V]M9Q$OMDD8%Y2^%/*JJ[<$<9X/7IJ,4
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MK'2EO8&U!8C,ULK@R*F0-Q7J!EAUZU<KSP1HO[0SE$4,_A<,QQ]X_:@,GWP
M/PKT,\ T 4]1U?3='MUN-3U"TL8&?RQ)<S+$I;!.W+$#. 3CV-1V6NZ/J44<
MMAJMC=1R2F%&@N$<-(%+E 0>6V@MCK@9KSKX66,GBB^O_B'K"--=WD\D.E&8
MJ?LUJI*X0 X4DEE/?Y2>=Y+=;JG@RQN_%FE>)[9(K?5;&1][K&H%RCH(SYA
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M<9&[HN-V6XXR,@'5Y ZFEK@=5^(%_IOCJX\*Q>&)[NX:R^U6#PW:#[4<=&#
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ML6+C!7'SF_-\4--B\%>'-9>:W2?6Y8K=%=@L<#D[9G<,03'$0V2.I"C(#;@
M>@Y!Z&C('>O/-.^),%Q\1[;PJMYI^JP7UJ9K>]TTC;%(H<M')\[YX0D$$8R!
MM.=U=MJNF1:QHU[IEP\B0WEN]O(T1PP5U*D@D'!Y/:@#&M?&*:B%N-.T75;S
M3&<*NHQ)$(F7NZJSB1E!SRJ'.#MSQ5_0/$>G>(M!CUNQE8:?(9=DLHV95'9"
MW/0':2,X.#R <BO)].\8Z_\ ">6R\->)](\[P_#+Y$&MPHP!B9VVLP7<"P 8
ME.&P.^,MT'Q!U.WB^"NJZGX6O8#IUXC.SJAD,HN)P)<%C\I)DD!!&1G VD<
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MC&%.%-.\,^)+F6\\8^'-7UYTU'2Y7DAOKF&&(QVK1@I)@ *VP_,S%=OS+V.
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MQ)R#R#VP,=*PXOAKX*AM8+=?#&F%(""A> ,YQ_>8Y9Q[,3F@#'!'_#0>>O\
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MC6@_VI_:G]B:=_:&_?\ :_LJ>;N]=^,Y]\U-=Z+I5_>V]Y>:99W-U;$-!/-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "B@G%)D&@!:*** "BBB@ HHHH **** "BC(SCO1D4 %%)N'K
M2@@]* "BBB@ HJ.>XAMK>6XN)4AAB4O))(P544#)))X  [T6]Q!=6\5Q;S1S
M0RH)(Y(V#*ZD9# C@@CO0!)1110 4444 %%%% !1110 4444 %%%% !1110
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M-6D@9@QB8C)4D<''3(XXJ;(]: %HI,BF37$-L@>>5(D+J@9V"@LS!5&3W+$
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M;M((Q@ ]2'045G:#>7E]X>TR[U&#[/>W%K%)<0["GER,@++M/(P21@\BM&@
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M\H,,J"40C)'(7J?2N(^+&/\ A(/A^>>=?A_]"6I=.U>RNOB?XI@LGM=)6W$
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M*"[*P7&X[?E!VYYK,31_%EQI7C/PQ'X4C:_NGEEN==GN?)74"SEHA&NUA]S
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M>XEN8'_L]D6%Y9&D<,OG$NN6./F!'<GL >>?LZ:?9OX+U"_-K#]L-_)!]I"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M29KB"U>^G:-'/4[2^#WX/'S-Q\S9S?\ A=OP\_Z&'_R2N/\ XW1_PNWX>?\
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M>!(=H7PU;$#GYW=N@ [L>P_/GJ<U,/A7X&QSX9L?^^3_ (T =:LJF1H]ZEU
M)4=0#G!QZ<'\JR[GQ3H%E;PSW6O:9!#.76*26[C59"APX4DX)4\''0]:Q_\
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MR_O8M=TVPM]-::UN(YI+F[WE1;A-NT8VD,S%^!D<*QYQ6D#V[T .HI,BC(H
M6BH;:ZCN[6&YBSY<J*ZY&.",C^=2[A0 M%)GZT9H 6BBD)Q0 M)D55TW4;?5
M=+L]1M2QM[N!)XBPP2C*&&1]"*I>)M4N=#\.W^K6UK%=&RA>X>*6<Q91%+-A
M@C<X' Q@^HH U\BEK,T'4QK7A_3-5,/DF]M8KDQ[MVS>@;&<#.,XSQTK2W4
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M]NUS,B#&794R57+ 9.,YXSS@ Z&BL"S\7Z=<:ZFAW,5UI^JO'YL=K>1A3*H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&W[> ,<$DXQ0!YW9^/+;7[B34-9\?P:) LK?9-/TS9N"!CL>9W1]S$8RH &
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MM,T74]+\&VVAQ:O +JVMTM8;U++A$4!0?+9V!?:#R3C.#M(^4U8_!BR>!?\
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M?_THDKT"O/\ X)?\DAT+_MO_ .E$E>@4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5Y_XM_Y*]\.O^XE_Z(6O0*\_\6?\E>^'?_<2
M_P#1"T >@45PUK+XAT7XA7"ZUXC@NO#UQI]U>PQO;QP?9/+EBR&8#)54D'S%
MN>20, GJ--U_1]9\W^R]5L;[R<>9]EN$EV9SC.TG&<'KZ&@#1HJEJ6KZ;H]N
MMQJFH6MC"SA%DNIEC4L03C+$#. 3^!HTW5]-UBW:XTO4+6^@5RC26TRR*& !
M()4D9P1Q[B@"[16?IFO:/K7F_P!E:K8W_E8\S[+<)+LSG&=I.,X.,^AI+K7M
M'L=0AT^[U6QM[V?;Y-M-<(DDFXX7:I.3D\#'>@#1HK'\0>*M"\*V@NM;U."S
MC;[BN27DP0#M099L;AG . <GBG:7XGT36M%;6=/U.WGTY QDG#;5BP,G?G!3
M P2&Q@'- &M17+^'?B)X6\6:C)8:)JGVNYCB,S)]GE3" @$Y90.K#\ZK_P#"
MT?!O_"0_V#_;'_$S^U_8O)^RS?Z[?LV[MFW[W&<X]Z .PHKG_$7C?PUX3\L:
MYJ\%I))@K$<O(0<X;8H+;?E(W8QD8SFKVA^(-)\2::FH:/?17EJS;=\9^ZV,
M[6!Y4X(." >10!I45SNG^.O#6JZ[?Z+9ZFKZAIXD:ZC:)T$0C8*Y+,H4X) X
M--T3Q[X8\2:Q<Z3H^JI=WELC/(L<;[=JL%)#D;6&6'()SG(XH Z2BBB@ HHI
M"0#B@!:*\O@^,.C6VLZ_;WRZJRVEQOB0:>ZF&W$408N" RCS"Y^89^8>PKN]
M!U^T\2:1'J5E'=QV\GW?M-N\+,, A@&'*D$$,,@^O6@#5HKR?P3XTM=)?Q-I
M=]>:KJ=[;Z[>):VD:SWUPELAC4?WBJ G&6(R<XR<UZ+H>OV'B+3C>V#N521X
M98Y4*20R*<,DBGE6'H><$'H10!IT5RMYX_TJVU"YL[:SU?4FM9##/)IVGR7$
M<<H )C+J,;@",CMG!YR*UM \1Z1XHTQ=1T6]2[M2Q3>H*E6'4%6 (/0X(Z$'
MH0: -2BBH+R![BV>**YEMG88$T(4NGN-P9?S!H GR*,UYWX=T?Q1JFD75W>>
M.]0_M!+B[M(9(;*V6%1'*T09HRAW$F/=]X'!QGJ3H_#KQ'>^(=$OEU-X)KS3
M-0ETZ6Z@/R7)CV_O0!]W<#VXXR, @  [/(HKE(/'-IJ$-S<Z3I>JZE:6SE7N
M;6!3&X!8%XBS+YP!1A^[#$G& <C.KH6OZ=XCL'N]/D=EBE:":.6)HY(95QNC
M=6 (89&10!K9HKE8?&,UQ;O<0>%?$;V\>0[O:I$RXY.(Y'61N/[JG/09(Q6U
M;ZG#?:'#JMBDES#/;K<0(H"O*K*&4#<0 3D#DC!ZXH T*,UR#_$#2X9FLKVU
MN[75C<+;1:5)Y37,[,@92H1V780<;RP4$$$C%;%GK)EMKF?4-.NM(CMT\QWO
MGAV[,$EMT;NH P<Y(QWX- &O17#7VLV'BS0%DN/!VL:GH<H$Z2F*$"11R'6)
MI1*?4#9EN, Y&;/PPFL;CP';3:7'Y>GO=WC6J;<;8C=2E!CMA<4 =A1FBLW6
M="TSQ!8_8]7L(+VV#!Q',N0&'\0]#@D<=B1WH TLBC->>>!?$US<>!-#33_#
M>KWD5M8P022CR859DC53Y?F2*7Y_BP%(SALC;75:#X@LO$GANVUS3!++:W,9
M>-&4*^X$J5(/&X$$9SCCJ1S0!LT5QMUXOUK38K_4-0\&WT&D6D+RF5+VW>?:
MJAF9H@^T*/FZ2,W ^7GCHKC6+2TT"7692_V.*U-TQ"Y;RPNX\>N.U &A17"7
MOC/Q'9Z3=:R_@R5-,AM7NAYNH)'<*@0L-\17Y#QR-Q(&>&(VGJM!U/\ MKP_
MINJ>3Y'VVTBN?*W;O+WH&VYP,XSC.!0!HT45C^)O$%EX6\/W>M:@)3:VH4LL
M2AF)+!0 "1W8=P* -BD/3BN(N_%'C#3K"YO;OP3$8+>%Y6%OJRR2':I( 4QK
MGIS@Y S@,< ]?<R3Q64TEM"+BX6-FCB:38)& )"EL' )P,XXH KV6MZ??:QJ
M.E6UQYE[IWE?:HMC#R_,7<G)&#D#/!/OBM&N/\)W<]QXHUY=0\,P:/J1AM9I
MIHKP7'VI#YB(20JXV^6PY_\ UV_&/B2^\+V=O?6^BOJ5H94CN?)FVS)OD1$\
MN/:?,8ESQE>@YYH Z7-&:X;4_%'BS2K:;5KCPI;II%JCO<1C45:[$0PWF!0/
M+RJ!\IN.20 W'._XB\1V?AJSM9[F.>:2[NX[.V@@4%YI7.%4%B%'0G+$# ZY
MQ0!M45YQJ^O?$?1M)U/6+C1/#TMC#;22I;1W<AF@VKG<[%0L@ !RJ[2<C!K>
MU?Q=_8WAO2]1N-.F:_U-X;:WL5.TFYE7*QLS@%0"""2H(Q]W/% '4T5Y]<^(
M/'NA6]UJ^M:'HUSI,0,SPZ=>.+BVA'S,6,BA)"JYX&W)''45WMO/'<VT4\+;
MHI4#HV,9!&0: )*0]*6N:\4>([K39[72-&LOMVNWZ.UM&QQ#"JD!I9V'*QC<
M.G+'"CDT )J'CSPYI7B2W\/7]^\&J7#QI#"UK-B0N<+M?;M()XSG ((/0UTH
MZ5Y/K^J^-["31+3Q1:>'Y;/4-:L((YM+DE#0R+.DOS+(/F!$9'&,?I79>*_$
MS:(^GZ981PRZYJSO%I\5PQ2'<H!9Y&_NJ"/E'S,2 .N0 =/D>M&1ZUY6_C[Q
M%H-Q9R:[>>#]0@N?)'V?2;UUN0LC@+*BN3YJ;3G@#.<YP,FS\7]+\0ZCI^@/
MH<MG"+75K>4RSD[HYV=8H6'!!4-(=P()Z8!YH ]+R/6BN2T!?B!_:B_\)$/#
M']G[3G^SO/\ -W=OO\8]:A\:^-/^$?NK32;*?28]4O(WE675;U8+>WC7 WR<
M[FW,=JJHYPQR IH [.BO)+;QU)X4F6?6/'NA>)]*<A9GM_*BN[<D@!ECC8B1
M!GYA]X Y&<8/3?$B/Q/;^')]6\-Z\FFMIMO+<3PO:I*+A5 ;[S [2%5\8')(
M!QUH [7-%>?BX\;>*X+?6M#OK30M.\E)[2UNH%N'OPPW#SB#^Y4C:,(6898D
MYP [6+7QY=^,;ZPT?7;*ST>:VAF%Q+9K)+9-\RE8USB3>4))?H&XP1R =]D4
M5Y#/K'Q+U/X=:GK[:AI.B7FG27#-;6]GYC.L!99 7=W4<J^ %.2B_, 37>I/
MJ/BGP-9WNE7W]BWVHVL%S'/Y2W/D;@KE=K8#<97)QUS0 _PWXEA\2'6/)MY(
M?[-U*;3GWD'>T>,L,=CNZ5O5R7@9]=2+6K#Q%JB:E>V6I- MRD*Q!HC#%(F5
M4  XDYZX/&3Q6?XZE\96&M:)<>&-0M'6\N!9'3+NV7RF;RY9&F:4$. JI]U?
M[O?.T@'>Y'K1FN N+/Q9HW]F:Q?^*3.[WEO#?Z?':QBW/G3K&JPL5WJJ>:?F
M8LS[1G';/^*/Q ;PW?Z=H-GK%OI%U>#S[G4)[=Y_LT ; V($(=F(<#/ "G.-
MP( /3Z.U>%GXHZ!X<O;.ZTOQKJ.OVLDHBOK+4;=MRQGI+$XB3#)W4Y# ]B :
M[_Q+JM_J'BNQ\':3>MI\TML=0O[Q0"\=J&V;8PP(WLQQN/W0,X.<4 :%_P"(
MM2L/$-O9/X<NWTZ>=+==22:-HP67.60'>HS\N2 ,X]1GI%^F*\QU?3O$WASQ
M)X;0>*KG4=!O=2C@GMKZ*(S!P#(I$BH"5S&?3&!U!./3A0 M4=7O)M.TB^O;
M>TDO)[>WDECMH\[IF520@P"<G&!P>O0U>K%U[0I=:\CR];U73/*W9_L^1%\S
M./O;D;.,<8]3UH /"VKWFO>'+74K_29])NI]^^RN,[X\.RC.54\@!N@ZUJ>?
M&ERENS?O71G48ZA2H/ZL/SKC_A1JM]K7PTTG4=3N9+F[E\[S)9#EFQ,ZC/X
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M=V3P!@T(DDUUM2FU/P_XAU>-[^[MPL-_%':&..9XE40FX0'A 270DMDYQMP
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9Y /;%_Q+X#L?$FJV^J?VIJ^EW\,+6YN-+N1"\D98-L8[3D C(''4^V'>'/
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MS?-([?W@<8!+9/(J?Q#\.=%U_51JZ3ZAI.KX"O?Z5<F":10"-K'!!ZCG&?E
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MT!1[T >+^-6T&?1KY-(\0>)O$&HZBD\<=KI.HO=1ARA.9(XSL6/)'RXZ'A2
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M!/.X'R@>@QD]:UO'5QXO&M:(WASPPFI06%P+QYY+Z.(,2DL3Q;6((.V3(?D
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M^-T =\!@8K \=_\ )/?$O_8*NO\ T4U8'_"[/AY_T,'_ ))7'_QNL;Q9\7O
MVI^#M<L+/7/-N;K3YX84^R3KN=HV4#)0 <D<DT ;'P2_Y)#H7_;?_P!*)*]
MKS[X)G'PCT,?]=__ $?)7H- !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+_H<M#_[\K_\CUZ_10!Y!_PCWQS_ .ART/\ [\K_ /(]'_"/?'/_ *'+0_\
MORO_ ,CUZ_10!Y!_PCWQS_Z'+0_^_*__ "/1_P (]\<_^ART/_ORO_R/7K^:
M3(]: /*K;PY\8V=?M?CK3(DP-QBLHW(.\ X!B7.$R1SR0%X!W#2A\*?$ED/G
M_$N-'WL $T2!QMR=IR<<D8)&."2,G&3Z)10!YX?"GQ&$BC_A9@*$'+?V%!D'
MC QGZ\Y[#UX>/"7Q$Q_R4[_R@V_^->@44 >?_P#")?$3_HIW_E!M_P#&J3>
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M_P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY7H%% 'G_\ PI+X>?\
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M\FS9H6F+L&U<6D8VCC@<<?=7_OD>E3?V%H__ $"K'_P'3_"M"B@#/_L+1_\
MH%6/_@.G^%']@Z/_ - JQ_\  =/\*T** ,_^P='_ .@38_\ @.G^%']@Z/\
M] FQ_P# =/\ "M"B@#/_ +!T?_H$V/\ X#I_A1_86C_] JQ_\!T_PK0HH ;'
M&D4:QQHJ(H"JJC  '0 4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HS2$XKPOXZ>
M);FZT)%T>[DCM+#5!:7<T3 !KCRBP165MV4!.X$ 98#.58  ]UHHHH ****
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M/;D;SW;M65XJN?#]WXIN;:]N/%6J2P0)%<:7I/V@V\&?G1G$(7YSR1ECP.G
MP >D;A2@YKS'X?W0A\;:OI=I+XA_LTV,-S%;:YYN^W;S)%VQ"3D1[=HSR25Z
M\5Z;G'% "T444 %%%% !1110 4A.*"<#-<K<:[J&J^*[_P /:.UM;_V=!#+=
MWLJ^<5:7=MB6,%<-M&[>20.!L.<T =5N%<%J/C_4)-5U^S\-:'%K/]@B+[6%
MO=DDKN&RD2A&#%=O.2#D%0I.,WO#WB+57\4:EX8\1I9KJ<,8O+.6R1ECN;0G
M9O(9F*L&X()[C&0,GE/A-8:V/$?C"YFU@/I4>MW<1M5@0--<[ANE9L94;=N%
M!QG/3'S 'I&A:A-JNB66H7-A/83SQ!Y+6<$/"Q'*G(!X/J!ZX'2H=?UP:;X7
MU+6;&."^^P12RM'Y^Q6\HGS%W!6PPVN,8ZC!QU$/C:2>V\">(+BVN);>>'3I
MY(Y8FVLK+&Q!![=.HY';!YKSCP9%<?\ #.&J7<U_<W N-+U B*79MB(:?)4A
M0QW'D[BW/3% 'JN@ZG_;/A[3=4,/DF]M8KGRMV[9O0-MS@9QG&<"M#->'WVJ
M^._#OPGT3Q)8ZEI5K8:?:V?^@+ TK7$#)$H,DC#AMQ^Z@7"L?G) KOO$7B.Y
M_P"$ML?"6F+=K=7%J][<W%JD9DAA!VKM\P%,LXP2V< 8 RP*@'99H/2N6\,R
M>)H-4U33=<AGNK**4O8ZLY@0S1G'[MXXSD,#G#;0&&<A3@'.^,MQ-;?";79(
M)7B<I$A9&()5ID5AQV()!'<$B@ TKQEKOBE[RX\.:#9MI$%SY4-_J%\\0O I
MP[1*D;?+D$!B<>V0RC1\->)M2UC7-:TC5=$CTVXTSR3F.\%PLZR;\,#M7 ^3
M.",\\@5J^&K>*V\+:1;PKMBCLH41<YP @ %/U6YM-$L-1UR:#=]FM6EF:)!Y
MCQQ!G"YXSC+8!.,L?6@#0S@=^*7/.*\IGF\>ZKX9TOQ-HMS>/JTL$,XT_P J
MV2PECDVLR89_,' !WLY/W@NS?@;^LS^*I?%6GV&FW\5C%J.D3F2.6!)A8S1O
M'F8'(,A_>A N0H^\=WW: .SFN8H$#R-A2ZH#C/+$*!^)(K%U^_\ $-IJFCQ:
M-H\5]93S[-0G>=4-M'N0;@"06X+G S]WWKS37_#VL6?C'P'/KWBF\U&_?5'0
MHGE10E$8LC+&H4J2NT/PX^8@N %W:OQ$UC6]!\7> ]-L]:NOLFI7L<%XC+$#
M-Y<T/S%E0$%MY#!2%(XV@9! .UU_6[G3M0T?3+&&*2[U2Y:(23$[(D1&D=B!
MRQVJ0%XR3R16-'J7Q$_X2J+3Y?#^E-I G DU-;G :+&21&6+ANV,$9XSCYJH
M>-?#L&H?$#P<YO\ 5+<W%W.)1;7\J*0EN6PHW?N\A-IV;20S<Y.1T6LM<:;J
MOA2"TN;O[.]ZUK+#O#^:GV:9@SN_SDJ8P<[N><ACB@#I=PHW"N+EGU'Q!\0+
M_1&NI+;0],LHI)TM9FBGN)I22F74!E11&W"LI)(R6!(%;2-(\:Z+X5\0:<-2
MCU"[667^Q;F[N-\HC;[ID<H=S+G.".2",A<$ '>[ABJ;:M8+K":1]I0Z@]NU
MR+<<MY2L%+'T&Y@!GKSC.#CSC2[N33?%?@ZTTW5-7N;6]6X@OY[N6>:&\:.W
MWAXVF. -PW!HP%<-P2 0,70-*MG_ &F?$T6ZZ18K);D;+J527/V=B&(8%ERQ
M^0Y7&!C  H ]M# ]*-P SVKSF6.X\63^(KB!O$*F&:33K(VM_P#98X7B!5GV
MI*-Q,A8[F!^4(-O!ST?@D>)%\.1Q>+/*;58W<--$ZD3(3E6PBJ%X)7 _NY[T
M :>K'5_]"&D&Q!^UQ_:_M>__ (]^=_E[?^6G3&>.N:O@X'-<)\29[FQN/!TU
MI>7=NTOB*UM91#<.BRQ.265U! 8':.H..<8R:J>-M0N-&\8V^IZZ-1'@U-/\
MAY;.1@D-V\A_>2+&P? 0 *V#M9E*X8YH ](I"P'>N;\!LI\'61BU=]8A=YG@
MOI9FE>6(RN4WLP!WA2JL,#!!':JGBNXCO?$?AWPW/++%;:D;F6<PW#1-*L47
M^JRI#<F0,<$<1X(()P =?N%&X5Q+6&H>#+OQ5XA6[6YT,6'VJWTLLZ^1+$C,
MZH22J*W4X7DMT&SYLW2O"\NO_"^UNKV_NKO7[VU.H1:@)WBDCGD0O&%VN-J)
MN " A,KG:.P!Z1N%&X8]*\9\1>)+SQ#^S:=?DDEAU QPK))%*5+2)<+$S?+M
M W8)VXP-WL#6IK?@N_L?"WB#7]4\1ZE<:J_A]DG$,WEQK,B^8S)M5<*2B* %
M'R[MVXN< 'J6><4;A7D_AK0I-%\&:?X\OM;UC4;^TT4W1M6N1';RQ_9]R0E
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M9(?)5GG(V'[+(A8[DVOG+L H>/MM#%GNM/VAHU?2K6Q:ZT-]JVTV2_[TD/*
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M:6>H>'_ FB:=H6I^(K2)[:!(XS>7")(Z9VJVTG.WMGH,>U8WA/!^+GQ$]/\
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M&XCCG@'E[!=5\!^-CXSU+,VD^*!(#9V$6YTG;,EO%Y:X$DC*NT.!]YGR>=Y
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M3_P,N/\ XU0!1^&]CXLCCO\ 4/&4$<6I2K!:QA9%8M%"IPS%21DN[L3DG)/
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M222S/*Q"YVKER2%&6( XRS'J3GF8_BGX1EC62.^O71P&5ETNZ((/0@^73O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2:-I]: .,@\7>*+A"Z?#W40 [)\]_;(<JQ4\%QQD'!Z$8(R"#4G_  DWBO\
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M<:]XDEAR&\M[R-ER"[ X,?K)(?J[>IS6_P"&<?"'_02US_O_  __ !JO7Z*
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M0!6MK"TLR/LUI!#MB2 &*,+B-,[$X_A7<V!T&3CK5G%%% !BC%%% !BC%%%
M"$>U)@TZB@!N#[]?6@ ]_P!#3J* &J,4ZBB@ HHHH **** //_C;_P DAUW_
M +=__1\=>@5Y_P#&W_DD.N_]N_\ Z/CKT"@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJWBJYT;4?&&H>&[/2YV5X--@F^TW9$>3(944A$4DX7!R%8G&5VW? 7C#3?\
MA*$\/Z+K&N>)-/O87G^W7P=VM)4 W*S.J_NRI3']UB.N_@ ]7W'T^M*#FO,/
MB!<6ESK@A'B?Q)]HMK;(T3PN";G<67=+*5!P-KQX#[1@$J2214WPOU:[N=9\
M0Z0^H:U=66GQV;6Z:W"$NX6E5WD5R0&;G')XP.,C!(!Z23S2;O:O*?&]RY\?
M"+Q)J>OZ;X8AL@\ TR.40W;_ #-*LTD0+<(C';@84,<KU;1^'6H>';W7-:ET
M+Q9>:Q'<1Q,MMJ%Q+)+;A6D+;/- 8Q_O$&>>1R<D4 >B[L<'K2@YKPC7?$,G
MBSQEJMMK&C^*=1\-:9<2V"Z=HUHS0W$J$;FGD5U)(8 A1T^0_P![=K?#[5];
MT_QHVBV^C>*$\*W<9:V_MFS=6TYU4XC60EOW6%V@$Y!*CU+@'L5%("2.:6@!
MNZC<:\C\1Z78ZMX[O;?QMX=U[5;(%?[+N+*&:2TMH=F6!6 [A(S@AB0Q.%X5
M0">A\ V.B66K:]_8=Q*80+6$VMU]H6XM%2,[499_F$9!RG'=AD@ * =WNXSQ
M06Q7BJP6OCWQ)KK>)/"^L:Z+#4KFQL5LYTBM;6*$J#UF0^:Y<,Q;.X ;>%(&
MO\.YM9T_QKJNAI8:_!X92W,ELNL0'-K*K*GDQ3!F5XMO*\GA1CH68 ]3W<<_
MC0&R<$<UY'/X:TOQ;J.HZKKW@[6M<N?MUS;17,=]%'$D4,SQ(D:FX0J $R<K
MRS.<X(KJ? >E7.B3ZE80:/?:5H2^5)8VM[=1SLCD-YP7:[E4R$;!)Y9B.N
M=K112$GM0!!<7UK:,BW-S#"9#A!)(%+'VSUZC\ZF+8KRR230?$.N:IK&C?#^
M/Q,LLJP7&I2R0&*62-0O[H3-]T# W( &([X!JY\&T\C0==LEAGMX+/7;F"&T
MFDWFU4!"8@=S A69AD'DY/4T =/:>-=&NM?UC1OM AGTGRA/)*ZJC&1<C8<Y
M..AR!@\5N6]W!=Q>;;S131YQOC<,/S%>5>'O!WAS4/C#XX-WHME,ME]A^SQ/
M$#&ADA)<[/NDD@')&<\]S7J%AIEAI5J+73K*VL[<$L(K:)8U!/4X4 4 9%EX
MTT>]U?4[!;NWC^P-&C2R3H%E9TW_ "<\@ J,^N1CC)W(+F*YA6:"6.6-ONO&
MP93SCJ*\[\.^#_#,_C7QE;R^'=(DAM[FU6&-K*,K&#;(Q"C;@9))X[UZ%8V%
MGIEG'9V%I!:6L>=D,$8C1<G)PHX'))_&@"&?5].MIFAGU"TBE7&Y))E4COR"
M?2K4<R2QK)&RNC@,K*<@@\@YKSVPL-&\1W]U<VOP^TJ>RDEFD35;T6[+=OYA
M#,N [D,VXJ2,$#/&0*L_">$6WA.\M!;/:16VJW<4=H\OF&W42G]WNR<X)Z@G
M)Y[T =I=:A:66W[5=00;\[?-D";L=<9^M-6ZM[Q)$M[M"P0$M"ZLR;AE3WZC
MD9X-><?#;PUH7BGPVWB[6M,MM3U36IY)YWOH5F6+:[((X@^[:BA<#G)&,\
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MUMY2P !8Q)+D<\C;(OX@^U $<'B+1;K39M2M]8T^:Q@)66ZCN4:*,@ D,X.
M<$=3W%4KO7++5O#NISZ'K5M,\$+L)[*:*;RG"DC/WE[="*X/5_[1^W>(_LGF
M?\(+]H7^UO,W;]V\_:_LNSGR_P#GKGG/F[/FS7I<4=A/H2Q644,VG26P6&.U
M*B-XBO 0@@ %>F"![T 8?AKQEI5QX7TB;4]>TT:A)IL-S="2YC1LE 6<KD;1
MN)[ #VKIK:Z@O+:*YM9HIX)5#1RQN&5U/0@C@BN9^&>E6.E?#O0DL;5(!<64
M-U-MZR2R1J69B>22?R  '  K4\+V-MIN@Q6%I'Y=M;2S0PIN)VHLKA1D\G
MY- &5IM[INL^.FU/3/&%K?0KIOD-I-K=+*H;S0QGPKGG!"?=[CGM4WQ#M7F\
M"ZO<PWU]9SV5K-=Q26=RT+;TB<@$J02N>H[X%/NX(E^)6E3B)!,^D7J/(%^9
ME6:U*@GJ0"S$>FX^IJSXSA:Y\"^(8$,8>33;E%,DBHH)B8<LQ 4>I) '>@"E
M8^-M#2QT];S6+7[3- &E<,"D;",.WF,/EBX.?F*YSQ6W_:UD=)?58[F.>Q2)
MIO.MSYH9%!)*[<[N >!G\:R? BZ:G@31%TAXI+%;.,(T6/F;'SDX ^;=NW=]
MV<\YJ'P'_9#Z3?R:#;+!I3:C/]G$>/+;!"NT>"1L+JY7'&,8 Q@ "^'M:T37
M_$6J:AI5Y/+.+2V@GBEM98=BJ\[(PWJI.2[CC^[6UK&L6.@Z3<:GJ4K0V=NH
M,LBQM(5!(&<*">X[<=>E,B_Y&*\/_3K;_P#H<U:../PH \]T#XJ^'[CP[ID]
M_=W)O7M8VN/*TRY9!+M&\ K&1C=GH<5Z$#ZUS7P_GCN/AWX<>%MRC3;="<?Q
M*@4_D0:Z"VGANK>.XMY8Y8)4$D<D;!E=2,@@C@@@YS0!-5/4+6:[MC#!?W-B
MY8'SK98RP]OWB,N/PS5RN2^(37UQX6ET;2HH9-0UICIT(G)"*'1C(Q/;;&LC
M=^0.">" <MX'\4Z])XCM_P"V-7%]H.MFZ&C2SVHCF)AD^7<410 \99AN )*<
M <;O50<FN&\36EWI?@A6M],L([?0%AO;=?MCLRI;$.45C'D%HT:/.>CG.<G/
M6:3J46L:-8ZG;*Z07EO'/&LH 95=0P! .,X(X!H O45EV'B'2=4O[VPL=1M[
MB[LI#'<Q1N"T3 #.1Z#.,],Y'4$5J#I0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'G_QM_P"20Z[_ -N__H^.O0*\
M_P#C;_R2'7?^W?\ ]'QUZ!0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5YC\5I'C\1_#YHW92=>A4E3C@LH(_$$BO3J\O^+/
M_(Q?#[_L8(/_ $-* -_QC#XHDU+1)M!TJQNX[&Z^U.UQ=F,M^[DB:/;MXRLN
M0^3@CE2.O2:7+J$]GOU.S@M+C>P\J"X,R[0< [BBGD<XQWJ[10!D:W)XA2,K
MH5GIDSM&V);Z[DC"/_#\J1MN'K\RGMQUJKX>3Q):VEE9:K8:4D<%NL;SVM])
M(695 R$:%< X_O''O70T4 <-=>'/$VD>-+G6O#-W92Z=J6'O],OY&C02JJJ)
M(F1&VLP&#D<XR=W&W0L;?QI=>(DN]3O-+L-)@SML+)6N'N=R$?O)752NUL,-
MJ\Y(/0&NIHH X#4-$\=:=XJU;4?#%SX?DLM3,,LD6IQRAXI$C$9 ,8R00JGD
M\9. .2R>&_"_BW1?&$VKW>HZ=>V^JQ(VJ[C('BE3S2B6RXP(UWHOS$D@,< F
MO0** .%U?2/'D'BB^U7PYJ>E&SN(H8Q8:GYK1Y4'=(-GW6^Z,#A@3G&U:M^'
M=#\0MKC:_P"*9M-.HI;-96\.EK((A$S*[,YDY+;E  &  #US\O7T4 <%?>%?
M$VCZ]J&L>#-1TZ--3=7NM+U*)OLXE PTR-'@AVPN1CYB223A0-31=-\8-J$%
M_P"(-=LEC6)D?2],M,0L^3M<RR$R'@C@!>0.P.[J:* $7..12T44 < _AOQM
MI.I:KJ&@:]ILL=[<O,NEZC:N88]VT;A*AW[L*/EQMRQ[\UM>'-!U*PU/5M7U
MF^AN=1U!HXRMM$8X8H8MPC"JQ9MQWLS98C+8' R>EHH XZ]\-ZYINN/J'A*\
MTZTAOY0VHV5[;L\3.?O7";"#YNT %<A6ZDYY-O1/#NKV6L7&JZOXEN]3GD1H
MH[5(Q;VD,98,,1 L2X((WEB=IP<XS7344 <?)X6UZSUZ6]T'Q,++3II&GETR
MZL!<1><V=[*P='4$_/M!QN+'N15_PQH>LZ2;J77/$D^MW,VQ49K=+>.)%W8"
MQIQN)8Y;/("C^&NAHH *:U.HH \^/P^UFSEFL]#\97>E:#-*\C:?#8PEHA(Q
M9UAEX,8^8[< [>O-7O"W@,^$?$>J7>G:I,-%O@&&DNK.(Y@%!E\QW9B3AL\#
M.X9SM%=G10!Q^O\ @[4;[6FUOP_XCN=#U*6!+:<K;QSPS1J6(+1L/O@M@-G@
M C')K5\/Z#-I'VBXO=5O-4U"Z$8GN;@A5^1< 1Q* D:Y+' &<L<DUMT4 <=X
MB\'ZO?\ B)=:\/>*)M#N7MA;W*"T2XBG"MN1BC$#<,D;N3C &!G.GX>\-)X>
M^UM_:FJZE/=,&>?4KDRLH&<*H "JH)8X []< 8WJ* .0_P"$!@2&XLH-<UJV
MTF>;S6TZ":-(E7()B1@GF1QG&-J.HP2!C)JWH'@VQ\,:E?7&E7-Y#9W9W_V;
MO4VL+]2T:[<H2<\ XYZ8"@=)10!RC>!K:'Q!>:SI.JZGH\]Z/]*BLFB,,SYR
M9#'(CJ'.!E@!W[L29M)\&66BZ'?:=;7FI-<7R.MQJ<MQNNV+!L-YF."NXE<#
M .3C))/2T4 <3H7PVM] &HK;>)/$DHOX)8W$]\#Y;R'+3)A1B7/(?D\FK'AC
MP)%X7U.YOHM?U_4'N4(ECU"\$J,WR@2$;1\X5%7)S\HQ7744 <->_#&PENI)
MM-USQ%HL4KM+):Z7J+10M(S$L^PAL$YZ# X' K?\/>&[/PU9/;VLMW<22/YD
MUU>3F::9O5F/\A@<DXR3G:HH XJZ^&>DRW1DM-1US3;625I;BQL-1DBM[AG;
M+[DR< ],(5X]*T?#O@G1/"VH7]YI%O+;&]D+O"LSB%,A<A8\[!RI(.,C<0"%
MP!TE% !4-W;QWEK+;2A_+E1HWV.4;!&#AE((//4$$5-10!Q4'PK\(VT"6\.G
MW<4"$E(X]3NE5<GG $F.:O6_@'P[::)/H]O9316-Q<FZE5;R8,TN "V_?N_A
M'&<5T]% &!IO@W0=(\/76@6-BT>E72R+-;F>1@0Z[6 +,2 1Z$>M4[+X=^&-
M.T6\TBST^:*PO-GG0B]G((5BPP2^5Y)SM(SWR*ZNB@#F[3P-X?L=!GT6VLI8
MK&<J9$6[FW?+C:!)OWA1M& "!UXY-2:9X,T31[*_M+&VN(X+]"EPK7DSEA\P
MX+.2I^9N5(/Y"N@HH XP_"SP>6WG2I6EW*1,U]<&5<!@ KE]P'SMD @'(R#@
M5JZAX0T;5- @T2[M)&TZ#!6%+B5#PI7EE8,V0QSN)R3DY/-;U% '*/\ #GPH
M\T<@T:.,( #%%*\<4F/^>D:L$D)Z$L"6'!R*Z"+3K*"P6PAL[>.S5=JVZ1 1
MA?0+TQ[5;HH RO\ A&M"-Q]H.B:=Y^S9YGV5-VW.<9QG&>U:$<:Q1K'$BI&J
MA551@*!P !V'2I:* .9F\ >%;B^^UR:':ECG="JE8)"<Y9X0?+=N?O,I/ YX
M&.CBC2&-8XT"(@"JJC  '0 4^B@ K)U+PUH6L7(N-4T73KZ<*$62YM4E8*"3
M@%@>,DG\36M10!2N],L;^P;3[RQMY[(A5-O+$K1D Y VD8XP"/3%)INDZ=H]
MNUOIFGVMC"[;VBM85B4L0 3A0.< #/M5ZB@"A;Z1IUI?3WUMI]K#>7'^NGCA
M59)?]Y@ 3^-7ATI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \_^-G_)(]<]/]'_ /2B.NF\'W4M[X)T&[G96FGT
MZWDD*J%!8QJ3@  #D]  *YGXV?\ ))-<_P"W?_T?'76>&I&F\*Z1*SSNSV4+
M%[A2LC$H.7!9B&]068Y[GK0!J4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5Y?\6?^1B^'W_8P0?\ H:5ZA7E_Q9_Y&+X??]C!
M!_Z&E 'J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/_BEQ_PA>._BJQ_]
MGKT"O/\ XI_\R5_V-=C_ .ST >@4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%1
M3SPVT8>>5(D+J@9V"C<S!5'/<L0 .Y(% $M%9L>NZ1,0L6K63D[<!;A#G=(8
MQW[R H/]H8Z\41:[I$WD>5JMD_G[/)VW*'S-V[;MYYSL?&.NQO0T :5%9?\
MPD.BA/,.L6 01K+N-RF-C(SJW7H41V!]%8] <-;Q+H:A"VM:<H=&=,W2?,JQ
MB1B.>0(V5R>RL#T- &M16 _C?PI%(T<OBC14=2596U"($$=01NI/^$[\(?\
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M44J,@%Y?FY''^L_'G'3KV,D5Q\9'>(&Q\'QAP=Q=I\1XZ;L,>OMGKV[>E44
M>>N?C J@A/!+\@84W6>3UY(X'7\._2G?\7?_ .I'_P#)NO0** //_P#B[_\
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M.0B;4F PF?EP@7@@X/<#[I6@_![0"A7^T->!\M4W?VD^<A&4OZ;B6#GMN1<
M+N4^AT4 <7!\+/"\5O%')%J4[H@5I9-4N0SD#[QVN!D]> !Z 5)_PJ_PI_SZ
M7W_@UNO_ (Y7844 <?\ \*O\*?\ /I??^#6Z_P#CE'_"K_"G_/I??^#6Z_\
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M ,_^P='_ .@38_\ @.G^%']@Z/\ ] FQ_P# =/\ "M"B@#/_ +!T?_H$V/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 444W=F@!U%-W9H+8H =1110 4444
M %%%% !1110 44A.#2;A[T .HHI,\=* %HI,T Y% "T444 %%%% !1110 44
M'BD!S0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,[$X"J >23VK<W'VKA'TS1/B*UOK%HUNKZ5K4<UM?0Q*QF$)7>I;JR,0P!!
MX0\XP?.OB[K9\2?$W1/ IFEBTX7-O%>"(;79YG7/)R" A4CC ).<X& #V6#Q
MIX7NKB*WM_$FCS3RN$CCCOHF9V)P% #<DY&!WK5NKVWL;62ZNYXK>VC&Z2:5
MPJ(/4D\ 5F:_X>M-<\*7NA-%#%!-;-!'^X#K =N%94X&5.",8Z<$5YG^SMXA
MNM1\-ZGH]RSR+ILT;0R/)NPD@;Y ,< &,GK_ !XXQ0!Z-_PGGA'_ *&G0_\
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MP! !X!**>,8'9?#[PUHD'@CP]<KI5H;F338I'G>(/(3)$N_YSDX(XQG&  .
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M)_W*O_MU7H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY94R,$#<!P2#]($9&*I'2+$ZRFL?9HQJ*P-;?: /F,196*D]QE01GISC&3D
M\4^-6B:G8^-/#GB/P^AM;^ZE6S-W!D,9R<(&P.<J2O0Y"D'@ 5[A86=MIFG6
MUA:1^5;6L*0PQ[B=B*,*,GDX ZFDNM/M+[R/M=K;W'D2K/$)HP_ER+]UUR.&
M&>".14D]M#=02P7$4<L,JE)(W7<KJ1@@@]01QB@#Y[T*STW6?VD-=MKZSL[Z
MU+3AHYXEE3<H'8Y&01CVY]ZJ_&71]$T#X@^&7TVULM/5D1YXK<+$JJLO#L@4
M 9RPW;CG;C"[<M[M!X*\+6UQ%<6_AO1X9HG#QR1V,2LC Y!!"Y!![BI;[PEX
M=U.\DO+_ $#2KJZDQOFGLXW=L# RQ&3P /I0!RGQPN(8OA/JR2RQH\S0)$K,
M 7;SD;"YZG"L<>@)[4> -(\+Q>"O#WB6VM;"UFM].4W%]$B19(CVS>8V!G#!
MB2>A7.>N>IE\'>&IX(()?#VDR0VX*P(]E&5B!.XA1MP,DD\=^:B/@3PC_P!"
MMHF1_P!0^+_XF@#!UC7EUWX6^*]4$UJVG36M['8RQ,PWQK&8\MN ^8R!\8XP
M5[]?*/AEX!T7QU\+M:@D@B76XKR3[+=;BK1GRD*!B <H6W C!X+8YP:^@)/#
M.A2Z9#IDNBZ:^G0N7BM&M4,2-S\P3& ?F;H/XCZT:;X9T/1[AKC2]%TZRG9-
MC26UJD;%>"02H!(R ?P% 'D_P.\720?:O FL;(-0L))!:J=B\*<21  #+*P9
M\Y8D,W]VN3\1:A:6G[3_ -LGNH8K:*[MP\SN B8@0')Z#!X/3%?0<WAC0KG5
M!J<^BZ;+?AE?[5):1M+N7&T[R,Y&!@YXP*J?\()X1_Z%;1#_ -P^+_XF@#!M
MO%O@3PG9SV^E:QI#)<3F2VLK&56&]@HV 1[MN6YS@ ;O0&N'^,/AJ\TGQQHW
MCW3=,GOHK9XYK^.!#\I@8.'=AG 9!MSMPNP9ZXKUJ#P7X7MKB*XM_#>CQ3Q,
M'CECL8E9&!R&!"Y!!'!%;9!- '&>(OB/X>TOP?=:S9:YIMQ(89!9HLHD$LX4
M%4VJ=W5TW#C 89Q7+?!3PQ+X)\):EK'B#=ILU](K2+=N(UBA0':6!P5)+OG)
MZ;>G->DVGAG0]/OC?66C:=:WC9S<06J)(<]?F SS]:T]OO\ A0!X/\)M>\/K
M\3O&\LU[9I<:C?DZ?+(0IF1II"51CW8M&=N<G X.TX]NLK:WT?1[:SA#"VL[
M=8HU +'8BX P!R<#L*M;?\XZ4;3ZYH R?#OB72/%6G'4-%O5N[42&(N$9"&&
M"00P!'!!Z=ZUVZ5G:1HUOI"71A2)9;RY:ZN6C38LDK  L%R<<*H]\9.223HD
M9H \2\6W.A-<:GK'@K78M$\76]S)!<V"%0^HNLI79Y7S;W9EW*0IW;L,/FRO
M0ZIXJND\?Z3HWB W6EZ7/IRS0M#OC-Y>ET_=J\9+$+DC9\I)/(8%<^E[?>@*
M?6@#S;X:7,6F?\)A%>+<6B)KU[=F2[AD15AVQ,&>1P "58-\QR1STR:\[^'^
MCW7B/]GKQ5H^G;'OWU#S4A+<ML$#XQZML8#L3W%?1NWWHV_RQ0!XM\0/&^F^
M(_@YJEM!)=2ZC$+6&_B:T=&M9?-0L)<@!?F5EXX)&!TKV+3KO[?IMM>>1/;^
M?$LODW";)(]P!VLO.&&<$=B#4^VE P* .4^)6DZAK?@#5;+2L?;BL<T()P6:
M.19,#C[QV8'OCIUK,TGXC2>(H&L=.T#4[;7XY(HKJTO;9E2R#@$S2,2H* ;B
M%RKOMX4 [AWQ&3UI,'/M0!YGHD-WX6^+?B@W6F7?]EZXL,]K>HC2AI(U^:/"
M*<$[Y",XXC[YS6MIFFJGC?Q)XODL;D@6L5I; Q2++(J+YDNV,@9!)C [[D8<
M#KVQ3.?4T;: .$^#D-Q8_#/3=/O+.[M+NU:9)8KJV>%@3*[#&X#(PP.1D=NH
M-<[\'=6M['0_$D<L=X636[B0^39S2@@JG0HI!/!^4<\CCD9]=VG'8GWKB?AK
MX4UCPEIVK6FJ_8&^UW[WL;6LSR8W@ HP9%Z;1SSG)X&.0#G[CPSK,/@6TUBT
MTJ2+74U\^(9]-27>TQ>5@8MYX4B)U!('\!^7)K:\9$^+M&T_3=-TJ[GDFU*V
M=IKJRD@^QQK)N>8>:BY("LN 02'XX.#WQZ4T*10!PDX,7QN@O#IVI>4^A&S:
M\%O(\!D,X=4R$PI W$L6QR!P1S4\9?VFWCFPCU#2-1U7PD]B=UK:0B9&O%9F
M7S4'++A4 W$(&()(PQKT8+@8HQ]* /.?#,-VD?BS1T\(7.B)=2RSVB*L(M]I
M@BC50R-MWL5+$#*C)&XD&G_!]K[3O $6DZGH^IV$^F-*LC7,&T2EI'?]T 2S
M@ CG')/&>:]#V\]J4#GM0!Y!9^%O%.H_ O3M)C\^V\1Z;*)H4N6*MNBE9HT5
MCP/DVA3]T8 X&<=+K+W'C7P;!I%UH6H6EQJ<D45Y!-%Q:H'#2/YA&TD*AV$9
M.YDRHYQW=% '%:DFH6_Q7TB]BTR>>PETR:SGN5!VP%G#J3@'.3&!CC&[)( H
MM/M4GQ<O;HZ9?1V7]E1VB7<D.(I)$E=R <YQA\ D $J<?PY[6B@!#TXKR_7=
M$U27]H#P[KL5A</I=M8-!+<HA*H[+. #^+IST&>>AKU&B@#CDAO5^+LUS]BN
M#82:*EO]JV'8)EF=]F<=U?.>F1CJ<5YI<:!XPO\ X8ZYH,OA>XDU^6=6OM3G
MF1C?QI*&3:Y.YF4 *%(VA%)!R0I]\HH X;4=2U75+32+?5O!4D^D:E$XU2U=
MEFDM"#'L8C.&&XN< ;L -@%2E)\-]#;1SKLT&D7.CZ5>7BRV=A<L-\>(U5V*
MAF"[G!P,] . ,5W5% "$'(Q7D(L_B%X'\2>(!H6A6^MZ5K-U+>VY^T*AM[F0
MGE\X)7Y>1TQMPX.<^OT4 >4^.?#GCK4M)\-;1;ZTUO>&?6-/AE6WANAYBR)'
MA^&C7:4^;)/RL03G%FRTWQLWQ/L_$][H6G):W6FC3Y(8M0RUDF]929"4_>/N
MW !!CIE@!N/IM% 'D_A70O'7A/5=<T73]+TYM*O-3:\MM5NKC<(T8KN#1*0S
MML  'R ,#\Q!%6/ FB>+/!GPJ-K_ &1'-K4=WYL=@EVBET,B[@SG**=NX\$\
M8YR<#U"B@#AO#'AI;'Q==ZS8Z#)X>LI+);=[',2BXEW[A)LA=D7:HP#U/F-T
MQ\W&Z1H'Q9\+7-YX:T&/2CH.Z06%]=%=MLK;G! !\PMEL'>KC<!_#DGVNB@#
MS?QEX'U5[[1_%/ANX%QXBT6W\A%O.?MR],.P9%4X:4D@#<6QP,8HQ:)XXUSX
ME>'_ !1J>C6&G6MC'*IMC>;WB1AL(9U!#N=SN %"[0 6!/'JU% "#..:Y'XB
MZ#J&M^'[>;2(EGU;2[Z#4;*"1PL<LL;?=?.."K-W'..177T4 >7^)_!GC#Q+
M<^#M5N7T3^T]$NWN;J**:6.&7]Y&R!"49A\L>"2.">];_B#P]K&H^/O"^MVD
M=B;/2/M'G":X=)'\Y=AVJ(R/E !&3R21QUKL:* //-,\&:U8_&35_%\AL&T[
M4+86WEB=_-0!8\-C9@DF(<;NC9R<8,FO>&_$OB;2+W0]6L]"NK.:\D:"]EG?
MS;>$R':RQ"+'FK&Q4'>.<9SSGOZ* $'3IBJ6JZ39:YIEQIFIVR7-E<+LEB<<
M,.OU!!&01R" 0015ZB@#S#2/"GQ \&6;:-X9U#P_>Z-'*\EL=6299XE8Y*'R
M_E(!).>Y)Z# KM[?1[B:SO(=;O%U#[9'Y4T2P^5 $P5*HF6(R#SN9B3W P!L
M44 >5:!X \=Z+J$6F_\ ";;_  M;.C11>5FXD12N82Q&8UP&4%7. !@#.!T5
M]X&GN/%WAO5[/55L[#08##;Z<MJ&!#*4;#YR 4V+C!QMR,9KLZ* .$^(O@.\
M\7'1[_2]2%CJVD7(GMGE0/'RR%LC!Y&Q6'4'!!'.5D\2^!]2\11>&7?7(DO=
M$F2Z>>6QWBZF7;ABJR+L!*DD#UP",<]O10!S6OZ#K6J:UI5]8:S:V<&G.\RV
MT]@9Q+*R/'N9A*AP%D8 #')).> *?B[P=J'BC6=#NX]:2SM-)NDO%M3:&3SI
M5;(+-Y@XQP !QEN3D8[&B@#B/%W@"?Q!K=MKND>(+W0]7AA^RM/"N])(,LVP
MID<[B#G...A."&ZG\-K;6?!5QH>HZE=76H7"(9=5EYE:1.4.W.!&"6Q&#C#-
MSN8N>YHH \^D^&UW?S>';W5_%-]>ZEH]PS_:/)2,2Q-@&,*OW3\J_/DMRW/W
M=FU?>&+^X\96^NVFNW%E;FV2WO+..%&^TJC.R?.V=G,A!(&<="O6NGHH \_U
M/X8[O$SZSX=U^^T!KQ]VIQ6HW+=G=G<,G"/RW.&'/0<[NSTS3TTNPAM(Y9I1
M'G=+.^YY&))9F/J22> !SP .*NT4 (>E<-8_#N70M1D'AGQ#=Z+H]Q*9[C3H
M+>&4&0J%W1O(K%!\H)&&'88XQW5% ',Z[X(TS7/"/_",[[BPTTLI=+0H&<!M
M^"65NKX8G[Q(R2<G.YIMF=.TRVLVNKF[,$8C\^Z<-+)@8R[ #)]3CFK5%  >
MG%<E??#[2I]6FU73;B^T74+C/VB?3)5B\_)S\ZLK*3GG=@'/<UUM% '/V7A6
MWAGBN;^^U#5KF&=IX9+Z8,(F(Q\L:!8QCG!VY&XX.#45]X.M[C77UNQU'4=)
MU"5!'<R63IMN0!A3(DB,K%1D XR-Q]L=+10!SLO@W2SX?U71;03V-OJC2/=2
MPOOED:3_ %A+2!N6''3ITQQB]H^AVVB:!::+;27+VMM ($>69FDVXQ][J/;&
M .@   &I10!D>'_#FE^%M,_L[1K4VUH',@B\UW^8XR<L2>W2L/\ X5=X52ZN
MY;:RN;.&]C:.ZM+.]E@@G!P!N1& P!N  P,.V0>,=G10!SNO^"?#WB>SM+76
M-,2YAL_^/<!WC,? & RD'' XSC@>E7-'\.Z7H)N#IUIY<ERX>>=Y&EEF(SC?
M(Y+-C)QD\9/2M:B@# T7P?HWA^WN;?2H+BU@G#;H4O)MB[NI12^$/NN#4FC^
M$]&T'1Y=(T^S9=-D#*UK//)/'M;.X!9&8 ')R!@')S6W10!AVWA/2+."S@CM
MI7@LG5[:&:YEE2(K]W"NQ'R_P\?+@8Q@8?>^%]*U'7;'6[J&=]0L<_9I!=2J
ML6>&P@8+R.#QR.#FMFB@#,&@Z</$!U[[.W]IF$6_G^:_^J!)V 9P!DYQCK@]
M1FM.BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **3)STXI3TXH **09S2T %%
M%% !130<DC-.H **** "BL2/Q;H<GB(Z -2B_M4$K]D8$/D+N[CIMY]QS6W0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M112,<<T +15&/5;2;5Y]+1W-Y!$DTBF)P CDA3N(VG)5NA['TJ\.E !1110
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M- '(^$M7&F#Q!IVN3V=@]KK-T\"RRJI>WE;STD.6Y!,C<C'3!&0:B^%ZQ?\
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MP\QQXAQ_VY7'_P ;I/\ A=?P\'3Q"/\ P"N/_C=>A44 >>_\+K^'F./$./\
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M]:HH \ST[1_B9H]NUOI=A\/;&$L7,=K#<Q*6( )(4 9P!S["KF/B_P#]2/\
M^3=>@44 >?\ _%W_ /J1_P#R;J2%?BRSD7$G@I$V,08TNF.[:=HP2."V 3G@
M$G!Q@]Y10!R%I;?$-[R=+S4/"\-JI/D2PV-Q)(XR<%D,JA#CT9N?7K5NWM/&
MK6T37&L^'XYR@,B1Z3,ZJV.0&-R"1GO@9]!7244 <_\ 8_&'_0=T/_P33?\
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MPJRA5'L  .V*W:* ,FW\.V=LC*D^I$,VX[]3N7Y]MTAP/8<5-_8UK_SUOO\
MP/G_ /BZT** ,_\ L:U_YZWW_@?/_P#%T'1;4_\ +6^_\#I__BZT** ,"+P9
MH,%W!=1631W%O"+>&5)Y%>*(=$4ALA1S\HXK._X57X&_Z%JQ_P"^3_C7844
M<?\ \*K\#?\ 0M6/_?)_QH_X57X&_P"A:L?^^3_C7844 <?_ ,*K\#=O#5C_
M -\G_&NKMK>&TMH[>WBCAAB4)''&H544#   X 'I4M% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#/UK7-,\/:5+J6JWD=K:1?>D?)Y[  <D^
MPYJU;3Q75O%<6\L<L,J"1)(V#(ZD9!!'4$<Y[UY-XWTQ_&7_  E>H76HK+HG
MANTN(;6QA8%9+T6V]I9#ZIY@4#J&4],,'['X7ZDFK?#/P]<QQF-4LUMMI.>8
MOW1/XE"?QH ZZH;F>*UMY;F>2.*")#(\DC!510,DDG@ #J:FKGO'?_)/?$O_
M &"KK_T4U '%Z?\ $GQ1)H>G>);OPO:_V!?3!&:&](GM5:98E9U=1OSGC;UZ
MDK7JN:\>%XVL:)\.O!-J7+W5E8ZCJ.(R56TA16 8X^7?(@ ((P0 ?O#/J.HK
MJQDLAIAL@GVE3=FYWD^3SN$87^/.,$G YZT :%%(!BEH **** "BBB@ HHHH
M Y+^SH;WXK27TRHSZ9I$0@#("5:>64,P/8@0X&.SL#UKDOBOIEQXUNX?#WAQ
MXGUW38);NX?S&0Q1.FSR-X^4/*&^ZQ&54Y(!YZOQ)\/K/Q'KL6L_VQK6EWT=
MM]D\W3+OR"\6XMM)VGN<_P#ZABWX2\&:?X/T^:&T>6XN[J0S7E]<-NFN9#D[
MG;\3@=LD\DDD 7P#<07/P_\ #TEL6\H:; @#')&U I!.!D@@C.!FN=\=WDFO
M>+M \#6<[HER_P!OU-XX=YCMXB'0$D84/(H&<Y!"]CAN?\,>/)/"6B-I,^BW
M-QH_AZ[?3=2UH%8HXR)RD;+'DM)P4+ '*[NAXSUWP\N8?$4&J^,8K:6 :S<@
M0K-)N98(!Y2#&2!\PE; Z%R,G - ';CI129 XH)[8H \J^/ULMWX&L8V8@"_
M,F1_L6T[?TKN?!4\UUX&T"XN)9)IY=-MGDED8LSL8E)8D\DDGO7&_%R6*\N/
M#WA^>,^3=M>W<DJSK$52&UDW*&<;5)$A^9CA=O/'3JOA](TOP[\..\#PG^S;
M==K[<D", -P3P0 1SG!&0#D  Z6BD)Q1N% "T4F>:6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*H6=F[Y,7&",@ X#5?A[IT'P<U/Q%K>FA_%-U;-?75U*&1UE>0OC9G"$!L$
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M<I''!Y'T/(JU45M!#:VT5O;Q)#!$@2..-0JHH&  !T '&*EH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*Y#0U^(AU6/_ (2$^%QIP#%QIXN#*3CY<;SM'.,]>![Y'7CI0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M960-]XD#@@'H[5?&NJ:%X#;Q/J6A6\ 2".9[0WK^8A<@*AS",-E@#QP<^F:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M652?+14R=JJK8&22<DDY-0_8_%__ $'-"_\ !--_\E4?8_%__0<T/_P33?\
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MKU[<.D/DI>)''&\2!0H"#:0  .-VX\]>F*NF^ (=(\)?\(U8Z_K$5B"X5O\
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M@<DF@#'_ .$[\(?]#7H?_@QA_P#BJ/\ A._"'_0UZ'_X,8?_ (JN@HH Y_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^'ENK:768H;*Y6X#"*X8%8Y&0@'H[XZX*YX.TGL+^:Y@L)YK2U^U7"*62#S
MAD/]T,> 3VSQGJ1UKRGXG>-/#<U[X;LX]7MFN--\3VLMY&"<PI&7#EN.QZUZ
M7HWB#2?$5D]WH]_#>6Z2&-I(CP& !(_(C\Z .8@\<ZR^C:5JS^%)9+?5=BVD
M-K=B:XW.A=#(NQ42,@9+[SM!&0.0-C0O$-UJ6K:II&H:>MI?Z<(7D\FX\Z&1
M)02I5BJMGY6!!48QU.:RK7Q-HT7@[PSKDFH1)IBLBM<MD*"(9(R#QG[_ ,OU
MHTBZAM_BYXEM)699[NPL98$V'YT3S@S XQ@$@9]2!UH [8=*I:UJ2:-H.HZK
M)&TB65M)<,BG!8(I8@?E5X<BJ]_96^IZ=<V%Y'YEK<Q/#,F2-R,"&&1R,@GI
M0!P_A#PM:ZQH2>(-=:2_U+7+?[1,3,ZQP)*JE8XDW?)M7 #CYNI##.!L^&O"
M9\/SZM$]_<7]A=E/L\5Y*TS01@$&'+$Y09./8X.2,G%T'Q5IWA#PSIFB^*[N
M/3-0LH1:9>.013+%\BO'(RA7!0(QQ]W=@X/%=7IFO6>KVDMW9+=26J*&69[:
M1%E!&<QA@"XQ@Y4$'<,$T >:>$-;\)Z:/&*^(K_2HI+;Q!>B&*[9&D6!=NU8
MT.6*\, JCKD 5>@NB-/N?B7HR16UA_PCDJQ:;M#KYZN7#L(B5_A"GD, ,-MP
M0)?AX\8_X2JPU+2]22/5-=N[F*.ZTN=8IK>38H+%H]H!Y!#'.,Y%=8WA#3[?
MP/=^%=*4V-C-:SVT?+2^7YH;)^9LGER<$T 9'A[X>6D.GM-XK2U\0ZU<N9KF
MZO8$E5&/\$08?+&O8 #Z 842>%FO-%\6ZMX4FN'N=/AMXK[3&ED,DL4+EE:)
MW;DA74[<[B%."QX GT#7KVSTJ/3_ !%8:BFJV46R>:*UEN8KD( /.22-"#O^
M]L(#@Y!7C)B\'Q:IJ.OZWXFU2SELEO#'::=:W$2K+':Q!B&/1AO=V8JPRN,<
MC& #LZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BC-% !1110 4444 %
M%%% !12 @]Z7(H **,CUHR/6@ HHR/6C- !129'K2Y% !1110 449I,@G% "
MT444 %%&110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.X&XK'H]VQ ]>(NG(KJJ0C- '/?\)CI>3_HNN<_]0&]_^,TH\8Z6.EKKF/\
ML WO_P 9KH>U% '/_P#"9:7_ ,^NN?\ @BO?_C-'_"9:7_SZZY_X(KW_ .,U
MT%% '/\ _"9:7_SZZY_X(KW_ .,T?\)EI?\ SZZY_P""*]_^,UT%% '!S_$]
M(;B6./P3XTG1'*K+'HYVN ?O#<P.#UY /L*C_P"%J?\ 4A^.?_!/_P#9UW^*
M,4 <!_PM3_J0_'/_ ()__LZN1_$&>72Y=17P/XM$$3!65K.)92<@<1&7>PY'
M(4CKZ&NSQ1MH P/^$BU/_H3=<_[_ %E_\D4?\)%J?_0FZY_W^LO_ )(KH**
M.?\ ^$BU/_H3=<_[_67_ ,D4?\)%J?\ T)NN?]_K+_Y(KH** .?_ .$BU/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%(3B@!:*9N-&X^M [#Z*9N/K1N/K0
M%A]%,W'UHW'UH"P^BF;CZT;CZT!8?13-Q]:-Q]: L/HIFX^M&X^M 6'T4S<?
M6C<?6@+#Z*9N/K1N/K0%A]%,W'UHW'UH"P^BF;C1N/K0%A]%,W'UHW'UH"P^
MBF;CZT;CZT!8?13-Q]:-Q]: L/HIFX^M&X^M 6'T4S<?6C<?6@+#Z*9N/K1N
M/K0%A]%,W'UHW'UH"P^BF;CZT;CZT!8?13-Q]:-Q]: L/HIFXTH:@+#J***!
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTRRCMEFGG*@;YIWWR2$ #<Q]3CM@>@%6Z:[K&I=V"J!DL3P!0M '8XKE-/\
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M **** "BBB@!Z]*6D7I2TR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQD\'C$I\$W</C237=-U^YL;6Y2);VR6%9/M)C&%.]B2O& 2!NZ\\\--6^_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^A% 7)****!A1110 4444 /7I2TB]*6F2%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %,/4T^F'J:0T)1110,**** "D/44M1S!_+8
MQJK/M.T,V 3VR<''Y'Z4/8#R&6%+CP5\54< @:A=/^*QJP_45'H'Q'O8O"/A
M>TDN]/L[NYL999+[56S&5A)15 W+EG('.[C!X.>-B#P7XIGL/$>F7G]DV]KK
MU\UQ-/;W<CR01MM#(JF)0Y*KC)91R3CM5K7_  %J5O>^'-0\&W%E:7.BQ-;+
M!>[_ "I8B,88IR3_ #)SD8Y:6EGY?E_F)OWKKS.3UC66OM5\2:S;V]NZ7'A2
MWG:WN0SHR.Q+(=K*<[3C(/'6KF@>-]>@O]+\/>3H]K;W.A1W>F+';RG+^6-L
M9S+G (;W('7FM;7? WB34]4\07$,FF/'J&DIIT3S3R*VX,"78",XZMP">@]>
M-"#P%</'X(ENGMA=^'U$<YC9B)$$>WY3@$_,%.#C^*E'9?UW_P" $NO]=B/Q
M+X[N?#FH)9W-[I$4UKIZWMUYP*?:R6(\N!3)E3A'.3OZKQUJM_PF7BN7QGK>
MCV=KI=Q;:5/;O(Y1T86SC<_5R"X!&#QG!X[#6UWPSX@D\<6.OZ#>V4*-:_8K
M^.ZWG,6_<&0+P7&6QDCMU!-)H?A75;+QYXFUF^%B;#5DC2-(IG:0",;1N!4#
MD9)P3CISUI:_F5HOP.3D^-:P6$UZ8;*Z66S-U;P02[9+<^:(Q%-RV6PRMD;>
MXQWK3\+F^/QBU)M1DMY+IM'A+O;1LB'+9P%9F(QTZG.,\9P$3X;ZS/X(U'PC
M?:K:G3$RNF/$C>:/WGF*9B>#@@#"]B>>F-;PWX5U^U\92^(M6N=.1I+".S>W
MMM\N_;U;>P3;R <;3U([9-1LOZ[K_,SEM9?UJOT.ZKS;XVV4%QX'CN9%<RVU
MY"T1$A !+8)QG!.">HXR<5Z37'_$?P[J_BKPVNE:3]B5VG25Y+N9T"A""  J
M-G/X8H3M)/S13V9B>+;F1_BWX+L#_J%M[R4J.[&%A^@'ZUG_  SU3Q&?AQX=
M32K&WNHTOVMKMIY-IBM@YRR\C)&0._3H>HZW7?#5_JLNC:S"EI%K>FB0"-I6
M,3"1"C+OV[N,A@=O;&!G(HCP/JFE:'X8TGP_K!M8-,O$EO6)*&Z3)+C SG))
M^4\<\GBDM/O!ZI?UT/,8=5N3I U;<QNO^$\##!]4QM^F.,5WDFFVEC\?K.Z@
MC*S7NE2RSL79M[ A1U.!P ,# J]%\.=FODEX/['_ +6_MM8P3Y@N-FWR\8QL
MW?/NSG^';_%5FZ\/:_/\3[/Q$D6FC3K:U:TVFY?SF5CDOCR\9[;<_B.S_E7]
M?#_F#U;_ *ZG6WUS]ET^XN  3%$SX^@/^%><?".VNM!O_%?AB]N?M%Q9WJ7'
MF[=N\2IG<!V^Z#^-=CXGLM9OX;2UTN*P>V,Z->"ZG9"\2D$HH"-G=C!)[9'?
M(PI?"FLV/Q)@\0:';:1;Z<;46EW 96C:=<D[@JQD!@3QR<@8XS26X/8Y[3[<
M>%OC$NH%@ECKUE<[P#C]]$Q9C_WROZFCP,LB_'#Q:TR;)9+.*21,YVLRQ,1G
MV)Q757/A6^UZPTF/6H+*":PU07G^C3M*KH-QVY9%/)8 CH0.O.*I:+X3\0:=
M\4=9\3SKIAL-201;([F3S8U4*%;!C ).P9&1C)Y..6O/M_D3_7XLGOI6D^,,
M4#<HGA^9P/0M,@)_)17#7_B#4=!\/> O$\%NUZ(--D@N;, [C#MC!ER =H!5
M,D_WE]:]+UW0=1EU^VUO2!:-=I9RV4L5S(T:E'*L&#*K'*LO3'.3R,<T[CPI
M?Z:=,ET);*X>UTM]+>*]E:)&0["K@JK<@IR,<@]>*EK3^O/_ #*]?ZV,S0[Y
M+;X:>'4LY#,9;<W)<J%VB-6E/ Z8<*N/>N$\)W4\7_"L)5=_,NFU**5AU96D
M.2?Q.?PKU;PMX0;P_;6EI--%<06FGBUC.W!+L[-*<= #\F!GL<UEZ#\/'TC5
M+"1Y(9+/1EN1IB!FW,9F+$R<87:#M&-V<YXZ4UI*_P#7];#?PV"U\+:1IWQ0
MT^70[*WL?LNER_;%MXPH=78+$&QU.5D.>IV\DXXL7FCZ1JVBZQJOB"V2>S:6
MXF,<H#*J(OEAQW#!8R01C&]L5F>$O"WC_3_$\E]KVM:7+ITLLEQ+;V@^9Y""
M%!8QABJYP 6. !@<5K>+] \3ZAX6T[3/#MSIT%U"T;32W>60A%X 78P;YL'D
M<8'?H/X;!]JYP^@V>H^'O"_PYTFZ#1M<ZHUS)&1@JI#NJD=C\P)'8UL^ ]*L
M-<3Q+;ZK:Q7EK9>(+MHH+A \8+8Y(;N,MCTW&MVU\->(;CPW8MKUY9ZAXBLK
MT7D<P/EQ,0<!<J@V@H2,A.O.#67J/@?Q'#X-GTO0+S3XM0U*]DO=0GN&8+N<
MY*(-C;EX"_,.0#D<X!KK\_QM_P $%_7X_F4]'\(6T7P3O;#4D:2VDCGOX(1*
MZ;%Y>('!!.!AL'(S]*ZSX9C'PVT =OLBU0L=$\8Q^![[3]4N].U'6[OS(S*9
M##"D;)M7&V+MC.-HSD\UL^"-)U#0?"5AI6I"V^T6D?E;K:5G1P.A^95(/MC\
M:+MR?R$MEZLZ&BBB@84444 %%%% #UZ4M(O2EIDA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !3#U-/IAZFD-"4444#"BBB@ HHHH
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M_!_ %_7S M@9J*2YAB@,\LJ)$!DR,P"@?6N/^*]@U]\.]59;Z\M1;PM*5MI
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK0 M%)D>M+0 ]>E+2+TI:9(4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,>O2EI%Z4M,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex3-7_002.jpg
<TEXT>
begin 644 ex3-7_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" <6!7P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+^S-!)"HV(L.W:5 &,#;QQTH S?$7BR#PQH=KJ=[IU](UQ+% MG!Y3S^8_1
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M/%N2-D?()5@?-0<'(R..N.=\0_\ )T/A/_L%2?\ H-U70?&W_DD.N_\ ;O\
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ME]0N#!)+'CB145'^4GIN()'S=,9L>-()KKP+XAM[>*2:>73+E(XXU+,[&)@
M .22>,4[P>T#^"=!:U1DMSIUN8D;JJ>6N >3V]Z #0/$*>(=-N9X+26VO+2=
M[6YM+GY3%.@&5++D$8*D,N00P/7BN>TSXAW.J>!9_&$/AZ0:;$LDGEF[3SGC
MC.'=5QMP,-P6!.TX'(SE>#["\_X7=XYU"U;9HVR""0 $++<[$;@XP2O[S/.1
MY@XYKS_2)_%D/P?\-Q1*DOA&XEF&K/9P'[3#;>>XE5F+'*,I<[E5<!<$XY8
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M/A3>:<NGW.GW7DQ>,$=SK43ONN)'5R [-_&N&!&TE5WX%2_%/_F2O^QKL?\
MV>@#=U[6=;T?0]3U+^SK+;96INP1=,XD$9W21D;%*DH#M8;AGJ.,-S/BGQ_K
M.B?">Q\6V]K8&\O#%*(9 [1QQ2Y95X(+,%*@G@$Y. ,"NI\=_P#)//$O_8*N
MO_135YC\04+?LU:&05PEGIY.6 _@4<9Z]>@^O:@#T*8^/HM0CE4^'Y;$W<8>
M".*7SE@:0!B'9PI94).=O.W@<XJ2RO?$DGCN_P!,N;G2CI5M;Q72^7:R+.RR
MM*J(6,A4%3$<MCGL!GBUI_AR?3M;AOAKNJ7,"V;6[VMU+O1W)0B;MAOD;/&/
MGXVC(+;/_DH>L_\ 8*L/_1MW0!FZ7XKU'Q;=:I#X=M[:UM-.O'LWU&]_?++(
MF-PCB1@2.1\Q=>", \A=#3]8U>/Q*FA:O8VV9+-[J#4+64A)MCHKJ8FRT9'F
M(?O,.>O4#G/A%/%#I>N:-)8FRU.PU69KN-\AY!(=\<I! P"N%'7(0'O7?B[@
M-ZUF)5-PL8E:,<E4)(!/IDAL9Z[6QG!P <=\0/B O@N33((K,W,MU,K3N3\E
MK;"1%>1^>,[PJDX&3R>-K=7JTE]#HU]+I<,<^H);R-:Q2'"O*%.Q3R."V!U'
MU%<%J4.O>,;#Q+]GT/3KG1]0A^QV+W5Z8GECC#;9T41R(09'9D?*Y 0XZ$Z?
MPM\52^)O!\*:C.IUW3R;74H&5DEB=6*J75N06502>F[<.,$  S]2UWQSIGBW
MPYH,MYX=8ZR+C,RZ?/\ N3$F\\>?\V01CD5/XBUKQQH'A63496T W4%W'"P%
MO,T<T<C1HK+^\!0JSL"#G(&1CH4\6_\ )7OAU_W$_P#TG6KOQ5C,OP\OHP[Q
ME[FS7>APRYNHN1[T 79X_&ML]K)'>Z)?1FYB6XA33Y('\DN!(RL;AAE5);!'
M..YX/13SPVMO+<7$L<,$2%Y))&"JB@9))/  '.:R+Y++P^HU>XU1[2RMU87)
MO+F22-D;&,;GPK[@N#@Y!9<98$3>(]/EUOPGJVFVS(DU]8S01-+E5#.A4%N,
M@9//&: .<\.>)->\<Z:=:T5K'2]*=VCMUO[)[B:;:2&<[9451GC W=#SV%W1
M?$NH7^JZMX;U""UL==L((Y8Y5+2072.O$T:':Q17X9<G!^7>3S61\$W"_"[3
M[)PR75C/<6]U"ZE7AE$SL48'D'#*<>]2Z:L6K_&K4]7L;F&:UTW1DTNY*DDK
M<-.TA0<8.U5^;G@L!U!P 'A?4_&_B3PX-5^W^'K:1Y9HTA_LV9P3'(T>2WGC
M&2A[' ]:['2GU!]+MSJL4$6H;,3K;L6C+C@E,\[3U /(!P>:\U\$>%M/\2_#
M;4+"76=447=_=I<"UOB/L_[YLQ!.54,H!*LISYC'^(5ZM0!A^,/$/_"*^$[_
M %D6TES);HHBA09+R.P1!]-S+G'.,XR>*D\*^(;?Q7X7T[7+5=D=W$'*9)\M
MP<.F2!G:P89QSC(XKF_%,7B75?%ED?"T^AR-HR&2:+49)<)/*I53B+^(1[L!
MNTN<'((YSX16.I>#_%/B+P;JPMXBRQZI:16FYH0C?(Y1G^<@'RU^;/W#]2 :
M^G^/=:7XPW?@_5+:T_LYO,6RNH8)%9Y!&DVPL6*DK&_. .2IXR!71>/?%9\'
M>%+K4XH&N+PADM81&SAY-C/EMO155'=CD?*AY'%<QXFTW5+_ $OQG<Z%+)%K
M.FZS%?6319+%TLK;<H !W%D+KMQABV#P31:W5IXX\.ZEXUN 8(4TF2WL"XQ]
MD)A)N9$=N"=Q\O=M'^I..&.0";4O&7B*U\(>"M2A.E_:]?N[6WG9[60QQ"X4
MLI5!*"=HX.6YQVS@=;9V_B>.^A:]U32+BTR?.CATZ2&3&TXVL9W'WMO4=,UY
MCXG-NOPL^%QO)_(M1J&DF:7SC%Y:>0VYMX(*8&3N!&.N17ITEGI^C:C!J4VI
M7D(D LEAGO9)(I7D==GR.2-^1@$8X9LYXP <I<_$#5=#^(W]@:SIHFTB\N8K
M:RU.UMW18Y9 2L4A)96;E>05X&=N#QU.NW^I6>K>'X+*6T2"^O6M[D30,[;1
M#)+E"'4*<1%>0WW@?X<&M>:9IOB6#Q-X?OG1TN'031JRF2-6ACV. <X.Y"5)
M&,I[5P.AW'BC1/''A_PAXIGFU$IJ,MWIFJM@BX@6TG5E8YW;P70X.3\QY(VD
M@&_9^)O%6J?$CQ#X7M[O1K>#2TCECFDT^61G6158*0)U&0&QGOC.!G%3OXRU
MSP_XSTOP[XCL+.YBU9W%EJ6GDQK\H7*/"[,003DD.1AEP,@XS/#'_)P'CG_K
MTM/_ $5'4GC74%\3>-/#/AO2(Y+N33-8AU#4IX49DLQ&&*(YQM!?+X^;(VXP
M210!)J/CG4/#?QAM_#VK21R:+K$49L'$)#6\Q^0(6'W@SJ<Y!QYB\@ UO>/_
M !;+X1\.O=65FMYJ,HD%M SA5&R)Y7=LD$JJ(Q(').%&,Y&7XZTD^);+78-,
MF4ZOIL%K=6C18>2&ZB:61% R,,RD 9Z"0'!K$77[SQQX!\4>*I+22QTS^P;B
MULK=Y Q9_+8W$G"C*[E1%.?^6;'"[L4 8FL^)/&.F_!K3/&$7BV[;4+AT,L;
M6=KY6UBPPH\K((^7DD]#QSQV7]@>/K&ZM'E^)-M<EIU"6EQI$,*W.,LT>Y26
MY17/RC. 3QC(X'Q5_P FO:)_VP_]":O5+_P]I&C3Z=KDVIWT$.ESM,_VS4+B
MY5PT4D04+)(PW$RC! +'&T?>H Y'4O'.L?#CQHMAXHO[G5_#UW&KIJ(L%C>T
M=W<*C&/"OA8V)P-QZ@<8/<>(H=3U!]&_L;Q!+IB37.)G@@AF$T7ELYQO4X/R
M<,.!N.0W&)KNQT_6-6U33-0@@N[>2RMO-MY0&!'F38)'U7(/J..E<+H%SXJ\
M.^.K/PKK=I+=:(UY*^CZGNW[8Q!*5AD;')V_WOFRK?>4@@ O^.(_%^A^'/$7
MB"V\721^0!+96<=E!Y<*!L$.S(6<E>GW<'^\*Z/2='\2:=J\$M[XGDU:Q-IY
M<\,]K#"PGR#YJ&-!\IP1L)XSG<U4?BO(D?PM\0L[JH-MMRQQR6  _$D"NN@G
MANK>*XMY8YH)4#QR1L&5U(R""."".<T 9NL:?JNH7%FMAK4NF6Z%VN3!#&\D
MO&%4&165>>2<'ICOD<#H!\8^)=+\4BS\97<&H:;K%SI]D9K2U,3+%MV^8!#G
M)R02.G!VG&#ZI7G_ ,+/^9U_[&N^_P#9* +=YK.M:_XQU#PWH=Y;Z;;Z4L#:
MC>M'YMP3+\ZI"K#8/E4@LV[[XP,BJ>J:[J/P_P!<LI=>UV;5-!U6=;2-[BUA
MB>QEP,,\J;$9#\Y.5! 48S@YCTRZMO#OQA\3+JUPEI_PD"V1TQI056X,<9C=
M%8C;O#%?ESD[EQUJC\7-.?QP-)\(:3)'-=KJ*3WQC=6:RA"$;W3(QQ)D D%L
M<9S0!ZG1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ65I?L<#121 M@D#S4=E4D$[5(&6)'6K'A?Q;I'C&RN;W19I)[2"X-OYS1E
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M$49)/T KE?\ A8,']C_VW_PC^N?V)]_^T/)BV>3NQYWE^9YWEX^?.S.WG&*
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M$D<8. 0G)!QFK \<Z)%X07Q/?R3Z=I^\QNMW"RRQR"0QE&1<G<&!! ST)Z4
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M=&N&N-+T33;&=D*-):VJ1,5R#@E0#C(!Q["L#7_%6L^#-%N=9UW3K6\T^.Y
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M:G_HMB+2Q>?[-$@'F2+''S\D9^51WV\;0Q'*_"Z_70?&^O\ @Q9-072F O\
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M[K5$F\R>UMGG*2;82H&2Q(!!8\G@<$>Z:1X;L=%6^>U,AOK]_,N[YPGG3/C
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MV>[A>"78<$HP(8 ]N":RM*\*C1M#M]'M-:U46EO%Y,>^2-G"_P"^4R/;!&.
M,  4 <SK.H0Q?&3PU=7TD4NE2V=S9:?,K(5@O]^) S9&"541@9)W9 &<UL?$
M[6[GPY\/=4U2VM[.Y,01'M[V(R12H[K&RL P[/\ TQS5Z]\&:-J'A[3=$N(I
M_LNF>4;-X[AXY(7C0HCAU(.X _GSBHM8\&6WB#3DTW5M4U.ZTT%?,M6D15FV
MD%=[*@<X(SPP]\\4 <5\28[\^/OAK&ES;+?^?<CSVMV,6_;%D^7O!QG/&_\
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M[8W)-)!YR@"UN"RE,KD,H*\$$;L@@BKOBWP?I7C73(=/U@3-;13"=5BDV'>
M5!)^C'\Z74O"L&J7&E3S:EJB2:60]N8KG;E\;2[C'SD@D'=D8+#&&.0#)L/
MDS>//^$PU[58]0U""W%O91V]J;:*V7#!CC>Y<G>WWCQN;_9V\CX-TOQ-JA\>
M0:1XAMM)MI?$EV@D^P^?,C[@696+J!E=HY![D8/->O>6WV?RO.DW[-OFX7=G
M'WNF,]^F/:L/PQX.TSPE]N.G27<C7TOGSO<S&5GDYRQ8\DG/.: .!\::-%X8
MLOAGH-BRBRM=?M%8':&D<-]_'7DLY..,M]*]8N;N"SB66XE6-&D2(,W=W8(H
M_%F _&L7Q/X.TSQ;]A.HR7<;6,OGP/;3&)DDXPP8<@C'&*5O"L4NJ6]_<:OK
M$[P,&6%KLK"Q#%ANC4!6P3QD<8 Z 8 .>_YN%_[E3_V[K#^ )AL?#6M:!+')
M#JVG:FXOH6<. Q 0%2!C'[MEP"W*DYPP [R/PC9Q>+9O$RWE\=2EB^SL6E#(
M(=P;RU4KA5RHZ8/4YR22^Y\):;+XB_X2"W-Q9:JR".6>UEVB=0" )$.4? /!
M8$C YX& #9,\*W"6[2QB=T9TC+#<RJ0&('4@%E!/;</6O,-5M]2\;V'B@Z5H
M^F:CIFJPFUM-1EU)DR(,JH6,(P.V?S75LJ&!&3TKOO[!MQ;7R+<WB7%ZH6>\
M68^>0,X"M_ !EL!0 I9B "2:DT+1K?P_HUMI5I+<26ULNR+[1(9&5>R[CS@=
M .PP.@% '/?"_P 8GQMX(M=1F#?;8#]EO"0/FE502PP /F#*V ,#=CM3M=_Y
M*CX0_P"O34?Y05>\+^"]+\(R:A)ITEY(]_();AKJX:4NXS\V3W.XY/?BK=SX
M<LKOQ/9>()9+HWEE"\,""=A$H;.X[.A)R,G_ &5_NC !0\>R00^%UENIEAMT
MU'3VEE:3RPB"\ARQ;(VX'.<C%<_XEN;;3OC7X0GOH(C'>6=U:6T\LH3RIN#D
M>I((0#C/F<9/%=AXC\-Z;XJTDZ7JT<LMFTB2/''.\>_:<@-M(R/8^QZ@$3:S
MH>E^(=.>PU>P@O;5LG9,F=I((W*>JM@G##!&>#0!@_$_5[+1_AOKLE[,L8N;
M.6TA4D9DED0JJ@=^N3CH 3VK'A\.F#PK\/\ P_KL*W!6?R+J&7# ?Z!<Y3()
M!V_=!![#%;EK\/\ 1H=4MM0NI]4U*:TD\VV74K^6Y2!_[RJY(R.Q.<8!'(S6
MI>^&M*U#7K#6[J&5]0L PM9!<R*L6[(;"!@O(."2.1@'@"@#SF\N&^%R7'AN
M2VGE\+ZMYJ:3.F7:SGD'-O(3_ 6)93][[V=W)7L?&O@[2_&45M;7,\UIJUNK
MSZ=>P,PDMG!3+C! /.S(//H0>1T=]8VNI6<EI>P1SV\F-T;C(R""#[$$ @]0
M0"*R_$'A/3/$DUG<7ANXKRRW_9;JTNI()8=^ ^TJ1U"@'.>,^M ''^!-9\7Z
M?XUOO!?BZ>#4)([(7]GJ$>%+Q;ECVD #/)/7# JW+ @CTRN<A\':7I^C:Q:6
MUJ]Y+JD3K=/>W<C2764**CS'<X4+\HQG:,D#.<O\&>&E\)^'(]+1L()99EA6
M1G2 .Y;RD9N65<XW'!;EB!G  .@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1*JO\[Y.0 1] *ZS2/$FB^('NTT?5+2^-HZI-]GE#A2R[AR."".XXR&'52
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MGD$:+D@#+'@9) _&N6^'6HK=Z7K-@D ABTG6[VPB ;Y?+64N@48^555P@4<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!$@2..-0JHH&  !P !QB@#@/B#*MEXQ\%:IJ0<>'[*YN'O970O!#*T86W>0
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MC&<<LASD$_*N",G.&/M-S\-?%MW:/%>64_BR2Z$J3%A';+<QL9%P"" 4+'D
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M=A$@W<L47!R=U:'BK0(-%\#_ ! M(-26YL#''+#IB6VR'3F)+[$.2N3E7*@
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M%W$HD89B O)(&!D9/(KR/2+K2;?PM\9-\L45_P#;[]9F?Y<HX=85W'@Y?S
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MUUBQBO((9TN$CE&5#KT)'?J00>""000:CU+PSHNKZA:ZA?:?%)>VI!BN1E)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<#YB>,# "XZ'K6AIWA,VWA/2M"O-3GN5T][9UE2-(]_D,C(N,'"YC7/.>O-
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M64-NCQ("=RKA_,"MG STVK^$;;7K&YT[5=0O[K3;F82R6;,@4@,'"!@@<+N
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MES#,T3(5//RDG) (W!23M&/2-;T33O$>CSZ3JUO]HL9]OF1;V3=M8,.5((Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!'X4 6**K_;[/^T?[.^UP?;O*\_[-Y@\SR\[=^WKMSQGIFK% !1110 4444
M%%%% !16/?>+/#>F7DEG?^(-*M+J/&^&>]CC=<@$94G(R"#^-2:;XET'6;AK
M?2];TV^G5"[1VMTDK!<@9(4DXR0,^XH U**** "BBB@ HHHH ***S=3\0Z)H
MLD<>JZQI]@\@W(MU<I$6'J Q&: -*BJ>FZMINLV[7&EZA:7T"N4:2UF650V
M<$J2,X(./<5<H **** "BJ>JZK8Z'I=QJ>IW,=M9VZ;Y97Z*/YDDX  Y)( R
M34EA?6^IZ=;7]G)YEK=1)-"^TC<C %3@\C((ZT 6**** "BL>X\4Z-:>*+3P
MU/>;-7NXC-!;^4YWH Q)W ;1]QNI[?2M"^O[/3+.2\O[N"TM8\;YIY!&BY(
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M$L4;"83R^7%LD5S'DL0.6 !W<G8Q#M)\;W%_XB_L2[\)Z]8W D=7N'A22UC
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KCOBLJM\+O$(8 C[*3R.X88KL:Y7X
MD6ESJ'P^UBPLK>6XNKF Q111(6+-G/;ITZGB@#B=.U;P?_P@/A72=2\.SW3Z
MK%9::S/I4D*%Y$4%_.=%!Q@D%&)/!'J+GQ*=]+U+P)IRV4=_IYU!(%MY[QHE
MEE "Q>9M0@JK%6S@YP1MP:UM$U>33/ 6AV-]X4UNZN;2VMH9;5;-6*R1#AP6
M8+PT:L"#GYE.,@[:7C*PUC4)OA_>2Z4]Y-9WT-SJ"HK,(>%WO\FTDJ<D#')7
M[I&10!5\6)J%G\3_  5;V&E:8J7$U[>-!]J:..YN1 -TDN(C\R@_*^&)S_#6
MMJGC?2/"MWJVF:=:Z);?V>OFRP3ZA%9-/*ZB0K''M)8E6!W':"Q R?F*Q>)A
MJ%[\4?!5[9:1?36>G?:#<W)B*1H)XP@Z\Y7&3Q@9 SG.*FJZAXX\*^/=7N-*
M\-/KNB:J8IHT29(FAG6*.-CNY."$&0PQTP1AL@'5V?B^WU>WT271K?[6=6MW
MNH]\JHL,:!0^\C=\P=T0JN3N)[ D<;X\\9>)E^%6LZC:Z5<Z'?6UX+*X:5_F
M6,E5:6%MHW LP4, .,L,$"M+Q*GC+2)O#6O65C_;=]9Q7$.J6ENZ1K()MC8C
M9EW!$=%VX4L54;C]XFEXST_Q5XV^$FI)=:##::G+-'-:Z<DWFRI$K)G<Y*KY
MAQ(V /ND+C=F@#9\7>)DT/6?"MOJ6@V-Y/J.H);P2FY4M:NS!2Z!DW' 8<J!
MUP2,KNU-(\437WC'6_#E[81V<^GI%-;/]H+_ &R%\_O%4HIPI 5L;@&.,\<\
M=XZ@\1^(M9\!7EKHU_!I]OJJWEY;R;6>)4>+:\@4D X,N ">#S@Y N_$7PUX
MEOO$N@:MX2N/L5V^_3K^[C"LZ6SD-NPW!5-KGJ#EEQR> #='C1+?P[IVKZI%
M9::FHSF.V,]\/)*%7=':4+A=R)D#G[P&<TG@[QU9^+[[6;*WBC$NERJCRV\X
MG@F5]VUD< 9^X<\<>II/&:ZQI6B:7=^&M/-]-IEW&YL0W^NA\MXF7).00'!!
MYP5!((S5KPGJ'B#6(KC4=<TI]&5PD<&G/*DI7;N+2EP ?FW!=A''E9_BH M:
MGJ][:ZI%96FF"5#;27,UY<RM#;Q*I "[PC?.2<X./E!.>,5S4/Q2L#X#T/Q1
M<V;6R:O>+9)'),H2!R[J6DD.,(/+8EL>G'HOC"UU2Z\9:7$V@W&MZ!-:21W%
MJ)U6%9@ZNCR*Q"L!L PW8D@$C:>4\,P^(M%^%]EX<U?P'/?PVVH&VO;9FCD\
M^W<R2&2,;N&1RG7@\8;)R@!ZWIT^H3_:AJ%C':M'-LB,5QYJS)M4[\[5*\EE
MP1_#GD$50N_$2Q^*H?#EG%'-J#V3WSK)(T:I$'5 <A6R2Q/';:<XR,\[\-M*
MU;3[C79I[6\T[0IYX_[)TV]FWR6R*#YGR@D(I8C"YXQ]"6>*--US1OB#8^-=
M'L#JULUD-,O[&,XG2(R;Q+%D@,<XRO'3_:+* ;.E>+VU+Q!K7ATV4<6L:5Y;
M.GGEH9(Y &5EDV9! (R"O4X!(YK)^%T5S>>![ ZI:6<IBN[N42ARY$WVF7+*
MK+\O);!W9Q]:M:'!J]UXHUKQ7?Z1/:Q-90VFG6+-&+B2- TC%P'*!B[E5RXX
M'S =3-\-+'5M,\$6UCKFGM9:A%/.TD?F(ZMOE:3*E&;CY\<X.0>V"0!OCW2=
M<U:+35TVQTW4M/MI7N;[3;R9H_MFU?W<8."A&XEL/QN5#T!IWPYU;2-8\,//
MI.B1:(\=S)#>Z=' (O(N%P&5@%7)QMYQZ X((%O6M>US3-=M+:T\*76IZ9*G
M[R]MKJ)7CD^;Y?+<KD<+\Q8#YO48+_"6AW&BV>H2WOD+?:EJ$U]<);$&*,N0
M%52$3.$5,DC+-N)ZT <_XKBGUW5/ 5AJ<,EFEU>_:[NS217 DB@:41LV,.H8
M8/8C\",C5;^Z\)_%#Q;<:?*6CG\+/K+VTP!C^TPGRT(Q@@;5Y&>23SP,=!XL
MT_7-7T+0->TW3WCU_3+F"]_LX3J"X8;9K?S"0H^5F!;!^[P.:@TGPS?ZSXX\
M0>(_$-E+;V=U8)I5E87#Q%OLY :;>(RPY?./G)P6R!\M '(-IC:)^SQ!K<[V
M:ZVHCU9=1=6:1I99UD!,@7?YC(RQD^^"VWFO;:\A@\&^)8/!%E\/!IL4EC%J
M(,^KR/&T,MH)3/D1[]ZR%MJ;"K+P?FP<CUZ@#@[_ ,=ZU8^&]0U__A%XY;+3
M[N>"=8[\M*Z13>4TL:B(Y488G<4P$)Z8)[#2=2AUG1K'5+=9%@O;>.XC60 ,
M%=0P!P2,X/J:\S1_%6J>#O%&@:?H6_[;JNH6MI?O+$(%@DN761I!YOF;E+38
MVH>B\'G/>6D%WH T#0M.TV2[TN*W-O/>R7**ULL48$9*8S(7(Q\N,=: .=C^
M(&IW.F^*=1M= MC:^'KFZMY&EU$HT_D $E0(CC*Y.#WP,G)(V+?Q'J;WNC?:
M=(MH;#5G"02+>EYD)@>8!X_+"CB-@<.><=:Y'2M!\10^"OB#9SZ#/'<ZS>WM
MQ8P&X@+N+A=HW8?:NW@GYO7&>,]!<V^N):>!O)T226>TN(I+]!<Q!;53;O"^
M6)RY4RD@*#G8>1D9 .THKG9]2\30:]JL,>A176EQ6'G6,RW*QO-<#K"V2<;L
MC#8 7!SG/$/@'Q!JGB/PX]QK>G_8M3MKN:TN41-L3/&Y!,9W-N4?=)S]Y6]*
M *OB&_;2_B%H$T&D7FHSW&G7T&RS2/< 'MFR[.RJ%&",D]6 ')J]H%S8Z[JM
M]JK:)/IVIV$KZ?)]IV"4ADAD.=C,I!_=X.3P.",FL_6+KQ#!\0;&[M/"EW?:
M7:V4]O)=17ENK,TIB?*1NX)"F$*<E<[B?X1NDDU'QEJGB.RALM&_L;2(XI9+
MJYU%X97ED*,L:+'%(WRABKGYE)VD97'S &7+\1[ZPO= 35=)M+,ZU<0V\>G/
M>_Z=;"1W59GCVX*$!<C@H<@EB<+L:1XSDUSQ%K.C6FGQPW&DW:PS1WD[12O$
M<?OE41D%3\Q7YN0%)V[A7G,'ASXAR>$_#MO>>'(I]1TW7XM0N9Y]61I[O9N(
M=S@C 4K'G>S (,+C&-SQ?HOB/Q/#<^5X6EL/$=O>-#I>O6U[%$J6OFX#NRR^
M:,Q,X*[6Y)( +8 !/H^K:YJ'[0.MV4^6TS3-,$"B,N(D,ACE5B#E?,.2/X<A
M#_=IZ_%"\O(GU;2-&N]4T@DQP06VG79GGQ-L,JR^7Y6-H8["<\<L#E18M/"^
MLZ9\<[_Q%#:QW&CZIIZQS7#.B-;R*% 4#EFSY2GHH^?N5YRM.TOX@^#-0N/#
MGA[2K*[\,O<E[&\EF57L8Y) S*59RSA 9,<$DD-D_<H [&YUWQ!_PEM[HVGZ
M+8W$,%I!<K<3W[0C#M(N& B8ALQM@ $84DL"0M8Z>,O%-[XK\2Z'IV@6,CZ-
M'!(&-X<2EP7V9*KAG3"CC:A#$LPP#L6*ZR/B5K$T^C^5I$FGV\,%_P#:4;S'
MC9V(\L?,,^>PY_YY]]PQAZ#9^)-.\;^/-:F\.R;+](FTY1>0[;DVZ,BJ3NRA
MDRI&5PN3D\#(!UOA?75\3>&-.UI;<VXO(1+Y)?=L/<9P,_7 KF?%-UKWAGQ<
MWB/3_#CZWIT^G1VEPEH?]*@=)792J]65O-Y !^[DD!>=?X>Z;?:/X!T?3M2M
MFMKRV@\N6)G5MI#'NI(.1SU[_A5C4=0UW3]=S!HLNIZ3+;#'V2:)989U8[MR
MRL@*LK+@AB04.1SF@#@M7U:UN/A)KWB3P#JUKIJ7TQO+MIL1- _EHDD2;?N3
M,53&<Y9R0?F5AT^F7>MZ7\-O#S1_89;@6D"W=[-<*T%K"(LM.QW@2@ #.UQG
M.0<5SL/PTU.Y\,>- C6VB:GXDD1X[>V<F*"),%8WV]&;=(LA4LOS< C@V;GP
MWXIO?"/@Z.6PLI'TY4@U/0;B91;W2X5%9F52OR;1)LVL!VW%0& -+3/'5Q>^
M!O$FLQ-IVH3Z)+<QB>T+I;W0B02!E!W$?*P!&6!*G#$$&M6XU[5;#Q;I&FWM
MI9BSU02Q1&&5GDCEC1I"6)4 J5&, 9!'4YXYG4;'QH^D>.[(^'[2Y?54W6TD
M%\J"1I8(H&10PZ1JC$NQ3>0,*-WR[FO6VK7OBKP9J-OH\[VMK+/)>YFB#VWF
M0^6H8%\-@N2=A;[AQG(R 8&O>)M8\4>!/%5YIEC:P:1:PW]HS79D$EVB1[?-
MB( "@'?P0VXKMRG)&GH^H:O9?#KPBNF06B0OI4#W>I7L@\BQC2%&+.FY6?(R
M!@@#J2 .>=O/#7CK1M-\5^%]%T^SU'1M4%Q/974]V4-J)0?,MPA))/)VG(7<
MVYCR5%C^P_'%CH7@%UTZVOI-(C:'4-*CO?)B?Y5$#N6RK&+8K$C.'&4&.0 7
MK;XBZI?_  [\0Z]I^FV-W>Z+<36S&*Z_<3B)%+7"<?<^8L$W9*C 8DBM,^)]
M?T[3TU'5++3)(=0ELK?3(;6616\V;"MYSLI"KN((VJ2!G@FL#3O!_C"W\->/
M=$8:5YVL7LL]I=NSK%*+@ 2DH-S)A>@.?F_O 9.]XS\-ZUJ'P^M;'19HDUG3
MC;W-L3C:\L." "PQR1QN&,X!P"2 #C[VXU=/VB?!]IJDMFTXTN4R/90F-9-R
MSG!R2V 5& 6(R-P"EB![%+!#/L\Z*.3RW#IO4':PZ$9Z'WKS&WT+QUK7Q$\*
M>)M:LM/LK;3K.59[6.\+[)74H[ ;>"V\$*"PQ%@ODC/J5 'F?AR":'X^>,WE
MBD1)K*T>)F4@.NQ%ROJ-RL,CN".U;VM:[<Z7X_\ ">A06=F;+5#>222,I,B/
M'&7RF,!<ECD\D[CTZF'3=$UVW^+>MZS=B.31[K3X8;202C=&5(S'MQG[V]L]
M/F'4D@6M?\.7^I>.?">NVKVWV?2#=?:$E=E=A-&$&S"D'&">2* (;W7?$CVW
MBC^SK;2EETJX\NW>X>1E*B"*8[E4#)/F$9##&1P<9;+N_'&O6\7A#6#8Z:ND
M:_<6EJUL)'>>-IU+!Q)@+A>/EVG.#R,\;D.D:QL\7++#8K_:DK266VY=L_Z.
MD($G[L;/]4K<;OO$<[<M@ZCX-\0W7@[P7IL*Z9]MT"\M+F8/=2".46ZE0%81
M$_,,$Y7Y>GS=: )M>\?W46MZYHFCV<YO-(BBD9_[,GO1.\B,XB582 F1L^=W
M'.1M(&X=1X6UB\U[PY::G?Z3/I-U-OWV4^=\6'91G*J>0 >@ZUQ?B/PSXQT?
MQU+XG\$S6ER=7\J#4K._.(H]BA4ER""5 '(!+ DX#!L+J7NI>-=%E\*VTD.F
MZFU]=O%JTR8B\K<P95@4N"P1#)V8E8MQQR: .LU;4H=&T:^U2X61H+*WDN)%
MC +%44L0,D#.!ZBN0U;Q7K?AKPY%XJU465SI!$3SV=G;,L\"28 Q(TNV0J64
M?<3=G/R]*Z_5M-AUG1K[2[AI%@O;>2WD:,@,%=2I(R",X/H:\YBT;QCXDTBW
M\&^)=$MH-(MY(UNM52[4B^AAD!55A7YT+A5R=RXY/'"T :Z>)?%&I^*O%^@Z
M3!HZ2:2+3[)+=F7!,L9<^8%^]TP,;=O^U6OX!\2S>+_!&F:[<6\=O/<HXDCC
M)*[D=D)&>0"5SCG&<9.,U1TCP_K>E^.?%NN^5I\MOJ\<!MD^U.KAX8]BA_W9
M #9))!.W'1L\3?#?P[J7A/P19Z%JAM&GM'D"R6LK.KJSE\G<JD'+$8YZ YYP
M #/$_B>3XN/8?VQ8_P!FP:8MR+?[ WW'G(QGS,^9MCQOSM_Z9]:P;75-<\-Z
M?X\U/1M/L[FWLM?ENYXYYV\R6/RXFF5>@3"_,&RW0C9TKL+O0]77XCV^O6$]
MM]BFTX65VDRG,>R;S%9<<L6#.N,J%^\=V IQKOP7KTW@_P ::9%/8"\US4IK
MBV8SS*B0N(UPY4;@VU&X&5)P#E210 E_\3#)>:)INF:==K=:KID>J-<?8I+Q
M+2%P<;HH3O<EALX*@;@<GI6SX%\0ZUK]C>C7-(DL;FUN6B28VTL$=TF3MD1)
M1N48QP2?PS@<MK'@+Q-I]EX6UCPO=VB>(M#TR.PNHG=O*OHD0?N^<#&X-C(7
M.\'<I45W?AN#Q!%82R>);JRFU"64MY=@C+! @  1=WS-T+$GG+D=%% &3?\
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MGW0>2W/3 !1;QIXELKOP-J]]+9R:5XB$-M+8V]JX,,LR(5D$I)'WB?E)'RY
M#D%Q:UKQAJYU_P 80Z?=06@\+:>ETEO)$)5OF>(R,7Z,JJ %&PC#-DEA\E1Z
MGX-\577AKP-IMN-&W^'[BWN+I9+F4"5K<!8PCB/@,NXME>"1C.#G$N+?7O$_
MQ#\53Z#=>%-3M 8]/DT_6]\C(L.TM^[49"^<9,$\$C(XP: /2?!6K7^O>#=*
MU;4XXH[N\@$SI#&R( Q)7 8D_=QSGGKWK&76=;_X7)<Z U[#_9AT'[;;PB ?
M))YP3<YSN8_>X! P1QD9.[X3U.]UCPU:WVHBS^U.9%=K&0O!)MD90\;'DJP4
M,/8UD_\ ".ZP/BU_PD^;%M,.E?V=M\UUF7Y_,W;=I5OFX^\.#GM@@'GY\;>.
MYOA"GCIM3TVW\B[:46\5IO\ M41N!&(GW'Y IW#*DLR[<D,"3[A7C]O\-?%D
M?P7N_!$]YI4UU+=@P2><ZQPP;UE(R(LLV\-P1T?KP!7K%@+I=.MEOC&UX(D$
MYC.5,F!NP<#(SGL/H* . T?3=7M'\?/J'B*XU&%)7BCBDMHH^3:1.'8JHRP1
MD3 VK\K-C+<85GJ_BW0-!^&UZFHV*Z3?O8:;)IRV^XE)(P [2GDM@%L*%"D@
M?. 2>VF\/ZZ=3\2O#>V8T_41YT$&PB1YC;+ 5E<@A8QY:M\J[LGK@%6YW4/!
M'C"[\%^$=,BNM#2_\/RQ7.6$QBED@(6%<XR%,9<N<9+  8!) !7U7Q-XT\3Z
MCKT?A&"^M+7299+"&6&.SD^T7:$;_-\YP4C P%V GY]Q/&RO2-#GU.YT.RFU
MFTCM-2:)3<P1N&5).^"">._4_4UY_J_PZ\2V/C.YUOP-XA@T>'5G5M4BGA63
M# \O&I4AB=S'!*\D_-AL+Z-IMM/9Z;;6]U=M=W*1@37#+M\U\?,VW)"Y.3M'
M S@<"@#AK;4O$GB^3Q-/HVL'2QI.HOI]G;K:Q2B=X@ID,I?DAB<+M*;1R<UR
M7Q*U:X\=? BV\46DT^G6XE62YL/,#+,!-Y6&8 $X?##H.Y&0N.V?PKXAT76=
M6?PI=:?#IVLR?:+E;YI&>UN68"2:(*/GW)_ S## $$#Y:C\3_#@W_P ,(_!G
MA^_73X(0O,T0D^T;<MM<C&W=)M8LH['C!Q0!3\?:)?M+X.B'B74R_P#;D*>8
MT=N#N"S/YGRQ#YL?)C[F.JDY)M:MJ?B+2OBOX0TE=5\W1-1M)XYHGBC\R6:&
M-V9V(08SNC/RD#(/ '76\2^']9UJ7PP\%_9QG3=1BO+TF!E\W:K*?+&YMN=S
M#:<_>!W?+\SM4\)W&I_$#0_$K:KLM=)BF2.P^S@[GD5E9_,SD9!3C!^YVR:
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M@8))(  .<*5Z?1=/N-,TN*WO-1GU&[Y:>ZF 4R.>I"CA%[!1T'J<D@''^(-
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M003PW5O%<6\L<T$J!XY(V#*ZD9!!'!!'.: )**XV[^)F@V<]^SQZ@VG:;/\
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M<9BAW!#G:7$C "122J-CGJ0<=%!/#=6\5Q;RQS02H'CDC8,KJ1D$$<$$<YH
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M0PF,$L04R&& >G.0>.A(!U+31I)'&\B*\A(12P!8@9.!WXI]><ZAK,VJ>._
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M$3P>'G>VT2V%PUQ=3M ETOE[V$1$;!BH# ^AP.^0FI^,KNTUGPWI]EHC7O\
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MHP%SSSCG?$FM^,$\>> K2U%G91:@LLMSI\LK'YTBS*CR(/F"JY"8&-X#'/&
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MPS&EAK%[%:$QWS226XD;8LC@1!=N[C[PZKW.  >@45SNK:W?PZC?6E@ELO\
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M'[V%QG*YM1^)-%E_:)F1=4M 8M"_L]MTH4&Y^TAO*4GAGPPX&3G(Z@@>J44
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MXY( X-8%MX-U:S^)]_+"JGPI?R1ZK,F_ 6]3(VA=Q)R^V8MM&2B#/RX/HU%
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M2R1J223L3'8501YM/^(O@V]U!W&D76BK96C/*PBBO2,]/NAW0[1G!;D#.,4
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M]/<)=1R6\L+1,2P (D53G*,,=L<UY-K-YH?_  A7P@3?9F<W]BRN%!"H@47
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MY)ST)W+-XAT6\\)>%9]:T'4[Z?4-+MVGD&K:A<7,5U&B'>'0OM#$?,"H7YE
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M%@TZNLH0H,98,> 1G/:KM_K%[X;\,?#C3[R._LK"[@BL]1EMH6^T(WV=0D
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M[>:?9:U*TILEC6.VA#N.%)!.T#HHPJ\D@5ZW<^*(#!H[:7;2ZC+K 62U6/Y
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MC@#)]> !^%<_J&LW]GX[T725^S-8:C;7+L#&WFH\6PY#;L8(<<;>-O7GCHJ
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M55&T8XS[XH YCPQI5KXK\':'XD-ZUEJ,^HQZG//#*S"1_-*M;Y9B1&1E @.
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MBM*YDF\3?%GQ?X8N=0TO8+.VBMK:_L'GS"8BTGELDD>PYER3DL<C& G'9/\
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M9HY5*_,^4>)01\P(0 #*9Y!].ETWX=?"W2M<@6+4SXA@/V:Y(,ODF60X*GG
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MNO;7UW$1OF6,!961\I+M(PK?*KX'"MT/ -: C02-($4.P"EL<D#.!GVR?S-
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MS-#O8&UG<A45UX#$;)NN<85AU4US%K;W_C'P)#XHTN^M]%O)KN34CJD]X[M
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M$\@@4 6/$NM7FCWOA]+98&BU#4ULIQ(A+!6C=LJ0PP?D[@]:Z"O&[B+1M?\
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M6()';MS42_#_ $>'QY9>*[6..VFM;(V@MH845#@;4<8'!5-R?3:!@+@]910
M5P^C>%?&.B>'DT:#QE8RQQ1"&WGFT7,D"! JA<3!3MQD;E;GKD<5W%% ''^(
M_!]]=>&]#TWPUJW]DW&CW$#6UQ)'YI$:1M$00>"=CL>>"1@XSD06O@;4]&\4
MZCK>A^(8XSJ<,2WL-_8"<2RQC E!C>+:2,D@<99CC[H7MZ* .!D^%FGR>"FT
M1M2O!J+7AU,ZLKE9?MY_Y;A0<#TV@].^[YJLIX-U^;PQJ^F:KXODU*\U"V:T
M2XELE2*")AAL1(PW.06^<M_=XP"&[6B@#S2V^%=[IK^'KW2?$4=EJVE0FWN;
MM; D:A$"NQ)5\T$JJH%ZGMC;M&/2Z** ..^)46I:GX3E\/Z*LAU+5V%LCKPD
M46097D;^&/8"I(!)+J "35P:?J5EXITI;75+@Z3#9?9I+ VN5) ;$S3=-WRH
MNW\>A-=+10!A^+M%OO$?AJ[T>PU./3C=H89IVMO//E,"&51N4 D'&><#.!G!
M%?Q5X27Q=X:BTZ^O9+>_@=+BWOK0-&8+E <2*NXG&2?E+$X/!R PT-2\0Z9I
M.J:;IEY/(MYJ;LEI$D$DAD*XW?=4A0 P))P ,GH#6I0!RFC>'/$>FVMQ+>^+
M7U35&41V\US9[+>&/()S!&Z[W.#\Y;(XQ@;@U"#P!>Q_"V;P5-KD4I:,P17H
MLBNR(L#@IYGS$?, <CMD'!SW5% '#^)_ %UXBMM#NHM?DL?$>E;<:Q%;_-(-
MA#CRPX4!FY(Y &5Z$U8U3P)_;7A$:5J&MWTVJ*Z7$>K9VO%<J25DC0$*@!)&
MU<';QG/S5V%1SS+;6\L[B0I&A=A'&SL0!GA5!+'V )/:@#G/"?AG5=#,TVM>
M)[W7+IQLC:1?)BC3C@1@D%B1]XY/88RV[$T_X:7>G?"^\\&Q>)92TX:-+S[,
M (HF?<R",-SNRX)+9^?K@ #LM$UO3O$>CP:MI-Q]HL9]WER[&3=M8J>& (Y!
M'(K0H Y/5/"FI:IXL\-:\^K6B/HJ2!H18L1.TJA)2#YOR J/E'S;3U+=*YZ\
M\.7/@30/'FJIK=Y,FM/+<0K! X&GR2%P9?D9CA=ZLSJ 0L6<$@"O3:* /%O"
M-S>VESIVG>'OB/9:O:VTT7F:5::%'$I@:55D8LF2N Y;=Z]3SFO7=6TV'6=&
MOM+N&D6"]MY+>1HR P5U*DC((S@^AHT_5+35/M7V1Y&^RW#VTN^)TQ(N,@;@
M-PY'S#(/8US,GQ1\*Q3A6N;PV[DI!>1Z?/)!<NI8.L3JA#[=F21Q@C!/. "A
M:?#6]MCH+-XQU-GT<-';LMO  D7EO&JHI4J#M8!F<.3MXVYX]!ID,J3PQS1D
ME)%#*2"#@C(X/(I] &'I7A^33/$_B#5S?>;%JSP.MMY6WR#'&(R=V?FW8!Z#
M&*W**S=9URTT30[O5IQ+-!; [DMD,KNP;;M4#ONX[ 'J0 30!S\'P_ANO UU
MX9\1:C+JXNIY;B2Y$20,DDDADW1A?NX9BW);DD?=.T.@\#SW%YI\^O\ B*^U
MA-,NS<V4$D44: @$1M+M7,DBY^]E0<#Y1SGJK2ZBOK*"[MRS0SQK+&60J2K#
M(R" 1P>A&:FH YWP]X:NM&USQ!J=UJS7SZM<K,L?V=8Q BKM5."=V%VKDXSM
M!QDG/1444 9.FZ$FG:[K6J+>7,AU22*1K=V_=1&.,1Y0=BP49/?"CM67#X8U
MU/$-W=2>,]0;2)Y#*FG"WB#(202GG%2VS[P 4*P!&&R,GJJ* (X(([:WBMX5
MVQ1($1<YP , <UBZ9X5M]+\5:OX@AOKQY]6$8N()#'Y7[L;4*X0,,+D?>YR<
MY."-ZLG3_$>GZGKVJZ-:F4W6EB+[5OC*JIDW%5&>3PN<@8PPP3S@ YJY^',X
M\53ZGI7B;4=)TR]<SWVG6G FF.=T@<GY"WRYPN3CJ.,:_BWP7IOBOP=+X<=(
M[2 (HM7BA4_9F3[A1>@ 'RD#'RD@$9KI** ,.^\(Z-?>#I/"K6WE:4UN+=8X
MSS&!C:03GY@0&R<\C)S6?H/@J32W\[4?$.JZQ<0NQLI+R7/V4%64$+T>3:Q!
M=@<\X"[F!ZRB@#E=&\$1>'/!%YX9TC5]01)8YEM[F=U:2U:13RFP)T8EAWR3
MSZ+I?@L6FOP:[J6L7FJZE;PRVT$L\,,>R)FR ?+168@#&6)&2Q 7=@=36/K_
M (BM] BAW6MW?74^\PV=DJO/($4L[*I89  ]>I4#)8 @&-I'P_CTF]W)KVK/
MID5SYUKI?FJMO"N0RH<+N8*^6'(& JD'!W=+JUG-J.C7UE;W<EG/<6\D4=S'
MG="S*0'&"#D$YZCIU%-T?5(M:TFWU"&&Y@28',-U"8I8V!(974]"""#VXX)&
M#5Z@#!TKPM#IVLOK%QJ%YJ6H&V%HEQ=K"&2(-N*CRXTSEL'YLGCC&3G,TSX<
MZ;8>%ET&:^O[R*&836<\\B^;9LAS&T1  5EZYQSD@Y4[:[&D9E498@#(')[G
MI0!@6GA."/6K?6-1U&^U:^M49+26\\I1;!AA]BQ(BY88!)!. ,8YSEZ?\-=,
MTC6+JYTO4M5L-.NW>6?2K6Z,5OYC*%W)MPR=S\K#G:!@*%K<D\16\7BV'PXU
MI?&XEM/M2W*P%H -Q&UG'W6^4GD =!G) .Q0!RMYX T?4/$<VKWQEN4EL!IQ
ML)4B-LL 8.%"[-W#@,#NR#TX  T?"_AV/PMH<6DP:A?WMO"<0M?2*[QI@ ("
MJCY1C@'IG'3 &S10!A:YX;?6VG4ZYJ=I;7%M]FFM8! T4B_-DD21/@D.02",
M@#TKD-?L+2#X@> M L=7GTZ6TL+Q(?LSQF4((XU4%75E((1^J]4..17IE8OA
MSQ/9>)X]2DLHKF,:??RV$HN(PA,D>,D#)./F'7!]0* *H\%V']C:S8O<W<EQ
MK*,E_J#^7]HF!78 2$V@*GR@!0 .@R237N/ 5I<^"[#PLVKZJMG9/&R3+)'Y
MKB,[D1B4*E5.W V_P+[YZRN=\1^,K#PQJNAZ?>VUY(^L7(M8)((U*1N651O)
M88SO[9Z'TH FN_"MC=^+;/Q+YUW#?VUN;5A#+M2>(MN"..X#?,,$9[Y'%1Z)
MIE]9>(M=N9+R^FTZZ>)K>*\FW^7(-YD,0_AB.8P ><HW&-I/044 >8_&2ZME
MC\'V<E\UI-+XAMI5DC(WHB[@TBY!'REUZ@]1P:[6RT![3[5+)K.IW=[.AC6[
MN&C+0*0/]6BH(EY .=AR<;L@ #9HH YW2O!NG:=X3_X1F[FN=7TP#8J:F4E*
MH,;4!"CA2,KGD<8(  #-/\%VM@EO;-J>IW6FVCI)::?/*AA@*$&/!50[!,#:
M'9AP"06 (Z6B@#G?%G@K1O&D>GQZO"SBQN5N(R@4%L=8V)!.QN-P&,[1SQ4_
MBSPQ:>,/#T^BW]Q=06L[(TAMF56.U@P&64C&0#T[5MU1U;5;;1K'[3<[CND2
M&*),;YI78*D:Y(&68@<D =20 2 #'U;P5::M=6>H'4]4L]7MH!;_ -I6<RQS
M31<DHXV[""QW8VC! QCI26/@+0[/2=;TN6.:]LM9NY;NZBNY-_SOC(4\$8*@
M@YW C.[(%6]*\31ZG%J;2Z5JMA+IS[9X;FUW,WR[LQF,NLG'9"3TXY&9="\3
MZ/XE6[.E79F:SF,%S&\3Q21..H9' 8=QTZ@CL: *OAWPFOA^5I'UO6M5DV&.
M-M3NA,8E)RV,*,Y(7DYQM&,<YY^_^$.BW^ERZ0=5UJ#2&<R1:?#/&(8&+[_D
M!0GJ6X)/WC[8ZV/6U?Q+-HCZ??12);_:([IXQY$RY (5P3\P+ %6 /?D8-:E
M '$7&D:V/BGIEYI][JBZ-!:.-0BN+DFV<[=L2QJ<EI,_,S'C 'S9.#M^+?"]
MMXQ\/RZ+>W=W;VDSJTOV4H&<*=P4EE; W 'C!X'.,@[E% &'/X9BN?$>DZU+
MJ-\TVF020Q0[H_+?>,.S_)N).%/W@,J,#KFI+X(LI)]1":AJ,.GZFSM>Z;'(
MGD3%P0YY0NF[)SL9<FNGKC9/B5I$<$M_]BU.30HIV@;68;<26NY026&UC(R;
M@4\P(4W<9[T ;VJ^'M-U?PU<>'Y[:--/FM_LXCB10(EQA2@((4K@%>."!Z5#
M<^%-(NGT,O:J$T202640 *)B,HH((/3((/4%5(/KL-(B,BLZJ7.U03C<<$X'
MKP"?PIU '-^)_ ^C>*VAN+I9[74K?'V?4K&3RKF$ YPKXZ<G@@@;B1@\UJZ1
MI%OHUF8(7FF=V\R>XN)"\L\F "[MW.% XP      !?K)\3:ZGAGPW?:U)9W-
MVEI'YC0VR[G(R 3[ 9R3V )[4 1^&?"ND^$=/GL='@:&">YDNG4MGYW/0>@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.,L5X)VA !D <Y_AKJ/%VFWFJ7FFP-H5GK6C$2B\MKET4QN2@25-RG+*OG
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M99+K[%;O-Y*'!?:,XSS@>IP<#)P:PM%U[5[_ ,,ZAK(U70M1M_L0FLI[&"5
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M%=5CO1!!*G,,T!=1]H\O?E=J,Q,9?),9P?F%8OB/PWXL-AX;O_#=[9V^M:1
M89X)F+07$;*A>/.W)RT2 <+P2<J0*M:CX?\ $VI>!+JRN[O3;K7;FXBN'28-
M]A4++&QA  W&(HA!!R6+-D@'@ 70=?U+7+K7-/M]8TN\,%E#+9ZA96;I#YDA
MF7^*1Q*JF)>5;&=RGD''*> M6\0V'P&FUZ.\L[JXA@NKR$74$C,2LTKR^:_F
M9D+8." N">=U=-IFD^.$\?+K=_<Z&FF7-I]FN[2V\UG0(\K0[69?G8>8,M\@
M.YALX4UC^&_!?C#2/A?JWA"]?0Y=]I);6#PS3+CSC)YC2L4/3>"H5><8..M
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M!B;B-A&O101$I/J<GZ<#->:[-\)M".G:Y>6VIRZ_]E2[DE,C$&\DC42%LEU
MVY!ZA0#D9!] U/PJ=1\36^L1:QJ%B%@6&Y@M'""Y".6C#'!( WR@XP3O&",<
MY<7PULXO"L&@#6M76*"_&H1S)*GF1R [L*61L+O)?G+9/+&@#+\3V&M>%-"2
MY&J:WK.DB_EO=99;D)>+!MRHA=2@2-2H+*F"<G&U216+=:[!=^&/ VHZ#X@U
M*XBF\416TC/=RB012R.YMYP7.\HNQ<L3D#(.&Y].U?19M3NK2X@UO4]->V#C
M%F\>R7=M^^LB.K8V\''&3ZUS>J?"S1M2\&ZCX?:XN3+>WDFHO?R[6D^U,?\
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M:%]I&Y& *G!Y&01UH L5'//#;0M-<2QQ1+]YY&"J.W)-<==^.;VW\(S^*HM
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M*101N4RV9'!Y'T/([US[_&+2FMK.^LAI]W9W%X;9HTU)4O$3S#&LOV=E!()
M.,@@,#C&< 'I5%<W8^)[B?QWJ'AB[TV.V-O:)>6UP+H.;F)FV[MFT%<-D')/
M(]"":5AXWGO]'FGBTR.348-9.D2V<,\CJLBR!6;?Y0^4(3(3MQM')!R  =C6
M>^O:/'<26[ZK8K/']^-KA R\D<C.1R"/P-6;V&2XL+B&&4Q2R1,B2 D%&((!
MX]*\9TWQ)HVD:"_PM\?Z?'HSK;?98[N*,&UN48X2=6(.UR3OWL,!E9B5/R@
M]MHKE=>UC5;7QMX=TFR@MGM[N.ZGE,DS1L3&J@#A2,?O,X(.2!TQS:DU^^ND
MU9M$TV#4#I\K6^U[SRO/E5%9E0[&7@MLR2,,K XQF@#H*KWU_9Z99R7E_=P6
MEK'C?-/((T7) &6/ R2!^-<?9_$JSU71?#USIFGSRZAK[RI964KB,#RB1*SR
M<A47;G@%B",*3D!OB/6;^_\ "7CK3[[1Y;(V.ES;+@,SP7(>%S^[<JN=H #<
M<$XYZD [:">&ZMXKBWECF@E0/')&P974C(((X((YS4E</X UF:^\*>'[33+>
M"XM[/3[6&^N)+@IY4A@1MB*%;>P5E+9*@;@ 2=P7N* "L:\\7>&M.NY+2]\0
MZ3;7,9P\,][&CJ<9Y4MD<5LUYCJFH3:?\?XG@TN\U%Y/#&SRK3RPR_Z23N)D
M=% XQUZD4 >A6&K:;JJNVG:A:7BIMWFWF60+D9&=I.,@@CVJY7.Z=J45W!JV
MNQZ'J$&H0H;66UF"B>40[V10 Q3DR-M(.&# YQC%!?&E];>*_#_A_5=%CM;C
M6+:24&*^$QMW1-[(PVC/0C<#@D<9YP =C6>FN:7)KC:)'?P2:FD1FDM4?<\:
M#9RP'W?]8F,XSG(S@USQ\9:I=Z+?:UHWAM]0L+:9XXE^U!+BY6-RDCQQA3P"
MK;5+!FVG@<9Y^[O-2'QWMI;'2A)<S>%1OAN;E8A /M!;YV4/T("_(&Y8=LF@
M#U&BN=\(>)W\3VNIM-9+9W&FZC-ITT:3>:A>/&65BJD@[NX%6-0\01VGB&RT
M.)8C?7<$D\2W#O$KA",JC;"';!)*@Y &2,$4 ;5%<%XKU7Q)'-X-V6MG:07]
M]"E_:R3;Y!-L,BQAPI78I0Y8<DA<<9ST<>KW]WJ.J6MA86SII\JV[//=-&7D
M,22\ 1M\NV1.<YSNXX!(!M5#=W=M86LEU>7$5O;Q#=)+,X1$'J2>!7$Z/\4=
M/\1:3H]UHUC/<76I7K67V65A&872,R2,S'(*JN&XR2&&!G*B;Q1J6HW/A+QO
M8W^D-9I:Z1*\%RDWF17*O#)G:=HP5*D%2,\@]"* .NL+ZWU/3K:_LY/,M;J)
M)H7VD;D8 J<'D9!'6K%<'X UZ>_\,^&K+2;."\LK?3((K^^^V*JV\JQ1_N50
M!F:0!LD':HZ;LY [2_OK?3-.N;^\D\NUM8GFF?:3M102QP.3@ ]* +%%9%EJ
M6IW:Z?/_ &9#]EN@&>1+K+0J4+!BI09Y"K@$G+9Z US-W\22K:H-,T6ZU1]/
MNWM&BM8+IV9D8!QN6W,8;J0-^"-N2,\ '>T5R]WXHOV\26VCZ7I4$[7&F'4(
MY+RYDMB )%0HR>4S*<.#R,YR"!5*QO\ 7)/BO<V%]]C^QQ:2DT,4+$F(/(RL
M2Q4%V+1C^Z ,8YR2 =1I^K6.JO>+97 F-E<M:W&%(V2J 2O(YP&'(XK%O?B)
MX1TZ>2&[UVUB*0O-O.[8ZH<,$<#:[@\;%);.1BGV.O:EK=EXBCTZSM(=0TV]
MEL;?[1.S12,J(RN^U00/G&5&>F,]ZXOX::K>:+^S_'JD=M!)]AM+NXB5I2/,
MV2RL0WR\=.,$Y]J /6**SKO49X=9L-.M[02_:$DFEE>0HL4:% <84Y<F1<*<
M @,<C&#0MM4\1G2B]QX<C74%O!;F);Y/*>+< ;@-C(7!)V$;N,8[T =!17G=
MQXSU230O&5I#<Z:^K^']/\YKVS^:(RE92R^6Q;:R>7C#,V3R0/NU6\.^)K[P
ME\)=!OM>E?4M0OVB2T8S3327#W#%T5R$9@51N<!ON87)P" >FT5QF@>+]5U#
MQ&FD7>A7AMV@>;^U5LKBVA#!SMC*3("#LQR&()Z#GB+XB7&M17'A6#2[B".W
MNM;@CND?(:4*?-50P!VJ?*;/&3\O;((!U9U:Q&MKHQN!_:#6QNA#M.?*#!2V
M<8^\0,9S5VO/]6GU2+XLZ6+"R@FNI="G1_,GVQ0#SHB7)QN8 @  #))'W1DB
MQH7C+7=7\+ZQ<Q:!!=ZWI.H/ILEG;W@CCN9(R@=T=U&Q?F8@')PN,Y- '<45
MP.D>,M5O/%>H>$FN-$O=3@TY[M;VR+"&&4.(_)EBW,V5<DD[P<8^4&F?!J[U
M;4OA];:CJ=U;SB[FN)D\N HX9IY3(7.[:<L20%50!Z]@#T&LW2=?TO7)+^/3
MKM9WL+E[2Z7:RF.5>HP0,_4<'G!XK2K@HO'.IW?A/QKJUM86:W.@WMU;0122
M-L98$4LS$#)).\@ #/"Y'+4 =[17G]OXP\2+:^$]1N;#2GL==BAA\N.:1)([
MB2(RA\E2/+PK#;R0<'<W2M7PWJWB676-;TC7K?3C<V44$]K+9AHXYTE#CG<S
ME</&R_AG!XH ZNBO*5^)/B9/"OA7Q ^D:7<1ZQ?_ &-K2VN<R.9"XBVN3L0C
M8 P8G).#L(..FTWQ+K'_  LFZ\+ZI;V/E-I@U*VEM2^Y%\WRRC[OO$]<@+C'
M0YX .PHKRR'XIZEJ>E0Z]H^B7=U8L[*--32[J2>9!(R;UN%7R5( 5BGS=&&_
M/3IIO$.IZOXEUC0?#[6=M<:.D37,U_ TJ2/*F]%14=2!@'+$\'@*>M %Y_&F
M@Q^&X_$+7DG]F22^2LHM92V_>8]NS;O!W@CD=:WZ\ND\2:SX1^#.H:YY5A+J
M]MJ-WYRX<P>8VH2(^T9#%<L<9(/3/I74>)]:UK3+EC NF:=I$-MY\^LZB_F1
MJ^XJ(1$KHVXDH0V[')&"<4 =317B^L^,/$'B;P#X'UBS>QLGU76[6WFMVA:1
M6E29BK;MV1'OA5BH&[MOZYZG6O'5S9>*H?"MK+"VH16*W=Y>1:;/>JIR%\L6
M\+;T)R'RS8 *CG<#0!V.IZQ8Z.MHU],T0N[F.TA(C9\RN<*#M!VY/&3@>]7J
MX1]6U#7/ASHVHZMILFFZA+J6G">UDC9"CK?Q*3M;D XW 'L1R>M6-0\3:MIO
MQ2T?P_-]E.DZK!-) ZVK^:)(TRR%S)MQQNR%)Y"XYW4 =G16'X<O-8U :A=:
MC]D6S:[D33TA@=',*.RAW+,0V[ *E0 5PW\6%W* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#G*XSVSWQ7=44 <UJDWB;4%O[33K%+"%],G$%U/,OFB[.!'@*6"H!DD\DG'
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M49!JZUI'BW6/"9%XEC<7LFIQ73:6DNR$6JLN;9I"O[S(4EBRX)9@!@ 5WE%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC</O7=P(GRH//8A23AR^-;B?X<6?BFSTN"[NKOR!#8P7P*EY9EB5#*5 # N
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M2^ALVME2SCCC::/";4_A!P(D5=Q 4<<"LWXC6M[J'A)M/TZQGO+NXN[?9'$
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MU<O:B5GW[4B)B97/R<G(4%@,YSB_H&O0>(;&:YAM[BV:"YEM9H;@+O22-BK
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MM=C110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0!C[W3GIUKI*\%M;3Q(=#^(>JZ1X@;3(-+U_4+R.*&(;II8V1SYC'.4V*0$
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M%/(+AEY&1B:)>V$Q^&,NB7MY/I[B[MHY+H*DIB6!_P!T^T ':T2CI@F-3EB
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M%W@JSO3.L4MQ=Q2&"4QLT9MRSQDC^%]@5N^TD C- 'H4DB11M)(ZHB LS,<
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M17&^./%M_P"&M5\+6ME#;2)JVJ1V<YF5B51F4$K@C!Y[Y^E '94444 %%%%
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M<QCC<.O7CG%E^&?CFZ7P9]HNO#2#PU.IBC@$Z[T4Q$,S$'<S&,Y "^N3N^4
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MR,^HKC?%?ASQ#J7CCPOKND/I?D:.9O-CNWD5G$H"/MVJ1]P<9Z'KD<5UU_\
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M>'(R2-O45K2>%;]?!.D>'[;5;9)=.-I_I,MFSK(+=E=/D$@QDQIGYCQNZ9!
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M6/ R4..N.U9NC_#'4;#X777@Z?Q ID:\\^UNEMMP@19DD4;"PSDH6(SP7(Y
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MDD\8]!O_  A>W'Q&L_%EGK7V18K(6,]I]E$GGQ^8SD;RWRY)7H,_+UYJC8^
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M) 4< D&]X L+O3)_%=K?:A+?SC7'?[1,1O97MX&0'  X5E7   QP ,"HM?\
MA])?:CI6KZ#KMQHNLZ=;"S6[\D3K+;X/R/&Q"D@G(/N>#A2NOX9\,R^'9]7D
MDUJ^U/\ M&[^U$W@3=&VQ5/*J,YVCCA0H4!1@E@#E?B9J\NF:KIG]J3:]9^&
M6@D^T7NC%D,-PS+&C3.OS*BARP ^\V.'QBH/$4.I3S_#2/0M7CEN_-S'J%T#
M,)HQ;$N[#@L70-W!);JO4=GJ^E^(+C6+:]TCQ#%8P1QE)K.XL?M$<QYPQ.]&
M7&?X2,X&<@8K$F^'6R'PG#INK/91:#=&Z?;"2]TS',@R' 0/F3( (P^  !@@
M&9X4O-7TSQ)\0]*NO$$EY%IOD7-K<ZJP*0-+"\C%RNW$8PN57:H"G 7)K%T/
M4[NW^(GA!+/Q#J^J6NJ1WT-_<SW >SO)HE+LUNA^X%?Y0555VJH4GYR>ND^'
M?VCQ?XGUB?69_L/B#3_L,]C%'MV?NTC$FXL06 5L97C>??.7#\*+U5\,S3>+
M[Y[_ $"55@GC@$:?9@%'DB,-@$A<%SDL"0P8;0H!C^$].\:>*/$NL7-QXVNX
M])T?Q&T0MO*7?<^00"KE-@5"FT%1E22Q*YY-_3V\7>,_#]AXKT*^CM;Z6[>:
MWCNM0?[/]F$CH()((T*-\O5B2^[^)<!5Z7P5X+O/"FHZ_>76M?;_ .V+O[88
M4MS#'!(2Q<JI=_O;E'KA!DFLF'X5/!XIN[V+Q-J$6@74YGDT*,8@<L0SHV6*
ME&(.5V#*L5SCJ 9_C'6(=+\87,?B.]\1:79W)@73-4LIY$LH<*6*RJI +LZN
M""&^3;]P#=7JU<=J_A#5]6NM9@?Q#'_8FK/$9K&2Q\QXD54618Y"^%WA>I4[
M2<K@Y)[&@#RFXM=?3X=Q^.K/Q#>2:V(%UEHKF=Q:&#RMQMO)4[,"/^+:&+C=
MN7/$?B;2[#Q+/\/_ !7(=0MY]1O( T":A+LC2:W+D)@C81Y:C*;,\D@G&-Z#
MX=W<5G-H;^)KM_"TC@C35@2.58\EFA\]<'RF+$$!0=H"A@,YU/$/A"36]:\-
M7L&J26-KHMP9S:1192<X4*.H"X 8 X)PYQB@#I((5MK>*!#(4C0(IDD9V( Q
MRS$EC[DDGO7$_!LVQ^$V@_95E6/RY,B5@3O\U]_0#C=NQZ#&<GFNZKDX/!CZ
M'J-W=^%=0CTQ+US)=6=S US;/*3DRHGF(8W[':VT@ ;> 0 <G<>;_P --6G]
MD>1M_L0_VOY6S=MRVW?WW9^S_P"UMV_PU"_B-_#O@W61#*T-SJ7BR[TZ&<#(
M@,D[;I#CD;4#D$!OFV\$9KT?0_#MGH1NYHFDN+V]E\V[O9POG3L.%W%550%'
M    YXR23AI\-],'@N_\,3W=W>074SW"W5T^Z=)F(;S"XQN8/\V>,YP<\Y (
MHM(M="^)VDM#=:K,MYI5Y$(KFZGNTC99+=MP+EBF0<$DA3M0=3ST'BG1]+\0
M>'+O2-9?R[&\V1,PE\LARZ^7M/\ >W[< YR<#!S@\_H?@'4=/US1]8U3QAJN
MJW6G6DMJ4<+'%*K8VY4<G  +%BS,RHQ8;<5T7B7P_;>*= N-'NY[F"&<HQEM
MG"R*4=7!4D$#E1VH \XTR^\6_"BVM=(UFU?Q!X;$T4%OJL#A)+178J$=#DE0
M=N,D!=P7<?E4=#!X4T^7XN:AJC3ZEY]OIELZ*-0FVDR3SLP/S9V9B7$>?+Y/
MRGM))X"U*\N[.#5/&&I7VAV3PRQ6,D,0DFDB8,OGS 9E7(.5*C/RDDL,G4U+
MPBNH>+[3Q!%JM]9216ZV\\-LP N529945B0<+D."!@L'QD#(8 Y66'5Q\/9?
M'4&M7C:TUL-92*6>3[(D6P.;;R VPKY>5W8W%OGW ])(-;F\:>,=#TV:XO+#
M3IO#T>N&VLKEXFDDD;9L>9"KE5#9 7;D\GH!5M/ADT)GTVW\3:G'X6N7>6?1
M@$Y+ON:-9@-Z1'H4')RWS?,:T_%7@*Q\2-97-O=W>C:C9[8XK[37\J409^:'
M(_A(SC^Z>>1N# 'GGQ(TC7M!^&ND1ZQK1UZYL]>@ECD9%BD:((R(@&<R.3R>
MK?,<Y"DUV_P]U"W\5K>^,H-1OG74'\E--ENBT5@(PJE?+!VAV*[R2 <., 9)
M:Q??#?1;_0+#2)9KX):7J7[7/G!I[F=5(WRNP.XG//3H ,  59LO ]CIWCB^
M\56E]?PW-^H6YM%:/[/)A0H)79G.1NSNSDGL2" 3^-FU!/"5W)ID%W<7$;PR
M-!9R&.:6)94,JHP((8QAP-IW<\<XKE4U2SU;X1>+[BQEU#R5MKZ(VNI,[7-H
MZP;6BD+NY)W MUX#@8&*] U&TDOK%[>*]N;)V*D7%MM\Q,,#QO5EYQ@@@\$U
MS:>")+KPAJ>BZQKMY=76JR>9?:A:HEM)+PB@*H!51Y<:(1SD;O6@#G[>PU?P
MC\1_#,$OB'5]937([R._^W2DP1R)&LH:&-<+%E@P YPN0/6N6\1ZS=>&M"_X
M2"UU#Q#K4D.NEY[_ .WR06;(L[;K9(BX!7"A<K&Z9+88XVCURY\,V][K.@ZK
M<WEY+=Z,LHB8L@$QDC",T@"@$X&1MV@$GC'%<IJ'PCM-0T'5M%?7]3&GW5R]
MW9VQ*F.SD;#9'&YQNW_*6"X?IO&^@"GXG@NU_:$\$7#O*;)[.Z2)"PV"18I2
MY SD$AH\G SA>3CCHO#'_(^^.?\ K[M/_26.G'X>Z<WBK1/$;ZCJ<FHZ19K9
MQ/)*C^<@#@M)E,LS"1LD$?A6MI/AZ+2=8UC4UO;NXFU65)95F\O;&57:H3:H
M. H4<DGY1SG)(!S?Q0N[ZVM_"L5AJ-W8/=>([2VDEM7VL48/D'((8=#A@0<#
M(-8U]]KM?&^@^ HM5U&YMX+"74))KS6GM[B]9I&54,D:;VV .P4%01@GA.>U
M\4>$X/%7]F_:-1OK/^SKM;V'[)Y7,R_<8[T;.WGCH<G(/&*OC#P'IWC&2PN9
MKJ\L-0L)-T%[8R^7*JG[RY]^QZ@]."00#D=7G\4>$/#G]FZGJL?E:OX@BLK&
M[2[DDELK69RS!I' 9B%5E#9W#=D,-HQT]W:2>#&U?6[?4KJZT^'29)SI=Y=R
MS.TL.Y]Z22NY4%6"D 8^Z>>E2GX>Z1-X3NO#]]<ZEJ"7+^9)>WET9+GS!C8X
M<]"N%  &..0<MF/P?X$;PVD\NJ:]J6OWUQ%Y$LU_(601[B=J(Q; .1G).<=L
MXH QO"=AX@U'2?#/B"WU --<F.YU&2XU2XG2>)T;S$6# CC;<P("X"%<<@$&
MYHDUSJ?Q%^(6E3ZA>_94BL8X46=E^S^9 VXQ<_(3P<C'//:IO#WPOTCPQJ:W
M-AJ>M&TCE>6+3)KS?:1LV<$1XY*YX))/ .21FM?2?"<&D>*-8U^/4;Z:XU;9
M]HAF\KRQL&(]NU PVKE1R<@\Y/- '#^$[O6M2\,)X,OKR[?7M/U4P:G<F^D2
M;[,D@F\Y6XD*2*5B4Y!(?(X4U#9KJWC_ ,1>-"FH-;_V?<MIVG11:M- ]BZ*
MZ&<QQ !][,2-W]UES@5Z3!X=TVW\3W?B&* +J%U;1VTK@  JA)SP,ECE022>
M$4#&.>?U[X8Z/K?B%]?AO]8TC595V3W6EWAB:9=JJ V00  @^[C/?- &_P"&
M+35;#PQIUGK=S%=:E! L<\\19A(1P&RWS$D8R3U.3@9Q57QT73P#X@EBGG@F
MAT^>:.6"9HG1T0LI#*01R!WYZ'()%8NJ>#)U\5>&;W1KC4+>VTPK'+";O%MY
M&)-QVY+M*Q* L>".IS797]C;ZGIUS87D?F6MU$\,R;B-R,"&&1R,@GI0!QMS
M>78USX=XN[D"Y$PN%$S!9O\ 1&;YUSAL, 03G!Z5R9\(/XN\>_$31KC7]7@M
MXQ:>6@N-Z9DBE<*P/S&-'D8B,,J\\YP,=AI7PQTO2Y]+G;5]>O9-,G,MLUW?
MLVP;-@C   5,?PKC=T;<N!6%I_A?4-7^*'CJ^-_K^BVLZ6MO%-:A8EN5\K:Y
M4R(P)4IPZX*[C@C- '.>'/%.K^)8?#'@_4=3:>&74;^QU#4+.Y)>^CM8UD3;
M* "$<.%8CYF"YW#<:[;2?"\'ACQ]>Z;IDDEOH6NZ?/=/8Q2,@M[B-XD9HBI!
MC#+,/NG(*C! "@;EYX$\/76AZ?I"67V6WTQQ+8/;.4>UD&<2*W=LG=\VX$\L
M#4VG>%X]/N-1O3JFH76J7T8B;4+@QF6)%!"K&H01J 26QLY8DMF@#Q^UT^9/
MAOX*\62:OJ<^MQZI%Y5U-YTOEI+,PD3RE(:0-DY_C?H&V[5'OU<1=?"_1[OP
M!:>#7OM3&FVTOF+()(_.?YF;:Q*$8RW8#H/?/6R60GTIK"XGEF#P&&29MH=\
MK@L< *">O  ]NU 'DWP\MK;PKXOL-#\1:?<6WBV:UNU&HJRRPZHC3F4NSCYB
MX$>1OP<9SR5%<HR@_L_>-[<NLL-EK[1VH&=D2>=!Q&"/E'S,<8'WCZFO7M&^
M'ECI.J:7J$VL:SJDNE12Q6*ZA<(X@$G#$;44L<97YB0!@8X&,_4?A!H.HMK"
M'4-9M[359/.FLH+L"!)2R,9$0J1N)3'.0 Q  XP <3JVAGQ3JWPL2_U;4P=5
MT.:&X:.<$\6H9V&X'YGWE7)SD =,9KHK_P &6=SXZT_PX=0U*/3U\)26+"*8
M*SQI+&@R0O4[@3C ;8 05W*>NB\":/;ZSHVI0M>(VC0?9[& W+/%$FQT88;)
M.0ZY.<_NHP" "#:NO"]K=>,;'Q-]LOHKRTMWMA#%-B&6-LG#KCGD@\$<JN<X
M% 'GLNBS^*?%7C;PS-';7EMIMA9V>G-?-D61DMVS*BA""^XY+<-P #CI!XA\
M-7K>-/AAIFI:S>R7RQ7<5S>07,B-*L4:L<$,"I895F&&(/).!CM/%?PUT7Q9
MJ":C/<:C87P01O<:?<>4TJ#.%8$$'&3SC/O@"M*;P;HLMUH-P()(Y-#9S9[)
M6X#+M8-DDMGAB3R2O)Y8$ Y!1;^ ?!'CR/1+.Y%OIMRPM((6>4Q%[2W;=DMN
M"AW9V.>!N/:L7X@>&-)T+Q#\.Y+.TC%Y_;<$4]XR*)[H[TR\K #>Y(R6/.2?
M4UZDGAS3Q-K;RB6=-9(^UPRR$QD")8MJKT&57D]3W. H'+1_!_PVDEB9+G6I
MH;"Y>>T@DU*79;@CY4CP0452 P((;(&6(XH YB'3KGXG7OCJUU3^R[LVMY)I
MFGQ2L5?31&6VS* "?G;!8Y&[RBI^4 "OXA\--K/B7X<Z-K.L2W<SP:A8WEW8
M73CS1#'@@[BV&;!20]6^8'H .\\1?#+P_P")?$,&MW!O+2]0!)VL9_)^U(",
M+*0,G@8R"#CC/"XN7W@31;WQ)HFN 7-M<:-&8K6*UF,46S& I4= ,GA<9'#;
MEXH VM)TV'1M&L=+MVD:"RMX[>-I""Q5%"@G  S@>@JY110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9^N:S:^'M#O=
M7O?,-M:1-*XC7+$#L!ZGIS@<\D4 :%5-0U33])M_M&I7]K909QYES,L:Y^K$
M"N$UCX@:[X1ETR_\6:%9V6B7T@@DDM+PW$UG(5W 2#8H?HV=F<!3R> UK79_
M&"?$2RCTJ'1GMSI]T8%NKF9-RA[;>7"H0&#$!<9X+9QT(!VMG>VNHVD=W8W,
M-S;2#*302!T89QPPX/(J>LO5[R'PYX:U34H+2,I9V\]X8$Q&)& :1N0."S9)
M.#R2>:P-%\2^(]5N+68Z+#_9M_HHU*UGC<_+,=A%NY/&</\ >XW8) &"  =G
M17FLWQ,OQ\(+3QW#I5L3Y@^U6CSL/D\XPG8P7J6VGD< GKCGH;_Q->S>+)?#
M6@VEO/=VUD;J[N;B1A# QXBB.P$[W/.#C"?, W2@#?O=2L--5&OKVVM0YVH9
MY53<<@8&3SR0/Q%6J\5^('BG4]2\!>%=>E\/W.FZE#XD@==.O,J2Z"4J,L%.
M&P.<#J?3->B^'M:UR\U_6-*US3;.TDLT@G@>UN#,DL4ID Y*J<@QD'(&2#QC
M!(!TM%<[XT\2OX6T..^CBMG>:YBM5:ZG\F*(R-M#NV#A5ZGVS7,>,]=\76_P
M^\43K;V]C=V-R\"W"NZ>9:F-2)HC@_.2^.N 0WS96@#TFBN3D\0:Y%>Z3H+6
M-B^O7:/<7312L;:UMD<*9,L SL=R ( .2<D 9-/2_'EU"OB&U\3:1)8:EH=N
MUY(ML?,BNK8!B)(6.,YVD8..>X.X* =Q5>SO[/486FLKN"YB5RA>"0.H8<$9
M'<>E<AIGBKQ+=R>'+V;P_#)H^MPAVDLYFDDL2ZET\S*C<I7&6  !)'9=^5X;
MUN:SL->T_1_LEUKTOB"]:&RED(Q&;DAI7VY*QJ WS$8) 498@$ ],HIL8<1J
M)&5G &XJN 3WP,G'YFO/[[QOXEETN^U[0?#L5_H]M.8((O,=KN]*RB-V2-%(
M5<[\9RV$R5 / !Z%17#ZO\0(K/Q!%HPETW2YEM!=7<NL7<<0B+ [(54-^\?(
M^8J=J@=6) KG;;XQ7=_X;\-:M8Z"MP=1U0:9?1I. 8)LC:B;MH8NAW YVKT)
M[T >M57AO[.XO+FSANX)+JUV_:(4D!>+<,KN4<KD<C/6N5M[_P <3W&CM>VF
MD:7'/<3Q7,.][AP C-&P(VC!VG(SD84YY*!V@ZM]N\=^,]-CTRQM+JQ^R WD
M:;GN=\3%#*< MM   SQD@'O0!O7WB'1-,F\F_P!8T^TE!5=D]RD;9/(&">^#
MBK5C?V>IV<=Y87<%W:R9V302"1&P2#AAP<$$?A7E'@**ZF\.?$ ZM8Z7>1)K
M=]++9R*9(I+A0C$98?ZL%1@E2>_&,'J;7Q<&\$^&9]#L+.>^UB.*"SLXIEC@
M@81EI,D<A(@C@A03E0N,G@ [:BN-OO%7B#1I->2Y\+7FHI801365QIZ9%Z7P
MNS9EF4JV<D;L*"Q ^4-4M?'>H6_CK2?"6LZ?'%?:IIBWBO!R+>;$A:)QN.X#
MRV^93R<<8.0 =[17FOA7Q9=V6E>.-;\1:DLUGI>LW<(78%(6-8U1(\MM&>@7
MJ6;)8DG,^D_$@7_BO0-(%SH]]'J]K)(QT^Y\Q[.9$WE)!D_+C(#<$D'Y1CD
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M8=LH(!C,3.Y.02P8' Q@C/)Y#5O'^LV7PAN/%UO;6#7T-R\;1R*_E[!=-""
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MUNHDFA?:1N1@"IP>1D$=:\@\(W&MZE\!O%&LZU>PW3ZE:ZA<(XB D($;(=[
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MP$GS<\G'&./2L?4/&GBC1CX.EO1I4J>()8+>2".UD1K:21%Y#^:P<*S9Q@9
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M]-C$T#SEFC _>$ATX);[N.,=30!TNHZC::3I\U_?SK#;0C+N03WP  .222
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MZSX0U#QH_B.YO]/73TO=(33[*VNIP9/-1WE660Q%E4"1EP SY"Y.,[:]&HH
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M-HK82?NI47]WY;LK=X\;L'!^8=&X]0GGAM;>6XN)8X8(D+R22,%5% R22>
M.<U)0!YYJD?Q'\1>']3:WCM/#ER]IY-K:+=":5I#(I>1I@N$Q&&10HZN26&%
M(YVQ\-^,$\3^"=63P=I=A#IL4\=W#%>J'$DBE&DD?YBP((8 ;VSNW-DYKV6B
M@#RA? 6N7^A>.?#E[;6\-GK.HW.HV=ZMWSYC.C1(R;#A<Q@L<YP< 9YKH_"U
MSX[E-C9^(-*L;2.US]HO(KOS3= (0H5,$J<LI+%N2C<885VE1F>%;A+=I8Q.
MZ,Z1EAN95(#$#J0"R@GMN'K0!0TC4[C4)M4BN;6.W>RO6ME"3B7>FQ'5SP-I
M*N#MYQZFN9\6Z;KDOBS3[^RT&UUW3TM'@>TNKM8HXI2ZNLN&5@2-F,@9^8>E
M=G;VEM9K(MM;Q0"21I7$2!=SL<LQQU)/)/>IJ .*^&MAXCTC1+K3-?T^UM4A
MNI9+1X+CS#(DDCN=WT)R#QD,,@$',O\ 8FH_\+?_ .$A^S_\2W^Q/[/\S>N?
M,\[S,[<YVXXSUSVQS7844 >7Q>!M;N?!GC+3"T=E>ZIK<NJ6+L5D &^.2-6P
M2 <QX/4#.?FZ5UOAV]\67<R+X@TBPL(XX,.]O<F8S2Y7E1@;%&&X.X\CG@YZ
M.J]U?V=CY'VR[@M_/E6"'SI GF2-]U%SU8X. .30!PUAX(U./XE:YJ%W+;R^
M%KY1.E@S>9NN6B$3ED92 "IE!P<$,@YQ@6_AAX-N?!'ANXTN\G^T2?;)6CES
MUBSA,#G:#RVW)P7;UKMJ* .+^)7A34_%&AV3Z'<06^L:9>QWUI),@(+)GY<D
M''4'D$$J >#D9^LZ!XM\=>'-5TS7(['2;>6R\J"UMY_.,MT'6197DV_)&"@7
M8 20SDGA:]$HH X/P?%\0;.WL-(\016,L5J["?51=F26>-0=BA"GWB=@+L<E
M0W\1S5OP#H>IZ(WB3^T;=(4U#6KC4+?$H9MDF,!@. 1M]3UKL:* /.=.T'Q)
M;_#W7_"]QIEL"\%Y%9W$5X&\]IWE()4J-@&\9R2>.G:K5QH_B&+X4:3I-E90
M'7+%+()'+*#%OMY(VRS C*GRN@Y^8#U([RB@#B/'.D:SX@NO"R6&G V]CJUO
MJ=U)+.BL@C)^15YW-ACSD#@8SGC*?PSXJ\)>,=?U7PG:V-_I^MIYS6MS<M']
MFN^\ASG<I)9B 5SNQ\H4$^F44 >>:GH/B[_A)/#>KJEEJJVMM(+JREG\F&&Y
M<@M*CE68J,X4%<JJ#'+&LZ/PEXPN/A[X@TF[M]*CU6YU/^T+=X[AS%*YN%F8
M8*Y1?EPN22<\[<9/JE% 'F_B32_'LNLZ+XHT"WTJ'4H[26TO-/N)S+'L=@PP
M^U2>54G&W!  W#-=EX?77#933Z^]L+J>=I([:VY2UBP L>\@&0\%BV!RQ &
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M,=6ZTS6_"UYJWC3P]K\6IP01Z-YNVV>T+F7S1MDR_F#'R@8^4X/)W#BNHHH
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MVHGX>:OKVLZ=>76J7UAY367GR"26*"$QK&A7[OF.)9 4'_+?(+<&@#.^'7Q
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M9(Z].V2)+Z\&I?#+Q9>Q>&9=#MI-+N5B2ZB6&XEQ$^2\2CY #PN6)/)P!@L
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M^++B3XE7?A&?2O)CBT\7\%[]H#><FY4/R ?+\Q8<G^#.,$5DO\2)TNM$NO\
MA'Y?^$?UJ_6QM-0,^R4LW$;F!E!".02IW9VC<0"0IQY='USQ9X^U.[N]&N=)
MT_4/"TFF)-*R2-$9)7*EU! W8!)16; *9(+8$W@C5O&.E6UKX+OO#,[W>FQF
M'^UY&VV30J?D96"_/A"H"CYB1\VWYBH V'5KSPYXJ\?MH?A>YU65;FWN&@M6
M2% 3;HS$D\LS$NV$5V)Z@;@3Z-I.H1ZOHUCJ4(Q%>6\=P@]G4,.H'KZ5S/AZ
M/4+?Q5XWOYM(O$BEN83;!C&#=;+=5/E_/CD@8)('S8)!#!=;P;;7=CX*T2RO
M[62UN[6RBMY879&(9%"$Y0D$';D<]",X.0 #)\1^-KW2Y=772=";4HM&MC<:
MC/-<&VCC.T.(HR4;S'V'>0, #;SE@*L0>-4U6WT@:'I\MS=ZK9O>PQ7;_9EB
MB4H"TI(9ADN I1'#'D';\U<NUYXH\#>.-7CA\/7FNZ1KURMU:/8@#[-,0J.L
MI(^7.$^9F"X7(ZMME\8VGB+3=8TKQ6V@6>OI#;26=_IULC/(BR2!E:($'>5P
MJEL GD[5!.P 6Y^,$,/P^N?$Z>'-2,]I>C3[JREPGD384OO?!*H"VT$J"6P"
MHSPFK?$+Q0EW;QV/A)[:TN-9@TZVN;^9XGN0X+EA%Y19$VKRQR5ST)#!6>,M
M#U[Q!\-M6L+'PM!97FH/ D5C!)")$"2AVDEDW*F"%P%7<1D$D[B$WO'&F7VL
M:3H%];:=++/IVKVFH/8$KYK $JR@APFY=^[.[;\O4B@"KK%U8Q?$_P &QZAX
M<C;6+JWN1%J4=S\MN5B)>,  &4<D9=5 WY')8#/@N?$&I?%>\L=4T+3?LZZ/
M'$\,FHM+$8))6\QT!AY+8"LC!<^4,G&#4WB$:M=_$OX>WPT#4/*@CNFNWCV.
MENTL07:[AL#:1DGHW\&X\5M6MEJ9^*FH:E+ITD6F_P!E16D-V98RLKK(SGY0
MVX?ZPCD?P'U&0#G_  CXI\->&_ ?B"^M]$DT72=$U.>U>!6:669P4 9L\[V+
MJN&)VX W8''0:5XMU*3Q+;Z#KOA^33KN[LOMD#V\S747!Q)&[B-0KKE>F5^8
M?-DJ&XS_ (0SQ'>>#?&^GK97&GZE=:[+J^ER_:8QO^=70 HYVO\ N\?-@ LI
MSP<=GX<\1>(]?N?]*\,2:);VTK1W1O9=S2L%/$ 4 ,H;:?,/RD<*#DE0#G],
M^*]W?IHFI2^&)(-!UK4SIUI>?;D:7<6*HSQ;> S!@<,<;&Z_+NM>&/%OBC5_
MB9XBT2^TBV@T[31$I9;H$PY#,K#"YD,H(./E"*N#\WWN%73O%VI>'M$O=1\*
MZE=^(M(\2QSWES<NGF3IYC';!D_+",Q@[<1C 89&\KWGAZTUG3_BQXDN[K19
MTL-;@M98KL2(R1F"%59&P20=SX'KM8C(!- &E)XRN8Y]/NUTN*;0;^_%C%?0
M71DD!8LB2,BH4$;2  -YG1U) )VCI-2U"#2=*O-2NBPM[2!YY2HR0B*6.!WX
M%>8^"$U30;NU\(WG@;SYM-<*=<1%2WDBW B0.RY+@,/E!)R#TYQZ=J6[^RKS
M99+?/Y#[;1F4"<[3^[);@;NG/'/- &7HNJ>(+N]$&L^'HM.1[99UEAOOM #D
MX:)OD7##(/&0>Q.#CSWP!XXGTOP1X+MSX=OGTR\E&G/J/FQ;4E9RB%4#%BI<
M$$L%QCC=D"M3X=:;Y&N3W>CZ;XGTC03;O$^GZVVU$F'E;#"C,S@;1)N8G'(
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M&UL[PN<H0",U9\=Z;J.H:-9/I=I]LN;+4[6]^S"18VE6.4,P#,0H./4CI^%
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MG]]'E7=D))^7&[@94<CI[&+4!\0-8N)M,ECL)+"U@@N_-C*2-&TK,-H;>/\
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M_'OA#4Q91BTM+>[6^>&Y5EB>2-,+AE#.NY  5 /<A1P>O95=2K %2,$$<$4
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MQ7/$7G2B-F.W<5VM@A@#DJ1D=P* -2BLV#Q#HUSILVI0ZK9M90$K-/YZA(6
M!*N2?E(R,@X(S7(V/B"6^^-LVF6NM_;-+CT(W'V:*1&CAF,T:D?*,D[0I&XD
MC><8#8H ] HJ*YN8+.W>XNIXX($&7DE<*JCW)X%4-(\1Z1KJ!M.OHY7*;S"P
M,<JKN*Y:-@'49!P2!GM0!J45CZ5XIT36[Z:RT[4([B>)!(0JL%=./F1B,2+R
M,E20-PSU&=&\O+;3[.6[NYDAMX5W/(YP%% $]%8^B>*=&\1>8-,O/,DBY>&2
M)X9 /[VQP&V]MV,9!&<@U:U36=.T2WBGU.\BM8IITMXVD;&^1SA5'\_8 DX
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M-6; XR<8&1D\B@#2HK&/BS05T"YUQM4MQIUJ#]HE+<PM@?(Z_>63Y@-A&[)
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M8P)&><'C(!Z@5:T[3;+2-/AL-.M8K6TA&(X8E"JO.3Q[DDD]R2:M44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/^
M._\ DGGB7_L%77_HIJZ"L'QM;7U[X(UJRTVS:\O+JSDMHH5D5,F1=F<L0. V
M>O:@#QWQM9^'[[X ^$H;<P-JS16PTR"S16DGG(59T 4$GDL6QCYPN3G .GXL
M\1V-]+X]LK66/PY);PNE_)=K&+C6)/L\B111[R=L>$!&T%F# KL+$GO/ W@_
M3-(T#1KB?PU96&N6]I'#/+Y$)F$BKL=MZ9SNY.<Y(;GG@;[>'M&DU"\OWTJS
M>[O8/L]S,T"EIHL8V,2.01@$'J  >@P >=QW=M)X%^%,L=Q$T8O[&+>K@C>+
M:5"N?4,"N/7CK6M9>)M T_Q[XQTC5I([>\?R[L/<H L]HMK'N56/W@A$K%?]
MIB,_-CKCX>T1EL5;1]/(L#NLP;9/]&.0<Q\?)R >,=!4>J>%] UNZBNM5T73
M[Z>(;4DN;9)&"\_+DCD?,3CIDYZT <C\#IX9OA)I"12QN\+SI*JL"4;SG;#>
MAVLIP>Q![U5\/3VUG\?O&%K=6K)>7UG:SV4[Q@;HDC59 K'DY;' R#Y1S]VO
M0-*T;3-"LOL>DV%M96^=QCMXP@9L ;CCJ< <GGBH]6\/:-KRPC5]*L[\0G,7
MVF!9-G()QD<9VC([XP: /)?&\%E%\*_B0^G+BUFUU7!R>9-]LLQYY_UJR^W'
M'&*]FM[2VM(TCMK>*%$C6)%C0*%1?NJ .@&3@=LU1D\-:#-I<.ERZ)IKZ?"^
M^*T:U0Q(W/*IC /S-R!W/K6A!!#:V\5O;Q1PP1($CCC4*J*!@  <  <8H \I
MM==TG0_CUXF;Q%<M9RSV%LFF75Y+Y<"P!5,B*6(7F09'&,H_(.06W\^FS? ;
MQ,FE2VCVD-QJ"(MJRE$7[7(R ;> -C(0/0@C@BO2]4T#1]<,)U;2K*_\@DQ?
M:H%EV9ZXW XS@?D/2F1^&M!ATN;2XM$TU-/F??+:+:H(G;CEDQ@GY5Y([#TH
M \YL]"O]2TCP-J/AS7K;3O$.GZ!"WV6X1FCO(&2,;7P?N @Y(!(+*>#M-8_B
MK5;:\T?X<:P;.VTNTB\0@7(CPD$+I.1(V<  %D=LG'&2>]>L2^#_  Q/;P6\
MWAS2)(;<%88WL8RL8)+$*-N!DDDX[FK5UH6CWVG0:=>:58W%C!M\FVFMT>./
M:-J[5(P, D#'04 >?_\ $G\0?'S_ )<=2MU\*?[$R#?-^(^:.7\5D]&Y=8,&
M_:1U,!%4KX>4$C/S?O8SDY/OCC'2NZ@\-:#:W\5_;Z)IL-Y$@2.XCM461%";
M  P&0 ORX]..E2?V%H_]L?VO_95C_:?_ #^_9T\[[NW[^-WW>.O3B@#Q/PO/
MX<TW]F+46NI;0/>)=)*CMYA:\)81#;SA]JQ,  , !^.37;:M>6F@>+? 3:O=
MVU@D.G7D4DES,J(K[(!C<3CJ/6NL'A#PT-5;5/\ A'],^WF02FX^R)O\P,6W
MYQPV3G=U/'/ J[J>CZ;K4"6^J:?:WT"/YBQ7,2R*&P1G# C."?SH \PL-8TW
M5_ _Q6DTZ>T=/M%\^+=54%?LJJ),*S9#LCG?GYR&; R0,_X@^)_# \?^%=9O
MM3GNM$2*Y@2YT>_XAG.P,6:)MP 1U)"D,01]X?*?8$TG38[>[MTT^T6"]=WN
MHUA4+.SC#EQC#%AP2<Y[U7_X1O1?^$?_ +!_LNT_LG9L^Q^4/+QG=T]=WS9Z
MYYZ\T >6SKX$\+V=SK6FF74K#^W+*34+]KUID,J@G<'4EG*%Q,W!#%RN3@JF
MM8Z[H^I_M 1RV&JV-W')X:,"/!<)(&D%P7* @\L%!;'7 STKT#^PM'_L?^R/
M[*L?[,_Y\OLZ>3][=]S&W[W/3KS4=MX:T&RN+:XM-$TV">U0I;R16J*T*DL2
M$(&5!+N2!_>/J: ,;XDZA;:;X*N+B\TT7UOY\"NKS^5'$?-7;([ @[5?:<+D
MG@' R1R%CXAT!?B-JSZGXFL=9MIO#FZ=U$3PE4DE>6)$C!RH3+;&+OM)R6QF
MO5+ZPL]3LY+._M(+NUDQOAGC$B-@@C*G@X(!_"J_]A:/_P! JQ_X]/L/_'NG
M_'O_ ,\>G^K_ -GI[4 >>^"-5O=%U[1_#4.N6>M^'K^PDNM+E*E+NWA3:$60
M# *XW*"0"2&^[MVUTGQ(UFTT3PH+B^TQK^![RW0J<B*%O,#+)*1T164>S':I
MX;-;6F^&M!T:X:XTO1--L9V0HTEK:I$Q7(."5 .,@''L*N7UA9ZG9R6=_:07
M=K)C?#/&)$;!!&5/!P0#^% 'F_AO6M.G^+]Q&/%%IK%Q=:)&$DA>+9O6:1GB
MC"=E!W!69GP22S8S6U\3([:?2]"M;M(I(KC7[&)HI0"LH,HRI!ZY&<CTS750
M:3IMK<17%OI]I#/%;BUCDCA562$'(C! R$!YV]*CU/0M'UORO[6TJQO_ "<^
M7]KMTEV9QG&X'&<#IZ"@#SWXK/9Z;XI\%:YK#W,&B6L]W!=7-M,\<D;RQ#R\
M&,B3G8V=O8$'K@IJFF^!=7\(^*K:TUF2&PNGM8;W6&O9;N/S]R^5EY&8$+F(
M,00-K %EVY7TN^L+/4[.2SO[2"[M9,;X9XQ(C8((RIX." ?PJO\ V%H_]C_V
M1_95C_9G_/E]G3R?O;ON8V_>YZ=>: /-FUC5KKP]\2-$U^.PFU71])\I]2M(
MRANHGMY'3>IZ,,L2 =H+D #&3G1>+-$GTKX4Z+;ZC;3WBSVCRK#,C>04MS&4
MDP<JQ:0  CG#>E>O:;I.FZ-;M;Z7I]I8P,Y=H[6%8E+8 R0H S@ 9]A38=%T
MJVM;6U@TRSBM[23S;>)(%5(7Y^9 !A3\S<C^\?6@#)M9X5^)>K6[2QB=]'LG
M2,L-S*LUT&('4@%E!/;</6N9^!NI64_PQTFPANHI;NW$QGA1@S0YGD*[P/NY
M!R <9&2,X-=]'I.FPZI-JD6GVB:A,FR6[6%1*Z\<,^,D?*O!/8>E%GI.FZ?<
M75Q9:?:6T]V^^YDAA5&F;).7(&6.6)R?4^M '!O!=Z;^T%#>7T_F6FK:)):V
M VHOEM&Z.\?7+="^2/X\#A3B_H<4=GXN\>^(X7$UK(UO"P5@<RV\!\P#'&!O
M5>N0RN#C%=;J6DZ;K-NMOJFGVE] KAUCNH5E4-@C(# C."1GW-2?8+/^SO[.
M^R0?8?*\C[-Y8\OR\;=FWIMQQCIB@#@_@=/#-\)-(2*6-WA>=)55@2C><[8;
MT.UE.#V(/>K'B[5++2/B1X.GOIO*C:WU"-,*6+N5A(50 26., #DG &20*[#
M3=)TW1K=K?2]/M+&!G+M':PK$I; &2% &< #/L*DNK"SOO(^V6D%QY$JSP^=
M&'\N1?NNN>C#)P1R* //]7^Q_P!D_%C9Y'V[RG\W;CS/+_LZ+9N[[<^9C/&=
MV.]<;K=[8V?A[X2^(;R25]$M+8V=W<V5TT;Q/) B<-$P?Y3')N"_W"IZX/M
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M31W$4SY9N!^[4N6SMZ@'M71:TUK/\7UTX3017UWX7N(8_,.TN6F4J,]_NR'
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MB("@$A5W95 %VBN=N]>TW4?V7KBSM;AFFLX[:WF#1.BB7ST;8K, '(49(4G
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M4<%N-C1/$-GX@^/7VRQBO!:OX8"0S3VKQ"=3.KB1 P!V8; 8@ D'&>,^K44
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8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex3-7_003.jpg
<TEXT>
begin 644 ex3-7_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" <6!7@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ]01^!H ]1HKFO!/BJ7Q=HDM]<6*:?<17,EM+:>>9'A=" 5?*+AN^!G@CGG
MU=8UJPT'2[C4]3N!;V=NH:25@2%R0!P,DDD@8 H T**\U\/>.?%WC>!]2\/>
M';"TTE+D+'-JURZM=1@L'V!$.T_=&[YE4Y'SX.V]X0^)*:YK]]X9UFP_LCQ#
M9N5^S-(62X4#):-B!_O8QRI# D9P =Y17E/CSXP7O@+7$TV\\.VUT)H_.ADA
MU,@F/<R@LIBRI^7IR.P)P:NW'CSQW:Z>]]-\,I%@1/,;&LQ%@.O*A-WUXR*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"\[!S\W"YR0#R;X8_$&3P!X5U6X.@W6H02W _?QOLC20;0%=L';E2Q!QR5
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HQ110 8HP/2BB@ Q1BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.@AMH9_N.\DR1@'YE_O^HKS#QM\0_B5X"@L)=5L_#$J7A<(;6.X<(5"\,2P
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M?F'\"I\/?B?_ ,))J-WX=\000Z=XELY9(W@C;]W-L)W;#D_,N.1DY W#(R%
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M$1VM(7$LWF)O0[6E/EC!7)(()RH)P2 #NJ*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC*EF!4\]5#'!(Q@LPYGP]+J'_#+=_P#9;A$D6&X4%<S$1&7]XI4(=I*EQSG
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4L2!GMDX]30!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&<L2!T'RJ HYP!FO/?CB)=-\)#7;#4+VRU**6.".2WU)[<%&)+*(P<.3P2
MV%!)PF" >J;AZT9'K7D_P;O/L_PSE\1ZQJ&I2B/SC+)=7,\R)#'_ '(V&T
M'[F[)R-V<HO.^&-7UGXP>.]0FDU*^L_"NGMN6SM[C[.SJ_RJCE.6W!&W<_+N
M(4C/(![UD9Q2UY?XM\$:II&CRW7@K4]4M]J&.ZT][N6YCD@.XN8T;<XF/RX*
MLIP" 03SZ?N]C0 9&<4M>%?#_P")%YK?QLUBRN-0DETN_$L=A;J2T0,6-C+D
MG9F-7)VX#,<XZ8]6\8Z;J6M^%[G3M(OY=/O9Y(56ZB<H\*^:A=@00<[ W&1G
MIWH WLBC(/0YKYI^+::KX#O](LM%\4^(PD]N\DK3:G(S2/YA.XX(&?FQP!G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,#I7G/@;X5)X"U2>\T[7+B>.XC$<UO/%\C ,"&PK#YA@@$YQN/'->B_P\^E
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3@ 'L!GC.O#\0_#[ZW!H]Q+>6-Y<R>7:IJ%E-;?:/E!RI=0,9)7G!+# '(R
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M2'^]N!DD.[.<NQS\QRWPKIDO@KP)!8ZOJ*W"Z9'*6NV)QY*NS(2#DC$>T8Y
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M7@N)]%EFG2V5(8W<RM^\D^8&4M\V1M)!5&YP2H!Z@*6D' I: "BBB@ HHHH
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M(LF$9GGW$ LO0[B , \XR#S5/X#Z-I%_\.)&N[2SO&.IO*1-")/*D5%"_>4
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MGGFH-!^'_ASP[HLNEV5@K0SPF"XDG8O),A&&#,>@/)VKA06) &30!:\-^,=
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M<A0N,!655'IEK\,?"%G<WTT&CI&+U2)81*_EJ2=VY%W8C;.,%<%<#;MYI/\
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M2I8 E2-IQTI__"!^'_[8OM6%O=+>WZ.EU*M_<#S592I!&_& #@#'RX&W&!@
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M*H /*C)'#!NG3)Z UG_$KQ=+X)\&SZM;013W7F)#"DS@)N8]2-P9N >%R>_
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MBR4#=<;L8)QCH>X]16G7SSX$\=6'@FU\31O;WFHW,FLRN(K,EL0)CS)MI;Y
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M+QZ['R3C&% SNXZ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOK3P%K-OM_X1._:[EERZB95W>2!D@D;WWK\NTJB?C["F@Z;'KTFN):1KJ<L
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M6::W$HW,8DE=YN/F"Y 91G)W#.5P&/MDG@3PS.;4W.CVUT+2/RK=+K,R1)C
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MSR3R>>34FD>"_#N@:G<:CI&D6MG=3J4=X5VC:=N0 .%'RJ< #GZF@#S"P9M
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M3(QROF8;A>6QS@X[:J6F:59:-IUOI^FVT=M9P+MCAC& HZ_F222>I)SWJ[0
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M,-O:P!(R50R95L';\\F4Y'RHN0?;CX<TI]#;19+*.73&01FVF)D0*,;5 8G
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MP"@!(Y.3X)UB;3O&GQ%@T[1KW5+\ZD9$AMYXUAZR8W,P54.[ ;EF.?NML<D
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M/=B2,^1(3@*$+!W&0WS8' ! .> #T:BN$U'XE+80VFJ)X>U.X\.7+PJFJH@
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MB&P>QU>QAO+9L_NYDS@D$;E/56 )PP((SP:=I6C:;H=D+/2;"WLK?.XI;Q!
M6P!N..IP!R>3B@#S#P(]L/CAX[4&)I2$92X E R-X48/RY(R=PZ+E23\M;PY
M$^L3_&"SMYWN;J>6:W1I1^\R4E14P-QV*<JO)R!]U>E>E0>#/"]M(9+?PUI$
M3E60LEC$I*LI5E^[T*D@^H)]:L:=X:T/1[EKG3-%TZRG9#&9;6U2-BN0=I*@
M'&0./84 <9\)?%&BW/PNM&2:"W_L>W*W\7 ,.W<3(P"CA@"^<'G<"2P8UF^
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MA@C/!IFC>&]&\.I,NCZ7:V0F8O+Y$04N<LPR1S@%FP.B@X  P* .'\/W2?\
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M/P;(/A"-"\26TI2^:5GM+A"K0*QPHPQ.TY4., 8+ XR"3B^!/[0U#58? M_
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MK=)=F<9QN!QG _(50_X03PAC_D5-#_\ !?#_ /$T >0_#2WUF6T^(MIX7/\
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M.&'UZ@YP01R" 1SBJ$G@WPU*EDC:!IP2QE::V1;9%6-V&&(4#'/!Y[A3U4$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M()C*.XR"@/;^$CL: +&J^,_#.B27$6I:]IUM/;IOE@>Y7S5&W=_J\[B2,$
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M5Y9RAS/'L9"K8(^894JQ!(V =#4=]XV;[;<6OA[1KC7WL)UBU$VL\:+;#!+
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M=&T&RL]2U.01>3;P1,C2F.-!ND=G9%51\HSD#+J .0*I>&_B#:ZYKMUX<O\
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M;]X)/ ^4@\X)VMMU)7$<3.02%!/RJ6/X <G\* ,R_P#%/A[2KHVNHZ[IMG<
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MZH LS[6\N13N).U\!CCBM\6/ _AZP\(6\^BZ7;6.LI>6\.G?9(EC>>5G "'
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M"0L,Q@R, [! Y(!X(53@L2H!UU%9'AKQ#:>*/#ECK5D&\B[CW!&!!1@2&4Y
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M$J[L?$OP6U>_TR>2ZLY[=)XI;6+S"0LBMRI(( *G=GE &)'RXK4M_$6F^%/
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M.W*_=)% 'F>O7^B^$)_AUKVFZ?<6?AVRN[V#R[E95=(YOE,N&#.5QOD /)!
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MF?9;=(M^,XSM SC)Q]3535_"/A[7M0MK[5=&L[VYMU*QO/$&^7GY6!X9?F)
M.0"<CGF@#B_AO/;Z9X9\1^,K^=K;3-6U&YU.)92^Z*#>P!9,E0QP?N DC;RW
M ":=XI\,^+-1M]?UO5=/L[&QN)1H]G=7R*LQ5BHO&1B#N[(K+E,,>2P(]'O-
M/L]2LGL[^T@N[:3&^&XC$B-@@C*MD'D _A63_P (+X0_Z%70_P#P71?_ !-
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M$-9%O<M;3_8)_+G7?F)O+;##8"W!Y^4$\< FO-/A1=V4'P+NI)!;P)$+I9Y
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MJ-E;7EN2&,5Q$LB9'0X8$4 >4_#A"W[/-UM9T9[6^^:/8K _.,J<CGT+$'\
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MHE6.= K,S(?,X"L=JKAAE21P&[J7P9X6N662?PUH\KA%0-)81$A54*HY7H%
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MJN15>]OH=/LWNIEG:-,96"!YGY.!A$!8]>P]^U<+8_$;4+V+3+(>#]0@U_4
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M-PRISFJ5S\0=0T_X:+XLGT*2ZN S^?:0.8A:@3%-LAD ?<H^5B$(W*QP%.0
M=U8WD5]86]Y#O$4\2RIO4JVUAD9!Y!P>AJ?</6O._$OQ$O\ 0O#&@:I'HWG'
M4S:"2X9B+>+S1N=<*#,3@''[OC(/S$;#!!\2=:A\8:3IVL^$Y-+TW6F,=A--
M=(9^,G,D8^Z3OB&PX*DMRW0 'IF129'K7)>(_%=Y9^(+/PSH=A'=ZU>6\DZ/
M<.5MK:-0P$DI0,V-X"@8 ).-P-8WAOXEWNK>-Y/"%]X<EM=2M6F^US1REHD5
M NV10RJQ5R>..C(1G<< 'HVX9QFLW7-<LM TV34+\W MXP2S0V\DQ4 %B6"*
M=J@*<L< =S3/$5WJ5AX=OKO1[6&ZU"*(M!%/,(XV/JS'   R>2,XQD9R/*?A
M[KFM^(/A;XFN=2M5E66*\:2_GD0O<2F/H(MBJ4"X7+.?NA1A0 H!ZKX>U^Q\
M3Z%;:QIS.;2X+^69%VL=K%3D?536O7@^@?$+7O#GP=T34[/0'O[*T0QWMW<3
M^6D8%P$14W$L_P GRY4%5)7&=K(/3M0\;6\?AG2=5L+87,NK^3]DMIIA$=K@
M,S.0&VJB;F8@-@*>W- '4@@]#2D@=:\\T_XCS6?C>/PIXFMK*WO;QBUE<V%S
MYD&TEP(W9]I#@ILX'S,>B\9[VX:86\C6R1O.%)C21RBLW8%@"0/?!QZ'I0!S
MVN>.=(T.[N[>5+VZDL8!/>"SMFF%JAZ&0CA<C+8Z[06P!S6GX>\0Z9XHT6#5
M=)N/.M9L@$J5*D'!5@>A!_Q&1S7D?PKU'7[GXA>.)7L()7FU*-+WSK\YM55Y
M@ A\L^8% *@?+T7H#D=G%K6H$WEEX"T'1Y]+TB41R'[4L*3R%#(\,"QJ55@7
M3+/@;F88X) !VE]>PV%G)<S+.\:8RL$#S.<D#A$!8]>P]>P-<_:>/=!O?"Y\
M1Q27ITL.Z&;[!.V N2S$*A.P 'Y_N@\$@C%/\%>,;'QKH7VZU22WN(G\J[M)
M?OV\H'*GID>A[CK@Y \^^'*VQ^ 6M1"UDE18[])(XE\J:;Y#P?DP'*D#/[S&
M ,G&U0#U30-=LO$>B6VKZ>[-:7()C+#!X8J<CL<@\5I9%>9>!O$5EX5^!FDZ
MOJ;N(((&RJL"[GS&PJ[GP3Z#(^@^Z+=_XX\0>&)+&\\5:#9VNC7TT<)FL[TR
MR:>64<394!_FS\R'  (^8XW 'H61ZT%@.IQ]:XCQ3XUU+PUXDTG2_P"R+.:#
M5YS;VEU)?2(!)A<+(%@;;N9L+@GU.!G!-XUU:#XD0^$6\/PK'.GGPWTE^0)8
MA]XJHC/SC!^4D=.N"#0!VS&N>\(^-='\:V5Q=:0URT4$GENTT#(,XSPQ&#[@
M'(R,XR,PCQ'JS^,+_2(- 2>QL;=9WO([U=[,RDK$L94 2$@\%P N&)&0#@^
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M-W '&>:,CUKQ^]^+VN#P-:^)].\*>;9QLGV^ZDG"0#YD4K$#AW.6VEMNU6!
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MW ZYZ8.:XO4OC!X9TF."6^35((;E/,MIGL9%CN%(4AHR0-PPRGMC/.#Q6?\
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M1S!B?G#!68JBXW.%*'&5/.U9_#WCO5KOQ/J/A'6M)M+?7[.U\^*2&Y;[+=G
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MM]P_(0N58$%P#Z"W#UHR*Y%/',$OP[@\5QV;O)<P!H+%9 7EG)VB%3U)+\#
MS[9XK#OOB5J/A[Q3I6F:_I-@++5YQ';WNGZCYRPY"##AD3/+JQ;Y1L<8W$'(
M!Z71110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 9'BJ[^P>$=9NP6'D6,\N59@1M0G@JRMGCLRGT(ZUY-KV@R:A\$/"WB+
M362'5/#UI%?6\B1AAM4*7!4$KG*JY)!Y0Y"Y./:KFTMKV,1W5O%.@.X+*@8
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M;I%%=2+NW!=H&X+D?-T.\[2>:K_$_P )/XR\#7FG6T8DOXF%Q9[FV_O5SQU
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS8';<?6@#Q_X2>)=)T9==\-WK/;:E#JMY//%M#16T**-SM(B)$B J5Z 9Q@
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MV2$SE0/()+;!A0 "26QC&"2>H!ZGX6\>:;XIO+VPCMK[3]3L\&:PU&$0SA"
M0^W)^7D?3(SU&<_Q-\3+;PGJ%K9:GX>ULR7LKQ69MT@E^TE2!\BK+NYW+@$
MG/2N8\)Z<WC3XHM\1K2&"/18X6M[4S-F>60+Y9<*K83JP^?)VX^7)!6?XNR;
M/%'P]PH=O[9C81C&]L/'T)(QUQ]2N2.X!JZI\6[;1;=KG4O!_BRVMD1':>2P
M01J' VY;S, _,!@G(/! (Q72>(?%EOH%YIEA]CN[[4-3D:.UM;55W.$&YV)=
ME4!01U/?TR1%<:T]SJ5KHUUX?OE@O3Y4[744;PE&BF8J2KD$_NL$8(PR@_>%
M<;\1?"_B./QMH_CWPY$M[)I4 CGT]<++)&"Y8(2"&W)(ZXQN'!4$G  .A7XA
MM!K^E:%JOAK5M.U'4B?)WJDT) SN^>)F.0!DC;QD%MJ_-6_XA\26'AG31>7Y
ME;?((8(((S)+<2L#MCC4=6;&!V]2*\[\-_$/PK\3M1T2VO8+BPURSNS=6UIE
MF#NB/TE51E=OS$';DJ!AAUJ2ZA<ZU^TS%IMW(QLM'MM]M "=A=H=V]E.1N_>
MGD8^ZOI0!V$OCZ\L+-M4U;PEJ]AHP5':[D>%GB5BHW20JY=0-V2 "PP>/39E
M\4VLGAN+7M+MY]7L9$\P-9-&"$ )+'S&3&",%<[@>,<'&U+'')$Z2(KHRE65
M@""#U!KQKX.*VFW?CWPZDMQ+I^E7ICMP?WD@&Z93A?NDD1J<!>3GB@#L_!OQ
M)LO',CG2=%UA;6-_+DO+B.)(D;:3C/F%F/3A0<;ES@'-=;=W$EO:R2Q6LMU(
MHR((2H=_8;RH_,BO*?V<Q_Q;[4/^PK)_Z*BKU[% '!^&_BE9^*M8GTS3?#NO
MB>U<+=-/!%&MM\VT^83)D$$'Y<%OE. <&MOQ?XKC\':&^KW.GW5W:Q.@F-N4
MS&K,%R0S GDX&,\]<#FO-/%UU<^ ?C=H^N1"--*UY1;74<8"[B&"LS  DE2\
M;Y')P5SU-=MXGLK?Q)XS\/Z)*$F@T]SJUY"X(! #1PD'^(^86.WIA6W?P@@$
M>N_$K_A&M-BU/5_"FO6U@Y"&4_9F97(RH*+,2,@'DXP<#O3;KXER6%K=3WW@
MKQ3 MG$TMRXM(VC0*VUB'\S# 'GCJHW?=YK#_:#VCX;Q;E4G^T(MN9-N#M?H
M/XN_'X]J['4O$]Y8FR5O#FK*+J^BM/.*PR)&&<+O?9*2JD$X..#C.,@$ SM?
M^)^F^'/#^F:]>:5JCZ9J,44D,\(A.&D0N$93(#NVJ2< K[FJK_%B&/2I=3?P
M9XO2RA 9Y6T]% 4JS;N9.5 4DL.!QDC(SF_'2.*R^%#6UND$$"7$$21*R( H
MZ*BE3G&!\J%2 "<[05/H>AC_ (IW3,?\^L7_ * * &Z'X@TKQ)IRZAH]]%>6
MK';OC)R&&"00>5."." >16G7@/AR>7PQ^TQJNB:>JQ6.I%O.@#DH,P^>& &
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M<7 V;@QDP/F&QN%PO+*6) 82WGQ U[P_'I6@>)M2T;2=:DM9;BZU"1))T$2
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M;@J&S\VU>1\W4KW(Y%>)_&JZBN=9^'\\-T\MI->F119J)FE4M"0\:X9)#@\
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MNY(YV#K-!O\ Q6WB=;;4IM+U'0;FR>ZM-2L('3<VZ/"M\[*!AVVX)W!<YX-
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M_'*@@$@Y(4J<DYWR_%;4;6;Q%X&N[:<W4%EJ@N+DVI:811J\9+,J ]@<=^H
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M8WL[=K(03^9"8PTABSY3/&S)(X8J,N<93:,E4)UO'VN:AX)^(FE>)8=(FO\
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MC\'Z1>>$?%$=[8ZK:73/!;O#)*9D8J-L*KN+'=EL(,$-N&?F->UX]:-I]<4
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M/%:W.8C&IR"V-J18Y1<H!T&0!L%4-.T:]U3X%ZG#I]GYVI0:DU_!:_8((7D
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M%L%V#D?+QVSU'09(PU^(YM/BSI'AZT\0VNK:+?PGS;AC%(8YV+[(U:(*.HC
M!!^^<GN #US=SBDW5Y9%KOC2\^)VI>%(M<T?;#8+<^?#9D?9V+1]8F8EFP<8
MWXQ)NSD!*TO GBG5[KQAXE\*Z_>6]S=Z8R/;2);>0\L;9W';DC:,QX_WNI[
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M[<R P &:+9(J*5*KM(58OG5<, <%LJPP/AO;>)M1U;QO%HVL?V9:#59&%Y+
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M4J2X !)5A7JE% 'D>B7LS?'+6-7DT354TZ]L8K6VOYM-NUR_[K*X*X12<Y+
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M6 *E57Y@Q(W#<H&!U.>O^+?AZ]\0>!I3I9N/[3T^9+^T%NQ#F1,],#).UF(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUE*HQR$4C;C:Q<%=QVEB6 /6]WL:-P]?:O)_#'Q(U.'X-ZCXGUU'NM0T^:2
M_NTC,CEU5-RK@* S@'@' )P>^GK'AOQ[8P65_H?BV;4=666**ZAOXXHK22+<
M<D1JF5(SR0VXJ#@DA10!Z*>1Q7"3>+M?LOBQ;>&[G2;=-#O8V6TO-^)9'6+S
M&;&>5!!4C Y(.>0#W49<Q*9%57(&X*V0#WP<#/Y50BT.QBURXUGRM^H3Q+ 9
MG.2D2\A$_NKG+''4G)S@8 .<\!^)O$FO7&K6_B3P]_8\MNT<ELN2=\+EP <]
M678<D8SD?*O?M*HZ?H]CIEQ?3VL3+-?3^?<2/(TC.^ !RQ)    48 '0"KU
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M._"NQU?0/!^G^']7T2[M)K1)6:X:6!XG+3,P5=DA;.&[J!P>>F>^I,#&,#%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!DH<QL(V57P=I89 /8D9&1[9KS&T\>^*-1^(>K>$+33M+$
MVGQ-,9[EI8@Z#;@A1N(R77\.>>A]0)Q7@-A-KD'[0/C#_A'+6SNK]K)\?;+D
M^6@_<G)*C)Y 79QC/)^4F@#TZWUWQ'!XU70-5LK)+>[M9Y[&^M!)(&:-E&)$
M_@^5@3D[<L%#$FL7P/X_UKQ3XMUG0KRTT^U?2'*3/#OD$A5RC!22N.AP2/PK
MJ/"LNL3#6&UM(([H:@P6*"5I(XX_+CV!2QYXY. G);Y037 ?#%)C\7_B%)+M
MXN<?Z.J>5@R/MW%#C?M R#\V=^[Y@: .V^(7B._\(^$;G7;.&WG6U9/-AFW
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M.<@9*\L(]0T7Q5IWC71-8\+Z3KPM!\NIVVIZPLD4B'@<-.S%E#OZ@%5(!YR
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M<EN"@SAA5SXH^%)[#X3KJ6I7MW+KIDB>_<WS^5([D;U$1;9@'9@*HXC7& ,
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M1)R,"O+]8T+Q1I/Q7N_$?AS18=034],6U>:YN(XH[>;< '8 ;W15C0D#).2
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MQD]:YGPW\-_[&UR'5M2\3:UK=Q;!OLJ7URS)"S*59@,\DJ2/3D\9P1W(&.E
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M?8]Z,4 >"^,-"^('BGP=X>2'PA8V!TR:-5M/M$<S/A%"MY;C:L0Y!1F8\\C
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M?A"Y\9>$6T^REM8[R*XCN86N@3&"N0<X!_A+=CGIWS6QH/AR+1?.N)+V]O\
M4;I5%S>7<Q9I,,[* OW8U!D;"H  #WZUM4 >4ZA#XO\ &_@NS\+ZMX:N+*6Y
M\N+5=3GNH0D?E2(Q>-$R7WA#@;54%A@D<T_XQ>%=7\1^$M-T#PWHK2BWN8YA
MY<D,444:1N@0!F4C[PP ,8'X5ZEM&*-HQB@""QN);NSCGFLI[.1LY@G9"Z<D
M<E&9>>O!/7UXKRW7] \667QKM?%&G:5%K-A);+;H9YU@6RR&#8;)8 ?,Q;8<
MB1E S@UZU28% 'E_@'0_&&C>/O$<NL1P36NH/%<S:@OW6D$>3!&"WF;%,H"L
MV0%A(P"_R^HT8HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&^H'UKSYO
M&VJ>(O&=[X7\+QP0G3'!O]4NHVFB7&,Q*B[<N6)7EAPCX[$>@M7CG[/L\-UH
M_B*XGE2;69=2+WDH8,SJ5!4DC@@L92"/>@#I-9;QUX6\.WEY#JUGKJPQ"21K
MJW2VFA ">8ZE2(V4 2,%8#&1EGV[6[X9SUI'1)86CE571UVLK#(8'J"*\MUS
MQ'JNK?$#6/#EOX>GU6QTVR\N6VAU!+<3--&'W2;F4%?NQX&<!W8[LA: /5:0
MY!ZUX]X9TKQI80>+CXB>XT[P^UO+-8";5B9K3&XH$E0OL14^\2#R%(#<BH?A
M5X5/B3P?HNNZGK>N-/!>W%Q'''?2)&Y+,"6&.229264Y/F,"3T !ZCI?B"TU
M?4-5M+-@_P#9DXMIG#JP,FT,0,$GC.TYQ\P8?PFJ6AV'BBTUW59]7UNWO=,F
MD9K*U2U"/;KN)4;QC/RD Y!)P#D<[O.?@-I<-O;Z^'@O+:>SU1H_)DNR=F$*
M[)%7:K$9.21@G! !6I/AW<27'Q?\<6,NL7MU%&&BBCGNV+*BRMPHRQPA=E#;
MU(W<KECL -^37?$7B_Q/XCT/P_JL6B)H9B0SM:K/)<R.LG4L=J("!P%).,Y&
M<5M>$;#QO:RS2^*]:TZ]1X46."TMRH1UX+[\*3NZD%>I^7:!@\;\.]*M_P#A
M9/CQ!)>?Z)>6IC/VV;+$"3'F'=F3_@>[-6]*OY=,^+GC.+^U9;J"UTR&>*QD
MNY&V8121AU/<YW*V!YHX8L=@!ZFN<<]:6O*/!>D3>._ABFIZQJ^H2:OJ*S&.
M[-PZBU=)6\LQQQE5&UHU?U) R<  7=837= \$^'%U[Q;96*6=S'_ &M<EI!)
M=QH2PCC<?.7(7! &Y^3D<JP!Z4>E9-OK]I<^)[O0H6#W5I;)/.0ZX3>2%7&=
MV<+N/' 9?[PKS30M5.G?'"?PY9/-;Z+/I:K#9W$TD8WJJX:-""00JE<'9\H)
M'10:7PVTW3_^%O\ C1+<7*K:3*8V6\D&Y@S!O,'F,9<MDDLQ&<DJI(50#VZB
MO#M(NO%'BWP?<:C_ &!JUW=ZA)=7-CJ$&N1I'9R%2D(B3S%*A275@>?O?>WE
M1Z/\.K;Q'9^"K*W\5,S:K&7#F242R%=QV[V!()QW!/&,\YH ZJD/0UYWXCU6
MZN_C!X>\,IJ#VME]BEO;B))GB:Y/S!%#(<DJ8RV,@%0P).<5G:Q(? ?Q-\*V
M^GW5Q'HNM&6VETX2LT:3 \2KO? ):5<@8SM)PS-0!K^+?%E^/&FD>!M'N&T_
M4-2A>X;4FA67R$59"H5&X8EHR#GH.G)RNUX4LO%6GQWL'B;5[;5?WP:TNHH1
M"Y3'(=%4*.1Q@GJ>:\Z\16$+?M+>&82]SMETZ20D7,@8'%R>&W949'W00,<8
MQQ7LMM"MM;QP(TA6- BF21G8@#&2S$ECZDG)H R_$OB"U\+^'+[6K[=]GM(]
MVU<DNQ.U5&/5BHST&<GC-8WPQ\6MXS\#V6HS3"2^B)M[TA-G[U<<XQCE2K?+
MQ\V.,8%7Q?<6%_XT\/Z9>?:I(M.+:S+%;VDLQWJ"D'^K4D?-YK>A,84@[Q7'
M^#=8ETKXZZYH_F7L.E:TCWUK!<6SP!YB%<N$D 8<+*I.!DJ,C@8 /;**\E^-
M#WEK_P (Y)9:EJUA]KU!;2>2"X86QC;&1(G.6XX&T@@/D'@5#X^LKG0/&?A9
MM#U74[%]:NS8W\IO6E#1%EP 9F959=\I0!>K''. 0#V"BO*7MG\.?&[1+#2[
M[4FLM2LYI;VUDO7G5G1& E?S'=LG8B D*/D4!F^90R'5]3\2ZWXB9_#6J:I9
M6^I&P5+;5TAB@^SNF'53(A\PDR29XP4B /5P >LT5X?%9^,]$^#?B"7Q9J5]
M::C;,9+*X_M5A, =G!="X(+#:%/)W$94$,&>+H;S1?@IH7B"UU?5!JZ0VD@N
M#J$@4;UR0(PPC( <J/E)VCDGDD ]Q;/\/6O-?%_B;Q#I'Q1\*Z3'>I%HVI2D
M,D<4<;/C:-K2R%@W/.$"L0VT98J:@\1>,I]1\9^"?#=I=/;1:DB:C=S6DWRR
MQE6*1I(2I*,5;/R@D;<<_+6-XKT.P\._&'P')IW^@PSLT9Q,Z@E0J!02K#E2
ML>T=1A24&U@ >V45Y+;6LEY\=]2TDZWJ9TZ#21,UJFJ2':[;%*]FCX(?"L3G
M:=W.P4?#$%U<?%OQ-X4N-<U4:/9K]JALC?3I*S-L.X2AB^P>8<C>-Q93@\X
M/:**\G\*7VH^%K'X@PF349[#0&9M.M[V+$<:+$SK&DA=F9<;!@GA=C<%R!@W
MNG>,=;\ Z:NG:%K5SK8"7%OK<FNQ KO56=XPLO ;?)&%P/DVDG/  /=J#TKQ
M_P <-K"W'P]$^JW6FZS?W<4%]';W^T99$64I&0R$KD@$'@L,!]WRFJ03^&/C
MSX>-C>74=CK-NZ7<4]S/()G028RS[@<;DVJIX[A0P+ 'IJZO&?$?]C""<RBT
M^U-* #&@+[ K'/#,0Q48Y"M_=K2;@9KR'2-(TMOCYK]K&+P2)ID3O*FHR*Y8
MM&Q#'S"[C&P#E% 7:4.0Q]6N[5+VSDMY6E5)!@F*9HG'T=2&'U!H KZ1J\.L
M1W<ENL@CM[N6U)=&7<T;;6(R "-P894D<=<Y T:\;^$SZ3I7@#6]=CCNEMM/
MU"\N3'!=$HZ)&",1"0J/DP KLYR VXY4BY\/K27X@>#;C7=?ENGO[NYG%K+N
M>-+5-RE1#MD^ZLB*P)PVY .=BM0!ZQ67K&L+I*V(,$L\EY>16L:1#)RQY8^R
MJ'8]<!2:X#X(>-;_ ,6>&KRWU69KB_T^8 SL1F1'R5W<YR"&&< 8VXR0<0_$
M_1K-_&_@?4)+3?)-JD=O)<+-)'(N"#&JOS&JAMS%>'8CY,$N0 3^-/$_BC2O
MBEX6T:TU&WM](U&9=RBV 9P&4.C22?(<]MA#?/C:3L+>HKR*\+^(VCVS_%[P
M-8037GF%%1FB<W%RB"0D,2_S #YCYA=BH5F"@K\_2VH'AKXWP:19W4WV'5-(
M:>2"ZU&69I+A6(W@2%B7\N-5Y*C:IP?EP0#U"BO%-)U;6?&#>(;RZ\-W^M6<
MUS/:1P0:O'!;VZ(FQ4"F16#.'?S'/8J5!!VCL_A=:^++'PD;3QAYOV^*Y<1/
M/<+-(\1 (+.&;)W%QR<@ >U &WXN\5:=X,\/2ZQJ;2&%'5%CBV^9(S' "AB,
MG&21GHI/:N=LX?'GB?2H=1;7[3P^MS )[6WL[$7#H'*LHG,OWBJ9&%"?,Q/0
M 'BOVDA?C2-!V;_[.^T2^=C[OF[1Y>??;YN/QKVVT:!K2$VVP0% 8]@PNW'&
M/;% '):'K'B4?$#4M"UM;6:W73X;JVGL8F6)!YCH=^[)#N02%W$ 1\$G)/:5
MSWC/4SX?\,ZCX@@M()[VRM9/(,J]-Q7C(YVDA"0",[1[$>5O8>,=5\&VTNG:
M%K+ZX]I');Z^=<BWR%VCD==JR@"(YD"KR,+'D9/R@'NM8WBCQ!%X8T1M2EMI
M[K$T426]N TLK.ZH%1<C<WS9QWQ7G'Q$_M&/Q!\/HIK]K?4;V[\JZ%I>R1QK
M(R)&TD2DXRN]]N>N0&5PQ%97Q=\':7H?A"WN7N+^^:36%VF_U%V>*.0,7BA9
M\JF2,EF#'@EBQ P >L>)K/7[ZPMH_#NK1:;<K<J\LLL F5X@#E,$=R5/;IUK
M+^)/C<^ _"CZHEK]HN991;6R-P@D96(9^^T!2<#D\#C.1SGQ?MI=(\$P3Z??
MZQ:XOXUF>.[F=?+?=N$K%CM3YNNUAD*N,'C._:+MT/@C3[@F0R#4HX\>8VPC
MRY3]W.W/OC/OB@#9O_#GQ4CN2NF>/+*>W<8+76G11O%\PZ!4(8[<C)P/8=1Z
M-;^<L$2W$B23A )'C0HK-CDA220">@R<>IKS+XR6;:5\+[^6QO-3C;S45S]K
MFDW(Y5&5RS\(1CCD9/3+$TS4]>U,_$;P3X->ZO(;>6P-W?2).1)<,(WVJS;$
M88:(DD!=V_E5P* /5J*Y+2/"4VA>,I;W3+CR-!FT\0R6'G.P%PI54D4-D >4
MH3@CA1P>WFFOI+%X$UFZ;5M5U77K/4)YK?4M)NIKE+$8!(W918E"'8R@L5#E
ML$#"@'LNNZQ'H6DSZC+#-.L10"& !I)&9@H5 <98D@ 9Y.!WK3KPSQ\@UWX)
M^&]:OP]Y.?L9N&%U*@.1M=@0/*20GC?(I50S#).W/1_$;7;[PR= \/:+'=22
MZW?$/*U^WG!5>,M'&\C?*S[]H). ,@#D8 /4**\AMM-\6V7BK0;O0O"MYHUA
MYX35K>;5DG@DB,<,>Y4$N 8PKA=J@X1#@Y*#N/'GB2?PCX)U/7(($GGME7RX
MW8A2SNJ G') +9QQG&,C.: .FJCJ^I1:-H]]J=PDCP6=O)<2+& 6*HI8XR0,
MX!ZD5YMX<TK^W/A/'K][J4MQK\ME+,FIPW,NZ.1?-$>,%<% [*5'',@Y#,35
MTG7I/&_P&U+4M1DG-_8V%Y!*\=PT:RNL+89E1_FRI4D./O9( &#0!IZ?9_$#
M5[71?%&G>*+3-W!YSZ5>6W^C)',=X 9,,Q1?+ W<Y5OF 8BMWXA:CKNA>';C
M7=&OK:);"%GFM;FV,BS_ #(1\P8%2 &'?.\]" 1-\/;""V\$:!<(]P9)M,MB
MRR7,CJ,Q)]U&8JO3H ._J:B^*>#\+_$/?%J?YB@"7X>WNNZKX1T_5=>GB>>[
MMHY$1(!&0N"0[$,P8N"&XV@9 VKR*ZNO'S&VG?LXVUU'>3:?<6^FK-#-;7;6
MQW,P8<I&N2Q(&"IR6QO.XR'#\=:=+X>^%/AKQ%%K&K+KD+6[1W#74A +Q-N1
M8V951=O'RIN(7# Y8T >^45Y/:>)9/'7Q-D\-7)":-:Z.+J6*TN&:.^:9(3A
MVVJ3&!+P,*3CGABHWFTJ_P#!">+-<M=0-SI'V22]M].G,CF&=59W(=G.%=MS
M'CDMVV_, =U17F'A'0&\6_#+3[_4-7N9];N899(=4BNYBUK*VY%9 &7:5&%9
M5P"0P.023R%YXQU+6/V>QK1U2^M]9LKH6KW,-VT32-YB]D)W?(PX;:>"1QC<
M >_45Y2G@M]!\!W^NC7-9.JCPXT93[4\$,;I$70H@5&0(2P52!M!.1DDUBP^
M"]2U_P"%5EXE;7?$;^*(+)[NQF:9O,7Y6S$B*<D2+@;L[V^4GCY* /<**\<N
M/&][J_A[X<V27C6TFORK'?7C3^4S"$JLJ*8\X:1F(!!!!P/E))6W\0C_ ,*_
MN= \0:3=W-M9OJ@AU&R6=V2Z63+LY#N%#_(WS'&2W+8'(!ZQ17D_B/3[G4?C
M=H>F1:MJ$-B;"2]N((KJ4X.Z1<K@$1%MVS>"OR[E!4D;KM_X<CT6]\.Z/=^)
MKV?0_+N(I-.N'EGN]2=EP%/E_>B16Y 4!0HSD-E0#TL]*RM(UZRUPZB+&0R"
MPO7LICM(Q*@4N.1V+8STXXS7G?@"^O=3\;^.M#GDOCI,<J&));F59(-Q;.PC
ME=WWC\RL".F2VT^"NEJ?#FJF<7]O-!JMU!]E:Z91 "$RA6,JA8?WMBD$G %
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M7*D-&X&2,# 89!KHSIUQ??!@>)8]5NH_$":8M^=22XD9RT>Z381N QAI$QC
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M"Q#DG<"S< #;UK(\;>%?$=IXFB\9^!TM&U?[/]EO;.945;N/<I!R<?,,#)+
M[44 \8/H^.<YI: .#@T/Q=<^'Y[S4[FPG\336LUK (YGMH+*.3!.UD4NS96,
MD\?< 4KRS2_##PKJ_@[PO_8NJBP;RY6DCFM)W??N))R&1=N.,8)S[8Y[8#'>
MEH \W\"^"O$/A+7]91KW3X]!N;Y[R&"&(EW5MX"\;5B( C)"H0<8! %1^"/
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MY1@L.&P,AN].>U 7%+0!Y?%X/U_X=ZC)=^"8?[6TJ\D:2[T:YN5A9).<-"Y
M51RH((SA ,GC;TVDCQ3K<T=SKEK!HEDBJRZ?;71FG:59,YDE4!0F%7Y%SN#'
M<<94]21FE Q0!YU=^'O$'ACQY=:[X4L+&]L=;>)=3LYI1 8Y%# 3*P7A><MP
MS$LV <_+<\/>&=7TZ[UCQ3=PV,WB;5O+#VBSO%;0QH H3?M9BVT;BVT@G@ #
MD]P5!H YSF@#A?AQX=\4>%]/N]/U^>SNXYKF6Z2XBO9I61G*DIMD0';G>Q;<
M22QR#DFN7\*7WB*W\6>.QHFG6U^KZLP,=U*UE]G<(QW[ C(ZL55=RD.^%9P
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MX."N" 2&VCU&DV\YS0!SOA&W\1#3OMOBBYA.I7(#&TMEQ#:KR0@Y.YN>6SV
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M+M!+?,=HXR8M?O8/"GPU\-QS30#6X$BGNK>41R)%'&GRH5S@G<OS9!PO3)X
M/7\GO2%B.X!KAK3P)J&B>,[?4_#^NS6NC.CF]TZZ>6Z6:5F!9QO?AF!)WYR"
MHX8,P''^([&6*7Q9/K&O7>JZK,[OHUEIMU,J:8BM^[DF*LL<05A&Q:3 'DEL
ML<X /6->UZQ\-:)<ZOJ<IBM+8 NRH6/)"@8'JQ _&K5C>I?Z?;7L0Q%<1+*O
MSJ_# $<H2IZ]02/0FO$_'DL^N?L\Z5K&J2RRWPC@;>+CRU<LP&YD#LLAP!U^
M8$DX3YE&QJ.M7V@Z+X+T33X]7U.7Q$4ENI;B]D2[**D1D"%Y#Y3-G) <!?F
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MVXL  =]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA3QSX,UC5H/"ZZ!<:%J5Z]S%!=;XOL;,A/1!]P%53 )Z+@+\Q'JE% ' >+_
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MT_5_%UE;_P!B0Z9KD\ET-0FMS<3?O2P,31DA7"\G#?*/,_CRRCT^B@#R31/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBDR* %HI-P]:,B@!:*3<,9S2T %%%% !1110 44F1ZT;AZT +1110 4444
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M*(HG1@SA3D.I.>>V>@XZFN^'2O-?CGM_X55?Y R9H-N2O!\P>O/_ 'SS^&:
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MZ%=H,8-C0]0N?"OA;XG/H\EJD5AJMP]GY-JZK"[  J-RA#LPHV@<%3G<K+D
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M%>V=QKVOA[VZGE8/J$[J[ .$ 5I6.\9*C*84%MN-P8GTYIXDA,S2((@NXN6
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MAP1D<9'I5@G!%>8^"X;31OC)XTTBQL(;2VEMK.XB2)4B10L8!V(,%@2Y)8#
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M2'IT7.?XE_,>M>)6WA/3+W]G234I=-BO=6^P-/\ ;5,33J(W^4"0EL*B(%*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:J AP6<%U(R&]0...<SPYX,\6>&M#;2;?QE;W=OMVPM=Z8[O N, (PG& .,
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MM6FNKBWF696D9B((R5/!5EDD!YZ<XW#/HNH6-OJ>G7-A=Q^9:W,3PS)DC<C
MAAD<C(/45G>'/"^D>$]+73]%L4MXA]]NKRGGYG8\L>>_0<# P* -H=**!THH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** $;G%<YI6C/8^*-7NF\17MZ+I4D_LR656CME)8*RJ<E0=K
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M5\9KF*23P!>EK&2ZEF$GVL.(@RCRCPS&2)8R6SE]X'!!(W9Z_P ;6ME#\2O
M=]+:2H6O+B-[N*41*',0"([<;BS 8!;D*Z[6W8H V[WQOIMOX_TOPA%(LU]=
M1RRS&/YO(VIO0-V&Y0QZD@*ORX<,,#0+B_B^-&K:3=^)+S4(K;24>*WN&C7!
M9U+,4B4)D9'S,$?#@!67YJYFZT>UN_VE_LTNB6\MF]@TDHFMR4;=&V9<*@5L
MLVPE]XR2,[MJKOII%IK/QWUD:A UU;6^DPCR<+) 6;C$VW&&P7VI(')!+9 "
M@ 'IEO<0W5M%<6\J303()(Y(V#*ZD9!!'!!'.:22]M89XX);B))9 61&< L
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M2O*W[PL7DVDDL3Z^V[C/7_"M!'\,/#X"2+FU!PZ.AY).<.Q..>#G!&"H52
M"UXI\5P^';_0K$M!]IU>_2U1968;4/WF 522<E5 X&74D@ UT,]S!;6\MQ<2
MI%#$A>221@JHH&223P  #S[5Y?\ $G3=.D^(G@26?3[9C<7[+-*\:#S-H78K
M,2I;DG:N_K_!)]TU+>[.I_'I_#$UO;IHFAZ>3:6<5L/*!=(B2PZ#&_ /0
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M8'=N+<L%8EL8+-0M=-7XJO+.DFL:A+I">7IIMT/V:$38,BN[JA4L<D$,_'!
M^4@'<2WEM'9M>27$26JQF5IF<! @&2Q;H!CG-8O@[Q/%XLT6358%3[,UW-#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMZ'@>E&* /.]<^&\U_X]TKQ9I>KM9WT(,-XY@C9I(_+9-ZX7!DP<9<$8(/1
MK6HO!>L6_P 0;_Q9'K]J\MU$+9;>>PD=8+<%3L0B<<G:"3C&22 ,D5W5% '
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MD-Q@E^'&JS?#M?!;Z_IS6 7RS*NDLDF X=3\LX7=N&22#NSSDY)])HH \_\
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M?@#6_%T^CS7GB#3(GTN;[1'Y>B[MSY!&2TQ.W &5!P>ISQM]#HP/2@#SB_\
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MR#DG<TGJ*7PSX#T_PWXDU_78W\V[U>X,A)C \E"=Q13R>6))Y .%X&WGKJ*
M. \0_#R[UOXB:9XN@UQ;273HTCC@%JS;E5F)#.LJGG>PQC&."",YDU/P/?3?
M$(>)])U=--,]D;2](M4>1@'0C9D8W87&]MV-JC!' [NB@#@8_ NKQ?$J;QE_
MPDL;>8GD?8GLW*);\?NP?-X/&<XQN);;VI-!\ ZKHWCG4/$\FN:?.^H@+=0+
MI C&T8_U;>:2OW1GJ#U() ([_ HP/2@#'\4^';;Q5X8U'1+IML=W"4$F"?+<
M'<CX!&=K!3C/.,=*XC5?A=JVL>![;PO>>*HG@MS"L4ATI/DCB7:H7Y]P8YY;
M=R    6W>GT8'I0!Y_K?@?Q%K?AS2M'?Q:D0LC#)+<QVDHFNI(B=K.PGS_<)
M[[TW C@"'Q3\.-0\0:CIOB"W\0?V?XGT]=B7EM;%870%R%\LNQ'W\$[F!!8%
M2" /1L#GCK1B@#F/#6A:U9^7?>)-:75-56'RE,=LD4<"L$+JN &;<R EC@'
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MY P<XKQWQ+X.\4_"XW.N>"=3N9/#RSBXN=,!WF!<88X8,&4 8W8W ;2<[2P
M/0/B-\1]/\":6N2D^J7&!!:@@E5.?WKKD'8,'N,D8R.2.BNO%?A^RT>#5[C6
M;%=.GE6&*Z$ZM&[EMN P)!P0<^@5B< $CR?XUWEEK?@_PAJJK'##>744R/+$
MCS1Q21[C\K,$(QMW L 2%YQDUV?BEM)M/%^B7%M!=7WB:UANI+#2K61$642*
M0[R%QMC7(/SY!)R,/C;0!TFD^*=$U_0I-9TJ_CN;"/?OD56!3;RP92 P..<$
M9P0>A%<YX*^)VD>,=;U>SM[NTC2&X"6".QCGN8PF6?8W495R"#G;C<JXRV%X
M*&IR_&#QO%K$5JSS6]LUQ':AY($^0"-&9]N6,9Y^0@_-@KC:>4^%/G:5X>^(
M]W;)]BU6S63RXYTAW6S*DI4%^ <,O(**GR9'4A0#V*[\>^$K'4AI]UXCTR*Z
MRZLC7*_NV0@,KG.$.3C#$$X.,X-=%7C&E^!]7\:_#'3+(>+;!=*NX(YS##I0
MD*2'8S R>;G>)%?<>.9) 0!M5?2?!D)@\)6$1\0+K^P./[35@WG_ #MW#-G'
MW<Y/W: +VLZ[I7A[3WO]7OX+.U7(WS-C<<%MJCJS8!PHR3C@4NEZUIFNV7VO
M2;^VO8,[2\$@<!L [3CH<$9!Y&:X2Q=+WX^ZHE]'(9-/TJ,Z>)\8VN5\R2(>
M6.,G86+YSO R"1'ERV,.C_M*60TR"*VCU+27FOPH($K%I,MCH"6CC)['D_>/
M(!4O/&.@^*/BS=Z3JNLVJ>&;#328)%U/RH)[AC'EPZLN6"NR@9.-K$8)-=]X
M1\'3>&=%O])N-<O]3MIYY&A::1DD@C88V*X.[/4[@5Y.0%.<\%HME9W7[2/B
M^SN+2":VETI?,ADC#(^1;$Y4C!R23SU->S X'- 'A/A'2[_7/BGXFT>[\5>(
MQI^EW!>&"WUB3:R>9Q&S!V)&/E.&##'.&R!K^)(M<^$Z1>([7Q'JFN:-O6*\
MTW5;H22.Q#!624H=H!()  SMZG. O@&7SOC?X\;[1Y^-J[_-WXPP&W.U?NXV
MXQQMQEL;CK_'.\AM?A7J,4K8>ZEAAB&1RPD5\<^R-TH [#3_ !/I%[X8MO$7
MVZ"WTR>%)?.N)D18]Q VN<[0P8[2,\$8IN@^+- \56_G:)JMO>#&XHK8D09Q
MEHVPR\CN!GKW%>%6%CK6F:E\//#=]??V1:+:&\MTU*Q++]O:67: JGF1?,CP
M&=<<$@,VP^EZ3X(N](\=V?B76?$Z7>H3V[6&(-/6U-ZV&D'FE68,0B]@.(DY
MX.0#G?A6)(OBCXYM/[0N+N"UG*0[VEE5 96^4O(N[<,;?O#<0QQ( &7T?_A.
M?"W_  D(T#^W;'^T^GD>:/O;]GE[ON^9NXV9W>U>6_#FYLK'XL?$6]O[BSB:
MWDFDSL&Y8%E8NP93@ 83<,$DXY!!SEZ]8VY^"FJ67AS3Y9O#EE.)H-2OS')-
M<.+@HYA6,#:H&3YC8.TLNW!)4 ]RU'Q+H6D7"6^IZUIUE.Z!UCN;I(V922 0
M&()&01GV-5Y_&GA6UN);>X\2Z/#/$Q22.2^B5D8'!!!;((/:N(^+7A]M6^'4
M&NQQ7$6M:+&EW;-;SONAY0R_,P#$ +NW$*V4!XY!YKQUXNA;7?"WB[3;;S7T
M9+6;5[JW@!>."Z7*QC<>A3S/O8VF1,$%C0![,_B'1(]5&E2:QIZ:B2 +1KE!
M-DC(&S.>00>E49_'/A6VU-=-F\0Z<MX9?),/VA25?YOE;^Z?D(YQS@=6 .#X
M>GM-0US7_'<]XDFF1Q?9-/N"@"I:1JKS/N7[RF4-]X978<8R17FNK64%K\%M
M;L?"\3IX9%UYLNIZLZ[[DK(JA;=84.X%XT&^3'WL=!E0#W;6?$&D>';,W>L:
MC;V4.&*F9P"^!DA5ZL<=@"3Z4VW\2:)=OJ:0:I:.=*8I??O0!;D+N.\G@  '
M)Z JPZJ0/(_C4EO'X>\)ZQ)%,FI_:H T\CQ6][M"%L&15(1@W.0=JL<A3VT?
MB/X5\-^'-$T[[!:Z5HUO>ZI;V]]<36Y9'@4-)L8+\Q4O&F0I7) R0,D 'H.G
M>-?#&KZLVEZ?KUA=7J@$113JQ?()^0]'("DD+G'?%;N17E6N?#W6+O7-*\2:
MQX\M;:?3!'&ES'IBVY?) (9Q+SO)(QG;ER HW$'U+ ]L4 8NH^-O#&D:JNF:
MCKVGVMZ028I9U79@ _.>B9# @-C/;.#5R]\1:+INFP:E>ZK9P6,Y00W$DRB.
M3<,KM;.#D<Y'8$]!7DT^FZ5<Z7X]M/!]K>ZPU^9Y-0NKJ%9((KA1*_E0\*\L
MF[;MQN"[E?<3\K\M%IMNW[/^A:LR&WOK?456+4H8AY]O']I?[K[!@!F) ,B#
M=CYQG80#WX^)]#'B0>'3JEM_:YC,GV3?\^  ?H#@[MO7&3C )J76M<TOP_I[
M7^K7\%G;+D;YGQN."=JCJS$ X49)QP#7BWQ>T;0_"^I^"KC2+"STJ5;[<;F%
MHX0H5HSE_P!VQ8C@[R&"\Y5MU=987YUGX_:I9WODE=#T]3IZ;6W*95C,DF<X
MR0^T\=-O3!R <QX?UV#4/VC+Q-/UF>_TUK=_*S=K)"K>6&81[RQ9=V\@1X(R
M<?(&S[5J.I6.D:=-?:A=16MI"N9)I6VJO.!R?4D >I(%>200K9?M/S!!%:K=
M:<7"QF2,W)V#.X,I#G*$_(57Y 2V]65O6-6BCFT:]CF6!XVMY%=;A28V!4Y#
M@?P^OMF@#F/A[\0+'QO83R+-:Q7:7$VRT63$P@#?(SH>AVLN2I9<GJ"2J[,G
MC+PW%KG]BR:W8KJ6](Q;F8!B[%@J_P"]E2,=1E?[RY\3\%7=]I/[.VMZGH<C
MC4X+IR)(K="\*EH?,QC)(V#<68 C'3"JQ[&+2=.N_P!FP02P1RQ1:*]V@#?=
MF5#)NR .=_)'U!SSD ]7SGI5.\U?3=/N;:VO=0M+:>Z?R[>.:94:9L@;4!.6
M.67@>H]:X_X.:KJ>L_#:PN]5GDN)S)*BSRL6>5%<@%B>I'(S[5@_$K1]-?XC
M^"I9+")?[0N9[>\G4"/SU,:($D8,A;()4 MTR KYVD ]"T?Q7X?\02O%I&LV
M-[*F\M%#.K. K;2VWKMSC#8P<@@D$5'JWC+PWH-W%::KK=C:7$KJ@BEF 89!
M(+#^%>#\S8'OR*\Z\3^'[3PK\4_ MWX7TBUMIKR>:WNXH?D62':@9O+!'W4+
MMD#J 6SP*M^(V>=O&=OX4TJYU::_MIK?5;]KK?';2) =EO%'RSM\S?*OW6E
M)/W5 /0KOQ+H.GV]K<7NMZ;;0W:;[:2:Z1%F7 .4).&&&'(]14AU[1QI']K_
M -JV/]F?\_GVA/)^]M^_G;][CKUXKS+X4Z)#XE^!RZ-JV][*Z>>- ",HOF$@
MKE  0^6&2_(Z_P "X^D^(=3\1^"[/X?QQI#JUO?KHVII:L=ZZ?$-LLX+<)P
MASG))P,L  #VRRU"SU*TCN["[@NK:3.R:"0.C8.#AAP<$$5G:SXN\/>'IXH-
M7UFSLYI062.64!BN&.['4#Y& )X)P!R0#I6EG!8V<%I:QK%;01K%%&O1448
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MM+;<YVYQAL8.002"*K^)/%7AK1/+T_6]9@LI+S$2Q^<R2 /D!\H=T:\']YP
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M1H@)VJJY Y+'/+&N+TGX,3Z')<6VE>.-<LM+G.7M;=@C9W DAP<!L*HW!0<
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MMRTLF6+?,3UQG ]@*U*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***0MCMF@!:*;NYXH#'N/RH =13-^"<
MX'XTN2* '44W=Z4;N,\4 .HINX\\=*-Q]* '44@.:0L0>E #J*;NH#$C(% #
MJ*0'-+0 444T-D]* '44A.*3<?QH =1110 4444 %%(20>E)NXH =1110 44
M4A./I0 M%-W?2@,2<'% #J*** "BBF[N<8H =12$X&:3<>N.* '44@.12T %
M%%% !1110 4444 %%(QP*,G% "T4TMP<=J7//:@!:*** "BBB@ HHHH ****
M "BBB@ HHHH **0G%)NYH =1110 4444 %%%!.!0 44W<>..M*#D9X_"@!:*
M0G%(&R3]: '4444 %%%-)P: '44T-D\?C3J "BBB@ HHHH **** "BBB@ HH
M)P*;NH =12 YI: "BBD)P* %HINXCM3A0 4444 %%%% !1110 4444 %%%%
M!13=WTS2@Y/X4 +112$XH 6BF[CZ4;J '44@;)I: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM3IS77FWCL0'<2+QO?*CD@*%.#\H0#YATOB#RW_:%\*+B-Y$TV=L+$2\8(D
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MD9E49&W:>Y\7W0DU#X7W4FI%9Y;Z,_:-T(:8,B[OFBW'#DA2(\Q-OPS*-AH
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M3-@@D= > ?7.#UQ5?Q3!93_L[M'!YDEFNC6SP><-KE5$90L%. W ) )&?44
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M=:<D<+WI>8*VW< S &,H_P S$LC;09#7IZ^$VLO'VD>)-4\3W4U\\7]FPPK
M(TN (I'*ML_W7DYXW#C&%  -%_B9X-CLIKUO$%J+:*0Q%_FP[J S!./WF RY
MVYQN&>M=!IFJ66LZ?#?Z;=1W5I,"8YHSE6P<']01]17DGP5M++_A*_'=VGDO
M=KJ)B#;1O2(R2'C:NT*Q'16(.P< !2V187EUIO[,NN1!IXI;>XELV@G*![=7
MG57C.TALX=B0X!RQXV[<@&_\6?$?A;6_AQJ<L&H37ABD$$!L[F1('F+J=I(!
MBE("[]IR< D%<AJ[C2=8T[P_X"T2YU>]MM/@%A;INN"L(W>4#M"YQG /RC/3
MC-<MXZLH$_9[DM;=_,MX=-M!$[SQ*2J&,@[@2A. .%)W'A2<BJ&I7[V4_P )
MH4U$V=O-%M1U5&5I3!&D8,:Y!5@[QY7 7S,AAQ0!Z+IOBO1M5U.33+6\)U"*
M+SI+26%XI8T^7ED=0P^\O4?Q"HM3\3:#'=W>CW&H,;Q8=UQ!:>8TT,;8&X^4
M"R?>!W<8!!R.M<W<> HU\;:+XHU?Q7<2ZC;A;6$2)%")SASL7:!R0SDCDGYN
MW K?!35[CQ!X7U?6+R7?>7FKS2S89B$.R/"KGD*%V@#+8 '/8 &!^SK$B:/X
M@:W5WM3>JL4\EJL;2 *>"P8DD @[.0N[AFW'&Q\:;&U%CX>U*YCGEBBUJU2X
MC,W[GR?GSF.1O)R<XWN!P<$XK'_9X@%MI_B.%XG@N([U4D@E6/S(\!@ QXDS
MG(PP"@@[>2^-[XU6]K=Z#X=MKR)Y;>;Q!:QR(B.Y92L@8;4^=LC(PI!/;F@#
MI+/XB^#[[55TRU\0V,MX["-%5^'8D@*K?=8DCH#SD>HSH2>*M'AUN+19+LIJ
M<W,5LT3AW'/S 8Y7Y6.X<8!YXKS;XV:%IFGZ'HFK:9:+::S;:A;V]C+:1*A(
MP2L9.0%4; 5.&P5   8FK_Q8BU#PW>Z5\0=)DD,NENMMJ$"E4$]J[@[2Q[;B
M!C#8+AA@KF@#T:;5;2WU2WTV6;;=W*,\,90_.J_>(.,<<9^H]15ZO/O"4L_B
M[QEJ7BV6.>+3K-#I>E0S KG!!GEV\C)<! Z$9"$,,BO01TH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBD+8H 6BJ,>LZ;+JDNEQW]J^H0KODM%F4RHO')3.0/F7G'<5>H **** "
MBBB@ HH)P,U4L]4L-0EN(K.]MKB2VD,4ZPRJYB<=58 _*1Z&@"T1FO/H/AC-
MHSO-X7\4:EI$TK2>8K!;J%E9W<?NY<_,I91NSDA3W=C7H5% '-:#X0CT2UO)
M&OY[G6;_ "UWJSI'Y[.5 RN5(5%P-J8*K@#![\IIOP.T72-1?4-/\0>([>\=
M)$:=+F+>0X(;GRNO)YZ@X(P0#7J%!.!F@#B+#X:VMIX@L]9NO$/B#5)K.1Y8
M8=1O%EA5F4KD)L&",Y&,8P*V/%?@[2/&6E/8:M;*XVXBN%5?-@.0248@[<[1
MGU P<UN[O:JEIK&G:A<75O97]K=3VK[+B."97:%LD8< Y4Y4C!]#Z4 <):_#
M+6[1/L,?Q$U\:2^?,AROV@ ,2@CG.3& /+! &&PW0-@=SI6DVFC6$5E9Q!(D
M'+'[\C=W<_Q,>I8\DY)J^.110!YZ_P )[&PUN\UOPQK.H:!?SC CMEC:U7C'
M,)7##J<$\$Y&,"KNC_#?3K'79M=U:\NM>U9G)@N-2VN+91(SJ(EQA",CD=""
M5"@E:[6D+ 4 <QKG@UM=U6TOY/$.LVALYA/;16C0HD3[=IY,19@1NR&)!W$8
MP<5T"6W^A);3R-<XC"2/,%S+Q@E@ %Y[X 'H!4V[V-+NYP.: .?TWPE::)I^
MHV6BS/I<5Y=&Z3[)'&# 2$#!0ZLN"4/4' ; P ,<MHWP8TKP]J,VH:5XA\06
MUW,NUYA-"S,-ZO@[HCG+(N?49!R"0?2"V#CO2EL#H: .2\._#G0/#6H'58([
MF]UAE=7U&_N&EFDW'DG/R@XPN0H./7)S<\0>%!KVL:'J']IWMH=*N#,8K>3:
MMPIP=C^VY5_#<,<Y'0;AQ6=I_B+1=665M.U>PO!$560VURD@0L<*#M)QD@@>
MN* -.N?\5>%D\6:2VF7.IW]G:2@K/'9M&OG#((#,R,1@KT4C.2#D5OYHS[4
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M(Y4DH>NT'KU,FL:=%JD6F27]JFH3(7BM6F42NO/*IG)'RMR!V/I5V@#D-/\
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M.-H)%;/BWPG8>,=&&FZA)<PHDR3Q36LNR2-USA@<$="1R#U[$ C>HH X[3/
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MKL++GY<KDD ?,.3SCKK2[BOK&"[@+&*>-94+(5)5AD94C(..Q&:\KU;3M?\
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M%_X65H"WL4,GVZ.UFG^SPZB]E)]DF<E0H2;&TABS -T_=L<@;2WCOABUO/\
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M*72,0=K1EL+'D$<;0,Y!!4$,^,5O:WWQ:\$6DZ96::*.7;(BL4:<#&5Q*O\
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M%QNDP@(4=-PZNZYR6)(!-+\9/!D,%W,VH2F.VNTM21;O^\)QET&,E%R=QZC
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M^Y,!BQ&TA2,DD$#DGFM7X:QW<7PU\/+>SB>4V,;*P4+B,C,:_P# 4*KGOC-
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MQLLSLK(78F,M\PWKPYR4W @A2H!Z1JWQ&\,Z/X8MO$,^HK+I]V#]E,"EVG8
MG:!V/!!W;0IX8BH;3XG>&;[5[33H+J?-YY8M[B2V>.&5G5F"!V ^;"CCN74#
M)W >9^-O#>F>%O@UK>E:%-?RV<6L)YTUUEQ*X6-6"M$ NU6 4^8,!T=?OA2-
MWQ_'(WPR\#@-&9UO].V/;_*N_P LC*K;G+#T6$Y[J>* /2-<\3:7X=MXY-2N
ME228[+>V0;YKA\A0L48^9SEE& .,C.!7E^F:CI=W^T):RZ7ITVG^;ILPNHYK
M66T>27S)&\QD"C<6 5LR<$$='4"K%[=%/VGM/CNTD;?I1BM#Y:87Y9')RRDX
MXD&5(.3C.W<IU=01_P#AHC27C++G07$A#.=RB1\ A.%Y(YDRAX &\*: .FU?
MQQI.CW\MBR7MY<V_EM=1V%G)<?94?.'E* A1@%L$[L#(!R*O:9XGT;5_#XUV
MSU")M+(9C<R9B50I(8MOQMP0>N*\F^'>GP:Q=>(]*/BG7-+UFVU*\:[M+2ZC
M'FAV"-,,Q$D_*%R&8JPW KOJ/QEX:T_P3\-'T/1KBZETM]?MSJSWT32(D;(C
M?,8U4^7D0\H0<G:&SQ0!4^./B/0=>\*6,MI:79O/M2^1>2Z?+ "@63>JR2(-
MP!VY4$<D'G!%>[:>V_3K5CWB4]6/8=V^8_CSZUY?^T&B2?#>)V0EH]0B9"9E
MCP=KC.T\OP2-JX/.[HIKU*Q#"PM@Y);RER2&!)Q_M?-^?/K0!S6J_$/1M)U"
M:VEAU*:&U9TO;VVL99;>S94#XD=0>2&'W=V/XMM3WWCK1M+T;2M1U"2>W;54
M0V=F86>YE9E!""-,G=R >P) SR,\)=Z=XG\$:AX@\6^&+NUU+0I[B:\U#2KL
M20LC)(1*T1/&["O\W0@#"OA*;#XB\/>(6\"0:1X>5M0:VG.C'496,-CY0*$L
M%),A'DY&><JO*DY !Z%H7C#2O$=Y>V5HUQ#?61_?VMU;O!*BDG8Y5P.& ##N
M RY )Q61X8G\'7/C;Q ^@%CJP6,ZC(L\ABE)+8PI;:2NW[RK@;P >6%<QX.L
M=1L/COXH_M2^%S<SZ?'-YGV<VZR*2@'EIO8%$ V;CDY!&<YRG@8P_P#"]_'0
M"Q>9Y:892G3Y=W##S.N,E3LR.>L> #MM=\7:)9W-SH]Q;7>IR)'B]MK2Q>Z6
M&-T8CS0H( 8*1M/)W D;<D<-^SV(D\-ZY#!*LL":FPC=6<AEV* 1N51R .P;
MU X%:'P/OY+OPSJRWTRG6/[6GFU"%T$<L<CXR70*N,D-VZ@C/&!2_9_B$'AS
M78HQMACU9T1?.\X#"*/]8O[M^,?,@&>O0K0!Z^:\;^*VN:^FJ"^TI8/[-\)R
MVM]=I*#NN)I6*JJ_*>%0G/*\29P?EKU/7=9M/#VA7NKW[[+:TB,CX(!;'15R
M0"Q. !GDD"N!TGPWXKU3PA>0:K+IFW7V-W>1RP2K/ )4.Z(;B<,H\M48@[-F
M-K8& #T/3=2M-5TRVU"PF6>TN8Q+%(H(W*1GH>0?8\@\5QU]\8O!UC)J:-?S
M2G3AB7R;=V#R99=BG&"<J!N.$^=?FY.,;X)SZEIUAKG@[5$87.@7FU6VX7RY
M"Q&W(!()5W#$<AQVP*9X!63_ (7-X^:1&<AHAYC)*-H.=JYD.>F,?PG;E,)@
M4 )_PN&SU#XBV.D:>\HT98#-)*+*9IKIVC)1(XU1F*X96R0N=I(.,!^CBN/!
MT_Q498&9O%*V;>;+'/(J")2J^6PW!&/S9Q@XV$G! KCVN3_PU&L<ETT9.G>7
M&D=RW[S]V7V,HWC^\VP^4/E#\G'F7&BBD_:95BJETT8L"D1<JW3+$HVS@XW
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5BVU[7SU3C[2) 3O82)\G1<(APQW;?>*AGMHKE D\4<J!UD"NH(#*P93SW!
M(/8@&@#R[PWI$<?B72;CPEKWB&_\-RBXANH;B5GLX81'B-87?:1M?8HV;CPP
M++M(;M+'P3H6G'5/LEK/%_:C%KS%[.?-8G)/+\$Y.2,'\*Z$+SG/Y4Z@#EK#
MX?>&]+T2[T:QL9H-.NRQG@6]GVON7:V?GSR./RK$\8Z%H?A[X9R:%%IEY_8<
MD\:W MV>4VD)E$DLWS%F"J S< \XXZFO1*0CG- 'B$%CX NT6/PSXW\1PWTR
M%88M,O9FED0#]U$4*D[(QD <;06W'C(]?T(:C_PC^F?VN/\ B9_98OM?W?\
M7;1O^[\OWL].*NK$B,[*J@N=S$#[QP!D^O  _"I* .5?X>>%VUZ?6QI?E:A<
M.'EEAN)8P[ JV2BL%SN56SC[P#=>:NV'A+2=,OM0OK2*Z2ZU$*+J9KV9VDV_
M=Y9SC X&,8' XXK=HH YS0O _AWPU8WMCI6F)%:7HQ<022/,D@P1@AV/!!(/
MK6);?!WP99ZI]KBTZ0VY 9M/DG9[9I%+;9&1L[F 9E&25 8_+DYKOJ* &@'-
M<]-X&T&XUZWUR:VN7U2VC\J&Y-]/O12&R!\_3YV_,UT=% #2"?:N=N? N@WG
MB-/$$]M=-JL8VQW OYP8P<@A0' 5?F;@#')]37244 <YJO@?0=:U6UU/4;:Y
MN+NTD\VV=KV<"%]P;**'"KR!T'8>E6=>\*Z/XFTI-+UFS^UV<;*ZJ\CA@R@@
M'<#NS@GG/<UM44 <QJ?@/0=9TBWTG4+:XN+"!T=(9;N5L%595^8L6& QZ$9Q
MSFB?P1I]Y.HOKK4KVP54 TZZNVEMRRD$,P;YG/ X=F4]<9 -=/10!')'YL;(
M2P# @[6*GGW'(^HYKG](\!^'-#U^XUS3K"2'4KG?YTYNIG,F\[FR&8@Y//2N
MDHH 0UC:QX7TO7[BRGU*&>9[*59K<+=RQJDBG*OM5@"P/0D9K:HH CDC\V-H
MVW!6!4[6*G!]".17/Z7X'T'1=2O=1T^VN;>[ORS73K?3GS6))+,I?&<L<'J,
MG&*Z2B@##\/>$](\+6K6NC6TMM;EBWE&YED3)QDA78@=.W]35>7P/H4WB9_$
M+VLHU"5HVF*W,@CE:/:8RR;MI*[%(XQD9QG!KI** .=TCP3H6@ZM=ZIIEK/!
M=WC%[E_MDS"9B22S*S%2<D]N,FL:X^$?A&;4TO(["6UC\PR3V=M.T=O<MM*K
MOC'&%#/@+M'SL#D$BN[HH Y[7/!6@>(]-MM-U/3A)86I4P6\<LD4<>T%5PJ,
MHX!(^E)K?@CP_P"(]/MK'6=/^VPVQ)B:::0RIGK^\SOP>_S=AZ"NBHH Y?PI
MX"T'P<A.EVC&Z:,1R7D[^9-(HQA2W8?*OR@ <#CBN@N[2&^LI[.ZB66WGC:*
M6-NCJP((/L0<58HH Y%?AIX531'T8:?<'37 !MFO[AD W;\*#)\H+88@8R0"
M<XJS>> _#VH>'X-!N[.>;3(,>7;O>3D*%  &=^<  8&<#M72T4 <SJ/@'PSJ
MVAV6C:AI,=Q96*!+99)'+Q*,?*LF=X& !C/.!Z5!X8^'FA>%%D>R2ZFO98!;
M27US<,\[1#A4W# 4 !0-H'"+Z UUM% '/:#X)T#PQ=W5UHUE);2W9#7#?:97
M$A&2"0S$?Q-V[UG>(OACX7\3ZPFJZA8R"]R!-+!.T9G0*5V/@\@@@9&&P ,X
MXKLJ* ,&T\'>'K'PZ_A^WT>V72I.9+<IN60\?,Q.2S<+\QY^4<\"J,/@#28H
MQ:2RW]WI*!!#I=U=-+;1!,;1M;EAD9VN64<8 P,=910!CZ[X:TSQ+8R66K0S
M7%K*%#PBYD1&"MN&0C#G(!_"M"VM5M8RD;2D$Y_>S/(?S8DXXJQ10!A7WA6R
MO]=_MIIKJ&_%NELLMO+Y9$2R>8R9 Y#' .<X ^7:<DQVW@S0H--O+&73X[M;
MX*;Z:Z4/)=LO1I&[D'D8P 3P!70T4 <I;?#_ $:SMS9PO?KI>^1AIHO9%M@'
MQE=@(RF0YV$E3YKY!&T+U0&!2T4 8>J>$]&UC6;+5[RS8ZC9 K!=0SR0R*IZ
MKN1@2.3P<CYCZG-.#X?^&K;6[+68=-,>H648BMY5N91Y:!2H4#=C&TD8(QCC
MI7444 <_9>#=$T_Q%/X@M[65=6GC\N6X:ZF<NN ,$,Q!X5>W85DP_"CPC%:7
MEDVFR26-S/\ :/LCW,IAB<H%)1 V%. ?F^\,D XP!VU% ',6_@'P_!X./A5[
M)IM+<)YP>1@\[*5(=W4@DY1>F   !A0!7.>-? >C7EI96UMI>K7.J>;/+:W$
M<[RF.5H@GFS2RN,JI6$@%MQ\L!05#"O2J;MR<YH ,'-<K/\ #KPW/XBNM<-G
M,MW=PR0W:I<R+'<J^T$.H.",+C'0Y)() (ZRB@#D[7X<>%+&QN+*VT=4M[@L
M719Y."S(Q*_-\AS%&?EQ]P>@JU#X-TU;VVNKM[S4GM&WV@OYS.+=MQ(==W\0
M!4;FR<(ISNW%NBHH H:KI5EK>F7&FZE;)<V=PNV2)QPPZCIR"",@CD$ @@BN
M9@^%GA>#3;6P6UNS%9W#7%H[7DN^V)D$F(V#909 'RX)QDDMEJ[6B@#F&\ ^
M'GO+"\^R7"W5@'%O.E].KKO8LY+!P6+%F))R3DYS5J7PGI,NLIJ[170U!(C"
M+A+V9&,9.=AP_*YY / /(Q6[10!S;>!?#S>*D\3&P/\ ;*G/VH7$H/0KT#8/
M!QR#QQTQ69K?PI\*:WJHU22RFM+UY"UQ+8S-";A6#!T< XPX9@Q #'/WN3GM
MZ* .:U/P#X9U?0[/1;O2D.F6;;X;:&1X41N><(1D_,W)]3ZTW4_ /AS6=&L]
M'O["6;3[)46W@-U,%0(I5>C\D D9/:NGHH YKQ!X%T'Q+]GEO[21;VU0+;7T
M,S)<P$?=*R Y)4G<-V1GGUJ&+X>Z&NL6FL7!U"[U2UA$,=Y/?2F0#YMQR& &
M=[9 &!G"@"NKHH XK6/A7X3UG5'U.73WMKV5R9YK.=H3,K9$B,%."'#,&( 8
MACSS6JO@OP\OA9O#*Z7$NCNN'M@S?-R#DMG<3D YSG@5T%% '!M\)/#$NAIH
MLJZA)I\=P+B*W>^D9(FWLQ"C. "'*''.#G.[+'M;*SAL+*&TMPXAB4*@=V<@
M>F6))_.IZ* .;N?!.EW)NT,NHQVM[YOVJTCOI1#+YC;G.S.%SEP=N ?,8G)V
ME:^H_#CPMJ-OI\3Z4MN=-#"R>SE>!K<DAMRE".0PW<YYR>YSUE% '+VW@#PY
M9ZX=8M]/9+MFWR_OW*3/N#AY%+$.P;Y@2"0<'J 1:TOPAH^C:Q>:K86\\=[>
M?\?$ANYG$I'0LK,5)'.#C(R?4UO44 <C-\/=);7I]8LKC4M,N;J2.2Z33[HP
M1W!7?G>J\$MO.3UR 5*DL3:\*^!]#\&Q3QZ+;SPK.[/)ON'<'+9 P3CY1\H.
M,X R222>DHH R->\.:;XGT\V&KP27%HQ!:%;B2-7Y!^;8PS@@'G/2M&&!;>
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MLI# ' S@C.!FMRB@#D_#7P\\/>%KK[98VTLM^8_)^UW4S2R",<*@SPH50JC
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MBRZA):V806UI->RO#%L8LIV$X;'R ;L[?+4C!R3LZA80ZGIUU87*DP74+PR
M'JK @@?@35NB@##U'PKI6H^$7\,20,NEFV6V1%;)C50 A!;/*[5()SR!G-.U
M/PQIFJ^&?^$>GM]NEA8H_(CX'EQLI" GH,*!D8('0@X(VJ* .9;P/I,\T1O6
MOM0AMY4GM[>]O))XX9%W?.-Y)8G<?OE@,#&*O2>&].E\41^(FCE&I1VPM5D6
M9U7R]S,5* @-DMGY@>0",$9K8HH !THHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "B@G'6HH[F"9Y4CFC=X7\N558$HVT-M;T.UE.#V(/>@"6BJ_V^S\CS_M
M<'D^;Y'F>8-OF;_+V9_O;_EQUW<=:D6XA:=X%E0S(BN\88;E5B0K$=0"5;![
M[3Z4 244F1ZT9'K0 M%)D'O1N![T +15&36]*AO8[*74[..[DD,20/.HD9PJ
ML5"YR6VNAQUPP/<5:AN(;B,R031RH'9"R,& 96*L..X8$$=B"* )**,BF)+'
M("4=6 )4E3GD'!'X$$?A0 ^BB@G'6@ HHS4<]Q#:V\MQ<31PP1*7DDD8*J*!
MDDD\  <YH DHJM9:A9:E:1W=A=P7=M)G9-;R"1&P2#AAD'!!'X59H **** "
MBBB@ HHHH **** "BBB@ HHHH **HZEK6E:-&DFJ:G9V*2':C74ZQ!CZ L1F
MI[6\MKZUCNK.XBN+>4;HY8G#HX]01P: )Z*3(JIINK:;K-NUQI>H6E]"K[&D
MM9EE4-@'!*DC."./>@"Y1110 44=*K7FH66GQB2]NX+:,YPTT@0<*7/)]%5F
M/LI/04 6:*JVFIV%_8Q7UG>VUQ:2G;'/%*K(YW;<!@<$[N/KQ5J@ HHHH **
M** "BBB@ HHHH **3(SBJTNIV$&H06$M];1WLX)AMWE422 #)*J3DXQVH M4
M444 %%%% !15:[U"RL!";R[@M_/E6"+SI GF2-T1<]6.#@#GBK&1G% "T44F
M1G% "T5FWGB'1-/E,5[K%A;2*64I-<HA!55=A@GLK*Q] P/<5H"1#(T8=2Z@
M,5!Y .<''O@_D: '451L]:TK4+RXL[+4[.YNK8E9X89U=XB#@AE!RO(QS5Z@
M HHHH **** "BHGN8(GB22:-'F?RXE9@"[8+;0.YPK''H">U*+B%KA[=9HS.
MB*[1AAN56)"DCJ 2K8/?:?2@"2BBB@ HHHS0 453DU?38M4BTN34+1-0F4O%
M:-,HE=>>53.2/E;D#L?2KE !1137D2)0TCJH)"Y8XY)P!^)(% #J*3<,9S[T
MM !1110 4444 %%&:3(]: %HJK=:G86-@;^[OK:WLE"L;B654C 8@*=Q.,$D
M >N:=8W]GJ=FEY87<%U;29V302!T;!(.&'!P01^% %BBBB@ HHILDB11M)(Z
MI&H+,S'  '4DT .HK/L]>T?4+,W=EJMC<VPE6 S0W".GF,5 3<#C<2R@#J=P
M]:T* "BBB@ HHHH **** "BBB@ HI,C.,\U276M*?5GTE=3LVU)!N:S$ZF91
M@')3.X<$'IT- %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCKZ##+T!%< +6\A_9QT2SNC+ UUJ48A@BC+RSHT[,H$++B4G[ZIE P"G=V8
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MK$Y50@V[VP[9!7&,@JN1Q@UBVES)9_'O7Y;^[:.U708Y5-Q\B11JRY*G<5*
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M.N$_M*52FVX=EVH_R<!@D04@<?*".N  >B4444 %%%% !1110 4444 %%%%
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M2KB#4)=.CC6);5M5NC%M4Y4;?,P0#C&>F!Z"M'PWXHT;Q9I\E_HEY]JM8Y3
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M!?D':PWX*?*OR$;< #&!BNDR.U8,/C#P_<^)CX>M]5AGU4*SM;PY?9M)#!F
M*JP(.5)!]J *.L_#_1-:UTZS(;RTO98!!/)8W3P&XCW(=LFS&X878?\ 9;U"
M%=-?#&C?\(O_ ,(W'9^3I/E>2;>"5X\IU(W*0QSSN.?FR<YR:V./:ES0!R@^
M&WA8: ^@_8KK^RG97-H=1N3'E22,#S.!EB2!P3@G) (V=#T'3O#FFKI^EQ2Q
M6BG*1R7$DH3IPN]B0..@XZ\<FM*C(]>E $5Q;P75M+;W$,<T$J%)(Y%#*ZD8
M((/!!'45B:AX1TK4_!7_  BMRDITP6L=LNV0AU6,#80?4%5/((..01Q709%(
M<8_PH HSZ58W&C2Z0]M&-/EMS:M;Q@HOE%=I0;<;1MR.,8[5R4'PB\%P:)<Z
M2FED0W,CN\HF<2D%LA"X()1<)A#E<HI(+<G>C\7:)-XKE\+Q7;OK$*AY;=;>
M4A%VALL^W:!AEY)ZD#J:W1C% '+:AX \/7W]E.+>:UN-*B2WL[FTN9(9HX5P
M/+WJ=Q4KE>23AFP03FM;0=$M/#^G)96GFN<[Y9YW,DUQ(0,R2.>68X'/H !@
M  :?'M6/X;\4:-XLT][_ $2\^U6L<IA9_+=,. "1AP#T8<T ;-%&11F@ HHR
M/6N?T7QEH'B+5+NPT;41?36@W3M#&[1*"<#$F-ASSC!).#CH: .@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %+3XBYM4MG$DK';M*J 2(_F&YFP1E<*^3AOCBQO;WXH?#_[&I_<27DTSC>
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M7>8,0<!5"\%@17OH.!B@#"\9:E>:5X2U*ZTT$ZAY8BM ,$^=(1''P003O9<
M\'I7GWPW@NO WC_6_!^KZC=WC:CLOK&[FCVK=2;29CRS'>>,\G/EDG'&=GQ$
MMYXQ^(=EH>F:A-9VWAUEOM0N(XT++/(I$**'4_-L,AS@KAN>0!7'?$SPMXAT
M)])\;WOB!M=_L:ZMF>&2SB@V*&!9LH1D&0 !<$@/U."2 >H^-O'&F>!=+M]0
MU."\FBFF$*BUC#$-M+9)8J ./7/MUQA'XLZ9;3V<NIZ/JVFZ/>J@M]5N81Y+
M.0QP=I.%P%VL,ALDCY1N.-\?)8;SX86MS;FUN8)+V&1)C,,;2CX:/# .2#C
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MZLTMC=1QR&,Y#!6/#!5SQN&"S@;C\B%@[8]C/;W?[2;W$"+Y4NC+)#.RC;<
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M19+Z]_X3KP-?2ZU<W\OE-:Z>TR2(=LB*DL0 D(2,<XW85\XW/GVP@'K28!H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 451U/6M*T6..35=3L[!)#M1KJ=8@Q] 6(S6;
M_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?
M@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H
M:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\
M\&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__
M !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =
M!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__
M ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@
M_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:
M]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8
MP_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%
M4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )
MWX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\
MZ&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_
M /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/
M_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5
M'045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/
M_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)W
MX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z
M&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\
M&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\
MQ5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\
M"=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_
M .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0
M_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C
M#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 5
M0!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045
MS_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"
M=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\
M^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0_
M_!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_
M ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_
M  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#
M_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AK
MT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P
M8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\
M%4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%
M%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\
MPG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_
M /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT
M/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#
M_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51
M_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?
M@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H
M:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\
M\&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__
M !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =
M!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__
M ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@
M_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:
M]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8
MP_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%
M4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )
MWX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\
MZ&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_
M /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/
M_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5
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M=K=)*P7(&2%).,D#/N*U* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\
MXFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_
M /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\
M0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H
M?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P
M?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+
MH?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B
M@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\
M'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_
M (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_
MX03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:
M'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B
M:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\
M^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"
MIH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_
M^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!_
M_0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA
M_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH**
M.?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?
M_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\
M@NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A
M!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?
M_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)K
MH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X
M03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*F
MA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_X
MFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]
M"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_
M .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y
M_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__
M $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""
MZ'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$
M\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^
M"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@
MHH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!
M/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'
M_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:
M/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*
MFA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\
MXFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_
M /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\
M0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H
M?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P
M?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+
MH?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B
M@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** ,K3O#6AZ
M/<M<:7HNG6,S(4:2VM4C8KP<94 XX''L*U:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<S-XTL;?QO9^%);:Z34;N)YXBVSRS&N[YL[\\[&P ">.0!S739% !11D>M%
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MY/ _QCT'69(91X?FT]=.FO,!(X6 *C>(RJ*O$9^8; "2 "@V@'30>+=2\/\
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M_$SAL_LV6$7EO(K.2Y.]BR QALAWP  'V@&SHWB'Q9KFFZ'KEEK5AJ&GWMY
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MP74$%V7 (!.[<<XPS"[#XC'PL\?^([/5].NY=(UFX;4;*]@A#N\SJ6,7'7+
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M-\]ND,#,B_+SD2X(^9>0<<T >@;10% KC9/B/I5CJMKIVM6>IZ+<W3.L(OX
M$<J5& Z%E.=W&#_#SC*[NSH 3:/>C:/US0>G7%<AX>\9W>O>,-9T.71)M/72
MHX6=KB=7D9I%#*"L89 ,9/\ K">G'WMH!U^VC:,YH'2EH 3%(% & 3^=.HH
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M?K[TM% ";11BEHH 3:*-HI:* $V\T;12T4 )@9!]*4C-%% "%0:-HQCM2T4
M)M'/O1BEHH 3:*4#%%% "%0:,4M% "8]Z-HQBEHH  ,#%)MY[TM% ";0>O-&
MT4M% ";1BC I:* $VBC:*6B@!-HHVBEHH 3:*3: .!3J* .<\3?\)>#:CPI_
M8?\ ']H_M3S?]G;L\O\ X%G/M4OA'PXGAK2'@:9KB^NYVO+^Y;CS[E\&1P
M%&1@  8 '?).[@>E+@"@!",T;1C XI:* $VT 8I:*  C-)M%+10 FWGJ:,"E
MHH 3:*,<4M% ";11M&:6B@!NT>E+M&,=J6B@!-HSGO1MZ<G\Z6B@!-H)S1M%
M+10 F.:-HI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "$9I-O/6G44 -V^]&W
M!IU% ";:-M+10 W;QBEVTM% #=HX]J7;^=+10 W;[FC:*=10 T+B@+[]Z=10
M W;VS1MYS3J* $V^])M]Z=10 FVC;S2T4 )M]Z,4M% #=N>]4]7AOI='O8]+
MF2#4'@D%K+(,JDI4["W!X#8/0_2KU&* .#\'>$?$5OJB:_XQU\:IJJ6S6T,$
M4*I#;*S[F*X W,0J#< O&0=PP1WE &** "DVTM% #=OO2[:6B@#%T3P\NEN]
MY=WDVHZO/#'%=7TWRF79NP%C'R1J"S?*H'7)+').R%Q2T4 )BC;QS2T4 -VC
M.:4KQ2T4 (% HV^]+10 W;Z'%. P,444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%(3CM7D;_&#Q)'X3_X2A_A^RZ-@,+EM709
M!?8#LV;N6([>_3F@#UVBO(+7XQ^([[PQ/XCM?A])-I,&[S)TU5"5"_>.SR]V
M!U)Q@#)Z FM7Q]\3M4\ 2VS7GANVN[6ZDD6"6#47SA<8W@PX5B#G )Z'GC-
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M''&,$'(.,9 .JHKR#PK\9=;\9WEQ;:+X)CE>WB,LA?5U0  ' YBZL0%'N1G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWWF8DNR@%54'&>5W++X6\2^/M*T*Q\+2>!K@ZI:Q):PWTTF+18QN0/(R@_=
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MEF''39E=V0>>LY?%W@/XA>(/*\,7NJ>&]5O/M8-F0[1R.1N=03W)(96QT!R
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,UJPM$GF\JX6:-\[-W3[O^L0@9;@G)R.0#T&BN(/C:YUGQAJGACP[9Q22Z;
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 ASVKB/&'@[6_$?B#0=0M-6L+6+2[G[0JR61=\[><N'!*EE4%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &)XKT.Z
M\0Z%)866L7>D7#,&2[M&(=2.W!!(]1D4GA7PU'X7TR2U%_?:A//-Y]Q=7TOF
M22OM5,Y] J* .P K<HH **** "BBB@"EJNG+JMBUH]S=VZ,R,SVD[0R85PVT
M.O(#;=IP0<$X(ZU+86-OIFG6UA:1^7;6L2PPIN+;44 *,GDX ')YJQ10 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% "$XIN30>M)0-!D^IHR?4T44AAD^IHR?4T
M44 &3ZFC)]3110 9/J:,GU-%% !D^IHR?4T4AH 7)]31D^IKFM4\1:A:7&H-
M8Z5%>VFFJ/M9^U[)L[0Y$<>PAB$*GEER3@=*VGOHH[JWM6?$UPC.B=R%QD_A
MN'YT ]"WD^IHR?4TW) S4%M>P79G$$@D,$GE2$<@-@$C]10(LY/J:,GU-(#D
M4M PR?4T9/J:;D\UR.G>.6U3QI-H=II%Q+9V\DL$^H!ODBFC )5AC !S@'=D
MD'C S1?6P'89/J:,GU-(<C/M7":YX\U72O'5GX7M]!M;F6^C:6VF;4&C#!58
MD,/*.T_*<<D=.?0ZV#S.\R?4T9/J:P?"OB:/Q1I+72VTEI<P3O;7=K(0S0S(
M0&3(X(]^X(X%5?%OBV3PLVC8L1=IJ5\ED6,_EF,OT;&T[NAXXH6KLA'49/J:
M,GU-(,YI,D#U-%QCLGU-&3ZFBB@- R?4T9/J:** #)]31D^IHHH ,GU-&3ZF
MBB@ R?4T9/J:** #)]31D^IHHH ,GU-&3ZT44 *":?4=/'04"8M%%%,04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!&>M%!ZT4B@HH
MHH **** "BBB@ HHHH *0]:6B@#Q_P"('@S6W\17_C+PKJ_V>XM8U:\M&+()
MC$@;!(.&!3:-K#'OS6ZA@U7XB^'+^:R1'N-#EGV2("R$O"1GW&3S783Z!I]S
M+=/)'-FZ.9U6XD5)#M"_,H8 _* .G(%%WH6FWNH6=_/:AKJS5EA<.RA0<9!
M.&&54X(." :.W]=&)_U^'^1Y9X4U*XF^(&BQ)<2RVMUIMUOE<!3=;9F D=!Q
MGY< DDX[C-5-%NCIOAB"&U@@5=0\7-:3;OD#Q^86"$CH"5 [C!(QS7I^F^"/
M#^D7=K=V.G^5<6D;QV[^=(VQ7)++@MR,DG!X!)QBA_!'AR2RO;0Z8GD7<_VF
M91(ZGS,YW*0<ISS\N.I]30U_7SO^0[_U\K!X-T[5-*TB>RU6Y@G>.[E,!AF:
M3RX6.Y$)8 Y4'&/3%=!(Q2-F52Q4$@#O4%C8V^GVP@MU8*.2TDC2.QQC+,Q+
M,< <DD\59H>HD>-Z'K%Y+=^ -1,[?:M9EO!?J&PLZDL?F'0[#C'H!@5M_"J&
M*+4O&GEQH@_MN50%4# '0?0>E=A!X7T:WOH+R*R GMS(8"9&(A,ARY12<)GG
MH!3]&\.:7H,EY)IMN\+7LIFN"T\DF]_[WSL<'Z8H6G]>@V[_ ->O^9K<5Y1X
MH_Y."\'_ /7I/_Z!)7JQK!OO!VB:CKL&MW5M,^I6ZE(9TNYD,8((.T!@!P3V
M[T?:3[?Y,.C1YC?:A=Z5#\3]5L'V6K7MO:JRM@(YVI,P(Y!PXY[&F^,=+U33
M-1TE;R:V^PS^)K2XLK:"=I#;J58,.57:"5R,<=>G.?5X_#&C0Z)/HT>GQ_V?
M<;O.B8EO,+?>9F))+'^\3FJ<W@;0+FTM+:>UGE2SF6>!I+V9G5USM._?N.,G
M )P.<5479IOR$]4[' :)J<S^/-*\B\FN8)=8U*"2YE&QI0L1;R\9.Y$. I)[
M<*!6;XCD?0[SQ)86\3NVDWT&MPNQ8@P/L#P_[N2<*<C /I7J5IX&\.V%W'=V
MVG^7/%<R74;B>3Y)7&'(&[ ##@CH<#C@5<O/#>D7\NH/=6*2-J,"V]T2Q'F1
MKG .#QU/(P?R%2M-?ZZ,.K[?\/?\SB-?N(([;PU=0W$T3:OJBW L%3*W@<8"
MR9("J%VDG#<\X)YKG;G4M1O?@AX?N7O)%O/[3CB6;><@"=T'/4_* *]8U7PO
MH^M2V$E]:;Y-/?S+5TD>,Q-QT*D'L..G JH? OAXZ%%HHL&73H9_M$4*W,J[
M'W%L@ALXR2<9QFFK+1?UK_D+7^O1GFVJVFKCX@R>$['5)=PTV>\L7N;J1=D\
MDI8/GYBQ09 SD\$\5[+9M(]I"TK(TC1J6,;94G')!]*RM1\(Z'JM_9W]Y8"2
M\LUVPSB1T<+@C:2I&X$$@AL@Y/K6TBA1@  #C Z4-Z D[W'4444B@HHHH **
M** "BBB@ HHHH *>O2F4]>E F+1113$%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX[E+C;)+" 1Y<AQR.3T ([$5UT:+&@15VJHPH]!Z57EU"U@N4MGG07#HTBQ
MY<JO4@>@R/S%4O#7B*S\4Z#;ZQ8I-';S[@JSH$8;6*G(!/<>M C7HHR/6DR/
M6@8M%&1ZT4 %%%% !1110 4444 %/7I3*>O2@3%HHHIB"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME/7I0)BT444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3W/G3:E)"SS.HP0H)DRN,#G/;M6WX*\,7OA;2Y[;4==NM:N9IO,-U<AMX7
M3EFX&">O>GU8=CI1TI:**104444 %%%% !3UZ4RGKTH$Q:***8@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex3-7_004.jpg
<TEXT>
begin 644 ex3-7_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" <6!7@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW487D;8I#D,CA6_@^9OO9<[%(4F[XM\/^(=2^'GA73M.T"9+[39K.XEM(;B
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M''%=0Y?S%?:=^\A>2![9!P>: .Y\':ZWB;P=I6LR)&DMW;J\JQLI4/T;&&;
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MD-V7PN=V3L SOZ9XQ[D;5 !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 8?C"PUK4_"=_8^'KZ.QU2=%2&X=BH0;AOY
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MXL[0.H&1@<E@#B)K7Q+XO\,7&M6&C>)8-9U,"ZL[S^VXX8;9/FV)&BR+\NS
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M#N<$$EADJI5=71IA\0?%OB/[?/?06&B7?]GV]I:WDUN'=&RTLAC<;FW+\O3
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M3C/&<#I7C\VIWMG^TKJ,EI8ZEJ(BTQ(I(+>>.0A&$9&U791&@9E)4GJ2W1N
M"?P;+XD\*?$:]\ :CK.HZM:WEDUY;ZB8,R6SD<R9<L F0PYW OMX&YL\YX)\
M.:]X^T[6EA\>ZS8K9:J1"#<FY8K@?-)(C*)#\D>UE8J-C$#Y@:](TCP]/=>.
MM3\>W^CSPR_8D@TZQE:(W POSL1G:CGA5_>="V[&>,_X.Z-XJ\/V^KVWB?2Y
MXI[V[:^^UM<12*[L%# A9"0Q/.0O8Y/04 0>$IY_B5KOB&YU6]U,:-I\_P!A
MLK**XDMP3M DDD>(('9MH.W<=N]@0 5)7PW+J-S?>+_AK>ZWJ$MU9#SK'5VN
M_P#2(XY%5D!PRR.49@21E3DJ=HVAH?#_ (=\1?#OX@Z_<VFBR:OX?UJ03*]D
MT:RP/O8JA5Y%X&]@3TQM.1RM=5X.\/W":SK'B[6-,73]:U<QHUKYR3_98HT5
M HD4<[RN\X./N#&5H YCX:WMUIVA^--,\6ZKJ-Q/H]U(+FYGN9C(MMY?#ISO
M4$*[*5Y.01T%/\86&I:!\$[BYA\1:O8:A'''<S2S7DDKF1W3,7F%3(H&=BA=
MG;<<%B;7BCX>3:[\2K.\1Y(]"OK<-K4*2$)=- RF%67!!))4?[J-@@]=CXJ:
M;JVM^ K_ $?1M-DO;R\V*N&B58PLBL2WF,.P.,9(..G6@#DM3U^_T_X.>#=1
M==1N;#-J=5>SE/G^0L9).],%1N5?FW*1@*3\QKI/ AT+5$UF[\*^(]1NM/F2
M*V19IY)6L716_P!6LZD@$.I&=P)!'08K+CM/%>E^$O!MH=$DNH+."2#6M-:1
M)9)81'Y>T?,(G4]0I);[@&</5WPOX;.E^+-4\0Z9H%WHNG-I_P!G_L<>2K75
MPLCL9 %E,8P,(N2!\Y^Z.2 </\,_&%_X<\ >+_$6NW%WJTEC=QQX:YDFWOP@
M E+-$5RR\ID@<G<"@K<N-+U>[^$EOXQAU_4HO$D5E_:;W37,WENH'FM&(<B(
M*0JC&S:=HZ@Y-/X=?#;5HO!GBCP_XFTF.QEU?E+@+%(JD#Y#^[EYVN=P7:H&
M#\QSA;^GP>-+#X=/X%_X1D_VH(FLH=0+QR6#0,^TRL2P8'86.W:3P#MYV@ P
MO%7BK6O%_P '[+Q38ZGJ>E7*W*6US9:>"8Y7W,A8,B[QNW*<.^W@+RV"=/QK
M::QX(\1^&M<M_$VM7DM_JRQ7=I)<,]N5D.72*W 9@AY  WE?EQEL$KXQ\ ZO
M:?##3/!'AO1Y=8>WE2X:_N)(41&W.S[ T@(;<<8VLNQR,D\U?^+FA^(_%=KH
M,>C^&GNS:S+>3Q7<L"Q]/]2_[T$GLVT[2#PQ[ %7Q_XF?2/B/;)XGM=;@\("
MU2*&XLII(HC=,X;S6:)E8[0A&PDL-I95YR>]\$67V'P^4C\0R:_:O<2/;7\E
MQY[/&3@*7R02I!7CCCH.@P-:.LS>(M3@U3P==:YX8NK:$I&'@9H)55B^V-Y3
MN)W ;ALP5X#'YFT?AMX<NO#>AZC!<6[6<=UJEQ=6UDS*QM8&8!(R59EZ+G@D
M?-ZYH ROB)XCOT\3>'/!^G:@=*;6)B;F_$JHPA (:.,E6Q(V?E88(8*!UXR_
M&,LGPIUK3/%%I>W]QH-PZV%[I<MW+.2Q5F\Y&E=AN"HHQQPN,C<2-3XH>"M?
MUZZTC7_"E[':ZUI!D9 QVF52 0H;D9R"NUAM(<Y('6S<1ZEXYU;0X[_PY>:9
MI6G7#7MT;UD5VN$7$*Q-'(6P&=F+8 .P#/)! .7^(^@0GXI>"";[4R-0OYW<
M?;I!Y(581LBP?W8."3MP?F//"X]:TK3ETG2[>P2YN[D0IM\^[G::60]2S.W)
M)/X#H   *X/QK9:YJGC3PQ?6/A6[N+;1KN266Y^T0*SJP48B!F&0<9.]0?E7
M!'.?1()&FMXI7AD@=T#-%(5+(2/NG:2,CIP2/0F@#S'Q]\.=:NM>?Q=X*U67
M3]<,8^TP^<52[*;=@Y^7HH!5OD.%SCDF'PK\44U7QE:^&_%?AS^S?%$+R0),
M%5HT)3<V&8[D#!5QM+!OE.<$5I+)XOT#XB>(-0AT274_#=](C%+>5%GBDCMH
MAYB*[*'#'Y" <Y3M@!JJ>&M7\6?%NQ\5ZCI,FDZ7H]OY5O%=/&T]U)E^?W;'
M:JLV>6(.T$ [S@ K3ZO=>-O$FL(FBZ_<6.C3RZ;''INK0VP\X;@\S#?&^X_*
MJ@EEVE^^16,/&?CSX<?#!SXFTE7U*.\CM[*[N[L7/GB3?(WF;7+?*$(!W#[R
M\?*<ZFN:3X[\&>.=3UGP7IEMJ>D:N4GNK-]J^7-D!B/G#9/+;AQ\YROR@UJ:
MMX(U_P ;?#J^L_$MQ9Q:]>2)=01QAS!8NBJ%C'S-U ?<PSS(V-P49 )W^'VK
M:6^@WVB>(;^75+*=#J,E_?2M%?Q$ 2@HV\*Q"J%P./4D*1QVJZ'877[2<%G<
M7M]']HT]Y86BU&5)4D*OD(R[F4 ;R$S&H'J,*^YX5N/B=?)8>'M<TK^S[>U\
MG[9J[W(DEF1&9BJE7Y9U$:%@3M^<G)8!7^)]'\9VGQ>M_$^@:*FIVG]FBS/F
MZ@(50DMU&02 2&VD.#U&&QM +4UQ?V'QZTZQ?Q!>7-K>:5-)]ADEC18OG8CY
M=BAE^7 VDR_(2QV YJ>%+J?XFZ_XCO-5N=0BT:PN/L5EI]O<RP(#M D=Y(PG
MF$X&%+MM#L",%2;UW:>)W^-%AKEOX>G&BQV3:=<3O- &(,C-YBA9=S)GRSA@
M2!NPF[%9?A_P[XB^'?Q!U^YM-%DU?P_K4@F5[)HUE@?>Q5"KR+P-[ GIC:<C
ME: #1K[5T/C;X?3:[J4E[IL37%CJ_FB:Y6&1%=4*@&1V&[!9%)^; *'R\\GX
M*T'6O$WPGU/7+OQ5XC@N;9[F:T4WY@AD=5#AF=R0R>8OWLKM8/SWKT"U\-7T
MNG^+/$VH>'9!K^O6_P!F_LR*Y@D:&)8Q$%$S#9\Q&]LY& HVDK@X/@GPSXJ\
M-_"+7M N_#TKZG>27"6\<<MJRXD@"AW)D (#+@YR<$8!'0 ]&\#:C<:OX$T*
M_NVD:XFLHFE>16#.VT L=P!Y(SG&#G()&"=J62VLH)[J9XH(E!EGE<A5  Y9
MB?0#J>PKE_AEI^I:1X!TW2]6TI=-O+,-$\2.C*_S$B0%7;[V<G./FW< 8KG/
MB))\0M2U.*Q\/^%K6]T2(J\PO9H@MTXW?*RB8$Q<H=I )*\Y'! -OPI&?$/B
MG4?&SVK16L]M'8:0\B-')):J2[RE2>CNV5R =J*<#=SR]OX\\.>(-7O]2U7Q
M#IEM&D#6VCVKLI>W\QVA>:0LK)O8@8^\$B.2-K,3K>&+OXIZOKD,?B>PL=#T
MR#]\\ED(Y'N2.!"<R2;5.<E@N?EP",YK:U3X>^%&L+N2V\)Z0UT(&\I4L8^7
M"L%&W* \M_>7M\PP" ##^".KZ5/\-]'TNWOK9K^&.9Y;07"M,@\Y\L5'(!+
MC(Z,.3U.M\0-2FNK$^$-(6.?6=:B:%D()%K:M\LMQ)@C"@$@9/+$ !L$5E^
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MYFR55"B,V(E&6.2"S;,#:&W ',Z&7^(/BSQ8-5U*Y_LK2[PZ?;:5;7S0%2N
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M+CPY$C(DF#*5DP21M.W [U''X=\0I\?)O%)\+R#273[,+E;BW+GY GG,K.Q
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MR0QLK*?F)#Y5F&6!R>?O$\ 8KK* "BBB@ HHHH **** "BBB@ HHHH ****
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M&7BGQ#KGC3QEINMZD+N+2[KR8%BMEBC7]Y(IQ@$_P# 9R<9^]R1ZC0 4444
M%%%% !1110 4444 %%%% !4<\;2PLB320L>DD84L/IN!'Z5)10!S?@[P99>"
M-+_LW3;R[EM-[/LG6+.YL9)9(U+'C&6)XXZ 8;XR\$V/C>SM[/4KR\BMX)UN
M$CM_*P74, 3O1L\,>.GM7344 1P1M%"J/-),PZR2!0Q^NT ?I4E%% !1110
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M+91:I'N\\RG;DOD8XP_0XP5[YP ;U%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC3YGCNK;3((?+N 0H5OD<#"MO7) )7&" 0?.?A]XY\9>*OB&- U#QB_V9%F
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MM2U-=0OA<S1SN"6*$-PI.X@_+M(*X&&'!.6(!WU%%5[>_L[N62*VNX)I(O\
M6)'(&*?,R<@=/F1U^J,.H- %BBL#6?%NGZ-KVC:*[QR7VIS^6(!*!)''L<^8
M5/5=R!>V<G&2,5P[ZQK%M^T)::%+XANIM,EM'N%LRL6T,5D(C; 0X&-P/SM@
M+G/)4 ]7HJ.&>&Y0O!+'*@=D+(P8!E8JPX[A@01V((IMQ=VUFL;7-Q% ))%B
M0RN%W.QPJC/4D\ =Z )J*;)(D4;22.J(@+,S'  '4DTT3PM</;K+&9T17>,,
M-RJQ(4D=0"58 ]]I]* )***:LB.SJKJQ0[6 .=IP#@^G!!_&@!U%1F>%;A+=
MI8Q.Z,Z1EAN95(#$#J0"R@GMN'K39+NVBLFO)+B)+5(S*T[. @0#)8MTQCG-
M $U%-21)%+1NK $KE3GD'!'X$$4Z@ HHK#\*:;J&DZ+]EU/7/[:N%E?_ $PQ
ME&(SC:1O89!!'&!QTSDD W**JQZE83,JQ7MLY:=K8!95.95!+1]?O *Q*]1M
M/I67:Z3J%OXROM3G\02S65S %MM)*!4AVA S@YRW(]!C?WXH WJ*AN+NVLUC
M:YN(H!)(L2&5PNYV.%49ZDG@#O3H)X;JWBN+>6.:"5 \<D;!E=2,@@C@@CG-
M $E%4_[6TW9;/_:%ILND5[=O.7$RLR*"G/S M)& 1W=1W%6)YX;6WEN+B6.&
M")"\DDC!510,DDG@ #G- $E%1PSPW*%X)8Y4#LA9&# ,K%6''<,"".Q!%24
M%%5TO[.2\:S2[@:Z3.Z$2 NN A.5Z\"2,G_?7U%<_P#$77[CPO\ #_6-8LVV
MW4$06%]H;8[LJ*V#P<%@><].AZ4 =117%GPQXGL/%FE7FE^*)YM'5-FHVNI'
MSBX"@ QX489B"2<@*3D K\E:OB+Q7:>'-0T*SG422ZO?"SC02*K*"I^< _>
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M^T^&&IW>L_#C1M0O[EKFZFC<R2L02Q$C#G!/I_\ 6'0 '744V21(HVDD=41
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MJ+PAJ TOQ'-<-83:[X@3RKR:,RQ0(BQ&*,*N6;@<GD$ECR,# !Y3-X TBZ^
M8\275KJ4VL1V2R02&$J8(U<?*D*L$\HC<YD.20[RG).*[;QOJ.I+\/O#&NC2
M+?7=.MTCO-2M)\R&93 1D@!U*C>SEB2 44\U>_X036_^%3#P1Y^E^9Y7DF\\
MH;=OF;\^5LQNQD;L[MWSYW5KKHOB2UTSP\MG+IK7>E1B&82L1%=((U4\K'NC
M)(.,95>ZOQM ,GX73^$M6NM:U_PF%M(KT6\5SIGDK$UL\?F -M4D .K C'&5
M;G.0)/C-XLO_  CX#:XTT*+B]G^Q"4LRM"'C<EU*D$,-O!['GM6GHW@L6?C[
M5/%\XA@NKRV6U6VMCE-N59I'8JI+DJ.W '4Y^71\9>%K;QGX5O=#N96@%P 4
MG50QB=2&5L'KR,$<9!(R,YH \\^(_AG2M!^%/]N:);QZ?J]@MO)'J5FHBN)"
MQ6-BTJ'<VX2,3\S9/.3UJM\1([+Q1\#E\97^F68UMK"W"SQX;RP\\18*<G'?
M .2NYAGEL]5>>#_$.O>"+;PCK=Y8BU7R8[K4('D>>>*)\C",,)(P2/+%G&2_
MRGBKWC'P?/KG@.3PAI(MK2R,$$,4LLKL8EB=2%VX);A ,EL\_F ;VB^'-&\.
MI-'H^G0623.7D6%=H8EF;./^!$#T& .  /+_ (J>'=$E^(_@B[N+&!9-0U!8
M;N9XV*3A"FQ'P&!)SMY7YAP655R/7K9KEHR;J**)\\"*4R#'U*K_ "KD?'?@
M_4?$M]X?U'2KZ"TO='NS<(9PY1_NG:0I&0=H!]LCO0!P7C?PSI\'Q:^'^EV=
ML]E9I 8$DMKB6&39&2P3S#QQD_=;S#O.<$H3;\.:7I_@GX^2:#HL4MGIM]I
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M#DXP,"@"K\-?#FC:7X0T;4['3H+>]O=,MGN9HUP9288\D_\ ?(/U+'JS$O\
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M+PIJ:PZI-XGU5=2O]0MTM&:&,)'%"J%3L4@X9B69NQ.,  4 <GX.\!:%XO\
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MJ&SN'. <#DL<D\M9_"74(['QK:7&I1!?$CB59(6*M ZN[JI^0!E)<!L!> <
M9X .*U#3M#\-Z-X2O-"ACG32M86.3Q(56W6_?S<M"@W 2+C=^\=EC"Q%1(=Q
MKH?CMIB7?B7P0Z2,]Q/>&V%MCS#("\?*QR?N>"<'<1NW*#E1\NC+\-?&=SX-
MTO0Y_$6F)_94RO:)!:;4;8X*/,2")-J[ALVJ"2"S,1SI^./A_KOC&WT!9-1T
M_P [3I&N)WEB(\V1B#L0IM=(QC P^XC;DEE#4 8_BGPCIVI_&K2;1YM39+_3
MIVO527SL1AR=NYG,EO&^60E0JD-L7[[[<_PA96/@[]H;5?#VC2+#IES8+_H:
MS,0CA$<;O,8%F^^PV[\+(>@W;>]U'PSK-Y\0]+\41C3$2PMI+<P.[N\H?=R&
M*D1D9'*KN(W L0<"I_PA&L+\7/\ A,X[JQ2U:+[-):X=G>/;C=N8$*V0#A H
MXQW9B =Y/"MS;RP.9 DB%&,<C(P!&.&4@J?<$$=J\/\ @'I<,^A^*-.N4N[6
M07J)+"LH@GBVYP"\968'(((.U>#MY+@>Y2%Q&QC56< [0S8!/;)P<?D:X+X=
M^!M0\!Z?JL >RN#>7/GQ11,T<<0X&P%E9\ =V9N@X!+,0#S?PMX T+5_AAXA
MO]2CGV:<]\FF7%S*1#&J*3]H @R)"3@,P,N?)"J2% KT;X)WLU[\*=(,\SRO
M"980SON(59&"KU) "X !Q@ 8&,$O\+^#=8\/^$-8T.1M+G-[)/+&Z-+&J&4
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MHGA/X@.+/3_$GBV"32;4Y?[$K"YO%!&U)9" 5'RC)7YF#,"3G=7I% !1110
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MTR1L2V>1N(W8XX'// )P" :E%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!@ZUX0TK7;Z"_N3>1:A:A_LMU;WDD;VY=0I9 &V
M\@#(*D'N""<[U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% &=KNBVWB'1;K2KN2XC@N8FB=K>4QL RE3R.O
M7H00>X-+H^C6FA6,=C8&=;.) D4,L[RB,#H%9R6 Q@8S@ # '.="B@ HHHH
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MBG_^4"W_ ,: /0**\_\ ^$2^(?\ T4__ ,H%O_C1_P (E\0_^BG_ /E M_\
M&@#T"BO/_P#A$OB'_P!%/_\ *!;_ .-'_")?$/\ Z*?_ .4"W_QH ] HKS__
M (1+XA_]%/\ _*!;_P"-'_")?$/_ **?_P"4"W_QH ] HKS_ /X1+XA_]%/_
M /*!;_XT?\(E\0_^BG_^4"W_ ,: /0**\_\ ^$2^(?\ T4__ ,H%O_C1_P (
ME\0_^BG_ /E M_\ &@#T"BO/_P#A$OB'_P!%/_\ *!;_ .-'_")?$/\ Z*?_
M .4"W_QH ] HKS__ (1+XA_]%/\ _*!;_P"-'_")?$/_ **?_P"4"W_QH ]
MHKS_ /X1+XA_]%/_ /*!;_XT?\(E\0_^BG_^4"W_ ,: /0**\_\ ^$2^(?\
MT4__ ,H%O_C1_P (E\0_^BG_ /E M_\ &@#T"BO/_P#A$OB'_P!%/_\ *!;_
M .-'_")?$/\ Z*?_ .4"W_QH ] HKS__ (1+XA_]%/\ _*!;_P"-'_")?$/_
M **?_P"4"W_QH ] HKS_ /X1+XA_]%/_ /*!;_XT?\(E\0_^BG_^4"W_ ,:
M/0**\_\ ^$2^(?\ T4__ ,H%O_C1_P (E\0_^BG_ /E M_\ &@#T"BO/_P#A
M$OB'_P!%/_\ *!;_ .-'_")?$/\ Z*?_ .4"W_QH ] HKS__ (1+XA_]%/\
M_*!;_P"-'_")?$/_ **?_P"4"W_QH ] HKS_ /X1+XA_]%/_ /*!;_XT?\(E
M\0_^BG_^4"W_ ,: /0**\_\ ^$2^(?\ T4__ ,H%O_C1_P (E\0_^BG_ /E
MM_\ &@#T"BO/_P#A$OB'_P!%/_\ *!;_ .-'_")?$/\ Z*?_ .4"W_QH ] H
MKS__ (1+XA_]%/\ _*!;_P"-'_")?$/_ **?_P"4"W_QH ] HKS_ /X1+XA_
M]%/_ /*!;_XT?\(E\0_^BG_^4"W_ ,: /0**\_\ ^$2^(?\ T4__ ,H%O_C1
M_P (E\0_^BG_ /E M_\ &@#T"BO/_P#A$OB'_P!%/_\ *!;_ .-'_")?$/\
MZ*?_ .4"W_QH ] HKS__ (1+XA_]%/\ _*!;_P"-'_")?$/_ **?_P"4"W_Q
MH ] HKS_ /X1+XA_]%/_ /*!;_XT?\(E\0_^BG_^4"W_ ,: /0**\_\ ^$2^
M(?\ T4__ ,H%O_C1_P (E\0_^BG_ /E M_\ &@#T"BO/_P#A$OB'_P!%/_\
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M"W_QH ] HKS_ /X1+XA_]%/_ /*!;_XT?\(E\0_^BG_^4"W_ ,: /0**\_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** &R!S&PC95<@[2RY /;(R,_F*\8\3?%'Q;HGQ1@\(6\.BRQW$]M
M#'/+:S*?WNT9/[S'!8],]/7(KVFOF/XB1D_M(6("N2][88"+\Q_U8XW_ "D_
M^.^O.: /2_B?XV\7>!DTV338M)U!;H3>9&ULXD01J'+!1-DJ%W%CC"X&2,BK
MOPP^)B_$#2+F*<6EGKEMG?;H6973 Q*%.#MW'! 8XP,D;A6EXK,<GCGP3;2*
MKK+<WFY&:/##[+(#E2-Y^]_#\H_BY*5XWX\\':I\)/%MOXS\,,ATQIR5C=01
M;LP.8F7O&PR 1@CID$*S 'N7AK4->U&YU3^TOLB6]IJ$EM"8[1XS/&JKAP6D
M(^\64D C*D<=G>-M0UO2/"U]JNAOI_G6,#W,D5]"[K(B#<P!1E*G ..#DX''
M48_PJ\06WBCPY?ZQ;Q+";G497EA!!,;E4)4D(N[@C!);C'(^XG=4 >6?"?XC
M:Y\0[?65O8=.M9[$P^6\,+E6#[NJE\\;#W[^W.)X:^+'BV]^*4/@_6[;1+8+
M<RV\\L,,HR45B-A:3^(J "1_$.*XS2-<MO@W\9=?@O8);C3F#Q!+1AE$<K+$
M=IV@D+A2.,;FP3C!9\1=(U7POKV@?$)8)H[G4IA?36UPI*VLX82+"Y"IQL(7
M!PQV/SZ 'O>M:OKD7C?0M%TG[ ;:ZAGN+YIXB\D$490!E D7[S.%'!P>>0"*
MX;XI_$OQ5\/M5L+>VBTB[@NX"X>6SG4AE;!&?,VG@KP"2.X *YZ[P%JY\7_:
M_%YL?LUO>)':V(DP9#%'G>3AB!^]:4=B0BDCI7DG[2D9'B'0Y<<-:.N=DG9_
M4_(>O1?F'\7!2@#UN;6/%$]YX8L+"YT-Y=0LI[N^O%ADF@4((MIA D4LI:4#
M)/(.>.E<'K/Q5\8:1\4(_!?_ !(Y=]W;6WVS[#,N/."'=L\\]-_3=SCM7LVF
MM$^E6;6\JRPF!#'(LYG#KM&")#R^1_$>3U[U\Y^,8DD_:@L%>9(1]OL&W2.7
M!(6,A0%!*DD  'N<D@'( /:+6?QJOB&ZTR^GT06S6WG65[#9R?.P(#J\9FR,
M%E/#8((YSD+YEX6^.VL3>,;72O%UII>G6,XPUQ&DB>667=&Y)=@4;*_-P,,&
MS@5[W7C_ (M^&\/CCX8:->Z9:P+K\&GV\D,NY%-POEKF-G7Y3D?=/0$<%030
M!W7B;4];TS4]#CTY[-H-0OQ9R1RVKR.@,;N7#+(!P(SQCOG/'/%?%CXD>)/A
M]>:9'91:7<Q7D3DF>VE!5DV@X(D P=V<=1W[$\+\-?&5U->>&?!&J6<JW>F:
MR9(FF*KL00S*T;AQD,KOP.IZ#:5&;O[2ZD:CX=;L8IQT;L4[_=[]N?7M0!ZA
M+>>.)O#$.J:7J7AR\NKFW2:VM'L)8EG)7?M63[01G;G!Q@XYP,D9>N?$^31/
MAEH>NS2::NKZPD(B0EF@C+8,CLJGS-B#@[=Q#%1SFJ?A;2_%-MXT\-7>N7\%
MSIATB2*P2VC=5@;9#E'8J2Q95W?,_)5B,8P>@^(VB:1XVT6'PO-J4%MJ5T[W
M&G,^6!D@($F " 2%=E(Y(!)P=IP 3ZM!XST31K[4-.U>WUBYAMMZV5U88\PH
MG_+,Q$'>Q!8@A@QPJ^6.:Q_'WQ&N?!_A;0+FV-F;_5&C'F7P9HXTV@O(RQX8
MX++]T=^G0'R*63XA_ W4&C1DN-(E<!&=#+:S':Q [-&W+' *DE?X@*]7\6Z%
MIGQ>\&:"ECJ4-A<S1&_MEV^;\JJ$DC.U@!M>1%)Y((QCK0!I>*/^$M\+^$]2
MU:U\0#4FM[7?)'<6,:NNW[SQ,@ 4[3N.]9!E>B@D5WM?+(N_'OP6U4VM[%)>
M^'Y)0K1R#?:W2$,-JL0?+<@,<<'Y02&4#/TMH>LV?B'0[+5[!]]K=Q+*F2"5
MSU5L$@,#D$9X((H \Q^*WQ%\6_#S4K+[+'HEU87XD,(EMY1+&4*[@V),'AUP
M1COP,9.GXN\=>(M'^&&F>,-,M].<W$-M-<03PR,(UE7.0RN.A9!S[^H%6?C/
MX83Q)\.KZ165+G3 ;^)F. 0BG>I.">4W8 QE@N3BO-_AUK=IX^\$V7PRNX=0
MC,9>2[NH74@VRL9$P6!VD2&-<8QM'WN=M 'J7PN\7ZEXX\(OJ]^;&.?SWA\N
MUC8",K@_-ER3D$'''ZU'H>O^*M:\/ZWJ\<VC&""XNHM+:*TEE6ZCB+*LA\N5
MF(9E(PJD\9 ;(KQ3P1K>I_#WQ7X@\$3022S:BYL;=MI7;<DE(9 &88C;>"3U
M(VD'CGZ-O-)M=.\%W6DZ=;K#:PV$D$,2K*^%V$ 8C/F-_P !.\]CDT ><_"C
MXF>)_B!K-[!>P:5;6EI$LCF"UG+,2V -Q<HO ;J<^@(#8AUGXB^*M%^*EGX,
M,VGR6]S<PXO);3$FV1@VT 2A2!G8,@-@?Q-RW$? 2T\1RWNN7/A^[TN$QQPQ
MS)?V[2!MQ<J5*$,,;3QG!SR#@876?[3B_:/TC^V+FQFOOM=H)/L2B.-,A0%P
MY)SC!Y))SQCY: /2/BUXX\1^ ]+TV>RN=-EENKC:5:UP=J88]9B<'[IPIP&^
M\AVYUM(NO&FN^#K+5HM9TNSOM1CBNH+:XT_Y0=N[R@RS,=CA0<D,X#.<*<*G
M&_M*2 >'M#BSRUV[8WQ]D]#\YZ]5^4?Q<E*M^ ]/\0/;_#R^N=6L+K1(8IDA
MBL@Z-O>W<@3!04<H%=,_*0<Y)).0#J;CQ'XDB^%T_B&=;&#5[.*=[JW@A,\?
MF12,I3(DX V$,<G'S$'BN?\ AIXU\9>/]*U>]%WHUK-!<*L44EA(Z &/[N1*
MI ) .3N(RW48 Z[XC30W'PW\41Q.TKPV<B2I P+1ML#8;T^5E8@_PG/?->#_
M  W\0>*?#/P\\0ZGX>TZUO(HIA]I9]S26_RKB4(.&15#YYX+*WW5;(!ZA\+O
MBIJOC+Q!?Z#K>DQ65_:0-*QB5DP5<(R,C$E2"R]^QK-\7_%'Q7X8^(]MX8$>
ME26UR\ 2X_LZY>0+(0I(0./,(.[ 0G/3.[(&?^SGH^D)!J.KP:E]IU0Q+#<6
MOV<I]D4NY'SGA]X13\N,8P<\5S7Q<C:/X[6+^?%:[S9L)YFFB2/Y@-[/N& ,
M9+1%0 .H<,: /8O$FH^-]%TVXNK'4O#.H36:K/=6TEI);F.W.[,FXW#8 VL>
M1R%;&2,&7XE?$2V^'NCPSM:M=WMV62UAWA5)7&YF/7 !'0'G XSFH_ ]KK-I
MXJ\4CQ!J$5WJ,IMI1Y"LD2PD/LVH4 &"'7=O<G8,XQEO(OVBW>Y\0Z#>PWGG
MZ;/I^;<(6:,G>2SJV-AW*T?W23A1D ;<@'K_ (9;QCKOAZPUVXURQMIKV(7*
M6@TW?"B.B;5/[W>V "P.X<R'.0 !E?#GXHS^)=:U#PWXCM;/3M?LW9!%#(=L
M[*S"15!R,IM'1CD9(X!KN_#SVTGAG2GLW62U:SA,+J@0,FP;2%"H!QC@*N/[
MHZ5\W36[7_[3HCTZ.2,KK"R,$N%E)$8#2G=NP 0KDKG*@E=N1MH [?QO\4O&
M/A;Q_'X:M;?1KA;CR?(EDL;K<?,P.0K$M\V?]6&]/O J.Q\7:KXQ\,:,=674
M= N+=+F&.97T^2(I')($W!FN=I(++PQ1<9)88KQ_XR03#XW:;]GBDM9YDM3'
M.RFY$C;RHD6(;B0"-OE[?F*$X.[GT_PC:>);7XM^()?$GENUUI\+6LMN56W9
M$(#+&KEI!AF.0#@%LL/GC- 'IE%%5[ZQM]2L9K*[C\RWF0HZ[BIP?0C!!]""
M"#R* .>MO$]WKF@Z]?:/;"!K"YGMK26ZA>6.Z,2C+JL?S,A?<HV;B=O3/RAG
MPTU?4=>^'FD:IJT\D]]<)(TDKPK$6_>,!\J\8P!@CJ,'O7G?PJTS2U^%&NZC
M!% ;V,W\;DW+"-,QK\I;<@4;53!\QL DB1=S 9>E>$K!OV?7\07$U\NI):2S
M6[O<RQI!MD(54C0A<'&[)!RSEB>> #Z$HKQ2^\9:K?\ @?X>Z/;;&N?$)CAN
M;J;4 K%86C#CS 2-TG<'<W+(59C@=2_A7Q#:^-M+UO0['0=)MD#0:G%'<2,+
MJ!I-W"")5#C+,&SDLV"2HY /0JX'2O%VK^,_$FK6OAJ;3X-!TTK VJ2023FZ
ME(!81<H@V\Y)+C[AP0U=-XL-PO@W7#9S^1=#3[@PS><(O+?RVVMO) 3!P=Q(
MQUR*X+]GR6&3X9[8R-\=]*LN!CYL*?QX*T :GBJX\7^$M AO;76!JT27MO\
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M,'- 'K=%>$^'H_$>O?LX2Q:+JS3:B))FE'FL\ZQHY<PH8P&#M@85MV0^,@,
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M9;:,2VT*R$JN2A=@N&'!*_QKM)P$_N 'MU%%% !1110 4444 %%%% !1110
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M=\&6&H:1K$.CWVG:BQ^T-'=2$A=A7;Y;1 ,#T.6'!/7I7JM% 'B7AKX3^,/
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MBC&&P6Y52#R4$WBWX9>+-#L]7UZ?Q-I>LRKIL9G;RVMY#(I$AW;RQ_>2#KR
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"21GAAZJW&*W@WP':>&+W4=8G:.XUS5',MY<)'M12S%BL8)+*I)R>3D@'@
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MT%FMEF0'@NT39=<9RA^4Y&<XQ7944 8>EZ=KMMX@U6YO];^UZ7*X^PV9@0-
M, DEU52?FW  Y^4*2Q)-;E%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M U]I>H>!M%FT62>335M$A@-PN) (QY9#XXW J0<<$CCC% '05XCXF%['\?\
M1M"CU?7H=+U"#[1/;)JLJHS'S2=F) 57*#@$8P=HZ"O;J\8\3R/_ ,-/>%,+
M(FW3BH8 '<"+C., \<D'('0]!\U 'I?_  DOAS3+R+19-;M$NH[=W$<]UN<1
MQ#YR[,2<@9)+')VL>=K$3:-XGT+Q"91H^KV=ZT18.D$P9EPQ7)'7!(.#T(P0
M2"#7!>(+2"\_:&\-+-IZ78BTIY=S1AQ 59RDAP05PV &;<N6&T!OF%'2XY+7
M]J+6F99D6ZTI64NJHK@)"/ESRZY0\K@Y![*: /2;[Q7H&F7;6M[JUI!,B;Y
M\@Q&-P7+GHN2>,XR QZ*Q&E:7=M?VL=U9W$5Q;RC='+"X=''J".#7G_PM>+Q
M+\-;NVUB-I;^XN;RWUM'B,,C3.[;E? 4@^6R#C[H 48VX'3>#M'T;P_H?]D:
M$\\EI9RM$S2RO(#*,;]I;Y?O9W!,*'WC 8,  =!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV3SUSS5WQ5X,A\6R61NM8U.TCLITN8(K,PJ%F3=MDRT;-GYL8SC@<9YKIJ*
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MK>:RFD5XAOW,,A@6W N/F)&6S@D"NHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*1>?X7^$I+RTNS878N;.)(+65=2N0T$:#"JA$GR@<]/4^M9__"K/^I]\<_\
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M^.?_  <?_84?\*L_ZGWQS_X./_L* /0**\__ .%6?]3[XY_\''_V%'_"K/\
MJ??'/_@X_P#L* /0**\__P"%6?\ 4^^.?_!Q_P#84?\ "K/^I]\<_P#@X_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6=%N"':ZCMY(I(5>-5*R$OTW Y"CKCVR:]%KR7]HB81_#>!,K^]U&).8E?\
M@D/!/*=/O+SVZ,: /2=":>31+.:YNI+F::%)6>14!R5!( 50,9_G5Z.:.4N(
MY$<HVQ]K [6]#Z'D5Y5X_N[B4_#_ ,+-YEG::O<*M]''<- 6B1$5X"2ZDJPD
M(()+$@  M@&K\1M*TOX?ZQX9\7Z+%;:0BWZ6-_%:QM#'/ ^7)<1_W=C?PDG(
MZ[0* -CQ=XCUK2/BOX4TFWU:2WTK4R?/B:T656(XV@A=PSP,YPN[<>!BNVU&
MUOYM8TJ:WUK[%9Q/(+BT$",;PE<JH=N4V[6/RC)&>F,UYYXXBD_X7CX!D2VN
M)MRSC$4ABX ))W9&0H.YE[@8P=V*=X]TZV'Q<^']P3=/)/=7#,A9YT!1(\%8
MV#K'R 254?WBRD;P >IO(D:AI'502%RQQR3@#\20*(Y$EC62-U=' 964Y!!Z
M$&O*H8)_&?Q,\0SWNDZ7J5GHHCTZVL[ZY!C0,=\DQC,<A\P[5 ;" @;<L5)&
M_P##;PMK7A&SU33K\:;'ILEVUQI\%I-)*T"N3NC9W5=P'RX.,GYL]L %?XN>
M(==\)>%%UO0[B-7CN(XIHYE0H(V#?, <,6W;!@$\9.."1<U76[_2_ EK.M[+
M=:_?Q1K91QQQ RW#JH"A2 !&&.6).0N?FZ5@_M &,?#"3>JEC>0["6C&#STW
MC<>,_<PW_ =X/(^%-9N/!7CVS?Q_#'++J-G'%IFOF1A%%#M7$6WA% .,D*"I
M9BQ*ONH ]@\(P>(UT6WG\47<;ZG(A,MM B"*+)X&0,E@.ISC).,\&MUIHUD6
M-I$#L<*I89)P3P/H#^1]*?7S-K?AS1[3X:^(;8Q-JVLV.HO)?^(9(V58)]X4
MQ;V422%ON[1O4-('9E!! !ZS\6-=UCPUH>GZAI&HM;O+J$-M)&3"JLC;B</(
MC+&>!\S?* .GKWPD0R-&'4NH#%<\@'.#CWP?R->0?%&XN+_X1^&+R.X>&YEN
MK&9;D3+NB=HR0_FGY003]_>@_P!KL:?B#P?H_@OXC^ KS27F%]>7TL=W+-/-
M+/=DA0TK'!7^)MWW<^9TQDJ >VTU)$D4M&ZL 2N5.>0<$?@017C'B;PO;WW[
M06@117&L1A[&2ZN);>]D+( TG&[=NAC).WY<+\VU<$DU<\ Z/I_A?XS^*]#T
M<"+3Q8V\HMT:5A$V%X8N,%OG+#YCP_'\04 ]=HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KAO$.A>*+WQ_HNNZ=!I)LM)2=!'->RQ27(E0 AML3!0
MK $#YLXSQGCN:* ,GQ+X<T[Q9H-SHVJQ,]M..J':Z,.0RGL0>?3L002*X;4O
MAC?W7P9C\%PWEJU];2[H)V9UB<"9F!;AF!*-R!D!N <"O3Z* /&-:^'OQ#\0
MVOAN]O\ 6='6]TF:$I8PVY6%<$9E8]'?A<H%"X!VXS@[VB^%_&=G\29?$^H'
M29[>>QCL&B%XWF(@*%I"5MU61\JYQA?O8!  KTFB@#RWPWX'\5:%\2]>\4N-
M(DMM3CF5;6.^G&UB0T98M&V>5P<<+O8J, +5WP]X1\16_B?Q3?:S;:*++Q$$
M29;&ZD+0(B.@PK1 .S;ADDKSDXYQ7HM% 'BOA[P)\4_"<1T'2/$>F)HQG)2Y
M=#))"C,"66-E(!PA^3)7,IY)^9?0/$NE>)!X?TK3O".J_8IX;B&*>ZN%6=_L
MP4JQPX.]ONMV)P>>:ZJB@ KQZ^^&WC3Q']LT?Q'KUK-HEQJXU#SX)I?-2+$@
M,*1N"%4Y0@%R$QD;Z]AHH X;XB^![WQ1INE2:#=V]AJNCW27%DTJ?NAC'!P#
MC&%(X(^7!'.1&VA>*O%.HZ#)XG@T>RL-,FBOVALII)9I;N,,%Y("I'EMV/G/
MRXR<Y'>T4 ><^-?!>O:U\0/#WB+2AICP:2 6AN[F6)I&W$D QH<8&,$D@GJI
M&0;/CCPMX@USQ;X8U;2DTQK?197G:.[NYHC,S%>/W:'& N022"6(*D AN]HH
M \I\4_#[Q1;_ ! D\8>"=1M(;N^@-O=PWG"IE0@=<*=P&U7P?XD!^8':.U\(
M:?K=IIDUSXDN+>;6+R9IIA;J!'"O1(E. 2J@=\G);D]3T-% '"_%3PGK'C7P
MQ%HVDC3TW3B66:\GE39MZ!512&SDYW<#T)P5GU/PQ=^(?A[)H&M:5ITMPJ)%
M"D5^X7Y0H$HE,.4<?,<;&'&#D,:[.B@#R?PAX)\=:-X:N/"FM7.C7VA744EN
MSQ7<RW-O'( K>66B*D ;B%(')^\!Q67IWPT\?I\.KWP==ZSI4=BCDVR0;@TP
M;+%6EV96,.0V-A9L,NY5(->V44 >0>(O 7CKQ#X T?0)+O28[NTEBG>X%R\:
MH8T:-8T18>F-CEBWWRP "A<:WBWPQXP\2^(?#6IQ6VBP1:+<_:6@;4YR)V.P
MXR(!MQM8 \YW<CJ#Z310!YUJGAOQ?=?$K2_%=O;Z$8+*Q-LUI+=/N9F5BY63
M[.2N&; (Y*J>F]EJ31?"OB2T^+&J>*[T:9]@O[86PBCO)7D@50F" 8PIR4R1
MQC<<$X.[T&B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB]3TOQ
M;<ZEK5Y'XJGTK3XG'V*".SMI 8Q"A9RSC/,GF##$8V]<$5VE5=3S_95YCR\^
M0^/,<JOW3U((P/?(H \C^%^H>-?'WAJYU6Z\:W-J\5XUL$BT^U8$!$;/*?[?
MZ5W$.@:O=Q^&;C6?$-S'J%@6^U102&**_D.#\RHR[@-A*C'(SN7&5KC?V<?^
M2>:A_P!A63_T5%6I\0+&Q_X6-X NG2"&=M0E#3M.D9;"+A2FY7<DJH!#84X!
M5]X4@'27WC&&V^(6D^$X%@FFNK>:>Z+3!&MU4 QD _?+8;Y1\P W=!7/^,9=
M5LOBCX*%OK^I0V-]<3K+9Q!6CPL:878J[F5N=S/N"9W I7.W^E6-U^TU;0_V
M;:74)TQI+E6M3A&*N-YV\,3E1NDR/GQU"UT'Q"#_ /"ROAR4C5B+RY^8<N!L
M3.%VOQC))V\8'SQ_> !Z--/#;('GECB0NJ!G8*"S,%4<]RQ  [D@5)7BFCWW
MB'Q3\1_&\NG6>B7D-C.MG';:S+*_V9HP\:/%A" K,KLRC!/3(ZGJ?AUX.N_#
M%KKVC:C>V;6=U.9[?2;:=I?L<$FX<R,%<[L%>0!^[)!R6P =]!/#=6\5Q;RQ
MS02H'CDC8,KJ1D$$<$$<YKE?B1XU'@/PFVK+ L]P\Z001/D*SG).2.GRJQ^H
M%;'AKPYIWA/0;;1M*B9+: =7.YW8\EF/<D\^G8   5YC\<IEL-9\"ZI>"1M+
MM-3+W2B-F4@-$W/&TG:KX!.3SC/. #K=/\(:QJ%I!J.M^)]=MM5F"W$EM97*
M1P6DI*$HB!6#JH0)ARZG+MC+$T[3-/\ $\FM:QIVI^)IML:6LUI=65O&CF,K
M(K*ZR1O'N+(6)7GI]U<*.UIHD0R-&'4NH#%<\@'.#CWP?R- 'D'POO\ Q?XZ
M\.WFI7GC6ZB:"]DM4%M8VVU@(U8-\T6>KCCC@=L\=E:7VK>$="\0:AXKU.34
MK2QE,MM.MM&DLD/E(<;4PN=Y=1D#IDG!&/+/A/X8UCQ#X8U>:R\7WVD1+JER
MBQ62QLI=H I<L -W+QD8P!L)7#,&3J_&>AWFF_LY3:1.J"ZL[&W$H#9 *21L
MV#DYZ'_ =  6/"0U_P")7AZ'Q)J>OWFCP7!>.TL]$<1@(LO+2M(K%G+1@<8&
MT$?QL*G_ +>U3P%XNT+PYK.J?VMI.LNT%E>7*XNK=U"JJ2%5Q*"60!S@Y=BQ
MP.=[X::A!J7PT\.3VY8HEA' =PQ\\0\MO_'D-<!^T':2ZI#X5TBVV&[O;]HH
M59@ 6.U1[XRPY[4 >TT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex23-1_001.jpg
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_X0O!17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    >    <@$R  (    4    D(=I  0    !    I    -  "OR    G
M$  *_(   "<0061O8F4@4&AO=&]S:&]P($-3,B!-86-I;G1O<V@ ,C P-SHQ
M,CHQ.2 Q-3HQ-SHR-@   Z !  ,    !__\  * "  0    !   #T* #  0
M   !   !90         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   J+
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ .P"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MU/4K]9;?UZZ'TG!JQ^MXS68>53:VDUU@-;>UX<S9Z;!M]:EGZ7U/]!7;6_\
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M;MMMV.L=L^FA5_6CZLV.+:^KX+W .<0W)J)VL!LL=I9]%E;7/>LSZAGJ.?\
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M4I))))2DDDDE*22224__V?_M+OI0:&]T;W-H;W @,RXP #A"24T$!
M!QP"   "  ( .$))300E       01@SRB2:X5MJPG &AL*>0=SA"24T#Z@
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M=%1I8VME=#PO<W1R:6YG/@H\+V1I8W0^"CPO<&QI<W0^"CA"24T#Z0
M>  #    2 !(      ,/ B__[O_N S@"00-G!7L#X  "    2 !(      +8
M B@  0   &0    !  ,# P    %__P !  $               !H"  9 9
M     "                                   #A"24T#[0      $ !(
M     0 " $@    !  (X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24T$"@       0  .$))32<0       *  $          CA"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-!         (  #A"24T$ @
M     @  .$))300P       ! 0 X0DE-!"T       8  0    (X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #3P    8              64   /0    #0!& &$ : !N $L 80!N &X
M90 M %( 1P!"     0                         !              /0
M   !90                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !90    !29VAT;&]N9P   ]     &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   64     4F=H=&QO
M;F<   /0     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     3_P        .$))3001       ! 0 X0DE-!!0
M  0    ".$))300,      JG     0   *     [   !X   ;J    J+ !@
M ?_8_^  $$I&248  0(  $@ 2   _^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  [ * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MTW_!IZOK%]9<<=*ZAU/'Q?V=UBZJ@48_J?:,<Y4?87776N]#):W^;R]E./\
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M #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
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M Q$!_]T ! !Z_\0!H@    8" P$             !P@&!00) PH" 0 + 0
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M5UM"P3U(-/V]+_VCZ:Z][]U[I![G[4ZPV36QXS>?8^P]HY*:$5$6/W/N_;V
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M F-E>@8Q.5(:-N%#2I"OTNA>TYKL)Q) ([Z/%>-"?A(/'2:&JGT/G0];6?\
M,HS2U'\N/Y@;AP.1E$53\:.R,MB,I0S34\IAJ=HU=515M+,ABGA+Q2*ZL-+"
M_P"#[Q]Y'BISKRW#,F1?1@@YX. 0>@3M"_[MK!6'^C*#^WK3'_EF=)_S&/GI
MUCOWXM]-=MYKJ?XJU6_3NCOWMG)U66D&0R>5V[AL/3[!%53Y*GW#O=?X)BON
MAMRCJ*+&N:@RY6H19*&V3?/6Z<E<HW]IO^Y[<MQS (=%O" , ,S&2E"J=QIX
MA#-BD8-'ZD#>+C:=LFBO;B />Z:(N. ).KT&334:G^$<>CL?S"OY FP_AO\
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MG3_<6R_YJ'_!U[^<K_V_1^'?_EH7_O\ ?/\ OWMG_P!.HYE_ZC/^K"]>Y?\
M^5;O_P#F[_QP=;L'O%SJ/.M)_P#F6_\ <15\1O\ Q,'P/_\ ?I;8]Y1\C_\
M3E^8_P#GFO\ _JTW4A[1_P JI?\ _-.;_CIZNP_X4)?]NMNZO_#PZ9_]^IM;
MW%OLW_ROVU_\TIO^K3]![E;_ )+5O_I7_P".GKW_  GM_P"W6W2O_AX=S?\
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MP5#2DG]FH&<DFE!)L:;-%]5'M+EF&G6:L:_%IR:#U^$4]>MQOY>_]N;.X_\
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M/Y]'7A_X52==4T,5/3_"O=D%/!''#!!#W/@HH888E"1111)ULJ1QQHH"J
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M .$OG_9 G;O_ (N!O[_WR_Q_]C;WY_Y6_;?^E;'_ -7[CHWYR_Y*D'_-!?\
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M.LPI<56IR:0I^L,_@%%' *!0='TEEREK:\:Z30<Z ^/]X'?^7#RI3H%_E?\
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M](?=W6W55;]]7XE6R$'\.Q^^9:N+QCU30(K>DGW[KW6E%_T&\_*?_O!_X_\
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M2Q(;W+'*&W?2;9]4X_6G-?L087]N6^PCH3[5;^':F1AWOG\AP_S]$:JQ>_\
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MWOW7NKH?Y+__  H3^4/\KS=NV>L-Z9'<G??PMR&4I*+<?268R3Y'/=;X^MR
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M^R3?_K<>_=>ZHA_GB_R%/^&9-J_';<W^S6?[,A_I\W!V/@OLO]!G^A_^Z?\
MH_QVS\A]U]S_ *8NTOX[_%_[UZ-'CH_M_M[ZI-=D]U[JH#X4_&[_ &<+Y<?'
M+XL?WS_T=_[,!W!L?JC^_?\ =W^]W]TO[YYNEPW\>_NQ_'=L?Q[^&_<^3[7^
M(T7FTZ?,E]0]U[K==_Z 8_\ P:)_[)-_^MQ[]U[KW_0#'_X-$_\ 9)O_ -;C
MW[KW5S_\DO\ X3M?\,Z=^]K]X_[.#_LQ?^D_I^3JC^Z_^R_?Z(OX'KWIM?=_
M\>_C?^FWL_\ B=O[M?;_ &OVE/\ Y[R>;T:&]U[KYT?\ZW_M[A_,:_\ %O\
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M)44E9322TM932)-#(\;JQRWVK<K'=[&#<-MN4FLY!564U!]0?,$'!4@$$$$
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M>!ABHLGNG&;*FZOC[5K<1% E738_(;@HL&S0J@GCAEJ5L)%4ZA[KW6O+B?\
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M&Y+'5,U%D,=D**9*FCKJ&LIGBJ*2LI*B)9(I8V5XW4,I! /OW7NOLC?\)_\
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M9#Y$.AC"_:68,!_1)\NA#RS%(^YK(GP(C:OL(*@?M-?RZTBFSP_XZ?ZW^/\
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MJOC_ //C9LLC'#X'N+IG<U#$9JAD3);MV5O'%961:=I32Q-+2[*H@71%DD"
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M>+?*@\R 1;M=:5^FC.3\7^;_ #_LZMIRX]3'_$^XZ3CT3)\(Z/1_*]P,E?\
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M_)"E\^0DR;_W:W=!LO34R>?5'#_<['8+[?'C[EM-)'II4LNF,:$T^Z]TD/\
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M5WQF[AK,71^B.62+S;DQU"=8 "Z?40FH^_=>Z^CG_/X_[<V_S"?_ ! &7_\
M=[@??NO=?&&]^Z]U][CJ;_F5?6G_ (C_ &;_ .\YC??NO="![]U[HH'\PG_L
M@7YP_P#BH'R6_P#?,;U]^Z]U\,;W[KW7W,_Y=U/3T?\ +^^"])200TM+2_#K
MXR4]-34\204]/3P=*;)BA@@AB58X888U"JJ@*J@ "WOW7NCB^_=>Z#_MG_F5
M?9?_ (C_ 'E_[SF2]^Z]U\$?W[KW7V>?Y __ &YM_E[?^( Q'_N]SWOW7NA
M_G6_]NC_ .8U_P"*@=X?^\3E/?NO=?%&]^Z]U]SG^7M_V0+\'O\ Q4#XT_\
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M06^?69</]/1_M[>]>)UK4>LRX?CE?]]_MC[UXGSZ]7[>LRXB_P#9_P!O<_\
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M$XD;W[KW6L'_ ,)]NW\9T=_.8^ .^,Q5QT5#DNZ)^JVJ9O$(HZGOC8V[^C:
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M(8E:2:::1@JJH+,Q  O[]U[K[QGQRZYFZ>^/71'4=3$L-1U;TSU?US40I/\
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MM^+^\GN6MQ7<-HMKM6%7%3\FH P_)@1^74AV%P)[5)1Y_P"&F?YUZ+$N#/\
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M;_W[KW0?]L_\RK[+_P#$?[R_]YS)>_=>Z^"/[]U[K[//\@?_ +<V_P O;_Q
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M5U?7UU1%245#14D3U%565E54/'!34M-!&SR2.RHB*22 /?NO=?+6_P"%3?\
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MG/R].A9PK<1_[#_??[Q[02],OQ/0J8MN5M?Z#_>O^->T#?BZ3D8Z$''-]/\
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M,_P8C5YI'E<0_)3Y?4\0:1B["*"#O^."",$^E$544<  "WOW7NK'_B)_+?\
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MO?NO=&YIZ>GHZ>"DI((:6EI88J>FIJ>)(*>GIX$6*&""&)5CAAAC4*JJ JJ
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)NO=>]^Z]U__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>igap-20211231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaGEibP9z5Z8OekhvWB1bZmKPykjKQ73oCtuDtGmIcwN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:IGAP="http://integrity-app.com/20211231" elementFormDefault="qualified" targetNamespace="http://integrity-app.com/20211231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://integrity-app.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit" id="StatementsOfChangesInStockholdersEquitydeficit">
	  <link:definition>00000005 - Statement - Statements of Changes In Stockholders' Equity(Deficit)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
	  <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/General" id="General">
	  <link:definition>00000008 - Disclosure - GENERAL</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/Inventories" id="Inventories">
	  <link:definition>00000010 - Disclosure - INVENTORIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/Leases" id="Leases">
	  <link:definition>00000011 - Disclosure - LEASES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
	  <link:definition>00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
	  <link:definition>00000013 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/LoansFromStockholders" id="LoansFromStockholders">
	  <link:definition>00000014 - Disclosure - LOANS FROM STOCKHOLDERS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilities" id="CommitmentsAndContingentLiabilities">
	  <link:definition>00000015 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtection" id="CommonStockAndWarrantsWith-downRoundProtection">
	  <link:definition>00000016 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ResearchAndDevelopmentExpenses" id="ResearchAndDevelopmentExpenses">
	  <link:definition>00000017 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/MarketingExpenses" id="MarketingExpenses">
	  <link:definition>00000018 - Disclosure - MARKETING EXPENSES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/GeneralAndAdministrativeExpenses" id="GeneralAndAdministrativeExpenses">
	  <link:definition>00000019 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/IncomeTax" id="IncomeTax">
	  <link:definition>00000020 - Disclosure - INCOME TAX</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/SegmentInformation" id="SegmentInformation">
	  <link:definition>00000021 - Disclosure - SEGMENT INFORMATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/RelatedParties" id="RelatedParties">
	  <link:definition>00000022 - Disclosure - RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000023 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/InventoriesTables" id="InventoriesTables">
	  <link:definition>00000026 - Disclosure - INVENTORIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000027 - Disclosure - LEASES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
	  <link:definition>00000028 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
	  <link:definition>00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionTables" id="CommonStockAndWarrantsWith-downRoundProtectionTables">
	  <link:definition>00000030 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ResearchAndDevelopmentExpensesTables" id="ResearchAndDevelopmentExpensesTables">
	  <link:definition>00000031 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/MarketingExpensesTables" id="MarketingExpensesTables">
	  <link:definition>00000032 - Disclosure - MARKETING EXPENSES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/GeneralAndAdministrativeExpensesTables" id="GeneralAndAdministrativeExpensesTables">
	  <link:definition>00000033 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/IncomeTaxTables" id="IncomeTaxTables">
	  <link:definition>00000034 - Disclosure - INCOME TAX (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/GeneralDetailsNarrative" id="GeneralDetailsNarrative">
	  <link:definition>00000035 - Disclosure - GENERAL (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfOfficialExchangeRateDetails" id="ScheduleOfOfficialExchangeRateDetails">
	  <link:definition>00000036 - Disclosure - SCHEDULE OF OFFICIAL EXCHANGE RATE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails" id="ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails">
	  <link:definition>00000037 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails" id="ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails">
	  <link:definition>00000038 - Disclosure -  SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfInventoriesDetails" id="ScheduleOfInventoriesDetails">
	  <link:definition>00000040 - Disclosure - SCHEDULE OF INVENTORIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/InventoriesDetailsNarrative" id="InventoriesDetailsNarrative">
	  <link:definition>00000041 - Disclosure - INVENTORIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails" id="ScheduleOfLeaseCostsLeaseTermAndDiscountDetails">
	  <link:definition>00000042 - Disclosure - SCHEDULE OF LEASE COSTS, LEASE TERM AND DISCOUNT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails" id="ScheduleOfOperatingLeaseMaturityPaymentsDetails">
	  <link:definition>00000043 - Disclosure - SCHEDULE OF OPERATING LEASE MATURITY PAYMENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails" id="ScheduleOfPropertyAndEquipmentNetDetails">
	  <link:definition>00000044 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/PropertyAndEquipmentNetDetailsNarrative" id="PropertyAndEquipmentNetDetailsNarrative">
	  <link:definition>00000045 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" id="ScheduleOfOtherCurrentLiabilitiesDetails">
	  <link:definition>00000046 - Disclosure - SCHEDULE OF OTHER CURRENT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative" id="LoansFromStockholdersDetailsNarrative">
	  <link:definition>00000047 - Disclosure - LOANS FROM STOCKHOLDERS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" id="CommitmentsAndContingentLiabilitiesDetailsNarrative">
	  <link:definition>00000048 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails" id="ScheduleOfFairValueAssumptionsDetails">
	  <link:definition>00000049 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails" id="ScheduleOfStockGrantsActivityDetails">
	  <link:definition>00000050 - Disclosure - SCHEDULE OF STOCK GRANTS ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails" id="ScheduleOfStockGrantsByExercisePriceRangeDetails">
	  <link:definition>00000051 - Disclosure - SCHEDULE OF STOCK GRANTS, BY EXERCISE PRICE RANGE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails" id="ScheduleOfAssumptionsUsedToValueOptionsDetails">
	  <link:definition>00000052 - Disclosure - SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative" id="CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative">
	  <link:definition>00000053 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" id="ScheduleOfResearchAndDevelopmentExpensesDetails">
	  <link:definition>00000054 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails" id="ScheduleOfSellingAndMarketingExpensesDetails">
	  <link:definition>00000055 - Disclosure - SCHEDULE OF SELLING AND MARKETING EXPENSES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" id="ScheduleOfGeneralAndAdministrativeExpensesDetails">
	  <link:definition>00000056 - Disclosure - SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/ScheduleOfDeferredTaxesDetails" id="ScheduleOfDeferredTaxesDetails">
	  <link:definition>00000057 - Disclosure - SCHEDULE OF DEFERRED TAXES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/IncomeTaxDetailsNarrative" id="IncomeTaxDetailsNarrative">
	  <link:definition>00000058 - Disclosure - INCOME TAX (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/SegmentInformationDetailsNarrative" id="SegmentInformationDetailsNarrative">
	  <link:definition>00000059 - Disclosure - SEGMENT INFORMATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://integrity-app.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
	  <link:definition>00000060 - Disclosure - RELATED PARTIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="igap-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="igap-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="igap-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="igap-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="IGAP_BoardOfMembersMember" name="BoardOfMembersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_ComputersMember" name="ComputersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_OfficeSpaceMember" name="OfficeSpaceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_ShareHoldersMember" name="ShareHoldersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_IsraeliInnovationAuthorityMember" name="IsraeliInnovationAuthorityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_AdvisoryAgreementMember" name="AdvisoryAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_AndrewGarrettIncMember" name="AndrewGarrettIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember" name="SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_AccreditedInvestorMember" name="AccreditedInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_PlacementAgentAgreementMember" name="PlacementAgentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_TwoThousandandSeventeenOfferingMember" name="TwoThousandandSeventeenOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_PlacementAgentMember" name="PlacementAgentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_WarrantOneMember" name="WarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_WarrantTwoMember" name="WarrantTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_WarrantThreeMember" name="WarrantThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_WarrantFourMember" name="WarrantFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_TwoThousandandTwentyOfferingMember" name="TwoThousandandTwentyOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_WarrantFiveMember" name="WarrantFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_IntegrityIsraelsPlanMember" name="IntegrityIsraelsPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_ErezBenZviMember" name="ErezBenZviMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_ShalomShushanMember" name="ShalomShushanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_MrPaulVMember" name="MrPaulVMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_MrJamesPMember" name="MrJamesPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_MeasurementInputFairValueMember" name="MeasurementInputFairValueMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_ExercisePriceOneMember" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_ExercisePriceThreeMember" name="ExercisePriceThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_AndrewSycoffMember" name="AndrewSycoffMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_PlacementAgentFeesMember" name="PlacementAgentFeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_FinancingIncomeExpenseNet" name="FinancingIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_WarrantsIssuedAsConsiderationForPlacementServices" name="WarrantsIssuedAsConsiderationForPlacementServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" name="IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_LinkageDifferenceOnPrincipalOfLoansFromStockholders" name="LinkageDifferenceOnPrincipalOfLoansFromStockholders" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_NumberOfCommonStockIssuedForSettlementOfFees" name="NumberOfCommonStockIssuedForSettlementOfFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_DisclosureMarketingExpensesAbstract" name="DisclosureMarketingExpensesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_SellingAndMarketingExpensesTextBlock" name="SellingAndMarketingExpensesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract" name="DisclosureGeneralAndAdministrativeExpensesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_GeneralAndAdministrativeExpensesTextBlock" name="GeneralAndAdministrativeExpensesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_RoyaltyBearingGrantsPolicyTextBlock" name="RoyaltyBearingGrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_ModificationOfEquityclassifiedContractsPolicyTextBlock" name="ModificationOfEquityclassifiedContractsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_ScheduleOfPropertyRatesOfDepreciationTableTextBlock" name="ScheduleOfPropertyRatesOfDepreciationTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" name="ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_ScheduleOfSellingAndMarketingExpensesTableTextBlock" name="ScheduleOfSellingAndMarketingExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" name="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_AverageForeignCurrencyExchangeRateTranslation" name="AverageForeignCurrencyExchangeRateTranslation" nillable="true" xbrli:periodType="duration" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage" name="IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo" name="IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_PropertyPlantAndEquipmentDepreciationRate" name="PropertyPlantAndEquipmentDepreciationRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_CumulativeResearchAndDevelopment" name="CumulativeResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_NumberOfStockOptionsExcluded" name="NumberOfStockOptionsExcluded" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_NumberOfStockWarrantsExcluded" name="NumberOfStockWarrantsExcluded" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_LongTermLeaseCost" name="LongTermLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_QuarterlyPaymentsEqualsToSalesPercentage" name="QuarterlyPaymentsEqualsToSalesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_RoyaltyPercentage" name="RoyaltyPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_AdvisoryServicesPeriod" name="AdvisoryServicesPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_CashExpensesOnIssuanceOfStock" name="CashExpensesOnIssuanceOfStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits" name="CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_NonaccountableExpenseAllowancePercenatge" name="NonaccountableExpenseAllowancePercenatge" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_AggregateSalesPriceOfUnitsPercentage" name="AggregateSalesPriceOfUnitsPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_PercentageOfDulitedCommonStock" name="PercentageOfDulitedCommonStock" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_SalariesAndRelatedExpenses" name="SalariesAndRelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_ResearchAndDevelopmentProfessionalFees" name="ResearchAndDevelopmentProfessionalFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_SellingAndMarketingOtherExpenses" name="SellingAndMarketingOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_BadDebtExpense" name="BadDebtExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_DeferredTaxAssetValuationAllowance" name="DeferredTaxAssetValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_FinanceIncomeExpenses" name="FinanceIncomeExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_InceptionThroughDecemberTwoThousandFourMember" name="InceptionThroughDecemberTwoThousandFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_SeriesDUnitsMember" name="SeriesDUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_SeriesD1WarrantMember" name="SeriesD1WarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_SeriesD2WarrantMember" name="SeriesD2WarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_SeriesD3WarrantMember" name="SeriesD3WarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_NISMember" name="NISMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_MedicationGroupsMember" name="MedicationGroupsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_ExercisePriceFourMember" name="ExercisePriceFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_OCSMember" name="OCSMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_ResearchAndDevelopmentProfessionalFee" name="ResearchAndDevelopmentProfessionalFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_FederalNetOperatingLossForOffsetAgainstTaxableIncomeTerm" name="FederalNetOperatingLossForOffsetAgainstTaxableIncomeTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_FederalNetOperatingLossOffsetAgainstTaxableIncomeMember" name="FederalNetOperatingLossOffsetAgainstTaxableIncomeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_GlucoseMonitoringDeviceGroupMember" name="GlucoseMonitoringDeviceGroupMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_PercentageOfCommissionPaid" name="PercentageOfCommissionPaid" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_PercentageOfManagementFee" name="PercentageOfManagementFee" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_PercentageOfNonaccountableExpenseAllowance" name="PercentageOfNonaccountableExpenseAllowance" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_PercentageOfNumberOfSharesOfCommonStock" name="PercentageOfNumberOfSharesOfCommonStock" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IGAP_PercentageofNumberOfWarrantsIssued" name="PercentageofNumberOfWarrantsIssued" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>igap-20211231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://integrity-app.com/role/Cover" xlink:href="igap-20211231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/BalanceSheets" xlink:href="igap-20211231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/BalanceSheetsParenthetical" xlink:href="igap-20211231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="igap-20211231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit" xlink:href="igap-20211231.xsd#StatementsOfChangesInStockholdersEquitydeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/StatementsOfCashFlows" xlink:href="igap-20211231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/StatementsOfCashFlowsParenthetical" xlink:href="igap-20211231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/General" xlink:href="igap-20211231.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="igap-20211231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/Inventories" xlink:href="igap-20211231.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/Leases" xlink:href="igap-20211231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/PropertyAndEquipmentNet" xlink:href="igap-20211231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/OtherCurrentLiabilities" xlink:href="igap-20211231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/LoansFromStockholders" xlink:href="igap-20211231.xsd#LoansFromStockholders" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilities" xlink:href="igap-20211231.xsd#CommitmentsAndContingentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtection" xlink:href="igap-20211231.xsd#CommonStockAndWarrantsWith-downRoundProtection" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ResearchAndDevelopmentExpenses" xlink:href="igap-20211231.xsd#ResearchAndDevelopmentExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/MarketingExpenses" xlink:href="igap-20211231.xsd#MarketingExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/GeneralAndAdministrativeExpenses" xlink:href="igap-20211231.xsd#GeneralAndAdministrativeExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/IncomeTax" xlink:href="igap-20211231.xsd#IncomeTax" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SegmentInformation" xlink:href="igap-20211231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/RelatedParties" xlink:href="igap-20211231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SubsequentEvents" xlink:href="igap-20211231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="igap-20211231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="igap-20211231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/InventoriesTables" xlink:href="igap-20211231.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/LeasesTables" xlink:href="igap-20211231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/PropertyAndEquipmentNetTables" xlink:href="igap-20211231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/OtherCurrentLiabilitiesTables" xlink:href="igap-20211231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionTables" xlink:href="igap-20211231.xsd#CommonStockAndWarrantsWith-downRoundProtectionTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ResearchAndDevelopmentExpensesTables" xlink:href="igap-20211231.xsd#ResearchAndDevelopmentExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/MarketingExpensesTables" xlink:href="igap-20211231.xsd#MarketingExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/GeneralAndAdministrativeExpensesTables" xlink:href="igap-20211231.xsd#GeneralAndAdministrativeExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/IncomeTaxTables" xlink:href="igap-20211231.xsd#IncomeTaxTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/GeneralDetailsNarrative" xlink:href="igap-20211231.xsd#GeneralDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfOfficialExchangeRateDetails" xlink:href="igap-20211231.xsd#ScheduleOfOfficialExchangeRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails" xlink:href="igap-20211231.xsd#ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails" xlink:href="igap-20211231.xsd#ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="igap-20211231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfInventoriesDetails" xlink:href="igap-20211231.xsd#ScheduleOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/InventoriesDetailsNarrative" xlink:href="igap-20211231.xsd#InventoriesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails" xlink:href="igap-20211231.xsd#ScheduleOfLeaseCostsLeaseTermAndDiscountDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails" xlink:href="igap-20211231.xsd#ScheduleOfOperatingLeaseMaturityPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:href="igap-20211231.xsd#ScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="igap-20211231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" xlink:href="igap-20211231.xsd#ScheduleOfOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative" xlink:href="igap-20211231.xsd#LoansFromStockholdersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:href="igap-20211231.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:href="igap-20211231.xsd#ScheduleOfFairValueAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails" xlink:href="igap-20211231.xsd#ScheduleOfStockGrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails" xlink:href="igap-20211231.xsd#ScheduleOfStockGrantsByExercisePriceRangeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails" xlink:href="igap-20211231.xsd#ScheduleOfAssumptionsUsedToValueOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative" xlink:href="igap-20211231.xsd#CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:href="igap-20211231.xsd#ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails" xlink:href="igap-20211231.xsd#ScheduleOfSellingAndMarketingExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:href="igap-20211231.xsd#ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfDeferredTaxesDetails" xlink:href="igap-20211231.xsd#ScheduleOfDeferredTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/IncomeTaxDetailsNarrative" xlink:href="igap-20211231.xsd#IncomeTaxDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SegmentInformationDetailsNarrative" xlink:href="igap-20211231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/RelatedPartiesDetailsNarrative" xlink:href="igap-20211231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCashNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapDueToOfficersOrStockholdersNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_FinancingIncomeExpenseNet" xlink:label="loc_IGAPFinancingIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_IGAPFinancingIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit" xlink:title="00000005 - Statement - Statements of Changes In Stockholders&apos; Equity(Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:label="loc_IGAPIssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IGAPIssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:label="loc_IGAPLinkageDifferenceOnPrincipalOfLoansFromStockholders" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IGAPLinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/General" xlink:title="00000008 - Disclosure - GENERAL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/Inventories" xlink:title="00000010 - Disclosure - INVENTORIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/Leases" xlink:title="00000011 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/PropertyAndEquipmentNet" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/LoansFromStockholders" xlink:title="00000014 - Disclosure - LOANS FROM STOCKHOLDERS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommitmentsAndContingentLiabilities" xlink:title="00000015 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtection" xlink:title="00000016 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ResearchAndDevelopmentExpenses" xlink:title="00000017 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/MarketingExpenses" xlink:title="00000018 - Disclosure - MARKETING EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/GeneralAndAdministrativeExpenses" xlink:title="00000019 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/IncomeTax" xlink:title="00000020 - Disclosure - INCOME TAX" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SegmentInformation" xlink:title="00000021 - Disclosure - SEGMENT INFORMATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/RelatedParties" xlink:title="00000022 - Disclosure - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/InventoriesTables" xlink:title="00000026 - Disclosure - INVENTORIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/LeasesTables" xlink:title="00000027 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/PropertyAndEquipmentNetTables" xlink:title="00000028 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionTables" xlink:title="00000030 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ResearchAndDevelopmentExpensesTables" xlink:title="00000031 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/MarketingExpensesTables" xlink:title="00000032 - Disclosure - MARKETING EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/GeneralAndAdministrativeExpensesTables" xlink:title="00000033 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/IncomeTaxTables" xlink:title="00000034 - Disclosure - INCOME TAX (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/GeneralDetailsNarrative" xlink:title="00000035 - Disclosure - GENERAL (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfOfficialExchangeRateDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF OFFICIAL EXCHANGE RATE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails" xlink:title="00000038 - Disclosure -  SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfInventoriesDetails" xlink:title="00000040 - Disclosure - SCHEDULE OF INVENTORIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryGross" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryGross" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryGross" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryAdjustments" xlink:label="loc_us-gaapInventoryAdjustments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryAdjustments" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/InventoriesDetailsNarrative" xlink:title="00000041 - Disclosure - INVENTORIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF LEASE COSTS, LEASE TERM AND DISCOUNT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF OPERATING LEASE MATURITY PAYMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000045 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative" xlink:title="00000047 - Disclosure - LOANS FROM STOCKHOLDERS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="00000048 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails" xlink:title="00000050 - Disclosure - SCHEDULE OF STOCK GRANTS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF STOCK GRANTS, BY EXERCISE PRICE RANGE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative" xlink:title="00000053 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:label="loc_us-gaapCostOfPropertyRepairsAndMaintenance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_us-gaapCostOfPropertyRepairsAndMaintenance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_us-gaapOtherGeneralExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF SELLING AND MARKETING EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_SalariesAndRelatedExpenses" xlink:label="loc_IGAPSalariesAndRelatedExpenses" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:to="loc_IGAPSalariesAndRelatedExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ResearchAndDevelopmentProfessionalFees" xlink:label="loc_IGAPResearchAndDevelopmentProfessionalFees" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:to="loc_IGAPResearchAndDevelopmentProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_SellingAndMarketingOtherExpenses" xlink:label="loc_IGAPSellingAndMarketingOtherExpenses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:to="loc_IGAPSellingAndMarketingOtherExpenses" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_BadDebtExpense" xlink:label="loc_IGAPBadDebtExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_IGAPBadDebtExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:label="loc_us-gaapCostOfPropertyRepairsAndMaintenance" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapCostOfPropertyRepairsAndMaintenance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInvestmentExpense" xlink:label="loc_us-gaapInvestmentIncomeInvestmentExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapInvestmentIncomeInvestmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfDeferredTaxesDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF DEFERRED TAXES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/IncomeTaxDetailsNarrative" xlink:title="00000058 - Disclosure - INCOME TAX (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SegmentInformationDetailsNarrative" xlink:title="00000059 - Disclosure - SEGMENT INFORMATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000060 - Disclosure - RELATED PARTIES (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>igap-20211231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://integrity-app.com/role/Cover" xlink:href="igap-20211231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/BalanceSheets" xlink:href="igap-20211231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/BalanceSheetsParenthetical" xlink:href="igap-20211231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="igap-20211231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit" xlink:href="igap-20211231.xsd#StatementsOfChangesInStockholdersEquitydeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/StatementsOfCashFlows" xlink:href="igap-20211231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/StatementsOfCashFlowsParenthetical" xlink:href="igap-20211231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/General" xlink:href="igap-20211231.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="igap-20211231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/Inventories" xlink:href="igap-20211231.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/Leases" xlink:href="igap-20211231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/PropertyAndEquipmentNet" xlink:href="igap-20211231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/OtherCurrentLiabilities" xlink:href="igap-20211231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/LoansFromStockholders" xlink:href="igap-20211231.xsd#LoansFromStockholders" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilities" xlink:href="igap-20211231.xsd#CommitmentsAndContingentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtection" xlink:href="igap-20211231.xsd#CommonStockAndWarrantsWith-downRoundProtection" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ResearchAndDevelopmentExpenses" xlink:href="igap-20211231.xsd#ResearchAndDevelopmentExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/MarketingExpenses" xlink:href="igap-20211231.xsd#MarketingExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/GeneralAndAdministrativeExpenses" xlink:href="igap-20211231.xsd#GeneralAndAdministrativeExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/IncomeTax" xlink:href="igap-20211231.xsd#IncomeTax" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SegmentInformation" xlink:href="igap-20211231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/RelatedParties" xlink:href="igap-20211231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SubsequentEvents" xlink:href="igap-20211231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="igap-20211231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="igap-20211231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/InventoriesTables" xlink:href="igap-20211231.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/LeasesTables" xlink:href="igap-20211231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/PropertyAndEquipmentNetTables" xlink:href="igap-20211231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/OtherCurrentLiabilitiesTables" xlink:href="igap-20211231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionTables" xlink:href="igap-20211231.xsd#CommonStockAndWarrantsWith-downRoundProtectionTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ResearchAndDevelopmentExpensesTables" xlink:href="igap-20211231.xsd#ResearchAndDevelopmentExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/MarketingExpensesTables" xlink:href="igap-20211231.xsd#MarketingExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/GeneralAndAdministrativeExpensesTables" xlink:href="igap-20211231.xsd#GeneralAndAdministrativeExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/IncomeTaxTables" xlink:href="igap-20211231.xsd#IncomeTaxTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/GeneralDetailsNarrative" xlink:href="igap-20211231.xsd#GeneralDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfOfficialExchangeRateDetails" xlink:href="igap-20211231.xsd#ScheduleOfOfficialExchangeRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails" xlink:href="igap-20211231.xsd#ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails" xlink:href="igap-20211231.xsd#ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="igap-20211231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfInventoriesDetails" xlink:href="igap-20211231.xsd#ScheduleOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/InventoriesDetailsNarrative" xlink:href="igap-20211231.xsd#InventoriesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails" xlink:href="igap-20211231.xsd#ScheduleOfLeaseCostsLeaseTermAndDiscountDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails" xlink:href="igap-20211231.xsd#ScheduleOfOperatingLeaseMaturityPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:href="igap-20211231.xsd#ScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="igap-20211231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" xlink:href="igap-20211231.xsd#ScheduleOfOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative" xlink:href="igap-20211231.xsd#LoansFromStockholdersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:href="igap-20211231.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:href="igap-20211231.xsd#ScheduleOfFairValueAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails" xlink:href="igap-20211231.xsd#ScheduleOfStockGrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails" xlink:href="igap-20211231.xsd#ScheduleOfStockGrantsByExercisePriceRangeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails" xlink:href="igap-20211231.xsd#ScheduleOfAssumptionsUsedToValueOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative" xlink:href="igap-20211231.xsd#CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:href="igap-20211231.xsd#ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails" xlink:href="igap-20211231.xsd#ScheduleOfSellingAndMarketingExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:href="igap-20211231.xsd#ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfDeferredTaxesDetails" xlink:href="igap-20211231.xsd#ScheduleOfDeferredTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/IncomeTaxDetailsNarrative" xlink:href="igap-20211231.xsd#IncomeTaxDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SegmentInformationDetailsNarrative" xlink:href="igap-20211231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/RelatedPartiesDetailsNarrative" xlink:href="igap-20211231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_50" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_50" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_50" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_50" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_50" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_50" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_50" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_50" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_50" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_50" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_50" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_50" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_50" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_50" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_50" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_50" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_50" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_50" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId_50" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName_50" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation_50" xlink:type="arc" order="60" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit" xlink:title="00000005 - Statement - Statements of Changes In Stockholders&apos; Equity(Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantsIssuedAsConsiderationForPlacementServices" xlink:label="loc_IGAPWarrantsIssuedAsConsiderationForPlacementServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IGAPWarrantsIssuedAsConsiderationForPlacementServices_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_BoardOfMembersMember" xlink:label="loc_IGAPBoardOfMembersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPBoardOfMembersMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_NumberOfCommonStockIssuedForSettlementOfFees" xlink:label="loc_IGAPNumberOfCommonStockIssuedForSettlementOfFees_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_IGAPNumberOfCommonStockIssuedForSettlementOfFees_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/General" xlink:title="00000008 - Disclosure - GENERAL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/Inventories" xlink:title="00000010 - Disclosure - INVENTORIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/Leases" xlink:title="00000011 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/PropertyAndEquipmentNet" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/LoansFromStockholders" xlink:title="00000014 - Disclosure - LOANS FROM STOCKHOLDERS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommitmentsAndContingentLiabilities" xlink:title="00000015 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtection" xlink:title="00000016 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ResearchAndDevelopmentExpenses" xlink:title="00000017 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/MarketingExpenses" xlink:title="00000018 - Disclosure - MARKETING EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/GeneralAndAdministrativeExpenses" xlink:title="00000019 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/IncomeTax" xlink:title="00000020 - Disclosure - INCOME TAX" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SegmentInformation" xlink:title="00000021 - Disclosure - SEGMENT INFORMATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/RelatedParties" xlink:title="00000022 - Disclosure - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/InventoriesTables" xlink:title="00000026 - Disclosure - INVENTORIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/LeasesTables" xlink:title="00000027 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/PropertyAndEquipmentNetTables" xlink:title="00000028 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionTables" xlink:title="00000030 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ResearchAndDevelopmentExpensesTables" xlink:title="00000031 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/MarketingExpensesTables" xlink:title="00000032 - Disclosure - MARKETING EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/GeneralAndAdministrativeExpensesTables" xlink:title="00000033 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/IncomeTaxTables" xlink:title="00000034 - Disclosure - INCOME TAX (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/GeneralDetailsNarrative" xlink:title="00000035 - Disclosure - GENERAL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCash_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecurities" xlink:label="loc_us-gaapDebtSecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtSecurities_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfOfficialExchangeRateDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF OFFICIAL EXCHANGE RATE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ComputersMember" xlink:label="loc_IGAPComputersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_IGAPComputersMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_FurnitureAndOfficeEquipmentMember" xlink:label="loc_IGAPFurnitureAndOfficeEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_IGAPFurnitureAndOfficeEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PropertyPlantAndEquipmentDepreciationRate" xlink:label="loc_IGAPPropertyPlantAndEquipmentDepreciationRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_IGAPPropertyPlantAndEquipmentDepreciationRate_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails" xlink:title="00000038 - Disclosure -  SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfInventoriesDetails" xlink:title="00000040 - Disclosure - SCHEDULE OF INVENTORIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/InventoriesDetailsNarrative" xlink:title="00000041 - Disclosure - INVENTORIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF LEASE COSTS, LEASE TERM AND DISCOUNT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_OfficeSpaceMember" xlink:label="loc_IGAPOfficeSpaceMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_IGAPOfficeSpaceMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseCost_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_LongTermLeaseCost" xlink:label="loc_IGAPLongTermLeaseCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_IGAPLongTermLeaseCost_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShortTermLeaseCost_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF OPERATING LEASE MATURITY PAYMENTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_FurnitureAndOfficeEquipmentMember" xlink:label="loc_IGAPFurnitureAndOfficeEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_IGAPFurnitureAndOfficeEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000045 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative" xlink:title="00000047 - Disclosure - LOANS FROM STOCKHOLDERS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ShareHoldersMember" xlink:label="loc_IGAPShareHoldersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPShareHoldersMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfLongTermDebt_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfLongTermDebt_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersNoncurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapDueToOfficersOrStockholdersNoncurrent_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_QuarterlyPaymentsEqualsToSalesPercentage" xlink:label="loc_IGAPQuarterlyPaymentsEqualsToSalesPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_IGAPQuarterlyPaymentsEqualsToSalesPercentage_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="00000048 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="loc_us-gaapLegalEntityTypeOfCounterpartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="loc_us-gaapLegalEntityTypeOfCounterpartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_IsraeliInnovationAuthorityMember" xlink:label="loc_IGAPIsraeliInnovationAuthorityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" xlink:to="loc_IGAPIsraeliInnovationAuthorityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_IsraeliInnovationAuthorityMember" xlink:label="loc_IGAPIsraeliInnovationAuthorityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_IGAPIsraeliInnovationAuthorityMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AndrewGarrettIncMember" xlink:label="loc_IGAPAndrewGarrettIncMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_IGAPAndrewGarrettIncMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AdvisoryAgreementMember" xlink:label="loc_IGAPAdvisoryAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IGAPAdvisoryAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_RoyaltyPercentage" xlink:label="loc_IGAPRoyaltyPercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_IGAPRoyaltyPercentage_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AdvisoryServicesPeriod" xlink:label="loc_IGAPAdvisoryServicesPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_IGAPAdvisoryServicesPeriod_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_80" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_MeasurementInputFairValueMember" xlink:label="loc_IGAPMeasurementInputFairValueMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_IGAPMeasurementInputFairValueMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_80" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails" xlink:title="00000050 - Disclosure - SCHEDULE OF STOCK GRANTS ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF STOCK GRANTS, BY EXERCISE PRICE RANGE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ExercisePriceOneMember" xlink:label="loc_IGAPExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IGAPExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ExercisePriceTwoMember" xlink:label="loc_IGAPExercisePriceTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IGAPExercisePriceTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ExercisePriceThreeMember" xlink:label="loc_IGAPExercisePriceThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IGAPExercisePriceThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative" xlink:title="00000053 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember" xlink:label="loc_IGAPSecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IGAPSecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PlacementAgentAgreementMember" xlink:label="loc_IGAPPlacementAgentAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IGAPPlacementAgentAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AccreditedInvestorMember" xlink:label="loc_IGAPAccreditedInvestorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPAccreditedInvestorMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PlacementAgentMember" xlink:label="loc_IGAPPlacementAgentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPPlacementAgentMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ErezBenZviMember" xlink:label="loc_IGAPErezBenZviMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPErezBenZviMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ShalomShushanMember" xlink:label="loc_IGAPShalomShushanMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPShalomShushanMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_MrPaulVMember" xlink:label="loc_IGAPMrPaulVMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPMrPaulVMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_MrJamesPMember" xlink:label="loc_IGAPMrJamesPMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPMrJamesPMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_TwoThousandandSeventeenOfferingMember" xlink:label="loc_IGAPTwoThousandandSeventeenOfferingMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_IGAPTwoThousandandSeventeenOfferingMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_TwoThousandandTwentyOfferingMember" xlink:label="loc_IGAPTwoThousandandTwentyOfferingMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_IGAPTwoThousandandTwentyOfferingMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantOneMember" xlink:label="loc_IGAPWarrantOneMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_IGAPWarrantOneMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantTwoMember" xlink:label="loc_IGAPWarrantTwoMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_IGAPWarrantTwoMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantThreeMember" xlink:label="loc_IGAPWarrantThreeMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_IGAPWarrantThreeMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantFourMember" xlink:label="loc_IGAPWarrantFourMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_IGAPWarrantFourMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantFiveMember" xlink:label="loc_IGAPWarrantFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_IGAPWarrantFiveMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_IntegrityIsraelsPlanMember" xlink:label="loc_IGAPIntegrityIsraelsPlanMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_IGAPIntegrityIsraelsPlanMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_CashExpensesOnIssuanceOfStock" xlink:label="loc_IGAPCashExpensesOnIssuanceOfStock_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_IGAPCashExpensesOnIssuanceOfStock_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits" xlink:label="loc_IGAPCommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_IGAPCommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_NonaccountableExpenseAllowancePercenatge" xlink:label="loc_IGAPNonaccountableExpenseAllowancePercenatge_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_IGAPNonaccountableExpenseAllowancePercenatge_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AggregateSalesPriceOfUnitsPercentage" xlink:label="loc_IGAPAggregateSalesPriceOfUnitsPercentage_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_IGAPAggregateSalesPriceOfUnitsPercentage_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_210" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_210" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_210" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_210" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapOfficersCompensation_210" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_210" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PercentageOfDulitedCommonStock" xlink:label="loc_IGAPPercentageOfDulitedCommonStock_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_IGAPPercentageOfDulitedCommonStock_210" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_210" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_210" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF SELLING AND MARKETING EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLaborAndRelatedExpense_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfessionalFees_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_BadDebtExpense" xlink:label="loc_IGAPBadDebtExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IGAPBadDebtExpense_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:label="loc_us-gaapCostOfPropertyRepairsAndMaintenance_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfPropertyRepairsAndMaintenance_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInvestmentExpense" xlink:label="loc_us-gaapInvestmentIncomeInvestmentExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentIncomeInvestmentExpense_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_30" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfDeferredTaxesDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF DEFERRED TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/IncomeTaxDetailsNarrative" xlink:title="00000058 - Disclosure - INCOME TAX (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaapIsraelTaxAuthorityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapIsraelTaxAuthorityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SegmentInformationDetailsNarrative" xlink:title="00000059 - Disclosure - SEGMENT INFORMATION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://integrity-app.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000060 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AndrewGarrettIncMember" xlink:label="loc_IGAPAndrewGarrettIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_IGAPAndrewGarrettIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AndrewSycoffMember" xlink:label="loc_IGAPAndrewSycoffMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPAndrewSycoffMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PlacementAgentFeesMember" xlink:label="loc_IGAPPlacementAgentFeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IGAPPlacementAgentFeesMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_40" xlink:type="arc" order="2" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>igap-20211231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_BoardOfMembersMember" xlink:label="IGAP_BoardOfMembersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_BoardOfMembersMember" xlink:to="IGAP_BoardOfMembersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_BoardOfMembersMember_lbl" xml:lang="en-US">Board of Members [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ComputersMember" xlink:label="IGAP_ComputersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ComputersMember" xlink:to="IGAP_ComputersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_ComputersMember_lbl" xml:lang="en-US">Computers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_FurnitureAndOfficeEquipmentMember" xlink:label="IGAP_FurnitureAndOfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_FurnitureAndOfficeEquipmentMember" xlink:to="IGAP_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_FurnitureAndOfficeEquipmentMember_lbl" xml:lang="en-US">Furniture and Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_OfficeSpaceMember" xlink:label="IGAP_OfficeSpaceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_OfficeSpaceMember" xlink:to="IGAP_OfficeSpaceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_OfficeSpaceMember_lbl" xml:lang="en-US">Office Space [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ShareHoldersMember" xlink:label="IGAP_ShareHoldersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ShareHoldersMember" xlink:to="IGAP_ShareHoldersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_ShareHoldersMember_lbl" xml:lang="en-US">Shareholders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_IsraeliInnovationAuthorityMember" xlink:label="IGAP_IsraeliInnovationAuthorityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_IsraeliInnovationAuthorityMember" xlink:to="IGAP_IsraeliInnovationAuthorityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_IsraeliInnovationAuthorityMember_lbl" xml:lang="en-US">Israeli Innovation Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AdvisoryAgreementMember" xlink:label="IGAP_AdvisoryAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_AdvisoryAgreementMember" xlink:to="IGAP_AdvisoryAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_AdvisoryAgreementMember_lbl" xml:lang="en-US">Advisory Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AndrewGarrettIncMember" xlink:label="IGAP_AndrewGarrettIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_AndrewGarrettIncMember" xlink:to="IGAP_AndrewGarrettIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_AndrewGarrettIncMember_lbl" xml:lang="en-US">Andrew Garrett, Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember" xlink:label="IGAP_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember" xlink:to="IGAP_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement And Registration Rights Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AccreditedInvestorMember" xlink:label="IGAP_AccreditedInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_AccreditedInvestorMember" xlink:to="IGAP_AccreditedInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_AccreditedInvestorMember_lbl" xml:lang="en-US">Accredited Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PlacementAgentAgreementMember" xlink:label="IGAP_PlacementAgentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_PlacementAgentAgreementMember" xlink:to="IGAP_PlacementAgentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_PlacementAgentAgreementMember_lbl" xml:lang="en-US">Placement Agent Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_TwoThousandandSeventeenOfferingMember" xlink:label="IGAP_TwoThousandandSeventeenOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_TwoThousandandSeventeenOfferingMember" xlink:to="IGAP_TwoThousandandSeventeenOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_TwoThousandandSeventeenOfferingMember_lbl" xml:lang="en-US">2017 Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PlacementAgentMember" xlink:label="IGAP_PlacementAgentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_PlacementAgentMember" xlink:to="IGAP_PlacementAgentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_PlacementAgentMember_lbl" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantOneMember" xlink:label="IGAP_WarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_WarrantOneMember" xlink:to="IGAP_WarrantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_WarrantOneMember_lbl" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantTwoMember" xlink:label="IGAP_WarrantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_WarrantTwoMember" xlink:to="IGAP_WarrantTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_WarrantTwoMember_lbl" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantThreeMember" xlink:label="IGAP_WarrantThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_WarrantThreeMember" xlink:to="IGAP_WarrantThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_WarrantThreeMember_lbl" xml:lang="en-US">Warrant Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantFourMember" xlink:label="IGAP_WarrantFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_WarrantFourMember" xlink:to="IGAP_WarrantFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_WarrantFourMember_lbl" xml:lang="en-US">Warrant Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_TwoThousandandTwentyOfferingMember" xlink:label="IGAP_TwoThousandandTwentyOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_TwoThousandandTwentyOfferingMember" xlink:to="IGAP_TwoThousandandTwentyOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_TwoThousandandTwentyOfferingMember_lbl" xml:lang="en-US">2020 Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantFiveMember" xlink:label="IGAP_WarrantFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_WarrantFiveMember" xlink:to="IGAP_WarrantFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_WarrantFiveMember_lbl" xml:lang="en-US">Warrant Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_IntegrityIsraelsPlanMember" xlink:label="IGAP_IntegrityIsraelsPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_IntegrityIsraelsPlanMember" xlink:to="IGAP_IntegrityIsraelsPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_IntegrityIsraelsPlanMember_lbl" xml:lang="en-US">Integrity Israel's Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ErezBenZviMember" xlink:label="IGAP_ErezBenZviMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ErezBenZviMember" xlink:to="IGAP_ErezBenZviMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_ErezBenZviMember_lbl" xml:lang="en-US">Erez Ben Zvi [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ShalomShushanMember" xlink:label="IGAP_ShalomShushanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ShalomShushanMember" xlink:to="IGAP_ShalomShushanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_ShalomShushanMember_lbl" xml:lang="en-US">Shalom Shushan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_MrPaulVMember" xlink:label="IGAP_MrPaulVMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_MrPaulVMember" xlink:to="IGAP_MrPaulVMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_MrPaulVMember_lbl" xml:lang="en-US">Mr Paul V [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_MrJamesPMember" xlink:label="IGAP_MrJamesPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_MrJamesPMember" xlink:to="IGAP_MrJamesPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_MrJamesPMember_lbl" xml:lang="en-US">Mr James P [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_MeasurementInputFairValueMember" xlink:label="IGAP_MeasurementInputFairValueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_MeasurementInputFairValueMember" xlink:to="IGAP_MeasurementInputFairValueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_MeasurementInputFairValueMember_lbl" xml:lang="en-US">Measurement Input Fair Value [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ExercisePriceOneMember" xlink:label="IGAP_ExercisePriceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ExercisePriceOneMember" xlink:to="IGAP_ExercisePriceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ExercisePriceTwoMember" xlink:label="IGAP_ExercisePriceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ExercisePriceTwoMember" xlink:to="IGAP_ExercisePriceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ExercisePriceThreeMember" xlink:label="IGAP_ExercisePriceThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ExercisePriceThreeMember" xlink:to="IGAP_ExercisePriceThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="us-gaap_IsraelTaxAuthorityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl" xml:lang="en-US">Israel Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AndrewSycoffMember" xlink:label="IGAP_AndrewSycoffMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_AndrewSycoffMember" xlink:to="IGAP_AndrewSycoffMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_AndrewSycoffMember_lbl" xml:lang="en-US">Andrew Sycoff [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PlacementAgentFeesMember" xlink:label="IGAP_PlacementAgentFeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_PlacementAgentFeesMember" xlink:to="IGAP_PlacementAgentFeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_PlacementAgentFeesMember_lbl" xml:lang="en-US">Placement Agent Fees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory (Note 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets, net (Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net (Note 5)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities, current (Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities (Note 6)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOfficersOrStockholdersNoncurrent_lbl" xml:lang="en-US">Loans from stockholders (Note 7)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, non-current (Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingent liabilities (Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses (Note 10)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Marketing expenses (Note 11)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses (Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expense (Income)</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_FinancingIncomeExpenseNet" xlink:label="IGAP_FinancingIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_FinancingIncomeExpenseNet" xlink:to="IGAP_FinancingIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="IGAP_FinancingIncomeExpenseNet_lbl" xml:lang="en-US">Financing income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Loss for the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive loss:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss for the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Loss per share (Basic and Diluted)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common stock outstanding used in computing basic and diluted net loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Loss for the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Common Stock, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Common Stock, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantsIssuedAsConsiderationForPlacementServices" xlink:label="IGAP_WarrantsIssuedAsConsiderationForPlacementServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_WarrantsIssuedAsConsiderationForPlacementServices" xlink:to="IGAP_WarrantsIssuedAsConsiderationForPlacementServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_WarrantsIssuedAsConsiderationForPlacementServices_lbl" xml:lang="en-US">Warrants issued as consideration for placement services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of restricted shares as compensation to directors</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of restricted shares as compensation to directors, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile loss for the year to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Capital loss from sale of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:label="IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:to="IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors_lbl" xml:lang="en-US">Issuance of restricted shares as compensation to directors</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:label="IGAP_LinkageDifferenceOnPrincipalOfLoansFromStockholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:to="IGAP_LinkageDifferenceOnPrincipalOfLoansFromStockholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_LinkageDifferenceOnPrincipalOfLoansFromStockholders_lbl" xml:lang="en-US">Linkage difference on principal of loans from stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease in accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Decrease (increase) in other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Decrease in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Decrease in other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investment activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investment activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of cash issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Change in cash, cash equivalents, and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_NumberOfCommonStockIssuedForSettlementOfFees" xlink:label="IGAP_NumberOfCommonStockIssuedForSettlementOfFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_NumberOfCommonStockIssuedForSettlementOfFees" xlink:to="IGAP_NumberOfCommonStockIssuedForSettlementOfFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_NumberOfCommonStockIssuedForSettlementOfFees_lbl" xml:lang="en-US">Number of common stock issued for settlement of fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">GENERAL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_DisclosureLeasesAbstract" xlink:label="IGAP_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_DisclosureLeasesAbstract" xlink:to="IGAP_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">LOANS FROM STOCKHOLDERS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_DisclosureMarketingExpensesAbstract" xlink:label="IGAP_DisclosureMarketingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_DisclosureMarketingExpensesAbstract" xlink:to="IGAP_DisclosureMarketingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_DisclosureMarketingExpensesAbstract_lbl" xml:lang="en-US">Marketing Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_SellingAndMarketingExpensesTextBlock" xlink:label="IGAP_SellingAndMarketingExpensesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_SellingAndMarketingExpensesTextBlock" xlink:to="IGAP_SellingAndMarketingExpensesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_SellingAndMarketingExpensesTextBlock_lbl" xml:lang="en-US">MARKETING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract" xlink:label="IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract" xlink:to="IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">General And Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_GeneralAndAdministrativeExpensesTextBlock" xlink:label="IGAP_GeneralAndAdministrativeExpensesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_GeneralAndAdministrativeExpensesTextBlock" xlink:to="IGAP_GeneralAndAdministrativeExpensesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_GeneralAndAdministrativeExpensesTextBlock_lbl" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAX</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Functional currency</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:label="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:to="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_lbl" xml:lang="en-US">Liability for employee rights upon retirement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_RoyaltyBearingGrantsPolicyTextBlock" xlink:label="IGAP_RoyaltyBearingGrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_RoyaltyBearingGrantsPolicyTextBlock" xlink:to="IGAP_RoyaltyBearingGrantsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_RoyaltyBearingGrantsPolicyTextBlock_lbl" xml:lang="en-US">Royalty-bearing grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="us-gaap_StandardProductWarrantyPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StandardProductWarrantyPolicy" xlink:to="us-gaap_StandardProductWarrantyPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StandardProductWarrantyPolicy_lbl" xml:lang="en-US">Warranty</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair value of financial instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of credit risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Warrants with Down-Round Protection</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ModificationOfEquityclassifiedContractsPolicyTextBlock" xlink:label="IGAP_ModificationOfEquityclassifiedContractsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ModificationOfEquityclassifiedContractsPolicyTextBlock" xlink:to="IGAP_ModificationOfEquityclassifiedContractsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_ModificationOfEquityclassifiedContractsPolicyTextBlock_lbl" xml:lang="en-US">Modification of equity-classified contracts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Operating Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">X. Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" xlink:label="us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" xlink:to="us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OFFICIAL EXCHANGE RATE</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ScheduleOfPropertyRatesOfDepreciationTableTextBlock" xlink:label="IGAP_ScheduleOfPropertyRatesOfDepreciationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ScheduleOfPropertyRatesOfDepreciationTableTextBlock" xlink:to="IGAP_ScheduleOfPropertyRatesOfDepreciationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_ScheduleOfPropertyRatesOfDepreciationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INVENTORIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF LEASE COSTS, LEASE TERM AND DISCOUNT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPERATING LEASE MATURITY PAYMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK GRANTS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK GRANTS, BY EXERCISE PRICE RANGE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xlink:label="IGAP_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xlink:to="IGAP_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ScheduleOfSellingAndMarketingExpensesTableTextBlock" xlink:label="IGAP_ScheduleOfSellingAndMarketingExpensesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ScheduleOfSellingAndMarketingExpensesTableTextBlock" xlink:to="IGAP_ScheduleOfSellingAndMarketingExpensesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_ScheduleOfSellingAndMarketingExpensesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SELLING AND MARKETING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:label="IGAP_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="IGAP_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Private placement of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecurities" xlink:label="us-gaap_DebtSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecurities" xlink:to="us-gaap_DebtSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecurities_lbl" xml:lang="en-US">Debt Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AverageForeignCurrencyExchangeRateTranslation" xlink:label="IGAP_AverageForeignCurrencyExchangeRateTranslation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_AverageForeignCurrencyExchangeRateTranslation" xlink:to="IGAP_AverageForeignCurrencyExchangeRateTranslation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_AverageForeignCurrencyExchangeRateTranslation_lbl" xml:lang="en-US">Official exchange rate of NIS 1 to US dollar</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage" xlink:label="IGAP_IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage" xlink:to="IGAP_IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage_lbl" xml:lang="en-US">Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo" xlink:label="IGAP_IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo" xlink:to="IGAP_IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo_lbl" xml:lang="en-US">Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PropertyPlantAndEquipmentDepreciationRate" xlink:label="IGAP_PropertyPlantAndEquipmentDepreciationRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_PropertyPlantAndEquipmentDepreciationRate" xlink:to="IGAP_PropertyPlantAndEquipmentDepreciationRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_PropertyPlantAndEquipmentDepreciationRate_lbl" xml:lang="en-US">Property plant and equipment depreciation rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US">Estimated useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_CumulativeResearchAndDevelopment" xlink:label="IGAP_CumulativeResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_CumulativeResearchAndDevelopment" xlink:to="IGAP_CumulativeResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_CumulativeResearchAndDevelopment_lbl" xml:lang="en-US">Cumulative research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_NumberOfStockOptionsExcluded" xlink:label="IGAP_NumberOfStockOptionsExcluded" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_NumberOfStockOptionsExcluded" xlink:to="IGAP_NumberOfStockOptionsExcluded_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_NumberOfStockOptionsExcluded_lbl" xml:lang="en-US">Number of stock options excluded</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_NumberOfStockWarrantsExcluded" xlink:label="IGAP_NumberOfStockWarrantsExcluded" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_NumberOfStockWarrantsExcluded" xlink:to="IGAP_NumberOfStockWarrantsExcluded_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_NumberOfStockWarrantsExcluded_lbl" xml:lang="en-US">Number of stock warrants excluded</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessor, Operating Lease, Term of Contract</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished products</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US">Inventory, Gross, Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryAdjustments" xlink:label="us-gaap_InventoryAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryAdjustments" xlink:to="us-gaap_InventoryAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_InventoryAdjustments_lbl" xml:lang="en-US">inventory write-down</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Inventory, Net, Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryAdjustments" xlink:to="us-gaap_InventoryAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryAdjustments_2_lbl" xml:lang="en-US">Inventory Adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Total Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_LongTermLeaseCost" xlink:label="IGAP_LongTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_LongTermLeaseCost" xlink:to="IGAP_LongTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_LongTermLeaseCost_lbl" xml:lang="en-US">Office space: Over 12 month</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Office space: Short term leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_DisclosureLeasesAbstract" xlink:to="IGAP_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="IGAP_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Operating Lease Maturity Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less - accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employees and related institutions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">Other Liabilities, Current, Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DueToOfficersOrStockholdersNoncurrent_2_lbl" xml:lang="en-US">Due to Officers or Stockholders, Noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_QuarterlyPaymentsEqualsToSalesPercentage" xlink:label="IGAP_QuarterlyPaymentsEqualsToSalesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_QuarterlyPaymentsEqualsToSalesPercentage" xlink:to="IGAP_QuarterlyPaymentsEqualsToSalesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_QuarterlyPaymentsEqualsToSalesPercentage_lbl" xml:lang="en-US">Quarterly payments equals to sales, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_RoyaltyPercentage" xlink:label="IGAP_RoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_RoyaltyPercentage" xlink:to="IGAP_RoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AdvisoryServicesPeriod" xlink:label="IGAP_AdvisoryServicesPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_AdvisoryServicesPeriod" xlink:to="IGAP_AdvisoryServicesPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_AdvisoryServicesPeriod_lbl" xml:lang="en-US">Advisory services period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number exercisable, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price exercisable, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number, grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number outstanding ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Number exercisable, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price exercisable, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of common shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_CashExpensesOnIssuanceOfStock" xlink:label="IGAP_CashExpensesOnIssuanceOfStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_CashExpensesOnIssuanceOfStock" xlink:to="IGAP_CashExpensesOnIssuanceOfStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_CashExpensesOnIssuanceOfStock_lbl" xml:lang="en-US">Cash expenses on issuance of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits" xlink:label="IGAP_CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits" xlink:to="IGAP_CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits_lbl" xml:lang="en-US">Commission as a percentage of cash amount equal to aggregate sale price of units</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_NonaccountableExpenseAllowancePercenatge" xlink:label="IGAP_NonaccountableExpenseAllowancePercenatge" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_NonaccountableExpenseAllowancePercenatge" xlink:to="IGAP_NonaccountableExpenseAllowancePercenatge_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_NonaccountableExpenseAllowancePercenatge_lbl" xml:lang="en-US">Non-accountable expense allowance percenatge</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AggregateSalesPriceOfUnitsPercentage" xlink:label="IGAP_AggregateSalesPriceOfUnitsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_AggregateSalesPriceOfUnitsPercentage" xlink:to="IGAP_AggregateSalesPriceOfUnitsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_AggregateSalesPriceOfUnitsPercentage_lbl" xml:lang="en-US">Commission as a percentage of aggregate sales price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Salary and Wage, Officer, Excluding Cost of Good and Service Sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PercentageOfDulitedCommonStock" xlink:label="IGAP_PercentageOfDulitedCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_PercentageOfDulitedCommonStock" xlink:to="IGAP_PercentageOfDulitedCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_PercentageOfDulitedCommonStock_lbl" xml:lang="en-US">Percentage of dulited common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Salaries and related expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Expenses due to slow inventory write-off</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:label="us-gaap_CostOfPropertyRepairsAndMaintenance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:to="us-gaap_CostOfPropertyRepairsAndMaintenance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfPropertyRepairsAndMaintenance_lbl" xml:lang="en-US">Vehicle maintenance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralExpense" xlink:label="us-gaap_OtherGeneralExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralExpense_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Total research and development expenses, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_DisclosureMarketingExpensesAbstract" xlink:to="IGAP_DisclosureMarketingExpensesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="IGAP_DisclosureMarketingExpensesAbstract_2_lbl" xml:lang="en-US">Schedule Of Selling And Marketing Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_SalariesAndRelatedExpenses" xlink:label="IGAP_SalariesAndRelatedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_SalariesAndRelatedExpenses" xlink:to="IGAP_SalariesAndRelatedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="IGAP_SalariesAndRelatedExpenses_lbl" xml:lang="en-US">Salaries and related expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ResearchAndDevelopmentProfessionalFees" xlink:label="IGAP_ResearchAndDevelopmentProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ResearchAndDevelopmentProfessionalFees" xlink:to="IGAP_ResearchAndDevelopmentProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="IGAP_ResearchAndDevelopmentProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_SellingAndMarketingOtherExpenses" xlink:label="IGAP_SellingAndMarketingOtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_SellingAndMarketingOtherExpenses" xlink:to="IGAP_SellingAndMarketingOtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="IGAP_SellingAndMarketingOtherExpenses_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total selling and marketing expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_BadDebtExpense" xlink:label="IGAP_BadDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_BadDebtExpense" xlink:to="IGAP_BadDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_BadDebtExpense_lbl" xml:lang="en-US">Bad debt expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInvestmentExpense" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl" xml:lang="en-US">Insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">&#160;Total general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Provision for employee-related obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Non-capital loss carry forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_DeferredTaxAssetValuationAllowance" xlink:label="IGAP_DeferredTaxAssetValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_DeferredTaxAssetValuationAllowance" xlink:to="IGAP_DeferredTaxAssetValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_DeferredTaxAssetValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">&#160;Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_FinanceIncomeExpenses" xlink:label="IGAP_FinanceIncomeExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_FinanceIncomeExpenses" xlink:to="IGAP_FinanceIncomeExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_FinanceIncomeExpenses_doc" xml:lang="en-US">Financing income (expense), net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_WarrantsIssuedAsConsiderationForPlacementServices" xlink:to="IGAP_WarrantsIssuedAsConsiderationForPlacementServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_WarrantsIssuedAsConsiderationForPlacementServices_doc" xml:lang="en-US">Warrants issued as consideration for placement services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:to="IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors_doc" xml:lang="en-US">Issuance of restricted shares as compensation to the board of directors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:to="IGAP_LinkageDifferenceOnPrincipalOfLoansFromStockholders_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_LinkageDifferenceOnPrincipalOfLoansFromStockholders_doc" xml:lang="en-US">Linkage difference on principal of loans from stockholders .</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_BoardOfMembersMember" xlink:to="IGAP_BoardOfMembersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_BoardOfMembersMember_doc" xml:lang="en-US">Board of Members [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_GrossProceedsFromIssuanceOfCommonStock" xlink:label="IGAP_GrossProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_GrossProceedsFromIssuanceOfCommonStock" xlink:to="IGAP_GrossProceedsFromIssuanceOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_GrossProceedsFromIssuanceOfCommonStock_doc" xml:lang="en-US">Gross proceeds from issuance of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_AverageForeignCurrencyExchangeRateTranslation" xlink:to="IGAP_AverageForeignCurrencyExchangeRateTranslation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_AverageForeignCurrencyExchangeRateTranslation_doc" xml:lang="en-US">The foreign exchange rates used to translate income and expense items denominated in the functional currency to the reporting currency.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage" xlink:to="IGAP_IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage_doc" xml:lang="en-US">Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2020.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo" xlink:to="IGAP_IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo_doc" xml:lang="en-US">Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2019.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_PropertyPlantAndEquipmentDepreciationRate" xlink:to="IGAP_PropertyPlantAndEquipmentDepreciationRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_PropertyPlantAndEquipmentDepreciationRate_doc" xml:lang="en-US">Property plant and equipment depreciation rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ComputersMember" xlink:to="IGAP_ComputersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_ComputersMember_doc" xml:lang="en-US">Computers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_FurnitureAndOfficeEquipmentMember" xlink:to="IGAP_FurnitureAndOfficeEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_FurnitureAndOfficeEquipmentMember_doc" xml:lang="en-US">Furniture and Office Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ScheduleOfPropertyRatesOfDepreciationTableTextBlock" xlink:to="IGAP_ScheduleOfPropertyRatesOfDepreciationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_ScheduleOfPropertyRatesOfDepreciationTableTextBlock_doc" xml:lang="en-US">Schedule of Property Rates of Depreciation [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_RoyaltyBearingGrantsPolicyTextBlock" xlink:to="IGAP_RoyaltyBearingGrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_RoyaltyBearingGrantsPolicyTextBlock_doc" xml:lang="en-US">Royalty Bearing Grants [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_CumulativeResearchAndDevelopment" xlink:to="IGAP_CumulativeResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_CumulativeResearchAndDevelopment_doc" xml:lang="en-US">Cumulative research and development.</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_InceptionThroughDecemberTwoThousandFourMember" xlink:label="IGAP_InceptionThroughDecemberTwoThousandFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_InceptionThroughDecemberTwoThousandFourMember" xlink:to="IGAP_InceptionThroughDecemberTwoThousandFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_InceptionThroughDecemberTwoThousandFourMember_doc" xml:lang="en-US">Inception Through December 2004 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_SeriesDUnitsMember" xlink:label="IGAP_SeriesDUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_SeriesDUnitsMember" xlink:to="IGAP_SeriesDUnitsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_SeriesDUnitsMember_doc" xml:lang="en-US">Series D Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_SeriesD1WarrantMember" xlink:label="IGAP_SeriesD1WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_SeriesD1WarrantMember" xlink:to="IGAP_SeriesD1WarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_SeriesD1WarrantMember_doc" xml:lang="en-US">Series D-1 Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_SeriesD2WarrantMember" xlink:label="IGAP_SeriesD2WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_SeriesD2WarrantMember" xlink:to="IGAP_SeriesD2WarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_SeriesD2WarrantMember_doc" xml:lang="en-US">Series D-2 Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_SeriesD3WarrantMember" xlink:label="IGAP_SeriesD3WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_SeriesD3WarrantMember" xlink:to="IGAP_SeriesD3WarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_SeriesD3WarrantMember_doc" xml:lang="en-US">Series D-3 Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_TwoThousandandSeventeenOfferingMember" xlink:to="IGAP_TwoThousandandSeventeenOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_TwoThousandandSeventeenOfferingMember_doc" xml:lang="en-US">2017 Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_PlacementAgentMember" xlink:to="IGAP_PlacementAgentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_PlacementAgentMember_doc" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_WarrantOneMember" xlink:to="IGAP_WarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_WarrantOneMember_doc" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ModificationOfEquityclassifiedContractsPolicyTextBlock" xlink:to="IGAP_ModificationOfEquityclassifiedContractsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_ModificationOfEquityclassifiedContractsPolicyTextBlock_doc" xml:lang="en-US">Modification of Equity Classified Contracts [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_WarrantTwoMember" xlink:to="IGAP_WarrantTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_WarrantTwoMember_doc" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_WarrantThreeMember" xlink:to="IGAP_WarrantThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_WarrantThreeMember_doc" xml:lang="en-US">Warrant Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_WarrantFourMember" xlink:to="IGAP_WarrantFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_WarrantFourMember_doc" xml:lang="en-US">Warrant Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_TwoThousandandTwentyOfferingMember" xlink:to="IGAP_TwoThousandandTwentyOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_TwoThousandandTwentyOfferingMember_doc" xml:lang="en-US">2020 Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_WarrantFiveMember" xlink:to="IGAP_WarrantFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_WarrantFiveMember_doc" xml:lang="en-US">Warrant Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_IntegrityIsraelsPlanMember" xlink:to="IGAP_IntegrityIsraelsPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_IntegrityIsraelsPlanMember_doc" xml:lang="en-US">Integrity Israel's Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ErezBenZviMember" xlink:to="IGAP_ErezBenZviMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_ErezBenZviMember_doc" xml:lang="en-US">Erez Ben Zvi [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ShalomShushanMember" xlink:to="IGAP_ShalomShushanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_ShalomShushanMember_doc" xml:lang="en-US">Shalom Shushan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_NISMember" xlink:label="IGAP_NISMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_NISMember" xlink:to="IGAP_NISMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_NISMember_doc" xml:lang="en-US">NIS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_MedicationGroupsMember" xlink:label="IGAP_MedicationGroupsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_MedicationGroupsMember" xlink:to="IGAP_MedicationGroupsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_MedicationGroupsMember_doc" xml:lang="en-US">Medication Groups [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_OfficeSpaceMember" xlink:to="IGAP_OfficeSpaceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_OfficeSpaceMember_doc" xml:lang="en-US">Office Space [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits" xlink:to="IGAP_CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits_doc" xml:lang="en-US">Commission as a percentage of cash amount equal to aggregate sale price of units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_PlacementAgentAgreementMember" xlink:to="IGAP_PlacementAgentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_PlacementAgentAgreementMember_doc" xml:lang="en-US">Placement Agent Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_NonaccountableExpenseAllowancePercenatge" xlink:to="IGAP_NonaccountableExpenseAllowancePercenatge_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_NonaccountableExpenseAllowancePercenatge_doc" xml:lang="en-US">Non-accountable expense allowance percenatge.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_AggregateSalesPriceOfUnitsPercentage" xlink:to="IGAP_AggregateSalesPriceOfUnitsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_AggregateSalesPriceOfUnitsPercentage_doc" xml:lang="en-US">Commission as a percentage of the aggregate sales price of the Units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_MrJamesPMember" xlink:to="IGAP_MrJamesPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_MrJamesPMember_doc" xml:lang="en-US">Mr James P [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_MrPaulVMember" xlink:to="IGAP_MrPaulVMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_MrPaulVMember_doc" xml:lang="en-US">Mr Paul V [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ExercisePriceTwoMember" xlink:to="IGAP_ExercisePriceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_ExercisePriceTwoMember_doc" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ExercisePriceFourMember" xlink:label="IGAP_ExercisePriceFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ExercisePriceFourMember" xlink:to="IGAP_ExercisePriceFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_ExercisePriceFourMember_doc" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ExercisePriceOneMember" xlink:to="IGAP_ExercisePriceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_ExercisePriceOneMember_doc" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_PercentageOfDulitedCommonStock" xlink:to="IGAP_PercentageOfDulitedCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_PercentageOfDulitedCommonStock_doc" xml:lang="en-US">Percentage of dulited common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_MeasurementInputFairValueMember" xlink:to="IGAP_MeasurementInputFairValueMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_MeasurementInputFairValueMember_doc" xml:lang="en-US">Measurement Input Fair Value [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xlink:to="IGAP_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock_doc" xml:lang="en-US">Schedule of Research And Development Expenses [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_SellingAndMarketingExpensesTextBlock" xlink:to="IGAP_SellingAndMarketingExpensesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_SellingAndMarketingExpensesTextBlock_doc" xml:lang="en-US">Selling and Marketing Expenses [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_SellingAndMarketingOtherExpenses" xlink:to="IGAP_SellingAndMarketingOtherExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_SellingAndMarketingOtherExpenses_doc" xml:lang="en-US">Selling and marketing other expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ShareHoldersMember" xlink:to="IGAP_ShareHoldersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_ShareHoldersMember_doc" xml:lang="en-US">Shareholders [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ScheduleOfSellingAndMarketingExpensesTableTextBlock" xlink:to="IGAP_ScheduleOfSellingAndMarketingExpensesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_ScheduleOfSellingAndMarketingExpensesTableTextBlock_doc" xml:lang="en-US">Schedule of Selling and Marketing Expenses [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_GeneralAndAdministrativeExpensesTextBlock" xlink:to="IGAP_GeneralAndAdministrativeExpensesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_GeneralAndAdministrativeExpensesTextBlock_doc" xml:lang="en-US">General and Administrative Expenses [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_QuarterlyPaymentsEqualsToSalesPercentage" xlink:to="IGAP_QuarterlyPaymentsEqualsToSalesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_QuarterlyPaymentsEqualsToSalesPercentage_doc" xml:lang="en-US">Quarterly payments equals to sales, percentage.</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_OCSMember" xlink:label="IGAP_OCSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_OCSMember" xlink:to="IGAP_OCSMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_OCSMember_doc" xml:lang="en-US">OCS [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_SalariesAndRelatedExpenses" xlink:to="IGAP_SalariesAndRelatedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_SalariesAndRelatedExpenses_doc" xml:lang="en-US">Salaries and related expenses.</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ResearchAndDevelopmentProfessionalFee" xlink:label="IGAP_ResearchAndDevelopmentProfessionalFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ResearchAndDevelopmentProfessionalFee" xlink:to="IGAP_ResearchAndDevelopmentProfessionalFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_ResearchAndDevelopmentProfessionalFee_doc" xml:lang="en-US">Research and development professional fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ResearchAndDevelopmentProfessionalFees" xlink:to="IGAP_ResearchAndDevelopmentProfessionalFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_ResearchAndDevelopmentProfessionalFees_doc" xml:lang="en-US">Research and development professional fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_RoyaltyPercentage" xlink:to="IGAP_RoyaltyPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_RoyaltyPercentage_doc" xml:lang="en-US">Royalty percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_AdvisoryServicesPeriod" xlink:to="IGAP_AdvisoryServicesPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_AdvisoryServicesPeriod_doc" xml:lang="en-US">Advisory services period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_AdvisoryAgreementMember" xlink:to="IGAP_AdvisoryAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_AdvisoryAgreementMember_doc" xml:lang="en-US">Advisory Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_AndrewGarrettIncMember" xlink:to="IGAP_AndrewGarrettIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_AndrewGarrettIncMember_doc" xml:lang="en-US">Andrew Garrett, Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="IGAP_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_doc" xml:lang="en-US">Schedule of General and Administrative Expenses [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_BadDebtExpense" xlink:to="IGAP_BadDebtExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_BadDebtExpense_doc" xml:lang="en-US">Bad debt expense.</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_FederalNetOperatingLossForOffsetAgainstTaxableIncomeTerm" xlink:label="IGAP_FederalNetOperatingLossForOffsetAgainstTaxableIncomeTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_FederalNetOperatingLossForOffsetAgainstTaxableIncomeTerm" xlink:to="IGAP_FederalNetOperatingLossForOffsetAgainstTaxableIncomeTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_FederalNetOperatingLossForOffsetAgainstTaxableIncomeTerm_doc" xml:lang="en-US">Federal net operating loss for offset against taxable income, term.</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_FederalNetOperatingLossOffsetAgainstTaxableIncomeMember" xlink:label="IGAP_FederalNetOperatingLossOffsetAgainstTaxableIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_FederalNetOperatingLossOffsetAgainstTaxableIncomeMember" xlink:to="IGAP_FederalNetOperatingLossOffsetAgainstTaxableIncomeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_FederalNetOperatingLossOffsetAgainstTaxableIncomeMember_doc" xml:lang="en-US">Federal Net Operating Loss (Offset Against Taxable Income) [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_DeferredTaxAssetValuationAllowance" xlink:to="IGAP_DeferredTaxAssetValuationAllowance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_DeferredTaxAssetValuationAllowance_doc" xml:lang="en-US">Valuation allowance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_AndrewSycoffMember" xlink:to="IGAP_AndrewSycoffMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_AndrewSycoffMember_doc" xml:lang="en-US">Andrew Sycoff [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_PlacementAgentFeesMember" xlink:to="IGAP_PlacementAgentFeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_PlacementAgentFeesMember_doc" xml:lang="en-US">Placement Agent Fees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_NumberOfCommonStockIssuedForSettlementOfFees" xlink:to="IGAP_NumberOfCommonStockIssuedForSettlementOfFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_NumberOfCommonStockIssuedForSettlementOfFees_doc" xml:lang="en-US">Number of common stock issued for settlement of fees.</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_GlucoseMonitoringDeviceGroupMember" xlink:label="IGAP_GlucoseMonitoringDeviceGroupMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_GlucoseMonitoringDeviceGroupMember" xlink:to="IGAP_GlucoseMonitoringDeviceGroupMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_GlucoseMonitoringDeviceGroupMember_doc" xml:lang="en-US">Glucose Monitoring Device Group [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_IsraeliInnovationAuthorityMember" xlink:to="IGAP_IsraeliInnovationAuthorityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_IsraeliInnovationAuthorityMember_doc" xml:lang="en-US">Israeli Innovation Authority [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_NumberOfStockOptionsExcluded" xlink:to="IGAP_NumberOfStockOptionsExcluded_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_NumberOfStockOptionsExcluded_doc" xml:lang="en-US">Number of stock options excluded.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_NumberOfStockWarrantsExcluded" xlink:to="IGAP_NumberOfStockWarrantsExcluded_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_NumberOfStockWarrantsExcluded_doc" xml:lang="en-US">Number of stock warrants excluded.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_LongTermLeaseCost" xlink:to="IGAP_LongTermLeaseCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_LongTermLeaseCost_doc" xml:lang="en-US">Long term lease cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_CashExpensesOnIssuanceOfStock" xlink:to="IGAP_CashExpensesOnIssuanceOfStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_CashExpensesOnIssuanceOfStock_doc" xml:lang="en-US">Cash expenses on issuance of stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PercentageOfCommissionPaid" xlink:label="IGAP_PercentageOfCommissionPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_PercentageOfCommissionPaid" xlink:to="IGAP_PercentageOfCommissionPaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_PercentageOfCommissionPaid_doc" xml:lang="en-US">Percentage of commission paid.</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PercentageOfManagementFee" xlink:label="IGAP_PercentageOfManagementFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_PercentageOfManagementFee" xlink:to="IGAP_PercentageOfManagementFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_PercentageOfManagementFee_doc" xml:lang="en-US">Percentage of management fee</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PercentageOfNonaccountableExpenseAllowance" xlink:label="IGAP_PercentageOfNonaccountableExpenseAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_PercentageOfNonaccountableExpenseAllowance" xlink:to="IGAP_PercentageOfNonaccountableExpenseAllowance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_PercentageOfNonaccountableExpenseAllowance_doc" xml:lang="en-US">Percentage of non-accountable expense allowance.</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PercentageOfNumberOfSharesOfCommonStock" xlink:label="IGAP_PercentageOfNumberOfSharesOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_PercentageOfNumberOfSharesOfCommonStock" xlink:to="IGAP_PercentageOfNumberOfSharesOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_PercentageOfNumberOfSharesOfCommonStock_doc" xml:lang="en-US">Percentage of number of shares of common stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PercentageofNumberOfWarrantsIssued" xlink:label="IGAP_PercentageofNumberOfWarrantsIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_PercentageofNumberOfWarrantsIssued" xlink:to="IGAP_PercentageofNumberOfWarrantsIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IGAP_PercentageofNumberOfWarrantsIssued_doc" xml:lang="en-US">Percentageof number of the warrants issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_FinancingIncomeExpenseNet" xlink:to="IGAP_FinancingIncomeExpenseNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_FinancingIncomeExpenseNet_2_lbl" xml:lang="en-US">FinancingIncomeExpenseNet</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:to="IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors_3_lbl" xml:lang="en-US">IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_2_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_2_lbl" xml:lang="en-US">Inventory, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_2_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_SalariesAndRelatedExpenses" xlink:to="IGAP_SalariesAndRelatedExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_SalariesAndRelatedExpenses_3_lbl" xml:lang="en-US">Salaries and related expenses [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_ResearchAndDevelopmentProfessionalFees" xlink:to="IGAP_ResearchAndDevelopmentProfessionalFees_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_ResearchAndDevelopmentProfessionalFees_3_lbl" xml:lang="en-US">Research and development professional fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IGAP_SellingAndMarketingOtherExpenses" xlink:to="IGAP_SellingAndMarketingOtherExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IGAP_SellingAndMarketingOtherExpenses_3_lbl" xml:lang="en-US">Selling and marketing other expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Other General and Administrative Expense</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>igap-20211231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://integrity-app.com/role/Cover" xlink:href="igap-20211231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/BalanceSheets" xlink:href="igap-20211231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/BalanceSheetsParenthetical" xlink:href="igap-20211231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="igap-20211231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit" xlink:href="igap-20211231.xsd#StatementsOfChangesInStockholdersEquitydeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/StatementsOfCashFlows" xlink:href="igap-20211231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/StatementsOfCashFlowsParenthetical" xlink:href="igap-20211231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/General" xlink:href="igap-20211231.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="igap-20211231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/Inventories" xlink:href="igap-20211231.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/Leases" xlink:href="igap-20211231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/PropertyAndEquipmentNet" xlink:href="igap-20211231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/OtherCurrentLiabilities" xlink:href="igap-20211231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/LoansFromStockholders" xlink:href="igap-20211231.xsd#LoansFromStockholders" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilities" xlink:href="igap-20211231.xsd#CommitmentsAndContingentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtection" xlink:href="igap-20211231.xsd#CommonStockAndWarrantsWith-downRoundProtection" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ResearchAndDevelopmentExpenses" xlink:href="igap-20211231.xsd#ResearchAndDevelopmentExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/MarketingExpenses" xlink:href="igap-20211231.xsd#MarketingExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/GeneralAndAdministrativeExpenses" xlink:href="igap-20211231.xsd#GeneralAndAdministrativeExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/IncomeTax" xlink:href="igap-20211231.xsd#IncomeTax" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SegmentInformation" xlink:href="igap-20211231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/RelatedParties" xlink:href="igap-20211231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SubsequentEvents" xlink:href="igap-20211231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="igap-20211231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="igap-20211231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/InventoriesTables" xlink:href="igap-20211231.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/LeasesTables" xlink:href="igap-20211231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/PropertyAndEquipmentNetTables" xlink:href="igap-20211231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/OtherCurrentLiabilitiesTables" xlink:href="igap-20211231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionTables" xlink:href="igap-20211231.xsd#CommonStockAndWarrantsWith-downRoundProtectionTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ResearchAndDevelopmentExpensesTables" xlink:href="igap-20211231.xsd#ResearchAndDevelopmentExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/MarketingExpensesTables" xlink:href="igap-20211231.xsd#MarketingExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/GeneralAndAdministrativeExpensesTables" xlink:href="igap-20211231.xsd#GeneralAndAdministrativeExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/IncomeTaxTables" xlink:href="igap-20211231.xsd#IncomeTaxTables" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/GeneralDetailsNarrative" xlink:href="igap-20211231.xsd#GeneralDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfOfficialExchangeRateDetails" xlink:href="igap-20211231.xsd#ScheduleOfOfficialExchangeRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails" xlink:href="igap-20211231.xsd#ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails" xlink:href="igap-20211231.xsd#ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="igap-20211231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfInventoriesDetails" xlink:href="igap-20211231.xsd#ScheduleOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/InventoriesDetailsNarrative" xlink:href="igap-20211231.xsd#InventoriesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails" xlink:href="igap-20211231.xsd#ScheduleOfLeaseCostsLeaseTermAndDiscountDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails" xlink:href="igap-20211231.xsd#ScheduleOfOperatingLeaseMaturityPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:href="igap-20211231.xsd#ScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="igap-20211231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" xlink:href="igap-20211231.xsd#ScheduleOfOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative" xlink:href="igap-20211231.xsd#LoansFromStockholdersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:href="igap-20211231.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:href="igap-20211231.xsd#ScheduleOfFairValueAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails" xlink:href="igap-20211231.xsd#ScheduleOfStockGrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails" xlink:href="igap-20211231.xsd#ScheduleOfStockGrantsByExercisePriceRangeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails" xlink:href="igap-20211231.xsd#ScheduleOfAssumptionsUsedToValueOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative" xlink:href="igap-20211231.xsd#CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:href="igap-20211231.xsd#ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails" xlink:href="igap-20211231.xsd#ScheduleOfSellingAndMarketingExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:href="igap-20211231.xsd#ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/ScheduleOfDeferredTaxesDetails" xlink:href="igap-20211231.xsd#ScheduleOfDeferredTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/IncomeTaxDetailsNarrative" xlink:href="igap-20211231.xsd#IncomeTaxDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/SegmentInformationDetailsNarrative" xlink:href="igap-20211231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://integrity-app.com/role/RelatedPartiesDetailsNarrative" xlink:href="igap-20211231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRestrictedCashNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersNoncurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDueToOfficersOrStockholdersNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_FinancingIncomeExpenseNet" xlink:label="loc_IGAPFinancingIncomeExpenseNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_IGAPFinancingIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit" xlink:title="00000005 - Statement - Statements of Changes In Stockholders&apos; Equity(Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantsIssuedAsConsiderationForPlacementServices" xlink:label="loc_IGAPWarrantsIssuedAsConsiderationForPlacementServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IGAPWarrantsIssuedAsConsiderationForPlacementServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:label="loc_IGAPIssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IGAPIssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_LinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:label="loc_IGAPLinkageDifferenceOnPrincipalOfLoansFromStockholders" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IGAPLinkageDifferenceOnPrincipalOfLoansFromStockholders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_BoardOfMembersMember" xlink:label="loc_IGAPBoardOfMembersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPBoardOfMembersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_NumberOfCommonStockIssuedForSettlementOfFees" xlink:label="loc_IGAPNumberOfCommonStockIssuedForSettlementOfFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_IGAPNumberOfCommonStockIssuedForSettlementOfFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/General" xlink:title="00000008 - Disclosure - GENERAL">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/Inventories" xlink:title="00000010 - Disclosure - INVENTORIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/Leases" xlink:title="00000011 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_DisclosureLeasesAbstract" xlink:label="loc_IGAPDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/PropertyAndEquipmentNet" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/LoansFromStockholders" xlink:title="00000014 - Disclosure - LOANS FROM STOCKHOLDERS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommitmentsAndContingentLiabilities" xlink:title="00000015 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtection" xlink:title="00000016 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ResearchAndDevelopmentExpenses" xlink:title="00000017 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/MarketingExpenses" xlink:title="00000018 - Disclosure - MARKETING EXPENSES">
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_DisclosureMarketingExpensesAbstract" xlink:label="loc_IGAPDisclosureMarketingExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_SellingAndMarketingExpensesTextBlock" xlink:label="loc_IGAPSellingAndMarketingExpensesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureMarketingExpensesAbstract" xlink:to="loc_IGAPSellingAndMarketingExpensesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/GeneralAndAdministrativeExpenses" xlink:title="00000019 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES">
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract" xlink:label="loc_IGAPDisclosureGeneralAndAdministrativeExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_GeneralAndAdministrativeExpensesTextBlock" xlink:label="loc_IGAPGeneralAndAdministrativeExpensesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureGeneralAndAdministrativeExpensesAbstract" xlink:to="loc_IGAPGeneralAndAdministrativeExpensesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/IncomeTax" xlink:title="00000020 - Disclosure - INCOME TAX">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SegmentInformation" xlink:title="00000021 - Disclosure - SEGMENT INFORMATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/RelatedParties" xlink:title="00000022 - Disclosure - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:label="loc_us-gaapPensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_RoyaltyBearingGrantsPolicyTextBlock" xlink:label="loc_IGAPRoyaltyBearingGrantsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_IGAPRoyaltyBearingGrantsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="loc_us-gaapStandardProductWarrantyPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStandardProductWarrantyPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ModificationOfEquityclassifiedContractsPolicyTextBlock" xlink:label="loc_IGAPModificationOfEquityclassifiedContractsPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_IGAPModificationOfEquityclassifiedContractsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="loc_us-gaapOperatingLeaseLeaseIncomeTableTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOperatingLeaseLeaseIncomeTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" xlink:label="loc_us-gaapScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ScheduleOfPropertyRatesOfDepreciationTableTextBlock" xlink:label="loc_IGAPScheduleOfPropertyRatesOfDepreciationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_IGAPScheduleOfPropertyRatesOfDepreciationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/InventoriesTables" xlink:title="00000026 - Disclosure - INVENTORIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/LeasesTables" xlink:title="00000027 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_DisclosureLeasesAbstract" xlink:label="loc_IGAPDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/PropertyAndEquipmentNetTables" xlink:title="00000028 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionTables" xlink:title="00000030 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ResearchAndDevelopmentExpensesTables" xlink:title="00000031 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xlink:label="loc_IGAPScheduleOfResearchAndDevelopmentExpensesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_IGAPScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/MarketingExpensesTables" xlink:title="00000032 - Disclosure - MARKETING EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_DisclosureMarketingExpensesAbstract" xlink:label="loc_IGAPDisclosureMarketingExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ScheduleOfSellingAndMarketingExpensesTableTextBlock" xlink:label="loc_IGAPScheduleOfSellingAndMarketingExpensesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureMarketingExpensesAbstract" xlink:to="loc_IGAPScheduleOfSellingAndMarketingExpensesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/GeneralAndAdministrativeExpensesTables" xlink:title="00000033 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract" xlink:label="loc_IGAPDisclosureGeneralAndAdministrativeExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:label="loc_IGAPScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureGeneralAndAdministrativeExpensesAbstract" xlink:to="loc_IGAPScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/IncomeTaxTables" xlink:title="00000034 - Disclosure - INCOME TAX (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/GeneralDetailsNarrative" xlink:title="00000035 - Disclosure - GENERAL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecurities" xlink:label="loc_us-gaapDebtSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtSecurities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfOfficialExchangeRateDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF OFFICIAL EXCHANGE RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AverageForeignCurrencyExchangeRateTranslation" xlink:label="loc_IGAPAverageForeignCurrencyExchangeRateTranslation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_IGAPAverageForeignCurrencyExchangeRateTranslation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage" xlink:label="loc_IGAPIncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_IGAPIncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo" xlink:label="loc_IGAPIncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_IGAPIncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ComputersMember" xlink:label="loc_IGAPComputersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_IGAPComputersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_FurnitureAndOfficeEquipmentMember" xlink:label="loc_IGAPFurnitureAndOfficeEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_IGAPFurnitureAndOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PropertyPlantAndEquipmentDepreciationRate" xlink:label="loc_IGAPPropertyPlantAndEquipmentDepreciationRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_IGAPPropertyPlantAndEquipmentDepreciationRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails" xlink:title="00000038 - Disclosure -  SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSeveranceCosts1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_CumulativeResearchAndDevelopment" xlink:label="loc_IGAPCumulativeResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_IGAPCumulativeResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_NumberOfStockOptionsExcluded" xlink:label="loc_IGAPNumberOfStockOptionsExcluded" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_IGAPNumberOfStockOptionsExcluded" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_NumberOfStockWarrantsExcluded" xlink:label="loc_IGAPNumberOfStockWarrantsExcluded" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_IGAPNumberOfStockWarrantsExcluded" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLessorOperatingLeaseTermOfContract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLessorOperatingLeaseTermOfContract" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfInventoriesDetails" xlink:title="00000040 - Disclosure - SCHEDULE OF INVENTORIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryAdjustments" xlink:label="loc_us-gaapInventoryAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/InventoriesDetailsNarrative" xlink:title="00000041 - Disclosure - INVENTORIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryAdjustments" xlink:label="loc_us-gaapInventoryAdjustments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryAdjustments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF LEASE COSTS, LEASE TERM AND DISCOUNT (Details)">
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_DisclosureLeasesAbstract" xlink:label="loc_IGAPDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureLeasesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_OfficeSpaceMember" xlink:label="loc_IGAPOfficeSpaceMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_IGAPOfficeSpaceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_LongTermLeaseCost" xlink:label="loc_IGAPLongTermLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_IGAPLongTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF OPERATING LEASE MATURITY PAYMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_DisclosureLeasesAbstract" xlink:label="loc_IGAPDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_FurnitureAndOfficeEquipmentMember" xlink:label="loc_IGAPFurnitureAndOfficeEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_IGAPFurnitureAndOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000045 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfOtherCurrentLiabilitiesDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative" xlink:title="00000047 - Disclosure - LOANS FROM STOCKHOLDERS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ShareHoldersMember" xlink:label="loc_IGAPShareHoldersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPShareHoldersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfLongTermDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToOfficersOrStockholdersNoncurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapDueToOfficersOrStockholdersNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_QuarterlyPaymentsEqualsToSalesPercentage" xlink:label="loc_IGAPQuarterlyPaymentsEqualsToSalesPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_IGAPQuarterlyPaymentsEqualsToSalesPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="00000048 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_IsraeliInnovationAuthorityMember" xlink:label="loc_IGAPIsraeliInnovationAuthorityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" xlink:to="loc_IGAPIsraeliInnovationAuthorityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_IsraeliInnovationAuthorityMember" xlink:label="loc_IGAPIsraeliInnovationAuthorityMember_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_IGAPIsraeliInnovationAuthorityMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AndrewGarrettIncMember" xlink:label="loc_IGAPAndrewGarrettIncMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_IGAPAndrewGarrettIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AdvisoryAgreementMember" xlink:label="loc_IGAPAdvisoryAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IGAPAdvisoryAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_RoyaltyPercentage" xlink:label="loc_IGAPRoyaltyPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_IGAPRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AdvisoryServicesPeriod" xlink:label="loc_IGAPAdvisoryServicesPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_IGAPAdvisoryServicesPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_MeasurementInputFairValueMember" xlink:label="loc_IGAPMeasurementInputFairValueMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_IGAPMeasurementInputFairValueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails" xlink:title="00000050 - Disclosure - SCHEDULE OF STOCK GRANTS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF STOCK GRANTS, BY EXERCISE PRICE RANGE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ExercisePriceOneMember" xlink:label="loc_IGAPExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IGAPExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ExercisePriceTwoMember" xlink:label="loc_IGAPExercisePriceTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IGAPExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ExercisePriceThreeMember" xlink:label="loc_IGAPExercisePriceThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IGAPExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative" xlink:title="00000053 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember" xlink:label="loc_IGAPSecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IGAPSecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PlacementAgentAgreementMember" xlink:label="loc_IGAPPlacementAgentAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IGAPPlacementAgentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AccreditedInvestorMember" xlink:label="loc_IGAPAccreditedInvestorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPAccreditedInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PlacementAgentMember" xlink:label="loc_IGAPPlacementAgentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPPlacementAgentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ErezBenZviMember" xlink:label="loc_IGAPErezBenZviMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPErezBenZviMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ShalomShushanMember" xlink:label="loc_IGAPShalomShushanMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPShalomShushanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_MrPaulVMember" xlink:label="loc_IGAPMrPaulVMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPMrPaulVMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_MrJamesPMember" xlink:label="loc_IGAPMrJamesPMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPMrJamesPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_TwoThousandandSeventeenOfferingMember" xlink:label="loc_IGAPTwoThousandandSeventeenOfferingMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_IGAPTwoThousandandSeventeenOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_TwoThousandandTwentyOfferingMember" xlink:label="loc_IGAPTwoThousandandTwentyOfferingMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_IGAPTwoThousandandTwentyOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantOneMember" xlink:label="loc_IGAPWarrantOneMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_IGAPWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantTwoMember" xlink:label="loc_IGAPWarrantTwoMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_IGAPWarrantTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantThreeMember" xlink:label="loc_IGAPWarrantThreeMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_IGAPWarrantThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantFourMember" xlink:label="loc_IGAPWarrantFourMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_IGAPWarrantFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_WarrantFiveMember" xlink:label="loc_IGAPWarrantFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_IGAPWarrantFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_IntegrityIsraelsPlanMember" xlink:label="loc_IGAPIntegrityIsraelsPlanMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_IGAPIntegrityIsraelsPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_CashExpensesOnIssuanceOfStock" xlink:label="loc_IGAPCashExpensesOnIssuanceOfStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_IGAPCashExpensesOnIssuanceOfStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits" xlink:label="loc_IGAPCommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_IGAPCommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_NonaccountableExpenseAllowancePercenatge" xlink:label="loc_IGAPNonaccountableExpenseAllowancePercenatge" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_IGAPNonaccountableExpenseAllowancePercenatge" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AggregateSalesPriceOfUnitsPercentage" xlink:label="loc_IGAPAggregateSalesPriceOfUnitsPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_IGAPAggregateSalesPriceOfUnitsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PercentageOfDulitedCommonStock" xlink:label="loc_IGAPPercentageOfDulitedCommonStock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_IGAPPercentageOfDulitedCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:label="loc_us-gaapCostOfPropertyRepairsAndMaintenance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapCostOfPropertyRepairsAndMaintenance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapOtherGeneralExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF SELLING AND MARKETING EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_DisclosureMarketingExpensesAbstract" xlink:label="loc_IGAPDisclosureMarketingExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_SalariesAndRelatedExpenses" xlink:label="loc_IGAPSalariesAndRelatedExpenses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureMarketingExpensesAbstract" xlink:to="loc_IGAPSalariesAndRelatedExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_ResearchAndDevelopmentProfessionalFees" xlink:label="loc_IGAPResearchAndDevelopmentProfessionalFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureMarketingExpensesAbstract" xlink:to="loc_IGAPResearchAndDevelopmentProfessionalFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_SellingAndMarketingOtherExpenses" xlink:label="loc_IGAPSellingAndMarketingOtherExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureMarketingExpensesAbstract" xlink:to="loc_IGAPSellingAndMarketingOtherExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureMarketingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract" xlink:label="loc_IGAPDisclosureGeneralAndAdministrativeExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IGAPDisclosureGeneralAndAdministrativeExpensesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_BadDebtExpense" xlink:label="loc_IGAPBadDebtExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IGAPBadDebtExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfPropertyRepairsAndMaintenance" xlink:label="loc_us-gaapCostOfPropertyRepairsAndMaintenance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfPropertyRepairsAndMaintenance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInvestmentExpense" xlink:label="loc_us-gaapInvestmentIncomeInvestmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentIncomeInvestmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/ScheduleOfDeferredTaxesDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF DEFERRED TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_DeferredTaxAssetValuationAllowance" xlink:label="loc_IGAPDeferredTaxAssetValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_IGAPDeferredTaxAssetValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/IncomeTaxDetailsNarrative" xlink:title="00000058 - Disclosure - INCOME TAX (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaapIsraelTaxAuthorityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapIsraelTaxAuthorityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/SegmentInformationDetailsNarrative" xlink:title="00000059 - Disclosure - SEGMENT INFORMATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://integrity-app.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000060 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AndrewGarrettIncMember" xlink:label="loc_IGAPAndrewGarrettIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_IGAPAndrewGarrettIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_AndrewSycoffMember" xlink:label="loc_IGAPAndrewSycoffMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IGAPAndrewSycoffMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="igap-20211231.xsd#IGAP_PlacementAgentFeesMember" xlink:label="loc_IGAPPlacementAgentFeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IGAPPlacementAgentFeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519143376168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-54785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GLUCOTRACK,
INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001506983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0668934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8 Ariel Sharon Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">P.O. Box 6037607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Or Yehuda<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">7760049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">675-7878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,694,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,455,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">None,
except as noted for Part III information in the Company&#8217;s Schedule 14A to be filed on or before April 30, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">FAHN KANNE & CO. GRANT THORNTON ISRAEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv,
Israel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GCTK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519143417928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,062<span></span>
</td>
<td class="nump">$ 9,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory (Note 3)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,105<span></span>
</td>
<td class="nump">10,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net (Note 4)</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net (Note 5)</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">6,265<span></span>
</td>
<td class="nump">10,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">631<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current (Note 4)</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities (Note 6)</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">883<span></span>
</td>
<td class="nump">1,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersNoncurrent', window );">Loans from stockholders (Note 7)</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current (Note 4)</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">1,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock Value</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">102,612<span></span>
</td>
<td class="nump">102,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(97,466)<span></span>
</td>
<td class="num">(93,399)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">5,155<span></span>
</td>
<td class="nump">8,982<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 6,265<span></span>
</td>
<td class="nump">$ 10,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519143174328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">15,452,285<span></span>
</td>
<td class="nump">15,444,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">15,452,285<span></span>
</td>
<td class="nump">15,444,697<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519143153144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses (Note 10)</a></td>
<td class="nump">$ 1,810<span></span>
</td>
<td class="nump">$ 1,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Marketing expenses (Note 11)</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses (Note 12)</a></td>
<td class="nump">2,091<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,040<span></span>
</td>
<td class="nump">3,132<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">4,040<span></span>
</td>
<td class="nump">3,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (Income)</a></td>
<td class="nump">53<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_FinancingIncomeExpenseNet', window );">Financing income, net</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the year</a></td>
<td class="nump">4,067<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss for the year</a></td>
<td class="nump">$ 4,088<span></span>
</td>
<td class="nump">$ 2,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share (Basic and Diluted)</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common stock outstanding used in computing basic and diluted net loss per share</a></td>
<td class="nump">15,450,824<span></span>
</td>
<td class="nump">15,079,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_FinancingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_FinancingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519146821784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes In Stockholders' Equity(Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 89,155<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="num">$ (90,703)<span></span>
</td>
<td class="num">$ (1,412)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="nump">12,450,649<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,696)<span></span>
</td>
<td class="num">(2,696)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock, net</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,250<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock, net, shares</a></td>
<td class="nump">2,884,615<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_WarrantsIssuedAsConsiderationForPlacementServices', window );">Warrants issued as consideration for placement services</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">756<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted shares as compensation to directors</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">168<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted shares as compensation to directors, shares</a></td>
<td class="nump">109,433<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">102,351<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(93,399)<span></span>
</td>
<td class="nump">8,982<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="nump">15,444,697<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,067)<span></span>
</td>
<td class="num">(4,067)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">223<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted shares as compensation to directors</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">38<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted shares as compensation to directors, shares</a></td>
<td class="nump">7,588<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 102,612<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">$ (97,466)<span></span>
</td>
<td class="nump">$ 5,155<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2021</a></td>
<td class="nump">15,452,285<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than 1 thousand</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_WarrantsIssuedAsConsiderationForPlacementServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued as consideration for placement services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_WarrantsIssuedAsConsiderationForPlacementServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519143334744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the year</a></td>
<td class="num">$ (4,067)<span></span>
</td>
<td class="num">$ (2,696)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile loss for the year to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Capital loss from sale of property and equipment</a></td>
<td class="nump">42<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors', window );">Issuance of restricted shares as compensation to directors</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_LinkageDifferenceOnPrincipalOfLoansFromStockholders', window );">Linkage difference on principal of loans from stockholders</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease in accounts receivable</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventory</a></td>
<td class="nump">293<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Decrease (increase) in other current assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Decrease in accounts payable</a></td>
<td class="num">(257)<span></span>
</td>
<td class="num">(714)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Decrease in other current liabilities</a></td>
<td class="num">(172)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,769)<span></span>
</td>
<td class="num">(3,501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investment activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investment activities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of cash issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13,009<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(3,772)<span></span>
</td>
<td class="nump">9,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of the year</a></td>
<td class="nump">9,885<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of the year</a></td>
<td class="nump">$ 6,113<span></span>
</td>
<td class="nump">$ 9,885<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of restricted shares as compensation to the board of directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_LinkageDifferenceOnPrincipalOfLoansFromStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Linkage difference on principal of loans from stockholders .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_LinkageDifferenceOnPrincipalOfLoansFromStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519143173240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=IGAP_BoardOfMembersMember', window );">Board of Members [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_NumberOfCommonStockIssuedForSettlementOfFees', window );">Number of common stock issued for settlement of fees</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_NumberOfCommonStockIssuedForSettlementOfFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock issued for settlement of fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_NumberOfCommonStockIssuedForSettlementOfFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=IGAP_BoardOfMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=IGAP_BoardOfMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144916456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text"><p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zeoMebonz0R8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zQgOjzDROmtf">GENERAL</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GlucoTrack
    Inc (Formerly: Integrity Applications, Inc.) (the &#8220;Company&#8221;) was incorporated on May 18, 2010 under the laws of
    the State of Delaware. On July 15, 2010, GlucoTrack Acquisition Corp. Ltd. (hereinafter: &#8220;Integrity Acquisition&#8221;), a
    wholly owned Israeli subsidiary of the Company, which was established on May 23, 2010, completed a merger with A.D. Integrity Applications
    Ltd. (hereinafter: &#8220;Integrity Israel&#8221;), an Israeli corporation that was previously held by the stockholders of the Company.
    Pursuant to the merger, all equity holders of Integrity Israel received the same proportional ownership in the Company as they had
    in Integrity Israel prior to the merger. Following the merger, Integrity Israel remained a wholly-owned subsidiary of the Company.
    As the merger transaction constituted a structural reorganization, the merger has been accounted for at historical cost in a manner
    similar to a pooling of interests. Integrity Israel was incorporated in 2001 and commenced its operations in 2002 (The Company
    and Integrity Israel are referred as the &#8220;Group&#8221;) Integrity Israel, a medical device company, focuses on the design,
    development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Since its incorporation,
    the Company did not conduct any material operations other than those carried out by Integrity Israel. The development and commercialization
    of Integrity Israel&#8217;s product is expected to require substantial expenditures. Integrity Israel and the Company (collectively,
    the &#8220;Group&#8221;) have not yet generated significant revenues from operations, and therefore they are dependent upon external
    sources for financing their operations. As of December 31, 2021, the Group has incurred accumulated deficit of $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20211231_z44uHmdWrmD5">97,466
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand, and negative operating cash flows.
    As of December 31, 2021, the Company had $<span id="xdx_905_eus-gaap--Cash_iI_c20211231_zROskKYjTqS3">6,062</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in cash, which is sufficient to meet its capital
    needs for fiscal 2022 and for at least 12 months from the date of issuance of these financial statements, thus it is expected that
    the company will be able to operate as a going concern for at least 12 months from the date hereof. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin-top: 0; margin-bottom: 0">On December 8, 2021, we announced that our shares of common stock were approved for listing on the Nasdaq Capital Market (&#8220;NASDAQ&#8221;). Trading on NASDAQ commenced on December 10, 2021 under its existing trading symbol, IGAP.</p>
                                                                              <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0">On March 14, 2022, we announced that it has completed its corporate name and ticker symbol change on
the Nasdaq Capital Market (from IGAP to GCTK), to be effective at the commencement of trading on March 14, 2022.</p>

</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In connection with its application to list its shares on Nasdaq Capital Market (&#8220;NASDAQ&#8221;), as detailed above, on August 13, 2021, the Company
    effected a reverse split of its Common Stock in a ratio of <span id="xdx_90C_eus-gaap--StockholdersEquityReverseStockSplit_c20210811__20210813_z4gwqNKXxOCb" title="Stockholders' Equity, Reverse Stock Split">1 for 13</span> (the &#8220;Reverse Share Split&#8221;). For accounting purposes,
    all Shares, options and warrants to purchase Common Stock and loss per share amounts have been adjusted to give retroactive effect
    to this Reverse Share Split for all periods presented in these consolidated financial statements. Any fractional shares resulting
    from the Reverse Share Split were rounded up to the nearest whole share.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">B.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Liquidity and capital resources</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since
its inception date, the Company did not conduct any material operations other than those carried out by Integrity Israel. The development
and commercialization of the Product is expected to require substantial expenditures. The Group has not yet generated significant revenues
from operations, and therefore they are dependent upon external sources for financing their operations. As of December 31, 2021, the
Group has incurred accumulated deficit of $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20211231_zf5PUvewJyO3">97,466</span> thousand. During the year ended December 31, 2021 the Company incurred losses from
ongoing operation and has negative cash flow from operating activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 14, 2020, the Company closed on a
$<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20200213__20200214__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zKhk6IOqC86a" title="Private placement of common stock">15</span>&#160;million private placement of its common stock, for which it received net cash in excess of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20200213__20200214__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zw68En5p8nbg">13,009</span>&#160;thousand. In addition,
on September 27, 2021, the Company&#8217;s shelf registration statement on Form S-3 was declared effective by the Securities and Exchange
Commission (SEC) which permits the Company to register up to $<span id="xdx_904_eus-gaap--DebtSecurities_iI_pn3n3_c20200214__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z54tJQVgsUkb">100,000</span> thousand of certain equity and debt securities of the Company via
prospectus supplement. To date, funds have not been raised through this shelf registration statement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0">The management believes the cash balance amounted to $<span id="xdx_900_eus-gaap--Cash_iI_pn3n3_c20211231_zF0g2rsB2lU1" title="Cash">6,062</span> thousand as of December 31, 2021, is sufficient to
meet its capital needs of the Group for at least 12 months from the issuance date of these consolidated financial statements. Thus, it
is expected that the Company will be able to operate as a going concern for at least 12 months from the date hereof.</p>

</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect
    of the spread of the Coronavirus on the Company</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    December 2019, the Covid-19 epidemic erupted in China (hereinafter - the &#8220;Corona Virus&#8221;, the &#8220;Event&#8221; or the
    &#8220;Crisis&#8221;) and at the beginning of 2020, it spread to additional countries across the globe. In January 2020, the World
    Health Organization declared the outbreak of Corona as a global health emergency and in March 2020, it declared the Corona virus
    to be a global pandemic. The spreading of the Corona Virus is an extraordinary macroeconomic event in many countries worldwide. As
    a result of the event, many countries, including Israel, have taken significant steps in an attempt to stem the spreading of the
    virus. These steps include, inter alia, restriction of civilian movement and employment, closure of businesses and malls, restrictions
    of gatherings and events, restriction of the transportation of people and goods, closure of international border crossings, reduction
    in the number of employees permitted to come to their workplaces, etc. The event and the steps being taken by the various countries,
    as mentioned above, have had a significant impact on many global and local economies as well as on global capital markets, characterized
    by sharp decreases and extreme volatility in the prices of many securities. In addition, there is an ever-increasing risk of a market
    recession.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    a result of the COVID-19 pandemic, as near-term measures, the Company has transitioned some of its employees to remote
    working arrangements. which has had no material impact on the Company&#8217;s operations. Due to the uncertainty of
    COVID-19, the Company will continue to assess the situation, including abiding by any government-imposed restrictions, market
    by market.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144920408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SignificantAccountingPoliciesTextBlock_z1BKyx44ItVb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_zVso9ItbFJ2e">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States
    of America (US GAAP).</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p id="xdx_841_eus-gaap--UseOfEstimates_ziKlARtDDxOa" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;<span id="xdx_862_zEWBiyXPFVmg">Use of estimates in the preparation of financial statements</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                                         preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States
                                                         (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and
                                                         liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the
                                                         reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As
                                                         applicable to the consolidated financial statements, the most significant estimates and assumptions relate to the going concern
                                                         assumptions.</span></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
  <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
  <td><span id="xdx_863_ztnpQCdFXv9d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Functional currency</b></span></td></tr>
</table>




<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    functional currency of the Company is the US dollar, which is the currency of the primary economic environment in which it operates.
    In accordance with ASC 830, &#8220;Foreign Currency Matters&#8221; (ASC 830), balances denominated in or linked to foreign currency
    are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions
    included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses
    arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses.
    The functional currency of Integrity Israel is the New Israeli Shekel (&#8220;NIS&#8221;) and its financial statements are included
    in consolidation, based on translation into US dollars. Accordingly, assets and liabilities were translated from NIS to US dollars
    using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or
    losses resulting from translation adjustments are reflected in stockholders&#8217; equity, under &#8220;accumulated other
    comprehensive income (loss)&#8221;.</span></td></tr>
  </table>
<p id="xdx_897_eus-gaap--ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_z1sWopOdwVWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-transform: uppercase"><span id="xdx_8BA_z28uggO1Vjtd" style="display: none">SCHEDULE
OF OFFICIAL EXCHANGE RATE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; float: left; border-collapse: collapse; width: 87%; margin-left: 1in">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Official exchange rate of NIS 1 to US dollar</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90C_ecustom--AverageForeignCurrencyExchangeRateTranslation_pid_uPure_c20210101__20211231_znrsJigW8zN9" title="Official exchange rate of NIS 1 to US dollar">0.321</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_ecustom--AverageForeignCurrencyExchangeRateTranslation_pid_uPure_c20200101__20201231_zfN93fVY2Di6" title="Official exchange rate of NIS 1 to US dollar">0.311</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Increase (decrease) of the official exchange rate of NIS 1 to US dollar during
    the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage_pid_dp_uPure_c20210101__20211231_zYT7ZqLx3uid" title="Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2021">3.22</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo_pid_dp_uPure_c20210101__20211231_zRqPDmfBAOg5" title="Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2020">7.2</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table><p id="xdx_8A7_zyM3csyKUrU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_z2phvkjRX7Fg" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"/>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_862_zRzDn3jIhzna" style="font-family: Times New Roman, Times, Serif">Principles
    of consolidation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions
    have been eliminated in consolidation.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zFIoQm3Vw01f" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
&#160;&#160;&#160;<span id="xdx_86E_z8UwjAFbWYIc">Cash and cash equivalents</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less
    at the date of purchase, to be cash equivalents.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zr59NmoMCee3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
&#160;&#160;&#160;&#160;<span id="xdx_864_zOgYx08MLb5l">Inventories</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
    are stated at the lower of cost or net realizable value.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    is determined as follows:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    respect to raw materials, the Group calculates cost using the average cost method.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    respect to work in process and finished products, the Group calculates the cost on the basis of the average direct manufacturing
    costs, including materials, labor, subcontracting costs and other direct manufacturing costs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management evaluated
                                                         periodically whether inventory is required to be written-down due to slow-moving or obsolete items and recognize
                                                         inventory impairment, as applicable
..</span></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zBem59oZXABa" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
&#160;&#160;&#160;&#160;<span id="xdx_86D_zOiwGzfYuAWl">Property and equipment, net</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 96px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over
    the estimated useful lives of the assets. When an asset is retired or otherwise disposed of, the related carrying value and accumulated
    depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected
    in the statements of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rates
    of depreciation:</span></td></tr>
  </table>
<p id="xdx_897_ecustom--ScheduleOfPropertyRatesOfDepreciationTableTextBlock_zDE5uvUBGOJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-transform: uppercase"><span id="xdx_8B7_z9HqlgAfPPq2" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; width: 70%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_zNsi2Hf6ZZ9" title="Property plant and equipment depreciation rate">33</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zyefZsav84we" title="Property plant and equipment depreciation rate">7</span>-<span id="xdx_90F_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zWQ5zTaFrD62" title="Property plant and equipment depreciation rate">15</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zaCfxQEeQjR7" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Estimated useful life"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shorter
    of lease term <br/>
    and 10 years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p id="xdx_8AF_zrshgJhPm0e3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ze82Gzge5Av3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.
&#160;&#160;&#160;<span id="xdx_862_zIFCa5yk36p">Impairment of long-lived assets</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group&#8217;s long-lived assets are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment&#8221;,
    whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability
    of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows
    expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by
    the amount by which the carrying amount of the asset exceeds its fair value. To date the Group did not incur any material impairment
    losses related to long lived assets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zhsaGHsnbdFg" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.
&#160;&#160;&#160;<span id="xdx_86F_zCStbuEbnwma">Restricted cash</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
                                            cash is invested in certificates of deposit, which are used to secure Integrity Israel&#8217;s
                                            obligations in respect of its headquarters lease and credit card (See also Note 8B).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    presentation of statement of cash flows purposes, restrict cash balances are included with cash and cash equivalents, when reconciling
    the reported period total amounts.</span></p></td></tr>
  </table>
<p id="xdx_899_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zx2RjUoNBbvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none; text-transform: uppercase">SCHEDULE
OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; border-collapse: collapse; width: 85%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20211231_z0KKbVEHNyc3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20201231_zvJCzkll1hz1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzao3_z16YpaGo1Qh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,823</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RestrictedCash_iI_pn3n3_maCCERCzao3_zPyLjxmhuVOb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzao3_zsG11z4lis63" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,113</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,885</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zILf7TSGrnh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z3ySOspGUR39" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.
&#160;&#160;&#160;&#160;&#160;<span id="xdx_86B_zYL7iQmDU1K1">Income tax</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221;. Accordingly, deferred income taxes are determined
    utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting
    and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax
    rates expected to be in effect when these differences reverse. Valuation allowances in respect of deferred tax assets are provided
    for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial
    statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise&#8217;s financial statements.
    According to ASC Topic 740-10, tax positions must meet a more- likely-than-not recognition threshold. The Group&#8217;s accounting
    policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Group did not recognize
    such items in its fiscal 2021 and 2020 financial statements and did not recognize any liability with respect to unrecognized tax
    position in its balance sheet.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_zXrcacv4Rm95" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.
&#160;&#160;&#160;&#160;<span id="xdx_86B_zxZD9iX9mnw5">Liability for employee rights upon retirement</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrity
    Israel&#8217;s liability for employee rights upon retirement with respect to its Israeli employees is calculated pursuant to the
    Israeli Severance Pay Law, based on the most recent salary of each employee multiplied by the number of years of employment of each
    such employee as of the balance sheet date. Employees are entitled to one month&#8217;s salary for each year of employment, or ratable
    portion thereof for periods less than one year. Integrity Israel makes monthly deposits to insurance policies and severance pay funds.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    deposited funds may be withdrawn upon the fulfillment of Integrity Israel&#8217;s severance obligations pursuant to Israeli severance
    pay laws or labor agreements with its employees. The value of the deposited funds is based on the cash surrender value of these policies,
    and includes immaterial profits or losses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
    in 2011, Integrity Israel&#8217;s agreements with its Israeli employees are in accordance with Section 14 of the Severance Pay Law.
    Payments in accordance with Section 14 release the employer from any future severance payments in respect of those employees. Related
    obligations and liabilities under Section 14 are not recorded as an asset or as a liability in the Company&#8217;s balance sheet.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    year ended December 31, 2021, and 2020, severance expenses amounted to $<span id="xdx_90F_eus-gaap--SeveranceCosts1_pn3n3_c20210101__20211231_zY7fX3k5BpIb" title="Severance expenses">43</span>
    and $<span id="xdx_902_eus-gaap--SeveranceCosts1_pn3n3_c20200101__20201231_zEO4WrqohWq1" title="Severance expenses">24 </span> thousand,
    respectively.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zirsgiEM0ulf" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>K.
&#160;&#160;&#160;<span id="xdx_868_zpXQro7zIyQ3">Research and development expenses</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development expenses are charged to operations as incurred.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p id="xdx_845_ecustom--RoyaltyBearingGrantsPolicyTextBlock_z8sKHmrDPlp6" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>L.
&#160;&#160;&#160;<span id="xdx_862_zwtYQaEmhRE1">Royalty-bearing grant</span>s</b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalty-bearing
grants from the Israeli Innovation Authority (IIA) to fund approved research and development projects are recognized at the time
Integrity Israel is entitled to such grants, on the basis of the costs incurred and reduce research and development costs. To date,
the cumulative research and development grants received by Integrity Israel from amounted to $<span id="xdx_900_ecustom--CumulativeResearchAndDevelopment_pn3n3_c20210101__20211231_zFrVLd4EqThb" title="Cumulative research and development">93</span> thousand.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p id="xdx_84A_eus-gaap--StandardProductWarrantyPolicy_zvlibdTueNw9" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>M.
&#160;&#160;<span id="xdx_865_zaFGQFrnS42l">Warranty</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group provides a 24-month warranty for its products at no cost. The group estimates the costs that may be incurred during
    the warranty period and records a liability for the amounts of such costs at the time revenues are recognized. For the year ended
    December 31, 2021 and 2020 warranty expenses were clearly insignificant.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_z4dUfCu8MIal" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;<span id="xdx_861_zHwZZ6eGcibe">Basic and diluted loss per share</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is computed by dividing the loss for the period applicable
for Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon
    the exercise of options or warrants issued or granted using the &#8220;treasury stock method&#8221;, if the effect of each of such
    financial instruments is dilutive.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In computing diluted loss per share, the average stock price for the
    period is used in determining the number of common stock assumed to be purchased from the exercise of stock options or stock warrants.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares that will be issued upon exercise of all stock
    options and stock warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods
    for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these
    instruments was anti-dilutive</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An amount of <span id="xdx_90F_ecustom--NumberOfStockOptionsExcluded_c20210101__20211231_zOt36ZugXE08" title="Number of stock options excluded">6,404,238</span> and <span id="xdx_904_ecustom--NumberOfStockWarrantsExcluded_c20210101__20211231_z3TLRD8mnoWk" title="Number of stock warrants excluded">6,446,920</span> outstanding stock
    options and stock warrants have been excluded from the calculation of the diluted net loss per share for the years ended December
    31, 2021 and 2020, respectively, because the effect of the common shares issuable as a result of the exercise of such instruments
    was determined to be anti-dilutive.</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zhK42UAblaGb" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>O.
&#160;&#160;&#160;<span id="xdx_863_zgLyhfyW8zsa">Stock-based compensation</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values
    in accordance with ASC 718, &#8220;Compensation-Stock Compensation&#8221;. Share-based payments including grants of stock options
    are recognized in the statement of operations as an operating expense based on the fair value of the award at the date of grant.
    The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Group has expensed compensation
    costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit
    service period when a performance condition affects the vesting, and it is considered probable that the performance condition will
    be achieved.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
    January 1, 2019, following the adoption of ASU 2018-07, which aligns the measurement and classification guidance for share-based
    payments to nonemployees with the guidance for share-based payments to employees (with certain exceptions), share-based payments
    to non-employees are accounted in accordance with ASC 718.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zeCThVgBkQi2" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>P.
&#160;&#160;&#160;<span id="xdx_86A_z0MkNh8cKSO3">Fair value of financial instruments</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
    Topic 825-10, &#8220;Financial Instruments&#8221; defines financial instruments and requires disclosure of the fair value of financial
    instruments held by the Group. The Group considers the carrying amount of cash and cash equivalents, restricted cash, accounts receivable,
    other current assets, accounts payable and other current liabilities balances, to approximate their fair values due to the short-term
    maturities of such financial instruments. ASC Topic 825-10, establishes the following fair value hierarchy, which prioritizes the
    inputs used in the valuation methodologies in measuring fair value:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair
    value hierarchy gives the highest priority to Level 1 inputs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 - Unobservable inputs are used when little or no market data is available. Level 3 inputs are considered as the lowest priority
    under the fair value hierarchy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group did not estimate the fair value of the  loans from stockholders since their repayment schedule has not yet been determined.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zjGnLFw00Rp1" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;<span id="xdx_86C_zCHn20XqlR39">Concentrations of credit risk</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash and cash equivalents, and
    restricted cash. Cash and cash equivalents and restricted cash are deposited with major banks in Israel and the United States of
    America. Management believes that such financial institutions are financially sound, accordingly, minimal credit risk exists with
    respect to these financial instruments. The Group does not have any significant off-balance-sheet concentration of credit risk, such
    as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p id="xdx_847_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zay9jLDrdGd6" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>R.
&#160;&#160;&#160;<span id="xdx_867_zuq6SO3iGgmh">Contingencies</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability
    has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional
    information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--DerivativesPolicyTextBlock_zShPDLLDHhh5" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>S.
&#160;&#160;&#160;&#160;<span id="xdx_86C_zpnCZhkuvNI4">Warrants with Down-Round Protection</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
    the application of Accounting Standard Update (ASU) No. 2017-11, &#8220;Earnings Per Share&#8221; (ASU 2017-11), the Company disregard
    the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or
    equity classification. Based on its evaluation, management has determined that such warrants with Down-Round Protection are eligible
    for equity classification.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    accordance with the provisions of ASU 2017-11, upon the occurrence of an event that triggers a down round protection (i.e., when
    the exercise price of the warrants is adjusted downward because of the down round feature), the effect is accounted for as a deemed
    dividend and as a reduction of income available to common shareholders for purposes of basic earnings per share (EPS) calculation.</span></p></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_ecustom--ModificationOfEquityclassifiedContractsPolicyTextBlock_zXJeETtbbN6i" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>T.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;<span id="xdx_86A_ziJkWwfyEW19">Modification of equity-classified contracts</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification
    or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification
    of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value
    of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase
    of accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified
    share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment
    to earnings available to common shareholders for purposes of calculating earnings per share.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_z7eoZqo6Uc0d" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;<span id="xdx_86B_zp8JaOuYjnM2">Allowance for doubtful accounts</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The allowance for doubtful accounts is determined with
    respect to amounts the Company has determined to be doubtful of collection, in order to reflect the expected credit losses on accounts
    receivable balances. Judgment is required in the estimation of the allowance for doubtful accounts and the Company evaluates the
    collectability of its accounts receivable based on a combination of factors (including, among other things, the length of time that
    the balance is past due and the customer&#8217;s current ability to pay. If it&#8217;s becomes aware of a customer&#8217;s inability to meet
    its financial obligations, an allowance is recorded to reduce the net receivable to the amount reasonably believed to be collectible
    from such customer</td></tr>
</table>

<p id="xdx_845_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zYlRL3q7WdYf" style="margin: 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>V.</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span id="xdx_865_zMkUXWRi3xs9">Operating Lease</span></b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company entered into several non-cancelable lease agreements for vehicles for use in its operations, which are classified as operating
    leases.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
    January 1, 2019, the Company applies ASC Update 2016-02, Leases (Topic 842).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company determines if an arrangement is a lease at inception. Under the new guidance, arrangements meeting the definition of a lease
    are classified as operating or financing leases. A classification of a lease is determined based on the following criteria:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 96px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lease transfers ownership of the underlying asset to the lessee by the end of the lease term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lease term is for the major part of the remaining economic life of the underlying asset (Generally, 75% or more of the remaining
    economic life of the underlying assets).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    present value of the sum of the lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all
    of the fair value of the underlying asset (Generally, 90% or more of the fair value of the underlying asset).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease
    term.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these five criteria is met, the lease is classified as a finance lease. Otherwise, the lease is classified as an operating lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
are recorded on the consolidated balance sheet as both a right of use asset and a lease liability, calculated by discounting fixed lease
payments over the lease term at the rate implicit in the lease or the Company&#8217;s incremental borrowing rate. Lease liabilities are
increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating
leases, interest on the lease liability and the amortization of the right of use asset results in straight-line rent expense over the
lease term. Variable lease expenses, if any, are recorded when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also elected the short-term lease recognition exemption for all leases that qualify (leases with a term shorter than <span id="xdx_907_eus-gaap--LessorOperatingLeaseTermOfContract_iI_dtM_c20190102_zT2oUyH9Lhek" title="Lessor, Operating Lease, Term of Contract">12</span> months).
For those leases, right-of-use assets or lease liabilities are not recognized and rent expense is recognized on a straight-line basis
over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had no material capital leases throughout the reporting periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
note 4 for further discussion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zMFGQ4NQ6qF8" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>W.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>&#160;&#160;&#160;<span id="xdx_86A_zHQvnAq3pgAf">Reclassification</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    comparative figures have been reclassified to conform to the current year presentation. Such reclassifications did not have any significant
    impact on the Company&#8217;s equity, net income or cash flows.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zegEC1G2JUS5" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><b><span id="xdx_868_zXTHdpqWn82">X. &#160;&#160;Recent Accounting Pronouncements</span></b></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments&#8221; (&#8220;ASU 2016-13&#8221;), which changes the impairment model for most financial assets and certain other instruments.
For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities will be required to use a new
forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. The
guidance also requires increased disclosures. For the Company, the amendments in the update were originally effective for fiscal years
beginning after December 15, 2019, including interim periods within those fiscal years. In November 2019, the FASB issued ASU No. 2019-10,
which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined by the SEC) and other non-SEC reporting entities
to fiscal years beginning after December 15, 2022, including interim periods within those fiscal periods. Early adoption is permitted.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the company
is eligible to considered as smaller reporting company ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including
interim periods within those fiscal years. The adoption of this standard is not expected to result in a material impact to the Company&#8217;s
financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><b>&#160;</b></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144904040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--InventoryDisclosureTextBlock_z1YXDWujlYnd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3</b> &#8211; <span id="xdx_826_ztCMg31uZDb6"><b>INVENTORIES</b></span></span></p>


<p id="xdx_89B_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zc8V0fXVWzC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zrnsXl8O4ds2" style="display: none; text-transform: uppercase">SCHEDULE
OF INVENTORIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_ztdjoh3Df3Rb">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20201231_zOgIXePL4TF6">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Inventory</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryRawMaterials_iI_pn3n3_maIGzn5N_zQ5GzIkfahI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">94</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">95</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maIGzn5N_zWDi36o1kNZ6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maIGzn5N_zaLMdy8upMJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InventoryGross_iTI_pn3n3_mtIGzn5N_maINzWYt_zLNeCkoh9e4e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right"/><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">321</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">284</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InventoryAdjustments_iNTI_pn3n3_di_msINzWYt_z9gv4rshjGo9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">inventory write-down</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(321</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InventoryNet_iTI_pn3n3_mtINzWYt_znPOi37l1bi2" style="vertical-align: bottom; background-color: White">
    <td/><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0517">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">284</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zDJGTmscObKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)
Management evaluated periodically whether inventory is required to be written-down due to slow-moving or obsolete items
and recognize inventory impairment, as applicable. As a result of the development of the second generation of the glucose monitoring
device the Group has recorded in the fourth quarter of 2021 inventory written-down in the amount of approximately $ <span id="xdx_90F_eus-gaap--InventoryAdjustments_iI_pn3n3_c20211231_z8x8VFUNiLkg">321
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519145006856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--LesseeOperatingLeasesTextBlock_zPf1ye7BZtEg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_826_zLOdFgHGoyWf">LEASES</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into several non-cancellable operating lease agreements for few vehicles. the Company&#8217;s leases have
original lease periods expiring between 2023 and 2024. Payments due under such lease contracts include primarily fixed payments. the
Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably assured at lease
commencement. the company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89D_eus-gaap--LeaseCostTableTextBlock_zLbcPSlBJLOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease costs, lease term and discount rate are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zRsGUCR3CFsh" style="display: none; text-transform: uppercase">SCHEDULE
OF LEASE COSTS, LEASE TERM AND DISCOUNT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In
                                            thousand of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US
                                            dollars</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Operating lease cost:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: justify">Vehicles</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseCost_pn3n3_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_z0mDVy94eAJ1">72</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Office space <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Over 12 month</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_909_ecustom--LongTermLeaseCost_pn3n3_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceMember_zXYtEbGj2g98" title="Office space: Over 12 month">53</span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify"><p style="margin: 0">Short term leases</p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0"><span id="xdx_902_eus-gaap--ShortTermLeaseCost_pn3n3_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceMember_zXgDvxIa4iT6" title="Office space: Short term leases">46</span></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseCost_pn3n3_c20210101__20211231_zwYNiMxQj5jb" title="Total Operating lease cost">171</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Remaining Lease Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Vehicles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zZ0I6Rm1ey75" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.01
                                            </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Weighted Average Discount Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Vehicles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zz2FmmxhiL9h">10</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A6_z1eJGaAsTBy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211; LEASES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zxu4SEPCq9V3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a schedule, by years, of maturities of operating lease liabilities as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zBYWPBLIkEM3" style="display: none; text-transform: uppercase">SCHEDULE
OF OPERATING LEASE MATURITY PAYMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20211231_zpyzv9EMEht8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In
                                            thousand of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US
                                            dollars</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzYou_zoSxFXo8Kvea" style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: justify">2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right">24</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzYou_zR5T5VV0j14b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzYou_zF2vTrQGuc3h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total operating lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">44</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_zL5ELAg733eh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Less: imputed interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zwWf4InZ9Uj3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_z2JIF9lQ6ihe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144885176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zndzD9QDn7xg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_822_zshg62bIbfd2">PROPERTY AND EQUIPMENT, NET</span></b></span></p>


<p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6wHxThoOcPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zKONlzkJRMz4" style="display: none; text-transform: uppercase">SCHEDULE
OF PROPERTY AND EQUIPMENT, NET</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Property and Equipment</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Computers</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpwgU3E7tlPf" style="width: 16%; text-align: right" title="Property and equipment, gross">306</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zIzfuCWk5Py3" style="width: 16%; text-align: right" title="Property and equipment, gross">380</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zdMJOGy5YJNe" style="text-align: right" title="Property and equipment, gross">183</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zgxvPnsd5GAa" style="text-align: right" title="Property and equipment, gross">312</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z4NhPEhmhcr9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zzfKXgKvNa79" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross">82</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231_zvwAoM2vko4c" style="text-align: right" title="Property and equipment, gross">489</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231_zPjFhlZi4Fua" style="text-align: right" title="Property and equipment, gross">774</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20211231_zymk2K4tPJL8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less - accumulated depreciation">(420</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20201231_zMxf3fkw4KQa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less - accumulated depreciation">(625</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20211231_zvFTbtn2CRqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">69</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231_zaf1kzpQIA17" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">149</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zAOdjaMv6ZVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the years ended December 31, 2021 and 2020, depreciation expenses amounted to $<span id="xdx_90C_eus-gaap--Depreciation_pn3n3_c20210101__20211231_zbWBJHvtFlJe">42
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90C_eus-gaap--Depreciation_pn3n3_c20200101__20201231_zb8KGAHxe07i">47
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand respectively, and new equipment
    purchases amounted to $<span id="xdx_90D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_pn3n3_c20210101__20211231_z4270O9O71Ec">5
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_905_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_pn3n3_c20200101__20201231_zHMDRRy98yXg">53
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand, respectively.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519145005176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--OtherLiabilitiesDisclosureTextBlock_zHruYjp0sjY7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8211; <span id="xdx_825_zXCBHpmM3bwb">OTHER CURRENT LIABILITIES</span></b></span></p>


<p id="xdx_899_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zpVYTO3IUP6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zpdOqWdmDMi3" style="display: none; text-transform: uppercase">SCHEDULE
OF OTHER CURRENT LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zjPxOE5dmKeb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20201231_zNlP70h9iU7c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Other Current Liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maOLCzeFZ_zqb8htmtCzZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Employees and related institutions</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">244</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maOLCzeFZ_zUhlcLPgVGVl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued expenses and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCzeFZ_zcKkXLdVZWQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">229</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">392</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zUORVe4P7Ivh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144871016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOANS FROM STOCKHOLDERS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">LOANS FROM STOCKHOLDERS</a></td>
<td class="text"><p id="xdx_808_eus-gaap--LongTermDebtTextBlock_zVNGOwuv5Moj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7</b> &#8211; <span id="xdx_823_z9hbW0tranJe"><b>LOANS FROM STOCKHOLDERS</b></span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the years 2003-2004, Integrity Israel received loans from stockholders (four separate lenders) in a total amount of approximately
    $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfLongTermDebt_pn3n3_c20030101__20041231__srt--TitleOfIndividualAxis__custom--ShareHoldersMember_zAdJwHh04dR4">400
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand. However, following the repayment
    of the entire balance to certain lender in 2015, the remaining balance as of December 31,2021 is approximately $<span id="xdx_907_eus-gaap--DueToOfficersOrStockholdersNoncurrent_iI_pn3n3_c20211231_ze8tjFHbhHyj">210
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand. The loans are indexed to the Israeli
    consumer price index from their origination date and bear no insert.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group will be required to pay the loans, in quarterly installments, commencing on the first quarter following the first fiscal year
    in which the Group reports net profit in its annual report. At such time, the Group will be required to make quarterly payments equal
    to <span id="xdx_90D_ecustom--QuarterlyPaymentsEqualsToSalesPercentage_pid_dp_uPure_c20210101__20211231_zfSLo7WVcgsh">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
    of its total sales for each quarter until the loans have been repaid in full. Notwithstanding the repayment mechanism, the Group
    will not be required to repay the loans during any period in which such payment would cause a deficit in the Group&#8217;s working
    capital.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2021, the Group does not expect to make any additional material repayments during the following 12-month period,
    if any, and accordingly the entire remaining balance of the loans from stockholders have been presented as long-term liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144886296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zMVzl2xtMgra" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8211; <span id="xdx_824_zjrrsy7TI636">COMMITMENTS AND CONTINGENT LIABILITIES</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 86%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    March 4, 2004, the Israel innovation authority (IIA) provided Integrity Israel with a grant of approximately $<span id="xdx_909_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember_z9lChnwDXDZh">93
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand (NIS <span id="xdx_905_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_uIsrael_c20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember_zGv5YAbyijrg">420
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand), for its plan to develop a non-invasive
    blood glucose monitor (the &#8220;Development Plan&#8221;). Integrity Israel is required to pay royalties to the IIA at a
    rate ranging between <span id="xdx_90A_ecustom--RoyaltyPercentage_pid_dp_c20040303__20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MinimumMember_zYl6u9tAhxtk">3</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span id="xdx_90B_ecustom--RoyaltyPercentage_pid_dp_c20040303__20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MaximumMember_z5sP4qqOTPx7">5%</span></span>
    of the proceeds from the sale of the Group&#8217;s products arising from the Development Plan up to an amount equal to $<span id="xdx_90C_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20050304__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_z80bmMo4o7k3">93
    </span><span style="font-family: Times New Roman, Times, Serif">thousand, plus interest at LIBOR from the date of grant. As
    of December 31, 2021, the remaining contingent liability with respect to royalty payment on future sales equals approximately $<span id="xdx_902_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20211231__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_zQtMsBfaAJE2">43
    </span></span><span style="font-family: Times New Roman, Times, Serif">thousand, excluding interest. Such contingent obligation has
    no expiration date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2021, the Group accrued royalties to the IIA in insignificant amounts.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 1, 2017 the Company entered into an Advisory Agreement with Andrew Garrett, Inc. (AGI), pursuant to which <span id="xdx_90C_ecustom--AdvisoryServicesPeriod_c20170729__20170801__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__dei--LegalEntityAxis__custom--AndrewGarrettIncMember_zTImE9yTfk39">the
    Company engaged AGI as placement agent on a non-exclusive basis to provide certain advisory services to the Company for a period
    of 9 months which was subsequently extended twice and was in effect until October 31, 2019</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2020 the Company paid the placement Agent approximately $<span id="xdx_909_eus-gaap--PaymentsOfStockIssuanceCosts_pn6n6_c20200101__20201231_zxr4yrYXdH16">2
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million for placement services (see above)
    in cash. In addition, during the year ended December 31, 2020, $<span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200101__20201231_z7Wdp3F1o84b">756
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand representing the fair value of warrants
    issued as consideration for placement agent services to AGI. This amount was accounted for as warrants with down-round protection.
    Upon issuance, the fair value was recognized as an increase in additional paid in capital.</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 11%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 87%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Since March 2021 Integrity Israel is renting several workspaces
    at office building in the city Or &#8211; Yehoda. This workspace rent replaces the principal offices the Company in the city Ashdod.
    According to the new agreement the Company renting those flexible shared workspaces for period shorter than one year.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144868328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zVV6odsJGr38" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_82D_zIbT1ADCmog6">COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    of the rights attached to the Common Stock</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    share of Common Stock entitles the holder to one vote, either in person or by proxy, on each matter submitted to the approval of
    the Company&#8217;s stockholders. The holders of Common Stock are not permitted to vote their shares cumulatively. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><b>2.</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Description of February 14, 2020 Issuance of common
    stock</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0">On February 14, 2020, the Company
                                            entered into a Securities Purchase Agreement and Registration Rights Agreement with an accredited
                                            investor, pursuant to which the accredited investor purchased <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200213__20200214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zFVcyh1RViMg" title="Number of common shares issued"><span style="background-color: white">2,884,615</span></span> shares of the Company&#8217;s
                                            common stock, par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20200214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zdbBiuwm9lu9" title="Common stock, par value">0.001</span> per share, for an aggregate gross purchase price of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn6n6_c20200213__20220214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zRzNHAy0wsZ1" title="Proceeds from issuance of common stock">15</span> million,
                                            less cash expenses of approximately $<span id="xdx_90C_ecustom--CashExpensesOnIssuanceOfStock_pn6n6_c20200213__20220214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zQhwLsbbka76" title="Cash expenses on issuance of stock">2</span> million</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Placement Agent Compensation</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
    to a placement agent agreement (the &#8220;Placement Agent Agreement&#8221;) with the placement agent for the Offering (the &#8220;Placement
    Agent&#8221;), at the closing of the above mentioned sale of the common stock the Company paid the Placement Agent, as a commission,
    a cash amount equal to <span id="xdx_907_ecustom--CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits_iI_pid_dp_c20211231__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zH5GSxzu4NCe" title="Commission as a percentage of cash amount equal to aggregate sale price of units">7%</span> of the aggregate sales price of the Units, plus 3% of the aggregate sales price as a management fee plus
    a non-accountable expense allowance equal to <span id="xdx_904_ecustom--NonaccountableExpenseAllowancePercenatge_iI_pid_dp_c20211231__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zSnFiIi9s2ui" title="Non-accountable expense allowance percenatge">3%</span> of the aggregate sales price of the Units. In addition, pursuant to the placement
    agent agreement, the company is required to issue to the Placement Agent warrants to purchase up to such number of shares of Common
    Stock equal to <span id="xdx_90F_ecustom--AggregateSalesPriceOfUnitsPercentage_iI_pid_dp_c20211231__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zDdkHJBkAekf" title="Commission as a percentage of aggregate sales price">10%</span> of the aggregate Shares sold in the Offering plus warrants equal to 10% of the total number of the Warrants issued
    to the Purchasers in the Offering (collectively, the &#8220;Placement Agent Warrants&#8221;). The terms of the Placement Agent Warrants
    will be substantially similar to the Warrants except that the Placement Agent Warrants will also be exercisable on a cashless basis
    and will include full ratchet anti-dilution protection.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
    compensation</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grants
    to non-employees</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    connection with the 2017 Offering, the Company has issued to the Placement Agent (a) <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zhNsRFRtbNI9">5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
    warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zZdniGU28zh3">1,062,717
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock at an exercise price
    of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zSu3HABMcfa8">3.354
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, (b) <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zZqOOwFF1Vml">5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
    warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zbF2M5eKdh82">108,305
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock at an exercise price
    of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zqHO0BvfgJxb">23.40
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.(c) <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_zIfeaWgKJXDa">5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
    warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_z6EsU55v2hH2">8,331
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock at an exercise price
    of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_zV866NZbTnti">46.80
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, and (d) <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFourMember_zWMygPyCKyl9">5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
    warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFourMember_zos7YD9MmrXe">8,331
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock at an exercise price
    of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFourMember_zrg6EoIcxzr3">70.20
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The terms of the Placement Agent
    warrants are substantially similar to the terms of the Series D warrants except that the Placement Agent warrants may also be exercisable
    on a cashless basis at all times.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            connection with February 2020 Offering, the Company has issued to the Placement Agent <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandTwentyOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFiveMember_zfJ1R2VokEtc">5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
                                            warrants to purchase up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandTwentyOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFiveMember_zst9e293yR82">288,462
                                            </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            of Common Stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandTwentyOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFiveMember_zl6F5A7rLUX6">5.2
                                            </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
                                            share.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ending December 31, 2020, $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200101__20201231_z4pmWHm9FTT9">756
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand, respectively, representing the
    fair value of warrants issued as consideration for placement agent services to AGI. This amount was accounted for as Warrants with
    down-round protection. Upon issuance, the fair value was recognized as an increase in additional paid in capital</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2020, the key inputs used in the fair value calculations of the warrant that were affected by the down-round protection
    were as follows:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"/>

<p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zjCncJ4E5oH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><span id="xdx_8BA_zqKLcqcL0dIl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; border-collapse: collapse; width: 58%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Fair value calculations &#8211; Warrant</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31-Dec-20</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zG6kiQss7US5"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Expected volatility (%)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zOPAtKKPxUh3">56.32</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z39F9w5I5Xtk">2.5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zBonNKFffTbc">5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price (US dollars)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmXooMm7mJU3">5.2</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Share price (US dollars)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIn838AN9blh">5.2</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value (US dollars)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairValueMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfTuNhbuoQB3">2.6</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zbdKy8bGZnw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grants
    to employees</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    August 2007, Integrity Israel&#8217;s Board of Directors (&#8220;Integrity Israel&#8217;s Board&#8221;) approved a stock option plan
    (&#8220;Integrity Israel&#8217;s plan&#8221;) for the grant, without consideration of options exercisable into ordinary shares of
    NIS <span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20070831__us-gaap--PlanNameAxis__custom--IntegrityIsraelsPlanMember_zhMHHDwg8sV7" style="font: 10pt Times New Roman, Times, Serif">0.01
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">par value of Integrity Israel to employees,
    officers and directors of Integrity Israel. The exercise price and vesting period for each grantee of options was determined by Integrity
    Israel&#8217;s Board and specified in such grantee&#8217;s option agreement. <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20070801__20070831__us-gaap--PlanNameAxis__custom--IntegrityIsraelsPlanMember_zhQcFV1IPP95">The
    options vested over a period of 1-12 quarters based on each grantee&#8217;s option agreements. Any option not exercised within 10
    years after the date of grant thereof will expire</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
    compensation (cont.)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grants
    to employees (cont.)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    July 2010, following the merger with Integrity Israel, the Company adopted the 2010 Share Incentive Plan (the &#8220;2010 Share Incentive
    Plan&#8221;), pursuant to which the Company&#8217;s Board of Directors is authorized to grant options exercisable into Common Stock
    of the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    purpose of the 2010 Share Incentive Plan is to offer an incentive to employees, directors, officers, consultants, advisors, suppliers
    and any other person or entity whose services are considered valuable to the Company, as well as to replace the Integrity Israel
    Plan and to replace all options granted in the past by Integrity Israel.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
                                            June, 2020, Erez Ben-Zvi has joined the Company as its Vice President of Product.</span></p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 8, 2021, the Company announced that it has promoted Erez Ben-Zvi to General Manager in addition to his current role as Vice
    President of Product, effective immediately</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company granted Mr. Ben-Zvi annual award of NIS <span id="xdx_90C_eus-gaap--OfficersCompensation_pn3n3_uIsrael_c20200628__20200630__srt--TitleOfIndividualAxis__custom--ErezBenZviMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXzeXtxRz076">210
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand worth (approximately $ <span id="xdx_901_eus-gaap--OfficersCompensation_pn3n3_c20200628__20200630__srt--TitleOfIndividualAxis__custom--ErezBenZviMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdIJm3QzZJB1">65
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand) of restricted stock units (the
    &#8220;RSU&#8221;) effective as of the employee Start Date and on each one-year anniversary following the employee Start Date subject
    to the approval of the board of directors (the &#8220;additional RSU&#8221;). The RSU and each of the Additional RSU (if approved
    by the board of directors), as applicable, shall be based on the stock price at actual the date of grant (and not lower than US$
    5.20 per share). <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20200628__20200630__srt--TitleOfIndividualAxis__custom--ErezBenZviMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsQwno8EbTc2">1/12
    of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall
    vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the employee continues to be employed
    by the Company at the applicable date of vesting</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
    The vesting schedule shall be also applied to each of the Additional RSUs granted, mutatis mutandis, such that the vesting period
    of each of the respective Additional RSU shall commence from its actual date of grant</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
                                            November, 2020, Mr. Shalom Shushan has joined the Company as its Chief Technology Officer,
                                            Mr. Shushan will lead all technology and research and development activities for Integrity
                                            and will serve on the Company&#8217;s executive leadership team.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company granted Mr. Shushan annual award of NIS <span id="xdx_907_eus-gaap--OfficersCompensation_pn3n3_uIsrael_c20201128__20201130__srt--TitleOfIndividualAxis__custom--ShalomShushanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJ88080QpFha">90
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand worth (approximately <span id="xdx_90D_eus-gaap--OfficersCompensation_pn3n3_c20201128__20201130__srt--TitleOfIndividualAxis__custom--ShalomShushanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkFRWxhLCpg6">$28
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand) of restricted stock units (the
    &#8220;RSU&#8221;) effective as of the employee Start Date. Furthermore, on each one-year anniversary following the employee Start
    Date subject to the approval of the board of directors, Company shall grant the Employee with NIS 60 thousand worth of restricted
    stock units (the &#8220;Additional RSU&#8217;&#8217;). Both the RSU and each of the Additional RSU (if approved by the board of directors),
    as applicable, shall be based on the stock price at actual the date of grant (and not lower than US$ 5.20 per share). <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20201128__20201130__srt--TitleOfIndividualAxis__custom--ShalomShushanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLwY45ycWlJ7">1/12
    of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall
    vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the Employee continues to be employed
    by the Company at the applicable date of vesting</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
    The vesting schedule shall be also applied to each of the Additional RSUs granted to the Employee, mutatis mutandis, such that the
    vesting period of each of the respective Additional RSU shall commence from its actual date of grant</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            October 19, 2021, Paul V. Goode was appointed as President and Chief Operating Officer of
                                            the company, Inc, effective November 1, 2021. He has served as a member of Integrity&#8217;s
                                            Board of Directors since December 17, 2020. Concurrent with his appointment, Mr. Goode has
                                            stepped down from the Board.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0">Effective November 20201, the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
granted Mr. Paul V. Goode options to purchase up to <span id="xdx_909_ecustom--PercentageOfDulitedCommonStock_iI_pid_c20211120__srt--TitleOfIndividualAxis__custom--MrPaulVMember_z6tzXnTsnSbd">1.5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the fully diluted common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211120__srt--TitleOfIndividualAxis__custom--MrPaulVMember_zszgl8i0E16k">0.001
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (approximately <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20211118__20211120__srt--TitleOfIndividualAxis__custom--MrPaulVMember_zzc6LDjFnmIb" title="Number of options granted">330</span> thousand options),
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the Company (&#8220;Common Stock&#8221;) as of
the Effective Date, with a per share exercise price equal to the greater of (A) $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20211020__srt--TitleOfIndividualAxis__custom--MrPaulVMember_zlzQwBYYVhib">5.20
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share or (B) the closing price of a share
of Common Stock on the Effective Date, as reported by Bloomberg L.P., which shall vest in equal monthly installments over a three year
period following the Effective Date.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            December 3, 2021, James p. thrower was appointed as Vice President Engineering of the company.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    December 20201, the</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Company granted Mr. James
    p. Thrower options to purchase up to <span id="xdx_905_ecustom--PercentageOfDulitedCommonStock_iI_pid_c20211203__srt--TitleOfIndividualAxis__custom--MrJamesPMember_zHHHXGwbHqQ3">1.15</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
    of the fully diluted common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211220__srt--TitleOfIndividualAxis__custom--MrJamesPMember_zLiTUYHQD1Sc">0.001
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (approximately <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20211218__20211220__srt--TitleOfIndividualAxis__custom--MrJamesPMember_zPDtlpEup8O">250</span> thousand
    options), of the Company (&#8220;Common Stock&#8221;) as of the Effective Date, with a per share exercise price equal to the
    greater of (A) $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20211220__srt--TitleOfIndividualAxis__custom--MrJamesPMember_zAz2IRkZrMGf">5.20
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share or (B) the closing price of a share
    of Common Stock on the Effective Date, as reported by Bloomberg L.P., which shall vest in equal monthly installments over a three
    year period following the Effective Date.</span></p></td></tr>
  </table>
<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgTR23sZjut8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8BB_z804badvxNda" style="display: none">SCHEDULE
OF STOCK GRANTS ACTIVITY</span></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 82%; margin-left: 1.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Grants to Employees</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price (US$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; padding-bottom: 1.5pt">Balance outstanding as of December 31,2019</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zbzfYCNDNbm2" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Number outstanding beginning balance">156,007</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zXIfIndJGbNh" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Weighted average exercise price outstanding, beginning balance">63.44</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Balance exercisable of December 31,2019</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20200101__20201231_zIfi1YoFzeGl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number exercisable, beginning balance">132,630</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zp2yw1rOxRFd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price exercisable, beginning balance">60.19</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Granted during 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zMQngjh5lMgl" style="text-align: right" title="Number shares, grants"><span style="-sec-ix-hidden: xdx2ixbrl0675">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_z4Bprvx2fi78" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0677">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Forfeited during 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231_zHIzTlEkEyL6" style="text-align: right" title="Number, forfeited">(25,770</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zggqNa5rzt7e" style="text-align: right" title="Weighted average exercise price, forfeited">58.63</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance outstanding as of December 31,2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zZuvFDQJdUW1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number outstanding beginning balance">130,237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zfmzeJgTmwZb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price outstanding, beginning balance">64.35</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Balance exercisable of December 31,2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20210101__20211231_zt8AGEdZH1cd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number exercisable, beginning balance">128,296</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_pid_c20210101__20211231_z5ua8Ql99sFk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price exercisable, beginning balance">64.48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Granted during 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zxj2ZiyXilCb" style="text-align: right" title="Number, grants">577,064</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_z4mH7EONhW25" style="text-align: right" title="Weighted average exercise price, granted">5.20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Forfeited during 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231_z7LgUYtZDtpc" style="text-align: right" title="Number, forfeited">(98,177</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zxZtW5O8XOOc" style="text-align: right" title="Weighted average exercise price, forfeited">64.64</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance outstanding as of December 31,2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_zCa0YdSQQXWd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number outstanding ending balance">609,124</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zRbdkWAs6nY" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price outstanding, ending balance">8.10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Balance exercisable of December 31,2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20211231_zAgh22zbiUQ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number exercisable, ending balance">39,223</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zKH4QqiQmyba" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price exercisable, ending balance">46.41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p id="xdx_8A0_zrjGCV9FZQ99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zVgfwIHJyx75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize information about options outstanding at December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8B3_zKrNsKm2uhik" style="display: none">SCHEDULE
OF STOCK GRANTS, BY EXERCISE PRICE RANGE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; border-collapse: collapse; width: 64%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>price
                                            (US$)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding at December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable at December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average remaining contractual
    life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zub7MEbx4Vlf">5.2</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zuhEAQqCPheg">579,004</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBDndmflcIT4">9,103</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zL7uz27QZdKd">2.75</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zo4CMb3x2C77">58.5</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUTjAZuuGJ53">26,274</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z2KivElePXFd">26,274</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zd21c6BBm3vi">5.18</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWTtEQU3iu0c">100.75</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zBzFgPivlowj">3,846</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zL0f2niBp6jj">3,846</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z6I7Y9tz8loh">5.26</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231_zt0bXd0J8t3l">609,124</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231_zlRFEYgLjLya">39,223</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zbBkszpbZLaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
                                            INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>NOTE 9</b>
&#8211; <b>COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
    compensation (cont.)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grants
    to employees (cont.)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fair value of options granted to employees during the years ended on December 31, 2021 was estimated at the dates of grant using
    the Black-Scholes option model. The following are the data and assumptions used:</span></td></tr>
  </table>
<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLL1OEK6u81g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8BC_zfKXlYxCnMd2" style="display: none">SCHEDULE
OF ASSUMPTIONS USED TO VALUE OPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; width: 82%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
    value calculations - Warrant</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31, 2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zue5XlZzHbBk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0724">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility (%) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zbd5VVjAuA9c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    free interest rate (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_z9pq2FJk3Lv" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term of options (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zTrn6VHbCiQ" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    price (US dollars)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20211231_zHWICVB3oYJh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    price (US dollars) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20211231__srt--RangeAxis__srt--MinimumMember_znuEcG7VTrSl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20211231__srt--RangeAxis__srt--MaximumMember_zZF4yc5rk9Kf">4.65</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value (US dollars)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zTwn5sG0ukhh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.6</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zy60RI1frbdl">1.48</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><p id="xdx_8A8_zufHsVROlNUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144884616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zcccsdkPSwne" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_827_zxVETZ3pFKNk">RESEARCH AND DEVELOPMENT EXPENSES</span></b></span></p>


<p id="xdx_89B_ecustom--ScheduleOfResearchAndDevelopmentExpensesTableTextBlock_zj1niLzcqLz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8BD_zgjnOeehpJ7k" style="display: none">SCHEDULE
OF RESEARCH AND DEVELOPMENT EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20211231_zJkwsET1pU5j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20200101__20201231_z31ccH8YmWL7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><p style="margin: 0">Research and Development</p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LaborAndRelatedExpense_maRADEzgxz_zy7obYeNTb64" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Salaries and related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">916</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">754</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProfessionalFees_maRADEzgxz_zuFNn5S2zVm1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">462</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InventoryWriteDown_maRADEzgxz_zSeGenFyUPyf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expenses due to slow inventory write-off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">321</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DepreciationAndAmortization_maRADEzgxz_zrxmDqMWj5g4" style="vertical-align: bottom; background-color: White">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfPropertyRepairsAndMaintenance_maRADEzgxz_znL8tU2Lk2wa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vehicle maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherGeneralExpense_maRADEzgxz_zmbi7AQ6gqqj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">162</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEzgxz_zHdJWSUSuhRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total research and development
    expenses, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,810</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,532</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p id="xdx_8A8_zyau6CMNXzMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519145012312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETING EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_DisclosureMarketingExpensesAbstract', window );"><strong>Marketing Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_SellingAndMarketingExpensesTextBlock', window );">MARKETING EXPENSES</a></td>
<td class="text"><p id="xdx_804_ecustom--SellingAndMarketingExpensesTextBlock_zbLmABdAAtph" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8211; <span id="xdx_823_zGaun3mk2yg5">MARKETING EXPENSES</span></b></span></p>


<p id="xdx_899_ecustom--ScheduleOfSellingAndMarketingExpensesTableTextBlock_zH5ac9akaOp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8BC_zkjCBInLSFw8" style="display: none">SCHEDULE
OF SELLING AND MARKETING EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Selling and Marketing</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231_zohCQLqIHKr1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December
    31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20200101__20201231_zfvdPLlHFJv6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December
    31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--SalariesAndRelatedExpenses_maSGAAEz1YR_zTvk3hgUK9t9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Salaries and related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">22</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">156</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ResearchAndDevelopmentProfessionalFees_maSGAAEz1YR_zMazA1bRJbn3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--SellingAndMarketingOtherExpenses_maSGAAEz1YR_zs0inEMN6Yfb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--SellingGeneralAndAdministrativeExpense_iT_pn3n3_mtSGAAEz1YR_zxrFStdDZe83" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total selling and marketing
    expenses</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">139</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">415</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zlTbfS1xV4a1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_DisclosureMarketingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_DisclosureMarketingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_SellingAndMarketingExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling and Marketing Expenses [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_SellingAndMarketingExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144959400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL AND ADMINISTRATIVE EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract', window );"><strong>General And Administrative Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_GeneralAndAdministrativeExpensesTextBlock', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="text"><p id="xdx_805_ecustom--GeneralAndAdministrativeExpensesTextBlock_zBaFdEAgPQo9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 &#8211; <span id="xdx_824_zsTxyLV4rMia">GENERAL AND ADMINISTRATIVE EXPENSES</span></b></span></p>


<p id="xdx_893_ecustom--ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_ze3X159d1ns8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8B2_z9VxWPN7iCsk" style="display: none">SCHEDULE
OF GENERAL AND ADMINISTRATIVE EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZe2zEorLkb7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsUypMV9dnYh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">General and Administrative</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LaborAndRelatedExpense_pn3n3_maGAAEzQ9k_ze209rYWDyd7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Salaries and related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">608</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">368</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProfessionalFees_pn3n3_maGAAEzQ9k_zxYv3yAsdMni" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">694</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--BadDebtExpense_pn3n3_maGAAEzQ9k_zTh3ST4sVCE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bad debt expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0786">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CostOfPropertyRepairsAndMaintenance_pn3n3_maGAAEzQ9k_zox4jP414Iuj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vehicle maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DepreciationAndAmortization_pn3n3_maGAAEzQ9k_z1i1Fii3c0o" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InvestmentIncomeInvestmentExpense_pn3n3_maGAAEzQ9k_z5XvhHsnifhb" style="vertical-align: bottom; background-color: White">
    <td>Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_maGAAEzQ9k_zdFEX10ajw0j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_iT_pn3n3_mtGAAEzQ9k_zDWzqMVW1rZ9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total general and
    administrative expenses</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,091</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,185</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_z5Wn1FFQtVed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_GeneralAndAdministrativeExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General and Administrative Expenses [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_GeneralAndAdministrativeExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144879048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAX</a></td>
<td class="text"><p id="xdx_802_eus-gaap--IncomeTaxDisclosureTextBlock_zD1206RLb38h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 &#8211; <span id="xdx_823_zQfhPQppk788">INCOME TAX</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Measurement
    of results for tax purposes under the Israeli Income Tax (Inflationary Adjustments) Law, 1985 (the &#8220;Inflationary Adjustment
    Law&#8221;)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
    January 1, 2008, the results of operations of Integrity Israel for tax purposes have been measured on a nominal basis.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax
    assessments</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    federal, state and local income tax purposes the Company remains open for examination by the tax authorities for the tax years from
    2017 through 2020 under the general statute of limitations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding,
    pursuant and subject to the provisions of article 145 of the Income Tax Ordinance, Integrity Israel&#8217;s tax returns that were
    filed with the tax authority up to and including 2016 are considered final.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carryforward
    tax losses</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the Company had cumulative net operating losses (NOL) for US federal purposes of approximately $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231_z5AesVbqpV58">10.5
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. Integrity Israel has losses carry
forward balances for Israeli income tax purposes of approximately $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zj4KdvCzNdG4">41.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to offset against future taxable
income for an indefinite period of time.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2021 and 2020, the main reconciling item between the statutory tax rate of the Company and the effective
tax rate at the rate of <span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20210101__20211231_zFL23d7MV5Wi"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20210101__20211231_zvV9c6rX2yDf">21.0</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
for 2021 and 2020, respectively, is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating
losses carried forward and other permanent and temporary differences due to the uncertainty of the realization of such deferred taxes
and withholding taxes that were deducted by the Company&#8217;s customers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13</b> &#8211; <b>INCOME TAX (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    taxes result principally from temporary differences in the recognition of certain revenue and expense items for financial and income
    tax reporting purposes. Significant components of the Group&#8217;s future tax assets are as follows:</span></td></tr>
  </table>
<p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxta6JHExGt7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zBxd64DGl1Y7" style="display: none; text-transform: uppercase">SCHEDULE
OF DEFERRED TAXES</span></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zMyzFB15wbV6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20201231_z0NYxt4dnPcl" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Composition of deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_maDTANztgP_zBh0msQw1KXg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Provision for employee-related obligation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><p style="margin: 0">6</p></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 16%">22</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANztgP_zIRN9dDuIgt4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-capital loss carry forwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">11,654</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">10,889</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxAssetValuationAllowance_iI_pn3n3_msDTANztgP_z1DF1u6Qv6R3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0">(11,660</p></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(10,912</td>
    <td style="padding-bottom: 1.5pt">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3_z8qN6Od92Ql3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total deferred
    tax assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0820">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-hidden: xdx2ixbrl0821">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">-</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<p id="xdx_8AB_zpghoy2Je6L2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144978040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--SegmentReportingDisclosureTextBlock_z4GWlBfIRW67" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14</b> &#8211; <span id="xdx_82F_zxMqzbny23mc"><b>SEGMENT INFORMATION</b></span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates in <span id="xdx_904_eus-gaap--NumberOfOperatingSegments_dc_uSegments_c20210101__20211231_zDoyREnm7Iye">one</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating segment with no income in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
long-lived assets are owned by Integrity Israel and are located in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519146899144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zL4MFU8V2Ryh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 &#8211; <span id="xdx_820_z6LIDgdQs7id">RELATED PARTIES</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Garrett, Inc., which is controlled by one of our directors, Andrew Sycoff, received during the year ended December 31, 2020, cash
    approximately $<span id="xdx_90A_eus-gaap--RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_pn5n6_c20200101__20201231__dei--LegalEntityAxis__custom--AndrewGarrettIncMember__srt--TitleOfIndividualAxis__custom--AndrewSycoffMember__us-gaap--AwardTypeAxis__custom--PlacementAgentFeesMember_z5f5yxVYmoyd">2
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in placement agent fees and <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20201231__dei--LegalEntityAxis__custom--AndrewGarrettIncMember__srt--TitleOfIndividualAxis__custom--AndrewSycoffMember__us-gaap--AwardTypeAxis__custom--PlacementAgentFeesMember_zKZvKPMI9W34">3,750,000
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants for Placement Agent fees in 2020
    from us.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2020, $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200101__20201231_zjpRS4cnfMld">756
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand, representing the fair value of
    warrants issued as consideration for placement agent services to AGI. This amount was accounted for as Warrants with down-round protection.
    Upon issuance, the fair value was recognized as an increase in additional paid in capital</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144951512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zJ6r4XDoepWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    16</b> &#8211;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_zynLQNENpgC8">SUBSEQUENT
    EVENTS</span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated all subsequent events through the date when these
financial statements were issued to determine if these must be reported. The Company determined that there were no reportable subsequent
events to disclose in these financial statements.</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519141985752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Functional currency</a></td>
<td class="text"><p id="xdx_841_eus-gaap--UseOfEstimates_ziKlARtDDxOa" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;<span id="xdx_862_zEWBiyXPFVmg">Use of estimates in the preparation of financial statements</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                                         preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States
                                                         (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and
                                                         liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the
                                                         reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As
                                                         applicable to the consolidated financial statements, the most significant estimates and assumptions relate to the going concern
                                                         assumptions.</span></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
  <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
  <td><span id="xdx_863_ztnpQCdFXv9d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Functional currency</b></span></td></tr>
</table>




<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    functional currency of the Company is the US dollar, which is the currency of the primary economic environment in which it operates.
    In accordance with ASC 830, &#8220;Foreign Currency Matters&#8221; (ASC 830), balances denominated in or linked to foreign currency
    are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions
    included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses
    arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses.
    The functional currency of Integrity Israel is the New Israeli Shekel (&#8220;NIS&#8221;) and its financial statements are included
    in consolidation, based on translation into US dollars. Accordingly, assets and liabilities were translated from NIS to US dollars
    using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or
    losses resulting from translation adjustments are reflected in stockholders&#8217; equity, under &#8220;accumulated other
    comprehensive income (loss)&#8221;.</span></td></tr>
  </table>
<p id="xdx_897_eus-gaap--ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_z1sWopOdwVWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-transform: uppercase"><span id="xdx_8BA_z28uggO1Vjtd" style="display: none">SCHEDULE
OF OFFICIAL EXCHANGE RATE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; float: left; border-collapse: collapse; width: 87%; margin-left: 1in">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Official exchange rate of NIS 1 to US dollar</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90C_ecustom--AverageForeignCurrencyExchangeRateTranslation_pid_uPure_c20210101__20211231_znrsJigW8zN9" title="Official exchange rate of NIS 1 to US dollar">0.321</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_ecustom--AverageForeignCurrencyExchangeRateTranslation_pid_uPure_c20200101__20201231_zfN93fVY2Di6" title="Official exchange rate of NIS 1 to US dollar">0.311</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Increase (decrease) of the official exchange rate of NIS 1 to US dollar during
    the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage_pid_dp_uPure_c20210101__20211231_zYT7ZqLx3uid" title="Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2021">3.22</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo_pid_dp_uPure_c20210101__20211231_zRqPDmfBAOg5" title="Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2020">7.2</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table><p id="xdx_8A7_zyM3csyKUrU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_z2phvkjRX7Fg" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"/>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_862_zRzDn3jIhzna" style="font-family: Times New Roman, Times, Serif">Principles
    of consolidation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions
    have been eliminated in consolidation.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zFIoQm3Vw01f" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
&#160;&#160;&#160;<span id="xdx_86E_z8UwjAFbWYIc">Cash and cash equivalents</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less
    at the date of purchase, to be cash equivalents.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zr59NmoMCee3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
&#160;&#160;&#160;&#160;<span id="xdx_864_zOgYx08MLb5l">Inventories</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
    are stated at the lower of cost or net realizable value.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    is determined as follows:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    respect to raw materials, the Group calculates cost using the average cost method.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    respect to work in process and finished products, the Group calculates the cost on the basis of the average direct manufacturing
    costs, including materials, labor, subcontracting costs and other direct manufacturing costs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management evaluated
                                                         periodically whether inventory is required to be written-down due to slow-moving or obsolete items and recognize
                                                         inventory impairment, as applicable
..</span></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zBem59oZXABa" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
&#160;&#160;&#160;&#160;<span id="xdx_86D_zOiwGzfYuAWl">Property and equipment, net</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 96px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over
    the estimated useful lives of the assets. When an asset is retired or otherwise disposed of, the related carrying value and accumulated
    depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected
    in the statements of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rates
    of depreciation:</span></td></tr>
  </table>
<p id="xdx_897_ecustom--ScheduleOfPropertyRatesOfDepreciationTableTextBlock_zDE5uvUBGOJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-transform: uppercase"><span id="xdx_8B7_z9HqlgAfPPq2" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; width: 70%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_zNsi2Hf6ZZ9" title="Property plant and equipment depreciation rate">33</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zyefZsav84we" title="Property plant and equipment depreciation rate">7</span>-<span id="xdx_90F_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zWQ5zTaFrD62" title="Property plant and equipment depreciation rate">15</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zaCfxQEeQjR7" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Estimated useful life"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shorter
    of lease term <br/>
    and 10 years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p id="xdx_8AF_zrshgJhPm0e3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ze82Gzge5Av3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.
&#160;&#160;&#160;<span id="xdx_862_zIFCa5yk36p">Impairment of long-lived assets</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group&#8217;s long-lived assets are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment&#8221;,
    whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability
    of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows
    expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by
    the amount by which the carrying amount of the asset exceeds its fair value. To date the Group did not incur any material impairment
    losses related to long lived assets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zhsaGHsnbdFg" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.
&#160;&#160;&#160;<span id="xdx_86F_zCStbuEbnwma">Restricted cash</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
                                            cash is invested in certificates of deposit, which are used to secure Integrity Israel&#8217;s
                                            obligations in respect of its headquarters lease and credit card (See also Note 8B).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    presentation of statement of cash flows purposes, restrict cash balances are included with cash and cash equivalents, when reconciling
    the reported period total amounts.</span></p></td></tr>
  </table>
<p id="xdx_899_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zx2RjUoNBbvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none; text-transform: uppercase">SCHEDULE
OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; border-collapse: collapse; width: 85%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20211231_z0KKbVEHNyc3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20201231_zvJCzkll1hz1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzao3_z16YpaGo1Qh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,823</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RestrictedCash_iI_pn3n3_maCCERCzao3_zPyLjxmhuVOb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzao3_zsG11z4lis63" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,113</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,885</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zILf7TSGrnh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income tax</a></td>
<td class="text"><p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z3ySOspGUR39" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.
&#160;&#160;&#160;&#160;&#160;<span id="xdx_86B_zYL7iQmDU1K1">Income tax</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221;. Accordingly, deferred income taxes are determined
    utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting
    and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax
    rates expected to be in effect when these differences reverse. Valuation allowances in respect of deferred tax assets are provided
    for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial
    statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise&#8217;s financial statements.
    According to ASC Topic 740-10, tax positions must meet a more- likely-than-not recognition threshold. The Group&#8217;s accounting
    policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Group did not recognize
    such items in its fiscal 2021 and 2020 financial statements and did not recognize any liability with respect to unrecognized tax
    position in its balance sheet.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy', window );">Liability for employee rights upon retirement</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_zXrcacv4Rm95" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.
&#160;&#160;&#160;&#160;<span id="xdx_86B_zxZD9iX9mnw5">Liability for employee rights upon retirement</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrity
    Israel&#8217;s liability for employee rights upon retirement with respect to its Israeli employees is calculated pursuant to the
    Israeli Severance Pay Law, based on the most recent salary of each employee multiplied by the number of years of employment of each
    such employee as of the balance sheet date. Employees are entitled to one month&#8217;s salary for each year of employment, or ratable
    portion thereof for periods less than one year. Integrity Israel makes monthly deposits to insurance policies and severance pay funds.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    deposited funds may be withdrawn upon the fulfillment of Integrity Israel&#8217;s severance obligations pursuant to Israeli severance
    pay laws or labor agreements with its employees. The value of the deposited funds is based on the cash surrender value of these policies,
    and includes immaterial profits or losses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
    in 2011, Integrity Israel&#8217;s agreements with its Israeli employees are in accordance with Section 14 of the Severance Pay Law.
    Payments in accordance with Section 14 release the employer from any future severance payments in respect of those employees. Related
    obligations and liabilities under Section 14 are not recorded as an asset or as a liability in the Company&#8217;s balance sheet.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    year ended December 31, 2021, and 2020, severance expenses amounted to $<span id="xdx_90F_eus-gaap--SeveranceCosts1_pn3n3_c20210101__20211231_zY7fX3k5BpIb" title="Severance expenses">43</span>
    and $<span id="xdx_902_eus-gaap--SeveranceCosts1_pn3n3_c20200101__20201231_zEO4WrqohWq1" title="Severance expenses">24 </span> thousand,
    respectively.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zirsgiEM0ulf" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>K.
&#160;&#160;&#160;<span id="xdx_868_zpXQro7zIyQ3">Research and development expenses</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development expenses are charged to operations as incurred.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_RoyaltyBearingGrantsPolicyTextBlock', window );">Royalty-bearing grant</a></td>
<td class="text"><p id="xdx_845_ecustom--RoyaltyBearingGrantsPolicyTextBlock_z8sKHmrDPlp6" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>L.
&#160;&#160;&#160;<span id="xdx_862_zwtYQaEmhRE1">Royalty-bearing grant</span>s</b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalty-bearing
grants from the Israeli Innovation Authority (IIA) to fund approved research and development projects are recognized at the time
Integrity Israel is entitled to such grants, on the basis of the costs incurred and reduce research and development costs. To date,
the cumulative research and development grants received by Integrity Israel from amounted to $<span id="xdx_900_ecustom--CumulativeResearchAndDevelopment_pn3n3_c20210101__20211231_zFrVLd4EqThb" title="Cumulative research and development">93</span> thousand.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Warranty</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--StandardProductWarrantyPolicy_zvlibdTueNw9" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>M.
&#160;&#160;<span id="xdx_865_zaFGQFrnS42l">Warranty</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group provides a 24-month warranty for its products at no cost. The group estimates the costs that may be incurred during
    the warranty period and records a liability for the amounts of such costs at the time revenues are recognized. For the year ended
    December 31, 2021 and 2020 warranty expenses were clearly insignificant.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted loss per share</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_z4dUfCu8MIal" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;<span id="xdx_861_zHwZZ6eGcibe">Basic and diluted loss per share</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is computed by dividing the loss for the period applicable
for Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon
    the exercise of options or warrants issued or granted using the &#8220;treasury stock method&#8221;, if the effect of each of such
    financial instruments is dilutive.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In computing diluted loss per share, the average stock price for the
    period is used in determining the number of common stock assumed to be purchased from the exercise of stock options or stock warrants.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shares that will be issued upon exercise of all stock
    options and stock warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods
    for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these
    instruments was anti-dilutive</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An amount of <span id="xdx_90F_ecustom--NumberOfStockOptionsExcluded_c20210101__20211231_zOt36ZugXE08" title="Number of stock options excluded">6,404,238</span> and <span id="xdx_904_ecustom--NumberOfStockWarrantsExcluded_c20210101__20211231_z3TLRD8mnoWk" title="Number of stock warrants excluded">6,446,920</span> outstanding stock
    options and stock warrants have been excluded from the calculation of the diluted net loss per share for the years ended December
    31, 2021 and 2020, respectively, because the effect of the common shares issuable as a result of the exercise of such instruments
    was determined to be anti-dilutive.</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zhK42UAblaGb" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>O.
&#160;&#160;&#160;<span id="xdx_863_zgLyhfyW8zsa">Stock-based compensation</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values
    in accordance with ASC 718, &#8220;Compensation-Stock Compensation&#8221;. Share-based payments including grants of stock options
    are recognized in the statement of operations as an operating expense based on the fair value of the award at the date of grant.
    The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Group has expensed compensation
    costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit
    service period when a performance condition affects the vesting, and it is considered probable that the performance condition will
    be achieved.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
    January 1, 2019, following the adoption of ASU 2018-07, which aligns the measurement and classification guidance for share-based
    payments to nonemployees with the guidance for share-based payments to employees (with certain exceptions), share-based payments
    to non-employees are accounted in accordance with ASC 718.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zeCThVgBkQi2" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>P.
&#160;&#160;&#160;<span id="xdx_86A_z0MkNh8cKSO3">Fair value of financial instruments</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
    Topic 825-10, &#8220;Financial Instruments&#8221; defines financial instruments and requires disclosure of the fair value of financial
    instruments held by the Group. The Group considers the carrying amount of cash and cash equivalents, restricted cash, accounts receivable,
    other current assets, accounts payable and other current liabilities balances, to approximate their fair values due to the short-term
    maturities of such financial instruments. ASC Topic 825-10, establishes the following fair value hierarchy, which prioritizes the
    inputs used in the valuation methodologies in measuring fair value:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair
    value hierarchy gives the highest priority to Level 1 inputs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 - Unobservable inputs are used when little or no market data is available. Level 3 inputs are considered as the lowest priority
    under the fair value hierarchy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group did not estimate the fair value of the  loans from stockholders since their repayment schedule has not yet been determined.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zjGnLFw00Rp1" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;<span id="xdx_86C_zCHn20XqlR39">Concentrations of credit risk</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash and cash equivalents, and
    restricted cash. Cash and cash equivalents and restricted cash are deposited with major banks in Israel and the United States of
    America. Management believes that such financial institutions are financially sound, accordingly, minimal credit risk exists with
    respect to these financial instruments. The Group does not have any significant off-balance-sheet concentration of credit risk, such
    as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><p id="xdx_847_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zay9jLDrdGd6" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>R.
&#160;&#160;&#160;<span id="xdx_867_zuq6SO3iGgmh">Contingencies</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability
    has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional
    information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants with Down-Round Protection</a></td>
<td class="text"><p id="xdx_840_eus-gaap--DerivativesPolicyTextBlock_zShPDLLDHhh5" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>S.
&#160;&#160;&#160;&#160;<span id="xdx_86C_zpnCZhkuvNI4">Warrants with Down-Round Protection</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
    the application of Accounting Standard Update (ASU) No. 2017-11, &#8220;Earnings Per Share&#8221; (ASU 2017-11), the Company disregard
    the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or
    equity classification. Based on its evaluation, management has determined that such warrants with Down-Round Protection are eligible
    for equity classification.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    accordance with the provisions of ASU 2017-11, upon the occurrence of an event that triggers a down round protection (i.e., when
    the exercise price of the warrants is adjusted downward because of the down round feature), the effect is accounted for as a deemed
    dividend and as a reduction of income available to common shareholders for purposes of basic earnings per share (EPS) calculation.</span></p></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_ModificationOfEquityclassifiedContractsPolicyTextBlock', window );">Modification of equity-classified contracts</a></td>
<td class="text"><p id="xdx_846_ecustom--ModificationOfEquityclassifiedContractsPolicyTextBlock_zXJeETtbbN6i" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>T.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;<span id="xdx_86A_ziJkWwfyEW19">Modification of equity-classified contracts</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification
    or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification
    of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value
    of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase
    of accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified
    share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment
    to earnings available to common shareholders for purposes of calculating earnings per share.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Allowance for doubtful accounts</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_z7eoZqo6Uc0d" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;<span id="xdx_86B_zp8JaOuYjnM2">Allowance for doubtful accounts</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The allowance for doubtful accounts is determined with
    respect to amounts the Company has determined to be doubtful of collection, in order to reflect the expected credit losses on accounts
    receivable balances. Judgment is required in the estimation of the allowance for doubtful accounts and the Company evaluates the
    collectability of its accounts receivable based on a combination of factors (including, among other things, the length of time that
    the balance is past due and the customer&#8217;s current ability to pay. If it&#8217;s becomes aware of a customer&#8217;s inability to meet
    its financial obligations, an allowance is recorded to reduce the net receivable to the amount reasonably believed to be collectible
    from such customer</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Operating Lease</a></td>
<td class="text"><p id="xdx_845_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zYlRL3q7WdYf" style="margin: 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>V.</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span id="xdx_865_zMkUXWRi3xs9">Operating Lease</span></b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company entered into several non-cancelable lease agreements for vehicles for use in its operations, which are classified as operating
    leases.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
    January 1, 2019, the Company applies ASC Update 2016-02, Leases (Topic 842).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company determines if an arrangement is a lease at inception. Under the new guidance, arrangements meeting the definition of a lease
    are classified as operating or financing leases. A classification of a lease is determined based on the following criteria:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 96px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lease transfers ownership of the underlying asset to the lessee by the end of the lease term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    lease term is for the major part of the remaining economic life of the underlying asset (Generally, 75% or more of the remaining
    economic life of the underlying assets).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    present value of the sum of the lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all
    of the fair value of the underlying asset (Generally, 90% or more of the fair value of the underlying asset).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease
    term.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these five criteria is met, the lease is classified as a finance lease. Otherwise, the lease is classified as an operating lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
are recorded on the consolidated balance sheet as both a right of use asset and a lease liability, calculated by discounting fixed lease
payments over the lease term at the rate implicit in the lease or the Company&#8217;s incremental borrowing rate. Lease liabilities are
increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating
leases, interest on the lease liability and the amortization of the right of use asset results in straight-line rent expense over the
lease term. Variable lease expenses, if any, are recorded when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also elected the short-term lease recognition exemption for all leases that qualify (leases with a term shorter than <span id="xdx_907_eus-gaap--LessorOperatingLeaseTermOfContract_iI_dtM_c20190102_zT2oUyH9Lhek" title="Lessor, Operating Lease, Term of Contract">12</span> months).
For those leases, right-of-use assets or lease liabilities are not recognized and rent expense is recognized on a straight-line basis
over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had no material capital leases throughout the reporting periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
note 4 for further discussion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 &#8211;</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zMFGQ4NQ6qF8" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>W.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>&#160;&#160;&#160;<span id="xdx_86A_zHQvnAq3pgAf">Reclassification</span></b></span></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    comparative figures have been reclassified to conform to the current year presentation. Such reclassifications did not have any significant
    impact on the Company&#8217;s equity, net income or cash flows.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">X. Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zegEC1G2JUS5" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><b><span id="xdx_868_zXTHdpqWn82">X. &#160;&#160;Recent Accounting Pronouncements</span></b></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments&#8221; (&#8220;ASU 2016-13&#8221;), which changes the impairment model for most financial assets and certain other instruments.
For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities will be required to use a new
forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. The
guidance also requires increased disclosures. For the Company, the amendments in the update were originally effective for fiscal years
beginning after December 15, 2019, including interim periods within those fiscal years. In November 2019, the FASB issued ASU No. 2019-10,
which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined by the SEC) and other non-SEC reporting entities
to fiscal years beginning after December 15, 2022, including interim periods within those fiscal periods. Early adoption is permitted.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the company
is eligible to considered as smaller reporting company ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including
interim periods within those fiscal years. The adoption of this standard is not expected to result in a material impact to the Company&#8217;s
financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><b>&#160;</b></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_ModificationOfEquityclassifiedContractsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Modification of Equity Classified Contracts [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_ModificationOfEquityclassifiedContractsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_RoyaltyBearingGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Bearing Grants [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_RoyaltyBearingGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI http://asc.fasb.org/extlink&amp;oid=124502072&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for plans, other than pension plans, that provide postretirement benefits (including both defined benefit and defined contribution plans). This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235144<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235172<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519145718520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock', window );">SCHEDULE OF OFFICIAL EXCHANGE RATE</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_z1sWopOdwVWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-transform: uppercase"><span id="xdx_8BA_z28uggO1Vjtd" style="display: none">SCHEDULE
OF OFFICIAL EXCHANGE RATE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; float: left; border-collapse: collapse; width: 87%; margin-left: 1in">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Official exchange rate of NIS 1 to US dollar</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90C_ecustom--AverageForeignCurrencyExchangeRateTranslation_pid_uPure_c20210101__20211231_znrsJigW8zN9" title="Official exchange rate of NIS 1 to US dollar">0.321</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_ecustom--AverageForeignCurrencyExchangeRateTranslation_pid_uPure_c20200101__20201231_zfN93fVY2Di6" title="Official exchange rate of NIS 1 to US dollar">0.311</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Increase (decrease) of the official exchange rate of NIS 1 to US dollar during
    the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage_pid_dp_uPure_c20210101__20211231_zYT7ZqLx3uid" title="Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2021">3.22</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo_pid_dp_uPure_c20210101__20211231_zRqPDmfBAOg5" title="Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2020">7.2</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_ScheduleOfPropertyRatesOfDepreciationTableTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleOfPropertyRatesOfDepreciationTableTextBlock_zDE5uvUBGOJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="text-transform: uppercase"><span id="xdx_8B7_z9HqlgAfPPq2" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; width: 70%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_zNsi2Hf6ZZ9" title="Property plant and equipment depreciation rate">33</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zyefZsav84we" title="Property plant and equipment depreciation rate">7</span>-<span id="xdx_90F_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zWQ5zTaFrD62" title="Property plant and equipment depreciation rate">15</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zaCfxQEeQjR7" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Estimated useful life"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shorter
    of lease term <br/>
    and 10 years</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zx2RjUoNBbvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none; text-transform: uppercase">SCHEDULE
OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; border-collapse: collapse; width: 85%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20211231_z0KKbVEHNyc3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20201231_zvJCzkll1hz1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzao3_z16YpaGo1Qh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,823</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RestrictedCash_iI_pn3n3_maCCERCzao3_zPyLjxmhuVOb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzao3_zsG11z4lis63" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,113</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,885</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_ScheduleOfPropertyRatesOfDepreciationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Property Rates of Depreciation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_ScheduleOfPropertyRatesOfDepreciationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the U.S. dollar denominated balances, balances reported for financial reporting purposes and the differences between the two balances by each relevant line item on the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144850600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">SCHEDULE OF INVENTORIES</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zc8V0fXVWzC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zrnsXl8O4ds2" style="display: none; text-transform: uppercase">SCHEDULE
OF INVENTORIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_ztdjoh3Df3Rb">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20201231_zOgIXePL4TF6">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Inventory</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryRawMaterials_iI_pn3n3_maIGzn5N_zQ5GzIkfahI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">94</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">95</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maIGzn5N_zWDi36o1kNZ6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maIGzn5N_zaLMdy8upMJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InventoryGross_iTI_pn3n3_mtIGzn5N_maINzWYt_zLNeCkoh9e4e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right"/><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">321</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">284</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InventoryAdjustments_iNTI_pn3n3_di_msINzWYt_z9gv4rshjGo9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">inventory write-down</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(321</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InventoryNet_iTI_pn3n3_mtINzWYt_znPOi37l1bi2" style="vertical-align: bottom; background-color: White">
    <td/><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0517">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">284</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519236170920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">SCHEDULE OF LEASE COSTS, LEASE TERM AND DISCOUNT</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--LeaseCostTableTextBlock_zLbcPSlBJLOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease costs, lease term and discount rate are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zRsGUCR3CFsh" style="display: none; text-transform: uppercase">SCHEDULE
OF LEASE COSTS, LEASE TERM AND DISCOUNT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In
                                            thousand of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US
                                            dollars</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Operating lease cost:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: justify">Vehicles</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseCost_pn3n3_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_z0mDVy94eAJ1">72</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Office space <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Over 12 month</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span id="xdx_909_ecustom--LongTermLeaseCost_pn3n3_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceMember_zXYtEbGj2g98" title="Office space: Over 12 month">53</span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify"><p style="margin: 0">Short term leases</p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0"><span id="xdx_902_eus-gaap--ShortTermLeaseCost_pn3n3_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceMember_zXgDvxIa4iT6" title="Office space: Short term leases">46</span></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseCost_pn3n3_c20210101__20211231_zwYNiMxQj5jb" title="Total Operating lease cost">171</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Remaining Lease Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Vehicles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zZ0I6Rm1ey75" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.01
                                            </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Weighted Average Discount Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Vehicles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zz2FmmxhiL9h">10</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF OPERATING LEASE MATURITY PAYMENTS</a></td>
<td class="text"><p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zxu4SEPCq9V3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a schedule, by years, of maturities of operating lease liabilities as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zBYWPBLIkEM3" style="display: none; text-transform: uppercase">SCHEDULE
OF OPERATING LEASE MATURITY PAYMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20211231_zpyzv9EMEht8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In
                                            thousand of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US
                                            dollars</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzYou_zoSxFXo8Kvea" style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: justify">2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right">24</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzYou_zR5T5VV0j14b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzYou_zF2vTrQGuc3h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total operating lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">44</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_zL5ELAg733eh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Less: imputed interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zwWf4InZ9Uj3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144871896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6wHxThoOcPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zKONlzkJRMz4" style="display: none; text-transform: uppercase">SCHEDULE
OF PROPERTY AND EQUIPMENT, NET</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Property and Equipment</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Computers</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpwgU3E7tlPf" style="width: 16%; text-align: right" title="Property and equipment, gross">306</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zIzfuCWk5Py3" style="width: 16%; text-align: right" title="Property and equipment, gross">380</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zdMJOGy5YJNe" style="text-align: right" title="Property and equipment, gross">183</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zgxvPnsd5GAa" style="text-align: right" title="Property and equipment, gross">312</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z4NhPEhmhcr9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zzfKXgKvNa79" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross">82</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231_zvwAoM2vko4c" style="text-align: right" title="Property and equipment, gross">489</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231_zPjFhlZi4Fua" style="text-align: right" title="Property and equipment, gross">774</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20211231_zymk2K4tPJL8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less - accumulated depreciation">(420</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20201231_zMxf3fkw4KQa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less - accumulated depreciation">(625</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment,
    net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20211231_zvFTbtn2CRqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">69</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231_zaf1kzpQIA17" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">149</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519146929336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">SCHEDULE OF OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_899_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zpVYTO3IUP6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zpdOqWdmDMi3" style="display: none; text-transform: uppercase">SCHEDULE
OF OTHER CURRENT LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zjPxOE5dmKeb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20201231_zNlP70h9iU7c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Other Current Liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maOLCzeFZ_zqb8htmtCzZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Employees and related institutions</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">244</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maOLCzeFZ_zUhlcLPgVGVl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued expenses and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCzeFZ_zcKkXLdVZWQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">229</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">392</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519147719352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">SCHEDULE OF FAIR VALUE ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zjCncJ4E5oH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><span id="xdx_8BA_zqKLcqcL0dIl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; border-collapse: collapse; width: 58%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Fair value calculations &#8211; Warrant</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31-Dec-20</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zG6kiQss7US5"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Expected volatility (%)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zOPAtKKPxUh3">56.32</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z39F9w5I5Xtk">2.5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zBonNKFffTbc">5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price (US dollars)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmXooMm7mJU3">5.2</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Share price (US dollars)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIn838AN9blh">5.2</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value (US dollars)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairValueMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfTuNhbuoQB3">2.6</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK GRANTS ACTIVITY</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgTR23sZjut8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8BB_z804badvxNda" style="display: none">SCHEDULE
OF STOCK GRANTS ACTIVITY</span></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 82%; margin-left: 1.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Grants to Employees</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price (US$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; padding-bottom: 1.5pt">Balance outstanding as of December 31,2019</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zbzfYCNDNbm2" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Number outstanding beginning balance">156,007</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zXIfIndJGbNh" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Weighted average exercise price outstanding, beginning balance">63.44</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Balance exercisable of December 31,2019</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20200101__20201231_zIfi1YoFzeGl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number exercisable, beginning balance">132,630</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zp2yw1rOxRFd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price exercisable, beginning balance">60.19</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Granted during 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zMQngjh5lMgl" style="text-align: right" title="Number shares, grants"><span style="-sec-ix-hidden: xdx2ixbrl0675">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_z4Bprvx2fi78" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0677">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Forfeited during 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231_zHIzTlEkEyL6" style="text-align: right" title="Number, forfeited">(25,770</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zggqNa5rzt7e" style="text-align: right" title="Weighted average exercise price, forfeited">58.63</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance outstanding as of December 31,2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zZuvFDQJdUW1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number outstanding beginning balance">130,237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zfmzeJgTmwZb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price outstanding, beginning balance">64.35</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Balance exercisable of December 31,2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20210101__20211231_zt8AGEdZH1cd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number exercisable, beginning balance">128,296</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_pid_c20210101__20211231_z5ua8Ql99sFk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price exercisable, beginning balance">64.48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Granted during 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zxj2ZiyXilCb" style="text-align: right" title="Number, grants">577,064</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_z4mH7EONhW25" style="text-align: right" title="Weighted average exercise price, granted">5.20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Forfeited during 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231_z7LgUYtZDtpc" style="text-align: right" title="Number, forfeited">(98,177</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zxZtW5O8XOOc" style="text-align: right" title="Weighted average exercise price, forfeited">64.64</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance outstanding as of December 31,2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_zCa0YdSQQXWd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number outstanding ending balance">609,124</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zRbdkWAs6nY" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price outstanding, ending balance">8.10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Balance exercisable of December 31,2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20211231_zAgh22zbiUQ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number exercisable, ending balance">39,223</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zKH4QqiQmyba" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price exercisable, ending balance">46.41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">SCHEDULE OF STOCK GRANTS, BY EXERCISE PRICE RANGE</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zVgfwIHJyx75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize information about options outstanding at December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8B3_zKrNsKm2uhik" style="display: none">SCHEDULE
OF STOCK GRANTS, BY EXERCISE PRICE RANGE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; border-collapse: collapse; width: 64%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>price
                                            (US$)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding at December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable at December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average remaining contractual
    life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zub7MEbx4Vlf">5.2</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zuhEAQqCPheg">579,004</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBDndmflcIT4">9,103</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zL7uz27QZdKd">2.75</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zo4CMb3x2C77">58.5</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUTjAZuuGJ53">26,274</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z2KivElePXFd">26,274</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zd21c6BBm3vi">5.18</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWTtEQU3iu0c">100.75</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zBzFgPivlowj">3,846</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zL0f2niBp6jj">3,846</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z6I7Y9tz8loh">5.26</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231_zt0bXd0J8t3l">609,124</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231_zlRFEYgLjLya">39,223</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLL1OEK6u81g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8BC_zfKXlYxCnMd2" style="display: none">SCHEDULE
OF ASSUMPTIONS USED TO VALUE OPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; width: 82%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
    value calculations - Warrant</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31, 2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zue5XlZzHbBk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0724">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility (%) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zbd5VVjAuA9c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    free interest rate (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_z9pq2FJk3Lv" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term of options (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zTrn6VHbCiQ" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    price (US dollars)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20211231_zHWICVB3oYJh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    price (US dollars) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20211231__srt--RangeAxis__srt--MinimumMember_znuEcG7VTrSl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20211231__srt--RangeAxis__srt--MaximumMember_zZF4yc5rk9Kf">4.65</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value (US dollars)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zTwn5sG0ukhh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.6</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zy60RI1frbdl">1.48</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144975816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock', window );">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfResearchAndDevelopmentExpensesTableTextBlock_zj1niLzcqLz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8BD_zgjnOeehpJ7k" style="display: none">SCHEDULE
OF RESEARCH AND DEVELOPMENT EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20211231_zJkwsET1pU5j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20200101__20201231_z31ccH8YmWL7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><p style="margin: 0">Research and Development</p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LaborAndRelatedExpense_maRADEzgxz_zy7obYeNTb64" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Salaries and related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">916</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">754</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProfessionalFees_maRADEzgxz_zuFNn5S2zVm1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">462</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InventoryWriteDown_maRADEzgxz_zSeGenFyUPyf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expenses due to slow inventory write-off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">321</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DepreciationAndAmortization_maRADEzgxz_zrxmDqMWj5g4" style="vertical-align: bottom; background-color: White">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfPropertyRepairsAndMaintenance_maRADEzgxz_znL8tU2Lk2wa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vehicle maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherGeneralExpense_maRADEzgxz_zmbi7AQ6gqqj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">162</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEzgxz_zHdJWSUSuhRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total research and development
    expenses, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,810</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,532</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Research And Development Expenses [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144868888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETING EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_DisclosureMarketingExpensesAbstract', window );"><strong>Marketing Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_ScheduleOfSellingAndMarketingExpensesTableTextBlock', window );">SCHEDULE OF SELLING AND MARKETING EXPENSES</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfSellingAndMarketingExpensesTableTextBlock_zH5ac9akaOp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8BC_zkjCBInLSFw8" style="display: none">SCHEDULE
OF SELLING AND MARKETING EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Selling and Marketing</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231_zohCQLqIHKr1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December
    31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20200101__20201231_zfvdPLlHFJv6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December
    31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--SalariesAndRelatedExpenses_maSGAAEz1YR_zTvk3hgUK9t9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Salaries and related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">22</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">156</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ResearchAndDevelopmentProfessionalFees_maSGAAEz1YR_zMazA1bRJbn3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--SellingAndMarketingOtherExpenses_maSGAAEz1YR_zs0inEMN6Yfb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--SellingGeneralAndAdministrativeExpense_iT_pn3n3_mtSGAAEz1YR_zxrFStdDZe83" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total selling and marketing
    expenses</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">139</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">415</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_DisclosureMarketingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_DisclosureMarketingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_ScheduleOfSellingAndMarketingExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Selling and Marketing Expenses [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_ScheduleOfSellingAndMarketingExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519145014600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL AND ADMINISTRATIVE EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract', window );"><strong>General And Administrative Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock', window );">SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_ze3X159d1ns8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;<span id="xdx_8B2_z9VxWPN7iCsk" style="display: none">SCHEDULE
OF GENERAL AND ADMINISTRATIVE EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZe2zEorLkb7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsUypMV9dnYh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In thousand of US dollars</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">General and Administrative</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LaborAndRelatedExpense_pn3n3_maGAAEzQ9k_ze209rYWDyd7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Salaries and related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">608</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">368</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProfessionalFees_pn3n3_maGAAEzQ9k_zxYv3yAsdMni" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">694</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--BadDebtExpense_pn3n3_maGAAEzQ9k_zTh3ST4sVCE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bad debt expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0786">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CostOfPropertyRepairsAndMaintenance_pn3n3_maGAAEzQ9k_zox4jP414Iuj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vehicle maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DepreciationAndAmortization_pn3n3_maGAAEzQ9k_z1i1Fii3c0o" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InvestmentIncomeInvestmentExpense_pn3n3_maGAAEzQ9k_z5XvhHsnifhb" style="vertical-align: bottom; background-color: White">
    <td>Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_maGAAEzQ9k_zdFEX10ajw0j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_iT_pn3n3_mtGAAEzQ9k_zDWzqMVW1rZ9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total general and
    administrative expenses</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,091</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,185</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of General and Administrative Expenses [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144963304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAXES</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxta6JHExGt7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zBxd64DGl1Y7" style="display: none; text-transform: uppercase">SCHEDULE
OF DEFERRED TAXES</span></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zMyzFB15wbV6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20201231_z0NYxt4dnPcl" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Composition of deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_maDTANztgP_zBh0msQw1KXg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Provision for employee-related obligation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><p style="margin: 0">6</p></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 16%">22</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANztgP_zIRN9dDuIgt4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-capital loss carry forwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">11,654</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">10,889</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxAssetValuationAllowance_iI_pn3n3_msDTANztgP_z1DF1u6Qv6R3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0">(11,660</p></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(10,912</td>
    <td style="padding-bottom: 1.5pt">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3_z8qN6Od92Ql3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total deferred
    tax assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0820">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt"><span style="-sec-ix-hidden: xdx2ixbrl0821">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">-</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519141776552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 13, 2021</div></th>
<th class="th"><div>Feb. 14, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,466<span></span>
</td>
<td class="nump">$ 93,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">1 for 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 13,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Private placement of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519145909912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OFFICIAL EXCHANGE RATE (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_AverageForeignCurrencyExchangeRateTranslation', window );">Official exchange rate of NIS 1 to US dollar</a></td>
<td class="nump">0.321<span></span>
</td>
<td class="nump">0.311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage', window );">Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2021</a></td>
<td class="nump">3.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo', window );">Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2020</a></td>
<td class="nump">7.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_AverageForeignCurrencyExchangeRateTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The foreign exchange rates used to translate income and expense items denominated in the functional currency to the reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_AverageForeignCurrencyExchangeRateTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2020.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2019.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519142375416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=IGAP_ComputersMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_PropertyPlantAndEquipmentDepreciationRate', window );">Property plant and equipment depreciation rate</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=IGAP_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_PropertyPlantAndEquipmentDepreciationRate', window );">Property plant and equipment depreciation rate</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=IGAP_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_PropertyPlantAndEquipmentDepreciationRate', window );">Property plant and equipment depreciation rate</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful life</a></td>
<td class="text">Shorter
    of lease term
    and 10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_PropertyPlantAndEquipmentDepreciationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment depreciation rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_PropertyPlantAndEquipmentDepreciationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=IGAP_ComputersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=IGAP_ComputersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=IGAP_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=IGAP_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519146777272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,062<span></span>
</td>
<td class="nump">$ 9,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 6,113<span></span>
</td>
<td class="nump">$ 9,885<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519146836312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance expenses</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_CumulativeResearchAndDevelopment', window );">Cumulative research and development</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_NumberOfStockOptionsExcluded', window );">Number of stock options excluded</a></td>
<td class="nump">6,404,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_NumberOfStockWarrantsExcluded', window );">Number of stock warrants excluded</a></td>
<td class="nump">6,446,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Lessor, Operating Lease, Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_CumulativeResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_CumulativeResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_NumberOfStockOptionsExcluded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock options excluded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_NumberOfStockOptionsExcluded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_NumberOfStockWarrantsExcluded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock warrants excluded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_NumberOfStockWarrantsExcluded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519141790120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross, Total</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryAdjustments', window );">inventory write-down</a></td>
<td class="num">(321)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net, Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144974984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryAdjustments', window );">Inventory Adjustments</a></td>
<td class="nump">$ 321<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519143397896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF LEASE COSTS, LEASE TERM AND DISCOUNT (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total Operating lease cost</a></td>
<td class="nump">$ 171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total Operating lease cost</a></td>
<td class="nump">$ 72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">2 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=IGAP_OfficeSpaceMember', window );">Office Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_LongTermLeaseCost', window );">Office space: Over 12 month</a></td>
<td class="nump">$ 53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Office space: Short term leases</a></td>
<td class="nump">$ 46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_LongTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term lease cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_LongTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=IGAP_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=IGAP_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519147064616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OPERATING LEASE MATURITY PAYMENTS (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519141957256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 489<span></span>
</td>
<td class="nump">$ 774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation</a></td>
<td class="num">(420)<span></span>
</td>
<td class="num">(625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=IGAP_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=IGAP_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=IGAP_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519147175368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Payments to Acquire Property, Plant, and Equipment</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144793992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees and related institutions</a></td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other Liabilities, Current, Total</a></td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519141821080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOANS FROM STOCKHOLDERS (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2004</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersNoncurrent', window );">Due to Officers or Stockholders, Noncurrent</a></td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_QuarterlyPaymentsEqualsToSalesPercentage', window );">Quarterly payments equals to sales, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=IGAP_ShareHoldersMember', window );">Shareholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Issuance of Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_QuarterlyPaymentsEqualsToSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Quarterly payments equals to sales, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_QuarterlyPaymentsEqualsToSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=IGAP_ShareHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=IGAP_ShareHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519143086488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)<br> &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2017</div></th>
<th class="th">
<div>Mar. 04, 2004 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2005 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2004 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=IGAP_IsraeliInnovationAuthorityMember', window );">Israeli Innovation Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=IGAP_AndrewGarrettIncMember', window );">Andrew Garrett, Inc [Member] | Advisory Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_AdvisoryServicesPeriod', window );">Advisory services period</a></td>
<td class="text">the
    Company engaged AGI as placement agent on a non-exclusive basis to provide certain advisory services to the Company for a period
    of 9 months which was subsequently extended twice and was in effect until October 31, 2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=IGAP_IsraeliInnovationAuthorityMember', window );">Israeli Innovation Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=IGAP_IsraeliInnovationAuthorityMember', window );">Israeli Innovation Authority [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=IGAP_IsraeliInnovationAuthorityMember', window );">Israeli Innovation Authority [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_AdvisoryServicesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advisory services period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_AdvisoryServicesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=IGAP_IsraeliInnovationAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=IGAP_IsraeliInnovationAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=IGAP_AndrewGarrettIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=IGAP_AndrewGarrettIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=IGAP_AdvisoryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=IGAP_AdvisoryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=IGAP_IsraeliInnovationAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=IGAP_IsraeliInnovationAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519143260888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">56.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Measurement Input, Exercise Price [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=IGAP_MeasurementInputFairValueMember', window );">Measurement Input Fair Value [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">2.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=IGAP_MeasurementInputFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=IGAP_MeasurementInputFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519142001112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK GRANTS ACTIVITY (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number outstanding beginning balance</a></td>
<td class="nump">130,237<span></span>
</td>
<td class="nump">156,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning balance</a></td>
<td class="nump">$ 64.35<span></span>
</td>
<td class="nump">$ 63.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number exercisable, beginning balance</a></td>
<td class="nump">128,296<span></span>
</td>
<td class="nump">132,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price exercisable, beginning balance</a></td>
<td class="nump">$ 64.48<span></span>
</td>
<td class="nump">$ 60.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number, grants</a></td>
<td class="nump">577,064<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 5.20<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number, forfeited</a></td>
<td class="num">(98,177)<span></span>
</td>
<td class="num">(25,770)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited</a></td>
<td class="nump">$ 64.64<span></span>
</td>
<td class="nump">$ 58.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number outstanding ending balance</a></td>
<td class="nump">609,124<span></span>
</td>
<td class="nump">130,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, ending balance</a></td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="nump">$ 64.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number exercisable, ending balance</a></td>
<td class="nump">39,223<span></span>
</td>
<td class="nump">128,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price exercisable, ending balance</a></td>
<td class="nump">$ 46.41<span></span>
</td>
<td class="nump">$ 64.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519146858840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK GRANTS, BY EXERCISE PRICE RANGE (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</a></td>
<td class="nump">609,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</a></td>
<td class="nump">39,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IGAP_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit | $ / shares</a></td>
<td class="nump">$ 5.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</a></td>
<td class="nump">579,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</a></td>
<td class="nump">9,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">2 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IGAP_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit | $ / shares</a></td>
<td class="nump">$ 58.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</a></td>
<td class="nump">26,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</a></td>
<td class="nump">26,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 2 months 4 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IGAP_ExercisePriceThreeMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit | $ / shares</a></td>
<td class="nump">$ 100.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</a></td>
<td class="nump">3,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</a></td>
<td class="nump">3,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 3 months 3 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IGAP_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IGAP_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IGAP_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IGAP_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IGAP_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IGAP_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519143399272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">49.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="nump">$ 5.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">4.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 1.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519135631496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Details Narrative)<br> $ / shares in Units, &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 20, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 20, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Feb. 14, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2007 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 03, 2021</div></th>
<th class="th">
<div>Oct. 20, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 13,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">577,064,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=IGAP_IntegrityIsraelsPlanMember', window );">Integrity Israel's Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
    options vested over a period of 1-12 quarters based on each grantee&#8217;s option agreements. Any option not exercised within 10
    years after the date of grant thereof will expire<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=IGAP_PlacementAgentMember', window );">Placement Agent [Member] | 2017 Offering [Member] | Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,062,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=IGAP_PlacementAgentMember', window );">Placement Agent [Member] | 2017 Offering [Member] | Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=IGAP_PlacementAgentMember', window );">Placement Agent [Member] | 2017 Offering [Member] | Warrant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=IGAP_PlacementAgentMember', window );">Placement Agent [Member] | 2017 Offering [Member] | Warrant Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=IGAP_PlacementAgentMember', window );">Placement Agent [Member] | 2020 Offering [Member] | Warrant Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=IGAP_ErezBenZviMember', window );">Erez Ben Zvi [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Salary and Wage, Officer, Excluding Cost of Good and Service Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">&#8362; 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1/12
    of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall
    vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the employee continues to be employed
    by the Company at the applicable date of vesting<span></span>
</td>
<td class="text">1/12
    of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall
    vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the employee continues to be employed
    by the Company at the applicable date of vesting<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=IGAP_ShalomShushanMember', window );">Shalom Shushan [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Salary and Wage, Officer, Excluding Cost of Good and Service Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">&#8362; 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1/12
    of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall
    vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the Employee continues to be employed
    by the Company at the applicable date of vesting<span></span>
</td>
<td class="text">1/12
    of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall
    vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the Employee continues to be employed
    by the Company at the applicable date of vesting<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=IGAP_MrPaulVMember', window );">Mr Paul V [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_PercentageOfDulitedCommonStock', window );">Percentage of dulited common stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=IGAP_MrJamesPMember', window );">Mr James P [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_PercentageOfDulitedCommonStock', window );">Percentage of dulited common stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted | shares</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 5.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=IGAP_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember', window );">Securities Purchase Agreement And Registration Rights Agreement [Member] | Accredited Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,884,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_CashExpensesOnIssuanceOfStock', window );">Cash expenses on issuance of stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=IGAP_PlacementAgentAgreementMember', window );">Placement Agent Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits', window );">Commission as a percentage of cash amount equal to aggregate sale price of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_NonaccountableExpenseAllowancePercenatge', window );">Non-accountable expense allowance percenatge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_AggregateSalesPriceOfUnitsPercentage', window );">Commission as a percentage of aggregate sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_AggregateSalesPriceOfUnitsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission as a percentage of the aggregate sales price of the Units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_AggregateSalesPriceOfUnitsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_CashExpensesOnIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash expenses on issuance of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_CashExpensesOnIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission as a percentage of cash amount equal to aggregate sale price of units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_NonaccountableExpenseAllowancePercenatge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-accountable expense allowance percenatge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_NonaccountableExpenseAllowancePercenatge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_PercentageOfDulitedCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of dulited common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_PercentageOfDulitedCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=IGAP_IntegrityIsraelsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=IGAP_IntegrityIsraelsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=IGAP_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=IGAP_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=IGAP_TwoThousandandSeventeenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=IGAP_TwoThousandandSeventeenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=IGAP_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=IGAP_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=IGAP_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=IGAP_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=IGAP_WarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=IGAP_WarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=IGAP_WarrantFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=IGAP_WarrantFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=IGAP_TwoThousandandTwentyOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=IGAP_TwoThousandandTwentyOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=IGAP_WarrantFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=IGAP_WarrantFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=IGAP_ErezBenZviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=IGAP_ErezBenZviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=IGAP_ShalomShushanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=IGAP_ShalomShushanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=IGAP_MrPaulVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=IGAP_MrPaulVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=IGAP_MrJamesPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=IGAP_MrJamesPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=IGAP_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=IGAP_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=IGAP_AccreditedInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=IGAP_AccreditedInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=IGAP_PlacementAgentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=IGAP_PlacementAgentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519135545128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and related expenses</a></td>
<td class="nump">$ 916<span></span>
</td>
<td class="nump">$ 754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Expenses due to slow inventory write-off</a></td>
<td class="nump">321<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfPropertyRepairsAndMaintenance', window );">Vehicle maintenance</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Other</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses, net</a></td>
<td class="nump">$ 1,810<span></span>
</td>
<td class="nump">$ 1,532<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfPropertyRepairsAndMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs of keeping the property in good condition but that do not appreciably prolong the life or increase the value of the property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfPropertyRepairsAndMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519143408184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF SELLING AND MARKETING EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_DisclosureMarketingExpensesAbstract', window );"><strong>Marketing Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_SalariesAndRelatedExpenses', window );">Salaries and related expenses</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_ResearchAndDevelopmentProfessionalFees', window );">Professional fees</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_SellingAndMarketingOtherExpenses', window );">Other</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total selling and marketing expenses</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_DisclosureMarketingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_DisclosureMarketingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_ResearchAndDevelopmentProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development professional fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_ResearchAndDevelopmentProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_SalariesAndRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Salaries and related expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_SalariesAndRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_SellingAndMarketingOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling and marketing other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_SellingAndMarketingOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519141959560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and related expenses</a></td>
<td class="nump">$ 916<span></span>
</td>
<td class="nump">$ 754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfPropertyRepairsAndMaintenance', window );">Vehicle maintenance</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">&#160;Total general and administrative expenses</a></td>
<td class="nump">2,091<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and related expenses</a></td>
<td class="nump">608<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">1,224<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_BadDebtExpense', window );">Bad debt expense</a></td>
<td class="nump">59<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfPropertyRepairsAndMaintenance', window );">Vehicle maintenance</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInvestmentExpense', window );">Insurance</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">&#160;Total general and administrative expenses</a></td>
<td class="nump">$ 2,091<span></span>
</td>
<td class="nump">$ 1,185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_BadDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bad debt expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_BadDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfPropertyRepairsAndMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs of keeping the property in good condition but that do not appreciably prolong the life or increase the value of the property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfPropertyRepairsAndMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInvestmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the generation of investment income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInvestmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519145822888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Provision for employee-related obligation</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Non-capital loss carry forwards</a></td>
<td class="nump">11,654<span></span>
</td>
<td class="nump">10,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IGAP_DeferredTaxAssetValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(11,660)<span></span>
</td>
<td class="num">(10,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">&#160;Total deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IGAP_DeferredTaxAssetValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IGAP_DeferredTaxAssetValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IGAP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519143351720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 10.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 41.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519144904040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140519145936952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="nump">$ 756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=IGAP_AndrewGarrettIncMember', window );">Andrew Garrett, Inc [Member] | Andrew Sycoff [Member] | Placement Agent Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="nump">3,750,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=IGAP_AndrewGarrettIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=IGAP_AndrewGarrettIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=IGAP_AndrewSycoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=IGAP_AndrewSycoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IGAP_PlacementAgentFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IGAP_PlacementAgentFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:IGAP="http://integrity-app.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="igap-20211231.xsd" xlink:type="simple"/>
    <context id="From2021-01-01to2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-03-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2022-03-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_BoardOfMembersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:BoardOfMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_BoardOfMembersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:BoardOfMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-08-112021-08-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <startDate>2021-08-11</startDate>
            <endDate>2021-08-13</endDate>
        </period>
    </context>
    <context id="From2020-02-132020-02-14_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-13</startDate>
            <endDate>2020-02-14</endDate>
        </period>
    </context>
    <context id="AsOf2020-02-14_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-14</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ComputersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">IGAP:ComputersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">IGAP:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">IGAP:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-01-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
        </entity>
        <period>
            <instant>2019-01-02</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_OfficeSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">IGAP:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">IGAP:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">IGAP:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2003-01-012004-12-31_custom_ShareHoldersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:ShareHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2003-01-01</startDate>
            <endDate>2004-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">IGAP:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2004-03-04</instant>
        </period>
    </context>
    <context id="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">IGAP:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2004-03-03</startDate>
            <endDate>2004-03-04</endDate>
        </period>
    </context>
    <context id="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">IGAP:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2004-03-03</startDate>
            <endDate>2004-03-04</endDate>
        </period>
    </context>
    <context id="AsOf2005-03-04_custom_IsraeliInnovationAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IGAP:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2005-03-04</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_IsraeliInnovationAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IGAP:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2017-07-292017-08-01_custom_AdvisoryAgreementMember_custom_AndrewGarrettIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IGAP:AdvisoryAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IGAP:AndrewGarrettIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-29</startDate>
            <endDate>2017-08-01</endDate>
        </period>
    </context>
    <context id="From2020-02-132020-02-14_custom_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_custom_AccreditedInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IGAP:SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-13</startDate>
            <endDate>2020-02-14</endDate>
        </period>
    </context>
    <context id="AsOf2020-02-14_custom_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_custom_AccreditedInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IGAP:SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-14</instant>
        </period>
    </context>
    <context id="From2020-02-132022-02-14_custom_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_custom_AccreditedInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IGAP:SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-13</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PlacementAgentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IGAP:PlacementAgentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">IGAP:WarrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">IGAP:TwoThousandandSeventeenOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">IGAP:WarrantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">IGAP:TwoThousandandSeventeenOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">IGAP:WarrantThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">IGAP:TwoThousandandSeventeenOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">IGAP:WarrantFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">IGAP:TwoThousandandSeventeenOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwoThousandandTwentyOfferingMember_custom_PlacementAgentMember_custom_WarrantFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">IGAP:WarrantFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">IGAP:TwoThousandandTwentyOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2007-08-31_custom_IntegrityIsraelsPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">IGAP:IntegrityIsraelsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-08-31</instant>
        </period>
    </context>
    <context id="From2007-08-012007-08-31_custom_IntegrityIsraelsPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">IGAP:IntegrityIsraelsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2007-08-01</startDate>
            <endDate>2007-08-31</endDate>
        </period>
    </context>
    <context id="From2020-06-282020-06-30_custom_ErezBenZviMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:ErezBenZviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-28</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-11-282020-11-30_custom_ShalomShushanMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:ShalomShushanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-28</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-20_custom_MrPaulVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:MrPaulVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-20</instant>
        </period>
    </context>
    <context id="From2021-11-182021-11-20_custom_MrPaulVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:MrPaulVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-18</startDate>
            <endDate>2021-11-20</endDate>
        </period>
    </context>
    <context id="AsOf2021-10-20_custom_MrPaulVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:MrPaulVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-20</instant>
        </period>
    </context>
    <context id="AsOf2021-12-03_custom_MrJamesPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:MrJamesPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-03</instant>
        </period>
    </context>
    <context id="AsOf2021-12-20_custom_MrJamesPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:MrJamesPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="From2021-12-182021-12-20_custom_MrJamesPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:MrJamesPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-18</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_MeasurementInputFairValueMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">IGAP:MeasurementInputFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IGAP:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IGAP:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IGAP:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IGAP:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IGAP:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IGAP:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_IsraelTaxAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_AndrewGarrettIncMember_custom_AndrewSycoffMember_custom_PlacementAgentFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:AndrewSycoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IGAP:PlacementAgentFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IGAP:AndrewGarrettIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_AndrewGarrettIncMember_custom_AndrewSycoffMember_custom_PlacementAgentFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">IGAP:AndrewSycoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IGAP:PlacementAgentFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IGAP:AndrewGarrettIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Israel">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="Segments">
        <measure>IGAP:Segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-12-31">0001506983</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-01-01to2021-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-01-01to2021-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0056"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0059"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0203"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0204"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0205"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0209"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0223"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0224"
      unitRef="USD"
      xsi:nil="true"/>
    <IGAP:WarrantsIssuedAsConsiderationForPlacementServices
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0229"
      unitRef="USD"
      xsi:nil="true"/>
    <IGAP:WarrantsIssuedAsConsiderationForPlacementServices
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <IGAP:WarrantsIssuedAsConsiderationForPlacementServices
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0235"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryAdjustments
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl0640"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0675"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0677"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-01to2021-12-31"
      id="xdx2ixbrl0724"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:InventoryWriteDown
      contextRef="From2020-01-012020-12-31"
      id="xdx2ixbrl0745"
      unitRef="USD"
      xsi:nil="true"/>
    <IGAP:BadDebtExpense
      contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      id="xdx2ixbrl0786"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0820"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0821"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-01-01to2021-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2021-01-01to2021-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-01-01to2021-12-31">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-01-01to2021-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2021-01-01to2021-12-31">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2021-01-01to2021-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-01-01to2021-12-31">000-54785</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-01-01to2021-12-31">GLUCOTRACK, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-01-01to2021-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-01-01to2021-12-31">98-0668934</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-01-01to2021-12-31">8 Ariel Sharon Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-01-01to2021-12-31">P.O. Box 6037607</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-01-01to2021-12-31">Or Yehuda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2021-01-01to2021-12-31">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2021-01-01to2021-12-31">7760049</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-01-01to2021-12-31">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-01-01to2021-12-31">675-7878</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-01-01to2021-12-31">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2021-01-01to2021-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2021-01-01to2021-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2021-01-01to2021-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-01-01to2021-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-01-01to2021-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-01-01to2021-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2021-01-01to2021-12-31">false</dei:EntityShellCompany>
    <dei:Security12bTitle contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember">Common     Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember">GCTK</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityPublicFloat contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">32694000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-03-30" decimals="INF" unitRef="Shares">15455109</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2021-01-01to2021-12-31">None,
except as noted for Part III information in the Company&#x2019;s Schedule 14A to be filed on or before April 30, 2022.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="From2021-01-01to2021-12-31">1375</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2021-01-01to2021-12-31">FAHN KANNE &amp; CO. GRANT THORNTON ISRAEL</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2021-01-01to2021-12-31">Tel-Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6062000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">9823000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">66000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">284000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">43000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">56000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6105000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">10229000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">40000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">166000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">69000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">149000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">51000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">62000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6265000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">10606000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">631000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">869000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">23000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">84000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">229000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">392000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">883000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1345000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DueToOfficersOrStockholdersNoncurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">210000</us-gaap:DueToOfficersOrStockholdersNoncurrent>
    <us-gaap:DueToOfficersOrStockholdersNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">197000</us-gaap:DueToOfficersOrStockholdersNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">17000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">82000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">227000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">279000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1110000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1624000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">15452285</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">15452285</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">15444697</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">15444697</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">15000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">15000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">15000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">15000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">102612000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">102351000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">-6000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">15000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">-97466000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">-93399000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">5155000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">8982000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6265000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">10606000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">1810000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">1532000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">139000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">415000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">2091000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">1185000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">4040000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">3132000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-4040000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">-3132000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-53000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">338000</us-gaap:OtherNonoperatingIncomeExpense>
    <IGAP:FinancingIncomeExpenseNet
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">26000</IGAP:FinancingIncomeExpenseNet>
    <IGAP:FinancingIncomeExpenseNet
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">98000</IGAP:FinancingIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-4067000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">-2696000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-21000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">-109000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-4088000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">-2805000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="Shares">15450824000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="Shares">15079182000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12450649</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">89155000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-90703000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">-1412000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-2696000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">-2696000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-109000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">-109000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">22000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">22000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2884615</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">12250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">12253000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <IGAP:WarrantsIssuedAsConsiderationForPlacementServices
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">756000</IGAP:WarrantsIssuedAsConsiderationForPlacementServices>
    <IGAP:WarrantsIssuedAsConsiderationForPlacementServices
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">756000</IGAP:WarrantsIssuedAsConsiderationForPlacementServices>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">109433</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">168000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">168000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15444697</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">102351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-93399000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">8982000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15444697</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">102351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-93399000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">8982000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15444697</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">102351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-93399000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">8982000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-4067000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-4067000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-21000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-21000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">223000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">223000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">7588</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">38000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">38000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15452285</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">102612000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-97466000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">5155000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15452285</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">102612000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-97466000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">5155000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-4067000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">-2696000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">42000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">47000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-42000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">223000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">22000</us-gaap:ShareBasedCompensation>
    <IGAP:IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">38000</IGAP:IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors>
    <IGAP:IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">168000</IGAP:IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors>
    <IGAP:LinkageDifferenceOnPrincipalOfLoansFromStockholders
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">6000</IGAP:LinkageDifferenceOnPrincipalOfLoansFromStockholders>
    <IGAP:LinkageDifferenceOnPrincipalOfLoansFromStockholders
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">-8000</IGAP:LinkageDifferenceOnPrincipalOfLoansFromStockholders>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-68000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">-10000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-293000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">85000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-15000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">9000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-257000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">-714000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-172000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">-236000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-3769000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">-3501000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">4000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">5000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">53000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-1000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">-53000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">13009000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">13009000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-2000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">-46000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">-3772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">9409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">9885000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">476000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6113000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">9885000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <IGAP:NumberOfCommonStockIssuedForSettlementOfFees
      contextRef="From2021-01-012021-12-31_custom_BoardOfMembersMember"
      decimals="-3"
      unitRef="USD">38000</IGAP:NumberOfCommonStockIssuedForSettlementOfFees>
    <IGAP:NumberOfCommonStockIssuedForSettlementOfFees
      contextRef="From2020-01-012020-12-31_custom_BoardOfMembersMember"
      decimals="-3"
      unitRef="USD">168000</IGAP:NumberOfCommonStockIssuedForSettlementOfFees>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">756000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zeoMebonz0R8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 1 &#x2013;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_824_zQgOjzDROmtf"&gt;GENERAL&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GlucoTrack
    Inc (Formerly: Integrity Applications, Inc.) (the &#x201c;Company&#x201d;) was incorporated on May 18, 2010 under the laws of
    the State of Delaware. On July 15, 2010, GlucoTrack Acquisition Corp. Ltd. (hereinafter: &#x201c;Integrity Acquisition&#x201d;), a
    wholly owned Israeli subsidiary of the Company, which was established on May 23, 2010, completed a merger with A.D. Integrity Applications
    Ltd. (hereinafter: &#x201c;Integrity Israel&#x201d;), an Israeli corporation that was previously held by the stockholders of the Company.
    Pursuant to the merger, all equity holders of Integrity Israel received the same proportional ownership in the Company as they had
    in Integrity Israel prior to the merger. Following the merger, Integrity Israel remained a wholly-owned subsidiary of the Company.
    As the merger transaction constituted a structural reorganization, the merger has been accounted for at historical cost in a manner
    similar to a pooling of interests. Integrity Israel was incorporated in 2001 and commenced its operations in 2002 (The Company
    and Integrity Israel are referred as the &#x201c;Group&#x201d;) Integrity Israel, a medical device company, focuses on the design,
    development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Since its incorporation,
    the Company did not conduct any material operations other than those carried out by Integrity Israel. The development and commercialization
    of Integrity Israel&#x2019;s product is expected to require substantial expenditures. Integrity Israel and the Company (collectively,
    the &#x201c;Group&#x201d;) have not yet generated significant revenues from operations, and therefore they are dependent upon external
    sources for financing their operations. As of December 31, 2021, the Group has incurred accumulated deficit of $&lt;span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20211231_z44uHmdWrmD5"&gt;97,466
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand, and negative operating cash flows.
    As of December 31, 2021, the Company had $&lt;span id="xdx_905_eus-gaap--Cash_iI_c20211231_zROskKYjTqS3"&gt;6,062&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand
    &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in cash, which is sufficient to meet its capital
    needs for fiscal 2022 and for at least 12 months from the date of issuance of these financial statements, thus it is expected that
    the company will be able to operate as a going concern for at least 12 months from the date hereof. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;On December 8, 2021, we announced that our shares of common stock were approved for listing on the Nasdaq Capital Market (&#x201c;NASDAQ&#x201d;). Trading on NASDAQ commenced on December 10, 2021 under its existing trading symbol, IGAP.&lt;/p&gt;
                                                                              &lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;On March 14, 2022, we announced that it has completed its corporate name and ticker symbol change on
the Nasdaq Capital Market (from IGAP to GCTK), to be effective at the commencement of trading on March 14, 2022.&lt;/p&gt;

&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;In connection with its application to list its shares on Nasdaq Capital Market (&#x201c;NASDAQ&#x201d;), as detailed above, on August 13, 2021, the Company
    effected a reverse split of its Common Stock in a ratio of &lt;span id="xdx_90C_eus-gaap--StockholdersEquityReverseStockSplit_c20210811__20210813_z4gwqNKXxOCb" title="Stockholders' Equity, Reverse Stock Split"&gt;1 for 13&lt;/span&gt; (the &#x201c;Reverse Share Split&#x201d;). For accounting purposes,
    all Shares, options and warrants to purchase Common Stock and loss per share amounts have been adjusted to give retroactive effect
    to this Reverse Share Split for all periods presented in these consolidated financial statements. Any fractional shares resulting
    from the Reverse Share Split were rounded up to the nearest whole share.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;B.&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Liquidity and capital resources&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"/&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Since
its inception date, the Company did not conduct any material operations other than those carried out by Integrity Israel. The development
and commercialization of the Product is expected to require substantial expenditures. The Group has not yet generated significant revenues
from operations, and therefore they are dependent upon external sources for financing their operations. As of December 31, 2021, the
Group has incurred accumulated deficit of $&lt;span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20211231_zf5PUvewJyO3"&gt;97,466&lt;/span&gt; thousand. During the year ended December 31, 2021 the Company incurred losses from
ongoing operation and has negative cash flow from operating activity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 14, 2020, the Company closed on a
$&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20200213__20200214__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zKhk6IOqC86a" title="Private placement of common stock"&gt;15&lt;/span&gt;&#160;million private placement of its common stock, for which it received net cash in excess of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20200213__20200214__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zw68En5p8nbg"&gt;13,009&lt;/span&gt;&#160;thousand. In addition,
on September 27, 2021, the Company&#x2019;s shelf registration statement on Form S-3 was declared effective by the Securities and Exchange
Commission (SEC) which permits the Company to register up to $&lt;span id="xdx_904_eus-gaap--DebtSecurities_iI_pn3n3_c20200214__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z54tJQVgsUkb"&gt;100,000&lt;/span&gt; thousand of certain equity and debt securities of the Company via
prospectus supplement. To date, funds have not been raised through this shelf registration statement&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;The management believes the cash balance amounted to $&lt;span id="xdx_900_eus-gaap--Cash_iI_pn3n3_c20211231_zF0g2rsB2lU1" title="Cash"&gt;6,062&lt;/span&gt; thousand as of December 31, 2021, is sufficient to
meet its capital needs of the Group for at least 12 months from the issuance date of these consolidated financial statements. Thus, it
is expected that the Company will be able to operate as a going concern for at least 12 months from the date hereof.&lt;/p&gt;

&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 1 &#x2013;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GENERAL (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Effect
    of the spread of the Coronavirus on the Company&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    December 2019, the Covid-19 epidemic erupted in China (hereinafter - the &#x201c;Corona Virus&#x201d;, the &#x201c;Event&#x201d; or the
    &#x201c;Crisis&#x201d;) and at the beginning of 2020, it spread to additional countries across the globe. In January 2020, the World
    Health Organization declared the outbreak of Corona as a global health emergency and in March 2020, it declared the Corona virus
    to be a global pandemic. The spreading of the Corona Virus is an extraordinary macroeconomic event in many countries worldwide. As
    a result of the event, many countries, including Israel, have taken significant steps in an attempt to stem the spreading of the
    virus. These steps include, inter alia, restriction of civilian movement and employment, closure of businesses and malls, restrictions
    of gatherings and events, restriction of the transportation of people and goods, closure of international border crossings, reduction
    in the number of employees permitted to come to their workplaces, etc. The event and the steps being taken by the various countries,
    as mentioned above, have had a significant impact on many global and local economies as well as on global capital markets, characterized
    by sharp decreases and extreme volatility in the prices of many securities. In addition, there is an ever-increasing risk of a market
    recession.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    a result of the COVID-19 pandemic, as near-term measures, the Company has transitioned some of its employees to remote
    working arrangements. which has had no material impact on the Company&#x2019;s operations. Due to the uncertainty of
    COVID-19, the Company will continue to assess the situation, including abiding by any government-imposed restrictions, market
    by market.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">-97466000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:Cash contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6062000</us-gaap:Cash>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2021-08-112021-08-13">1 for 13</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">-97466000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2020-02-132020-02-14_us-gaap_PrivatePlacementMember"
      decimals="-5"
      unitRef="USD">15000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-02-132020-02-14_us-gaap_PrivatePlacementMember"
      decimals="-3"
      unitRef="USD">13009000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DebtSecurities
      contextRef="AsOf2020-02-14_us-gaap_PrivatePlacementMember"
      decimals="-3"
      unitRef="USD">100000000</us-gaap:DebtSecurities>
    <us-gaap:Cash contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6062000</us-gaap:Cash>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_807_eus-gaap--SignificantAccountingPoliciesTextBlock_z1BKyx44ItVb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2013;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82E_zVso9ItbFJ2e"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States
    of America (US GAAP).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--UseOfEstimates_ziKlARtDDxOa" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&#160;&#160;&lt;span id="xdx_862_zEWBiyXPFVmg"&gt;Use of estimates in the preparation of financial statements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                                         preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States
                                                         (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and
                                                         liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the
                                                         reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As
                                                         applicable to the consolidated financial statements, the most significant estimates and assumptions relate to the going concern
                                                         assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
  &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td&gt;&lt;span id="xdx_863_ztnpQCdFXv9d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Functional currency&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    functional currency of the Company is the US dollar, which is the currency of the primary economic environment in which it operates.
    In accordance with ASC 830, &#x201c;Foreign Currency Matters&#x201d; (ASC 830), balances denominated in or linked to foreign currency
    are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions
    included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses
    arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses.
    The functional currency of Integrity Israel is the New Israeli Shekel (&#x201c;NIS&#x201d;) and its financial statements are included
    in consolidation, based on translation into US dollars. Accordingly, assets and liabilities were translated from NIS to US dollars
    using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or
    losses resulting from translation adjustments are reflected in stockholders&#x2019; equity, under &#x201c;accumulated other
    comprehensive income (loss)&#x201d;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_897_eus-gaap--ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_z1sWopOdwVWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="text-transform: uppercase"&gt;&lt;span id="xdx_8BA_z28uggO1Vjtd" style="display: none"&gt;SCHEDULE
OF OFFICIAL EXCHANGE RATE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; float: left; border-collapse: collapse; width: 87%; margin-left: 1in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Official exchange rate of NIS 1 to US dollar&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--AverageForeignCurrencyExchangeRateTranslation_pid_uPure_c20210101__20211231_znrsJigW8zN9" title="Official exchange rate of NIS 1 to US dollar"&gt;0.321&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_ecustom--AverageForeignCurrencyExchangeRateTranslation_pid_uPure_c20200101__20201231_zfN93fVY2Di6" title="Official exchange rate of NIS 1 to US dollar"&gt;0.311&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Increase (decrease) of the official exchange rate of NIS 1 to US dollar during
    the year:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage_pid_dp_uPure_c20210101__20211231_zYT7ZqLx3uid" title="Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2021"&gt;3.22&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo_pid_dp_uPure_c20210101__20211231_zRqPDmfBAOg5" title="Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2020"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p id="xdx_8A7_zyM3csyKUrU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2013;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_z2phvkjRX7Fg" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"/&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.
&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_862_zRzDn3jIhzna" style="font-family: Times New Roman, Times, Serif"&gt;Principles
    of consolidation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions
    have been eliminated in consolidation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zFIoQm3Vw01f" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.
&#160;&#160;&#160;&lt;span id="xdx_86E_z8UwjAFbWYIc"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less
    at the date of purchase, to be cash equivalents.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zr59NmoMCee3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E.
&#160;&#160;&#160;&#160;&lt;span id="xdx_864_zOgYx08MLb5l"&gt;Inventories&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
    are stated at the lower of cost or net realizable value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost
    is determined as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
    respect to raw materials, the Group calculates cost using the average cost method.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
    respect to work in process and finished products, the Group calculates the cost on the basis of the average direct manufacturing
    costs, including materials, labor, subcontracting costs and other direct manufacturing costs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management evaluated
                                                         periodically whether inventory is required to be written-down due to slow-moving or obsolete items and recognize
                                                         inventory impairment, as applicable
..&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zBem59oZXABa" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;F.
&#160;&#160;&#160;&#160;&lt;span id="xdx_86D_zOiwGzfYuAWl"&gt;Property and equipment, net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 96px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
    and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over
    the estimated useful lives of the assets. When an asset is retired or otherwise disposed of, the related carrying value and accumulated
    depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected
    in the statements of operations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rates
    of depreciation:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_897_ecustom--ScheduleOfPropertyRatesOfDepreciationTableTextBlock_zDE5uvUBGOJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="text-transform: uppercase"&gt;&lt;span id="xdx_8B7_z9HqlgAfPPq2" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; width: 70%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 70%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computers&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_zNsi2Hf6ZZ9" title="Property plant and equipment depreciation rate"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zyefZsav84we" title="Property plant and equipment depreciation rate"&gt;7&lt;/span&gt;-&lt;span id="xdx_90F_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zWQ5zTaFrD62" title="Property plant and equipment depreciation rate"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zaCfxQEeQjR7" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Estimated useful life"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shorter
    of lease term &lt;br/&gt;
    and 10 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zrshgJhPm0e3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ze82Gzge5Av3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;G.
&#160;&#160;&#160;&lt;span id="xdx_862_zIFCa5yk36p"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group&#x2019;s long-lived assets are reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant and Equipment&#x201d;,
    whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability
    of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows
    expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by
    the amount by which the carrying amount of the asset exceeds its fair value. To date the Group did not incur any material impairment
    losses related to long lived assets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2013;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zhsaGHsnbdFg" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;H.
&#160;&#160;&#160;&lt;span id="xdx_86F_zCStbuEbnwma"&gt;Restricted cash&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
                                            cash is invested in certificates of deposit, which are used to secure Integrity Israel&#x2019;s
                                            obligations in respect of its headquarters lease and credit card (See also Note 8B).&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
    presentation of statement of cash flows purposes, restrict cash balances are included with cash and cash equivalents, when reconciling
    the reported period total amounts.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_899_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zx2RjUoNBbvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="display: none; text-transform: uppercase"&gt;SCHEDULE
OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20211231_z0KKbVEHNyc3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20201231_zvJCzkll1hz1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In thousand of US dollars&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzao3_z16YpaGo1Qh1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;9,823&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RestrictedCash_iI_pn3n3_maCCERCzao3_zPyLjxmhuVOb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzao3_zsG11z4lis63" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,113&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,885&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zILf7TSGrnh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z3ySOspGUR39" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;I.
&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_86B_zYL7iQmDU1K1"&gt;Income tax&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d;. Accordingly, deferred income taxes are determined
    utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting
    and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax
    rates expected to be in effect when these differences reverse. Valuation allowances in respect of deferred tax assets are provided
    for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial
    statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise&#x2019;s financial statements.
    According to ASC Topic 740-10, tax positions must meet a more- likely-than-not recognition threshold. The Group&#x2019;s accounting
    policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Group did not recognize
    such items in its fiscal 2021 and 2020 financial statements and did not recognize any liability with respect to unrecognized tax
    position in its balance sheet.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_zXrcacv4Rm95" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;J.
&#160;&#160;&#160;&#160;&lt;span id="xdx_86B_zxZD9iX9mnw5"&gt;Liability for employee rights upon retirement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Integrity
    Israel&#x2019;s liability for employee rights upon retirement with respect to its Israeli employees is calculated pursuant to the
    Israeli Severance Pay Law, based on the most recent salary of each employee multiplied by the number of years of employment of each
    such employee as of the balance sheet date. Employees are entitled to one month&#x2019;s salary for each year of employment, or ratable
    portion thereof for periods less than one year. Integrity Israel makes monthly deposits to insurance policies and severance pay funds.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    deposited funds may be withdrawn upon the fulfillment of Integrity Israel&#x2019;s severance obligations pursuant to Israeli severance
    pay laws or labor agreements with its employees. The value of the deposited funds is based on the cash surrender value of these policies,
    and includes immaterial profits or losses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commencing
    in 2011, Integrity Israel&#x2019;s agreements with its Israeli employees are in accordance with Section 14 of the Severance Pay Law.
    Payments in accordance with Section 14 release the employer from any future severance payments in respect of those employees. Related
    obligations and liabilities under Section 14 are not recorded as an asset or as a liability in the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    year ended December 31, 2021, and 2020, severance expenses amounted to $&lt;span id="xdx_90F_eus-gaap--SeveranceCosts1_pn3n3_c20210101__20211231_zY7fX3k5BpIb" title="Severance expenses"&gt;43&lt;/span&gt;
    and $&lt;span id="xdx_902_eus-gaap--SeveranceCosts1_pn3n3_c20200101__20201231_zEO4WrqohWq1" title="Severance expenses"&gt;24 &lt;/span&gt; thousand,
    respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2013;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zirsgiEM0ulf" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;K.
&#160;&#160;&#160;&lt;span id="xdx_868_zpXQro7zIyQ3"&gt;Research and development expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--RoyaltyBearingGrantsPolicyTextBlock_z8sKHmrDPlp6" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;L.
&#160;&#160;&#160;&lt;span id="xdx_862_zwtYQaEmhRE1"&gt;Royalty-bearing grant&lt;/span&gt;s&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Royalty-bearing
grants from the Israeli Innovation Authority (IIA) to fund approved research and development projects are recognized at the time
Integrity Israel is entitled to such grants, on the basis of the costs incurred and reduce research and development costs. To date,
the cumulative research and development grants received by Integrity Israel from amounted to $&lt;span id="xdx_900_ecustom--CumulativeResearchAndDevelopment_pn3n3_c20210101__20211231_zFrVLd4EqThb" title="Cumulative research and development"&gt;93&lt;/span&gt; thousand.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--StandardProductWarrantyPolicy_zvlibdTueNw9" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;M.
&#160;&#160;&lt;span id="xdx_865_zaFGQFrnS42l"&gt;Warranty&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group provides a 24-month warranty for its products at no cost. The group estimates the costs that may be incurred during
    the warranty period and records a liability for the amounts of such costs at the time revenues are recognized. For the year ended
    December 31, 2021 and 2020 warranty expenses were clearly insignificant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_z4dUfCu8MIal" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;N.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&#160;&#160;&lt;span id="xdx_861_zHwZZ6eGcibe"&gt;Basic and diluted loss per share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic loss per share is computed by dividing the loss for the period applicable
for Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon
    the exercise of options or warrants issued or granted using the &#x201c;treasury stock method&#x201d;, if the effect of each of such
    financial instruments is dilutive.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;In computing diluted loss per share, the average stock price for the
    period is used in determining the number of common stock assumed to be purchased from the exercise of stock options or stock warrants.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Shares that will be issued upon exercise of all stock
    options and stock warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods
    for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these
    instruments was anti-dilutive&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;An amount of &lt;span id="xdx_90F_ecustom--NumberOfStockOptionsExcluded_c20210101__20211231_zOt36ZugXE08" title="Number of stock options excluded"&gt;6,404,238&lt;/span&gt; and &lt;span id="xdx_904_ecustom--NumberOfStockWarrantsExcluded_c20210101__20211231_z3TLRD8mnoWk" title="Number of stock warrants excluded"&gt;6,446,920&lt;/span&gt; outstanding stock
    options and stock warrants have been excluded from the calculation of the diluted net loss per share for the years ended December
    31, 2021 and 2020, respectively, because the effect of the common shares issuable as a result of the exercise of such instruments
    was determined to be anti-dilutive.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zhK42UAblaGb" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;O.
&#160;&#160;&#160;&lt;span id="xdx_863_zgLyhfyW8zsa"&gt;Stock-based compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values
    in accordance with ASC 718, &#x201c;Compensation-Stock Compensation&#x201d;. Share-based payments including grants of stock options
    are recognized in the statement of operations as an operating expense based on the fair value of the award at the date of grant.
    The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Group has expensed compensation
    costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit
    service period when a performance condition affects the vesting, and it is considered probable that the performance condition will
    be achieved.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commencing
    January 1, 2019, following the adoption of ASU 2018-07, which aligns the measurement and classification guidance for share-based
    payments to nonemployees with the guidance for share-based payments to employees (with certain exceptions), share-based payments
    to non-employees are accounted in accordance with ASC 718.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2013;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zeCThVgBkQi2" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;P.
&#160;&#160;&#160;&lt;span id="xdx_86A_z0MkNh8cKSO3"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
    Topic 825-10, &#x201c;Financial Instruments&#x201d; defines financial instruments and requires disclosure of the fair value of financial
    instruments held by the Group. The Group considers the carrying amount of cash and cash equivalents, restricted cash, accounts receivable,
    other current assets, accounts payable and other current liabilities balances, to approximate their fair values due to the short-term
    maturities of such financial instruments. ASC Topic 825-10, establishes the following fair value hierarchy, which prioritizes the
    inputs used in the valuation methodologies in measuring fair value:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair
    value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 - Unobservable inputs are used when little or no market data is available. Level 3 inputs are considered as the lowest priority
    under the fair value hierarchy.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group did not estimate the fair value of the  loans from stockholders since their repayment schedule has not yet been determined.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zjGnLFw00Rp1" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Q.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&#160;&#160;&lt;span id="xdx_86C_zCHn20XqlR39"&gt;Concentrations of credit risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
    instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash and cash equivalents, and
    restricted cash. Cash and cash equivalents and restricted cash are deposited with major banks in Israel and the United States of
    America. Management believes that such financial institutions are financially sound, accordingly, minimal credit risk exists with
    respect to these financial instruments. The Group does not have any significant off-balance-sheet concentration of credit risk, such
    as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zay9jLDrdGd6" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;R.
&#160;&#160;&#160;&lt;span id="xdx_867_zuq6SO3iGgmh"&gt;Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability
    has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional
    information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2013;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--DerivativesPolicyTextBlock_zShPDLLDHhh5" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;S.
&#160;&#160;&#160;&#160;&lt;span id="xdx_86C_zpnCZhkuvNI4"&gt;Warrants with Down-Round Protection&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
    the application of Accounting Standard Update (ASU) No. 2017-11, &#x201c;Earnings Per Share&#x201d; (ASU 2017-11), the Company disregard
    the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or
    equity classification. Based on its evaluation, management has determined that such warrants with Down-Round Protection are eligible
    for equity classification.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    accordance with the provisions of ASU 2017-11, upon the occurrence of an event that triggers a down round protection (i.e., when
    the exercise price of the warrants is adjusted downward because of the down round feature), the effect is accounted for as a deemed
    dividend and as a reduction of income available to common shareholders for purposes of basic earnings per share (EPS) calculation.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--ModificationOfEquityclassifiedContractsPolicyTextBlock_zXJeETtbbN6i" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;T.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&#160;&#160;&lt;span id="xdx_86A_ziJkWwfyEW19"&gt;Modification of equity-classified contracts&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification
    or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification
    of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value
    of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase
    of accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified
    share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment
    to earnings available to common shareholders for purposes of calculating earnings per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_z7eoZqo6Uc0d" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;U.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&#160;&#160;&lt;span id="xdx_86B_zp8JaOuYjnM2"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;The allowance for doubtful accounts is determined with
    respect to amounts the Company has determined to be doubtful of collection, in order to reflect the expected credit losses on accounts
    receivable balances. Judgment is required in the estimation of the allowance for doubtful accounts and the Company evaluates the
    collectability of its accounts receivable based on a combination of factors (including, among other things, the length of time that
    the balance is past due and the customer&#x2019;s current ability to pay. If it&#x2019;s becomes aware of a customer&#x2019;s inability to meet
    its financial obligations, an allowance is recorded to reduce the net receivable to the amount reasonably believed to be collectible
    from such customer&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_845_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zYlRL3q7WdYf" style="margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;b&gt;V.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zMkUXWRi3xs9"&gt;Operating Lease&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company entered into several non-cancelable lease agreements for vehicles for use in its operations, which are classified as operating
    leases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commencing
    January 1, 2019, the Company applies ASC Update 2016-02, Leases (Topic 842).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company determines if an arrangement is a lease at inception. Under the new guidance, arrangements meeting the definition of a lease
    are classified as operating or financing leases. A classification of a lease is determined based on the following criteria:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 96px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    lease transfers ownership of the underlying asset to the lessee by the end of the lease term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    lease term is for the major part of the remaining economic life of the underlying asset (Generally, 75% or more of the remaining
    economic life of the underlying assets).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    present value of the sum of the lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all
    of the fair value of the underlying asset (Generally, 90% or more of the fair value of the underlying asset).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease
    term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
any of these five criteria is met, the lease is classified as a finance lease. Otherwise, the lease is classified as an operating lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
are recorded on the consolidated balance sheet as both a right of use asset and a lease liability, calculated by discounting fixed lease
payments over the lease term at the rate implicit in the lease or the Company&#x2019;s incremental borrowing rate. Lease liabilities are
increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating
leases, interest on the lease liability and the amortization of the right of use asset results in straight-line rent expense over the
lease term. Variable lease expenses, if any, are recorded when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also elected the short-term lease recognition exemption for all leases that qualify (leases with a term shorter than &lt;span id="xdx_907_eus-gaap--LessorOperatingLeaseTermOfContract_iI_dtM_c20190102_zT2oUyH9Lhek" title="Lessor, Operating Lease, Term of Contract"&gt;12&lt;/span&gt; months).
For those leases, right-of-use assets or lease liabilities are not recognized and rent expense is recognized on a straight-line basis
over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had no material capital leases throughout the reporting periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
note 4 for further discussion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2013;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zMFGQ4NQ6qF8" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;W.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&#160;&#160;&#160;&lt;span id="xdx_86A_zHQvnAq3pgAf"&gt;Reclassification&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
    comparative figures have been reclassified to conform to the current year presentation. Such reclassifications did not have any significant
    impact on the Company&#x2019;s equity, net income or cash flows.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zegEC1G2JUS5" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;b&gt;&lt;span id="xdx_868_zXTHdpqWn82"&gt;X. &#160;&#160;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU 2016-13, &#x201c;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments&#x201d; (&#x201c;ASU 2016-13&#x201d;), which changes the impairment model for most financial assets and certain other instruments.
For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities will be required to use a new
forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. The
guidance also requires increased disclosures. For the Company, the amendments in the update were originally effective for fiscal years
beginning after December 15, 2019, including interim periods within those fiscal years. In November 2019, the FASB issued ASU No. 2019-10,
which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined by the SEC) and other non-SEC reporting entities
to fiscal years beginning after December 15, 2022, including interim periods within those fiscal periods. Early adoption is permitted.
&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As the company
is eligible to considered as smaller reporting company ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including
interim periods within those fiscal years. The adoption of this standard is not expected to result in a material impact to the Company&#x2019;s
financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_841_eus-gaap--UseOfEstimates_ziKlARtDDxOa" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&#160;&#160;&lt;span id="xdx_862_zEWBiyXPFVmg"&gt;Use of estimates in the preparation of financial statements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                                         preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States
                                                         (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and
                                                         liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the
                                                         reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As
                                                         applicable to the consolidated financial statements, the most significant estimates and assumptions relate to the going concern
                                                         assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
  &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td&gt;&lt;span id="xdx_863_ztnpQCdFXv9d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Functional currency&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    functional currency of the Company is the US dollar, which is the currency of the primary economic environment in which it operates.
    In accordance with ASC 830, &#x201c;Foreign Currency Matters&#x201d; (ASC 830), balances denominated in or linked to foreign currency
    are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions
    included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses
    arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses.
    The functional currency of Integrity Israel is the New Israeli Shekel (&#x201c;NIS&#x201d;) and its financial statements are included
    in consolidation, based on translation into US dollars. Accordingly, assets and liabilities were translated from NIS to US dollars
    using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or
    losses resulting from translation adjustments are reflected in stockholders&#x2019; equity, under &#x201c;accumulated other
    comprehensive income (loss)&#x201d;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_897_eus-gaap--ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_z1sWopOdwVWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="text-transform: uppercase"&gt;&lt;span id="xdx_8BA_z28uggO1Vjtd" style="display: none"&gt;SCHEDULE
OF OFFICIAL EXCHANGE RATE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; float: left; border-collapse: collapse; width: 87%; margin-left: 1in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Official exchange rate of NIS 1 to US dollar&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--AverageForeignCurrencyExchangeRateTranslation_pid_uPure_c20210101__20211231_znrsJigW8zN9" title="Official exchange rate of NIS 1 to US dollar"&gt;0.321&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_ecustom--AverageForeignCurrencyExchangeRateTranslation_pid_uPure_c20200101__20201231_zfN93fVY2Di6" title="Official exchange rate of NIS 1 to US dollar"&gt;0.311&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Increase (decrease) of the official exchange rate of NIS 1 to US dollar during
    the year:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage_pid_dp_uPure_c20210101__20211231_zYT7ZqLx3uid" title="Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2021"&gt;3.22&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo_pid_dp_uPure_c20210101__20211231_zRqPDmfBAOg5" title="Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2020"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p id="xdx_8A7_zyM3csyKUrU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2013;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_897_eus-gaap--ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_z1sWopOdwVWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="text-transform: uppercase"&gt;&lt;span id="xdx_8BA_z28uggO1Vjtd" style="display: none"&gt;SCHEDULE
OF OFFICIAL EXCHANGE RATE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; float: left; border-collapse: collapse; width: 87%; margin-left: 1in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Official exchange rate of NIS 1 to US dollar&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--AverageForeignCurrencyExchangeRateTranslation_pid_uPure_c20210101__20211231_znrsJigW8zN9" title="Official exchange rate of NIS 1 to US dollar"&gt;0.321&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_ecustom--AverageForeignCurrencyExchangeRateTranslation_pid_uPure_c20200101__20201231_zfN93fVY2Di6" title="Official exchange rate of NIS 1 to US dollar"&gt;0.311&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Increase (decrease) of the official exchange rate of NIS 1 to US dollar during
    the year:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage_pid_dp_uPure_c20210101__20211231_zYT7ZqLx3uid" title="Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2021"&gt;3.22&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo_pid_dp_uPure_c20210101__20211231_zRqPDmfBAOg5" title="Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2020"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock>
    <IGAP:AverageForeignCurrencyExchangeRateTranslation
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0.321</IGAP:AverageForeignCurrencyExchangeRateTranslation>
    <IGAP:AverageForeignCurrencyExchangeRateTranslation
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="Pure">0.311</IGAP:AverageForeignCurrencyExchangeRateTranslation>
    <IGAP:IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0.0322</IGAP:IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage>
    <IGAP:IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0.072</IGAP:IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_z2phvkjRX7Fg" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"/&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.
&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_862_zRzDn3jIhzna" style="font-family: Times New Roman, Times, Serif"&gt;Principles
    of consolidation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions
    have been eliminated in consolidation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zFIoQm3Vw01f" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.
&#160;&#160;&#160;&lt;span id="xdx_86E_z8UwjAFbWYIc"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less
    at the date of purchase, to be cash equivalents.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zr59NmoMCee3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E.
&#160;&#160;&#160;&#160;&lt;span id="xdx_864_zOgYx08MLb5l"&gt;Inventories&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
    are stated at the lower of cost or net realizable value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost
    is determined as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
    respect to raw materials, the Group calculates cost using the average cost method.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
    respect to work in process and finished products, the Group calculates the cost on the basis of the average direct manufacturing
    costs, including materials, labor, subcontracting costs and other direct manufacturing costs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management evaluated
                                                         periodically whether inventory is required to be written-down due to slow-moving or obsolete items and recognize
                                                         inventory impairment, as applicable
..&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zBem59oZXABa" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;F.
&#160;&#160;&#160;&#160;&lt;span id="xdx_86D_zOiwGzfYuAWl"&gt;Property and equipment, net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 96px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
    and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over
    the estimated useful lives of the assets. When an asset is retired or otherwise disposed of, the related carrying value and accumulated
    depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected
    in the statements of operations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rates
    of depreciation:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_897_ecustom--ScheduleOfPropertyRatesOfDepreciationTableTextBlock_zDE5uvUBGOJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="text-transform: uppercase"&gt;&lt;span id="xdx_8B7_z9HqlgAfPPq2" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; width: 70%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 70%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computers&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_zNsi2Hf6ZZ9" title="Property plant and equipment depreciation rate"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zyefZsav84we" title="Property plant and equipment depreciation rate"&gt;7&lt;/span&gt;-&lt;span id="xdx_90F_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zWQ5zTaFrD62" title="Property plant and equipment depreciation rate"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zaCfxQEeQjR7" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Estimated useful life"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shorter
    of lease term &lt;br/&gt;
    and 10 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zrshgJhPm0e3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <IGAP:ScheduleOfPropertyRatesOfDepreciationTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_897_ecustom--ScheduleOfPropertyRatesOfDepreciationTableTextBlock_zDE5uvUBGOJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="text-transform: uppercase"&gt;&lt;span id="xdx_8B7_z9HqlgAfPPq2" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; width: 70%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 70%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computers&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_zNsi2Hf6ZZ9" title="Property plant and equipment depreciation rate"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zyefZsav84we" title="Property plant and equipment depreciation rate"&gt;7&lt;/span&gt;-&lt;span id="xdx_90F_ecustom--PropertyPlantAndEquipmentDepreciationRate_pid_dp_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zWQ5zTaFrD62" title="Property plant and equipment depreciation rate"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zaCfxQEeQjR7" style="font: 10pt Times New Roman, Times, Serif; text-align: center" title="Estimated useful life"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shorter
    of lease term &lt;br/&gt;
    and 10 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</IGAP:ScheduleOfPropertyRatesOfDepreciationTableTextBlock>
    <IGAP:PropertyPlantAndEquipmentDepreciationRate
      contextRef="From2021-01-012021-12-31_custom_ComputersMember"
      decimals="INF"
      unitRef="Pure">0.33</IGAP:PropertyPlantAndEquipmentDepreciationRate>
    <IGAP:PropertyPlantAndEquipmentDepreciationRate
      contextRef="From2021-01-012021-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.07</IGAP:PropertyPlantAndEquipmentDepreciationRate>
    <IGAP:PropertyPlantAndEquipmentDepreciationRate
      contextRef="From2021-01-012021-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.15</IGAP:PropertyPlantAndEquipmentDepreciationRate>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="From2021-01-012021-12-31_us-gaap_LeaseholdImprovementsMember">Shorter
    of lease term
    and 10 years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ze82Gzge5Av3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;G.
&#160;&#160;&#160;&lt;span id="xdx_862_zIFCa5yk36p"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group&#x2019;s long-lived assets are reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant and Equipment&#x201d;,
    whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability
    of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows
    expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by
    the amount by which the carrying amount of the asset exceeds its fair value. To date the Group did not incur any material impairment
    losses related to long lived assets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2013;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zhsaGHsnbdFg" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;H.
&#160;&#160;&#160;&lt;span id="xdx_86F_zCStbuEbnwma"&gt;Restricted cash&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
                                            cash is invested in certificates of deposit, which are used to secure Integrity Israel&#x2019;s
                                            obligations in respect of its headquarters lease and credit card (See also Note 8B).&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
    presentation of statement of cash flows purposes, restrict cash balances are included with cash and cash equivalents, when reconciling
    the reported period total amounts.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_899_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zx2RjUoNBbvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="display: none; text-transform: uppercase"&gt;SCHEDULE
OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20211231_z0KKbVEHNyc3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20201231_zvJCzkll1hz1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In thousand of US dollars&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzao3_z16YpaGo1Qh1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;9,823&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RestrictedCash_iI_pn3n3_maCCERCzao3_zPyLjxmhuVOb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzao3_zsG11z4lis63" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,113&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,885&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zILf7TSGrnh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zx2RjUoNBbvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="display: none; text-transform: uppercase"&gt;SCHEDULE
OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20211231_z0KKbVEHNyc3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20201231_zvJCzkll1hz1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In thousand of US dollars&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzao3_z16YpaGo1Qh1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;9,823&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RestrictedCash_iI_pn3n3_maCCERCzao3_zPyLjxmhuVOb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzao3_zsG11z4lis63" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,113&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,885&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6062000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">9823000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">51000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">62000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6113000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">9885000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_z3ySOspGUR39" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;I.
&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_86B_zYL7iQmDU1K1"&gt;Income tax&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d;. Accordingly, deferred income taxes are determined
    utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting
    and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax
    rates expected to be in effect when these differences reverse. Valuation allowances in respect of deferred tax assets are provided
    for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial
    statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise&#x2019;s financial statements.
    According to ASC Topic 740-10, tax positions must meet a more- likely-than-not recognition threshold. The Group&#x2019;s accounting
    policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Group did not recognize
    such items in its fiscal 2021 and 2020 financial statements and did not recognize any liability with respect to unrecognized tax
    position in its balance sheet.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84F_eus-gaap--PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_zXrcacv4Rm95" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;J.
&#160;&#160;&#160;&#160;&lt;span id="xdx_86B_zxZD9iX9mnw5"&gt;Liability for employee rights upon retirement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Integrity
    Israel&#x2019;s liability for employee rights upon retirement with respect to its Israeli employees is calculated pursuant to the
    Israeli Severance Pay Law, based on the most recent salary of each employee multiplied by the number of years of employment of each
    such employee as of the balance sheet date. Employees are entitled to one month&#x2019;s salary for each year of employment, or ratable
    portion thereof for periods less than one year. Integrity Israel makes monthly deposits to insurance policies and severance pay funds.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    deposited funds may be withdrawn upon the fulfillment of Integrity Israel&#x2019;s severance obligations pursuant to Israeli severance
    pay laws or labor agreements with its employees. The value of the deposited funds is based on the cash surrender value of these policies,
    and includes immaterial profits or losses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commencing
    in 2011, Integrity Israel&#x2019;s agreements with its Israeli employees are in accordance with Section 14 of the Severance Pay Law.
    Payments in accordance with Section 14 release the employer from any future severance payments in respect of those employees. Related
    obligations and liabilities under Section 14 are not recorded as an asset or as a liability in the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    year ended December 31, 2021, and 2020, severance expenses amounted to $&lt;span id="xdx_90F_eus-gaap--SeveranceCosts1_pn3n3_c20210101__20211231_zY7fX3k5BpIb" title="Severance expenses"&gt;43&lt;/span&gt;
    and $&lt;span id="xdx_902_eus-gaap--SeveranceCosts1_pn3n3_c20200101__20201231_zEO4WrqohWq1" title="Severance expenses"&gt;24 &lt;/span&gt; thousand,
    respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2013;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy>
    <us-gaap:SeveranceCosts1
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">43000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">24000</us-gaap:SeveranceCosts1>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zirsgiEM0ulf" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;K.
&#160;&#160;&#160;&lt;span id="xdx_868_zpXQro7zIyQ3"&gt;Research and development expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <IGAP:RoyaltyBearingGrantsPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_845_ecustom--RoyaltyBearingGrantsPolicyTextBlock_z8sKHmrDPlp6" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;L.
&#160;&#160;&#160;&lt;span id="xdx_862_zwtYQaEmhRE1"&gt;Royalty-bearing grant&lt;/span&gt;s&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Royalty-bearing
grants from the Israeli Innovation Authority (IIA) to fund approved research and development projects are recognized at the time
Integrity Israel is entitled to such grants, on the basis of the costs incurred and reduce research and development costs. To date,
the cumulative research and development grants received by Integrity Israel from amounted to $&lt;span id="xdx_900_ecustom--CumulativeResearchAndDevelopment_pn3n3_c20210101__20211231_zFrVLd4EqThb" title="Cumulative research and development"&gt;93&lt;/span&gt; thousand.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

</IGAP:RoyaltyBearingGrantsPolicyTextBlock>
    <IGAP:CumulativeResearchAndDevelopment
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">93000</IGAP:CumulativeResearchAndDevelopment>
    <us-gaap:StandardProductWarrantyPolicy contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84A_eus-gaap--StandardProductWarrantyPolicy_zvlibdTueNw9" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;M.
&#160;&#160;&lt;span id="xdx_865_zaFGQFrnS42l"&gt;Warranty&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group provides a 24-month warranty for its products at no cost. The group estimates the costs that may be incurred during
    the warranty period and records a liability for the amounts of such costs at the time revenues are recognized. For the year ended
    December 31, 2021 and 2020 warranty expenses were clearly insignificant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:StandardProductWarrantyPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_z4dUfCu8MIal" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;N.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&#160;&#160;&lt;span id="xdx_861_zHwZZ6eGcibe"&gt;Basic and diluted loss per share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic loss per share is computed by dividing the loss for the period applicable
for Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon
    the exercise of options or warrants issued or granted using the &#x201c;treasury stock method&#x201d;, if the effect of each of such
    financial instruments is dilutive.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;In computing diluted loss per share, the average stock price for the
    period is used in determining the number of common stock assumed to be purchased from the exercise of stock options or stock warrants.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Shares that will be issued upon exercise of all stock
    options and stock warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods
    for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these
    instruments was anti-dilutive&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;An amount of &lt;span id="xdx_90F_ecustom--NumberOfStockOptionsExcluded_c20210101__20211231_zOt36ZugXE08" title="Number of stock options excluded"&gt;6,404,238&lt;/span&gt; and &lt;span id="xdx_904_ecustom--NumberOfStockWarrantsExcluded_c20210101__20211231_z3TLRD8mnoWk" title="Number of stock warrants excluded"&gt;6,446,920&lt;/span&gt; outstanding stock
    options and stock warrants have been excluded from the calculation of the diluted net loss per share for the years ended December
    31, 2021 and 2020, respectively, because the effect of the common shares issuable as a result of the exercise of such instruments
    was determined to be anti-dilutive.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <IGAP:NumberOfStockOptionsExcluded
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="Shares">6404238000</IGAP:NumberOfStockOptionsExcluded>
    <IGAP:NumberOfStockWarrantsExcluded
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="Shares">6446920000</IGAP:NumberOfStockWarrantsExcluded>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zhK42UAblaGb" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;O.
&#160;&#160;&#160;&lt;span id="xdx_863_zgLyhfyW8zsa"&gt;Stock-based compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values
    in accordance with ASC 718, &#x201c;Compensation-Stock Compensation&#x201d;. Share-based payments including grants of stock options
    are recognized in the statement of operations as an operating expense based on the fair value of the award at the date of grant.
    The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Group has expensed compensation
    costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit
    service period when a performance condition affects the vesting, and it is considered probable that the performance condition will
    be achieved.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commencing
    January 1, 2019, following the adoption of ASU 2018-07, which aligns the measurement and classification guidance for share-based
    payments to nonemployees with the guidance for share-based payments to employees (with certain exceptions), share-based payments
    to non-employees are accounted in accordance with ASC 718.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2013;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zeCThVgBkQi2" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;P.
&#160;&#160;&#160;&lt;span id="xdx_86A_z0MkNh8cKSO3"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
    Topic 825-10, &#x201c;Financial Instruments&#x201d; defines financial instruments and requires disclosure of the fair value of financial
    instruments held by the Group. The Group considers the carrying amount of cash and cash equivalents, restricted cash, accounts receivable,
    other current assets, accounts payable and other current liabilities balances, to approximate their fair values due to the short-term
    maturities of such financial instruments. ASC Topic 825-10, establishes the following fair value hierarchy, which prioritizes the
    inputs used in the valuation methodologies in measuring fair value:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair
    value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 - Unobservable inputs are used when little or no market data is available. Level 3 inputs are considered as the lowest priority
    under the fair value hierarchy.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group did not estimate the fair value of the  loans from stockholders since their repayment schedule has not yet been determined.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zjGnLFw00Rp1" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Q.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&#160;&#160;&lt;span id="xdx_86C_zCHn20XqlR39"&gt;Concentrations of credit risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
    instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash and cash equivalents, and
    restricted cash. Cash and cash equivalents and restricted cash are deposited with major banks in Israel and the United States of
    America. Management believes that such financial institutions are financially sound, accordingly, minimal credit risk exists with
    respect to these financial instruments. The Group does not have any significant off-balance-sheet concentration of credit risk, such
    as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_847_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zay9jLDrdGd6" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;R.
&#160;&#160;&#160;&lt;span id="xdx_867_zuq6SO3iGgmh"&gt;Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability
    has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional
    information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2013;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_840_eus-gaap--DerivativesPolicyTextBlock_zShPDLLDHhh5" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;S.
&#160;&#160;&#160;&#160;&lt;span id="xdx_86C_zpnCZhkuvNI4"&gt;Warrants with Down-Round Protection&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
    the application of Accounting Standard Update (ASU) No. 2017-11, &#x201c;Earnings Per Share&#x201d; (ASU 2017-11), the Company disregard
    the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or
    equity classification. Based on its evaluation, management has determined that such warrants with Down-Round Protection are eligible
    for equity classification.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    accordance with the provisions of ASU 2017-11, upon the occurrence of an event that triggers a down round protection (i.e., when
    the exercise price of the warrants is adjusted downward because of the down round feature), the effect is accounted for as a deemed
    dividend and as a reduction of income available to common shareholders for purposes of basic earnings per share (EPS) calculation.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <IGAP:ModificationOfEquityclassifiedContractsPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_846_ecustom--ModificationOfEquityclassifiedContractsPolicyTextBlock_zXJeETtbbN6i" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;T.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&#160;&#160;&lt;span id="xdx_86A_ziJkWwfyEW19"&gt;Modification of equity-classified contracts&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification
    or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification
    of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value
    of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase
    of accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified
    share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment
    to earnings available to common shareholders for purposes of calculating earnings per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

</IGAP:ModificationOfEquityclassifiedContractsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_z7eoZqo6Uc0d" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;U.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&#160;&#160;&lt;span id="xdx_86B_zp8JaOuYjnM2"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;The allowance for doubtful accounts is determined with
    respect to amounts the Company has determined to be doubtful of collection, in order to reflect the expected credit losses on accounts
    receivable balances. Judgment is required in the estimation of the allowance for doubtful accounts and the Company evaluates the
    collectability of its accounts receivable based on a combination of factors (including, among other things, the length of time that
    the balance is past due and the customer&#x2019;s current ability to pay. If it&#x2019;s becomes aware of a customer&#x2019;s inability to meet
    its financial obligations, an allowance is recorded to reduce the net receivable to the amount reasonably believed to be collectible
    from such customer&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_845_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zYlRL3q7WdYf" style="margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;b&gt;V.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_865_zMkUXWRi3xs9"&gt;Operating Lease&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company entered into several non-cancelable lease agreements for vehicles for use in its operations, which are classified as operating
    leases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commencing
    January 1, 2019, the Company applies ASC Update 2016-02, Leases (Topic 842).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company determines if an arrangement is a lease at inception. Under the new guidance, arrangements meeting the definition of a lease
    are classified as operating or financing leases. A classification of a lease is determined based on the following criteria:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 96px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    lease transfers ownership of the underlying asset to the lessee by the end of the lease term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    lease term is for the major part of the remaining economic life of the underlying asset (Generally, 75% or more of the remaining
    economic life of the underlying assets).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    present value of the sum of the lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all
    of the fair value of the underlying asset (Generally, 90% or more of the fair value of the underlying asset).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease
    term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
any of these five criteria is met, the lease is classified as a finance lease. Otherwise, the lease is classified as an operating lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
are recorded on the consolidated balance sheet as both a right of use asset and a lease liability, calculated by discounting fixed lease
payments over the lease term at the rate implicit in the lease or the Company&#x2019;s incremental borrowing rate. Lease liabilities are
increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating
leases, interest on the lease liability and the amortization of the right of use asset results in straight-line rent expense over the
lease term. Variable lease expenses, if any, are recorded when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also elected the short-term lease recognition exemption for all leases that qualify (leases with a term shorter than &lt;span id="xdx_907_eus-gaap--LessorOperatingLeaseTermOfContract_iI_dtM_c20190102_zT2oUyH9Lhek" title="Lessor, Operating Lease, Term of Contract"&gt;12&lt;/span&gt; months).
For those leases, right-of-use assets or lease liabilities are not recognized and rent expense is recognized on a straight-line basis
over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had no material capital leases throughout the reporting periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
note 4 for further discussion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2013;&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:LessorOperatingLeaseTermOfContract contextRef="AsOf2019-01-02">P12M</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zMFGQ4NQ6qF8" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;W.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&#160;&#160;&#160;&lt;span id="xdx_86A_zHQvnAq3pgAf"&gt;Reclassification&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
    comparative figures have been reclassified to conform to the current year presentation. Such reclassifications did not have any significant
    impact on the Company&#x2019;s equity, net income or cash flows.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zegEC1G2JUS5" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;b&gt;&lt;span id="xdx_868_zXTHdpqWn82"&gt;X. &#160;&#160;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU 2016-13, &#x201c;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments&#x201d; (&#x201c;ASU 2016-13&#x201d;), which changes the impairment model for most financial assets and certain other instruments.
For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities will be required to use a new
forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. The
guidance also requires increased disclosures. For the Company, the amendments in the update were originally effective for fiscal years
beginning after December 15, 2019, including interim periods within those fiscal years. In November 2019, the FASB issued ASU No. 2019-10,
which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined by the SEC) and other non-SEC reporting entities
to fiscal years beginning after December 15, 2022, including interim periods within those fiscal periods. Early adoption is permitted.
&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As the company
is eligible to considered as smaller reporting company ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including
interim periods within those fiscal years. The adoption of this standard is not expected to result in a material impact to the Company&#x2019;s
financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_801_eus-gaap--InventoryDisclosureTextBlock_z1YXDWujlYnd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3&lt;/b&gt; &#x2013; &lt;span id="xdx_826_ztCMg31uZDb6"&gt;&lt;b&gt;INVENTORIES&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_89B_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zc8V0fXVWzC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zrnsXl8O4ds2" style="display: none; text-transform: uppercase"&gt;SCHEDULE
OF INVENTORIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_ztdjoh3Df3Rb"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20201231_zOgIXePL4TF6"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Inventory&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In thousand of US dollars&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InventoryRawMaterials_iI_pn3n3_maIGzn5N_zQ5GzIkfahI7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;94&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maIGzn5N_zWDi36o1kNZ6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maIGzn5N_zaLMdy8upMJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished products&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;34&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InventoryGross_iTI_pn3n3_mtIGzn5N_maINzWYt_zLNeCkoh9e4e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"/&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;321&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;284&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--InventoryAdjustments_iNTI_pn3n3_di_msINzWYt_z9gv4rshjGo9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;inventory write-down&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(321&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0515"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--InventoryNet_iTI_pn3n3_mtINzWYt_znPOi37l1bi2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0517"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;284&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zDJGTmscObKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)
Management evaluated periodically whether inventory is required to be written-down due to slow-moving or obsolete items
and recognize inventory impairment, as applicable. As a result of the development of the second generation of the glucose monitoring
device the Group has recorded in the fourth quarter of 2021 inventory written-down in the amount of approximately $ &lt;span id="xdx_90F_eus-gaap--InventoryAdjustments_iI_pn3n3_c20211231_z8x8VFUNiLkg"&gt;321
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zc8V0fXVWzC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zrnsXl8O4ds2" style="display: none; text-transform: uppercase"&gt;SCHEDULE
OF INVENTORIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_ztdjoh3Df3Rb"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20201231_zOgIXePL4TF6"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Inventory&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In thousand of US dollars&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InventoryRawMaterials_iI_pn3n3_maIGzn5N_zQ5GzIkfahI7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;94&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maIGzn5N_zWDi36o1kNZ6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maIGzn5N_zaLMdy8upMJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished products&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;34&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InventoryGross_iTI_pn3n3_mtIGzn5N_maINzWYt_zLNeCkoh9e4e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"/&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;321&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;284&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--InventoryAdjustments_iNTI_pn3n3_di_msINzWYt_z9gv4rshjGo9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;inventory write-down&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(321&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0515"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--InventoryNet_iTI_pn3n3_mtINzWYt_znPOi37l1bi2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0517"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;284&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">94000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">95000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">194000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">155000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">33000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">34000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">321000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">284000</us-gaap:InventoryGross>
    <us-gaap:InventoryAdjustments contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">321000</us-gaap:InventoryAdjustments>
    <us-gaap:InventoryNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">284000</us-gaap:InventoryNet>
    <us-gaap:InventoryAdjustments contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">321000</us-gaap:InventoryAdjustments>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_804_eus-gaap--LesseeOperatingLeasesTextBlock_zPf1ye7BZtEg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2013; &lt;span id="xdx_826_zLOdFgHGoyWf"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into several non-cancellable operating lease agreements for few vehicles. the Company&#x2019;s leases have
original lease periods expiring between 2023 and 2024. Payments due under such lease contracts include primarily fixed payments. the
Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably assured at lease
commencement. the company&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--LeaseCostTableTextBlock_zLbcPSlBJLOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of lease costs, lease term and discount rate are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zRsGUCR3CFsh" style="display: none; text-transform: uppercase"&gt;SCHEDULE
OF LEASE COSTS, LEASE TERM AND DISCOUNT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;In
                                            thousand of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US
                                            dollars&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Operating lease cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Vehicles&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseCost_pn3n3_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_z0mDVy94eAJ1"&gt;72&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Office space &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Over 12 month&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_909_ecustom--LongTermLeaseCost_pn3n3_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceMember_zXYtEbGj2g98" title="Office space: Over 12 month"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;p style="margin: 0"&gt;Short term leases&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_902_eus-gaap--ShortTermLeaseCost_pn3n3_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceMember_zXgDvxIa4iT6" title="Office space: Short term leases"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseCost_pn3n3_c20210101__20211231_zwYNiMxQj5jb" title="Total Operating lease cost"&gt;171&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Remaining Lease Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Vehicles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zZ0I6Rm1ey75" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.01
                                            &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Weighted Average Discount Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Vehicles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zz2FmmxhiL9h"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_z1eJGaAsTBy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2013; LEASES (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zxu4SEPCq9V3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a schedule, by years, of maturities of operating lease liabilities as of December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zBYWPBLIkEM3" style="display: none; text-transform: uppercase"&gt;SCHEDULE
OF OPERATING LEASE MATURITY PAYMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231_zpyzv9EMEht8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;In
                                            thousand of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US
                                            dollars&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Period:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzYou_zoSxFXo8Kvea" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;24&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzYou_zR5T5VV0j14b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzYou_zF2vTrQGuc3h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total operating lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;44&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_zL5ELAg733eh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zwWf4InZ9Uj3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;40&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z2JIF9lQ6ihe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89D_eus-gaap--LeaseCostTableTextBlock_zLbcPSlBJLOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of lease costs, lease term and discount rate are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zRsGUCR3CFsh" style="display: none; text-transform: uppercase"&gt;SCHEDULE
OF LEASE COSTS, LEASE TERM AND DISCOUNT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;In
                                            thousand of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US
                                            dollars&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Operating lease cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Vehicles&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseCost_pn3n3_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_z0mDVy94eAJ1"&gt;72&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Office space &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Over 12 month&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_909_ecustom--LongTermLeaseCost_pn3n3_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceMember_zXYtEbGj2g98" title="Office space: Over 12 month"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;p style="margin: 0"&gt;Short term leases&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;&lt;span id="xdx_902_eus-gaap--ShortTermLeaseCost_pn3n3_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceMember_zXgDvxIa4iT6" title="Office space: Short term leases"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseCost_pn3n3_c20210101__20211231_zwYNiMxQj5jb" title="Total Operating lease cost"&gt;171&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Remaining Lease Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Vehicles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zZ0I6Rm1ey75" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.01
                                            &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Weighted Average Discount Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Vehicles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zz2FmmxhiL9h"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-01-012021-12-31_us-gaap_VehiclesMember"
      decimals="-3"
      unitRef="USD">72000</us-gaap:OperatingLeaseCost>
    <IGAP:LongTermLeaseCost
      contextRef="From2021-01-012021-12-31_custom_OfficeSpaceMember"
      decimals="-3"
      unitRef="USD">53000</IGAP:LongTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2021-01-012021-12-31_custom_OfficeSpaceMember"
      decimals="-3"
      unitRef="USD">46000</us-gaap:ShortTermLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">171000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2021-12-31_us-gaap_VehiclesMember">P2Y3D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2021-12-31_us-gaap_VehiclesMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zxu4SEPCq9V3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a schedule, by years, of maturities of operating lease liabilities as of December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zBYWPBLIkEM3" style="display: none; text-transform: uppercase"&gt;SCHEDULE
OF OPERATING LEASE MATURITY PAYMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231_zpyzv9EMEht8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;In
                                            thousand of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US
                                            dollars&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Period:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzYou_zoSxFXo8Kvea" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;24&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzYou_zR5T5VV0j14b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzYou_zF2vTrQGuc3h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total operating lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;44&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_zL5ELAg733eh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zwWf4InZ9Uj3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;40&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">24000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">20000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">44000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">4000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">40000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zndzD9QDn7xg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_822_zshg62bIbfd2"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6wHxThoOcPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zKONlzkJRMz4" style="display: none; text-transform: uppercase"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Property and Equipment&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In thousand of US dollars&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Computers&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpwgU3E7tlPf" style="width: 16%; text-align: right" title="Property and equipment, gross"&gt;306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zIzfuCWk5Py3" style="width: 16%; text-align: right" title="Property and equipment, gross"&gt;380&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zdMJOGy5YJNe" style="text-align: right" title="Property and equipment, gross"&gt;183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zgxvPnsd5GAa" style="text-align: right" title="Property and equipment, gross"&gt;312&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z4NhPEhmhcr9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0558"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zzfKXgKvNa79" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross"&gt;82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231_zvwAoM2vko4c" style="text-align: right" title="Property and equipment, gross"&gt;489&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231_zPjFhlZi4Fua" style="text-align: right" title="Property and equipment, gross"&gt;774&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less &#x2013; accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20211231_zymk2K4tPJL8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less - accumulated depreciation"&gt;(420&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20201231_zMxf3fkw4KQa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less - accumulated depreciation"&gt;(625&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20211231_zvFTbtn2CRqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;69&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231_zaf1kzpQIA17" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;149&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zAOdjaMv6ZVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the years ended December 31, 2021 and 2020, depreciation expenses amounted to $&lt;span id="xdx_90C_eus-gaap--Depreciation_pn3n3_c20210101__20211231_zbWBJHvtFlJe"&gt;42
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90C_eus-gaap--Depreciation_pn3n3_c20200101__20201231_zb8KGAHxe07i"&gt;47
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand respectively, and new equipment
    purchases amounted to $&lt;span id="xdx_90D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_pn3n3_c20210101__20211231_z4270O9O71Ec"&gt;5
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_905_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_pn3n3_c20200101__20201231_zHMDRRy98yXg"&gt;53
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6wHxThoOcPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zKONlzkJRMz4" style="display: none; text-transform: uppercase"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Property and Equipment&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In thousand of US dollars&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Computers&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpwgU3E7tlPf" style="width: 16%; text-align: right" title="Property and equipment, gross"&gt;306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zIzfuCWk5Py3" style="width: 16%; text-align: right" title="Property and equipment, gross"&gt;380&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zdMJOGy5YJNe" style="text-align: right" title="Property and equipment, gross"&gt;183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zgxvPnsd5GAa" style="text-align: right" title="Property and equipment, gross"&gt;312&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z4NhPEhmhcr9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0558"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zzfKXgKvNa79" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, gross"&gt;82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20211231_zvwAoM2vko4c" style="text-align: right" title="Property and equipment, gross"&gt;489&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231_zPjFhlZi4Fua" style="text-align: right" title="Property and equipment, gross"&gt;774&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less &#x2013; accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20211231_zymk2K4tPJL8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less - accumulated depreciation"&gt;(420&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20201231_zMxf3fkw4KQa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less - accumulated depreciation"&gt;(625&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20211231_zvFTbtn2CRqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;69&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231_zaf1kzpQIA17" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;149&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      unitRef="USD">306000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      unitRef="USD">380000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_FurnitureAndOfficeEquipmentMember"
      decimals="-3"
      unitRef="USD">183000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_FurnitureAndOfficeEquipmentMember"
      decimals="-3"
      unitRef="USD">312000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      unitRef="USD">82000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">489000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">774000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">420000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">625000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">69000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">149000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">42000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">47000</us-gaap:Depreciation>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">5000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">53000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80A_eus-gaap--OtherLiabilitiesDisclosureTextBlock_zHruYjp0sjY7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 &#x2013; &lt;span id="xdx_825_zXCBHpmM3bwb"&gt;OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_899_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zpVYTO3IUP6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zpdOqWdmDMi3" style="display: none; text-transform: uppercase"&gt;SCHEDULE
OF OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_zjPxOE5dmKeb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20201231_zNlP70h9iU7c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Other Current Liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In thousand of US dollars&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maOLCzeFZ_zqb8htmtCzZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Employees and related institutions&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;244&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maOLCzeFZ_zUhlcLPgVGVl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued expenses and other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;148&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCzeFZ_zcKkXLdVZWQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;229&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;392&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zUORVe4P7Ivh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_899_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zpVYTO3IUP6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zpdOqWdmDMi3" style="display: none; text-transform: uppercase"&gt;SCHEDULE
OF OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 79%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_zjPxOE5dmKeb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20201231_zNlP70h9iU7c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Other Current Liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In thousand of US dollars&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maOLCzeFZ_zqb8htmtCzZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Employees and related institutions&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;244&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maOLCzeFZ_zUhlcLPgVGVl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued expenses and other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;148&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCzeFZ_zcKkXLdVZWQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;229&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;392&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">98000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">244000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">131000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">148000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">229000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">392000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_808_eus-gaap--LongTermDebtTextBlock_zVNGOwuv5Moj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7&lt;/b&gt; &#x2013; &lt;span id="xdx_823_z9hbW0tranJe"&gt;&lt;b&gt;LOANS FROM STOCKHOLDERS&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the years 2003-2004, Integrity Israel received loans from stockholders (four separate lenders) in a total amount of approximately
    $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfLongTermDebt_pn3n3_c20030101__20041231__srt--TitleOfIndividualAxis__custom--ShareHoldersMember_zAdJwHh04dR4"&gt;400
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand. However, following the repayment
    of the entire balance to certain lender in 2015, the remaining balance as of December 31,2021 is approximately $&lt;span id="xdx_907_eus-gaap--DueToOfficersOrStockholdersNoncurrent_iI_pn3n3_c20211231_ze8tjFHbhHyj"&gt;210
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand. The loans are indexed to the Israeli
    consumer price index from their origination date and bear no insert.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group will be required to pay the loans, in quarterly installments, commencing on the first quarter following the first fiscal year
    in which the Group reports net profit in its annual report. At such time, the Group will be required to make quarterly payments equal
    to &lt;span id="xdx_90D_ecustom--QuarterlyPaymentsEqualsToSalesPercentage_pid_dp_uPure_c20210101__20211231_zfSLo7WVcgsh"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
    of its total sales for each quarter until the loans have been repaid in full. Notwithstanding the repayment mechanism, the Group
    will not be required to repay the loans during any period in which such payment would cause a deficit in the Group&#x2019;s working
    capital.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2021, the Group does not expect to make any additional material repayments during the following 12-month period,
    if any, and accordingly the entire remaining balance of the loans from stockholders have been presented as long-term liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="From2003-01-012004-12-31_custom_ShareHoldersMember"
      decimals="-3"
      unitRef="USD">400000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DueToOfficersOrStockholdersNoncurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">210000</us-gaap:DueToOfficersOrStockholdersNoncurrent>
    <IGAP:QuarterlyPaymentsEqualsToSalesPercentage
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0.10</IGAP:QuarterlyPaymentsEqualsToSalesPercentage>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zMVzl2xtMgra" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 &#x2013; &lt;span id="xdx_824_zjrrsy7TI636"&gt;COMMITMENTS AND CONTINGENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 86%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    March 4, 2004, the Israel innovation authority (IIA) provided Integrity Israel with a grant of approximately $&lt;span id="xdx_909_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember_z9lChnwDXDZh"&gt;93
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand (NIS &lt;span id="xdx_905_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_uIsrael_c20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember_zGv5YAbyijrg"&gt;420
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand), for its plan to develop a non-invasive
    blood glucose monitor (the &#x201c;Development Plan&#x201d;). Integrity Israel is required to pay royalties to the IIA at a
    rate ranging between &lt;span id="xdx_90A_ecustom--RoyaltyPercentage_pid_dp_c20040303__20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MinimumMember_zYl6u9tAhxtk"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;span id="xdx_90B_ecustom--RoyaltyPercentage_pid_dp_c20040303__20040304__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MaximumMember_z5sP4qqOTPx7"&gt;5%&lt;/span&gt;&lt;/span&gt;
    of the proceeds from the sale of the Group&#x2019;s products arising from the Development Plan up to an amount equal to $&lt;span id="xdx_90C_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20050304__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_z80bmMo4o7k3"&gt;93
    &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;thousand, plus interest at LIBOR from the date of grant. As
    of December 31, 2021, the remaining contingent liability with respect to royalty payment on future sales equals approximately $&lt;span id="xdx_902_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20211231__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_zQtMsBfaAJE2"&gt;43
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;thousand, excluding interest. Such contingent obligation has
    no expiration date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2021, the Group accrued royalties to the IIA in insignificant amounts.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    August 1, 2017 the Company entered into an Advisory Agreement with Andrew Garrett, Inc. (AGI), pursuant to which &lt;span id="xdx_90C_ecustom--AdvisoryServicesPeriod_c20170729__20170801__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__dei--LegalEntityAxis__custom--AndrewGarrettIncMember_zTImE9yTfk39"&gt;the
    Company engaged AGI as placement agent on a non-exclusive basis to provide certain advisory services to the Company for a period
    of 9 months which was subsequently extended twice and was in effect until October 31, 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the year ended December 31, 2020 the Company paid the placement Agent approximately $&lt;span id="xdx_909_eus-gaap--PaymentsOfStockIssuanceCosts_pn6n6_c20200101__20201231_zxr4yrYXdH16"&gt;2
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million for placement services (see above)
    in cash. In addition, during the year ended December 31, 2020, $&lt;span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200101__20201231_z7Wdp3F1o84b"&gt;756
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand representing the fair value of warrants
    issued as consideration for placement agent services to AGI. This amount was accounted for as warrants with down-round protection.
    Upon issuance, the fair value was recognized as an increase in additional paid in capital.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 11%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 87%; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Since March 2021 Integrity Israel is renting several workspaces
    at office building in the city Or &#x2013; Yehoda. This workspace rent replaces the principal offices the Company in the city Ashdod.
    According to the new agreement the Company renting those flexible shared workspaces for period shorter than one year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember"
      decimals="-3"
      unitRef="USD">93000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2004-03-04_custom_IsraeliInnovationAuthorityMember"
      decimals="-3"
      unitRef="Israel">420000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <IGAP:RoyaltyPercentage
      contextRef="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.03</IGAP:RoyaltyPercentage>
    <IGAP:RoyaltyPercentage
      contextRef="From2004-03-032004-03-04_custom_IsraeliInnovationAuthorityMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.05</IGAP:RoyaltyPercentage>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2005-03-04_custom_IsraeliInnovationAuthorityMember"
      decimals="-3"
      unitRef="USD">93000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2021-12-31_custom_IsraeliInnovationAuthorityMember"
      decimals="-3"
      unitRef="USD">43000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <IGAP:AdvisoryServicesPeriod contextRef="From2017-07-292017-08-01_custom_AdvisoryAgreementMember_custom_AndrewGarrettIncMember">the
    Company engaged AGI as placement agent on a non-exclusive basis to provide certain advisory services to the Company for a period
    of 9 months which was subsequently extended twice and was in effect until October 31, 2019</IGAP:AdvisoryServicesPeriod>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2020-01-012020-12-31"
      decimals="-6"
      unitRef="USD">2000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">756000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zVV6odsJGr38" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2013; &lt;span id="xdx_82D_zIbT1ADCmog6"&gt;COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Description
    of the rights attached to the Common Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
    share of Common Stock entitles the holder to one vote, either in person or by proxy, on each matter submitted to the approval of
    the Company&#x2019;s stockholders. The holders of Common Stock are not permitted to vote their shares cumulatively. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;b&gt;Description of February 14, 2020 Issuance of common
    stock&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="margin: 0"&gt;On February 14, 2020, the Company
                                            entered into a Securities Purchase Agreement and Registration Rights Agreement with an accredited
                                            investor, pursuant to which the accredited investor purchased &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200213__20200214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zFVcyh1RViMg" title="Number of common shares issued"&gt;&lt;span style="background-color: white"&gt;2,884,615&lt;/span&gt;&lt;/span&gt; shares of the Company&#x2019;s
                                            common stock, par value $&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20200214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zdbBiuwm9lu9" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share, for an aggregate gross purchase price of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn6n6_c20200213__20220214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zRzNHAy0wsZ1" title="Proceeds from issuance of common stock"&gt;15&lt;/span&gt; million,
                                            less cash expenses of approximately $&lt;span id="xdx_90C_ecustom--CashExpensesOnIssuanceOfStock_pn6n6_c20200213__20220214__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorMember_zQhwLsbbka76" title="Cash expenses on issuance of stock"&gt;2&lt;/span&gt; million&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Placement Agent Compensation&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
    to a placement agent agreement (the &#x201c;Placement Agent Agreement&#x201d;) with the placement agent for the Offering (the &#x201c;Placement
    Agent&#x201d;), at the closing of the above mentioned sale of the common stock the Company paid the Placement Agent, as a commission,
    a cash amount equal to &lt;span id="xdx_907_ecustom--CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits_iI_pid_dp_c20211231__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zH5GSxzu4NCe" title="Commission as a percentage of cash amount equal to aggregate sale price of units"&gt;7%&lt;/span&gt; of the aggregate sales price of the Units, plus 3% of the aggregate sales price as a management fee plus
    a non-accountable expense allowance equal to &lt;span id="xdx_904_ecustom--NonaccountableExpenseAllowancePercenatge_iI_pid_dp_c20211231__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zSnFiIi9s2ui" title="Non-accountable expense allowance percenatge"&gt;3%&lt;/span&gt; of the aggregate sales price of the Units. In addition, pursuant to the placement
    agent agreement, the company is required to issue to the Placement Agent warrants to purchase up to such number of shares of Common
    Stock equal to &lt;span id="xdx_90F_ecustom--AggregateSalesPriceOfUnitsPercentage_iI_pid_dp_c20211231__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentAgreementMember_zDdkHJBkAekf" title="Commission as a percentage of aggregate sales price"&gt;10%&lt;/span&gt; of the aggregate Shares sold in the Offering plus warrants equal to 10% of the total number of the Warrants issued
    to the Purchasers in the Offering (collectively, the &#x201c;Placement Agent Warrants&#x201d;). The terms of the Placement Agent Warrants
    will be substantially similar to the Warrants except that the Placement Agent Warrants will also be exercisable on a cashless basis
    and will include full ratchet anti-dilution protection.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2013; COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock-based
    compensation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Grants
    to non-employees&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    connection with the 2017 Offering, the Company has issued to the Placement Agent (a) &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zhNsRFRtbNI9"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-year
    warrants to purchase up to &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zZdniGU28zh3"&gt;1,062,717
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Common Stock at an exercise price
    of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zSu3HABMcfa8"&gt;3.354
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share, (b) &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zZqOOwFF1Vml"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-year
    warrants to purchase up to &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zbF2M5eKdh82"&gt;108,305
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Common Stock at an exercise price
    of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zqHO0BvfgJxb"&gt;23.40
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share.(c) &lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_zIfeaWgKJXDa"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-year
    warrants to purchase up to &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_z6EsU55v2hH2"&gt;8,331
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Common Stock at an exercise price
    of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_zV866NZbTnti"&gt;46.80
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share, and (d) &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFourMember_zWMygPyCKyl9"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-year
    warrants to purchase up to &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFourMember_zos7YD9MmrXe"&gt;8,331
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Common Stock at an exercise price
    of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandSeventeenOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFourMember_zrg6EoIcxzr3"&gt;70.20
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. The terms of the Placement Agent
    warrants are substantially similar to the terms of the Series D warrants except that the Placement Agent warrants may also be exercisable
    on a cashless basis at all times.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            connection with February 2020 Offering, the Company has issued to the Placement Agent &lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandTwentyOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFiveMember_zfJ1R2VokEtc"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-year
                                            warrants to purchase up to &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandTwentyOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFiveMember_zst9e293yR82"&gt;288,462
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
                                            of Common Stock at an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--TwoThousandandTwentyOfferingMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantFiveMember_zl6F5A7rLUX6"&gt;5.2
                                            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
                                            share.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the year ending December 31, 2020, $&lt;span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200101__20201231_z4pmWHm9FTT9"&gt;756
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand, respectively, representing the
    fair value of warrants issued as consideration for placement agent services to AGI. This amount was accounted for as Warrants with
    down-round protection. Upon issuance, the fair value was recognized as an increase in additional paid in capital&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2020, the key inputs used in the fair value calculations of the warrant that were affected by the down-round protection
    were as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"/&gt;

&lt;p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zjCncJ4E5oH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"&gt;&lt;span id="xdx_8BA_zqKLcqcL0dIl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; border-collapse: collapse; width: 58%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Fair value calculations &#x2013; Warrant&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31-Dec-20&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zG6kiQss7US5"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zOPAtKKPxUh3"&gt;56.32&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z39F9w5I5Xtk"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zBonNKFffTbc"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price (US dollars)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmXooMm7mJU3"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Share price (US dollars)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIn838AN9blh"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fair value (US dollars)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairValueMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfTuNhbuoQB3"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zbdKy8bGZnw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Grants
    to employees&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    August 2007, Integrity Israel&#x2019;s Board of Directors (&#x201c;Integrity Israel&#x2019;s Board&#x201d;) approved a stock option plan
    (&#x201c;Integrity Israel&#x2019;s plan&#x201d;) for the grant, without consideration of options exercisable into ordinary shares of
    NIS &lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20070831__us-gaap--PlanNameAxis__custom--IntegrityIsraelsPlanMember_zhMHHDwg8sV7" style="font: 10pt Times New Roman, Times, Serif"&gt;0.01
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;par value of Integrity Israel to employees,
    officers and directors of Integrity Israel. The exercise price and vesting period for each grantee of options was determined by Integrity
    Israel&#x2019;s Board and specified in such grantee&#x2019;s option agreement. &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20070801__20070831__us-gaap--PlanNameAxis__custom--IntegrityIsraelsPlanMember_zhQcFV1IPP95"&gt;The
    options vested over a period of 1-12 quarters based on each grantee&#x2019;s option agreements. Any option not exercised within 10
    years after the date of grant thereof will expire&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2013; COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock-based
    compensation (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Grants
    to employees (cont.)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    July 2010, following the merger with Integrity Israel, the Company adopted the 2010 Share Incentive Plan (the &#x201c;2010 Share Incentive
    Plan&#x201d;), pursuant to which the Company&#x2019;s Board of Directors is authorized to grant options exercisable into Common Stock
    of the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    purpose of the 2010 Share Incentive Plan is to offer an incentive to employees, directors, officers, consultants, advisors, suppliers
    and any other person or entity whose services are considered valuable to the Company, as well as to replace the Integrity Israel
    Plan and to replace all options granted in the past by Integrity Israel.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
                                            June, 2020, Erez Ben-Zvi has joined the Company as its Vice President of Product.&lt;/span&gt;&lt;/p&gt;
                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    February 8, 2021, the Company announced that it has promoted Erez Ben-Zvi to General Manager in addition to his current role as Vice
    President of Product, effective immediately&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company granted Mr. Ben-Zvi annual award of NIS &lt;span id="xdx_90C_eus-gaap--OfficersCompensation_pn3n3_uIsrael_c20200628__20200630__srt--TitleOfIndividualAxis__custom--ErezBenZviMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXzeXtxRz076"&gt;210
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand worth (approximately $ &lt;span id="xdx_901_eus-gaap--OfficersCompensation_pn3n3_c20200628__20200630__srt--TitleOfIndividualAxis__custom--ErezBenZviMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdIJm3QzZJB1"&gt;65
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand) of restricted stock units (the
    &#x201c;RSU&#x201d;) effective as of the employee Start Date and on each one-year anniversary following the employee Start Date subject
    to the approval of the board of directors (the &#x201c;additional RSU&#x201d;). The RSU and each of the Additional RSU (if approved
    by the board of directors), as applicable, shall be based on the stock price at actual the date of grant (and not lower than US$
    5.20 per share). &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20200628__20200630__srt--TitleOfIndividualAxis__custom--ErezBenZviMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsQwno8EbTc2"&gt;1/12
    of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall
    vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the employee continues to be employed
    by the Company at the applicable date of vesting&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
    The vesting schedule shall be also applied to each of the Additional RSUs granted, mutatis mutandis, such that the vesting period
    of each of the respective Additional RSU shall commence from its actual date of grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
                                            November, 2020, Mr. Shalom Shushan has joined the Company as its Chief Technology Officer,
                                            Mr. Shushan will lead all technology and research and development activities for Integrity
                                            and will serve on the Company&#x2019;s executive leadership team.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company granted Mr. Shushan annual award of NIS &lt;span id="xdx_907_eus-gaap--OfficersCompensation_pn3n3_uIsrael_c20201128__20201130__srt--TitleOfIndividualAxis__custom--ShalomShushanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJ88080QpFha"&gt;90
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand worth (approximately &lt;span id="xdx_90D_eus-gaap--OfficersCompensation_pn3n3_c20201128__20201130__srt--TitleOfIndividualAxis__custom--ShalomShushanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkFRWxhLCpg6"&gt;$28
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand) of restricted stock units (the
    &#x201c;RSU&#x201d;) effective as of the employee Start Date. Furthermore, on each one-year anniversary following the employee Start
    Date subject to the approval of the board of directors, Company shall grant the Employee with NIS 60 thousand worth of restricted
    stock units (the &#x201c;Additional RSU&#x2019;&#x2019;). Both the RSU and each of the Additional RSU (if approved by the board of directors),
    as applicable, shall be based on the stock price at actual the date of grant (and not lower than US$ 5.20 per share). &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20201128__20201130__srt--TitleOfIndividualAxis__custom--ShalomShushanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLwY45ycWlJ7"&gt;1/12
    of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall
    vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the Employee continues to be employed
    by the Company at the applicable date of vesting&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
    The vesting schedule shall be also applied to each of the Additional RSUs granted to the Employee, mutatis mutandis, such that the
    vesting period of each of the respective Additional RSU shall commence from its actual date of grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                            October 19, 2021, Paul V. Goode was appointed as President and Chief Operating Officer of
                                            the company, Inc, effective November 1, 2021. He has served as a member of Integrity&#x2019;s
                                            Board of Directors since December 17, 2020. Concurrent with his appointment, Mr. Goode has
                                            stepped down from the Board.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0"&gt;Effective November 20201, the &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company
granted Mr. Paul V. Goode options to purchase up to &lt;span id="xdx_909_ecustom--PercentageOfDulitedCommonStock_iI_pid_c20211120__srt--TitleOfIndividualAxis__custom--MrPaulVMember_z6tzXnTsnSbd"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the fully diluted common stock, par value $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211120__srt--TitleOfIndividualAxis__custom--MrPaulVMember_zszgl8i0E16k"&gt;0.001
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share (approximately &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20211118__20211120__srt--TitleOfIndividualAxis__custom--MrPaulVMember_zzc6LDjFnmIb" title="Number of options granted"&gt;330&lt;/span&gt; thousand options),
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of the Company (&#x201c;Common Stock&#x201d;) as of
the Effective Date, with a per share exercise price equal to the greater of (A) $&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20211020__srt--TitleOfIndividualAxis__custom--MrPaulVMember_zlzQwBYYVhib"&gt;5.20
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share or (B) the closing price of a share
of Common Stock on the Effective Date, as reported by Bloomberg L.P., which shall vest in equal monthly installments over a three year
period following the Effective Date.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                            December 3, 2021, James p. thrower was appointed as Vice President Engineering of the company.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
    December 20201, the&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; Company granted Mr. James
    p. Thrower options to purchase up to &lt;span id="xdx_905_ecustom--PercentageOfDulitedCommonStock_iI_pid_c20211203__srt--TitleOfIndividualAxis__custom--MrJamesPMember_zHHHXGwbHqQ3"&gt;1.15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
    of the fully diluted common stock, par value $&lt;span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211220__srt--TitleOfIndividualAxis__custom--MrJamesPMember_zLiTUYHQD1Sc"&gt;0.001
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share (approximately &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20211218__20211220__srt--TitleOfIndividualAxis__custom--MrJamesPMember_zPDtlpEup8O"&gt;250&lt;/span&gt; thousand
    options), of the Company (&#x201c;Common Stock&#x201d;) as of the Effective Date, with a per share exercise price equal to the
    greater of (A) $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20211220__srt--TitleOfIndividualAxis__custom--MrJamesPMember_zAz2IRkZrMGf"&gt;5.20
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share or (B) the closing price of a share
    of Common Stock on the Effective Date, as reported by Bloomberg L.P., which shall vest in equal monthly installments over a three
    year period following the Effective Date.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgTR23sZjut8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&#160;&lt;span id="xdx_8BB_z804badvxNda" style="display: none"&gt;SCHEDULE
OF STOCK GRANTS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 82%; margin-left: 1.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Grants to Employees&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average exercise price (US$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; padding-bottom: 1.5pt"&gt;Balance outstanding as of December 31,2019&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zbzfYCNDNbm2" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Number outstanding beginning balance"&gt;156,007&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zXIfIndJGbNh" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Weighted average exercise price outstanding, beginning balance"&gt;63.44&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance exercisable of December 31,2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20200101__20201231_zIfi1YoFzeGl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number exercisable, beginning balance"&gt;132,630&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zp2yw1rOxRFd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price exercisable, beginning balance"&gt;60.19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Granted during 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zMQngjh5lMgl" style="text-align: right" title="Number shares, grants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0675"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_z4Bprvx2fi78" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0677"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Forfeited during 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231_zHIzTlEkEyL6" style="text-align: right" title="Number, forfeited"&gt;(25,770&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zggqNa5rzt7e" style="text-align: right" title="Weighted average exercise price, forfeited"&gt;58.63&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance outstanding as of December 31,2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zZuvFDQJdUW1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number outstanding beginning balance"&gt;130,237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zfmzeJgTmwZb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price outstanding, beginning balance"&gt;64.35&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance exercisable of December 31,2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20210101__20211231_zt8AGEdZH1cd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number exercisable, beginning balance"&gt;128,296&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_pid_c20210101__20211231_z5ua8Ql99sFk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price exercisable, beginning balance"&gt;64.48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Granted during 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zxj2ZiyXilCb" style="text-align: right" title="Number, grants"&gt;577,064&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_z4mH7EONhW25" style="text-align: right" title="Weighted average exercise price, granted"&gt;5.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Forfeited during 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231_z7LgUYtZDtpc" style="text-align: right" title="Number, forfeited"&gt;(98,177&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zxZtW5O8XOOc" style="text-align: right" title="Weighted average exercise price, forfeited"&gt;64.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance outstanding as of December 31,2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_zCa0YdSQQXWd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number outstanding ending balance"&gt;609,124&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zRbdkWAs6nY" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price outstanding, ending balance"&gt;8.10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance exercisable of December 31,2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20211231_zAgh22zbiUQ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number exercisable, ending balance"&gt;39,223&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zKH4QqiQmyba" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price exercisable, ending balance"&gt;46.41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p id="xdx_8A0_zrjGCV9FZQ99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zVgfwIHJyx75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize information about options outstanding at December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&#160;&lt;span id="xdx_8B3_zKrNsKm2uhik" style="display: none"&gt;SCHEDULE
OF STOCK GRANTS, BY EXERCISE PRICE RANGE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; border-collapse: collapse; width: 64%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;price
                                            (US$)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding at December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercisable at December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average remaining contractual
    life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zub7MEbx4Vlf"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zuhEAQqCPheg"&gt;579,004&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBDndmflcIT4"&gt;9,103&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zL7uz27QZdKd"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zo4CMb3x2C77"&gt;58.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUTjAZuuGJ53"&gt;26,274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z2KivElePXFd"&gt;26,274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zd21c6BBm3vi"&gt;5.18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWTtEQU3iu0c"&gt;100.75&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zBzFgPivlowj"&gt;3,846&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zL0f2niBp6jj"&gt;3,846&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z6I7Y9tz8loh"&gt;5.26&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231_zt0bXd0J8t3l"&gt;609,124&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231_zlRFEYgLjLya"&gt;39,223&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zbBkszpbZLaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
                                            INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 9&lt;/b&gt;
&#x2013; &lt;b&gt;COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock-based
    compensation (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Grants
    to employees (cont.)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    fair value of options granted to employees during the years ended on December 31, 2021 was estimated at the dates of grant using
    the Black-Scholes option model. The following are the data and assumptions used:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLL1OEK6u81g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&#160;&lt;span id="xdx_8BC_zfKXlYxCnMd2" style="display: none"&gt;SCHEDULE
OF ASSUMPTIONS USED TO VALUE OPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; width: 82%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
    value calculations - Warrant&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
    31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zue5XlZzHbBk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0724"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 82%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility (%) &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zbd5VVjAuA9c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49.21&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk
    free interest rate (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_z9pq2FJk3Lv" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term of options (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zTrn6VHbCiQ" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    price (US dollars)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20211231_zHWICVB3oYJh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share
    price (US dollars) &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20211231__srt--RangeAxis__srt--MinimumMember_znuEcG7VTrSl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.1&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20211231__srt--RangeAxis__srt--MaximumMember_zZF4yc5rk9Kf"&gt;4.65&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
    value (US dollars)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zTwn5sG0ukhh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.6&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zy60RI1frbdl"&gt;1.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p id="xdx_8A8_zufHsVROlNUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-02-132020-02-14_custom_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_custom_AccreditedInvestorMember"
      decimals="INF"
      unitRef="Shares">2884615</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-02-14_custom_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_custom_AccreditedInvestorMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-02-132022-02-14_custom_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_custom_AccreditedInvestorMember"
      decimals="-6"
      unitRef="USD">15000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <IGAP:CashExpensesOnIssuanceOfStock
      contextRef="From2020-02-132022-02-14_custom_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember_custom_AccreditedInvestorMember"
      decimals="-6"
      unitRef="USD">2000000</IGAP:CashExpensesOnIssuanceOfStock>
    <IGAP:CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits
      contextRef="AsOf2021-12-31_custom_PlacementAgentAgreementMember"
      decimals="INF"
      unitRef="Pure">0.07</IGAP:CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits>
    <IGAP:NonaccountableExpenseAllowancePercenatge
      contextRef="AsOf2021-12-31_custom_PlacementAgentAgreementMember"
      decimals="INF"
      unitRef="Pure">0.03</IGAP:NonaccountableExpenseAllowancePercenatge>
    <IGAP:AggregateSalesPriceOfUnitsPercentage
      contextRef="AsOf2021-12-31_custom_PlacementAgentAgreementMember"
      decimals="INF"
      unitRef="Pure">0.10</IGAP:AggregateSalesPriceOfUnitsPercentage>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantOneMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantOneMember"
      decimals="INF"
      unitRef="Shares">1062717</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantOneMember"
      decimals="INF"
      unitRef="USDPShares">3.354</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantTwoMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantTwoMember"
      decimals="INF"
      unitRef="USDPShares">108305</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantTwoMember"
      decimals="INF"
      unitRef="Shares">23.40</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantThreeMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantThreeMember"
      decimals="INF"
      unitRef="Shares">8331</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantThreeMember"
      decimals="INF"
      unitRef="USDPShares">46.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantFourMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantFourMember"
      decimals="INF"
      unitRef="Shares">8331</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_custom_TwoThousandandSeventeenOfferingMember_custom_PlacementAgentMember_custom_WarrantFourMember"
      decimals="INF"
      unitRef="USDPShares">70.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-12-31_custom_TwoThousandandTwentyOfferingMember_custom_PlacementAgentMember_custom_WarrantFiveMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-12-31_custom_TwoThousandandTwentyOfferingMember_custom_PlacementAgentMember_custom_WarrantFiveMember"
      decimals="INF"
      unitRef="Shares">288462</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_custom_TwoThousandandTwentyOfferingMember_custom_PlacementAgentMember_custom_WarrantFiveMember"
      decimals="INF"
      unitRef="USDPShares">5.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">756000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zjCncJ4E5oH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"&gt;&lt;span id="xdx_8BA_zqKLcqcL0dIl" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; border-collapse: collapse; width: 58%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Fair value calculations &#x2013; Warrant&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;31-Dec-20&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zG6kiQss7US5"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zOPAtKKPxUh3"&gt;56.32&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z39F9w5I5Xtk"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zBonNKFffTbc"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price (US dollars)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmXooMm7mJU3"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Share price (US dollars)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIn838AN9blh"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fair value (US dollars)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFairValueMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfTuNhbuoQB3"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      unitRef="Pure">56.32</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      unitRef="Pure">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExpectedTermMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">5.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2020-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">5.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2020-12-31_custom_MeasurementInputFairValueMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">2.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2007-08-31_custom_IntegrityIsraelsPlanMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="From2007-08-012007-08-31_custom_IntegrityIsraelsPlanMember">The
    options vested over a period of 1-12 quarters based on each grantee&#x2019;s option agreements. Any option not exercised within 10
    years after the date of grant thereof will expire</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:OfficersCompensation
      contextRef="From2020-06-282020-06-30_custom_ErezBenZviMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      unitRef="Israel">210000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2020-06-282020-06-30_custom_ErezBenZviMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      unitRef="USD">65000</us-gaap:OfficersCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="From2020-06-282020-06-30_custom_ErezBenZviMember_us-gaap_RestrictedStockUnitsRSUMember">1/12
    of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall
    vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the employee continues to be employed
    by the Company at the applicable date of vesting</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:OfficersCompensation
      contextRef="From2020-11-282020-11-30_custom_ShalomShushanMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      unitRef="Israel">90000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2020-11-282020-11-30_custom_ShalomShushanMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      unitRef="USD">28000</us-gaap:OfficersCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="From2020-11-282020-11-30_custom_ShalomShushanMember_us-gaap_RestrictedStockUnitsRSUMember">1/12
    of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall
    vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the Employee continues to be employed
    by the Company at the applicable date of vesting</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <IGAP:PercentageOfDulitedCommonStock
      contextRef="AsOf2021-11-20_custom_MrPaulVMember"
      decimals="INF"
      unitRef="Pure">1.5</IGAP:PercentageOfDulitedCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-11-20_custom_MrPaulVMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-11-182021-11-20_custom_MrPaulVMember"
      decimals="-3"
      unitRef="Shares">330000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-10-20_custom_MrPaulVMember"
      decimals="INF"
      unitRef="USDPShares">5.20</us-gaap:SharesIssuedPricePerShare>
    <IGAP:PercentageOfDulitedCommonStock
      contextRef="AsOf2021-12-03_custom_MrJamesPMember"
      decimals="INF"
      unitRef="Pure">1.15</IGAP:PercentageOfDulitedCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-20_custom_MrJamesPMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-12-182021-12-20_custom_MrJamesPMember"
      decimals="-3"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-12-20_custom_MrJamesPMember"
      decimals="INF"
      unitRef="USDPShares">5.20</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgTR23sZjut8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&#160;&lt;span id="xdx_8BB_z804badvxNda" style="display: none"&gt;SCHEDULE
OF STOCK GRANTS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 82%; margin-left: 1.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Grants to Employees&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average exercise price (US$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; padding-bottom: 1.5pt"&gt;Balance outstanding as of December 31,2019&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zbzfYCNDNbm2" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Number outstanding beginning balance"&gt;156,007&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zXIfIndJGbNh" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Weighted average exercise price outstanding, beginning balance"&gt;63.44&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance exercisable of December 31,2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20200101__20201231_zIfi1YoFzeGl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number exercisable, beginning balance"&gt;132,630&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zp2yw1rOxRFd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price exercisable, beginning balance"&gt;60.19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Granted during 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zMQngjh5lMgl" style="text-align: right" title="Number shares, grants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0675"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_z4Bprvx2fi78" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0677"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Forfeited during 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231_zHIzTlEkEyL6" style="text-align: right" title="Number, forfeited"&gt;(25,770&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zggqNa5rzt7e" style="text-align: right" title="Weighted average exercise price, forfeited"&gt;58.63&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance outstanding as of December 31,2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zZuvFDQJdUW1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number outstanding beginning balance"&gt;130,237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zfmzeJgTmwZb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price outstanding, beginning balance"&gt;64.35&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance exercisable of December 31,2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20210101__20211231_zt8AGEdZH1cd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number exercisable, beginning balance"&gt;128,296&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_pid_c20210101__20211231_z5ua8Ql99sFk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price exercisable, beginning balance"&gt;64.48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Granted during 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zxj2ZiyXilCb" style="text-align: right" title="Number, grants"&gt;577,064&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_z4mH7EONhW25" style="text-align: right" title="Weighted average exercise price, granted"&gt;5.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Forfeited during 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231_z7LgUYtZDtpc" style="text-align: right" title="Number, forfeited"&gt;(98,177&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zxZtW5O8XOOc" style="text-align: right" title="Weighted average exercise price, forfeited"&gt;64.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance outstanding as of December 31,2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_zCa0YdSQQXWd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number outstanding ending balance"&gt;609,124&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zRbdkWAs6nY" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price outstanding, ending balance"&gt;8.10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance exercisable of December 31,2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20211231_zAgh22zbiUQ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number exercisable, ending balance"&gt;39,223&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zKH4QqiQmyba" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price exercisable, ending balance"&gt;46.41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31" decimals="-3" unitRef="Shares">156007000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">63.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2019-12-31" decimals="-3" unitRef="Shares">132630000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">60.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="Shares">25770000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">58.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31" decimals="-3" unitRef="Shares">130237000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">64.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-12-31" decimals="-3" unitRef="Shares">128296000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">64.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="Shares">577064000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">5.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="Shares">98177000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">64.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31" decimals="-3" unitRef="Shares">609124000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">8.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2021-12-31" decimals="-3" unitRef="Shares">39223000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">46.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zVgfwIHJyx75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize information about options outstanding at December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&#160;&lt;span id="xdx_8B3_zKrNsKm2uhik" style="display: none"&gt;SCHEDULE
OF STOCK GRANTS, BY EXERCISE PRICE RANGE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; border-collapse: collapse; width: 64%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;price
                                            (US$)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding at December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercisable at December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average remaining contractual
    life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zub7MEbx4Vlf"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zuhEAQqCPheg"&gt;579,004&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBDndmflcIT4"&gt;9,103&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zL7uz27QZdKd"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zo4CMb3x2C77"&gt;58.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUTjAZuuGJ53"&gt;26,274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z2KivElePXFd"&gt;26,274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zd21c6BBm3vi"&gt;5.18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWTtEQU3iu0c"&gt;100.75&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zBzFgPivlowj"&gt;3,846&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zL0f2niBp6jj"&gt;3,846&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z6I7Y9tz8loh"&gt;5.26&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231_zt0bXd0J8t3l"&gt;609,124&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231_zlRFEYgLjLya"&gt;39,223&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-01-012021-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="USDPShares">5.2</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="Shares">579004</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="Shares">9103</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceOneMember">P2Y9M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-01-012021-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="USDPShares">58.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">26274</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">26274</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceTwoMember">P5Y2M4D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-01-012021-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="USDPShares">100.75</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">3846</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2021-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">3846</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceThreeMember">P5Y3M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">609124</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">39223</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zLL1OEK6u81g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&#160;&lt;span id="xdx_8BC_zfKXlYxCnMd2" style="display: none"&gt;SCHEDULE
OF ASSUMPTIONS USED TO VALUE OPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; width: 82%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
    value calculations - Warrant&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
    31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zue5XlZzHbBk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0724"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 82%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility (%) &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231_zbd5VVjAuA9c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49.21&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk
    free interest rate (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231_z9pq2FJk3Lv" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term of options (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zTrn6VHbCiQ" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    price (US dollars)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20211231_zHWICVB3oYJh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share
    price (US dollars) &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20211231__srt--RangeAxis__srt--MinimumMember_znuEcG7VTrSl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.1&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20211231__srt--RangeAxis__srt--MaximumMember_zZF4yc5rk9Kf"&gt;4.65&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
    value (US dollars)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zTwn5sG0ukhh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.6&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zy60RI1frbdl"&gt;1.48&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0.4921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-01to2021-12-31">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">5.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">3.1</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">4.65</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80A_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zcccsdkPSwne" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 &#x2013; &lt;span id="xdx_827_zxVETZ3pFKNk"&gt;RESEARCH AND DEVELOPMENT EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_89B_ecustom--ScheduleOfResearchAndDevelopmentExpensesTableTextBlock_zj1niLzcqLz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&#160;&lt;span id="xdx_8BD_zgjnOeehpJ7k" style="display: none"&gt;SCHEDULE
OF RESEARCH AND DEVELOPMENT EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210101__20211231_zJkwsET1pU5j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20200101__20201231_z31ccH8YmWL7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In thousand of US dollars&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;p style="margin: 0"&gt;Research and Development&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LaborAndRelatedExpense_maRADEzgxz_zy7obYeNTb64" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Salaries and related expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;916&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;754&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ProfessionalFees_maRADEzgxz_zuFNn5S2zVm1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;462&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InventoryWriteDown_maRADEzgxz_zSeGenFyUPyf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expenses due to slow inventory write-off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;321&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0745"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DepreciationAndAmortization_maRADEzgxz_zrxmDqMWj5g4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CostOfPropertyRepairsAndMaintenance_maRADEzgxz_znL8tU2Lk2wa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vehicle maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherGeneralExpense_maRADEzgxz_zmbi7AQ6gqqj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;162&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEzgxz_zHdJWSUSuhRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total research and development
    expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,810&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,532&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p id="xdx_8A8_zyau6CMNXzMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <IGAP:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89B_ecustom--ScheduleOfResearchAndDevelopmentExpensesTableTextBlock_zj1niLzcqLz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&#160;&lt;span id="xdx_8BD_zgjnOeehpJ7k" style="display: none"&gt;SCHEDULE
OF RESEARCH AND DEVELOPMENT EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210101__20211231_zJkwsET1pU5j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20200101__20201231_z31ccH8YmWL7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In thousand of US dollars&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;p style="margin: 0"&gt;Research and Development&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LaborAndRelatedExpense_maRADEzgxz_zy7obYeNTb64" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Salaries and related expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;916&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;754&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ProfessionalFees_maRADEzgxz_zuFNn5S2zVm1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;462&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InventoryWriteDown_maRADEzgxz_zSeGenFyUPyf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expenses due to slow inventory write-off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;321&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0745"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DepreciationAndAmortization_maRADEzgxz_zrxmDqMWj5g4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CostOfPropertyRepairsAndMaintenance_maRADEzgxz_znL8tU2Lk2wa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vehicle maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherGeneralExpense_maRADEzgxz_zmbi7AQ6gqqj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;162&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEzgxz_zHdJWSUSuhRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total research and development
    expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,810&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,532&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</IGAP:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">916000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">754000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ProfessionalFees
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">337000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">462000</us-gaap:ProfessionalFees>
    <us-gaap:InventoryWriteDown
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">321000</us-gaap:InventoryWriteDown>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">32000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">32000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostOfPropertyRepairsAndMaintenance
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">42000</us-gaap:CostOfPropertyRepairsAndMaintenance>
    <us-gaap:CostOfPropertyRepairsAndMaintenance
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">47000</us-gaap:CostOfPropertyRepairsAndMaintenance>
    <us-gaap:OtherGeneralExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">162000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">237000</us-gaap:OtherGeneralExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">1810000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">1532000</us-gaap:ResearchAndDevelopmentExpense>
    <IGAP:SellingAndMarketingExpensesTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_804_ecustom--SellingAndMarketingExpensesTextBlock_zbLmABdAAtph" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 &#x2013; &lt;span id="xdx_823_zGaun3mk2yg5"&gt;MARKETING EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_899_ecustom--ScheduleOfSellingAndMarketingExpensesTableTextBlock_zH5ac9akaOp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&#160;&lt;span id="xdx_8BC_zkjCBInLSFw8" style="display: none"&gt;SCHEDULE
OF SELLING AND MARKETING EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Selling and Marketing&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210101__20211231_zohCQLqIHKr1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December
    31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20200101__20201231_zfvdPLlHFJv6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December
    31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--SalariesAndRelatedExpenses_maSGAAEz1YR_zTvk3hgUK9t9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Salaries and related expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;156&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ResearchAndDevelopmentProfessionalFees_maSGAAEz1YR_zMazA1bRJbn3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--SellingAndMarketingOtherExpenses_maSGAAEz1YR_zs0inEMN6Yfb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--SellingGeneralAndAdministrativeExpense_iT_pn3n3_mtSGAAEz1YR_zxrFStdDZe83" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total selling and marketing
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;139&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;415&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zlTbfS1xV4a1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</IGAP:SellingAndMarketingExpensesTextBlock>
    <IGAP:ScheduleOfSellingAndMarketingExpensesTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_899_ecustom--ScheduleOfSellingAndMarketingExpensesTableTextBlock_zH5ac9akaOp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&#160;&lt;span id="xdx_8BC_zkjCBInLSFw8" style="display: none"&gt;SCHEDULE
OF SELLING AND MARKETING EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Selling and Marketing&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210101__20211231_zohCQLqIHKr1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December
    31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20200101__20201231_zfvdPLlHFJv6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December
    31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--SalariesAndRelatedExpenses_maSGAAEz1YR_zTvk3hgUK9t9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Salaries and related expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;156&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ResearchAndDevelopmentProfessionalFees_maSGAAEz1YR_zMazA1bRJbn3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--SellingAndMarketingOtherExpenses_maSGAAEz1YR_zs0inEMN6Yfb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--SellingGeneralAndAdministrativeExpense_iT_pn3n3_mtSGAAEz1YR_zxrFStdDZe83" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total selling and marketing
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;139&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;415&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</IGAP:ScheduleOfSellingAndMarketingExpensesTableTextBlock>
    <IGAP:SalariesAndRelatedExpenses
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">22000</IGAP:SalariesAndRelatedExpenses>
    <IGAP:SalariesAndRelatedExpenses
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">156000</IGAP:SalariesAndRelatedExpenses>
    <IGAP:ResearchAndDevelopmentProfessionalFees
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">115000</IGAP:ResearchAndDevelopmentProfessionalFees>
    <IGAP:ResearchAndDevelopmentProfessionalFees
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">241000</IGAP:ResearchAndDevelopmentProfessionalFees>
    <IGAP:SellingAndMarketingOtherExpenses
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">2000</IGAP:SellingAndMarketingOtherExpenses>
    <IGAP:SellingAndMarketingOtherExpenses
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">18000</IGAP:SellingAndMarketingOtherExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      unitRef="USD">139000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">415000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <IGAP:GeneralAndAdministrativeExpensesTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_805_ecustom--GeneralAndAdministrativeExpensesTextBlock_zBaFdEAgPQo9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12 &#x2013; &lt;span id="xdx_824_zsTxyLV4rMia"&gt;GENERAL AND ADMINISTRATIVE EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_893_ecustom--ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_ze3X159d1ns8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&#160;&lt;span id="xdx_8B2_z9VxWPN7iCsk" style="display: none"&gt;SCHEDULE
OF GENERAL AND ADMINISTRATIVE EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZe2zEorLkb7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsUypMV9dnYh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In thousand of US dollars&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;General and Administrative&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LaborAndRelatedExpense_pn3n3_maGAAEzQ9k_ze209rYWDyd7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Salaries and related expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;608&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;368&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ProfessionalFees_pn3n3_maGAAEzQ9k_zxYv3yAsdMni" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;694&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--BadDebtExpense_pn3n3_maGAAEzQ9k_zTh3ST4sVCE7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Bad debt expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0786"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CostOfPropertyRepairsAndMaintenance_pn3n3_maGAAEzQ9k_zox4jP414Iuj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Vehicle maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DepreciationAndAmortization_pn3n3_maGAAEzQ9k_z1i1Fii3c0o" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--InvestmentIncomeInvestmentExpense_pn3n3_maGAAEzQ9k_z5XvhHsnifhb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_maGAAEzQ9k_zdFEX10ajw0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_iT_pn3n3_mtGAAEzQ9k_zDWzqMVW1rZ9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total general and
    administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,091&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,185&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z5Wn1FFQtVed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</IGAP:GeneralAndAdministrativeExpensesTextBlock>
    <IGAP:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_893_ecustom--ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_ze3X159d1ns8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&#160;&lt;span id="xdx_8B2_z9VxWPN7iCsk" style="display: none"&gt;SCHEDULE
OF GENERAL AND ADMINISTRATIVE EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZe2zEorLkb7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsUypMV9dnYh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In thousand of US dollars&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;General and Administrative&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LaborAndRelatedExpense_pn3n3_maGAAEzQ9k_ze209rYWDyd7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Salaries and related expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;608&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;368&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ProfessionalFees_pn3n3_maGAAEzQ9k_zxYv3yAsdMni" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;694&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--BadDebtExpense_pn3n3_maGAAEzQ9k_zTh3ST4sVCE7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Bad debt expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0786"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CostOfPropertyRepairsAndMaintenance_pn3n3_maGAAEzQ9k_zox4jP414Iuj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Vehicle maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DepreciationAndAmortization_pn3n3_maGAAEzQ9k_z1i1Fii3c0o" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--InvestmentIncomeInvestmentExpense_pn3n3_maGAAEzQ9k_z5XvhHsnifhb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_maGAAEzQ9k_zdFEX10ajw0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_iT_pn3n3_mtGAAEzQ9k_zDWzqMVW1rZ9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total general and
    administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,091&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,185&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</IGAP:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">608000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">368000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ProfessionalFees
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">1224000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">694000</us-gaap:ProfessionalFees>
    <IGAP:BadDebtExpense
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">59000</IGAP:BadDebtExpense>
    <us-gaap:CostOfPropertyRepairsAndMaintenance
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">41000</us-gaap:CostOfPropertyRepairsAndMaintenance>
    <us-gaap:CostOfPropertyRepairsAndMaintenance
      contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">28000</us-gaap:CostOfPropertyRepairsAndMaintenance>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">10000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InvestmentIncomeInvestmentExpense
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">97000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense
      contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">73000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">52000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">7000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">2091000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">1185000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_802_eus-gaap--IncomeTaxDisclosureTextBlock_zD1206RLb38h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13 &#x2013; &lt;span id="xdx_823_zQfhPQppk788"&gt;INCOME TAX&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Measurement
    of results for tax purposes under the Israeli Income Tax (Inflationary Adjustments) Law, 1985 (the &#x201c;Inflationary Adjustment
    Law&#x201d;)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commencing
    January 1, 2008, the results of operations of Integrity Israel for tax purposes have been measured on a nominal basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Tax
    assessments&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
    federal, state and local income tax purposes the Company remains open for examination by the tax authorities for the tax years from
    2017 through 2020 under the general statute of limitations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Notwithstanding,
    pursuant and subject to the provisions of article 145 of the Income Tax Ordinance, Integrity Israel&#x2019;s tax returns that were
    filed with the tax authority up to and including 2016 are considered final.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Carryforward
    tax losses&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2021, the Company had cumulative net operating losses (NOL) for US federal purposes of approximately $&lt;span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231_z5AesVbqpV58"&gt;10.5
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million. Integrity Israel has losses carry
forward balances for Israeli income tax purposes of approximately $&lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zj4KdvCzNdG4"&gt;41.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million to offset against future taxable
income for an indefinite period of time.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2021 and 2020, the main reconciling item between the statutory tax rate of the Company and the effective
tax rate at the rate of &lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20210101__20211231_zFL23d7MV5Wi"&gt;&lt;span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20210101__20211231_zvV9c6rX2yDf"&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
for 2021 and 2020, respectively, is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating
losses carried forward and other permanent and temporary differences due to the uncertainty of the realization of such deferred taxes
and withholding taxes that were deducted by the Company&#x2019;s customers.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GLUCOTRACK
INC. (FORMERLY: INTEGRITY APPLICATIONS, INC.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13&lt;/b&gt; &#x2013; &lt;b&gt;INCOME TAX (cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    taxes result principally from temporary differences in the recognition of certain revenue and expense items for financial and income
    tax reporting purposes. Significant components of the Group&#x2019;s future tax assets are as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxta6JHExGt7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zBxd64DGl1Y7" style="display: none; text-transform: uppercase"&gt;SCHEDULE
OF DEFERRED TAXES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231_zMyzFB15wbV6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20201231_z0NYxt4dnPcl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Composition of deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_maDTANztgP_zBh0msQw1KXg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Provision for employee-related obligation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;p style="margin: 0"&gt;6&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 16%"&gt;22&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANztgP_zIRN9dDuIgt4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-capital loss carry forwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;11,654&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;10,889&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DeferredTaxAssetValuationAllowance_iI_pn3n3_msDTANztgP_z1DF1u6Qv6R3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;(11,660&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,912&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3_z8qN6Od92Ql3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total deferred
    tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0821"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

&lt;p id="xdx_8AB_zpghoy2Je6L2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="-5" unitRef="USD">10500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-12-31_us-gaap_IsraelTaxAuthorityMember"
      decimals="-5"
      unitRef="USD">41000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxta6JHExGt7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zBxd64DGl1Y7" style="display: none; text-transform: uppercase"&gt;SCHEDULE
OF DEFERRED TAXES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 89%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231_zMyzFB15wbV6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20201231_z0NYxt4dnPcl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Composition of deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_maDTANztgP_zBh0msQw1KXg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Provision for employee-related obligation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;p style="margin: 0"&gt;6&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 16%"&gt;22&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANztgP_zIRN9dDuIgt4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-capital loss carry forwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;11,654&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;10,889&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DeferredTaxAssetValuationAllowance_iI_pn3n3_msDTANztgP_z1DF1u6Qv6R3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;(11,660&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,912&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3_z8qN6Od92Ql3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total deferred
    tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0821"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">22000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">11654000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">10889000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <IGAP:DeferredTaxAssetValuationAllowance contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">-11660000</IGAP:DeferredTaxAssetValuationAllowance>
    <IGAP:DeferredTaxAssetValuationAllowance contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">-10912000</IGAP:DeferredTaxAssetValuationAllowance>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80F_eus-gaap--SegmentReportingDisclosureTextBlock_z4GWlBfIRW67" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
14&lt;/b&gt; &#x2013; &lt;span id="xdx_82F_zxMqzbny23mc"&gt;&lt;b&gt;SEGMENT INFORMATION&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates in &lt;span id="xdx_904_eus-gaap--NumberOfOperatingSegments_dc_uSegments_c20210101__20211231_zDoyREnm7Iye"&gt;one&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;operating segment with no income in 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
long-lived assets are owned by Integrity Israel and are located in Israel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      unitRef="Segments">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zL4MFU8V2Ryh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
15 &#x2013; &lt;span id="xdx_820_z6LIDgdQs7id"&gt;RELATED PARTIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Andrew
    Garrett, Inc., which is controlled by one of our directors, Andrew Sycoff, received during the year ended December 31, 2020, cash
    approximately $&lt;span id="xdx_90A_eus-gaap--RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_pn5n6_c20200101__20201231__dei--LegalEntityAxis__custom--AndrewGarrettIncMember__srt--TitleOfIndividualAxis__custom--AndrewSycoffMember__us-gaap--AwardTypeAxis__custom--PlacementAgentFeesMember_z5f5yxVYmoyd"&gt;2
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million in placement agent fees and &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20201231__dei--LegalEntityAxis__custom--AndrewGarrettIncMember__srt--TitleOfIndividualAxis__custom--AndrewSycoffMember__us-gaap--AwardTypeAxis__custom--PlacementAgentFeesMember_zKZvKPMI9W34"&gt;3,750,000
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants for Placement Agent fees in 2020
    from us.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the year ended December 31, 2020, $&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200101__20201231_zjpRS4cnfMld"&gt;756
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand, representing the fair value of
    warrants issued as consideration for placement agent services to AGI. This amount was accounted for as Warrants with down-round protection.
    Upon issuance, the fair value was recognized as an increase in additional paid in capital&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="From2020-01-012020-12-31_custom_AndrewGarrettIncMember_custom_AndrewSycoffMember_custom_PlacementAgentFeesMember"
      decimals="-5"
      unitRef="USD">2000000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-12-31_custom_AndrewGarrettIncMember_custom_AndrewSycoffMember_custom_PlacementAgentFeesMember"
      decimals="INF"
      unitRef="Shares">3750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-012020-12-31"
      decimals="-3"
      unitRef="USD">756000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2021-01-01to2021-12-31">&lt;p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zJ6r4XDoepWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    16&lt;/b&gt; &#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82E_zynLQNENpgC8"&gt;SUBSEQUENT
    EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has evaluated all subsequent events through the date when these
financial statements were issued to determine if these must be reported. The Company determined that there were no reportable subsequent
events to disclose in these financial statements.&lt;/span&gt;&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#xdx2ixbrl0235"
          xlink:label="xdx2ixbrl0235"
          xlink:type="locator"/>
        <link:footnote id="Footnote000308" xlink:label="Footnote000308" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Less than 1 thousand</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0235"
          xlink:to="Footnote000308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0285"
          xlink:label="xdx2ixbrl0285"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0285"
          xlink:to="Footnote000308"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !B ?U0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  8@']4<\"!7NT    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)TU (71[6?&D(+B@> O)[&ZP:4(RTN[;V\;=+J(/X#$S?[[Y
M!J8U49F0\#F%B(D<YIO)]T-6)F[8D2@J@&R.Z'6NY\0P-_<A>4WS,QT@:O.A
M#PB"\UOP2-IJTK  J[@26==:HTQ"32&=\=:L^/B9^@*S!K!'CP-E:.H&6+=,
MC*>I;^$*6&"$R>?O MJ56*I_8DL'V#DY9;>FQG&L1UER\PX-O#T]OI1U*S=D
MTH/!^5=VBDX1-^PR^55N[W</K!-<B(K+2C8[P17G2MZ]+ZX__*["/EBW=__8
M^"+8M?#K+KHO4$L#!!0    ( !B ?U297)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MXE&VN6;49R*] ,XO.7A>L9/^P/ZSW.6_4$L#!!0    ( !B ?U1^Z37=*P4
M &84   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULE5AM;^(X$/XK%K<Z
M=:528@="Z $2?3DM.J[M%;JG^^@FIEA-8M8VL/WW9R<T";'C=K]  C/C9\8S
M\W@\/C#^*C:$2/ S33(QZ6RDW%[V>B+:D!2+"[8EF?IGS7B*I7KE+SVQY03'
MN5*:])#G!;T4TZPS'>>_/?#IF.UD0C/RP('8I2GF;U<D88=)!W;>?WBD+QNI
M?^A-QUO\0I9$/FT?N'KKE59BFI),4)8!3M:3S@Q>7J-0*^02WRDYB-HST*X\
M,_:J7^;QI.-I1"0AD=0FL/K:DVN2)-J2PO'C:+13KJD5Z\_OUO_,G5?./&-!
MKEGR+XWE9M().R F:[Q+Y",[?"-'AP;:7L02D7^"0R$[\#L@V@G)TJ.R0I#2
MK/C&/X^!J"G ?HL".BJ@SRKX1P4_=[1 EKMU@R6>CCD[ *ZEE37]D,<FUU;>
MT$QOXU)R]2]5>G)ZS3+!$AIC26)PA1.<100LM3D!NN!I>0/.OGP%7P#-P&K#
M=@)GL1CWI%I9Z_>BXRI7Q2JH994;$ET 'YX#Y"%H4;_^O+IWJMY3_I9.H])I
ME-L+VIS><4XR"69"*#\=!OW2H)\;]-L,8K$!*C0@T@_DQX[N<:)6L(:J,-7/
M3>DJVT\#+T#CWKX>$%-H%"*_%#I!V2]1]ITH9U'$=@J4*K^(*(3/"3D'&9$V
MD$Y+NK=<BBV.R*2CFH<@?$\Z4V#;V,+.H.YL8/=B4'HQ<'HQS_8JLHR_@;,[
M)@GPO]KP.VW\ OZ!@1^%?;L#0>E X'3@7FX(5[5=Y""VY&#A0F LW?<;66**
M#%JB.RS!#9W@5DSBY!/@AN:^0F_0@&<*00^AD1UA6"(,W>';$HXES5Y 0E3_
M!EPWZBY;=W?JI0"<9_4Q/?K6] C-V'H-\*8(;$O=40E]Y(3^P!7]<OF6MPK=
M);:*$&4=[<"*=F0&>]1 :XK ?DN@H5=Q@^?$^TB$Y#32U* ;F[7O>V8*P@8V
MBTRMWYUBJ_$6="?J_6JV +/E\G:UM *#ED6#9H9:I*"GVG$+NHI@X.<89D'Q
M,TVHI,1%,[#B&>@FFK*%;_&;[M]6SWW3<]_8$U,H#-H2IB(8Z&:89FTFE?OG
M95-QU24T^0(UFYY%IJTEPXI4H)M53IMR#?<1;F"':Z$'U"Q-BY _:LO_BD2@
MFT5.&W72EF='G"91A*$15U,(^OU!"]"*4.#060IW+.M&OU8.%15 -Q<L&,X$
M6'.6 G52CEXW+(D)?]^SH7W/S,:.8+/Y6X3@:-@2BJK]0W?_=Y9'5HN3LT0L
MK7[8A&_*A"T9ARHV0&XV*#*N#O.#K$-FWT>H"=4F-&QI1*AB!_0!.^18/\)G
M:?[02 6;5(!:&@ZJC2!NAEC6\O7WWT($AW^ 6W4DD&^N :<B"O3!1,+25$W)
M^2K@.TYV5JI )@O )D6Z94[A542!/AA%XICJ,5YMTA;3N*O&RPAOJ=HT*TRS
MXZN#9 ";0Y-=SJ\=2$[A5NR W.R@:'>7[I)\2&8%4[!430X;?9^Q)VHZ5N\$
MG"5,"&O1(I,#ND$3O2G3&NB*)I";)NK(8[*F$;6.>\CL_=W1L!\8&&UROC]J
M*]B*)=!GY@YA*0IB*8HC:'.^&,"!D;^F5#AJ[885]2 W]13GS\5\=C5?S%?S
MVR68W=V Y>K^^J]O]XN;V\=E6=7_/,U7_UD=",VK /.,:I&RG5%[M4L@?0/W
M-^8O5+%C0M9*S[L8J@CPXE*K>)%LF]\+/3,I69H_;@A6H=<"ZO\U4R1T?-%7
M3>75XO1_4$L#!!0    ( !B ?U1KR_QN: (  ),&   8    >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&ULE55=;],P%/TK5L0#2*-)TR8=4QMIZS3! U*U"GA
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M7I?'D<TTY>GH=ZH@3!KE; M31A]G0+ J#QS+&R-W[LQN(XV1A;O,&(5O-6L
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M:ZKHZZ4"=)7W=^;%X!L/<:5K.'0^=1"P GQNCE_F;=8<6H_1&&YRCZ-WJ^<
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ML;1+A.N\J]X.(4>-)'0<-KD?3C'J+^F<--?_7?V/=5_LZ'Z <9XP+^]4TLW
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M\-<D!M-.R';CJ Y3:46.9UQ8EOQ10>,/L']-Y/8;'Z#_3,W_!5!+ P04
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M965T<R]S:&5E=#$S+GAM;*U446^;,!!^YU><F#1MTE0"R;JT2R(10ELTFD1
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MMRW-<X?2)IAX(83>&_: _@&-_P)02P,$%     @ &(!_5,F/_F?) @  $P8
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M_AH/^70,7\JIM+^PKWU;71?2G52\.H"U@JID]9<\'^IP NC[[P#" R"TNNM
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MKO00L<M"3VT4QD&?YYRKHV$"-/\#X[]02P,$%     @ &(!_5+I%T2!$!@
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MEJ0D/Q1JKQ[E#K\PC3]BH;%15,YJW09IZUD2ZP5ERTR1][U09=650M$M@RL
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M%C1L0-]3K5WSPAML?@2=_0=02P,$%     @ &(!_5!#2--Q7 @  "@4  !D
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M0PVEAK@BP[#D)Q"M#^#]PAC:3?P!PZ.Z_ =02P,$%     @ &(!_5&ROY/K
M'P  ?&4  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULW5U)<]M(EK[G
MK\AP=T]($2 M4O+:58Z@9<G%:EE6BU*Y.R;F  ))$F408"4 T>Q?/V_)#10(
M+X>)F#I4F021V\NW?&_)U$_;4G^N5DK5\LLZ+ZJ?GZSJ>O/ZZ=,J6:EU7 W+
MC2K@ET6IUW$-7_7R:;71*DZIT3I_.CXY>?YT'6?%DS<_T;,;_>:GLJGSK% W
M6E;->AWKW5N5E]N?GXR>V >WV7)5XX.G;W[:Q$LU4_7]YD;#MZ>NES1;JZ+*
MRD)JM?CYR63T^NWX.3:@-W[+U+8*/DM<RKPL/^.7:?KSDQ.<D<I54F,7,?SS
MH,Y5GF-/,(\_3*=/W)C8,/QL>[^DQ<-BYG&ESLO\4Y;6JY^?O'PB4[6(F[R^
M+;>_*+.@9]A?4N85_5]N^=UG9T]DTE1UN3:-80;KK.!_XR^&$$&#ER<'&HQ-
M@S'-FP>B6;Z+Z_C-3[K<2HUO0V_X@99*K6%R68&[,JLU_)I!N_K-[/[#A\GM
MO^7'2SF;OK^>7D[/)]=W<G)^_O'^^FYZ_5[>?+R:GD\O9O+HILRS)%/5\4]/
M:Q@:.WB:F&'>\C#C \.,QO)#6=2K2EX4J4K;'3R%.;N)C^W$WXY[>WRGDJ$\
M'45R?#(>]?1WZ@AQ2OT]/]#?)$G*IJBS8BGM.N5_3^95K8%Q_J=G@#,WP!D-
M<'I@@,NF($:,<]A7K561[+KHV-_)9"CO*R7+A515G0%3PBRS0M8K)4$H-[&.
MB=?A]T56Q$62P6A5#:^!(-65N%LIL?=>4A85K#>%=]+.1M@_O(0*(*MWP)[U
M"F3)$6NC,VBQR6$B2U4H'>?Y#G]7&^S0S.V^R/#;##NMQ-%__>7E>'SR]_OA
M;"C?3R8W]'WT]V,0\S^:3$-7Z[@ G8#CR[J$;Y]5L."X2&5<@1[9X"(J&"&N
M9;Q8@*#3:+# 4N-X\1IG6>$RX7U54U.19_$\R[,Z,UUADS2KDKRL&JT,37!M
M.+IO)UOM>*24Y@,M\,M7*1G9X437#+5Z4$5CYJ2^@-JMX$O::*2R7Q;17.FL
M3*NAG"1U T, Q4 )53"#)D]A+4 *+1>Z7$.[L@I(!RTJ$6\VP-_Q/%=(VV^<
M.;ZV+JM:5MFRR!;0'HAS>$NTRN&Y[7]9XJQAE$3I0@3O#<7;H>P0#&+4Q>/G
MEM3GY7H3%SN95<Q>,YF6>1[K2&Y76;*RS_>; :^BZ9$*IE*NLT2JXB'394%\
M!JQJ&M<2C)XF>HEI0<RN4Z")8N:?S,[ER].32!HV!NL NK^0YW:T#W%=*UT9
MKI9'IL%Q!/8CQWY@6Q5.H(B-C)0:N*OX#%^ 8@O3GR-&#%Q)>Y'*DN4)[%#F
M^$Y]258Q<*ND*:,>>(B!3X'BADN##3<3D&SQ<<.!_C#Z_I@2U%Y1Q43_2H"$
MYTWJQ=DQ!DZ!:87O15W3"08WDP?>@!FB9/LQC"3A2IM*I: 6 %!41)<2)!"8
M5F<5+HFXF@=PFF]O1.S _D1#Y$[950WL;[@T&C&)M<Y0&"O+_# 0K+E<*YR!
ME<4A<J4\P)73HE9+C0IR6NE8Y98%KP&7\)-,SE;J,_QBU=_U=.84'\I/5E?=
M"ACG:+= L#8VX@KSB B4,&<$B\T*X"0G%Z0JD(MA9?DN.J35MDI[DJ$J0&+#
M-&6K+]'03NQ4K >*=%5(?E9RAGJ!*H/EJ?7C(5!S/P #+1]M8Z#Y<"C/$H)9
MPF@]QQ3AZN/T=X!.GGJ ]! &,E\ IDH^K\H\-3(Z>O%WB7:G!L(T@$ZT%6P0
M_&;=\#Q+F(<6L"@0KQ6"T@=E%WF$\SDV6SF4L_-?+M[=7UT(@%0?+P%/32=7
M\N)?Y[],KM]?R-O)W85 R(*XY41\7( JQ>UN+1X9"LD^:A%>G@Q/H1W\?S0"
MO90 " >R'J6*/QU;?5!^3Y],96&I_)KG=CH<C^7?\/.)?#&$C_+]U?WYQ[O;
MR?D_Q/3Z?"B/+C_>?KBXO?KW:SF]OKMX?SN]^[><W-P 5IS<33]>SR*)[QW+
MZX]W%S-Q]U&>PT. DN^  ._DY?1Z<DV4F=W!@P\7UW< ,-'NFB9R3+LP OWY
M/1"5>^A!:\\<6GO6"[1N/*QI@23@KB[4UML9>E:OJTV<J)^? /M42C^H)V_.
MA\(/(O8'(0OX+=B,U *K>09EU;Z1M+JE:N95EF9@ $$;Y#FJ"*43\Y*S3 11
M0N6_ OF4<Z4*"3HLL%FMZ0YE#\V?.YH_[Z7Y>5RM:/P$/Z!(/L0Y+K.+XKU=
M=5/\W5 <'(+H_5Z7S886EJ%RD(!EP5("Z!H I=:PZ =EM(H%&JA<5N#X >;-
M,^@M#5]BN%#J;)FAN0"D!,)&BI9V2"N$5.04H9U3%5@Y#ROQG4VC08(K%:',
MSM6C2?=2_86C^HM>JD]APF LP )VTKFW<3>=+Q VN4Y;GP,H8]::EV 26,8
M70(A"@ FH-#R[#\$&F"IC8*-@U]%AL )MP)FP>8:E%BYK5Z+3T!I0-75AGR
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M;X+65]0^4!5&V+S,H4> UA5PGS:+YE^]^Q;$BEC!)8=<'B2 *DB\P*_,;1C
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M9 ]AN75.V+8HPU[0Z,5X2(Y+ZWA9IV$?@4F,*U>G'I!#^'Q_%^N$26V;@K1
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MSC#%'3#Y5%E['= Z\F4D%%?G$S]\?(%.8YC8A<Z62SK$&6[ QL_O*!NJ(==
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M!>GD":MK0MS![5;^O&#;TKL<IZ"NJ_YD6"@?Y*' H!BI-JX(O/1\<#*.>''
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ME-+X OR^* '#F2\X@/N#*V_^%U!+ P04    "  8@']4>J/BH[P#  #."
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M&Z;T<J*R!K1_D-*<)_: ]BV>_ -02P,$%     @ &(!_5+>9>D:_ @  V@4
M !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL?53;;MLP#'W/5Q >,+1
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M@6P:N3&TJ%SSI$*;5G3+PLP^E#; [.^$T$?#)NBF:?(74$L#!!0    ( !B
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MM!D^MZW,:X?2!ICS4@C=&S;!\'XF?P%02P,$%     @ &(!_5 BN8)7# @
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M!CWHM9Q[56B/G1!ZSHHK+;EY3=(A;Y-LO(87_B#0OH)^!S[Z,;R35JQ0;.S
MD9#R'5-U5S:GS4R+ZE9^#:\'XAT1FY))H)AKJ'_9Z[@@ZB%3;Q3?VL9><Z7'
MA%T6>BZC, 'Z/N=<'3=&H)GTX_]02P,$%     @ &(!_5%?D?B>; @  404
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M%E0#Q0O;]S9<Z2YJ'U-]E4)A%NCW6\[5T\"TTN9R-OT-4$L#!!0    ( !B
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M5-27@WJC>&D'\AU7>KS;9:8O5"B,@7Z><JXV&T/07-&&?P!02P,$%     @
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M165>9C8-R7X4,ADG0%E&1;\G,RO(FG2;UOX[(9=!NY!!(V30*611YFN4(+9
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ML;WHIX5]+4"Y!+N_E=(< M>0_?N3_@502P,$%     @ &(!_5*_20!D4 P
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M<RR(/.<5EOIDS45!E%Z*C2LK@22SH(*Y?J]WX1:$EDX<V;U'$4>\5HR6^"A
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MF !]ON9<O2U,AW</>OP?4$L#!!0    ( !B ?U34A.0=&@,  &\(   9
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MBD9.P1+R!(7F4H#"Q65MX'T<>UT+R&9\X;C1+Y[!NC*7\KL=^.%ES;6*,,;
M6 I&/VL<8AQ;)M+Q(R>M%38M\.7S,_M-YCPY,V<:AS+^RD,37=8N:A#B@J6Q
M>9";3Y@[U+)\@8QU]A\V^5RW!D&JC4QR,"E(N-C]LJ<\$%4 ]1Q0?P6H>T<
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M@8\KM@O5C.\_83:@ILFWY*%,?F&?M74L6.ZDXE$6K FB($[_V7WV((X"W+(
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M*Q^4B05=@E^V" &L-0OO6+2P5BULEJUU<H0:NO0@=)EG(H-CF.X>NJ8\J:V
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M^L^#P@3H_17GZFEBS*WYET5_ 5!+ P04    "  8@']4*'SRSY$"  ".!@
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M#:[ZE%V5C:B<&+ESQ;^1AEJ)&Z;4NU'9#11/I#3'B4U0_QN,_@%02P,$%
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M<6 TFX2-67X8A9>'#8B)6<>@+F?@@*3Z.6\DV3*J>A!B8M8QJ(L;;$#JR-%
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MWQ[=/6],U1[S6?]+S>P-4$L! A0#%     @ &(!_5 =!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  8
M@']4<\"!7NT    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    "  8@']4F5R<(Q &  "<)P  $P
M@ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !B ?U0=<[IN
MF@8  *(;   8              " @0P(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    "  8@']4?NDUW2L%  !F%   &
M@('<#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ &(!_
M5&O+_&YH @  DP8  !@              ("!/10  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( !B ?U3O#-7 )00  %0-   8
M      " @=L6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M"  8@']4[>1+MI,%   )'0  &               @($V&P  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ &(!_5&"#XF.$!0   A8  !@
M             ("!_R   'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( !B ?U1GM,\RU0(  #@'   8              " @;DF  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  8@']4$$XM(L$*  #2
M&0  &               @('$*0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ &(!_5&1#(Y ''@  2%@  !@              ("!NS0
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( !B ?U2D[8UW
M10,  +(&   9              " @?A2  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ &(!_5 DF9OZF!   ?PD  !D
M ("!=%8  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  8
M@']4Y6>T!1 #  "V!@  &0              @(%16P  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( !B ?U058W 1V0(  -@%   9
M          " @9A>  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#
M%     @ &(!_5,_.!KI;!   2@D  !D              ("!J&$  'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  8@']4UIAE=YL%
M#   &0              @($Z9@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;%!+ 0(4 Q0    ( !B ?U2F0R;=* \  %@M   9              " @0QL
M  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ &(!_5,X@
MQ' M P  @@8  !D              ("!:WL  'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6Q02P$"% ,4    "  8@']4T1W%[FX"  !,!0  &0
M    @('/?@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M !B ?U3)C_YGR0(  !,&   9              " @72!  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ &(!_5+I%T2!$!@  $ T  !D
M             ("!=(0  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    "  8@']4$-(TW%<"   *!0  &0              @('OB@  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !B ?U2*%X'"/P,
M +<&   9              " @7V-  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ &(!_5&ZA!&EK @  8 4  !D              ("!
M\Y   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  8@']4
M;*_D^L ?  !\90  &0              @(&5DP  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( !B ?U1ZH^*CO ,  ,X(   9
M      " @8RS  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ &(!_5+\;]OAZ @  ,@4  !D              ("!?[<  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  8@']453$&JE@#  "7!P
M&0              @($PN@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( !B ?U2WF7I&OP(  -H%   9              " @;^]  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ &(!_5$GIQ!&
M @  604  !D              ("!M<   'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    "  8@']4,_@=8LL$  "T#   &0
M@(%LPP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( !B
M?U3+\%E/T@(  /H%   9              " @6[(  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ &(!_5%27OY9M @  2P4  !D
M         ("!=\L  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    "  8@']4"*Y@E<,"  #U!0  &0              @($;S@  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( !B ?U17Y'XGFP(  %$%
M   9              " @171  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ &(!_5*&  STK P  J D  !D              ("!Y],
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  8@']4SGC&
M>(X"  #(!@  &0              @(%)UP  >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( !B ?U3$ZO/B  ,  *X)   9
M  " @0[:  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M&(!_5(=3O;ZM @  M 8  !D              ("!1=T  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    "  8@']4U81'91,#  #Q!P  &0
M            @($IX   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( !B ?U33NE+]L@(  +T'   9              " @7/C  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ &(!_5/*PKY\3 @
MBP0  !D              ("!7.8  'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    "  8@']4K]) &10#   +"0  &0              @(&F
MZ   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( !B ?U2-
MB9@M7@(  *X%   9              " @?'K  !X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ &(!_5(%@@#0? P  > H  !D
M     ("!ANX  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !B ?U1=<VE!2P,  !0.   9              "
M@0__  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ &(!_
M5%.[(CVU P  D T  !D              ("!D0(! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    "  8@']4>?1'J<4#   O$@  &0
M        @(%]!@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( !B ?U0(Y9V.00,  (<+   9              " @7D* 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ &(!_5)?<U\/""0  434
M !D              ("!\0T! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    "  8@']4*"!.J#T#   B"0  &0              @('J%P$
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( !B ?U0N[PUE
MK (  /,&   9              " @5X; 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ &(!_5'SH9VRZ P  &0T  !D
M ("!01X! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  8
M@']4$WS>];$"  #7!@  &0              @($R(@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( !B ?U0H?/+/D0(  (X&   9
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M 0!X;"]S='EL97,N>&UL4$L! A0#%     @ &(!_5)>*NQS     $P(   L
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64$L%!@    !$ $0 DQ(   \[ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>94</ContextCount>
  <ElementCount>253</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Statements of Changes In Stockholders' Equity(Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit</Role>
      <ShortName>Statements of Changes In Stockholders' Equity(Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/General</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/OtherCurrentLiabilities</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - LOANS FROM STOCKHOLDERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/LoansFromStockholders</Role>
      <ShortName>LOANS FROM STOCKHOLDERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/CommitmentsAndContingentLiabilities</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtection</Role>
      <ShortName>COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ResearchAndDevelopmentExpenses</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - MARKETING EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/MarketingExpenses</Role>
      <ShortName>MARKETING EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/GeneralAndAdministrativeExpenses</Role>
      <ShortName>GENERAL AND ADMINISTRATIVE EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - INCOME TAX</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/IncomeTax</Role>
      <ShortName>INCOME TAX</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/SegmentInformation</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/RelatedParties</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/Inventories</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionTables</Role>
      <ShortName>COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtection</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ResearchAndDevelopmentExpensesTables</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/ResearchAndDevelopmentExpenses</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - MARKETING EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/MarketingExpensesTables</Role>
      <ShortName>MARKETING EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/MarketingExpenses</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/GeneralAndAdministrativeExpensesTables</Role>
      <ShortName>GENERAL AND ADMINISTRATIVE EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/GeneralAndAdministrativeExpenses</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - INCOME TAX (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/IncomeTaxTables</Role>
      <ShortName>INCOME TAX (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://integrity-app.com/role/IncomeTax</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - GENERAL (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/GeneralDetailsNarrative</Role>
      <ShortName>GENERAL (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/GeneralAndAdministrativeExpensesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - SCHEDULE OF OFFICIAL EXCHANGE RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfOfficialExchangeRateDetails</Role>
      <ShortName>SCHEDULE OF OFFICIAL EXCHANGE RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure -  SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails</Role>
      <ShortName>SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - SCHEDULE OF INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfInventoriesDetails</Role>
      <ShortName>SCHEDULE OF INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - INVENTORIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/InventoriesDetailsNarrative</Role>
      <ShortName>INVENTORIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/InventoriesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - SCHEDULE OF LEASE COSTS, LEASE TERM AND DISCOUNT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails</Role>
      <ShortName>SCHEDULE OF LEASE COSTS, LEASE TERM AND DISCOUNT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - SCHEDULE OF OPERATING LEASE MATURITY PAYMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails</Role>
      <ShortName>SCHEDULE OF OPERATING LEASE MATURITY PAYMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/PropertyAndEquipmentNetDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - SCHEDULE OF OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfOtherCurrentLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - LOANS FROM STOCKHOLDERS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative</Role>
      <ShortName>LOANS FROM STOCKHOLDERS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/LoansFromStockholders</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/CommitmentsAndContingentLiabilities</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - SCHEDULE OF STOCK GRANTS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK GRANTS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - SCHEDULE OF STOCK GRANTS, BY EXERCISE PRICE RANGE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails</Role>
      <ShortName>SCHEDULE OF STOCK GRANTS, BY EXERCISE PRICE RANGE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails</Role>
      <ShortName>SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative</Role>
      <ShortName>COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - SCHEDULE OF SELLING AND MARKETING EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails</Role>
      <ShortName>SCHEDULE OF SELLING AND MARKETING EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails</Role>
      <ShortName>SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - SCHEDULE OF DEFERRED TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/ScheduleOfDeferredTaxesDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - INCOME TAX (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/IncomeTaxDetailsNarrative</Role>
      <ShortName>INCOME TAX (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/IncomeTaxTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - SEGMENT INFORMATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/SegmentInformationDetailsNarrative</Role>
      <ShortName>SEGMENT INFORMATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/SegmentInformation</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integrity-app.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://integrity-app.com/role/RelatedParties</ParentRole>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="form10-k.htm">form10-k.htm</File>
    <File>ex23-1.htm</File>
    <File>ex3-7.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>igap-20211231.xsd</File>
    <File>igap-20211231_cal.xml</File>
    <File>igap-20211231_def.xml</File>
    <File>igap-20211231_lab.xml</File>
    <File>igap-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="446">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-k.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "contextCount": 94,
   "dts": {
    "calculationLink": {
     "local": [
      "igap-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "igap-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "igap-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "igap-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "igap-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 404,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 42,
    "http://integrity-app.com/20211231": 4,
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 49
   },
   "keyCustom": 34,
   "keyStandard": 219,
   "memberCustom": 30,
   "memberStandard": 20,
   "nsprefix": "IGAP",
   "nsuri": "http://integrity-app.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://integrity-app.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - INVENTORIES",
     "role": "http://integrity-app.com/role/Inventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - LEASES",
     "role": "http://integrity-app.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "role": "http://integrity-app.com/role/PropertyAndEquipmentNet",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - OTHER CURRENT LIABILITIES",
     "role": "http://integrity-app.com/role/OtherCurrentLiabilities",
     "shortName": "OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - LOANS FROM STOCKHOLDERS",
     "role": "http://integrity-app.com/role/LoansFromStockholders",
     "shortName": "LOANS FROM STOCKHOLDERS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES",
     "role": "http://integrity-app.com/role/CommitmentsAndContingentLiabilities",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION",
     "role": "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtection",
     "shortName": "COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES",
     "role": "http://integrity-app.com/role/ResearchAndDevelopmentExpenses",
     "shortName": "RESEARCH AND DEVELOPMENT EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IGAP:SellingAndMarketingExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - MARKETING EXPENSES",
     "role": "http://integrity-app.com/role/MarketingExpenses",
     "shortName": "MARKETING EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IGAP:SellingAndMarketingExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IGAP:GeneralAndAdministrativeExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES",
     "role": "http://integrity-app.com/role/GeneralAndAdministrativeExpenses",
     "shortName": "GENERAL AND ADMINISTRATIVE EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IGAP:GeneralAndAdministrativeExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "role": "http://integrity-app.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - INCOME TAX",
     "role": "http://integrity-app.com/role/IncomeTax",
     "shortName": "INCOME TAX",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - SEGMENT INFORMATION",
     "role": "http://integrity-app.com/role/SegmentInformation",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - RELATED PARTIES",
     "role": "http://integrity-app.com/role/RelatedParties",
     "shortName": "RELATED PARTIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://integrity-app.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:UseOfEstimates",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:UseOfEstimates",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - INVENTORIES (Tables)",
     "role": "http://integrity-app.com/role/InventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - LEASES (Tables)",
     "role": "http://integrity-app.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "role": "http://integrity-app.com/role/PropertyAndEquipmentNetTables",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://integrity-app.com/role/OtherCurrentLiabilitiesTables",
     "shortName": "OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://integrity-app.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)",
     "role": "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionTables",
     "shortName": "COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IGAP:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)",
     "role": "http://integrity-app.com/role/ResearchAndDevelopmentExpensesTables",
     "shortName": "RESEARCH AND DEVELOPMENT EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IGAP:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "IGAP:SellingAndMarketingExpensesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IGAP:ScheduleOfSellingAndMarketingExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - MARKETING EXPENSES (Tables)",
     "role": "http://integrity-app.com/role/MarketingExpensesTables",
     "shortName": "MARKETING EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "IGAP:SellingAndMarketingExpensesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IGAP:ScheduleOfSellingAndMarketingExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "IGAP:GeneralAndAdministrativeExpensesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IGAP:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)",
     "role": "http://integrity-app.com/role/GeneralAndAdministrativeExpensesTables",
     "shortName": "GENERAL AND ADMINISTRATIVE EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "IGAP:GeneralAndAdministrativeExpensesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IGAP:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - INCOME TAX (Tables)",
     "role": "http://integrity-app.com/role/IncomeTaxTables",
     "shortName": "INCOME TAX (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - GENERAL (Details Narrative)",
     "role": "http://integrity-app.com/role/GeneralDetailsNarrative",
     "shortName": "GENERAL (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock",
       "us-gaap:UseOfEstimates",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "IGAP:AverageForeignCurrencyExchangeRateTranslation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - SCHEDULE OF OFFICIAL EXCHANGE RATE (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfOfficialExchangeRateDetails",
     "shortName": "SCHEDULE OF OFFICIAL EXCHANGE RATE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock",
       "us-gaap:UseOfEstimates",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "IGAP:AverageForeignCurrencyExchangeRateTranslation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "IGAP:ScheduleOfPropertyRatesOfDepreciationTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31_custom_ComputersMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "IGAP:PropertyPlantAndEquipmentDepreciationRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "IGAP:ScheduleOfPropertyRatesOfDepreciationTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31_custom_ComputersMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "IGAP:PropertyPlantAndEquipmentDepreciationRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure -  SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails",
     "shortName": "SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:SellingAndMarketingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - SCHEDULE OF INVENTORIES (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfInventoriesDetails",
     "shortName": "SCHEDULE OF INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryAdjustments",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - INVENTORIES (Details Narrative)",
     "role": "http://integrity-app.com/role/InventoriesDetailsNarrative",
     "shortName": "INVENTORIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - SCHEDULE OF LEASE COSTS, LEASE TERM AND DISCOUNT (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails",
     "shortName": "SCHEDULE OF LEASE COSTS, LEASE TERM AND DISCOUNT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - SCHEDULE OF OPERATING LEASE MATURITY PAYMENTS (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails",
     "shortName": "SCHEDULE OF OPERATING LEASE MATURITY PAYMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)",
     "role": "http://integrity-app.com/role/PropertyAndEquipmentNetDetailsNarrative",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - SCHEDULE OF OTHER CURRENT LIABILITIES (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfOtherCurrentLiabilitiesDetails",
     "shortName": "SCHEDULE OF OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToOfficersOrStockholdersNoncurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - LOANS FROM STOCKHOLDERS (Details Narrative)",
     "role": "http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative",
     "shortName": "LOANS FROM STOCKHOLDERS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "IGAP:QuarterlyPaymentsEqualsToSalesPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)",
     "role": "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails",
     "shortName": "SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Statements of Changes In Stockholders' Equity(Deficit)",
     "role": "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit",
     "shortName": "Statements of Changes In Stockholders' Equity(Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - SCHEDULE OF STOCK GRANTS ACTIVITY (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails",
     "shortName": "SCHEDULE OF STOCK GRANTS ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - SCHEDULE OF STOCK GRANTS, BY EXERCISE PRICE RANGE (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails",
     "shortName": "SCHEDULE OF STOCK GRANTS, BY EXERCISE PRICE RANGE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails",
     "shortName": "SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Details Narrative)",
     "role": "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
     "shortName": "COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2007-08-31_custom_IntegrityIsraelsPlanMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "IGAP:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails",
     "shortName": "SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "IGAP:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "IGAP:ScheduleOfSellingAndMarketingExpensesTableTextBlock",
       "IGAP:SellingAndMarketingExpensesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "IGAP:SalariesAndRelatedExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - SCHEDULE OF SELLING AND MARKETING EXPENSES (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails",
     "shortName": "SCHEDULE OF SELLING AND MARKETING EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "IGAP:ScheduleOfSellingAndMarketingExpensesTableTextBlock",
       "IGAP:SellingAndMarketingExpensesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "IGAP:SalariesAndRelatedExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "IGAP:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails",
     "shortName": "SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "IGAP:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
       "IGAP:GeneralAndAdministrativeExpensesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - SCHEDULE OF DEFERRED TAXES (Details)",
     "role": "http://integrity-app.com/role/ScheduleOfDeferredTaxesDetails",
     "shortName": "SCHEDULE OF DEFERRED TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - INCOME TAX (Details Narrative)",
     "role": "http://integrity-app.com/role/IncomeTaxDetailsNarrative",
     "shortName": "INCOME TAX (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Segments",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - SEGMENT INFORMATION (Details Narrative)",
     "role": "http://integrity-app.com/role/SegmentInformationDetailsNarrative",
     "shortName": "SEGMENT INFORMATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Segments",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://integrity-app.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000060 - Disclosure - RELATED PARTIES (Details Narrative)",
     "role": "http://integrity-app.com/role/RelatedPartiesDetailsNarrative",
     "shortName": "RELATED PARTIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_AndrewGarrettIncMember_custom_AndrewSycoffMember_custom_PlacementAgentFeesMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "role": "http://integrity-app.com/role/StatementsOfCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31_custom_BoardOfMembersMember",
      "decimals": "-3",
      "lang": null,
      "name": "IGAP:NumberOfCommonStockIssuedForSettlementOfFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - GENERAL",
     "role": "http://integrity-app.com/role/General",
     "shortName": "GENERAL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://integrity-app.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "IGAP_AccreditedInvestorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accredited Investor [Member]"
       }
      }
     },
     "localname": "AccreditedInvestorMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_AdvisoryAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advisory Agreement [Member]",
        "label": "Advisory Agreement [Member]"
       }
      }
     },
     "localname": "AdvisoryAgreementMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_AdvisoryServicesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advisory services period.",
        "label": "Advisory services period"
       }
      }
     },
     "localname": "AdvisoryServicesPeriod",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "IGAP_AggregateSalesPriceOfUnitsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission as a percentage of the aggregate sales price of the Units.",
        "label": "Commission as a percentage of aggregate sales price"
       }
      }
     },
     "localname": "AggregateSalesPriceOfUnitsPercentage",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "IGAP_AndrewGarrettIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Andrew Garrett, Inc [Member]",
        "label": "Andrew Garrett, Inc [Member]"
       }
      }
     },
     "localname": "AndrewGarrettIncMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://integrity-app.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_AndrewSycoffMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Andrew Sycoff [Member]",
        "label": "Andrew Sycoff [Member]"
       }
      }
     },
     "localname": "AndrewSycoffMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_AverageForeignCurrencyExchangeRateTranslation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The foreign exchange rates used to translate income and expense items denominated in the functional currency to the reporting currency.",
        "label": "Official exchange rate of NIS 1 to US dollar"
       }
      }
     },
     "localname": "AverageForeignCurrencyExchangeRateTranslation",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfOfficialExchangeRateDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "IGAP_BadDebtExpense": {
     "auth_ref": [],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bad debt expense.",
        "label": "Bad debt expense"
       }
      }
     },
     "localname": "BadDebtExpense",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IGAP_BoardOfMembersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board of Members [Member]",
        "label": "Board of Members [Member]"
       }
      }
     },
     "localname": "BoardOfMembersMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_CashExpensesOnIssuanceOfStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash expenses on issuance of stock.",
        "label": "Cash expenses on issuance of stock"
       }
      }
     },
     "localname": "CashExpensesOnIssuanceOfStock",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IGAP_CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission as a percentage of cash amount equal to aggregate sale price of units.",
        "label": "Commission as a percentage of cash amount equal to aggregate sale price of units"
       }
      }
     },
     "localname": "CommissionAsPercentageOfCashAmountEqualToAggregateSalePriceOfUnits",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "IGAP_ComputersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computers [Member]",
        "label": "Computers [Member]"
       }
      }
     },
     "localname": "ComputersMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_CumulativeResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative research and development.",
        "label": "Cumulative research and development"
       }
      }
     },
     "localname": "CumulativeResearchAndDevelopment",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IGAP_DeferredTaxAssetValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance.",
        "label": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetValuationAllowance",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IGAP_DisclosureGeneralAndAdministrativeExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General And Administrative Expenses"
       }
      }
     },
     "localname": "DisclosureGeneralAndAdministrativeExpensesAbstract",
     "nsuri": "http://integrity-app.com/20211231",
     "xbrltype": "stringItemType"
    },
    "IGAP_DisclosureLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Operating Lease Maturity Payments"
       }
      }
     },
     "localname": "DisclosureLeasesAbstract",
     "nsuri": "http://integrity-app.com/20211231",
     "xbrltype": "stringItemType"
    },
    "IGAP_DisclosureMarketingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing Expenses",
        "verboseLabel": "Schedule Of Selling And Marketing Expenses"
       }
      }
     },
     "localname": "DisclosureMarketingExpensesAbstract",
     "nsuri": "http://integrity-app.com/20211231",
     "xbrltype": "stringItemType"
    },
    "IGAP_ErezBenZviMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Erez Ben Zvi [Member]",
        "label": "Erez Ben Zvi [Member]"
       }
      }
     },
     "localname": "ErezBenZviMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_ExercisePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price One [Member]",
        "label": "Exercise Price One [Member]"
       }
      }
     },
     "localname": "ExercisePriceOneMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_ExercisePriceThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Three [Member]"
       }
      }
     },
     "localname": "ExercisePriceThreeMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_ExercisePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Two [Member]",
        "label": "Exercise Price Two [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwoMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_FinancingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "FinancingIncomeExpenseNet",
        "negatedLabel": "Financing income, net"
       }
      }
     },
     "localname": "FinancingIncomeExpenseNet",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IGAP_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture and Office Equipment [Member]",
        "label": "Furniture and Office Equipment [Member]"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_GeneralAndAdministrativeExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and Administrative Expenses [Text Block]",
        "label": "GENERAL AND ADMINISTRATIVE EXPENSES"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpensesTextBlock",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/GeneralAndAdministrativeExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "IGAP_IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2020.",
        "label": "Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2021"
       }
      }
     },
     "localname": "IncreaseDecreaseOfOfficialExchangeRateDuringYearOnePercentage",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfOfficialExchangeRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "IGAP_IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2019.",
        "label": "Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year: 2020"
       }
      }
     },
     "localname": "IncreaseDecreaseOfOfficialExchangeRateOfDuringYearTwo",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfOfficialExchangeRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "IGAP_IntegrityIsraelsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Integrity Israel's Plan [Member]",
        "label": "Integrity Israel's Plan [Member]"
       }
      }
     },
     "localname": "IntegrityIsraelsPlanMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_IsraeliInnovationAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Israeli Innovation Authority [Member]",
        "label": "Israeli Innovation Authority [Member]"
       }
      }
     },
     "localname": "IsraeliInnovationAuthorityMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors": {
     "auth_ref": [],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of restricted shares as compensation to the board of directors.",
        "label": "IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors",
        "verboseLabel": "Issuance of restricted shares as compensation to directors"
       }
      }
     },
     "localname": "IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IGAP_LinkageDifferenceOnPrincipalOfLoansFromStockholders": {
     "auth_ref": [],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Linkage difference on principal of loans from stockholders .",
        "label": "Linkage difference on principal of loans from stockholders"
       }
      }
     },
     "localname": "LinkageDifferenceOnPrincipalOfLoansFromStockholders",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IGAP_LongTermLeaseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term lease cost.",
        "label": "Office space: Over 12 month"
       }
      }
     },
     "localname": "LongTermLeaseCost",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IGAP_MeasurementInputFairValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input Fair Value [Member]",
        "label": "Measurement Input Fair Value [Member]"
       }
      }
     },
     "localname": "MeasurementInputFairValueMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_ModificationOfEquityclassifiedContractsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modification of Equity Classified Contracts [Policy Text Block]",
        "label": "Modification of equity-classified contracts"
       }
      }
     },
     "localname": "ModificationOfEquityclassifiedContractsPolicyTextBlock",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "IGAP_MrJamesPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mr James P [Member]",
        "label": "Mr James P [Member]"
       }
      }
     },
     "localname": "MrJamesPMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_MrPaulVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mr Paul V [Member]",
        "label": "Mr Paul V [Member]"
       }
      }
     },
     "localname": "MrPaulVMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_NonaccountableExpenseAllowancePercenatge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-accountable expense allowance percenatge.",
        "label": "Non-accountable expense allowance percenatge"
       }
      }
     },
     "localname": "NonaccountableExpenseAllowancePercenatge",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "IGAP_NumberOfCommonStockIssuedForSettlementOfFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock issued for settlement of fees.",
        "label": "Number of common stock issued for settlement of fees"
       }
      }
     },
     "localname": "NumberOfCommonStockIssuedForSettlementOfFees",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IGAP_NumberOfStockOptionsExcluded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock options excluded.",
        "label": "Number of stock options excluded"
       }
      }
     },
     "localname": "NumberOfStockOptionsExcluded",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "IGAP_NumberOfStockWarrantsExcluded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock warrants excluded.",
        "label": "Number of stock warrants excluded"
       }
      }
     },
     "localname": "NumberOfStockWarrantsExcluded",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "IGAP_OfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Space [Member]",
        "label": "Office Space [Member]"
       }
      }
     },
     "localname": "OfficeSpaceMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_PercentageOfDulitedCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of dulited common stock.",
        "label": "Percentage of dulited common stock."
       }
      }
     },
     "localname": "PercentageOfDulitedCommonStock",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "IGAP_PlacementAgentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Agent Agreement [Member]",
        "label": "Placement Agent Agreement [Member]"
       }
      }
     },
     "localname": "PlacementAgentAgreementMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_PlacementAgentFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Agent Fees [Member]",
        "label": "Placement Agent Fees [Member]"
       }
      }
     },
     "localname": "PlacementAgentFeesMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_PlacementAgentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Agent [Member]",
        "label": "Placement Agent [Member]"
       }
      }
     },
     "localname": "PlacementAgentMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_PropertyPlantAndEquipmentDepreciationRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment depreciation rate.",
        "label": "Property plant and equipment depreciation rate"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDepreciationRate",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "IGAP_QuarterlyPaymentsEqualsToSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quarterly payments equals to sales, percentage.",
        "label": "Quarterly payments equals to sales, percentage"
       }
      }
     },
     "localname": "QuarterlyPaymentsEqualsToSalesPercentage",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "IGAP_ResearchAndDevelopmentProfessionalFees": {
     "auth_ref": [],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development professional fees.",
        "label": "Research and development professional fees",
        "verboseLabel": "Professional fees"
       }
      }
     },
     "localname": "ResearchAndDevelopmentProfessionalFees",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IGAP_RoyaltyBearingGrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Bearing Grants [Policy Text Block]",
        "label": "Royalty-bearing grant"
       }
      }
     },
     "localname": "RoyaltyBearingGrantsPolicyTextBlock",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "IGAP_RoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty percentage.",
        "label": "Royalty percentage"
       }
      }
     },
     "localname": "RoyaltyPercentage",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "IGAP_SalariesAndRelatedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salaries and related expenses.",
        "label": "Salaries and related expenses [Default Label]",
        "verboseLabel": "Salaries and related expenses"
       }
      }
     },
     "localname": "SalariesAndRelatedExpenses",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IGAP_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of General and Administrative Expenses [Table Text Block]",
        "label": "SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES"
       }
      }
     },
     "localname": "ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/GeneralAndAdministrativeExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "IGAP_ScheduleOfPropertyRatesOfDepreciationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Property Rates of Depreciation [Table Text Block]",
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION"
       }
      }
     },
     "localname": "ScheduleOfPropertyRatesOfDepreciationTableTextBlock",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "IGAP_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Research And Development Expenses [Table Text Block]",
        "label": "SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentExpensesTableTextBlock",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ResearchAndDevelopmentExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "IGAP_ScheduleOfSellingAndMarketingExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Selling and Marketing Expenses [Table Text Block]",
        "label": "SCHEDULE OF SELLING AND MARKETING EXPENSES"
       }
      }
     },
     "localname": "ScheduleOfSellingAndMarketingExpensesTableTextBlock",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/MarketingExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "IGAP_SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement And Registration Rights Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementAndRegistrationRightsAgreementMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_SellingAndMarketingExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling and Marketing Expenses [Text Block]",
        "label": "MARKETING EXPENSES"
       }
      }
     },
     "localname": "SellingAndMarketingExpensesTextBlock",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/MarketingExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "IGAP_SellingAndMarketingOtherExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling and marketing other expenses.",
        "label": "Selling and marketing other expenses",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "SellingAndMarketingOtherExpenses",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IGAP_ShalomShushanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shalom Shushan [Member]",
        "label": "Shalom Shushan [Member]"
       }
      }
     },
     "localname": "ShalomShushanMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_ShareHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholders [Member]",
        "label": "Shareholders [Member]"
       }
      }
     },
     "localname": "ShareHoldersMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_TwoThousandandSeventeenOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Offering [Member]",
        "label": "2017 Offering [Member]"
       }
      }
     },
     "localname": "TwoThousandandSeventeenOfferingMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_TwoThousandandTwentyOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Offering [Member]",
        "label": "2020 Offering [Member]"
       }
      }
     },
     "localname": "TwoThousandandTwentyOfferingMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_WarrantFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Five [Member]",
        "label": "Warrant Five [Member]"
       }
      }
     },
     "localname": "WarrantFiveMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_WarrantFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Four [Member]",
        "label": "Warrant Four [Member]"
       }
      }
     },
     "localname": "WarrantFourMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_WarrantOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant One [Member]",
        "label": "Warrant One [Member]"
       }
      }
     },
     "localname": "WarrantOneMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_WarrantThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Three [Member]",
        "label": "Warrant Three [Member]"
       }
      }
     },
     "localname": "WarrantThreeMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_WarrantTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Two [Member]",
        "label": "Warrant Two [Member]"
       }
      }
     },
     "localname": "WarrantTwoMember",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IGAP_WarrantsIssuedAsConsiderationForPlacementServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued as consideration for placement services.",
        "label": "Warrants issued as consideration for placement services"
       }
      }
     },
     "localname": "WarrantsIssuedAsConsiderationForPlacementServices",
     "nsuri": "http://integrity-app.com/20211231",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r405",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r405",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r405",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r405",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://integrity-app.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://integrity-app.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://integrity-app.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r197",
      "r201",
      "r223",
      "r224",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r371",
      "r372",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails",
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r197",
      "r201",
      "r223",
      "r224",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r371",
      "r372",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails",
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r197",
      "r201",
      "r220",
      "r223",
      "r224",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r371",
      "r372",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails",
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r197",
      "r201",
      "r220",
      "r223",
      "r224",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r371",
      "r372",
      "r390",
      "r391"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails",
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r152",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative",
      "http://integrity-app.com/role/RelatedPartiesDetailsNarrative",
      "http://integrity-app.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative",
      "http://integrity-app.com/role/RelatedPartiesDetailsNarrative",
      "http://integrity-app.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.",
        "label": "Legal Entity of Counterparty, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r38",
      "r335"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r6",
      "r24",
      "r153",
      "r154"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r37",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less - accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r27",
      "r55",
      "r56",
      "r57",
      "r361",
      "r377",
      "r378"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r65",
      "r66",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r57",
      "r65",
      "r66",
      "r67",
      "r100",
      "r101",
      "r102",
      "r287",
      "r373",
      "r374",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r251",
      "r252",
      "r253",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile loss for the year to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r137",
      "r140",
      "r144",
      "r156",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r284",
      "r288",
      "r303",
      "r333",
      "r335",
      "r349",
      "r359"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r52",
      "r96",
      "r156",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r284",
      "r288",
      "r303",
      "r333",
      "r335"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r228",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r280",
      "r281",
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r34",
      "r335",
      "r379",
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/GeneralDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r34",
      "r89"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://integrity-app.com/role/ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets",
      "http://integrity-app.com/role/ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r16",
      "r90",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r84",
      "r89",
      "r91"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of the year",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of the year",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails",
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r84",
      "r304"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r43",
      "r175",
      "r351",
      "r365"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingent liabilities (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r182",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENT LIABILITIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r185",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/Cover",
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheetsParenthetical",
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23",
      "r335"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r60",
      "r62",
      "r63",
      "r71",
      "r354",
      "r368"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "negatedTotalLabel": "Comprehensive loss for the year"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r127",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentrations of credit risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfPropertyRepairsAndMaintenance": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      },
      "http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs of keeping the property in good condition but that do not appreciably prolong the life or increase the value of the property.",
        "label": "Vehicle maintenance"
       }
      }
     },
     "localname": "CostOfPropertyRepairsAndMaintenance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails",
      "http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities"
       }
      }
     },
     "localname": "DebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/GeneralDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative",
      "http://integrity-app.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Non-capital loss carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Provision for employee-related obligation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r87",
      "r164"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r87",
      "r164"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      },
      "http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails",
      "http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Warrants with Down-Round Protection"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueToOfficersOrStockholdersNoncurrent": {
     "auth_ref": [
      "r21",
      "r329",
      "r358",
      "r381"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company, which are due after one year (or one business cycle).",
        "label": "Loans from stockholders (Note 7)",
        "verboseLabel": "Due to Officers or Stockholders, Noncurrent"
       }
      }
     },
     "localname": "DueToOfficersOrStockholdersNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets",
      "http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r72",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r113",
      "r115",
      "r116",
      "r117",
      "r120",
      "r121",
      "r297",
      "r298",
      "r355",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Loss per share (Basic and Diluted)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Basic and diluted loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r97",
      "r259",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/IncomeTaxDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employees and related institutions"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r65",
      "r66",
      "r67",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r124",
      "r157",
      "r213",
      "r215",
      "r251",
      "r252",
      "r253",
      "r272",
      "r273",
      "r296",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r373",
      "r374",
      "r375",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/Cover",
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r87",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair value of warrants issued",
        "verboseLabel": "Fair Value Adjustment of Warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/RelatedPartiesDetailsNarrative",
      "http://integrity-app.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "SCHEDULE OF FAIR VALUE ASSUMPTIONS"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Capital loss from sale of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative expenses (Note 12)",
        "totalLabel": "Total general and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails",
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r162",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r168",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/IncomeTaxDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/IncomeTaxDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r260",
      "r262",
      "r266",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAX"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/IncomeTax"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r257",
      "r258",
      "r262",
      "r263",
      "r265",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income tax"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Decrease in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Decrease (increase) in other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Decrease in other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryAdjustments": {
     "auth_ref": [
      "r50",
      "r158"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.",
        "label": "Inventory Adjustments",
        "negatedTotalLabel": "inventory write-down"
       }
      }
     },
     "localname": "InventoryAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/InventoriesDetailsNarrative",
      "http://integrity-app.com/role/ScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Inventory, Gross, Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r49",
      "r335"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://integrity-app.com/role/ScheduleOfInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory (Note 3)",
        "totalLabel": "Inventory, Net, Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets",
      "http://integrity-app.com/role/ScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r50",
      "r94",
      "r122",
      "r158",
      "r160",
      "r161",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Expenses due to slow inventory write-off"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInvestmentExpense": {
     "auth_ref": [
      "r78",
      "r370"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses related to the generation of investment income.",
        "label": "Insurance"
       }
      }
     },
     "localname": "InvestmentIncomeInvestmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IsraelTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Israel.",
        "label": "Israel Tax Authority [Member]"
       }
      }
     },
     "localname": "IsraelTaxAuthorityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/IncomeTaxDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      },
      "http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Salaries and related expenses"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails",
      "http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "SCHEDULE OF LEASE COSTS, LEASE TERM AND DISCOUNT"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of the other party participating in a financial transaction."
       }
      }
     },
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "SCHEDULE OF OPERATING LEASE MATURITY PAYMENTS"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LessorOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r96",
      "r141",
      "r156",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r285",
      "r288",
      "r289",
      "r303",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r30",
      "r96",
      "r156",
      "r303",
      "r335",
      "r350",
      "r363"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r96",
      "r156",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r285",
      "r288",
      "r289",
      "r303",
      "r333",
      "r334",
      "r335"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r20",
      "r21",
      "r96",
      "r156",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r285",
      "r288",
      "r289",
      "r303",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "LOANS FROM STOCKHOLDERS"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/LoansFromStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset.",
        "label": "Measurement Input, Exercise Price [Member]"
       }
      }
     },
     "localname": "MeasurementInputExercisePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investment activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investment activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r84",
      "r85",
      "r88"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r58",
      "r61",
      "r67",
      "r69",
      "r88",
      "r96",
      "r103",
      "r105",
      "r106",
      "r107",
      "r108",
      "r111",
      "r112",
      "r114",
      "r137",
      "r139",
      "r142",
      "r143",
      "r146",
      "r156",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r298",
      "r303",
      "r352",
      "r366"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Loss for the year",
        "negatedTotalLabel": "Loss for the year"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows",
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit",
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "X. Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SegmentInformationDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficersCompensation": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold"
       }
      }
     },
     "localname": "OfficersCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r137",
      "r139",
      "r142",
      "r143",
      "r146"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedTotalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r316",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Total Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [
      "r123",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of income from operating lease.",
        "label": "Operating Lease"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfOperatingLeaseMaturityPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liabilities, current (Note 4)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liabilities, non-current (Note 4)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets, net (Note 4)"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r319",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r318",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/IncomeTaxDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/IncomeTaxDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/IncomeTaxDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "GENERAL"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/General"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r51",
      "r335"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "negatedLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r59",
      "r62",
      "r65",
      "r66",
      "r68",
      "r70",
      "r213",
      "r305",
      "r310",
      "r311",
      "r353",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "SCHEDULE OF OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/OtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralExpense": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses.",
        "label": "Other"
       }
      }
     },
     "localname": "OtherGeneralExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r40",
      "r335"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://integrity-app.com/role/ScheduleOfOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other current liabilities (Note 6)",
        "totalLabel": "Other Liabilities, Current, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets",
      "http://integrity-app.com/role/ScheduleOfOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/OtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expense (Income)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy": {
     "auth_ref": [
      "r221",
      "r222",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for plans, other than pension plans, that provide postretirement benefits (including both defined benefit and defined contribution plans). This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r228",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/GeneralDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock, net of cash issuance costs",
        "terseLabel": "Proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/GeneralDetailsNarrative",
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Private placement of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/GeneralDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      },
      "http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional fees"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails",
      "http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r37",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails",
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r170",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r36",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails",
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r167",
      "r335",
      "r356",
      "r364"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net (Note 5)",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets",
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r35",
      "r167",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails",
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r326",
      "r327",
      "r329",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTIES"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r256",
      "r346",
      "r392"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development expenses (Note 10)",
        "totalLabel": "Total research and development expenses, net"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails",
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "RESEARCH AND DEVELOPMENT EXPENSES"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ResearchAndDevelopmentExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r91",
      "r348",
      "r360"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfRestrictCashBalancesAreIncludedWithCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r9",
      "r19",
      "r91",
      "r384"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r26",
      "r215",
      "r254",
      "r335",
      "r362",
      "r376",
      "r378"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "negatedLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets",
      "http://integrity-app.com/role/GeneralDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r157",
      "r251",
      "r252",
      "r253",
      "r272",
      "r273",
      "r296",
      "r373",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/GeneralDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/LoansFromStockholdersDetailsNarrative",
      "http://integrity-app.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "SCHEDULE OF DEFERRED TAXES"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/IncomeTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the U.S. dollar denominated balances, balances reported for financial reporting purposes and the differences between the two balances by each relevant line item on the financial statements.",
        "label": "SCHEDULE OF OFFICIAL EXCHANGE RATE"
       }
      }
     },
     "localname": "ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r31",
      "r32",
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "SCHEDULE OF INVENTORIES"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r37",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails",
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
      "http://integrity-app.com/role/ScheduleOfPropertyAndEquipmentRatesOfDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "SCHEDULE OF STOCK GRANTS, BY EXERCISE PRICE RANGE"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r233",
      "r239",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "SCHEDULE OF STOCK GRANTS ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r133",
      "r135",
      "r136",
      "r137",
      "r138",
      "r142",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Marketing expenses (Note 11)"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "totalLabel": "Total selling and marketing expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfSellingAndMarketingExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance expenses"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://integrity-app.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Number exercisable, ending balance",
        "periodStartLabel": "Number exercisable, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price exercisable, ending balance",
        "periodStartLabel": "Weighted average exercise price exercisable, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number, grants",
        "verboseLabel": "Number of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r235",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number outstanding ending balance",
        "periodStartLabel": "Number outstanding beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price outstanding, ending balance",
        "periodStartLabel": "Weighted average exercise price outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r226",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted average exercise price, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r228",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r245",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfStockGrantsByExercisePriceRangeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r317",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Office space: Short term leases"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r92",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StandardProductWarrantyPolicy": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.",
        "label": "Warranty"
       }
      }
     },
     "localname": "StandardProductWarrantyPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r44",
      "r65",
      "r66",
      "r67",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r124",
      "r157",
      "r213",
      "r215",
      "r251",
      "r252",
      "r253",
      "r272",
      "r273",
      "r296",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r373",
      "r374",
      "r375",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/Cover",
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/Cover",
      "http://integrity-app.com/role/RelatedPartiesDetailsNarrative",
      "http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails",
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails",
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r124",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/Cover",
      "http://integrity-app.com/role/RelatedPartiesDetailsNarrative",
      "http://integrity-app.com/role/ScheduleOfAssumptionsUsedToValueOptionsDetails",
      "http://integrity-app.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails",
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r213",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of Common Stock, net, shares",
        "verboseLabel": "Number of common shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r22",
      "r23",
      "r213",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Issuance of restricted shares as compensation to directors, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r213",
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of Common Stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r213",
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Issuance of restricted shares as compensation to directors"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r22",
      "r23",
      "r215",
      "r227",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r28",
      "r29",
      "r96",
      "r155",
      "r156",
      "r303",
      "r335"
     ],
     "calculation": {
      "http://integrity-app.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets",
      "http://integrity-app.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r215",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtection"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/GeneralDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/GeneralDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/GeneralDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/GeneralDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r125",
      "r126",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Functional currency"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfLeaseCostsLeaseTermAndDiscountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/CommonStockAndWarrantsWith-downRoundProtectionDetailsNarrative",
      "http://integrity-app.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average number of common stock outstanding used in computing basic and diluted net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://integrity-app.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL77927221-108306"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235172"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235144"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(17))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r394": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r395": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r396": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r397": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r398": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r399": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r401": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r402": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r403": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r404": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r405": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r406": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r407": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r408": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r409": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r411": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r412": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r413": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.6)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001493152-22-008417-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-008417-xbrl.zip
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MDN83L5&K0H_,2#JA/$,P%)Q2\<++\U@JN_/DTT@VKMC5BMDLGOI15=.T/P[
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MKIE>P5LP4,Q_LX:Q*(9E;31K-)QNQ+X9D5?DH49OSKM7Z>F-^_\!4$L#!!0
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MIL &X9KP'D5+X)9+.6;,H[&1'*$DRQ5"51:A ="J@"@[GK$.!=Q,V"A2<U-
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MWGT:=?M1&!.^.A'9U1GN*3*1,4*(/*"HB@<#ZM)P3@6<MS2,A7:K6B$)^"S
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ML0[!+=$; Y:>+KULZ&B+TBQ;UM25.7.+'7X@&+IZ39B_-U2O%_\$4$L#!!0
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M)Z?!$XF@OB6CF6#H3@?W,$1PW+5,9^8[UOBA590!8(E'/X-',-X2CYXS'ED
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M!CA40=1VG)V!W)RF#-"1?CQ6""BO2@L"FY,%@7GG_I?GK9.+8^3P2PG@R4H
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M@='0Y+:C@Z,]XSG.92@3XT*2,4[>(M\H%HUF>"YP'3B=6%QC5UAIV&2'2Y[
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M@A>0NS$,KE3@*7(".MA_%T=%&Y;G *H2U>9GF"JLKKPP&UX7\2!,T%F+_ 1
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MC23%T)JAPXA4$$U4M!N;@IJJ25C5L^074B#/%(X3="+V)@RS+O)ZOR#CY?>
MS (%1* A#JK10'_@'R!Y<--7BEVG-GB*2F,\533X 8?8YM(A-E6'V.;2(;9D
M6W?=7\8ET+]1%\:RIB,2 U9H]CF"PTO^_7_-C8W7XC"-P@'_#+JD>+%_N$XE
M;C$&U2516)O%'/.B):'[;,"UNIF)FF5-N@<R:]*KB)BZ5W!8IPJNO"BD($>)
M)BV0BBE8!(,3 E=BS!BR !,@B32!S9(Z'HH6J^"\#CEZSP',47+=1M]:2;!\
M%A1W>W#XX;Q%E4^(N-/$[VI_U"I$U.W80:@%R';H#@L&Q!/SS3OX)LM(L:8%
ME./1\C=D.;(GD<^"G"X=!^-BR$P.K! MX10*0R$9YC3M_)^#?"+,X6>KMR<4
M9X0,UH97V3,GP1VE62>SI&NK3%\I.$H3UC:(%-!'8K 4*\?'SBS=!N"E'+DN
M2H*'!2C-SPOG@0> [P#EQMAJ%#UT^(_6@9#4 5_(+"S,HRE SCR/ZA "'-U7
M9G[)PBR?(-X^=;ITCE S2,B>3&3CD F,1*-[K%4J$S6/(=8HN)4@;Z)A#ZU+
MAY\-0E$MF\@S\4MD4I1N.$@T$30XMKKR2?NB#G@4+FV$^FT>WS\='%CD,[(J
MJ\?YP+9, V1#&JF"E!B0Z?^<L\"Z(^R!XO!)I(8S*<?!,\&LB=_":W0PH;D*
MI^[V: NP)B(U;*A L4BKLT:0/OR,ID= '@R1Q@-*A!O"B0!9 ^I$J@'HLR0R
M9\M$H;HT2HUJ U&BA0_D>^2$*3@,5C'4E!U&=)19HN4)G)G(87MD?V%&8*C1
MF*M;7<&125R/$XYI(TF]?$XO4:'ASDBDZ7M%,T9Y(7H4-DD2>:&X>'R2["J<
MO@>Z7K4]K.*_0*HQAX\I8P:S<8@+Z6-X/'MV?(+!L9 7T&U]2A,.$G3";L#K
M:YE*U P=YL Q\4@;.6QR$*B@JRO9Z##5!=Q13QQ*.)U6C#;43->!;S\BQQ:M
MOL+0Y0KZ;2BL, !TM48HC6U,KS/_#1V!CI7GO2]=.8M 8+D_&!NP*(HY&9(:
MBX:!0'6!22.=B$U0>=$-CQ^[L($(0VFS?*8"NK!+'V08  JD!I@QA(X)M %F
M9$-QSD2<**HT:&43BX*^UP$Q<NCXJI"+Q=7&V$P/*CZ.4A.?R#J!KB7X < X
MY\NT&S$+I_79^.<"C65K@1?9<\F9+[6U0ML9-6EL(]'):&? NZ)4,8ZZ=L.:
M.+XX%8V-S=TM+?21Q\ 0?R2(B-ZN%6JU6R-&C#/TM4B.R.PQ9HGQ,,9"0IAT
MAR*KH6N3;_ TT.G#E#W<V"-KK!7;D/$!B"I.[=+Y7'8SK^"%;:+,+!XKW18E
M4#?B^#CW!;[,%-32+35Y&!+OV:!BJ..U<??U5:)C"8SX;\TR>"8Z0J1ZC39P
MF\5F@S^T!##QW%[$Z[RV0M)6867D;!H3<8)I?$&*B1JIAD,#IA."3O*2"<]>
M='C6LH,D'@*L*F+@T\M'(L_^*OTZ+[UXC@61">2D3I6_'UJ&V@]=^S@#-D=.
M\,]D->.+0,:2V<(H,($,ZDQ&,(X<Z(^6\R/E*[2"%05^S:_0V$?649,J=5A%
M]F*&R)E)=:Y'3K1300_9>=_$H%/XNDYYS5&(L)-06!''N<>Y#$'8#RA^6;HI
M>P'HH@C2W)#D'AWBGY1UG*(8D1,P+$R#^I@!]61\B&$K)(SQU5A.2ZD;Y";7
MV7,J)^SF5%V2(RA! QAUQ9P+^B/UC:*VECLXXPI^NDSMJ3/M?9U-# R*THF-
M&Y&#+]ZCFST8(@*> =K\$P"L7S@422#^+?N#U^(W,J^ ](:>ZC0!'OF^W_ZM
M(GI*NJRAGT5AIR8.(B0]+O)N.Q1)NP7E?'5E1#LOQ#_@3G)R)F#611B%7R4:
M*S (#NFO4:GVR?I9$>^4BJH7/: <%1T:5,ES9B#Q\BJ,"&MTAD]M=<5TV++\
M19\.4)AKL;=7V_A7%G^6NEKT'X0>XC^%7N6L129A&SDR96/#G"W:V#OQ3Q@H
M2S'V?41(<1A%:/.(/,"U%YE1A_V<QMORC;I%=8:%&7#\%!"33&-%IX[)TXQ-
MK 9?#G ^BIN+F<E%)H@A\P%=H2%]7?LE&SNU^K_@A 'X6FWR0BM=NI=Z5'7T
M2P5GKHZ1(4CB8T08T^GW-DV-#A!M>QXJ:A2]DM.S] 'ES6D2;K!+Z<%Y4AH5
M\NOS@3-B *O47<&7VL3\$Z9C$(J*(*3MO&3/+"#PB\9ZV5"3^]ZZ/E$B&Q,9
MI-V,4N>< [!<H['4V@K&,3QF_2"52T!.$PMD" *&,VJJ]EJ\:*X;V28W"4J-
M9OS1I6MI.K9IS( C$BV4L!G<KW749A+5((R3*N@+@>OI$ U3ZX?SRE]LK)<P
MB.;J(R8#EC@>5UDP.!T9G'8M3HL79ZWS@W4*S]JM-?^%ZT,A&>@#I=%'>'*)
MJ;ZA]2)=GCLA^0.%.U@]#L-4)>; ,Q-/C?3Q2L*&R<D68C7H- 1!9K)HNY0[
M%G9_(->NKAB,SF2.8B@+\U;B$0HAAK ]!\*6W0&G;>PTX56=(HS&K)(@<=T+
MF3,#N,=.Y+7)0:$HU Z5>ZW-LA2-(G%?_HU_:VDBGVL?QZ'CT5K&!N_'*'BX
MXBMHZ1UT7F%8IDE4Y1UIGF==+2T](FF"QG=T08_"BP=F_'W@>*BMB1>'K0M
M132S>7$;Z>,9A@=UI:]C(FX0^;-2*ZPL4>@3YGYS-"061:%(*KMOK+"2#JA<
MF(-925U*3T<YH^KT0A^)#RB&JN_)"G_:@S..M!ZO/T)#3+\-^IG#%E;ZT/+@
M%Z!G^+ +#(LJE#.AL!:RLW@WN2_7\[<"8MEE)G#E&8"5(E"98C(<4XX$-E)&
M82/L>YC$7KAC+\AN#J/= Q.R9OQ6)0&DY,M[RF+$[=$56\OHBJE&5VPMHRN6
M?/.'^":2K;;JIH$I]E2R3)+M.^Q4X3^D@EC%9.#Y(=F<NY'LCW.N:Z7UA#S[
MON126-JO!)P:'>0!5ZDA[J#M<E('^E+P.Q7@^<<*Q&QFHI@ 4B[1>*@-5)$<
M>"[*?1Q/0)&P)3=D'VM.2!?/O6_*R@0*;7D2+<TV98,B'*[#B(I,8)]47 [Q
M9ZX0 CIAS!(M>@W::4(U[$;WBN:#"*0-'9*!2V OFD,Y=U[<0U:JS64ZIE^1
MGPZT9QTT2)'+3A3&K,GFO0;:B-LMW!,^Y(=4X@>@#OW/H+]RY91,F45Y N/%
M\1T?K2L4NXTUKDC5[0UC[*-$-DM>EN9M01K%)ENCC\D? "? ;2FHD,KH&0M\
M$31&SX;\&Z2KY\+**<6!CID,11QMPU'5>(5H3M9AU#4L9,KA,62$Q4#HB(42
M<E5[_3:NE*06;? MCY:+R:9 :DS 8#F+ZIB0GP3MGW@@#&"@GW&P9CZ6DHV<
M5Z#J]+6%-:]:4K4>.@4*<<&MQ>A]D7Y!M-#K" ,;TJ1/3K]30BNT5J&9WYX]
M^:>2\%J[&_*[-V%$2_5F8?=W25KQZDK!EP-Z=I1ZMK-SGBP ^&A@SXA9+O>!
M!/)2O!O@4ZZ64<_K]JK&!96OTX?CK:[\'5(H<^[U"ALOJ!Q1V!=MTJNU5^[*
MJ! DB# E\"*J;:?#4SHH&'!*)B\X]%$[0)T**,F%"C!+]%/F"6/C+C,+.H2^
MKKUW&*E_L M<]7]7'C(:W <0[FQZ%RGRI8*EYC.Q 4$ZBD@0G ZJ=GJ#<$H^
M1B0,E:2J7W^@"^8,%DX)&3CA&9-N326Q;EE$ G\8?C6"?SZ9 O0=$O[):.KK
M+44U$-]2OR+^J(GW80CTXJQW4*%U]*C4F*L<SD<7#A!-%>6S?;P@ .1.,M6+
M##M9'EO>@ EJS8&ZV=?%FC\!I?E$2K)+69(V@$\#QKL0O;RD,>JFF260J?!K
M S)4XT!Q[FRH N,^D,N...4R7+  W6FS9-#]72(VG"'MC$)0JGG[4B C#/$:
ME.W?V-$%K7$E%W#61)N+44_(= %B(SD4!Q>K*Y\OV#C.&]>%L?7UCKW1PP H
M@** O9KXF(*6_7L-+LJ75QQ/6BDLXAB8B0\L%O/.B=LG41CHM$)]P"A1Q+DI
MR;5N;5D ZWC,?/38WY!Y@P;<A!!?7U)!9K!G8H?.&S5AFIBQ1KI77@QW1Q6V
M[;6:JGLF(.<O"0CY#K.@BZGA^X>G!.4]S\=.>NR>02#,6E0[<. 'R+T G)U]
MV>E$P$$_O6N)3RV\1)"A?+<:J8 RL3%7'C <%H;V&'3]))Y-(.U2R5A-N AE
MD^RLT3D#W#"%^]9.(GVKCKG5"GN%?'4CJ4K9N1Q^[:&7 ,$)$U_R5EHZ3W9U
M(K-% /:!UA.%TE/3^##B :S7%?LU\<$/@[#3J?">A-D3)HF%0%L9X^QNM+QD
M<1%E$ PJ 3+.\A:1._8VH&RA390DU'K!%49L *E$^L= 8$J_4Q5;!@A3XE:1
M#QT%*AGG746&M#]=QOC4&3]&F5)\(7,[@]Y9#A+Z\095%_,]@9?X(+7'H^XM
M-LX#8_$+14@97C!6TX;0Y4(7R#7J);H:9ZRC=%97;&XAP6XWJZJMDYT+O,>:
M5'-NUBP&A70KT"&T.I$O]>"Q"S%2/2U!Z, +#DU"QZ>O=(F6 B,'U:*LAC9K
M]5KI]YR\;TJ?D'J'(2&Z!C2PO!YJ3V1% O:/N=LF'EU2+(^N(@ Z:I0,>L"H
MX))8=0DI@VS [AF3\ME15.2:&3*>O'+M\53RR5FPDB[J893<BE 9VP0 2]Y1
MUB!62?GWFK(#(:FBTY)BS_,.V"(D/&53XQ-"_5:,J8D ]6$:YQQ>1><EJY=Y
M;=2JFIDRB'%R+"H:Q;>H(([JYL":= 3OZ@K&V.;P3=P!W2KEJCHVC+&<=UB$
MS K2&UW!Q?%1YM:0K;>K2ZEZ&%$&4C?NJ837L,1>WFE8HH$<A8Q!;\;TH+ET
M+E _?[R$R;G,<V+9@%6K*UGFO3$26>.0]<.8G'BC"$2A=/MR0 =F[4;:9E.F
M3\C3<U69B"!)=YC%62VQ>"&P.!]W8*#9 H@.6"^BM(=)#=?E^F&?:Q<U"Z7,
M2_.:73OU?-T\(J$H%GJ^&V(J,;]5ZJ2 F!N8)#@;GGITT"HWA&#>A?JYP'@!
M79\@3JF$ $T%)\I4A9R F8FV: M#AFYPALJJD4\L"Z,T4@G;6_428B_)(KQQ
M2RQT4$4]?' ?@TNQF/XY*#,4(7Q:"*E^L7]^:@*UUYDJ4;8?A_JLKERP!M(Q
M"IM6)%NL,PU95XI+@CJ=-1TT"%]*]O/G8:\JZ]R!,)5%()@"'9E:4!1@M,A_
M3N%P!VB)Y! /M.?J*+J'*TCUU(7ZARD!R3+\ZLHA%:5^.H4@YZ1@YZS[)IT"
M!?\]#93 KF7->K-1&6<5RJ7%6GM847BQ"2.C=C48*2J.1O;3F.4/%&965S;J
M9(4D6JG]-5AG;\2P:NV;)GVBDJMNEP]2R!(+0/L8:&X@?5.IAIH#=/%@=-:J
M=T6))_!IE*0#T@=]5)"JH.ED1=M]+^9R_=9-\YNBLRG9@K'V#2?TC>E)E.^_
MP[P$UI;U;7*R<D-P!+JWSN<+XEZYYD6&WRTEI;G;RX5'SKQ3@'XT.#?KC9W*
M" [TR(@9794MRVBC/3WZ>/JGV#^UU44MU&H U&+3AQ"]J!=8U%,<FG*;-HW=
MUN5#Z^ U8!<I^UA5+8SI1]28?(32M#^HB2-$A-R:-[D](Y*&>F,;@]3)(+Y_
M2C;33][7*(PQC^0R9Q*IP49LR4N9C.QZ=>5:5W<IF-*M(5;Z0]B:%E0JY,XF
M@ST:E?LHU''8BQNEW:K).S,)5[3O>) &)+P06NLX:NTYJ.:EDJZ'ZN01!:!Y
M:2PN#G-KYW70EN,!KC' L-4A^RJH^4I2.#R]T+RUO%;P3,0D2FI/3]$H3^G$
M1L"KH)6_4$$W9Z_7>B=<P22_ Q C2E0B/_,5$$6,"-66<KAT$Y*7C+?D5V I
M5!Q7<3CX:&<Z6*D9=0RAS6H=EF$=]H:69#1[O9,.K"Z,++]P%2;><?5A  RV
MN;._"5E+FN2R*&R"02Z#@6 Q"%0<)AAI!Z.@;VW,\!<F(REWI)-&O"#Q'I#=
M! A@6O"[UL0%R&B(EH4G0HM_O!GX]C+:;:K1;MO+:+<%%#$>2;%$4=[P;\PB
M9FD>?>^9Z_UVE_8DSC+B&<]*2YY@)B?-R!-F-7#,(ZLK!R"HVLK=1F+.9)^\
M9[[0GWJ"/B%BE*^ 4SIZYAV:NEY#@XEI]T;V2F0X9.#E'9/XO;J"W$F?AO:3
M8'@1A1N0I\D2>>U+/M:-HS"\H9)_$Q4576:IJ /E)?P<2\TZ>>KL92R;D?,6
M58I].L=Q8/R<^DYEIAIKE,&"><#\HI03H+EN$*@2'#EGG"ST:,D*1C)(9J.E
M.Z(=PM1AHG33/\R3R<<34M*L+N2'Y^.F9!!J@_05]Z3V0%&QDY KW"N= %R(
M1\FJ=5(=$1V;3GE!.".L!8;&$$J,1*.N;F;L7QH[6Y5ZO8Z+(.U1!R"J[)%\
M37>J%-(3[3#@Z*"4'%[-^K]TRUMXF1J#M2D^44]&8C360^$&X<.Q*B_^#MJ?
MU"7Z^WTO293.0#<KZ4:24,[4O><S 9$]5GHEIX'2 90^2,(J8K/*"V"._UJW
M??-23/QQ/<P[<DW,/A7UKZ ]GC.%Q"_U&M8!QV.ABON5$OY:'-WG 4B!L$5S
MLDZ$)12N&)^@'1C#-"('=5U0H#&T &.JC&' >/E@L!>M=?'+5JU9S[T*X/CB
MW;K.R QC%CEULKXTSW1$?HDVAM8N3/"Z9)QE3,$=O?/#$"E#5WRLG=5,K2^^
M"A-YP$NEPIID.0#%W_=U2OH55>GBJI\4&\7988!"NN4 NZN+JV![,$,7U:;@
MM@-(J@(.9+&PD"M$Y/CR&EF#B+QN#S--Z.01>V-=PMUT@*,X4-,&.C9M(K)"
M 92>&F'-\W1@ND?"$!K<H_Q"LM:9QB-DEV$H(J H>IND?HZ&I ?U?-H:DRU(
M.X=UU)OUV=H<$5P@M<7SR0:NU[HT\]YC?X-DOG:(SA]=SAT)G_$0FBU/;9Y\
M@6^RRV$4$KH1=#L1G1=I*"%1B1,9N_*;V->-NC^Q:\G0O9/6Q4'K/UDQ0*SN
ME';A.$5CP\A-UP9Z"VUC8EB)C0'/STJEK 3Q6LKZ;!##;6R4FIGP*!=$W2YP
M+"L7/65(>?JX@++W!58K((FTN6.@B,%4^1UJ8FU*R(D<5=?]1R^J "H==*4%
M84UL;&Q4FUM[V]N;ZR2RNPHH-+HP,\%;RR(7A_NZ7L[(++FVRK;\F<XDH:=@
MH2QY_ (**@I2)$PA-NFZ-)J%<9&G-DAU"J1K]OJ5! IL"P$L@V@_FIS2@<ZN
M68+U0N\0P=KJ6;LYT@BR<IA2P#F972=38TXCYB0-72'*-Y75=6 .$6, XDBZ
M^F/^B+/=<1(BZ9F^5]>J)K?K)2?]C1XST8/$PWX[]"OB^'WK; F#"RQ&(03J
MZFB;=.U-;NE&<B@G4 22*S1E"JR.@R>)1$L"E$."D0D% *'7]B\_+.70A][?
MW"PD?] 3G\J@4+O)X6\0XOP0&'<O!<H'BV3;V646$*^-9Q73$<:E*M6LX7(?
M;C0"R6)IOC$F-NK*:*;ED@>FB0R&S<74 /XX$&59?)RI(A=RF9%P=*QQ05^O
M2PWCC # *8\<1#UJC+(Y%Y\#+),-.KJDFE/C$UYN346I9"'+<9Q2!!-:Z?39
MYNK!Q@,L3V,BCXMH.U^P]!21=DK[NV4*S%#&4L)M\K%&7OR5+<3%/HG&R+M_
M^L?Q0;6Q)S!G1/4]H/GG\(JN6.E0.*PN(XBTWUI735X0!<D62FODBDZNKHP,
M;^TE'F!55OL"OM.Q=YP:K"OAOZ8P.33V@:S>1:M2P,UA[$)T['P^ S&17Q5F
M4!E85Q;+S")><P8TI<;04KVL*.3D%0_"6.,->2Q1:(I4Z/!)HB-*USI$U,NW
ME='XOKJ2T2-*H];IY=1MZTHZ#NS'&(6PI5*2JQT9I@GYH.+7V==H?#.'V"EL
M3^>":2OI=T\#[T"7/^8PXBZ;E14W&U"ZI!._PK0W@N\H<(#"D,<?&[?4?*QB
MC?--2NXA L\@JH:+V&%Y!D1:E^R_>574]8C/FC));!E%0[1'S@;CF-&N"!U*
MCQ6S'!E%GN+05T#8D1:II&47V-_$#L<<X,(,$RM_Y<H<F\+H"&"8VDYI23>8
M+>E1_@Q/\QYK"Y&;#+<R5$FN$&$^'4*W+XM!*D !(N]W,IT?N6=4@F60T>B4
M96:231?CUB*J'D4-T#@71UMU.7S:BW+#4M=:],4976RC891"HIC9NCWVQ'$2
M4!^#UBBY A,2">5_V=NI;&YO4]9@C*$3XH SIO#LR.C.90I'9BI&DYM9_)"H
M*9X"*HO<T<^N6_M5T'?5E43#R!74P=H:^8.C2A04V3S=L+H)&+-$\PD*WY%J
M1RFZW[3.5R^B.!4L<;GT_2^-+=YZ']L+4C\S"N7DMBK&<8)$H^@M0SC7Y4*3
MK-AVH!(&#8^J;IOH_5\:&Y5Z?8\GRB"VD.:-3JHQ!L!Q0OA=#8(<+7>+[2^S
MQU&HF(D )!<D-_]]<7&XOZXWFF^!8(YRLC'08B8YAZ=I$A27H:;;G10KI5!-
M!*1S%& <28^JMNI^C^AY7UVY[<26B/HXB)H5K,"T=VKSQ[#%;G;I<U6B/A9#
M8M[WRW:EOMVT@*4]S6-X"=;^2U%[]JA=04CMD!B)M4,'.P]FJ<#$=3I8G!#$
M?E]A38M&TW1-M*HUH$1*:W*S#DY4GB:@T#,N;VP<FAE\$4M.8\K>*S!S4T?/
M0+Q58=L^RZFF_SII,,R2J+)4Q-$8MZV5EHC<.^P\EOEROH%^YGCZIOWVDTXM
M.\T:RCY(,LA"I+'PGUJ33 :SW\0;[ZTI[?GFI?=V$>\!MF"NXH$V,&NT-C="
M'3FD<'H44UZAIC%8W!0#@ +=6QM+ N2D+AOE$H3B:T -O4']J67U6ZE+!>6(
M:FFGK?OWD0@%9%H;,[CC-K9K $$E*C323A,/VVQS=320J<+ YCSH/AC9, -2
MI;1T1$T$B19+%P.%J'Z":;QE^\X7F_7J(@RQTL4L."UIJ!4K9#>HP76Y)35%
M+E=$'T,.VIA1Z@4)]\]%NY66M8A7!(E16+5UA>?&1$J,<M8Q>'U4JD C[F/Q
M72Q$ 9*5PSY@#HG#DC(U<8(U;7SLYZ5-*%2IP=BGJ?8W=3,9*8BO^Q'#38#
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M23-3W+G1O[27#1N%8=L6?\@GA@)^5@?']I9_[C1W/J2(W&U+UXVX0"'>=1J
M7L61@N3_+(13WA97)OLH;8]+YT8S T;# &AR<LIU:/(\R,F>Y]H.-LY0%#/;
MD:8NF99R7CT!R,ELH'F;9]DF>N]M%4RB$TVG:V3ZRQE([SK!FK$99I;2>Z]-
M5QQ]V%-/W*FL_$'2/_[]?WO;.WO36ON,%XOA&!5>'FC4.6I"U4&2*,5PX[Q
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M4<,N&-!S==9E%GZ5BV1D<G2-6;T<<>;%I61.=&>JA&%(NE?P$?58@A=]CAV
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M3ODE(N@*"JA):=2RLKLA%(%&??DG8522'MPJWY,\%4%W!N^@&L+TT94SW75
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MADI@6/.V7UD#D#3I&[3OL-9#4Z+TRY@ J'3@-'W!S7 ZT,#0=R7 ?U*@]0)
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M]9K.-5=+4U"(@;>O0OI\;V!"Q6UMPG..!.>Y*RXCS"3O/_V==DUPXV88="R
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M4:B9REQF3-&JE;ZEU)AP0FVGW95F^\JY9QP-VXYY>ID\?*Q-3_C"QX1W7(O
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ME4(QL\MU S-D/]=!/T9VH-ID14B%=-(5GY3$[LN3'OUQ1_]%*-/VFP$O2WH
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MVFT1VHU?%5W[-:].4F7U.QK^X(' .8/MO7,09#)C%[ECE!SNG_B.#C>N7-<
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MYBP7B[::\;CGX!=V-4TY--!$9^+,PYFMHAF*B.''G/=8\+CFF 3P27@L;"E
MK7MI0'TW/:DM-#_09!J 4"U&0T+7O0+V0JM=$J7;8HAW+DF3)=G&7B=Y"K1V
M# /@!(@T\?N-T^*5XV#$-6(02$V2?>,TF7D%G]@4<F?#935HZW(@KSJ1_YF8
M==A,^5;.I>)YCFE:_&.')P8A.$>@>SK>GU[K9L$%2)6P>1=)!)TKVJT:3U%3
MV >F>DD!:PPJ4((F' N2LRM7M(ZE>NY 6(F4Q"J36(AF( I.94O^1S=_TN]?
MRB.$@94J)WAN*66+#W*^-TWR;,,YHR H*CW>U1+UYC>:FQ)#SK*"==I2)0M
M''J\G/^%VPIP![U(EQ CML>NY&DF6\L]X=+,)] FR$$A[:Q-2$5PZ2G+DI^!
MF";BW$U/;B7V&DT'\6"TVHT$5/.3Y\D//%BATM 7S08SDC.?DN1T9"<'&;K0
M#V7AM"/S3G]\>D(>+N<QY6<*[$."_/OG%Y+GY,/H,YTTM.'L'@9?D S9<N(^
M.#R)?MKM]&0_[X8=5\>:KPS>8=PO-"@ &T#!'\&WN%X'J 9N-1V6 =]3)))$
M#99(\ N6@"2 ?'170& ,V4AOXM"$O[QF_==$V4D#!>CEM<JJNO%X+UF4OL[C
M7<("[F@>=8*8PG+?9>#WT'\\D!NS"]+ZWU_3\M%!S.W2_=]?G3^T/\R \&(
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M'3SAW%W1RII%(5%\W*0^?S JE35X>CZ0\7XT9;QO-^/]:,IXW_8E;%,:871
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MA."$*^A-X.5*RG?CNR"NIM'HH"&D/.6[W!;^0IAQ"(C=*B9/]FE*\:D^SG\
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M6#S@69Z2ZG_)XW[YTH[;##/#EV5@6'3ZFO8/P;!HI6"H0Q5[!O-:5\$M?ZW
MSNCPZ(KR#+5';];$L\J9?67IQ.?0U0GBB/=W<?RH]J5=YC*X$IN<7DOW.1D)
M#1.J85\L3D],P%^N_$[# :FM]E>6G5R )6LR^DZ!$TSBQ#18\KCXI+PLDCQS
M+<OBHM&#=4@^9O;2TQ/<L;5S[SQW/(<15Y Z4915_ F=@=2:L;/GLFHK5H'*
M78.BB-!_(1JFRE>/I=[C"PU/N)/B"E81']"J?(WSNU47P!#G[T/0AGX<UW[#
MMB )R_@!8H&*3N-8@3_W0THB.&]V6P@/?KHDH<$=DUKESR\MW3 B*=EF6]8D
M#S4]C6^ J;1C*NV82CN.*+I(EQ:9AW(X->M2Q*JKCFU/5TG>)39&[:J9(M]C
MV.YQCW42JZ,=ZXA47KHD2:B=T3!(73+;>>4<%KSZJO>^)VLP^?K;K^Z3C9]6
M[/N(V\A*$*96_\]DVY35MH0I1'\]^&@R@L[=.1E2Y1F)8V[<BB"#??3@._BM
M#?U1G\I_??C== [&(%KC'NLD5D<[UA&IUT5VE>4R/([95&@(C6BXH_\/%W:2
MN3%LX[C'.HG5T8YU1*HL*WYI-7 U2=<8-FS<8YW$ZFC'.B*E)3BRT!V$?%5D
M%Y95JKQ>46[ 1_KK.-0_*;M1;/2XQSJ)U=&.=43*SK<HQP!KE_T+=-,S3F87
M$L9#NGVS+:LFF:>3&3>.71WW6">Q.MJQCDBS795Y6S1I%6KAZ%=+CSUBH$;E
MD#\0A/RVG>?9 A"4&/ Q">88]GK<8YW$ZFC'.B)]UY1-FGM=MTVKA@D,O#/+
MQ;^B]^A?DP".84_'/=9)K(YVK"/2:PR!S3H<+C'F#G"[<NL &>G"8[G)4KY+
M"GI3%W#7L>\F*H.1R,&XQSJ)U=&.=42ZL'*KMC8K#\4/2#^$S(-+K#HJJG.J
MDX-U3O7$:? 10_[4)8MO?#KI]*1;&_?ZU04V#__#O5"UP585%9ALVZIN4RLD
MNKFFB:NXFE#&M9QY:H"X@XU_."K3M$8KK:52-JV=TBW,.E6Y5G<[2[A-C1:O
M%.%'6J!'4YDE#0J5K&7)#A5IY\F/5AV)QB?KM%,Q=7JRS.I%)6U6]*&]?HO#
M97DZ?)3?/:=Q9<HZWM!^2&\%'CXJU$B_8CF,S 'E=^5B@;(D(8^@H5S2>N!'
M**?B&B97<-FEU/W0>=EHF\9%VM(SM;AG3C\I]WM HD .K=.V+N4-)0,&M5-Q
MS11MXIG_6=V03>,X4+7'?R&+YQN+'_SAWB"DJ23*VN91QTKK2#.\I%=IA<?Y
M.LS3DW)X0ZST46K&: ,=BT'%39"DX;FODSOT6XC8TH%6@\;%I5++2L11Q38J
MC>6S8_5<^"[M&CO!"_I&=? 50?*PYUR.-DNX8[O4]!6[ PO!!_304Z6"<8,Q
M5#3OJ6YKJMOZ(K;35+=U<+"I#.V@ZL$MA]MRCEI9NGB73/(.%>!6*VG$-NO?
M<'QC3V;_&+9_W&.=Q.IHQWJG56 ST)3PMY(9>'8$C>MU%>F-GLQT%L8@7N,>
MZR161SO6$:E8YDJ1K,6*.3UJKU5!TB*^,<A1/,U1WTFO6_[EU/]Q)#L^[K%.
M8G6T8QV1UFO62@Z N-HFNURS^>:3%*![:M99M3Q#@&[7X4=!M?[#)]_5(78K
M;=<78(="[2O]<Q+8$<C N,<ZB=71CG6T>I#LOL4Z+2[)Y6WJ0QFK$AAD47KI
MLJ09 +X2I3GN8,;V Q3<WTP4W+=+P?W-1,$]81#Z?JKP<<Y.3ZZ91O9:"70]
M ^ZS%\FKM'K7I;S=H\A^>/Y \KVOGC^WC#(0>H@&DEN[:3<)^A24A1)M,Z_G
MM@+SZ,+-DK;(. L>]!WH5ZNRO5R7K:2*7_QD, 97U&0P+L^3-RD//=DXSH +
M%S)T*#0NDL([2?:#G73A;'C>T 1KJQ$KT^+F.Z7*57Y=>J$\^/2D^V1,S]6-
M\ 3S3"V+SUJ=GO$G](20SL#LXT?)_:;<&T>'9E3" ;1G_$WZWYGPLB) >C;?
MG>%_3T_F:9U)^K_BDSB+N%ZW%<*Z37*]=DQ62I]8JM]2Y'6[@(DMT=J8!-W]
M!O+STQ.C-]6DV(N?/GT#B1&>Y-NGS_\^8L.E\UJU6:,"7]$E%9K<K!C;L]\Z
M1? J2@KL\G(K**-#5-::!&"H!!V_B>S^RVGMGYT0,0<D$N]*#:;A:V&";PL[
M[0.B@?^L'*LY5T#+!F$Q9F77[(4DS\F8X&_I8R N8*8&(HCAV(Q[@4-?5AU
M-D0,PS<PF+Z,C-ZMJOO9 *>[=9V;V;_> YVSZ_2R8RBD#/+TA'MV>HB0HQW)
ME%MZ467<,,=W?N ) 1PFJU;X(869>3[]MFCK%M]&UQ]2G6N_V/2SG)0NW9+[
M/Y<-DDX\^":M!A!!]%W TVMC/Q=$F>_A$Y%AZYGT=+*34OU\/4G$-."FL8,T
M']++H;@LI:K =WOHZD[1LH(I6Y?7.)E1Q$N1DS=T9Q"CS M):/J$NOPTJ_H2
M<^D*E$/@R61695MN@L7M4%INZC3IZR_6O8Q!M4/T,9T@ ."O<^>*Y))QNLN9
M)H;HN]+<3 .I2R\LD*&,!2U$4ON-218TFJQH4VMBH/W+;GHLY):-]SDKWDW9
M*#X4[T*/@07+5LL(VPY#?Q;Z$WB^_0\0\P/7VD.S_^86/+)BH<D+.?3OTDOI
M]R+DM8FT!ZH<F"WX@YH&1&XGG3;^2I/5U@%&IFY]02)N;V]1#_5_.=1" -U)
M H)UT^4&[RH.,:IE]9HU"6$+["L0TGNHW5XG!%U\[US\O^C,0>KA[:YNW"9Y
MXW65;[_!M[3KN2&5P[> \J7G_U.? 4&BZXVG8'_S/3@8*G[M8%PH9+RLZ/;;
MEE*7L"%;@]9'1!Z%7/3Q4O3HLERT>*LZAJ_(GR$9J&:&$^FL%&U2U9V][&1W
M>[F[]RJ##"2O%.7R7)[VAK]>=U;+U@*/%C8 N(Y79%[#ACI/S$F.=I;&0>J6
M(W8;TB&=%$>WZ"RD,+1O!-ZZLT8O;2VSB"^&0""OPD+3BIX2'6_>GMX]!+$+
M!,K<,>3:,<!]2%8.M;LHPSG^^+Y%W!$C8R#ZE?9':8MW17E=!*0\O[DCZQ])
MDZ\S1T4 Q /:T2/R.R<1YWCJK#$AM(\[73(AM&\H=ILZ:QR3J$YCG1+&8]RJ
M$:F\W]]98_8[6VM,0CT&.1GW6">Q.MJQCDA71FTRD-C:ZY+!N,&LF-IEC&,[
MQSW62:R.=JPC4FE3NXS12=>8QSJ)U=&.=41*:V*0OYLB..:Q3F)UM&,=D6:;
M&.3_2((YYK%.8G6T8QV1OIL:G_UAI'+,8YW$ZFC'.B)E-[7+N(L"..:Q3F)U
MM&,=D5Z;VF5,0CO^L4YB=;1C'9$NG-IE_%[RE2<3^<KMDJ\\F<A7IK+0WC1>
M%JA5LM+)7U]OU2NQ?_&3U/BGB[75;WD2DX@=!?6;5]FR37-0G@1V*E"NN*P*
M5%1X6$1=$I%1:2N8Q!5D+** C=N?<"G6MI("RU(Y"09CA_V&&E$]V.E)J.I$
MQ62?UH3K.[-W+L_69;F<><Z 2@HPF;_B$@5BQ4;J/'UQ-@^2J6&J#!5U5;FQ
M@M+<76:UU7"#@"NN'Z,]6L@.N8RW17E.?BHRS/UMP^08^-F\*M.E5=P9?8#1
M,' %)!@7X@5!-5XFY9/&T\*3\_S;9+%OLH;>PZ5^>C<=+(.U;CSRXL4Z<U+^
M5I,\X]7TBU76:,GX1"CP60@%7M!QX'+>:\^J].$S$?;Z=Y9"ZU-4)DY/YC*(
M+1=&HG@TJL2<* *^X%W@Q>1W;'@YWU,P0](U4UH2K90+5!7<)"P%+[]1]B\@
M*D)KM2GQ]?6N1B$M(@A&PC)+UB[-FS4-">-+=Z64Y,4-GD RU190.E#IJ,Z'
M9O)]H);NLG)<&+[WXM,3UHK",B-<6*'CU3[7S%3!>_#M4P7O5,'[N7(LJ,FX
M]'%(/=09Z",TK\+D.F3]N";CJ\CTT!0,&L/^CGNLDU@=[5A'I..$X%/&QVXW
MVG6DBUW/GYTD;PR;.>ZQ3F)UM&,=D4)#Y [MW!8N*#5NUJRDF]P..5LZ[8,Y
MF6JCV-5QCW42JZ,=ZY@T6\DE:9803I=7:8&^[ARF6F9U_(<K$&CFC:N*5&*D
ME4N;J9YC1((YYK%.8G6T8QV1OJM):167S;H7@#-:VR52F]F\Y3A<W6Y1H3M)
MX1@V=MQCG<3J:,<Z(N6VK3+S4 ^V*IDE\[(!MW62SNLR;QNGW7ZD\46>6OK[
M@*4W@9U'(@SC'NLD5D<[UA$I1"6J9TR7UXO,D0X\IVB\;#-OJYI+.03X%D'D
M MXP[LTK.(X["'P^[B$+9NSEBL&8OP<+9(3_A@+< ];,I!^-1QH:3M%WD:EI
MC@R!1S,C;2/#,*(/XPHG&-F7@I%Q^Z(;#C_M5]-R>X?"7>?#76 ,M"7]-VKT
M76P+;8LH/2E6TGF. 82".4N7[I\MI,;>?7HB\&']<W<4 A66SDB])D8WP!X_
M0NH-_YH5ZVPN#Z>!#+1(,GEF9?B[,)8**IX/-NJ9,+9?Y@R@*R*);:3"@@@S
M34_.#8RT&V=\[]UP=G[-H>'FG%%OS=,3;;J)I_P.>:.CQJ[-LJ0E(/-/.D 5
MZL4P3E].4)W$N$GN<%?1% JY6&*;8<]<.'!HI37IGHD05R%$5H5]R WSM"60
MM.*1UF>G)_*OC-LL75;IIN:V#C2(I2!)R^HRM7ZQ]<U62O*WCS-G&)2OG?AH
MO#G:^#2-VVPY-J:]LJ#.8D0K]^M#0R'65_@B[T!GR;@J 0W[I.RVLVS@92?9
M]4A;^CXW2TH5ALM [9WT"\1=S ^68K3R"OE6OQ\T"?_(WRQ#+)FU!^IR_4<I
M3:!8FYV>=%K8^3*&FEO:<J$%YW_A,M,?W?NLYD6QVX*1OXKKY27*<UY"K$S+
MK;7*PIGK;C]R[Q?.+>OX1[C&Y%?238JQ@OX]UAMI;X=]]</O;R7&?5,_XCKS
M#:(VW(IWZ58@ Z/O&-:1?TJZ3U+I&Q(^4"4.UY'P=[F0A*>R;5'NP4]'"0RZ
M;=%8Z)GAJ'$73+E+O4R6J]F0Y5]6LR[BG[74_FW^4>J@I*OU]X#5J[U39L>/
MGY_1LF0<F:E%H-1<J'Q9>W= IR<KMDA)W71 [;P-CM$+O5&I#3#=T9_%I[&>
MM3B<*F99H<WC@L#!8U%YR_4R3J!!XIN\RNIWI#&V)1^CR=WXPHV(K24A[X@8
M57DFMD5F9U<Z$F?_;)W97/Z,7CN[Z*3<KZVD&WLHF$-1=E:SPC1YT3NW<MI'
M[_2D*$,O0GFG%=2E"VG2SC2.^LCP)%;RVO(=@E7/PO65;E T:7?5@+3ZQNHJ
MLERD%X1VD:?9AF_$:$%F_H:T :H#SEWJE])E.X4FFY.SQK %-4%"U0Z;8CQ:
M7HE@VG+[@]7IR1PW+=T6Y\G+!OX;]X[D,LJRKC/U]/=.(?T-39?11B]%'1#Z
M&M+X/&T(BD#]2Z,I';A&4-RJ5\? VJ$BDV/RJ_2JK"SZT,KZI/SFF6^/#%O#
M-\ -O1[9$&%F$]H?F_,,W1_H7;)PQ5(Y4>0ZQ I*NTW/A3(N_2_*U-3'H.;[
M0&G_MU-I_^V6]G\[E?9_5OD>PP00P34[TS0E>9#I==UFZE61D=]>KH.JA>K3
MD"RYJ&WW!HBU[6=;ED]M/=PA(VB5PBI)/-)0C-1 )1@)0>3Z&ZQ:G5QO$YEY
M4-(%5[&)4J?<B)AI#M+--@_A>^Y]2W9#ML(=%PBJZ>.:VS'GN;MT2UC3:2M6
MU"]MM6-R?KI\R<)1FT.B)M?@1F@+B"GK\Z7OJ,E/;5PM7;,W,578+$(8P2V4
MT:++>.R/16N@EI'*.L<>>)P:[*'U("\:(',XR;U719\L'?P"<G5CXP,-\-@(
M6H+5@CO@P5)DES)>YEE2N$L2%,?)$'4IHVV"ZYM +PN=!CT67=G9W'DFPQ?K
MA&TK&(%U31<2VJ*3H%4<:8>Y0TNY<15K@\9I/(!=;Z&)4'H+C0ZN6K0HQ@P1
MQ8)KF\/_-15Q:"$_4G$D4F0>WB5OH@V_YIDHX5O'V0JVE,36$:!39HV:!LBA
MSC>T<=4RU^BFU'U74',05["!H/E\V3:+<D,K[0>/QN]>#/1 T"D>E;:?*KBG
M"NZ[""I8.@Z2@W<&0URZ#>?]RFK_DL+I[5Y4$\AE#%L\[K%.8G6T8QV1FA-;
MV/-$(HQ4N6W;I!/W]WCD;<QCG<3J:,<Z(C7&^0&OQ=1]A!]F0!<X@)>34AN1
M](UYK)-8'>U81Z344G4],R3[E#(LQ)_^_7]]^^CAD^_(#:6G".B+C3<-2DWR
M.(8M'O=8)[$ZVK&.2,U%P7H9Y*8L')J/)NEU6BT9W=<P[(%[52TR>K&$UHV
M=1+*,>SSN,<ZB=71CG5$NJ[3,EX[*,^B7J."E4O!#]U/*B/OL"E]*X+0V&HJ
MUAZ/J(YYK)-8'>U81Z0!S:EU"U)QP,6RVUHWY>)=PLP6Y\E4<OWE(5T_H&XT
M*Z+*4:MS910Q_V?=@O$WXV*W/5Q.!%5'29K573,L!)4N U#K@!W;>YQ'RNSU
MV+%"UZ93;:A5<Q'^C''V2U2HE=O#./O#LVBW-.33D__]>/;@P0-Z6]G66(HM
M.@MA:%J'*+#YR\L*4"Y P')\]7*-MS.*>P#!I(!PCV'B[V%]T*J'$?BUN$)N
MB2J\%(5A;<6S+]QEB2(AQ^].D]HU32[P)$8G2%D9'S&/.^<RHM1W?//E";[T
M3E[30?Q+,554+X\QSDY/Z/=1Y;R(R"P6C$6ZI9?E-ATIAI0Y?7K8^1V!;WX:
M<.ZU"Q0)35.EBR8^V^_<+L:Z,14N[RA@<9#ZNBP*E\<@S+8P.>AA^?C,)5Q+
M&,[G?F$B2]/'57".$A=]1VX&7_%4."G6<>^W#!45"G@IC,U->GA#Y3\1PIG%
MM311G<K,Q*17P>S#V6PHH&*B+U^G)]NVJEMGT6^75HOU_N/VKP8::UDU]>^M
M)?Z!X:8\GM,3*3:OK2 'U9Q9 6QR=(_J89O926-4*2GQ*Z!EU]GEFM;NGRV-
M<Y6Y9?\,TL5W!L.)*^UY7O8/?R3/3T]0C)27 8Q:NTI+DSW:FHTN5V1E%;]"
M;E=I6R?-0*_D*G&=!>T=97_5_HX3G5QPASL:4L,Z95GZ:\9T4709^PY]\)RQ
MZUO8$5C<,#NWV>;ESKF:%N1G*S13D5T#Y!MU]O.+!VSZM?,;%XEW+%Y"(AE+
M&(1>JOWPT;S- (MF**"UI%-'_O1DU1;LMW^.ZV].6W%9 >&.0J.R^G-RO<X:
M-VFU0:TVP 5D-R,77?-Q/7@TAZY',PA5_I>A^A.,%<"=^Q9 =(*@B?SC2:\%
MH>368UV"C4A)6MV?JP^U7ARXX#&(PD%M(=(>WL6,2=*6L5X+?8P]G^R[7T2]
M![P]G0Y:42>%C04Z1F:%A\;BR$50>E)L&<V6:1:<L2@9L<B-YRMZL; S1/J4
MWEAW#K.9G'9JH^]F*!R1)T;UD@DWNG27I(5>%IID:/.T8N5TS:I4RN>EDZ@4
MF XKT,:EFT.\4G39D91864GEMGFZD-[R8KLCCTM+M$KKM;7AE/)3FX@?KQI<
MZ[3:0%"B>IH_6BGGTZF4\W9+.9].I9Q3*6=O A<U>XL=H^BJS*^4/"SE2TPJ
M[S(:6P8]7_ 7EE*C%A0Y;A?_=:X;B[^Y9U2&:Z;@]LTH(UMF""Z !\!9<5QZ
MR2D24I%D[%PW<G^(W68?A&KWCO<P>9)?V.9"WA\9_48X*Y@7JK=?LI&A/W3/
M[U0'<[@6DPTSML+)*@B4''.F?&*;B&UR=B.82TFN?UA2KS0JJ,W%:\628DCK
M;%N':D 3,37R5 1YJ&1OP':(RPGI.G',P["E!V5^1"!H".9%Y#4+OQ(Y,!O:
ME-B<B/SK^(296QNYXM_%W_4.(T,J>M^#7T06%EMQGECMDOD"(P,K#*SC9\]Z
M;<.CQ>^X0,'8_ X+Q"15<80@?B3961'W!E=@<<B UG17-VXCR<]8%$@,/,\(
MC"<4KJXSLBFY.E3V(TW$4#4_?6#<\6NS8E6E]&D+ 9O8DCX?6U(%>Y@;UT<G
M4V5?S[M*6;O=YKN8V6M2[%]8L6L I[QF3T:.D^LJZNBL"@N1J:9.?,EV]$",
M:>:Y#I%DXIQ2V9"-"Q2%1'XXAE24L:L*LZ'K37<'QO0^\!2DA,!BD$9TZ.^2
M75\8ASF+0;X3SZA>,#W CV6"()A/#44/6NX_A>^HM,/X%_T N9KD95VE+I\4
MU!<0^9<:$NC*$;:I<$J[&?(C(M&NPT3H<X>2')LA'."!/]E"K!"I-U:6@@-Q
MAM,35\,_0_@F]6:.7&J:PHT3='$#"%6C8M47<J[X;QGX.*,8Q3RMLSK.>/ZS
MA2$GEHP?,'L-.E@V87 ")4X;NMEWJ6=UL+%@BV[@*%J) )'C>8JQ-8GZ%Q#U
M_2C_LF1KRRRP#U-?YMD[B!';R,:YL:W<(JM)JI$#D3AH1\610 FCBIK'P\(2
MV/CJEH.&G)<N+DLU/+.2U#Z.8E&48(V#!'/V@%T-\@L@:-\_OXC"JT59G/UT
M_O:<1GK9D@=0 IG<-NNRRLP><<A,N$0I5"1ZFG(?4=;:-AFQ6>TY>&/,':R
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M%(LNJ'L5,@%K.8K)8BN*KU3:O/+ND/K4/!;\BC"#66@2&"R$(BE$M5WPK*@
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MMT1"KY(LJ]0O!;5P,&Z4\&16_I2*%^(L^/4U&P) !D81WP?C>>IPJ:09C9P
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M'.7*JGW0J&V#T9:0P25%D[+MY5MK.L"HG.8<3<3*E**AXI8=QANF0>AT2>Y
M<-E+BO:3_;PQ?2=I =_#VO .H6DK#^F$Y74G>2UT)X5%RX&;':%(%+Y#(4DM
MM&GK-7M.:RUW'WHZZVUH'P&.L"^  FK24!A_"N^$*C3^78J3(<T,>UK]'9&R
M.P03W33V>TK[I>=CS4;>8ZTTRF(2A9((959D%&42AW",RJB-&OF_QK\@2R,A
MP*_8_*8C5,A!B0DE4@JVI[:#38I.%D.!Q&+1,A%)LCS4CNO*$A9=OHKX<3H
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MAO"%[0X#BN9*G:$KJDMJBU-9"FZ>J<2@_HB=R]7EOI$-ZTUA):RVMHM^$;
M2]<1+N"D=U?I\-/5#&.925G-L#./DN')A<*JR$0==:$<C,-0#ZL(&X.6OLKY
M_R7<09OD2*J=3+TWTW0"G.V8R7X!H^C-=>C& 8NZ.#*GD+,T02*2JJ00->^G
M2.4&='+UW,Z%3*R;DE9M56G5V:956U5:M4JKEJ=5R4\2N:$84D\@_-&U=GFT
M[:FKF560EB9L>$+A^DBAKQ)JU M-0;NP2X/KJ$T[9?F7L&$+MA+U(G!+D/F
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MZ7HXTY,FF2(7H/_+.U/+(_0=ZL25!R 96#F46FY;,E'Y4TJSZV5;\\AK-%(
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M_*B2&+< Q*N*.0:P5)'H2/Z&#C*%"N/,5IX*I,,*UEDDW,NO_ XD6Q_+?*V
M7VQ-JU%P&+'$S5:8U.H,_ 1[J%*T+[(P <)*>E1Q.Y+C4\J#9RJ:A6:RC$$5
M5<4*J8A[),BG%("TJP*0V1: M*L"D*H I*QP62,]LTRB6A!+V\(OPFC@=VN$
M!T6D7,OY/P;3MN#=L3;-%\J;N'JA': ,-WP%S_69V,9YPN#9"MJB++UF,Z'
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MSEMITG[0,S3H\32*+S<VPRR):-)>$JTQ)JD?((J0PKU H[=,9MZKD]NV$>!
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M8 T@.(</AX1O5%?FQ2[I)MH GVX(W'^OP\7*VX8AJ*XJ_Y3%DQ:_ULP=6!@
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M4@74K9<G1S\F. W>IVI<'/V&@[W%1M3K/8LLV"K*@WM0%CFH26KAD"*TF1O
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MR12=].CG)JF7V_RHPE:S"=\NVOQX/\W\>#FQV$V,9E5$/1.B7JRD?K_1G&:
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M>=8-'D$2_YZ [630'L8)P,@4_)>.!&,27O=B"+.+XEG)1[?^^^[)/LH@+5G
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M#W0\K^NN^&UI^,V.--]5*3KO,+/];EW]26M8QK-<KM7,B[74PTKP-5$\@@%
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M[$R*J8A"K!M_+Q;JVHML]-SI&3ZVYI*,.NS-QX5*];0YG!MS.?:=J!$XES?
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M$QD]+4LTM4$@2U/-E X&WZ4?NF8(>#X= N[(8"1#P,OI$/!T"'@OFR_^E4/
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M!0(J8!#/6*CC;SP1+DP)VT-CI".LM(?X1O_$Z72MR'F*4YT11$K%\Q@?JIF
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M$$FW3B(V!-"!B:8NX$K%U$!]T_E:2.YYQ2PJX2H5S:_7WT?&_6-_G7!Y20K
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MN3*CPG57\KX/8PR=#'!74CB0Q2]V ],:/"U(4J.VV>?JMQIZ&IU]:')1P%:
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M\;(IO''!6_?XJ8">LQ(1)_125Z'@.!8=6T9O8141@4L5@I%Q#NEX[$KS/J^
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M+!@.$ IU=E#3AT@&-!3\6\AZS>R1! .L^H E^%-/\ !\*PFQ9@2-(PSK(#T
M>2482'^"^!,+.6'ALC\D3R"9)IL,8-'[00+L+\+?B(T&8H,O:8F" HMLL@&\
MA=% 40)DDZ;T5$/&^A0D1-?Z=!S!F.V(_QLA(D#I *MC,);14PK*_T;(2E-N
M2=R5A)*U<P2MKZ)J 0(L\<)RU0Q^ B:5V.I6HAH>U'/M]AX^4SG.GG(,?D(G
M582+&/H,21X+$GG>@\QO.)>H#7)H7_#8+W+N>')7P^N#G@^P#3Z0!SD^/?9B
M$;W=/F9\'V8)0/+EQUY8, :7ST#^_:V(OPB/XS3%XX@:CR.7XG%$6J=XD"@/
M*1['H>Q4)\7C2/$X4CR.[:+4+5'6B?W0';9XF5/;B<7[QJ6+KKATJ.=[<U2_
M&W\?G3U>R_G#C41?A8I$UWKS[.5C9UP9?+OM%K 1X@GM^-:2I4'I-"B=+!IC
M-CBPF\9BGV3$6B5?(B/66.C75B2"2Y.P@"_,UI159 049=*H]A]+AA"W=VK<
M<G1V81:=^SUC;&;SRGT2.'7'4'D\D47-15TGT5"G]H  ^!.?&_Z G'GE))7*
M1IF37V:<*7RT'QS.,0.8U&">BT#:Y\"%)V-$79_'KC+-KN+O\7[4#3#-!ZR2
M\:2DV_Z%A'19C-X5F1<DS!4Z:P>[Y)IN'D/RE9*"G[!T^D*>L/7E_XEK;A[?
M5+Q@3*=LC%F6P8EGN'9C+",=&L5GSC!!&? ">&Z"[]#4,ITB19,-5J !#1IT
MUA1M!&3**@N >+_H4QJ5>PMDI2'<).Y*0LF*75@N -J"DI<3CH5K2R.EFE!G
M;0@?+)5W0WRD$4L"K(%-N4?$>Z596!,9ADPTNKD4P"5Y0Y**I=.D8:J+H^5/
M[!PBI6)!IPHC_(U4^8[ET1B&B#+U.@.%3\C'E%/MFB:YW@19NQ3Z/!;Z;A\2
MML0@88)O2[:='V?7-XRW^$//B+9X'C)"WX)V(%W7L+LALCY,^DLX!&(JGF^"
MK%V*9P&+Y[VJ.0+*Y!!DDYB2I+8 :U)3(67NJN86."@@$)]$68%'3YBR++C?
MX2HO$ W6*OSL5K*4##KJ9<$+L75T*M=O@JS4,$WBKB24K%W7_O%1[+RL*Z!@
M#:LO465P?H8;R<"0(0U* P<Z8JEZP1B,D61AU0FE9?#Z&=:<I%;=*=\^#(B<
MND:JJ&F]WXUL/-:Q3I=-^--1\ CV%4_UYK_/U8O6<S9[,\T=:MP[COS-]3ZA
M<>J]>?V+FL_^^*/<%*I0@>/:0!+@&I =%'2\A6EH/@W-)XO&N =[!0?%B4=G
M0S@H,\&P^K\YM .]8DQ B%MQG*BQ3&UC?&0PA6OBY?BGE)"%P/F)4 ]ZB"4!
M/!\GAKHS=Y?4BDW$W]C:[XOJ(PD7,^15>!C6<Z^23]Z:!-Q.&U(J:N2V$4^$
M2U$51S0VTT<*E <S_O@$QV738A7DT(#%?P7\T[!3D&%%;%@30'<5--U/\(-N
MIJ$7V6#S,FUFD-F3-%QOH*!HO).SD#1$;V?22@;#+5T(=GAYPV.6*3BFD^L]
MN[BPB1D7-H9(,)$0?A<4]8U%=40<(A-ZWO#VL6)%^R>DX)LD*_A3V'@8D>P)
MM+I1COK&H))H+DPFLDD(KJD2OD6@[AQ*.=$:R/53C_40]B6]N3BK_KYHZ-*Y
M=,#0ZS>ADNBGO;GUIWS;+<CGH\F8W-$.8]([.;V3DT7C;OTX&R9U,- M4:&H
M=*3/=^ ^)EBERJ1+B'AR T64)_@[(&- IQ&[,L?X(M(A9DLB8;1IQMLIXT)D
MI92 LT></ ]FN@/4BF]=%7IG 'M)4_&+9DXW$;F7#.30[X&,H@T_(.7X&>BY
M@N'U!K5 V 4#>1")=NHX=@KMW89U]3%_@,&>L-T([E0ORKM,+B:5#5\F-H$O
M%Y'3,;5F&L@;K3&OI#7F4=>8Y],:\[1R.:TQ/Y2=ZJ0UYFF->5ICOIVCW,!O
M@CE 3^L<XZS+,0Y^J#>_'5\U+BX:7\;CTN$ZPK>^CG!@R'JJUG^-'ZVG3KMH
M3S!A[9@-[5D]OH%8DG"E:R:U9U,G.762DT2CVQ)-IH72XH7)#OHPPW>W&ZYI
M[37XU'RNDG _);5Y'VJW]Q^%CG8"'=FGQ[F<7<W.QV<(5]C1)F@EO)3] VO@
MAH]_I%"M '$"P5E)-G3LLNJ20XN$3[F@DU,^1%"/C1@H!O&/@2;\5^+-$S -
M.PP,SCQHNQ>*H@4S7>!-)+.;(:&#J:5/-8/6=KN!7YTA+!HK+*0@, NMY"?"
MF5WA!7AM=DEV!F^?'24?+^!YV;'RY_6ZC/K@>.-E@K0/E #=_M1XM!T1UH3+
MG<^U? AD<ZSPQ19\ JH"DX4,GO]QB7F&@JO"9PC:MTZ\7H!85048WV,R8!9=
M'HV@Y$!TB_W4$8@/\@DZR9 #X(,53B&.63F#"RK<"3+!6PDN#P>SX\AY2X>,
M'4P&="<;+OP!6H\+-"(LX^RHDID12*7Q,(9\!P.4F J158A-.:$IFC%S8/-X
MK<7BN0R$6__0O+K]Z 8!=!^ C1(HAVMH$@C(2TVRE4!WV"2Z@:L&1#(K) .U
MV@(M.[B6V[VO-__Q%37OS'Z_4Y8/U3B-PYVZVV?)1ZTWE[\^/CP/9\V'7/7H
MLWMO"= 5!3=SMM?)6*9V=&I')XO&726;)IY#HCOY_=4'AE8'P-5GW[P49)T.
MT+,? " Z:L#1"#;M>7%])^N"='TQ+>R8B,2"Y/9@L"DHB$.3F</N]V:6;W'H
MRQ$,&3-,U,%H5>$Q#?_,AQX&S^>#+7I"' 2[DH.:X0/:P2,J[DI+&[PWD,<?
M2&LI_;.\""UH4[)@Z3-&$LO#=^GNK_@(;' /5%ZR571D,E9SLX,:,)#3<VC
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M :ENP808'*9?IM-/W46*;KA).W_*7!'F["RX(E@!VJK;@,&P"]-*I_'5)"Z
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MMM7!?*WVIWB9\/1Y=%]HGIK*U=!N0/,H9\2?R @C"J2_L/RM1DNM7GFH N.
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MDXDCVH@("S!L>4G8Z#W#Q Z=C8B.J$1JJ1-]]\[;2ZP&B3K9X*(L7.(1\9:
M7K1NT=1Z [6G=T]3B7O7[_KJY@4W^W?WYGU=O>GV](^J:I-<JY)-94]^7-;O
M[BHM&CZ )B>7]1JT:U^GF"KBX9_8%QR$8/:?R%Y))HFI4"G$1Z5X/L?/H1"9
M]VV?'![I=;/9_1VO8DTW#9<G.*=GOB&LW\K*&W7Z\(8^4(C+^K12*7X#6^]-
M!$0(ER\;]'6L(V-!Y^&-7NZ(OC T44::AH5KQ_0VV9)5QS]I^(TJ^=BC92 X
MI]/)5#+MP*$M=DE310V;$4BKPDV+A749#TTLX0;QNL,!UBXF5=3GI1)^F3ZI
M]RY)];XZPN:*!_JWZ3FKV*M3M!;'\FT7I,N!/+[Z=?7;UVBT;J0-YNSEL4RF
MS\#?G;9<W*MH#".=_E#UX<QIK=)TF?^9L!C)H&L7*8:Z?LN\%#L3\8^Z$DG@
M*!F*CNX-OK@?IOJ6('X*\%V,L((.EH* WI"DC+ PP^2<B?(;KXEOID^N(RF*
MP/0EHZMHB,$V@:CCIT]!>(+*Q"7_O:)/$_<!@#B0C]E_OYV[1::HN;QZJC+A
M)=#M;7=]I<CP.L/3UY,H():P?6)1('T,AL+BB2C.'&(-,MS$[?FRF#Q%0WK1
M8'<:4VS@Z9E/DM_OL/TT-(;6D7B1LD9!+P[>]=>ECCG7U#UCA93;4^OS/=#6
MGB,M',^=5X>-W9R LT6^N?A@?,._._DFH]VG__ZMM^[?<X?G&R=IX?"-&TKG
MGWG&F8L%C\S(NAWK(RY;ZZ_SCDW\7<'H@F=?%360._8SBZ*.,48@MO /9E("
M<=RO1 #;6OW+4#84D @M"&R^6O>RS2<[PSLEK>1>4_NZ;#/1T]XVDR].%)^1
M9&AVAW>XO*J5BWICQC8DD(Q9C9@*Y\QJG][,B=:U%]GV@TVHY6%"!Q%G/SW!
MMA-?@:@"Z69%XQ*$*U=F+7 A<JC56V5;#GW0[[2+'E^\+7%[XM#%-E-[X-#T
M3NT+)Z/21''@*XM;SYDFA'\<;*9TL"%.;>$!;W*JK(!?651G>1&1#?1$U"L3
M4;(^>:@IHKL24;(B$^SBS;)R3]L1LC*PL._+8@\S"A9H5#7SBQW%3'A<9,42
M*XJ[$G*DX2+,2,.>H@M%HX\'9XBX8G-$'$&/70C DS(G F5#C<6B\"9JBCIA
MBGT5(9IW RI]4194_-YK7E61KD/Z?/><.2U>5[XE '(7\L&)OD_S=CPL3$NQ
MMEZ :7X3NR0K2U0$4,S97#+'%<"7@7_*)YV=[\ /4>\55?"V$:+FE75K3)MF
MRQ>Q7,>G<S*GA"=D:?:MRK!4F+1ZKZG"R>H .)L[2^;.N +]*7^6M/5S/[*L
M/WN^_L3I__!>+%";31?H;!O[?!]O(]X0R% 827R7;A[?-ZTNZD E6C9X4)D.
MKXGD<C*C2'8".F]Q@&:^U+K!K'>!BY8WDR_L2[' D)P,S62 ,29",SH:J4_5
ML4F'UXRBE^MC2&Z&" )\![\/]7I@*])\M'I75V97*UMPI2/LR/\6W\ ?@JSX
M!H[BKD24K(/4H/GT<$C.25B2?TM<P[8<+Q(YOD8<WTJ!KO=(R8U5LG6I:+K6
M'LE9.>N-E_ZNIB?JRR_AALT&Q4OW>D6X".E9VT.5==7V[#E6B9^28"G@%IQM
MCWU7GFH(WVX=Y0U]L_/UN[PV@(BCG>V8<"8V+N.*A'N/G8!K95Y4"<!&40#V
M!4KJO6<>U"2RR;Z@^+EG890JLTH^W5FUR4O?L3<<_%PF>[BN$V;RIYV)BE>$
M>8,E <5G;"Z%N=OX#- DT:[3K;O +50I<^I76&^#4C'1ZEI!E".>1O#P>$3E
MTNQW495<4,;R&0&T AU.1V15SBD=CR/\4M$\D(E%LF%P%765OHPG3*@%%I.[
M*G11)O6LL[1<JQ9@:1;]4EAB[SO-F:P6 +,Q(+1C/N>7L[4F_.H\T9ZO]F"V
M!5OQ<K6M&/ *<@[<%"%UF6:,D:I/[UP&RK :U*3B;82*",B.1":C\I 7!D69
M3,<0)=/O3OBD"P/553OK] 4-%($WN=,>AKP S@8PM6;&,3%AX@B_C(ZLS=UI
MSM&+VD!0!)-5BU:RMF5G0%,7WK8^G6.H]BF$A(^>A-Y%R/S4H)18<$R1'C=:
M2Z(-%%+OH@_PDBHRE;>KDK6=F;!S>;_NK%\G),Z>$JB=-;30DD2?0(Q_=>ZT
ML[==X#':TZ>GK")HM]=J*G]$:=,%W[3IJ_:TTFFQQ:O+H=(WTZ;K-0J-0?*F
MGXN-1A&2J)\KK9NSJ_ISC6G4'_$?[AMXZ$N T(F3J#]X$G6DF\]9=V(Z7!IW
ME$>] S+9(W+"8G*OL#17Q1%H5'.9/P2-$2M?NLYW!S-4 *AKP>H;$=&+\XS=
M#3%9Q^4%B5UF,5G'SL,E+)\I=<36 /GM%-*DP%273(N':M4@S,'<>,-J=8)!
M(NFF@XT@;)9H^#ELH'0F8+>_3Q(0GB&U^4-\$^!O:49G*.KZ[$(@;K\W8EC-
MO(FF462GACHK5RGLC%7&ND@MS #J<3$IL_< G2;0#)FCQG2-H2'Q9@- )C[
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M(VSS,X:&;# _AUC#O-$E#4>QZ+6<^:9DIK[[,5(1PV-EL@M"M3,AW_"4H&8
M@7Q?P]0"@*?V?9]%XZ2U]\FLMMO?6V/>PBR]A75EIE.?, C?KR, 6U,-M.A/
MF5WTFH:(6Z4J\AU1(F;P';X*#!4)=;D!IC&H,/@+-456K5\O(( !SY,%;Z'N
M0!;_&DAKP6JT,'$7$NWC,;*5F7PAZ:G,[/#][>F?2[E[FRYEE)L-2M]7;L^<
MLI:_*+:G?W]6NW^[U:10D>P7"J*&;W]\+/ 6(I/[-SLI)A4Z9FH-E*SOC#$"
MZ$\>"O";ES>EJ\=JZ>N7>IDI%RL-YJE8?2PQQ6;S\>Z>P)R%K#8M)6<52$$
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M@J5SPALZPE8:..V)N5*<T=T"TOP@Z*Y60-!M_J+VM%IEZZ6?62//]J,28-D
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M<M57;LSOZS)X0@.Q*R%F."/IL*P18,WV>,+2QWK"-EW&G:A9VRJFJR^DNCY
M*M:DD,I+7KZ$84?,%1^R_;]__X1HCOCXIP@Q@5Q$T6Z+N)3!/%9\C^>2#:"Y
M?[X^EJ%LV"XD !? -MVZ(=Q,,J0\L@(\0\)ML=4>R2DYU1[J,V%Q(]P^-Q^;
MQJ A[.8:]FE.-&<"+ 0MM\H8:"DZ+S&J,Q AS-:"DF=Y-A.,C/1U>C)%O>W7
MTD.QE#OV*<\2>3:Y]A'Y#%W;0MZ^74@W-I$)8$R$T@UL59+9A#>REW>U7],[
M(>))9FNT\,K&+;Q";N'%)3]9"Z\=<?9Q-VUR=N@Z7->M?630'?M.U4)IKQ7Q
M>>X[%YGFHF)ICR4]\8RHKTC'/]OIHCXYQVE'YFF I]O33G58O!"*17VT>>;W
M ;*+6=_LXE1[>LT;<FKXRDWZF9,?=\7&SU*K4KL^<#KQLNU8EDM<\,HE#CP8
M-A@S?+? O_+U42XJ6M=F\."O?RXO*G*U61[G ^4,-TO5*FP[I PO88)C2QC>
M;9:@R5C$#+=9:R\IL:QGPK RN'RH_JW<_%39W:7.+0)61S9W<+9:5YX)Q+TW
MX;XJW91OWW:0$.NY6G&VX4;9AIQ#J)NI?*[4+,A9:EX7BZ4I^])H3UMOKZE!
M__%G02_$&8?KI<#1F]AWG??H2N-6NV*./^-PD^7>B>LK$V)^IZ\SWSK'WNX^
MCSQ$QYF^XZ=%MM.X[<BISY"(2!@CV#KMT[W->J%T1#F.ONTZ[B2*EMXV*\W[
MA)66&K0D;NA]7VI)42[=U;(OO<Y^ F6?(<#NYY:8VX=]WJ=QH'W7&[>3F]D+
M7&%G$?><$YB#+H&9:@#I?<)0E$5-5WE=?$,>H7>'2'E7RTU=N/J-\F%>UX<)
MN&L.0W]H<<-\M/W3!-J#,<4^59)4(8ZW[W$7=Y)8&$"M#"7L[AF)<(;>L^VI
MU.KTFNS[4YIGH^($/E!,905[^ 96,C,]-/ 0[>D%7Q9*Q?[]@U+88-T]PHX'
M#+EPOB&7--:V6^^3ZE-:O1/YDQ_7I5JI4:P2SWOQZJY2JS1;C6*K\E0Z< QF
MY<XM"\2DO (QZXW8GJ+4+S93$%A9RV]W$*,'Z\*UIX6G]^?[6DZ\U(+!NJS#
M*,<6I_FHP"Z<5YRF[2@I["I#U-1YG>#!594N+:0AZ'/VMU8<&QOE%7'3DJ)6
M7SL1!T39\9IGO*(].UIS[7$RNGLJ"/++(-IK'H/0'"3LMI6<,GF06)WS7+C#
M<[2K0.@Q1(QW/?<X_KM1_#>U&FW&]#_QQ/WT4 #=D4L6U)?GJXF0BR/ ^\*<
M<<#,FH.T UVD(7@0LLG5;M+CCQ:'@4^S]ZU)94/<FM4BPA5%=@N']Y>WU*2H
M"7>R^!E"R9M@VASP*+,)CEN-?Q2M*/-V"#C[EY:%;1?8%S/!<OM<\,(5ZNC^
M-W1KD&JVTMK396E'-[1[ I@FO$ =W;J)#YB1,+\\$3V)F=61E0.!Y^2S!P+/
MN5H3%<3-]\I[^L]]FDU7C# 1##X^(,@!S\'6Z3K'MN2'OZ&XU3KC)L?W,B#V
ME?O8LB);%L54-ZF$>UL=/Q;6(57%U:7VT3R86^-F[7^IMTW\]#Z0Q06$14T'
MKSQUTL]^]]<B,[_>!C>:+/8&FV0NNH#I*K)FJ(>_*E>N1$3/8^%8D4LW6_##
MG\I<:B>GLN"#R.6; ^@^F$*Y](M-\G_&R4W4W#BE.# $U"8I>(>T*>,TY'UM
M=@3$TSY3EYVZ_1HYRS.1=?4\_7OW],RJOS>I&EPS9=F9%[2SQ.7^+(1,Z>+G
M5N/S92\?I\SD$LG":A=$G.0<PF8?7F:R"38?E6SH/#:PGF6V7'[0GU#4@<CV
MT.V2&@<M_GUU0TMNSK#U?PQ?.YC;LHUJ)Y4_*E29U#)4F8?>X/YA-'K-Y?,G
M/RJUR_I=B6D5?RW-9(XX\)0WS\UR:YVYM(NYMFM/; Z)SC>GUI5'NWG+><P_
M6S25MPG.<:/WR'9'MY(YTN'2B(]$\7R.I;<C<\=\C,F]0SS(H!EFK-(#4%E#
MTC6XOQB=?V=&ACI2H+D(5G$1_FB F(JF\D@2&2K.&"S/F-.*W).(VY)7)TQ1
M 'IA6.T;4^7'"88MY#/,*3P,PH)+_NOS?4H&?H1\C?WWV^)Z>F6]'8K;(\K@
M$25KWX(Y9I8C)FOGS'*I#+&\Z=KUN[>\;( H(AFZR7R""#I+%F*Q")%3(J_(
M;Q6L0O9549^8LM M+0<\-JL[",G,D I9@<%V"8]->FPS8$N\PVNB=AXSZT<@
M*Y9L4=R5D'6EB^-2[;!29GKZ-"R.-**+Q;K41R$KECA1W)6(DK5S9BDK)KYE
M#PG@&DW@47D=D9H72<&[SHC44IS3D$#!PEH8)F*"%2W(3M1 RY*)+H7>>="3
MB#.W,R'?A8=Y0Q\H6.^"BAJB<IF?3Q"OXD]494@)X9)L#O]158S^@%1<.:Q7
M*Q8"-!J82JS.2>)0U*EV%ZMD'X*L6$!&<5<B2M;.F:6FZ&-1'V")(X,K.$$I
MQ9)0,WA9)W)2,SI_4%>']KT@I$:J\B9JEKG) V](B&'3&?B5^.!FOK>ZB@>%
M7+6$RRXEGOG<OQH1DBK2#54&P<OKS!BIR!3:HH2-4Z#/)68GC#$"BH! +,(E
M Z@'X9K%)"&(I&@B%JOX\1X8M;'L_!!DQ;(SBKL2LGUX>5SF["6OJA.L\8UY
MU<Q@ 3DE*1I)6HG-VH]!5BQYHK@K$25KY\Q2U+Y^P=J6"[DD,6>Z#GB!Z1I#
M Z*9;PAZ;5JQ JPJ40'%G-;JU6_$8'UL6D;RS! &!6^$%;YW<8BM9FG"_&<^
MD:(P5QQ1MP:OXK&=8E%KBY7V2,[(V79WU@LD4T3:4^?OZ"F37YE?ZCOR?(94
M4:OWUD?NS-B93EEW]<ZY.]$)\GCF4,Q"VU?\E(3?<.Z.X@QXS=JR+LS_ZQ=S
M!9@.+X&&3;T.5OS;RZNQ>C,O-M[,1? JK/P7+4T=&@(N8%=1,IU?LN"J_J1_
M"F^7TYIPG=X-4]C)<GXTA, U:?;<7?6U<ZX!<TCI]31\S/D^^*QTIF=@NXJP
M >0 ??UBL@5P"FR\+"!L'8DZ-NKPT K!I-+QNV)KZ4.0%>LL4=R5D,V/JR.R
MEH@W'C04ZA1'6/X(;B6&^'3 ,TZU&7"_,RK"$KTK$HAS+*^&3 ?I8TAA@&]0
M=[FB3J@OB:>><Z<F!"/"[ZC70UU0AC 9UE=YG294F(\MWHE.M/F2];A]R37P
M4PV+-N*F+^IEJD4U+:KFOMP>B4);&-&K<[$[6KG*I83<W5/F6;26?49(>8^$
MO#T5NEGU%S>YZJVZA4,@)60D]DJM;%_-9YSC;K['=^&'FP[GI6MX?# /NQNR
M!A+Z@/\0_791'*A(&]'=D28)1M3,3*BNTL=K GN)S^\;+QEDEQA>DI0QJ,8,
M$2#D4?@&5GJ0"IYA+ (P403Z#N0*>).[IKV$_SIG+GW]XE"^1? JF]HW0?*$
MZC=0H?#,D.DTQS)JI*B0MB6(F*541%1TP4"6&]W 'Z@Z@%Q,+&FE(BQZ:84]
M?*09W<$"L5^_P-C@$!\H$O%XTSG8?G/\?<'H OEF:-*4@+:WG6(?(=4OFFB7
M71QEKOL:C=YS<:/W&6)F.(W>V;C1>TA*G3638VNK'3=Z/Z*=JD6OT?O>:J(V
M)OH056RPZK-*MHZC6&W)OASKSL35:G&U6N='Z8B\&E>FBFX'?XE1 >49S$@5
ML=DXPI;(A*0 ^I@%HNQER9CV ?[X#<D&S5DTT1"(#X1Z_'LDP48T0?BI@W<6
MAE;1"&"[L*%@A0'.F29>"+&'>16;*OC;(P6,%LTR0JY5Q1C9YL+,@4RRM?'7
M(+N&AU>#=:5]7V5%A%_@/&O68RT\^/ )<459J(I8.95(&N;2[C].)(X-1VQ/
MWW4^>WM3>K_6<Y$K/)_S'N4O2NWIQ;N035]=2^S+C-H%/(\E38+F&OU<E<JE
M1@,K"_@.\N[I<P0=?0*WQEB-UK,:+89LDV_#A&!->JAO[FXR+5^PF7'G:0<-
M2G;1_F(G*Y*>-<Z9)FLO[WI:D.^[TAHKXJE?=W[0)A@=GTLG "L$[GT1&F8T
M^'@4S;XWG"XC4VI_WS5TW>HON@;T;/RQY8<^L$N9.4C5!1$/F!?F9R9."JPG
M_B]O(E]>(!GU1-V,>U,0N:M6L3;5^_=8J@Z20^UAS/[\U0\1D6EYZXY[*P67
M%B0,1Y(R0>C,:N*A=/"7>2=8Z\*P!^@5X?;8K,8?W72CPL@)689,[^%='[G0
M;_;0R6/YUUR[,#."LO_L>?%#[$OO@\T7<)5\!$1NF8!8E0FS*!$JC5I!N#(J
M?3V]KZX!-44^PQJS"(!J$*B@.4)6D&+W/3U".-V[3?%:!F;%)K(9KUX3[C.]
M$3#L>H=TU^L68M/W9"*?]^F^L,[E7)PUY%B<W),5RRM:H3S'B=-F)XZ]*K-&
M]N$MV]AE(W=?W,<G=\CQ P!^>IWITR7M0E9O7N@'6<,$X\^\3G36*RCN/M&!
M]_A;"#NZ<R8PMVX'N[2-V/#;I62BP :]S7V6[EM0L%67V*PA?29+IOF_M6Q=
M*' /4LK/-;)38&A_P-6M7$$48558]$^:1N&!$54#]M')<\D5?70VP^5TM=K9
M/S:ISR.!%X8-Y,[?9GG69%Q_!,^MH^L@NR,SR$I0THOV=-0?*!/N%F6K7.1\
MPWL')6VB/L"\-*QHQ&IL4F>V8X"GV]/T];-TT:LTGK.;^^(/$-Q-SP=WY[WV
M7+D]?;_[.^W($RXU[)+GFJ5K",DSE1KD59 ,BKE0V8<( H="-)0WR(XHP8YG
MTAJ@KU^LA&.:.$A#>XN)O&D':^-#UD%JO6=;<2:O:VVAVS;L7SR3=*^42:,D
M#W.5R<JL5M_7;)2K"G<2*']C?+-H2'8EJ]IZGOV6'UB%6I&3BG<]M*V85;EI
ME **(2 K5ET4WA68V_GGSF4YX&'!U@:DU&)-0A+?D. ,+BMCF::ONFK@(, -
MWP#@'O!SXUVD?_D8^[C[:]CLQ7S/J_JD!5%>>A*UU=>QTY9:8Y3VM)J^*S_F
MG[C&Y*B0PS.^5W*R/<U6*U=]X4'+B<+)CT:I2M+F[HN-5L41"X\3LN*$K ^4
MD'5,\.%%65#1F-)WS:LJTG7 '^J>)YCQ0.P.H'($Q*F*F8Q>-5@](4BZALH(
MHHJZNJ+B\>DX3'/257H]J#[I(G)9"89*2B_,0C:?.K9D@NGRVL"$N@Q>1>\C
M7LVHFP:RWREUG[%FXWS$49J=M#5&FBC1%I!X=E9%?5XJR3J^6&E5MN5]I],U
M%PPOEUF2W=94_>RL)>J0(%61!?%-% Q>\GJ6KI3UG#VC(H0CH'9@_IE[B>\2
M@/=B'_\/M"*WBL SO<SD_>EEJ$R$59KMEJL5L,$*);GMLT)S?YU; _,O?C,-
MH=3<[4 US^6.:\VQ[C6R9L7P,"VFA^=%=+1E)927$E;UZKUGO(:\K-?5!KB;
M+/.DB;H&A5"\Y.%H7DS,[VGF%VG$510H>Q\74__\_?;S_JY2>$ZM1#;8<I&6
M>? /S,H+]N$ J_/8.DPE<IED(IGT DW8)3./S84C:33VS)CBC)VIH9@TX>@@
M@]>(<3@_!EDQ.D(4=R6B9.V^B(#HE&:(;J5BZ5(@G=UPR[RHDM+66>\:^R[1
MS(BGEWHX_3-J---=N7<GK52[EKXCF%(51N_.C#L7;[<WACY0# WK.& -C/#=
MA>=MF0(]O"2D^AQ,"4J%?;^(FF80+Y<-3$KS1>#>652C-*2^B5 5HBM,\;IR
MSK0&V%[AAXH!?DP\!-_MPL^T"!W&M-:=>CD%92R?D8 T0+7JB"S+.27H<02J
MFP;8KH#)ND V#&[6H$PIM00DJ*LB7B,^4[#W26,DB1GQ(G' F5EGNRTF=Y;V
MAA9.W%?HR^AHI!):+[V!+SQ0P,OOF?;T-JNF?UTI:/0L1B>LN)7+:$-'T%JW
M(7<P]X[M4@3"V*PSVA?D8EI)>,BT+GH[2^WI1*X^U$JU4?\R?_*C^7C1+#T\
MEFHM2G'I"<J#O9R>.Q $1QA?\239%7+)B'+(D4@'!J3&((J) B)=D@#.VQ0N
M#"+2Q>Y& ->! #!(XP%%5M+0UR^S^D+2.8'$\RC4B'FIX6M*0#I2AZ*,/^O1
MYY@AGBK3068!(A+@&IM193\@4.@2 %!!=%19,9\A,F1&[-<O%K7X?332@,S"
M2?R#%Y7S4:%E^1HL9G/^=R,_^O.8-M[2T1&L?B GRX!-\O\R]1%Q=GUGJCS>
MA1C=)!1T$VY3=!,O_)&C@1S!'RC"A/PPT(<2_N'_ U!+ P04    "  8@']4
M81^C9IL1   0M   $0   &EG87 M,C R,3$R,S$N>'-D[5UM<]LXDOY\6W7_
M@:LO-U<UBF-[DIEXX]VB)<KAC21J2-I)YLL63$(2+Q2I(4B_[*^_!O@BDB A
M2G9F46>FIL84T UV]X.71@,$/O[C<>,K]S@B7AA<#D[?O!TH.'!"UPM6EX,;
M:ZA:(UT?*/_X^W_^18%_'_\Z'"H3#_ONA3(.G:$>+,._*7.TP1?*-0YPA.(P
M^IMRB_R$IH03S\>1,@HW6Q_'&#+2-UTH[]Z<GCG*<-BAW%L<N&%T8^I%N>LX
MWI*+DY.'AX<W07B/'L+H&WGCA)MN!5HQBA-2E/;V\6WVKQO[S"-.P?SA_6Q+
M?GXTO2\K'/R2C%'P0#ZC:\V[6WSXU[O??S'PM_7]YZO3N]\WORZ>OOWOK[_]
M?!Z.XF0<7V]TYV&>OO(C<=9X@Q0 (R"7 ZI?IM[#^9LP6IV<O7U[>O)E-K48
MW2 EO'CTO>!;$_GIAP\?3EAN3LI1/MY%?E[T^0G-OD,$%R5#KB>@]P(2H\"I
MT+MQP5 F?G>29E9(O4;2]RFIEY.ZN$9'L/-F%=Z?0 ;0GYW^\5-.FI#A"J%M
M0;Y$Y(X5FV4P\N';T^'Y:<Y"HI@GA\1FTF'\M,6DD2'-:F!SXZC&5K$D9)_0
M;,KYEG*>%9SZM;HHF+P@QJO(BY^&:+NEU9R]ZO2,O@C[>(.#>!)&FS%>HL0'
MG?Y(D.\M/>P.E!A%*QS3>DNVR,%=BLQ;  J"$!H*M-8LA:9MMQZT!$CXCX^T
MREQ$H8]M4$&A#]!$!2^@%">C$/J:@>*YEX/TD18%!;/"7+ST H^],6N0I\J0
M-K^$J@B/C.7C29VX5$1"L&L$?V?/VP@3X&,J3"$A8\Q(6I@<Y#N)?QC/3I1&
MEBPA-]7QQKM"/FUSUAKCF*1&K":)C7D&%J1='RZL&9#0]UQ(<96L("4MJ;<Q
M,\,"1:#<&L<>B-Q@\&J^V/KGW:VO_% I^+]?+QJ%P8BQ-+;4NX!7$C5PJ4<1
MX34.B'>/IR')FL,!]&*T?A*AM7N+$BZ5W7L4%+A*Y4T*?54/'X5CM$;!"A,]
ML.+0^;8.?1=<0>V/!)BH.(X7\Q!VX!'#^*X&8Q6YK'A%#Y3R"_Y+25_QPSA]
M1]_^4C 064_\\*&AJ>VRQ'"\[]ZJ:)$**[.W?L7$#6-2!SHQ+C\?@TL_2N4X
MI1/?#(S\A]CBOU#'%N:1?DB2",./:VVNF>KT]1K12C8;%#T92\M;!3![<5 0
MJXX3)D'L!:L%5$?'PWG?TXU6#,&'.@36S6RFFE\58Z)8^O5<G^@C=6XKZFAD
MW,QM?7ZM+(RI/M(UZ_6BI ?WH$\8%5"4$X3V/GU;M[<^O]7FMF&^:H-.,2*Y
M+;-GL1E/ZV:<:JKUFBVXB$+PP.,G\/*IW[:E0]4<9]YD6Z;8QF=U&R],8Z&9
M]E=%G8\5[;<;?3&#JONC,M?LUVMX X;^:)1$U F8>NC.\^&E>5UNRQ0;_KQN
M>,/^I)G*Z,8TP=[*5%>O]*ENO^X>(T0!F43AICQGR3J0QBRQR7_B^A-#G5O*
MQ#1FBF4;HU\_&=.Q9KYB@\.,?N/%S -FD03F9#35^2Z$8C#>U<$8&;.9;M/.
MQF)]S\A@GDC?&$K8A&EX $S^&441N(+DLQ>OAV[X$)C@$KHP!L38H;+L8#J
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MUX:SKL1BN+@@2Q>(^J&NVD4VKRZV]8UB:C%<XO!+^\)DW[8:OTAJ;EG=2,5
M\9LGFC]FZMO4@1\X-4-V#*,80"XJTNT#J![/YCYR@KR('52G$I)LMO35;1VD
MB%2,&1_4*/6.$U4WE5MU>J,IJF7=S!8T<-EWC1646(=WS79>J [472!M 4E
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M8C.,_PFOO=$?F-L'X..(DUOH8WVI]YB0=YH=UFLG*.<"0&[<ZFF["6EYU<U
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M0> F%51&B*S]22Y&K*/2_9B+U?'B0)A5DME1SQ(Z1%%,_$F,/$YE/;K$XS8
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M1:&DTJ)"R)LQ]7+E8$?/X\!F+;]C@'?B2?@_-28%\/R3FT2*2>ROV94!04[
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MYXY)-\]WN5@R$=,<6B/248NBDP=TYD030>5#::8&1.Z^ET+X@$Y+%<#7]<3
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ML)5X&\E%7/%#!:[F1?]W$'Q0@!)>AG QQ.10*>BM]^M;A;1@[K+**O7%W+)
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M@-UUO%$(@Z"4#4*%^PU3NOR=::%:K3HM\\:F+UFR38N \#?L1&:A%')NV:.
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MB&B+=-#^(&U93&![!.D$,&2R # -6T^_8)=V1GJ5J[LVCT"O\,PU]D8; UG
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MFRQ="3 ,D<(2@EMN4S[3!0D*MX3@--P!(48G^!F/^+,S>PGK5-SZ!)O!=SV
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M!T>^@!;SXK!H%_!X:@WUD$W8PQB*\>5/%JOE2CT,8VRWT[+4=7H%.*0ZG0M
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M;8;BF5X6#$;Q+F:$XYKX?+%\C!!@#4CG]3[#A#*M9Y 2$8I35&*27$IQ$<2
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M :7/Q^(']*2-'J!^' 17_BS[H"YL_^F._AO]<_TG^C]LV4K_\O\#4$L#!!0
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M_-"/$WXK>R;0.4+[UWK*L!_)S'G5GS&YAG6>U&3!Q84_-^G*@2P7>8]:ET3
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M+3*9Q<L2G9Z$'ZZA&<QP&%07T"B.CR:HT;K)VMOQ8JN$7]X15$*A+4JGPOP
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MV/Z%_^>1'4_L-_\?4$L! A0#%     @ &(!_5-L,[.5L!   Y1X   H
M         ( !     &5X,C,M,2YH=&U02P$"% ,4    "  8@']4*Z],VO<!
M   9#0  "0              @ &4!   97@S+3<N:'1M4$L! A0#%     @
M&(!_5(L5,M(1"   >"\   H              ( !L@8  &5X,S$M,2YH=&U0
M2P$"% ,4    "  8@']4N"HCGQ0(  !>+P  "@              @ 'K#@
M97@S,2TR+FAT;5!+ 0(4 Q0    ( !B ?U3[OR3?H@0  *$<   *
M      "  2<7  !E>#,R+3$N:'1M4$L! A0#%     @ &(!_5#-<@3>3!
M91P   H              ( !\1L  &5X,S(M,BYH=&U02P$"% ,4    "  8
M@']45+*4<1 ' @#,7!( #               @ &L(   9F]R;3$P+6LN:'1M
M4$L! A0#%     @ &(!_5&$?HV:;$0  $+0  !$              ( !YB<"
M &EG87 M,C R,3$R,S$N>'-D4$L! A0#%     @ &(!_5)HZN%\&$P  O.T
M !4              ( !L#D" &EG87 M,C R,3$R,S%?8V%L+GAM;%!+ 0(4
M Q0    ( !B ?U2\LUR45"H  )1X @ 5              "  >E, @!I9V%P
M+3(P,C$Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  8@']4P4^Q]\U:  !@] 0
M%0              @ %P=P( :6=A<"TR,#(Q,3(S,5]L86(N>&UL4$L! A0#
M%     @ &(!_5&P^_M'Z/@  @>$# !4              ( !<-(" &EG87 M
F,C R,3$R,S%?<')E+GAM;%!+!08     #  , -0"  "=$0,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
